(lp0
(dp1
S'line'
p2
S'Serum levels of PAPP-A, S100 and hs-CRP were determined in 205 heparin-naive patients of acute ischemic stroke and 50 healthy controls.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I24
sS'uniprot'
p8
VP04271
p9
sS'lengthInChars'
p10
I4
sS'name'
p11
VS100
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I33
sg8
VP02741
p15
sg10
I6
sg11
Vhs-CRP
p16
sg13
I1
sa(dp17
g7
I16
sg8
S''
p18
sg10
I6
sg11
VPAPP-A
p19
sg13
I1
sasS'diseases'
p20
(lp21
(dp22
g7
I95
sS'cui'
p23
VC3272363
p24
sg10
I15
sg11
Vischemic stroke
p25
sg13
I2
sasa(dp26
g2
S'Serum PAPP-A level showed a progressive increase with the increase of stroke severity (P&lt;0.05).\n'
p27
sg4
(lp28
(dp29
g7
I6
sg8
g18
sg10
I6
sg11
VPAPP-A
p30
sg13
I1
sasg20
(lp31
(dp32
g7
I70
sg23
VC0038454
p33
sg10
I6
sg11
Vstroke
p34
sg13
I1
sasa(dp35
g2
S'Serum PAPP-A, S100 and hs-CRP were associated with stroke severity or outcome after ischemic stroke and may offer complementary information, essential for clinical decision making.\n'
p36
sg4
(lp37
(dp38
g7
I6
sg8
g18
sg10
I6
sg11
VPAPP-A
p39
sg13
I1
sa(dp40
g7
I23
sg8
VP02741
p41
sg10
I6
sg11
Vhs-CRP
p42
sg13
I1
sa(dp43
g7
I14
sg8
VP04271
p44
sg10
I4
sg11
VS100
p45
sg13
I1
sasg20
(lp46
(dp47
g7
I84
sg23
VC3272363
p48
sg10
I15
sg11
Vischemic stroke
p49
sg13
I2
sa(dp50
g7
I51
sg23
VC0038454
p51
sg10
I6
sg11
Vstroke
p52
sg13
I1
sasa(dp53
g2
S'Serum PAPP-A showed a potential value for the evaluation of stroke clinically.\n'
p54
sg4
(lp55
(dp56
g7
I6
sg8
g18
sg10
I6
sg11
VPAPP-A
p57
sg13
I1
sasg20
(lp58
(dp59
g7
I60
sg23
VC0038454
p60
sg10
I6
sg11
Vstroke
p61
sg13
I1
sasa(dp62
g2
S'By Cox regression analysis, we assessed the association of baseline levels of PAPP-A with all-cause mortality, combined cardiovascular events and the specific outcomes of sudden death, stroke, myocardial infarction and infectious mortality.\n'
p63
sg4
(lp64
(dp65
g7
I78
sg8
g18
sg10
I6
sg11
VPAPP-A
p66
sg13
I1
sasg20
(lp67
(dp68
g7
I219
sg23
VC0009450
p69
sg10
I10
sg11
Vinfectious
p70
sg13
I1
sa(dp71
g7
I171
sg23
VC0011071
p72
sg10
I12
sg11
Vsudden death
p73
sg13
I2
sa(dp74
g7
I193
sg23
VC0027051
p75
sg10
I21
sg11
Vmyocardial infarction
p76
sg13
I2
sa(dp77
g7
I185
sg23
VC0038454
p78
sg10
I6
sg11
Vstroke
p79
sg13
I1
sasa(dp80
g2
S'Categorical analyses showed that the patients in the 4(th) PAPP-A quartile had an adjusted 2.6 fold increased risk of sudden death and 2.8 fold increased risk of stroke as compared to the patients in the 1st quartile.\n'
p81
sg4
(lp82
sg20
(lp83
(dp84
g7
I118
sg23
VC0011071
p85
sg10
I12
sg11
Vsudden death
p86
sg13
I2
sa(dp87
g7
I162
sg23
VC0038454
p88
sg10
I6
sg11
Vstroke
p89
sg13
I1
sasa(dp90
g2
S'PAPP-A is associated with sudden death, stroke and infectious complications in diabetic dialysis patients.\n'
p91
sg4
(lp92
(dp93
g7
I0
sg8
g18
sg10
I6
sg11
VPAPP-A
p94
sg13
I1
sasg20
(lp95
(dp96
g7
I26
sg23
VC0011071
p97
sg10
I12
sg11
Vsudden death
p98
sg13
I2
sa(dp99
g7
I40
sg23
VC0038454
p100
sg10
I6
sg11
Vstroke
p101
sg13
I1
sa(dp102
g7
I51
sg23
VC0009450
p103
sg10
I10
sg11
Vinfectious
p104
sg13
I1
sasa(dp105
g2
S'PAPP-A levels above 34.6 mIU/l in cardiac chest-pain patients sets alarm bells ringing as a warning for higher risk of short-term cardiovascular adverse events, including stent thrombosis, myocardial infarction, ischemic stroke or cardiovascular-related death within 90 days, the combined primary end point of this study.\n'
p106
sg4
(lp107
(dp108
g7
I0
sg8
g18
sg10
I6
sg11
VPAPP-A
p109
sg13
I1
sasg20
(lp110
(dp111
g7
I189
sg23
VC0027051
p112
sg10
I21
sg11
Vmyocardial infarction
p113
sg13
I2
sa(dp114
g7
I177
sg23
VC0040053
p115
sg10
I10
sg11
Vthrombosis
p116
sg13
I1
sa(dp117
g7
I212
sg23
VC3272363
p118
sg10
I15
sg11
Vischemic stroke
p119
sg13
I2
sasa(dp120
g2
S'The aim of this study is to evaluate whether PAPP-A gene polymorphism is associated with the risk of ischemic stroke (IS) in northern Chinese Han populations.\n'
p121
sg4
(lp122
(dp123
g7
I45
sg8
g18
sg10
I11
sg11
VPAPP-A gene
p124
sg13
I2
sasg20
(lp125
(dp126
g7
I101
sg23
VC3272363
p127
sg10
I15
sg11
Vischemic stroke
p128
sg13
I2
sa(dp129
g7
I118
sg23
VC3272363
p130
sg10
I2
sg11
VIS
p131
sg13
I1
sasa(dp132
g2
S'The postoperative course was uneventful for 13 days; however, severe neurologic deterioration remained in the area of the cerebral infarction, due to vasospasm of the internal carotid artery.\n'
p133
sg4
(lp134
sg20
(lp135
(dp136
g7
I150
sg23
VC0085616
p137
sg10
I9
sg11
Vvasospasm
p138
sg13
I1
sa(dp139
g7
I122
sg23
VC0038454
p140
sg10
I19
sg11
Vcerebral infarction
p141
sg13
I2
sasa(dp142
g2
S'In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH.\n'
p143
sg4
(lp144
sg20
(lp145
(dp146
g7
I156
sg23
VC0751955
p147
sg10
I17
sg11
Vbrain infarctions
p148
sg13
I2
sa(dp149
g7
I134
sg23
VC0037763
p150
sg10
I5
sg11
Vspasm
p151
sg13
I1
sasa(dp152
g2
S'Diagnostic tests and imaging are consistent with recent myocardial infarction in the LAD vascular territory because of coronary spasm and cerebral infarction in the middle cerebral artery vascular territory probably related to khat chewing.\n'
p153
sg4
(lp154
sg20
(lp155
(dp156
g7
I56
sg23
VC0027051
p157
sg10
I21
sg11
Vmyocardial infarction
p158
sg13
I2
sa(dp159
g7
I119
sg23
VC0010073
p160
sg10
I14
sg11
Vcoronary spasm
p161
sg13
I2
sa(dp162
g7
I138
sg23
VC0038454
p163
sg10
I19
sg11
Vcerebral infarction
p164
sg13
I2
sa(dp165
g7
I85
sg23
VC0398738
p166
sg10
I3
sg11
VLAD
p167
sg13
I1
sasa(dp168
g2
S'Cerebral vasospasm has traditionally been regarded as an important cause of delayed cerebral ischaemia (DCI) which occurs after aneurysmal subarachnoid haemorrhage, and often leads to cerebral infarction and poor neurological outcome.\n'
p169
sg4
(lp170
sg20
(lp171
(dp172
g7
I104
sg23
VC0007124
p173
sg10
I3
sg11
VDCI
p174
sg13
I1
sa(dp175
g7
I184
sg23
VC0038454
p176
sg10
I19
sg11
Vcerebral infarction
p177
sg13
I2
sa(dp178
g7
I0
sg23
VC0265110
p179
sg10
I18
sg11
VCerebral vasospasm
p180
sg13
I2
sa(dp181
g7
I76
sg23
VC0007124
p182
sg10
I26
sg11
Vdelayed cerebral ischaemia
p183
sg13
I3
sa(dp184
g7
I139
sg23
VC0038525
p185
sg10
I24
sg11
Vsubarachnoid haemorrhage
p186
sg13
I2
sasa(dp187
g2
S'To assess the clinical efficacy of acupuncture at key acupoints combined with the routine rehabilitation training of limb function on spasmodic hemiplegia after cerebral infarction.\n'
p188
sg4
(lp189
sg20
(lp190
(dp191
g7
I144
sg23
VC0018991
p192
sg10
I10
sg11
Vhemiplegia
p193
sg13
I1
sa(dp194
g7
I161
sg23
VC0038454
p195
sg10
I19
sg11
Vcerebral infarction
p196
sg13
I2
sasa(dp197
g2
S'We describe a patient presented with sequential events of hemifacial spasm, cerebral infarction and fatal subarachnoid hemorrhage.\n'
p198
sg4
(lp199
sg20
(lp200
(dp201
g7
I69
sg23
VC0037763
p202
sg10
I5
sg11
Vspasm
p203
sg13
I1
sa(dp204
g7
I76
sg23
VC0038454
p205
sg10
I19
sg11
Vcerebral infarction
p206
sg13
I2
sa(dp207
g7
I106
sg23
VC0038525
p208
sg10
I23
sg11
Vsubarachnoid hemorrhage
p209
sg13
I2
sasa(dp210
g2
S'As it is unknown whether STAG2 gene is responsible for the occurrence and associated with the prognosis of acute myeloid leukemia (AML), the present study analyzed the relative expression levels of STAG2 in 127 de novo AML patients and 17 healthy volunteers using reverse transcription-quantitative polymerase chain reaction.\n'
p211
sg4
(lp212
(dp213
g7
I25
sg8
g18
sg10
I10
sg11
VSTAG2 gene
p214
sg13
I2
sa(dp215
g7
I25
sg8
g18
sg10
I5
sg11
VSTAG2
p216
sg13
I1
sasg20
(lp217
(dp218
g7
I131
sg23
VC0023467
p219
sg10
I3
sg11
VAML
p220
sg13
I1
sa(dp221
g7
I107
sg23
VC0023467
p222
sg10
I22
sg11
Vacute myeloid leukemia
p223
sg13
I3
sa(dp224
g7
I131
sg23
VC0023467
p225
sg10
I3
sg11
VAML
p226
sg13
I1
sasa(dp227
g2
S'Rare STAG2 mutations can amplify at the level of GMPs, from which it may drive the transformation to acute myeloid leukemia.\n'
p228
sg4
(lp229
(dp230
g7
I5
sg8
g18
sg10
I5
sg11
VSTAG2
p231
sg13
I1
sa(dp232
g7
I49
sg8
VP49915
p233
sg10
I4
sg11
VGMPs
p234
sg13
I1
sasg20
(lp235
(dp236
g7
I101
sg23
VC0023467
p237
sg10
I22
sg11
Vacute myeloid leukemia
p238
sg13
I3
sa(dp239
g7
I83
sg23
VC1510411
p240
sg10
I14
sg11
Vtransformation
p241
sg13
I1
sasa(dp242
g2
S'By 1 year most Spnb3(-/-) animals develop a myoclonic seizure disorder with significant reductions of EAAT4, EAAT1, GluRdelta, IP3R, and NCAM140.\n'
p243
sg4
(lp244
(dp245
g7
I109
sg8
VP43003
p246
sg10
I5
sg11
VEAAT1
p247
sg13
I1
sa(dp248
g7
I127
sg8
g18
sg10
I4
sg11
VIP3R
p249
sg13
I1
sa(dp250
g7
I102
sg8
VP48664
p251
sg10
I5
sg11
VEAAT4
p252
sg13
I1
sasg20
(lp253
(dp254
g7
I44
sg23
VC0014550
p255
sg10
I26
sg11
Vmyoclonic seizure disorder
p256
sg13
I3
sasa(dp257
g2
S'Integrating human genetic data with proteomic data showed that Arc-PSD95 complexes are enriched in schizophrenia, intellectual disability, autism, and epilepsy mutations and normal variants in intelligence.\n'
p258
sg4
(lp259
(dp260
g7
I67
sg8
VP78352
p261
sg10
I5
sg11
VPSD95
p262
sg13
I1
sa(dp263
g7
I63
sg8
g18
sg10
I3
sg11
VArc
p264
sg13
I1
sasg20
(lp265
(dp266
g7
I139
sg23
VC0004352
p267
sg10
I6
sg11
Vautism
p268
sg13
I1
sa(dp269
g7
I114
sg23
VC0025362
p270
sg10
I23
sg11
Vintellectual disability
p271
sg13
I2
sa(dp272
g7
I151
sg23
VC0014544
p273
sg10
I8
sg11
Vepilepsy
p274
sg13
I1
sa(dp275
g7
I63
sg23
VC0001857
p276
sg10
I3
sg11
VArc
p277
sg13
I1
sa(dp278
g7
I99
sg23
VC0036341
p279
sg10
I13
sg11
Vschizophrenia
p280
sg13
I1
sasa(dp281
g2
S"Phosphodiesterase-2A (PDE2A) is a potential therapeutic target for treatment of Alzheimer's disease and pulmonary hypertension.\n"
p282
sg4
(lp283
(dp284
g7
I22
sg8
g18
sg10
I5
sg11
VPDE2A
p285
sg13
I1
sa(dp286
g7
I0
sg8
VP22413
p287
sg10
I20
sg11
VPhosphodiesterase-2A
p288
sg13
I1
sasg20
(lp289
(dp290
g7
I104
sg23
VC0020542
p291
sg10
I22
sg11
Vpulmonary hypertension
p292
sg13
I2
sa(dp293
g7
I80
sg23
VC1521724
p294
sg10
I19
sg11
VAlzheimer's disease
p295
sg13
I2
sasa(dp296
g2
S"We propose that transaortic gradient indirectly calculated by using the simplified Gorlin's equation could be an alternative method to assess the severity of aortic stenosis.\n"
p297
sg4
(lp298
sg20
(lp299
(dp300
g7
I158
sg23
VC0003507
p301
sg10
I15
sg11
Vaortic stenosis
p302
sg13
I2
sasa(dp303
g2
S'In studying PWS-iPSCs and human parthenogenetic iPSCs, we unexpectedly found substantial upregulation of virtually all maternally expressed genes (MEGs) in the imprinted DLK1-DIO3 locus on chromosome 14.\n'
p304
sg4
(lp305
(dp306
g7
I170
sg8
VP80370
p307
sg10
I15
sg11
VDLK1-DIO3 locus
p308
sg13
I2
sasg20
(lp309
(dp310
g7
I12
sg23
VC0032897
p311
sg10
I3
sg11
VPWS
p312
sg13
I1
sasa(dp313
g2
S'Subsequently, we determined that IPW, a long noncoding RNA in the critical region of the PWS locus, is a regulator of the DLK1-DIO3 region, as its overexpression in PWS and parthenogenetic iPSCs resulted in downregulation of MEGs in this locus.\n'
p314
sg4
(lp315
(dp316
g7
I225
sg8
VP29074
p317
sg10
I4
sg11
VMEGs
p318
sg13
I1
sa(dp319
g7
I89
sg8
g18
sg10
I9
sg11
VPWS locus
p320
sg13
I2
sa(dp321
g7
I122
sg8
VP80370
p322
sg10
I16
sg11
VDLK1-DIO3 region
p323
sg13
I2
sasg20
(lp324
(dp325
g7
I89
sg23
VC0032897
p326
sg10
I3
sg11
VPWS
p327
sg13
I1
sa(dp328
g7
I89
sg23
VC0032897
p329
sg10
I3
sg11
VPWS
p330
sg13
I1
sasa(dp331
g2
S'The imprinted Dlk1-Gtl2 and Prader-Willi syndrome (PWS) regions are characterized by a complex noncoding transcription unit spanning arrays of tandemly repeated C/D RNA genes.\n'
p332
sg4
(lp333
(dp334
g7
I14
sg8
VP80370
p335
sg10
I9
sg11
VDlk1-Gtl2
p336
sg13
I1
sa(dp337
g7
I161
sg8
VP01893
p338
sg10
I13
sg11
VC/D RNA genes
p339
sg13
I3
sasg20
(lp340
(dp341
g7
I51
sg23
VC0032897
p342
sg10
I3
sg11
VPWS
p343
sg13
I1
sa(dp344
g7
I28
sg23
VC0032897
p345
sg10
I21
sg11
VPrader-Willi syndrome
p346
sg13
I2
sasa(dp347
g2
S'Twenty-two HCCs in 19 patients that were difficult to demonstrate on ultrasound (mean tumor diameter was 17.5 mm) were treated with CT-guided RF ablation by caudal-cranial oblique insertion to avoid pneumothorax, using MPR images after transcatheter arterial chemoembolization.\n'
p348
sg4
(lp349
sg20
(lp350
(dp351
g7
I199
sg23
VC0032326
p352
sg10
I12
sg11
Vpneumothorax
p353
sg13
I1
sa(dp354
g7
I86
sg23
VC0027651
p355
sg10
I5
sg11
Vtumor
p356
sg13
I1
sasa(dp357
g2
S'Compared with the conventional procedure, the use of MPR images does not increase the rate of pneumothorax or the procedure time.\n'
p358
sg4
(lp359
sg20
(lp360
(dp361
g7
I94
sg23
VC0032326
p362
sg10
I12
sg11
Vpneumothorax
p363
sg13
I1
sasa(dp364
g2
S'To evaluate the utility of multiplanar reconstruction (MPR) image for CT-guided biopsy and determine factors of influencing diagnostic accuracy and the pneumothorax rate.\n'
p365
sg4
(lp366
sg20
(lp367
(dp368
g7
I152
sg23
VC0032326
p369
sg10
I12
sg11
Vpneumothorax
p370
sg13
I1
sasa(dp371
g2
S'The use of MPR for CT-guided lung biopsy is useful for improving diagnostic accuracy with no significant increase in pneumothorax rate or total procedure time.\n'
p372
sg4
(lp373
sg20
(lp374
(dp375
g7
I117
sg23
VC0032326
p376
sg10
I12
sg11
Vpneumothorax
p377
sg13
I1
sasa(dp378
g2
S'Blocking interactions between NKp46 and its ligand protects mice from STZ-induced diabetes, but differential expression non-diabetic and diabetic donor samples have not been tested.\n'
p379
sg4
(lp380
(dp381
g7
I30
sg8
g18
sg10
I5
sg11
VNKp46
p382
sg13
I1
sasg20
(lp383
(dp384
g7
I82
sg23
VC0011849
p385
sg10
I8
sg11
Vdiabetes
p386
sg13
I1
sa(dp387
g7
I0
sg23
VC0233660
p388
sg10
I8
sg11
VBlocking
p389
sg13
I1
sasa(dp390
g2
S'Obesity drove the upregulation of ligands of the NK cell-activating receptor NCR1 on adipocytes; this stimulated NK cell proliferation and interferon-Gamma (IFN-Gamma) production, which in turn triggered the differentiation of proinflammatory macrophages and promoted insulin resistance.\n'
p391
sg4
(lp392
(dp393
g7
I157
sg8
VP01579
p394
sg10
I9
sg11
VIFN-Gamma
p395
sg13
I1
sa(dp396
g7
I268
sg8
VP01308
p397
sg10
I7
sg11
Vinsulin
p398
sg13
I1
sa(dp399
g7
I49
sg8
g18
sg10
I32
sg11
VNK cell-activating receptor NCR1
p400
sg13
I4
sa(dp401
g7
I139
sg8
VP01579
p402
sg10
I16
sg11
Vinterferon-Gamma
p403
sg13
I1
sasg20
(lp404
(dp405
g7
I0
sg23
VC0028754
p406
sg10
I7
sg11
VObesity
p407
sg13
I1
sa(dp408
g7
I121
sg23
VC0334094
p409
sg10
I13
sg11
Vproliferation
p410
sg13
I1
sa(dp411
g7
I268
sg23
VC0021655
p412
sg10
I18
sg11
Vinsulin resistance
p413
sg13
I2
sasa(dp414
g2
S'We previously reported that the NKp46 receptor is involved in the development of type 1 diabetes (T1D).\n'
p415
sg4
(lp416
(dp417
g7
I32
sg8
g18
sg10
I14
sg11
VNKp46 receptor
p418
sg13
I2
sasg20
(lp419
(dp420
g7
I81
sg23
VC0011854
p421
sg10
I15
sg11
Vtype 1 diabetes
p422
sg13
I3
sa(dp423
g7
I98
sg23
VC0011854
p424
sg10
I3
sg11
VT1D
p425
sg13
I1
sasa(dp426
g2
S'In the present study, we evaluated the expression and clinical significance of CCR6, CCR7, their ligands and CD4+CD25+Foxp3+ regulatory T cells in laryngeal squamous cell carcinoma (LSCC) and metastatic lymph nodes (LNs).\n'
p427
sg4
(lp428
(dp429
g7
I109
sg8
VP01730
p430
sg10
I15
sg11
VCD4+CD25+Foxp3+
p431
sg13
I1
sa(dp432
g7
I79
sg8
VP51684
p433
sg10
I4
sg11
VCCR6
p434
sg13
I1
sa(dp435
g7
I85
sg8
VP32248
p436
sg10
I4
sg11
VCCR7
p437
sg13
I1
sasg20
(lp438
(dp439
g7
I216
sg23
VC0023374
p440
sg10
I3
sg11
VLNs
p441
sg13
I1
sa(dp442
g7
I147
sg23
VC0280324
p443
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p444
sg13
I4
sa(dp445
g7
I182
sg23
VC0280324
p446
sg10
I4
sg11
VLSCC
p447
sg13
I1
sa(dp448
g7
I203
sg23
VC0023374
p449
sg10
I11
sg11
Vlymph nodes
p450
sg13
I2
sasa(dp451
g2
S'It was hypothesized that the expression profile of CCR6, CCR7 and the proliferation of CD4+CD25+Foxp3+ Tregs affected the process of LN metastasis in LSCC patients.\n'
p452
sg4
(lp453
(dp454
g7
I87
sg8
VP01730
p455
sg10
I15
sg11
VCD4+CD25+Foxp3+
p456
sg13
I1
sa(dp457
g7
I57
sg8
VP32248
p458
sg10
I4
sg11
VCCR7
p459
sg13
I1
sa(dp460
g7
I51
sg8
VP51684
p461
sg10
I4
sg11
VCCR6
p462
sg13
I1
sasg20
(lp463
(dp464
g7
I136
sg23
VC0027627
p465
sg10
I10
sg11
Vmetastasis
p466
sg13
I1
sa(dp467
g7
I70
sg23
VC0334094
p468
sg10
I13
sg11
Vproliferation
p469
sg13
I1
sasa(dp470
g2
S'To evaluate the expressions of chemokine receptor 6 (CCR6), chemokine receptor 7 (CCR7) and their ligands (CCL20, CCL19/CCL21) in laryngeal squamous cell carcinoma (LSCC), and then explore their correlation with the clinicopathological features of LSCC.\n'
p471
sg4
(lp472
(dp473
g7
I31
sg8
g18
sg10
I49
sg11
Vchemokine receptor 6 (CCR6), chemokine receptor 7
p474
sg13
I7
sa(dp475
g7
I82
sg8
VP32248
p476
sg10
I4
sg11
VCCR7
p477
sg13
I1
sa(dp478
g7
I114
sg8
g18
sg10
I5
sg11
VCCL19
p479
sg13
I1
sa(dp480
g7
I120
sg8
g18
sg10
I5
sg11
VCCL21
p481
sg13
I1
sa(dp482
g7
I107
sg8
VP78556
p483
sg10
I5
sg11
VCCL20
p484
sg13
I1
sasg20
(lp485
(dp486
g7
I130
sg23
VC0280324
p487
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p488
sg13
I4
sa(dp489
g7
I165
sg23
VC0280324
p490
sg10
I4
sg11
VLSCC
p491
sg13
I1
sa(dp492
g7
I165
sg23
VC0280324
p493
sg10
I4
sg11
VLSCC
p494
sg13
I1
sasa(dp495
g2
S'FCM showed the percentage of CD4+ CCR6+ T cells of LSCC was significantly higher than that of normal control (P &lt; 0.05), while that of CD4+ CCR7+ T cells was significantly lower (P &lt; 0.05).\n'
p496
sg4
(lp497
(dp498
g7
I29
sg8
VP01730
p499
sg10
I4
sg11
VCD4+
p500
sg13
I1
sa(dp501
g7
I29
sg8
VP01730
p502
sg10
I4
sg11
VCD4+
p503
sg13
I1
sasg20
(lp504
sa(dp505
g2
S'CCR6 and CCR7 are expressed in tumor situ, metastatic LN and PBMC,and might exert a potential role in LSCC development.\n'
p506
sg4
(lp507
(dp508
g7
I0
sg8
VP51684
p509
sg10
I4
sg11
VCCR6
p510
sg13
I1
sa(dp511
g7
I9
sg8
VP32248
p512
sg10
I4
sg11
VCCR7
p513
sg13
I1
sasg20
(lp514
(dp515
g7
I31
sg23
VC0027651
p516
sg10
I5
sg11
Vtumor
p517
sg13
I1
sasa(dp518
g2
S'To evaluate the expressions and clinical significance of chemokine receptor 6 (CCR6), chemokine receptor 7(CCR7) and CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) in laryngeal squamous cell carcinoma (LSCC) and metastatic lymph nodes.\n'
p519
sg4
(lp520
(dp521
g7
I57
sg8
g18
sg10
I49
sg11
Vchemokine receptor 6 (CCR6), chemokine receptor 7
p522
sg13
I7
sa(dp523
g7
I107
sg8
VP32248
p524
sg10
I4
sg11
VCCR7
p525
sg13
I1
sa(dp526
g7
I117
sg8
VP01730
p527
sg10
I10
sg11
VCD4(+)CD25
p528
sg13
I1
sasg20
(lp529
(dp530
g7
I203
sg23
VC0280324
p531
sg10
I4
sg11
VLSCC
p532
sg13
I1
sa(dp533
g7
I168
sg23
VC0280324
p534
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p535
sg13
I4
sasa(dp536
g2
S'CCR6, CCR7 and Treg could take part in the process of lymph node metastasis in LSCC patients.\n'
p537
sg4
(lp538
(dp539
g7
I0
sg8
VP51684
p540
sg10
I4
sg11
VCCR6
p541
sg13
I1
sa(dp542
g7
I6
sg8
VP32248
p543
sg10
I4
sg11
VCCR7
p544
sg13
I1
sasg20
(lp545
(dp546
g7
I54
sg23
VC0686619
p547
sg10
I21
sg11
Vlymph node metastasis
p548
sg13
I3
sasa(dp549
g2
S'This study was designed to observe the expression of CXCR4 and CCR7 in laryngeal carcinoma tissues in order to primitively clarify the relationship between Chemokine Receptor CCR7 and CXCR4 and the malignity of laryngeal carcinoma.\n'
p550
sg4
(lp551
(dp552
g7
I53
sg8
VP61073
p553
sg10
I5
sg11
VCXCR4
p554
sg13
I1
sa(dp555
g7
I53
sg8
VP61073
p556
sg10
I5
sg11
VCXCR4
p557
sg13
I1
sa(dp558
g7
I156
sg8
VP61073
p559
sg10
I18
sg11
VChemokine Receptor
p560
sg13
I2
sa(dp561
g7
I63
sg8
VP32248
p562
sg10
I4
sg11
VCCR7
p563
sg13
I1
sa(dp564
g7
I63
sg8
VP32248
p565
sg10
I4
sg11
VCCR7
p566
sg13
I1
sasg20
(lp567
(dp568
g7
I71
sg23
VC0595989
p569
sg10
I19
sg11
Vlaryngeal carcinoma
p570
sg13
I2
sa(dp571
g7
I71
sg23
VC0595989
p572
sg10
I19
sg11
Vlaryngeal carcinoma
p573
sg13
I2
sasa(dp574
g2
S'We examined the expression of Chemokine Receptor CXCR4 and CCR7 in 30 cases laryngeal carcinoma tissues (experiment group) and 18 cases normal laryngeal tissues (control group)with immunohistochemistry.\n'
p575
sg4
(lp576
(dp577
g7
I59
sg8
VP32248
p578
sg10
I4
sg11
VCCR7
p579
sg13
I1
sa(dp580
g7
I30
sg8
VP61073
p581
sg10
I18
sg11
VChemokine Receptor
p582
sg13
I2
sa(dp583
g7
I49
sg8
VP61073
p584
sg10
I5
sg11
VCXCR4
p585
sg13
I1
sasg20
(lp586
(dp587
g7
I76
sg23
VC0595989
p588
sg10
I19
sg11
Vlaryngeal carcinoma
p589
sg13
I2
sasa(dp590
g2
S'(1) Chemokine Receptor CXCR4 and CCR7 were positively expressed in laryngeal carcinoma tissues while they were negative in the control group.\n'
p591
sg4
(lp592
(dp593
g7
I33
sg8
VP32248
p594
sg10
I4
sg11
VCCR7
p595
sg13
I1
sa(dp596
g7
I23
sg8
VP61073
p597
sg10
I5
sg11
VCXCR4
p598
sg13
I1
sasg20
(lp599
(dp600
g7
I67
sg23
VC0595989
p601
sg10
I19
sg11
Vlaryngeal carcinoma
p602
sg13
I2
sasa(dp603
g2
S'; (2) Chemokine Receptor CXCR4 and CCR7 expression in laryngeal carcinoma declined with the rise of the differentiation grade of laryngeal carcinoma (P &lt; 0.05).\n'
p604
sg4
(lp605
(dp606
g7
I25
sg8
VP61073
p607
sg10
I5
sg11
VCXCR4
p608
sg13
I1
sa(dp609
g7
I35
sg8
VP32248
p610
sg10
I4
sg11
VCCR7
p611
sg13
I1
sasg20
(lp612
(dp613
g7
I54
sg23
VC0595989
p614
sg10
I19
sg11
Vlaryngeal carcinoma
p615
sg13
I2
sa(dp616
g7
I54
sg23
VC0595989
p617
sg10
I19
sg11
Vlaryngeal carcinoma
p618
sg13
I2
sasa(dp619
g2
S'Chemokine Receptor CXCR4 and CCR7 are highly expressed in laryngeal carcinoma, and their expression were associated with differentiation grade of laryngeal carcinoma, clinical stage and neck lymph node metastasis.\n'
p620
sg4
(lp621
(dp622
g7
I29
sg8
VP32248
p623
sg10
I4
sg11
VCCR7
p624
sg13
I1
sa(dp625
g7
I0
sg8
VP61073
p626
sg10
I18
sg11
VChemokine Receptor
p627
sg13
I2
sa(dp628
g7
I19
sg8
VP61073
p629
sg10
I5
sg11
VCXCR4
p630
sg13
I1
sasg20
(lp631
(dp632
g7
I191
sg23
VC0686619
p633
sg10
I21
sg11
Vlymph node metastasis
p634
sg13
I3
sa(dp635
g7
I58
sg23
VC0595989
p636
sg10
I19
sg11
Vlaryngeal carcinoma
p637
sg13
I2
sa(dp638
g7
I58
sg23
VC0595989
p639
sg10
I19
sg11
Vlaryngeal carcinoma
p640
sg13
I2
sasa(dp641
g2
S'Mutations in a number of genes encoding transcription factors - such as HESX1, SOX2, SOX3, LHX3, LHX4, PROP1, POU1F1, PITX, GLI3, GLI2, OTX2, ARNT2, IGSF1, FGF8, FGFR1, PROKR2, PROK2, CHD7, WDR11, NFKB2, PAX6, TCF7L1, IFT72, GPR161 and CDON - have been associated with pituitary dysfunction and abnormal pituitary gland development; the correlation of genetic mutations to endocrine and MRI phenotypes has improved our knowledge of pituitary development and management of patients with hypopituitarism, both in terms of possible genetic counseling, and of early diagnosis of evolving anterior pituitary hormone deficiencies.\n'
p642
sg4
(lp643
(dp644
g7
I204
sg8
VP26367
p645
sg10
I4
sg11
VPAX6
p646
sg13
I1
sa(dp647
g7
I79
sg8
VP48431
p648
sg10
I4
sg11
VSOX2
p649
sg13
I1
sa(dp650
g7
I149
sg8
g18
sg10
I5
sg11
VIGSF1
p651
sg13
I1
sa(dp652
g7
I110
sg8
VP28069
p653
sg10
I6
sg11
VPOU1F1
p654
sg13
I1
sa(dp655
g7
I162
sg8
VP20930
p656
sg10
I5
sg11
VFGFR1
p657
sg13
I1
sa(dp658
g7
I197
sg8
g18
sg10
I5
sg11
VNFKB2
p659
sg13
I1
sa(dp660
g7
I97
sg8
g18
sg10
I4
sg11
VLHX4
p661
sg13
I1
sa(dp662
g7
I142
sg8
g18
sg10
I5
sg11
VARNT2
p663
sg13
I1
sa(dp664
g7
I169
sg8
g18
sg10
I6
sg11
VPROKR2
p665
sg13
I1
sa(dp666
g7
I593
sg8
VP18509
p667
sg10
I17
sg11
Vpituitary hormone
p668
sg13
I2
sa(dp669
g7
I210
sg8
g18
sg10
I6
sg11
VTCF7L1
p670
sg13
I1
sa(dp671
g7
I72
sg8
g18
sg10
I5
sg11
VHESX1
p672
sg13
I1
sa(dp673
g7
I91
sg8
g18
sg10
I4
sg11
VLHX3
p674
sg13
I1
sa(dp675
g7
I124
sg8
VP10071
p676
sg10
I4
sg11
VGLI3
p677
sg13
I1
sa(dp678
g7
I156
sg8
VP55075
p679
sg10
I4
sg11
VFGF8
p680
sg13
I1
sa(dp681
g7
I85
sg8
VP41225
p682
sg10
I4
sg11
VSOX3
p683
sg13
I1
sa(dp684
g7
I136
sg8
VP32243
p685
sg10
I4
sg11
VOTX2
p686
sg13
I1
sa(dp687
g7
I225
sg8
g18
sg10
I6
sg11
VGPR161
p688
sg13
I1
sa(dp689
g7
I236
sg8
g18
sg10
I4
sg11
VCDON
p690
sg13
I1
sa(dp691
g7
I177
sg8
g18
sg10
I5
sg11
VPROK2
p692
sg13
I1
sa(dp693
g7
I184
sg8
g18
sg10
I4
sg11
VCHD7
p694
sg13
I1
sa(dp695
g7
I103
sg8
g18
sg10
I5
sg11
VPROP1
p696
sg13
I1
sa(dp697
g7
I130
sg8
VP10070
p698
sg10
I4
sg11
VGLI2
p699
sg13
I1
sa(dp700
g7
I190
sg8
g18
sg10
I5
sg11
VWDR11
p701
sg13
I1
sasg20
(lp702
(dp703
g7
I486
sg23
VC0020635
p704
sg10
I15
sg11
Vhypopituitarism
p705
sg13
I1
sa(dp706
g7
I269
sg23
VC0281947
p707
sg10
I21
sg11
Vpituitary dysfunction
p708
sg13
I2
sasa(dp709
g2
S'Mutations in the GH1 and GHRHR genes shed light on the phenotype and pathogenesis of IGHD whereas mutations in transcription factors such as HESX1, PROP1, POU1F1, LHX3, LHX4, GLI2 and SOX3 contributed to the understanding of CPHD.\n'
p710
sg4
(lp711
(dp712
g7
I17
sg8
VP01242
p713
sg10
I3
sg11
VGH1
p714
sg13
I1
sa(dp715
g7
I163
sg8
g18
sg10
I4
sg11
VLHX3
p716
sg13
I1
sa(dp717
g7
I141
sg8
g18
sg10
I5
sg11
VHESX1
p718
sg13
I1
sa(dp719
g7
I85
sg8
VP01880
p720
sg10
I4
sg11
VIGHD
p721
sg13
I1
sa(dp722
g7
I25
sg8
g18
sg10
I11
sg11
VGHRHR genes
p723
sg13
I2
sa(dp724
g7
I148
sg8
g18
sg10
I5
sg11
VPROP1
p725
sg13
I1
sa(dp726
g7
I175
sg8
VP10070
p727
sg10
I4
sg11
VGLI2
p728
sg13
I1
sa(dp729
g7
I155
sg8
VP28069
p730
sg10
I6
sg11
VPOU1F1
p731
sg13
I1
sa(dp732
g7
I184
sg8
VP41225
p733
sg10
I4
sg11
VSOX3
p734
sg13
I1
sa(dp735
g7
I169
sg8
g18
sg10
I4
sg11
VLHX4
p736
sg13
I1
sasg20
(lp737
(dp738
g7
I69
sg23
VC0699748
p739
sg10
I12
sg11
Vpathogenesis
p740
sg13
I1
sasa(dp741
g2
S'In humans, only 13 heterozygous LHX4 mutations have been associated with congenital hypopituitarism.\n'
p742
sg4
(lp743
(dp744
g7
I32
sg8
g18
sg10
I14
sg11
VLHX4 mutations
p745
sg13
I2
sasg20
(lp746
(dp747
g7
I84
sg23
VC0020635
p748
sg10
I15
sg11
Vhypopituitarism
p749
sg13
I1
sasa(dp750
g2
S'The aims of this study were to evaluate the prevalence of LHX4 mutations in patients with hypopituitarism, to define the associated phenotypes, and to characterize the functional impact of the identified variants and the respective role of the 2 LIM domains of LHX4.\n'
p751
sg4
(lp752
(dp753
g7
I246
sg8
g18
sg10
I3
sg11
VLIM
p754
sg13
I1
sa(dp755
g7
I58
sg8
g18
sg10
I4
sg11
VLHX4
p756
sg13
I1
sa(dp757
g7
I58
sg8
g18
sg10
I4
sg11
VLHX4
p758
sg13
I1
sasg20
(lp759
(dp760
g7
I90
sg23
VC0020635
p761
sg10
I15
sg11
Vhypopituitarism
p762
sg13
I1
sasa(dp763
g2
S'We screened 417 unrelated patients with isolated growth hormone deficiency or combined pituitary hormone deficiency associated with ectopic posterior pituitary and/or sella turcica anomalies for LHX4 mutations (Sanger sequencing).\n'
p764
sg4
(lp765
(dp766
g7
I78
sg8
VP18509
p767
sg10
I26
sg11
Vcombined pituitary hormone
p768
sg13
I3
sa(dp769
g7
I49
sg8
VP01242
p770
sg10
I14
sg11
Vgrowth hormone
p771
sg13
I2
sa(dp772
g7
I195
sg8
g18
sg10
I4
sg11
VLHX4
p773
sg13
I1
sasg20
(lp774
(dp775
g7
I40
sg23
VC0271563
p776
sg10
I34
sg11
Visolated growth hormone deficiency
p777
sg13
I4
sa(dp778
g7
I56
sg23
VC0599750
p779
sg10
I18
sg11
Vhormone deficiency
p780
sg13
I2
sasa(dp781
g2
S'This study, performed in the largest cohort of patients screened so far for LHX4 mutations, describes 6 disease-causing mutations that are responsible for congenital hypopituitarism.\n'
p782
sg4
(lp783
(dp784
g7
I76
sg8
g18
sg10
I4
sg11
VLHX4
p785
sg13
I1
sasg20
(lp786
(dp787
g7
I166
sg23
VC0020635
p788
sg10
I15
sg11
Vhypopituitarism
p789
sg13
I1
sasa(dp790
g2
S'In a subset of 50 patients, re-assessment in adulthood was performed, including GHRH-arginine testing, pituitary magnetic resonance imaging (MRI), and mutational screening for the growth hormone-1 gene (GH1) and the GHRH receptor gene (GHRHR) in isolated GHD (IGHD), and HESX1, PROP1, POU1F1, LHX3, LHX4, and GLI2 in multiple pituitary hormone deficiency (MPHD) patients.\n'
p791
sg4
(lp792
(dp793
g7
I271
sg8
g18
sg10
I5
sg11
VHESX1
p794
sg13
I1
sa(dp795
g7
I180
sg8
VP01242
p796
sg10
I21
sg11
Vgrowth hormone-1 gene
p797
sg13
I3
sa(dp798
g7
I236
sg8
g18
sg10
I5
sg11
VGHRHR
p799
sg13
I1
sa(dp800
g7
I216
sg8
g18
sg10
I18
sg11
VGHRH receptor gene
p801
sg13
I3
sa(dp802
g7
I309
sg8
VP10070
p803
sg10
I4
sg11
VGLI2
p804
sg13
I1
sa(dp805
g7
I278
sg8
g18
sg10
I5
sg11
VPROP1
p806
sg13
I1
sa(dp807
g7
I285
sg8
VP28069
p808
sg10
I6
sg11
VPOU1F1
p809
sg13
I1
sa(dp810
g7
I299
sg8
g18
sg10
I4
sg11
VLHX4
p811
sg13
I1
sa(dp812
g7
I326
sg8
VP18509
p813
sg10
I17
sg11
Vpituitary hormone
p814
sg13
I2
sa(dp815
g7
I203
sg8
VP01242
p816
sg10
I3
sg11
VGH1
p817
sg13
I1
sa(dp818
g7
I293
sg8
g18
sg10
I4
sg11
VLHX3
p819
sg13
I1
sa(dp820
g7
I80
sg8
VP01286
p821
sg10
I4
sg11
VGHRH
p822
sg13
I1
sasg20
(lp823
(dp824
g7
I336
sg23
VC0599750
p825
sg10
I18
sg11
Vhormone deficiency
p826
sg13
I2
sa(dp827
g7
I255
sg23
VC0271561
p828
sg10
I3
sg11
VGHD
p829
sg13
I1
sasa(dp830
g2
S'LHX4 mutations are rare in combined pituitary hormone deficiency, and even rarer in isolated GHD.\n'
p831
sg4
(lp832
(dp833
g7
I0
sg8
g18
sg10
I4
sg11
VLHX4
p834
sg13
I1
sa(dp835
g7
I27
sg8
VP18509
p836
sg10
I26
sg11
Vcombined pituitary hormone
p837
sg13
I3
sasg20
(lp838
(dp839
g7
I46
sg23
VC0599750
p840
sg10
I18
sg11
Vhormone deficiency
p841
sg13
I2
sa(dp842
g7
I93
sg23
VC0271561
p843
sg10
I3
sg11
VGHD
p844
sg13
I1
sasa(dp845
g2
S'Furthermore, the reduction of body weight, using low-calorie diet combined with exercise, reduces the severity of psoriasis.Visceral adipose tissue is the largest endocrine organ, producing proinflammatory cytokines (TNF-Alfa, IL-6, IL-17) and adipokines (adiponectin, omentin, chemerin).\n'
p846
sg4
(lp847
(dp848
g7
I256
sg8
g18
sg10
I11
sg11
Vadiponectin
p849
sg13
I1
sa(dp850
g7
I227
sg8
VP05231
p851
sg10
I4
sg11
VIL-6
p852
sg13
I1
sa(dp853
g7
I217
sg8
VP01375
p854
sg10
I8
sg11
VTNF-Alfa
p855
sg13
I1
sa(dp856
g7
I269
sg8
g18
sg10
I7
sg11
Vomentin
p857
sg13
I1
sa(dp858
g7
I278
sg8
g18
sg10
I8
sg11
Vchemerin
p859
sg13
I1
sasg20
(lp860
(dp861
g7
I114
sg23
VC0033860
p862
sg10
I9
sg11
Vpsoriasis
p863
sg13
I1
sasa(dp864
g2
S'It has been shown that systemic treatment of psoriasis leads to an improvement in cardiovascular-associated biomarkers, eg adiponectin levels.\n'
p865
sg4
(lp866
(dp867
g7
I123
sg8
g18
sg10
I11
sg11
Vadiponectin
p868
sg13
I1
sasg20
(lp869
(dp870
g7
I45
sg23
VC0033860
p871
sg10
I9
sg11
Vpsoriasis
p872
sg13
I1
sasa(dp873
g2
S'In conclusion, observed inflammatory and anti-inflammatory markers (CRP, adiponectin, leptin, resistin, and Lp-PLA2) are involved in both pathogenesis of MS and pathogenesis of psoriasis.\n'
p874
sg4
(lp875
(dp876
g7
I73
sg8
g18
sg10
I11
sg11
Vadiponectin
p877
sg13
I1
sa(dp878
g7
I86
sg8
VP41159
p879
sg10
I6
sg11
Vleptin
p880
sg13
I1
sa(dp881
g7
I108
sg8
VP04054
p882
sg10
I7
sg11
VLp-PLA2
p883
sg13
I1
sa(dp884
g7
I68
sg8
VP02741
p885
sg10
I3
sg11
VCRP
p886
sg13
I1
sasg20
(lp887
(dp888
g7
I138
sg23
VC0699748
p889
sg10
I12
sg11
Vpathogenesis
p890
sg13
I1
sa(dp891
g7
I138
sg23
VC0699748
p892
sg10
I12
sg11
Vpathogenesis
p893
sg13
I1
sa(dp894
g7
I177
sg23
VC0033860
p895
sg10
I9
sg11
Vpsoriasis
p896
sg13
I1
sasa(dp897
g2
S'In this study we assessed the adipose tissue cytokines visfatin, adiponectin, and tumor necrosis factor-Alfa (TNF-Alfa) levels in psoriasis patients and evaluated the relationship between disease severity and cytokines.\n'
p898
sg4
(lp899
(dp900
g7
I30
sg8
VP43490
p901
sg10
I33
sg11
Vadipose tissue cytokines visfatin
p902
sg13
I4
sa(dp903
g7
I65
sg8
g18
sg10
I11
sg11
Vadiponectin
p904
sg13
I1
sa(dp905
g7
I82
sg8
VP01375
p906
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p907
sg13
I3
sa(dp908
g7
I110
sg8
VP01375
p909
sg10
I8
sg11
VTNF-Alfa
p910
sg13
I1
sasg20
(lp911
(dp912
g7
I130
sg23
VC0033860
p913
sg10
I9
sg11
Vpsoriasis
p914
sg13
I1
sa(dp915
g7
I82
sg23
VC0333516
p916
sg10
I14
sg11
Vtumor necrosis
p917
sg13
I2
sasa(dp918
g2
S'Visfatin, adiponectin, and TNF-Alfa levels were measured in both the psoriasis and the control group.\n'
p919
sg4
(lp920
(dp921
g7
I0
sg8
VP43490
p922
sg10
I8
sg11
VVisfatin
p923
sg13
I1
sa(dp924
g7
I10
sg8
g18
sg10
I11
sg11
Vadiponectin
p925
sg13
I1
sa(dp926
g7
I27
sg8
VP01375
p927
sg10
I8
sg11
VTNF-Alfa
p928
sg13
I1
sasg20
(lp929
(dp930
g7
I69
sg23
VC0033860
p931
sg10
I9
sg11
Vpsoriasis
p932
sg13
I1
sasa(dp933
g2
S'These results indicate that TNF-Alfa and adiponectin play a part in psoriasis etiopathogenesis and can be used as parameters to evaluate the severity of the disease.\n'
p934
sg4
(lp935
(dp936
g7
I41
sg8
g18
sg10
I11
sg11
Vadiponectin
p937
sg13
I1
sa(dp938
g7
I28
sg8
VP01375
p939
sg10
I3
sg11
VTNF
p940
sg13
I1
sasg20
(lp941
(dp942
g7
I68
sg23
VC0033860
p943
sg10
I9
sg11
Vpsoriasis
p944
sg13
I1
sasa(dp945
g2
S'The following parameters were assessed in both groups: serum fasting glucose, fasting insulin, homeostasis model assessment-estimated insulin resistance (HOMA-IR) index, serum lipids, adiponectin, leptin, resistin, chemerin, omentin, vaspin, visfatin, retinol-binding protein 4, and high-sensitivity C-reactive protein (hs-CRP) levels; blood pressure; body mass index; and the psoriasis area severity index (PASI) scores.\n'
p946
sg4
(lp947
(dp948
g7
I205
sg8
g18
sg10
I8
sg11
Vresistin
p949
sg13
I1
sa(dp950
g7
I283
sg8
VP02741
p951
sg10
I35
sg11
Vhigh-sensitivity C-reactive protein
p952
sg13
I3
sa(dp953
g7
I252
sg8
VP02753
p954
sg10
I25
sg11
Vretinol-binding protein 4
p955
sg13
I3
sa(dp956
g7
I215
sg8
g18
sg10
I8
sg11
Vchemerin
p957
sg13
I1
sa(dp958
g7
I184
sg8
g18
sg10
I11
sg11
Vadiponectin
p959
sg13
I1
sa(dp960
g7
I242
sg8
VP43490
p961
sg10
I8
sg11
Vvisfatin
p962
sg13
I1
sa(dp963
g7
I86
sg8
VP01308
p964
sg10
I7
sg11
Vinsulin
p965
sg13
I1
sa(dp966
g7
I197
sg8
VP41159
p967
sg10
I6
sg11
Vleptin
p968
sg13
I1
sa(dp969
g7
I225
sg8
g18
sg10
I7
sg11
Vomentin
p970
sg13
I1
sa(dp971
g7
I234
sg8
g18
sg10
I6
sg11
Vvaspin
p972
sg13
I1
sa(dp973
g7
I320
sg8
VP02741
p974
sg10
I6
sg11
Vhs-CRP
p975
sg13
I1
sasg20
(lp976
(dp977
g7
I377
sg23
VC0033860
p978
sg10
I9
sg11
Vpsoriasis
p979
sg13
I1
sa(dp980
g7
I134
sg23
VC0021655
p981
sg10
I18
sg11
Vinsulin resistance
p982
sg13
I2
sasa(dp983
g2
S'Moreover, at the start of the follow-up, the psoriasis patients had significantly lower levels of adiponectin and visfatin and significantly higher levels of vaspin and resistin than those of the control group.\n'
p984
sg4
(lp985
(dp986
g7
I114
sg8
VP43490
p987
sg10
I8
sg11
Vvisfatin
p988
sg13
I1
sa(dp989
g7
I98
sg8
g18
sg10
I11
sg11
Vadiponectin
p990
sg13
I1
sasg20
(lp991
(dp992
g7
I45
sg23
VC0033860
p993
sg10
I9
sg11
Vpsoriasis
p994
sg13
I1
sasa(dp995
g2
S'The aim of this study was to investigate the association between miR-1207-5p expression in peripheral blood and the chemosensitivity of primary gallbladder carcinoma (PGBC).\n'
p996
sg4
(lp997
(dp998
g7
I65
sg8
g18
sg10
I11
sg11
VmiR-1207-5p
p999
sg13
I1
sasg20
(lp1000
(dp1001
g7
I144
sg23
VC0235782
p1002
sg10
I21
sg11
Vgallbladder carcinoma
p1003
sg13
I2
sasa(dp1004
g2
S'An miR-1207-5p mimic (mimic group), an inhibitor (inhibitor group), and a negative control (NC group) sequence were transfected into human gallbladder carcinoma GBC-SD cells.\n'
p1005
sg4
(lp1006
(dp1007
g7
I3
sg8
g18
sg10
I11
sg11
VmiR-1207-5p
p1008
sg13
I1
sasg20
(lp1009
(dp1010
g7
I139
sg23
VC0235782
p1011
sg10
I21
sg11
Vgallbladder carcinoma
p1012
sg13
I2
sasa(dp1013
g2
S'We found that miRNA-1207-5p (miR-1207-5p) was markedly downregulated in esophageal carcinoma (EC) tissues, and was correlated with EC differentiation, pathological stage and lymph node metastasis.\n'
p1014
sg4
(lp1015
(dp1016
g7
I29
sg8
g18
sg10
I11
sg11
VmiR-1207-5p
p1017
sg13
I1
sa(dp1018
g7
I14
sg8
g18
sg10
I13
sg11
VmiRNA-1207-5p
p1019
sg13
I1
sasg20
(lp1020
(dp1021
g7
I94
sg23
VC0152018
p1022
sg10
I2
sg11
VEC
p1023
sg13
I1
sa(dp1024
g7
I174
sg23
VC0686619
p1025
sg10
I21
sg11
Vlymph node metastasis
p1026
sg13
I3
sa(dp1027
g7
I72
sg23
VC0152018
p1028
sg10
I20
sg11
Vesophageal carcinoma
p1029
sg13
I2
sa(dp1030
g7
I94
sg23
VC0152018
p1031
sg10
I2
sg11
VEC
p1032
sg13
I1
sasa(dp1033
g2
S'Immunohistological analyses reveal that RBM4 is expressed in the human brain regions affected in tauopathy, including the hippocampus and frontal cortex.\n'
p1034
sg4
(lp1035
(dp1036
g7
I40
sg8
g18
sg10
I4
sg11
VRBM4
p1037
sg13
I1
sasg20
(lp1038
(dp1039
g7
I97
sg23
VC0949664
p1040
sg10
I9
sg11
Vtauopathy
p1041
sg13
I1
sasa(dp1042
g2
S'Programmed cell death 1 ligand 1 expression was significantly correlated with increased incidence of lymphovascular invasion (P = .038), extrathyroidal extension (P = .026), and concurrent lymphocytic thyroiditis (P = .003).\n'
p1043
sg4
(lp1044
sg20
(lp1045
(dp1046
g7
I189
sg23
VC0920350
p1047
sg10
I23
sg11
Vlymphocytic thyroiditis
p1048
sg13
I2
sa(dp1049
g7
I116
sg23
VC2699153
p1050
sg10
I8
sg11
Vinvasion
p1051
sg13
I1
sasa(dp1052
g2
S'In this study, we investigated the role of PD-1 systemic engagement with PD-L1-Ig in lupus-like nephritis in SLE mice.\n'
p1053
sg4
(lp1054
(dp1055
g7
I43
sg8
VP18621
p1056
sg10
I4
sg11
VPD-1
p1057
sg13
I1
sasg20
(lp1058
(dp1059
g7
I109
sg23
VC0014060
p1060
sg10
I3
sg11
VSLE
p1061
sg13
I1
sa(dp1062
g7
I85
sg23
VC0024131
p1063
sg10
I5
sg11
Vlupus
p1064
sg13
I1
sa(dp1065
g7
I96
sg23
VC0027697
p1066
sg10
I9
sg11
Vnephritis
p1067
sg13
I1
sasa(dp1068
g2
S'Our research demonstrated that the protective function of systemic activation of PD-1-PD-L1 axis with PD-L1-Ig attenuates the nephritis in SLE-prone mice, which facilitates us to understand the suppressive function of PD-1-PD-L1 axis in the pathogenesis and progress of the lupus nephritis, and to explore a possible effective therapeutic strategy to SLE.\n'
p1069
sg4
(lp1070
(dp1071
g7
I81
sg8
VP18621
p1072
sg10
I4
sg11
VPD-1
p1073
sg13
I1
sa(dp1074
g7
I81
sg8
VP18621
p1075
sg10
I10
sg11
VPD-1-PD-L1
p1076
sg13
I1
sasg20
(lp1077
(dp1078
g7
I139
sg23
VC0014060
p1079
sg10
I3
sg11
VSLE
p1080
sg13
I1
sa(dp1081
g7
I139
sg23
VC0014060
p1082
sg10
I3
sg11
VSLE
p1083
sg13
I1
sa(dp1084
g7
I274
sg23
VC0024143
p1085
sg10
I15
sg11
Vlupus nephritis
p1086
sg13
I2
sa(dp1087
g7
I126
sg23
VC0027697
p1088
sg10
I9
sg11
Vnephritis
p1089
sg13
I1
sa(dp1090
g7
I241
sg23
VC0699748
p1091
sg10
I12
sg11
Vpathogenesis
p1092
sg13
I1
sasa(dp1093
g2
S'PD-L1 was positively expressed in 53.2% PTCs, and its expression was positively correlated with rich tumor-infiltrating lymphocytes (TILs), background chronic lymphocytic thyroiditis (CLT), female gender, absence of psammoma bodies, and PD-1 expression.\n'
p1094
sg4
(lp1095
(dp1096
g7
I133
sg8
VP01765
p1097
sg10
I4
sg11
VTILs
p1098
sg13
I1
sa(dp1099
g7
I101
sg8
VP01765
p1100
sg10
I30
sg11
Vtumor-infiltrating lymphocytes
p1101
sg13
I2
sa(dp1102
g7
I237
sg8
VP18621
p1103
sg10
I4
sg11
VPD-1
p1104
sg13
I1
sasg20
(lp1105
(dp1106
g7
I101
sg23
VC0027651
p1107
sg10
I5
sg11
Vtumor
p1108
sg13
I1
sa(dp1109
g7
I151
sg23
VC0920350
p1110
sg10
I31
sg11
Vchronic lymphocytic thyroiditis
p1111
sg13
I3
sa(dp1112
g7
I216
sg23
VC0334607
p1113
sg10
I8
sg11
Vpsammoma
p1114
sg13
I1
sa(dp1115
g7
I184
sg23
VC0920350
p1116
sg10
I3
sg11
VCLT
p1117
sg13
I1
sa(dp1118
g7
I107
sg23
VC0332448
p1119
sg10
I12
sg11
Vinfiltrating
p1120
sg13
I1
sasa(dp1121
g2
S'Our results show that the distinctive pathological features of PTCs, including TILs, background CLT, female gender, psammoma bodies, and stromal calcification, are useful parameters for predicting PD-L1 or PD-1 expression.\n'
p1122
sg4
(lp1123
(dp1124
g7
I206
sg8
VP18621
p1125
sg10
I4
sg11
VPD-1
p1126
sg13
I1
sa(dp1127
g7
I79
sg8
VP01765
p1128
sg10
I4
sg11
VTILs
p1129
sg13
I1
sasg20
(lp1130
(dp1131
g7
I116
sg23
VC0334607
p1132
sg10
I8
sg11
Vpsammoma
p1133
sg13
I1
sasa(dp1134
g2
S'The primary outcome parameters included the changes of corrected distant visual acuity (CDVA), uncorrected visual acuity (UCVA), the maximum keratometry value (Kmax) and minimum keratometry value (Kmin), the surface regularity index (SRI), the surface asymmetry index (SAI), the keratoconus prediction index (KPI), corneal thickness, and endothelial cell count.\n'
p1135
sg4
(lp1136
sg20
(lp1137
(dp1138
g7
I279
sg23
VC0022578
p1139
sg10
I11
sg11
Vkeratoconus
p1140
sg13
I1
sasa(dp1141
g2
S'Corrected distance visual acuity, refractive astigmatism, Kmax, Kmin, and IRI all improved after the treatment (P &lt; .05).\n'
p1142
sg4
(lp1143
sg20
(lp1144
(dp1145
g7
I45
sg23
VC0004106
p1146
sg10
I11
sg11
Vastigmatism
p1147
sg13
I1
sasa(dp1148
g2
S'FAN1 is a major component of the Fanconi anemia-related pathway of DNA damage response (DDR) signaling.\n'
p1149
sg4
(lp1150
(dp1151
g7
I0
sg8
g18
sg10
I4
sg11
VFAN1
p1152
sg13
I1
sasg20
(lp1153
(dp1154
g7
I67
sg23
VC0012860
p1155
sg10
I10
sg11
VDNA damage
p1156
sg13
I2
sa(dp1157
g7
I33
sg23
VC3469521
p1158
sg10
I14
sg11
VFanconi anemia
p1159
sg13
I2
sasa(dp1160
g2
S'In contrast, chronic injection of cisplatin at 2 mg/kg induced KIN that led to renal failure within 5 weeks in Fan1-/- mice but not in wild-type mice.\n'
p1161
sg4
(lp1162
(dp1163
g7
I111
sg8
g18
sg10
I4
sg11
VFan1
p1164
sg13
I1
sasg20
(lp1165
(dp1166
g7
I79
sg23
VC0035078
p1167
sg10
I13
sg11
Vrenal failure
p1168
sg13
I2
sasa(dp1169
g2
S'Our data show that Fan1 is involved in the physiologic response of kidney tubular cells to DNA damage, which contributes to the pathogenesis of CKD.\n'
p1170
sg4
(lp1171
(dp1172
g7
I19
sg8
g18
sg10
I4
sg11
VFan1
p1173
sg13
I1
sasg20
(lp1174
(dp1175
g7
I91
sg23
VC0012860
p1176
sg10
I10
sg11
VDNA damage
p1177
sg13
I2
sa(dp1178
g7
I128
sg23
VC0699748
p1179
sg10
I12
sg11
Vpathogenesis
p1180
sg13
I1
sasa(dp1181
g2
S'Moreover, Fan1-/- mice provide a new model with which to study the pathomechanisms of CKD.\n'
p1182
sg4
(lp1183
(dp1184
g7
I10
sg8
g18
sg10
I4
sg11
VFan1
p1185
sg13
I1
sasg20
(lp1186
sa(dp1187
g2
S'It is associated with type II cobblestone lissencephaly, hydrocephalus, cerebellar malformations, eye abnormalities and congenital muscular dystrophy characterized by hypoglycosylation of alpha-dystroglycan.\n'
p1188
sg4
(lp1189
(dp1190
g7
I22
sg8
VP27037
p1191
sg10
I19
sg11
Vtype II cobblestone
p1192
sg13
I3
sasg20
(lp1193
(dp1194
g7
I30
sg23
VC0431376
p1195
sg10
I25
sg11
Vcobblestone lissencephaly
p1196
sg13
I2
sa(dp1197
g7
I83
sg23
VC0000768
p1198
sg10
I13
sg11
Vmalformations
p1199
sg13
I1
sa(dp1200
g7
I120
sg23
VC0699743
p1201
sg10
I29
sg11
Vcongenital muscular dystrophy
p1202
sg13
I3
sa(dp1203
g7
I98
sg23
VC0015393
p1204
sg10
I17
sg11
Veye abnormalities
p1205
sg13
I2
sa(dp1206
g7
I57
sg23
VC0020255
p1207
sg10
I13
sg11
Vhydrocephalus
p1208
sg13
I1
sasa(dp1209
g2
S"An overview of various clinical studies of peptide vaccination strategies focusing on molecular targets such as the Wilms' tumor gene 1 (WT1), proteinase 3 (PR3), and receptor for hyaluronan acid-mediated motility (RHAMM) is provided.\n"
p1210
sg4
(lp1211
(dp1212
g7
I137
sg8
g18
sg10
I3
sg11
VWT1
p1213
sg13
I1
sa(dp1214
g7
I143
sg8
VP63123
p1215
sg10
I12
sg11
Vproteinase 3
p1216
sg13
I2
sa(dp1217
g7
I157
sg8
VP63123
p1218
sg10
I3
sg11
VPR3
p1219
sg13
I1
sa(dp1220
g7
I116
sg8
g18
sg10
I19
sg11
VWilms' tumor gene 1
p1221
sg13
I4
sasg20
(lp1222
(dp1223
g7
I137
sg23
VC0027708
p1224
sg10
I3
sg11
VWT1
p1225
sg13
I1
sa(dp1226
g7
I116
sg23
VC0027708
p1227
sg10
I19
sg11
VWilms' tumor gene 1
p1228
sg13
I4
sasa(dp1229
g2
S"Current clinical LAA peptide vaccination protocols targeting Wilms' tumor gene, proteinase-3 and the receptor for hyaluronan-mediated motility are reviewed and an outlook to dendritic cells, adjuvants and short oligodenucleotides is given.\n"
p1230
sg4
(lp1231
(dp1232
g7
I61
sg8
VP63123
p1233
sg10
I31
sg11
VWilms' tumor gene, proteinase-3
p1234
sg13
I4
sasg20
(lp1235
(dp1236
g7
I61
sg23
VC0027708
p1237
sg10
I12
sg11
VWilms' tumor
p1238
sg13
I2
sasa(dp1239
g2
S"Current clinical peptide vaccination trials targeting different epitopes of the Wilms' tumor gene 1 (WT1), the proteinase-3 derived epitope peptide (PR1) and the receptor for hyaluronic acid mediated motility (RHAMM/CD168)-derived epitope R3 are reviewed, and perspectives but also limitations of immunotherapeutic approaches for AML patients are discussed.\n"
p1240
sg4
(lp1241
(dp1242
g7
I111
sg8
VP63123
p1243
sg10
I36
sg11
Vproteinase-3 derived epitope peptide
p1244
sg13
I4
sa(dp1245
g7
I210
sg8
g18
sg10
I5
sg11
VRHAMM
p1246
sg13
I1
sa(dp1247
g7
I149
sg8
g18
sg10
I3
sg11
VPR1
p1248
sg13
I1
sa(dp1249
g7
I101
sg8
g18
sg10
I3
sg11
VWT1
p1250
sg13
I1
sa(dp1251
g7
I80
sg8
g18
sg10
I19
sg11
VWilms' tumor gene 1
p1252
sg13
I4
sa(dp1253
g7
I216
sg8
g18
sg10
I5
sg11
VCD168
p1254
sg13
I1
sasg20
(lp1255
(dp1256
g7
I101
sg23
VC0027708
p1257
sg10
I3
sg11
VWT1
p1258
sg13
I1
sa(dp1259
g7
I80
sg23
VC0027708
p1260
sg10
I19
sg11
VWilms' tumor gene 1
p1261
sg13
I4
sa(dp1262
g7
I330
sg23
VC0023467
p1263
sg10
I3
sg11
VAML
p1264
sg13
I1
sasa(dp1265
g2
S"Quantitative real-time polymerase chain reaction (PCR) was performed for the following LAAs: preferentially expressed antigen in melanoma (PRAME), the receptor for hyaluronic acid mediated motility (RHAMM/CD168), Wilms' tumor gene 1 (WT-1) and proteinase 3.\n"
p1266
sg4
(lp1267
(dp1268
g7
I234
sg8
g18
sg10
I4
sg11
VWT-1
p1269
sg13
I1
sa(dp1270
g7
I213
sg8
g18
sg10
I19
sg11
VWilms' tumor gene 1
p1271
sg13
I4
sa(dp1272
g7
I244
sg8
VP63123
p1273
sg10
I12
sg11
Vproteinase 3
p1274
sg13
I2
sa(dp1275
g7
I205
sg8
g18
sg10
I5
sg11
VCD168
p1276
sg13
I1
sa(dp1277
g7
I199
sg8
g18
sg10
I5
sg11
VRHAMM
p1278
sg13
I1
sasg20
(lp1279
(dp1280
g7
I213
sg23
VC0027708
p1281
sg10
I12
sg11
VWilms' tumor
p1282
sg13
I2
sa(dp1283
g7
I129
sg23
VC0025202
p1284
sg10
I8
sg11
Vmelanoma
p1285
sg13
I1
sasa(dp1286
g2
S'Overall, the unique cystic lesion reported contained pilar squamous epithelium with in situ carcinoma and eccrine ductal structures, which was interpreted as a hybrid cyst composed of in situ trichilemmal carcinoma and a ductal eccrine component.\n'
p1287
sg4
(lp1288
sg20
(lp1289
(dp1290
g7
I192
sg23
VC1266009
p1291
sg10
I22
sg11
Vtrichilemmal carcinoma
p1292
sg13
I2
sa(dp1293
g7
I84
sg23
VC0007099
p1294
sg10
I17
sg11
Vin situ carcinoma
p1295
sg13
I3
sa(dp1296
g7
I20
sg23
VC0010709
p1297
sg10
I4
sg11
Vcyst
p1298
sg13
I1
sasa(dp1299
g2
S'The cells showed abundant glycogen-containing cytoplasm (confirmed by Periodic acid Schiff stains with and without diastase), consistent with tricholemmal differentiation, and areas of tricholemmal/pilar-type keratinization (without a granular layer), consistent with tricholemmal carcinoma in situ, most likely arising in a tricholemmal/pilar cyst.\n'
p1300
sg4
(lp1301
sg20
(lp1302
(dp1303
g7
I281
sg23
VC0007099
p1304
sg10
I17
sg11
Vcarcinoma in situ
p1305
sg13
I3
sa(dp1306
g7
I338
sg23
VC0086809
p1307
sg10
I10
sg11
Vpilar cyst
p1308
sg13
I2
sasa(dp1309
g2
S'Tricholemmal (pilar) cysts are common benign adnexal lesions and atypia/dysplasia or carcinoma in situ arising within them is exceedingly rare.\n'
p1310
sg4
(lp1311
sg20
(lp1312
(dp1313
g7
I45
sg23
VC0237053
p1314
sg10
I15
sg11
Vadnexal lesions
p1315
sg13
I2
sa(dp1316
g7
I85
sg23
VC0007099
p1317
sg10
I17
sg11
Vcarcinoma in situ
p1318
sg13
I3
sa(dp1319
g7
I72
sg23
VC0334044
p1320
sg10
I9
sg11
Vdysplasia
p1321
sg13
I1
sa(dp1322
g7
I21
sg23
VC0010709
p1323
sg10
I5
sg11
Vcysts
p1324
sg13
I1
sasa(dp1325
g2
S'We observed that mice with both outer-retinal degeneration and a deficiency in melanopsin exhibited complete loss of photoentrainment of the circadian oscillator, pupillary light responses, photic suppression of arylalkylamine-N-acetyltransferase transcript, and acute suppression of locomotor activity by light.\n'
p1326
sg4
(lp1327
(dp1328
g7
I212
sg8
VP18440
p1329
sg10
I34
sg11
Varylalkylamine-N-acetyltransferase
p1330
sg13
I1
sa(dp1331
g7
I79
sg8
g18
sg10
I10
sg11
Vmelanopsin
p1332
sg13
I1
sasg20
(lp1333
(dp1334
g7
I38
sg23
VC0035304
p1335
sg10
I20
sg11
Vretinal degeneration
p1336
sg13
I2
sa(dp1337
g7
I197
sg23
VC0221103
p1338
sg10
I11
sg11
Vsuppression
p1339
sg13
I1
sa(dp1340
g7
I197
sg23
VC0221103
p1341
sg10
I11
sg11
Vsuppression
p1342
sg13
I1
sasa(dp1343
g2
S'The role of FUT8 in breast cancer migration, invasion, and metastasis was confirmed using an in vitro transwell assay and mammary fat pad xenograft in vivo tumor model.\n'
p1344
sg4
(lp1345
(dp1346
g7
I134
sg8
g18
sg10
I3
sg11
Vpad
p1347
sg13
I1
sa(dp1348
g7
I12
sg8
g18
sg10
I4
sg11
VFUT8
p1349
sg13
I1
sasg20
(lp1350
(dp1351
g7
I156
sg23
VC0027651
p1352
sg10
I5
sg11
Vtumor
p1353
sg13
I1
sa(dp1354
g7
I59
sg23
VC0027627
p1355
sg10
I10
sg11
Vmetastasis
p1356
sg13
I1
sa(dp1357
g7
I134
sg23
VC1704436
p1358
sg10
I3
sg11
Vpad
p1359
sg13
I1
sa(dp1360
g7
I20
sg23
VC0678222
p1361
sg10
I13
sg11
Vbreast cancer
p1362
sg13
I2
sa(dp1363
g7
I45
sg23
VC2699153
p1364
sg10
I8
sg11
Vinvasion
p1365
sg13
I1
sasa(dp1366
g2
S'Importantly, FUT8 inhibition suppressed the invasive ability of highly metastatic breast cancer cells and impaired their lung metastasis.\n'
p1367
sg4
(lp1368
(dp1369
g7
I13
sg8
g18
sg10
I4
sg11
VFUT8
p1370
sg13
I1
sasg20
(lp1371
(dp1372
g7
I71
sg23
VC0278488
p1373
sg10
I24
sg11
Vmetastatic breast cancer
p1374
sg13
I3
sa(dp1375
g7
I121
sg23
VC0153676
p1376
sg10
I15
sg11
Vlung metastasis
p1377
sg13
I2
sa(dp1378
g7
I106
sg23
VC0684336
p1379
sg10
I8
sg11
Vimpaired
p1380
sg13
I1
sasa(dp1381
g2
S'Our results reveal a positive feedback mechanism of FUT8-mediated receptor core fucosylation that promotes TGF-Beta signaling and EMT, thus stimulating breast cancer cell invasion and metastasis.\n'
p1382
sg4
(lp1383
(dp1384
g7
I107
sg8
VP18075
p1385
sg10
I8
sg11
VTGF-Beta
p1386
sg13
I1
sa(dp1387
g7
I52
sg8
g18
sg10
I4
sg11
VFUT8
p1388
sg13
I1
sa(dp1389
g7
I130
sg8
g18
sg10
I3
sg11
VEMT
p1390
sg13
I1
sasg20
(lp1391
(dp1392
g7
I152
sg23
VC0678222
p1393
sg10
I13
sg11
Vbreast cancer
p1394
sg13
I2
sa(dp1395
g7
I184
sg23
VC0027627
p1396
sg10
I10
sg11
Vmetastasis
p1397
sg13
I1
sa(dp1398
g7
I166
sg23
VC2699153
p1399
sg10
I13
sg11
Vcell invasion
p1400
sg13
I2
sasa(dp1401
g2
S'Core-fucose-deficient mice generated by ablating the Alfa1,6 fucosyltransferase enzyme, Fut8, exhibit severe pulmonary emphysema, partly due to impaired macrophage function, similar to aged Toll-like receptor 4 (Tlr4)-deficient mice.\n'
p1402
sg4
(lp1403
(dp1404
g7
I190
sg8
g18
sg10
I20
sg11
VToll-like receptor 4
p1405
sg13
I3
sa(dp1406
g7
I53
sg8
VP19526
p1407
sg10
I33
sg11
VAlfa1,6 fucosyltransferase enzyme
p1408
sg13
I3
sa(dp1409
g7
I88
sg8
g18
sg10
I4
sg11
VFut8
p1410
sg13
I1
sa(dp1411
g7
I212
sg8
g18
sg10
I4
sg11
VTlr4
p1412
sg13
I1
sasg20
(lp1413
(dp1414
g7
I144
sg23
VC0684336
p1415
sg10
I8
sg11
Vimpaired
p1416
sg13
I1
sa(dp1417
g7
I109
sg23
VC0034067
p1418
sg10
I19
sg11
Vpulmonary emphysema
p1419
sg13
I2
sasa(dp1420
g2
S'The feature selection procedure extracted several cancer-related and lymph node metastasis-related genes, such as TP73, PDX1, FUT8, HOXD1, NMT1, and SEMA3E.\n'
p1421
sg4
(lp1422
(dp1423
g7
I149
sg8
g18
sg10
I6
sg11
VSEMA3E
p1424
sg13
I1
sa(dp1425
g7
I139
sg8
VP30419
p1426
sg10
I4
sg11
VNMT1
p1427
sg13
I1
sa(dp1428
g7
I126
sg8
g18
sg10
I4
sg11
VFUT8
p1429
sg13
I1
sa(dp1430
g7
I120
sg8
VP52945
p1431
sg10
I4
sg11
VPDX1
p1432
sg13
I1
sa(dp1433
g7
I132
sg8
g18
sg10
I5
sg11
VHOXD1
p1434
sg13
I1
sasg20
(lp1435
(dp1436
g7
I50
sg23
VC0006826
p1437
sg10
I6
sg11
Vcancer
p1438
sg13
I1
sa(dp1439
g7
I69
sg23
VC0686619
p1440
sg10
I21
sg11
Vlymph node metastasis
p1441
sg13
I3
sasa(dp1442
g2
S'Furthermore, decreased or blocked Alfa1, 6-fucosylation by FUT8 siRNA transfection or LCA Lectin blockage reduced stemness and EMT.\n'
p1443
sg4
(lp1444
(dp1445
g7
I86
sg8
VP09496
p1446
sg10
I10
sg11
VLCA Lectin
p1447
sg13
I2
sa(dp1448
g7
I59
sg8
g18
sg10
I10
sg11
VFUT8 siRNA
p1449
sg13
I2
sasg20
(lp1450
(dp1451
g7
I86
sg23
VC0339527
p1452
sg10
I3
sg11
VLCA
p1453
sg13
I1
sasa(dp1454
g2
S'Taken together, our study reveals that fentanyl upregulated FUT8 expression, which increased Alfa1, 6-fucosylation level through activation of Wnt/Beta-catenin signaling pathway, thereby, induce stemness and EMT of breast cancer cells.\n'
p1455
sg4
(lp1456
(dp1457
g7
I60
sg8
g18
sg10
I4
sg11
VFUT8
p1458
sg13
I1
sasg20
(lp1459
(dp1460
g7
I215
sg23
VC0678222
p1461
sg10
I13
sg11
Vbreast cancer
p1462
sg13
I2
sasa(dp1463
g2
S'The core fucosylation of N-glycans on glycoproteins is catalyzed by fucosyltransferase 8 (FUT8) in mammalian cells and is involved in various biological functions, such as protein function, cancer progression, and postnatal development.\n'
p1464
sg4
(lp1465
(dp1466
g7
I68
sg8
g18
sg10
I20
sg11
Vfucosyltransferase 8
p1467
sg13
I2
sa(dp1468
g7
I90
sg8
g18
sg10
I4
sg11
VFUT8
p1469
sg13
I1
sasg20
(lp1470
(dp1471
g7
I190
sg23
VC0178874
p1472
sg10
I18
sg11
Vcancer progression
p1473
sg13
I2
sasa(dp1474
g2
S'FUT8-mediated core fucosylation of L1CAM drives melanoma metastasis.\n'
p1475
sg4
(lp1476
(dp1477
g7
I0
sg8
g18
sg10
I4
sg11
VFUT8
p1478
sg13
I1
sa(dp1479
g7
I35
sg8
VP32004
p1480
sg10
I5
sg11
VL1CAM
p1481
sg13
I1
sasg20
(lp1482
(dp1483
g7
I57
sg23
VC0027627
p1484
sg10
I10
sg11
Vmetastasis
p1485
sg13
I1
sa(dp1486
g7
I48
sg23
VC0025202
p1487
sg10
I8
sg11
Vmelanoma
p1488
sg13
I1
sasa(dp1489
g2
S'Upregulation of core fucosylation (FUT8) and downregulation of Alfa-1,2 fucosylation (FUT1, FUT2) were identified as features of metastatic melanoma.\n'
p1490
sg4
(lp1491
(dp1492
g7
I92
sg8
g18
sg10
I4
sg11
VFUT2
p1493
sg13
I1
sa(dp1494
g7
I86
sg8
VP19526
p1495
sg10
I4
sg11
VFUT1
p1496
sg13
I1
sa(dp1497
g7
I35
sg8
g18
sg10
I4
sg11
VFUT8
p1498
sg13
I1
sasg20
(lp1499
(dp1500
g7
I129
sg23
VC0278883
p1501
sg10
I19
sg11
Vmetastatic melanoma
p1502
sg13
I2
sasa(dp1503
g2
S'Using both in vitro and in vivo studies, we demonstrate FUT8 is a driver of melanoma metastasis which, when silenced, suppresses invasion and tumor dissemination.\n'
p1504
sg4
(lp1505
(dp1506
g7
I56
sg8
g18
sg10
I4
sg11
VFUT8
p1507
sg13
I1
sasg20
(lp1508
(dp1509
g7
I76
sg23
VC0025202
p1510
sg10
I8
sg11
Vmelanoma
p1511
sg13
I1
sa(dp1512
g7
I142
sg23
VC0027651
p1513
sg10
I5
sg11
Vtumor
p1514
sg13
I1
sa(dp1515
g7
I85
sg23
VC0027627
p1516
sg10
I10
sg11
Vmetastasis
p1517
sg13
I1
sa(dp1518
g7
I129
sg23
VC2699153
p1519
sg10
I8
sg11
Vinvasion
p1520
sg13
I1
sasa(dp1521
g2
S'FUT8 and its targets represent therapeutic targets in melanoma metastasis.\n'
p1522
sg4
(lp1523
(dp1524
g7
I0
sg8
g18
sg10
I4
sg11
VFUT8
p1525
sg13
I1
sasg20
(lp1526
(dp1527
g7
I54
sg23
VC0025202
p1528
sg10
I8
sg11
Vmelanoma
p1529
sg13
I1
sa(dp1530
g7
I63
sg23
VC0027627
p1531
sg10
I10
sg11
Vmetastasis
p1532
sg13
I1
sasa(dp1533
g2
S'identified the glycosyltransferase FUT8 as a previously unrecognized mediator of melanoma metastasis, establishing core fucosylation as a potential therapeutic target for prevention and treatment of metastatic tumors.\n'
p1534
sg4
(lp1535
(dp1536
g7
I15
sg8
g18
sg10
I24
sg11
Vglycosyltransferase FUT8
p1537
sg13
I2
sasg20
(lp1538
(dp1539
g7
I81
sg23
VC0025202
p1540
sg10
I8
sg11
Vmelanoma
p1541
sg13
I1
sa(dp1542
g7
I90
sg23
VC0027627
p1543
sg10
I10
sg11
Vmetastasis
p1544
sg13
I1
sa(dp1545
g7
I199
sg23
VC0027627
p1546
sg10
I17
sg11
Vmetastatic tumors
p1547
sg13
I2
sasa(dp1548
g2
S'These findings support the proposal that deletions and insertions within the calmodulin-like domain produce pseudoachondroplasia, while amino acid substitutions with this domain may produce either pseudoachondroplasia or multiple epiphyseal dysplasia.\n'
p1549
sg4
(lp1550
(dp1551
g7
I77
sg8
g18
sg10
I22
sg11
Vcalmodulin-like domain
p1552
sg13
I2
sasg20
(lp1553
(dp1554
g7
I221
sg23
VC0026760
p1555
sg10
I29
sg11
Vmultiple epiphyseal dysplasia
p1556
sg13
I3
sa(dp1557
g7
I108
sg23
VC0410538
p1558
sg10
I20
sg11
Vpseudoachondroplasia
p1559
sg13
I1
sa(dp1560
g7
I108
sg23
VC0410538
p1561
sg10
I20
sg11
Vpseudoachondroplasia
p1562
sg13
I1
sasa(dp1563
g2
S'DATS can inhibit the proliferation and colony-forming of SP cells in multiple myeloma, and induce the G1/S arrest that may be carried out via suppressing the expression of cyclin D1, cyclin E, CDK2 and CDK4.\n'
p1564
sg4
(lp1565
(dp1566
g7
I202
sg8
VP11802
p1567
sg10
I4
sg11
VCDK4
p1568
sg13
I1
sa(dp1569
g7
I183
sg8
VP24864
p1570
sg10
I8
sg11
Vcyclin E
p1571
sg13
I2
sa(dp1572
g7
I193
sg8
VP24941
p1573
sg10
I4
sg11
VCDK2
p1574
sg13
I1
sa(dp1575
g7
I172
sg8
VP24385
p1576
sg10
I9
sg11
Vcyclin D1
p1577
sg13
I2
sasg20
(lp1578
(dp1579
g7
I0
sg23
VC0002395
p1580
sg10
I4
sg11
VDATS
p1581
sg13
I1
sa(dp1582
g7
I21
sg23
VC0334094
p1583
sg10
I13
sg11
Vproliferation
p1584
sg13
I1
sa(dp1585
g7
I69
sg23
VC0026764
p1586
sg10
I16
sg11
Vmultiple myeloma
p1587
sg13
I2
sasa(dp1588
g2
S'These results suggest that serotonin oxidation by myeloperoxidase or the action of other oxidants could cause functional alteration of cellular proteins, which may be related to neurodegeneration processes or irritable bowel syndrome.\n'
p1589
sg4
(lp1590
(dp1591
g7
I50
sg8
VP05164
p1592
sg10
I15
sg11
Vmyeloperoxidase
p1593
sg13
I1
sasg20
(lp1594
(dp1595
g7
I209
sg23
VC0022104
p1596
sg10
I24
sg11
Virritable bowel syndrome
p1597
sg13
I3
sa(dp1598
g7
I178
sg23
VC0027746
p1599
sg10
I17
sg11
Vneurodegeneration
p1600
sg13
I1
sasa(dp1601
g2
S'We recently showed that Man-A stimulated reactive oxygen species (ROS) which were upstream of serine/threonine (Ser/Thr) dephosphorylation and caspase-dependent cleavage of MEK and Akt in lymphoma apoptosis.\n'
p1602
sg4
(lp1603
(dp1604
g7
I173
sg8
VP45985
p1605
sg10
I3
sg11
VMEK
p1606
sg13
I1
sa(dp1607
g7
I143
sg8
VP39880
p1608
sg10
I7
sg11
Vcaspase
p1609
sg13
I1
sa(dp1610
g7
I181
sg8
g18
sg10
I3
sg11
VAkt
p1611
sg13
I1
sasg20
(lp1612
(dp1613
g7
I188
sg23
VC0024299
p1614
sg10
I8
sg11
Vlymphoma
p1615
sg13
I1
sasa(dp1616
g2
S'Taken together, we conclude that PP1Alfa is an important proximal effector of Man-A mediated lymphoma apoptosis and that the mechanisms of Man-A action warrant further investigation.\n'
p1617
sg4
(lp1618
sg20
(lp1619
(dp1620
g7
I93
sg23
VC0024299
p1621
sg10
I8
sg11
Vlymphoma
p1622
sg13
I1
sasa(dp1623
g2
S'Cytosolic Alfa-mannosidase (Man2C1) trims free oligosaccharides in mammalian cells, and its down-regulation reportedly delays cancer growth by inducing mitotic arrest or apoptosis.\n'
p1624
sg4
(lp1625
(dp1626
g7
I0
sg8
VP0C870
p1627
sg10
I26
sg11
VCytosolic Alfa-mannosidase
p1628
sg13
I2
sa(dp1629
g7
I28
sg8
g18
sg10
I6
sg11
VMan2C1
p1630
sg13
I1
sasg20
(lp1631
(dp1632
g7
I126
sg23
VC0006826
p1633
sg10
I6
sg11
Vcancer
p1634
sg13
I1
sasa(dp1635
g2
S'Here we report that manumycin A (Man A), an inhibitor of farnesyl protein transferase, reduces cancer cell viability through induction of non-apoptotic, non-autophagic cytoplasmic vacuolation death in TNBC cells.\n'
p1636
sg4
(lp1637
sg20
(lp1638
(dp1639
g7
I95
sg23
VC0006826
p1640
sg10
I6
sg11
Vcancer
p1641
sg13
I1
sasa(dp1642
g2
S'Here we show that Alfa-mannosidase 2C1 (MAN2C1) inhibits PTEN function in prostate cancer (PC) cells and is associated with a reduction in PTEN function in primary PC.\n'
p1643
sg4
(lp1644
(dp1645
g7
I57
sg8
VP60484
p1646
sg10
I4
sg11
VPTEN
p1647
sg13
I1
sa(dp1648
g7
I18
sg8
g18
sg10
I20
sg11
VAlfa-mannosidase 2C1
p1649
sg13
I2
sa(dp1650
g7
I57
sg8
VP60484
p1651
sg10
I4
sg11
VPTEN
p1652
sg13
I1
sa(dp1653
g7
I40
sg8
g18
sg10
I6
sg11
VMAN2C1
p1654
sg13
I1
sasg20
(lp1655
(dp1656
g7
I74
sg23
VC0600139
p1657
sg10
I15
sg11
Vprostate cancer
p1658
sg13
I2
sa(dp1659
g7
I91
sg23
VC0600139
p1660
sg10
I2
sg11
VPC
p1661
sg13
I1
sa(dp1662
g7
I91
sg23
VC0600139
p1663
sg10
I2
sg11
VPC
p1664
sg13
I1
sasa(dp1665
g2
S'hMan2c1 transgene promoted growth, invasion, and metastasis to lung of implanted hepatoma H22 and sarcoma S180.\n'
p1666
sg4
(lp1667
sg20
(lp1668
(dp1669
g7
I49
sg23
VC0153676
p1670
sg10
I18
sg11
Vmetastasis to lung
p1671
sg13
I3
sa(dp1672
g7
I98
sg23
VC1261473
p1673
sg10
I7
sg11
Vsarcoma
p1674
sg13
I1
sa(dp1675
g7
I35
sg23
VC2699153
p1676
sg10
I8
sg11
Vinvasion
p1677
sg13
I1
sa(dp1678
g7
I81
sg23
VC0023903
p1679
sg10
I8
sg11
Vhepatoma
p1680
sg13
I1
sasa(dp1681
g2
S'To study the effects of suppressed alpha-mannosidase Man2c1 gene expression on EC9706 human esophageal carcinoma cells, the cells were treated with short interfering RNA.\n'
p1682
sg4
(lp1683
(dp1684
g7
I35
sg8
g18
sg10
I29
sg11
Valpha-mannosidase Man2c1 gene
p1685
sg13
I3
sasg20
(lp1686
(dp1687
g7
I92
sg23
VC0152018
p1688
sg10
I20
sg11
Vesophageal carcinoma
p1689
sg13
I2
sasa(dp1690
g2
S'The data imply that induction of mitotic arrest and consequent apoptosis resulted from microtubule disorganization, which appears to be one of the major cellular mechanisms by which suppressed expression of the Man2c1 gene causes growth inhibition of EC9706 esophageal carcinoma cells.\n'
p1691
sg4
(lp1692
(dp1693
g7
I211
sg8
g18
sg10
I11
sg11
VMan2c1 gene
p1694
sg13
I2
sasg20
(lp1695
(dp1696
g7
I258
sg23
VC0152018
p1697
sg10
I20
sg11
Vesophageal carcinoma
p1698
sg13
I2
sasa(dp1699
g2
S'The growth of CNE-2L2 cell, a cloned line of human nasopharyngeal carcinoma with a high potentiality of metastasis to lung was inhibited to a certain extent after transfection with a recombinant antisense expression vector of a cDNA encoding a human alpha-mannosidase (pRc/CMV-antisense 6A8 cDNA) (the Genbank accession number of 6A8 cDNA is U37248) in comparison with that of the cell transfected with the Mock and of the wild cell.\n'
p1700
sg4
(lp1701
(dp1702
g7
I273
sg8
g18
sg10
I22
sg11
VCMV-antisense 6A8 cDNA
p1703
sg13
I3
sa(dp1704
g7
I269
sg8
g18
sg10
I3
sg11
VpRc
p1705
sg13
I1
sa(dp1706
g7
I244
sg8
g18
sg10
I23
sg11
Vhuman alpha-mannosidase
p1707
sg13
I2
sa(dp1708
g7
I287
sg8
g18
sg10
I8
sg11
V6A8 cDNA
p1709
sg13
I2
sasg20
(lp1710
(dp1711
g7
I104
sg23
VC0153676
p1712
sg10
I18
sg11
Vmetastasis to lung
p1713
sg13
I3
sa(dp1714
g7
I51
sg23
VC2931822
p1715
sg10
I24
sg11
Vnasopharyngeal carcinoma
p1716
sg13
I2
sasa(dp1717
g2
S'One hundred and ninety primary formalin fixed, paraffin embedded NSCLC lesions were stained with HLA class I heavy chain-specific mAb HC-10.\n'
p1718
sg4
(lp1719
(dp1720
g7
I97
sg8
VP30499
p1721
sg10
I42
sg11
VHLA class I heavy chain-specific mAb HC-10
p1722
sg13
I7
sasg20
(lp1723
(dp1724
g7
I65
sg23
VC0007131
p1725
sg10
I5
sg11
VNSCLC
p1726
sg13
I1
sasa(dp1727
g2
S'A 33-year-old Zimbabwean female presented with cryptococcal meningitis and newly diagnosed HIV with a CD4 count of 51 cells/ my L (4%).\n'
p1728
sg4
(lp1729
(dp1730
g7
I102
sg8
VP01730
p1731
sg10
I3
sg11
VCD4
p1732
sg13
I1
sasg20
(lp1733
(dp1734
g7
I47
sg23
VC0085436
p1735
sg10
I23
sg11
Vcryptococcal meningitis
p1736
sg13
I2
sa(dp1737
g7
I91
sg23
VC0019693
p1738
sg10
I3
sg11
VHIV
p1739
sg13
I1
sasa(dp1740
g2
S'However, over the ensuing 18 months, her clinical course was marked by periodic worsening with symptoms resembling cryptococcal meningitis despite having achieved CD4 counts &gt;=400 cells/ my L. Although initially treated for relapsing cryptococcal immune reconstitution syndrome, a brain biopsy taken 17 months after initial presentation showed budding Cryptococci.\n'
p1741
sg4
(lp1742
(dp1743
g7
I163
sg8
VP01730
p1744
sg10
I3
sg11
VCD4
p1745
sg13
I1
sasg20
(lp1746
(dp1747
g7
I250
sg23
VC1619738
p1748
sg10
I30
sg11
Vimmune reconstitution syndrome
p1749
sg13
I3
sa(dp1750
g7
I115
sg23
VC0085436
p1751
sg10
I23
sg11
Vcryptococcal meningitis
p1752
sg13
I2
sasa(dp1753
g2
S'Peptide receptor radionuclide therapy (PRRT) either using Lu-177 or Y-90 peptide radiopharmaceuticals has emerged as promising treatment modality in patients with inoperable metastatic neuroendocrine tumour (NET) including medullary thyroid cancer, because of overexpression of somatostatin receptor 2 (sstr-2) on these cells.\n'
p1754
sg4
(lp1755
(dp1756
g7
I278
sg8
VP61278
p1757
sg10
I23
sg11
Vsomatostatin receptor 2
p1758
sg13
I3
sa(dp1759
g7
I303
sg8
VP31391
p1760
sg10
I6
sg11
Vsstr-2
p1761
sg13
I1
sasg20
(lp1762
(dp1763
g7
I208
sg23
VC0206754
p1764
sg10
I3
sg11
VNET
p1765
sg13
I1
sa(dp1766
g7
I185
sg23
VC0206754
p1767
sg10
I21
sg11
Vneuroendocrine tumour
p1768
sg13
I2
sa(dp1769
g7
I223
sg23
VC0238462
p1770
sg10
I24
sg11
Vmedullary thyroid cancer
p1771
sg13
I3
sasa(dp1772
g2
S'The several investigators have used PRRT in non-iodine avid differentiated thyroid cancer patients with limited success, where other treatment modalities have failed, probably due to faint sstr-2 expression in these lesions.\n'
p1773
sg4
(lp1774
sg20
(lp1775
(dp1776
g7
I60
sg23
VC1337013
p1777
sg10
I29
sg11
Vdifferentiated thyroid cancer
p1778
sg13
I3
sa(dp1779
g7
I183
sg23
VC0039070
p1780
sg10
I5
sg11
Vfaint
p1781
sg13
I1
sasa(dp1782
g2
S'Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is known to overexpress somatostatin receptors (SSTRs), most commonly SSTR2 and SSTR5.\n'
p1783
sg4
(lp1784
(dp1785
g7
I137
sg8
VP35346
p1786
sg10
I5
sg11
VSSTR5
p1787
sg13
I1
sa(dp1788
g7
I81
sg8
VP61278
p1789
sg10
I22
sg11
Vsomatostatin receptors
p1790
sg13
I2
sa(dp1791
g7
I105
sg8
VP31391
p1792
sg10
I5
sg11
VSSTRs
p1793
sg13
I1
sa(dp1794
g7
I127
sg8
VP30874
p1795
sg10
I5
sg11
VSSTR2
p1796
sg13
I1
sasg20
(lp1797
(dp1798
g7
I23
sg23
VC0206754
p1799
sg10
I23
sg11
Vneuroendocrine neoplasm
p1800
sg13
I2
sasa(dp1801
g2
S'The present study detected the expression of SSTR2 and SSTR5 in GEP-NEN and investigated the efficacy and safety of octreotide long-acting release (LAR) in the treatment of advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) in China.\n'
p1802
sg4
(lp1803
(dp1804
g7
I64
sg8
g18
sg10
I3
sg11
VGEP
p1805
sg13
I1
sa(dp1806
g7
I55
sg8
VP35346
p1807
sg10
I5
sg11
VSSTR5
p1808
sg13
I1
sa(dp1809
g7
I45
sg8
VP30874
p1810
sg10
I5
sg11
VSSTR2
p1811
sg13
I1
sasg20
(lp1812
(dp1813
g7
I205
sg23
VC0206754
p1814
sg10
I21
sg11
Vneuroendocrine tumors
p1815
sg13
I2
sasa(dp1816
g2
S'Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2).\n'
p1817
sg4
(lp1818
(dp1819
g7
I231
sg8
VP30874
p1820
sg10
I5
sg11
VSSTR2
p1821
sg13
I1
sa(dp1822
g7
I208
sg8
VP61278
p1823
sg10
I21
sg11
Vsomatostatin receptor
p1824
sg13
I2
sasg20
(lp1825
(dp1826
g7
I175
sg23
VC0206754
p1827
sg10
I21
sg11
Vneuroendocrine tumors
p1828
sg13
I2
sasa(dp1829
g2
S'We have also evaluated the tumor targeting molecular imaging ability of these branched copolymer nanoparticle in vivo using nude/NCr mice bearing AR42J rat pancreatic tumor (SSTR2 positive) and A549 human lung carcinoma tumor (SSTR2 negative) xenografts.\n'
p1830
sg4
(lp1831
(dp1832
g7
I174
sg8
VP30874
p1833
sg10
I5
sg11
VSSTR2
p1834
sg13
I1
sa(dp1835
g7
I174
sg8
VP30874
p1836
sg10
I5
sg11
VSSTR2
p1837
sg13
I1
sasg20
(lp1838
(dp1839
g7
I27
sg23
VC0027651
p1840
sg10
I5
sg11
Vtumor
p1841
sg13
I1
sa(dp1842
g7
I205
sg23
VC0684249
p1843
sg10
I14
sg11
Vlung carcinoma
p1844
sg13
I2
sa(dp1845
g7
I129
sg23
VC1834174
p1846
sg10
I3
sg11
VNCr
p1847
sg13
I1
sa(dp1848
g7
I156
sg23
VC0030297
p1849
sg10
I16
sg11
Vpancreatic tumor
p1850
sg13
I2
sa(dp1851
g7
I27
sg23
VC0027651
p1852
sg10
I5
sg11
Vtumor
p1853
sg13
I1
sasa(dp1854
g2
S'There is also suggestive evidence of an association with two uncommon disorders, Kreiborg-Pakistani syndrome (craniosynostosis and dental anomalies), and insulin-resistant diabetes mellitus with acanthosisnigricans.\n'
p1855
sg4
(lp1856
(dp1857
g7
I154
sg8
VP01308
p1858
sg10
I7
sg11
Vinsulin
p1859
sg13
I1
sasg20
(lp1860
(dp1861
g7
I154
sg23
VC0743125
p1862
sg10
I35
sg11
Vinsulin-resistant diabetes mellitus
p1863
sg13
I3
sa(dp1864
g7
I81
sg23
VC3280073
p1865
sg10
I27
sg11
VKreiborg-Pakistani syndrome
p1866
sg13
I2
sa(dp1867
g7
I110
sg23
VC3280073
p1868
sg10
I37
sg11
Vcraniosynostosis and dental anomalies
p1869
sg13
I4
sasa(dp1870
g2
S'Investigating the association between plasma levels of cytokines and chemokines, Selenoprotein S (SELS) gene variation and osteoarthritis (OA) subtypes.\n'
p1871
sg4
(lp1872
(dp1873
g7
I81
sg8
g18
sg10
I15
sg11
VSelenoprotein S
p1874
sg13
I2
sa(dp1875
g7
I98
sg8
g18
sg10
I4
sg11
VSELS
p1876
sg13
I1
sasg20
(lp1877
(dp1878
g7
I123
sg23
VC0029408
p1879
sg10
I14
sg11
Vosteoarthritis
p1880
sg13
I1
sa(dp1881
g7
I139
sg23
VC0029408
p1882
sg10
I2
sg11
VOA
p1883
sg13
I1
sasa(dp1884
g2
S'Proliferative responses were assessed against rgp160, rp24, and a panel of recall antigens and mitogens.\n'
p1885
sg4
(lp1886
sg20
(lp1887
(dp1888
g7
I0
sg23
VC0334094
p1889
sg10
I13
sg11
VProliferative
p1890
sg13
I1
sasa(dp1891
g2
S'At day 56, all rgp160 recipients had stimulation indexes (rgp160/rp24) greater than 3.0, and five of six had differences in counts per minute (cpm) greater than 1000.\n'
p1892
sg4
(lp1893
sg20
(lp1894
sa(dp1895
g2
S'Renovascular hypertension was induced in rats by the two-kidney two-clip (2K2C) method.\n'
p1896
sg4
(lp1897
sg20
(lp1898
(dp1899
g7
I0
sg23
VC0020545
p1900
sg10
I25
sg11
VRenovascular hypertension
p1901
sg13
I2
sasa(dp1902
g2
S'Berberine could improve cardiac contractility of 2K2C model rats, and inhibit left ventricular remodeling especially myocardial fibrosis in renovascular hypertension rats.\n'
p1903
sg4
(lp1904
sg20
(lp1905
(dp1906
g7
I140
sg23
VC0020545
p1907
sg10
I25
sg11
Vrenovascular hypertension
p1908
sg13
I2
sa(dp1909
g7
I117
sg23
VC0151654
p1910
sg10
I19
sg11
Vmyocardial fibrosis
p1911
sg13
I2
sasa(dp1912
g2
S'In conclusion, these data indicate that different Nox expression might account for substrate preference and the formation of O(2)*(-) by NAD(P)H oxidase resulting from elevated Ang II in the 2K2C model contributes to the development of renovascular hypertension and subsequent cardiac remodeling.\n'
p1913
sg4
(lp1914
(dp1915
g7
I177
sg8
VP01019
p1916
sg10
I6
sg11
VAng II
p1917
sg13
I2
sa(dp1918
g7
I137
sg8
VP42898
p1919
sg10
I15
sg11
VNAD(P)H oxidase
p1920
sg13
I2
sasg20
(lp1921
(dp1922
g7
I137
sg23
VC1850380
p1923
sg10
I3
sg11
VNAD
p1924
sg13
I1
sa(dp1925
g7
I236
sg23
VC0020545
p1926
sg10
I25
sg11
Vrenovascular hypertension
p1927
sg13
I2
sasa(dp1928
g2
S'The aim of present experiments was to characterize the contribution of circulating ANF and its vascular relaxing effects in the two kidney-two clip (2K2C) experimental model of renovascular hypertension.\n'
p1929
sg4
(lp1930
(dp1931
g7
I83
sg8
VP01160
p1932
sg10
I3
sg11
VANF
p1933
sg13
I1
sasg20
(lp1934
(dp1935
g7
I177
sg23
VC0020545
p1936
sg10
I25
sg11
Vrenovascular hypertension
p1937
sg13
I2
sasa(dp1938
g2
S'The present study was designed to follow the development of 2 kidney-2 clip (2k-2c) renovascular hypertension in rats depleted of central NE and to analyze the central and peripheral renin-angiotensin system.\n'
p1939
sg4
(lp1940
(dp1941
g7
I183
sg8
VP00797
p1942
sg10
I17
sg11
Vrenin-angiotensin
p1943
sg13
I1
sasg20
(lp1944
(dp1945
g7
I84
sg23
VC0020545
p1946
sg10
I25
sg11
Vrenovascular hypertension
p1947
sg13
I2
sasa(dp1948
g2
S'The effect of chronic hypobaric hypoxia (CHH) on the development of 2k-2c Goldblatt renovascular hypertension has been analyzed in rats of both sexes.\n'
p1949
sg4
(lp1950
sg20
(lp1951
(dp1952
g7
I84
sg23
VC0020545
p1953
sg10
I25
sg11
Vrenovascular hypertension
p1954
sg13
I2
sa(dp1955
g7
I14
sg23
VC0220748
p1956
sg10
I25
sg11
Vchronic hypobaric hypoxia
p1957
sg13
I3
sa(dp1958
g7
I41
sg23
VC0220748
p1959
sg10
I3
sg11
VCHH
p1960
sg13
I1
sasa(dp1961
g2
S'Administration of angiotensin I converting enzyme inhibitor (SQ 14225) reduced the blood pressure both in the benign and malignant phases of 2K2C renovascular hypertension, and a ganglionic blocking agent (hexamethonium) also decreased the blood pressure.\n'
p1962
sg4
(lp1963
(dp1964
g7
I18
sg8
VP01019
p1965
sg10
I31
sg11
Vangiotensin I converting enzyme
p1966
sg13
I4
sasg20
(lp1967
(dp1968
g7
I146
sg23
VC0020545
p1969
sg10
I25
sg11
Vrenovascular hypertension
p1970
sg13
I2
sa(dp1971
g7
I190
sg23
VC0233660
p1972
sg10
I8
sg11
Vblocking
p1973
sg13
I1
sasa(dp1974
g2
S'For those with APA and mild tricuspid regurgitation (TR), a modified BTS and reduction atrioplasty may be the best initial option.\n'
p1975
sg4
(lp1976
sg20
(lp1977
(dp1978
g7
I28
sg23
VC0040961
p1979
sg10
I23
sg11
Vtricuspid regurgitation
p1980
sg13
I2
sa(dp1981
g7
I53
sg23
VC0040961
p1982
sg10
I2
sg11
VTR
p1983
sg13
I1
sasa(dp1984
g2
S'Patients in the BTS group required more tricuspid valvuloplasties and had more tricuspid regurgitation at follow-up evaluation.\n'
p1985
sg4
(lp1986
sg20
(lp1987
(dp1988
g7
I79
sg23
VC0040961
p1989
sg10
I23
sg11
Vtricuspid regurgitation
p1990
sg13
I2
sasa(dp1991
g2
S'However, the patients in the BTS group exhibited more tricuspid regurgitation, and the patients in the RV-PA group had increased pulmonary artery interventions.\n'
p1992
sg4
(lp1993
sg20
(lp1994
(dp1995
g7
I54
sg23
VC0040961
p1996
sg10
I23
sg11
Vtricuspid regurgitation
p1997
sg13
I2
sasa(dp1998
g2
S'CDY2 and HSFY were the only identified genes for which differences in expression were observed between the MA and obstructive azoospermia cohorts.\n'
p1999
sg4
(lp2000
(dp2001
g7
I0
sg8
g18
sg10
I4
sg11
VCDY2
p2002
sg13
I1
sa(dp2003
g7
I9
sg8
g18
sg10
I4
sg11
VHSFY
p2004
sg13
I1
sasg20
(lp2005
(dp2006
g7
I126
sg23
VC1321542
p2007
sg10
I11
sg11
Vazoospermia
p2008
sg13
I1
sasa(dp2009
g2
S'Men with obstructive azoospermia had 12-fold higher relative expression of CDY2 transcript (1.33 +/- 0.40 vs. 0.11 +/- 0.04; P=0.0003) and 16-fold higher expression of HSFY transcript (0.78 +/- 0.32 vs. 0.05 +/- 0.02; P=0.0005) compared to men with MA.\n'
p2010
sg4
(lp2011
(dp2012
g7
I75
sg8
g18
sg10
I15
sg11
VCDY2 transcript
p2013
sg13
I2
sa(dp2014
g7
I168
sg8
g18
sg10
I15
sg11
VHSFY transcript
p2015
sg13
I2
sasg20
(lp2016
(dp2017
g7
I21
sg23
VC1321542
p2018
sg10
I11
sg11
Vazoospermia
p2019
sg13
I1
sasa(dp2020
g2
S'CDY2 and HSFY were also underexpressed in patients with Sertoli cell only syndrome.\n'
p2021
sg4
(lp2022
(dp2023
g7
I0
sg8
g18
sg10
I4
sg11
VCDY2
p2024
sg13
I1
sa(dp2025
g7
I9
sg8
g18
sg10
I4
sg11
VHSFY
p2026
sg13
I1
sasg20
(lp2027
(dp2028
g7
I56
sg23
VC1384583
p2029
sg10
I26
sg11
VSertoli cell only syndrome
p2030
sg13
I4
sasa(dp2031
g2
S'Western blotting data revealed HSFY in the testicular tissues with normal spermatogenesis, maturation arrest, and Sertoli cell-only syndrome, but the amount of the protein in the maturation arrest and Sertoli cell-only syndrome samples was altered.\n'
p2032
sg4
(lp2033
(dp2034
g7
I31
sg8
g18
sg10
I4
sg11
VHSFY
p2035
sg13
I1
sasg20
(lp2036
(dp2037
g7
I91
sg23
VC0333951
p2038
sg10
I17
sg11
Vmaturation arrest
p2039
sg13
I2
sa(dp2040
g7
I114
sg23
VC1384583
p2041
sg10
I26
sg11
VSertoli cell-only syndrome
p2042
sg13
I3
sa(dp2043
g7
I91
sg23
VC0333951
p2044
sg10
I17
sg11
Vmaturation arrest
p2045
sg13
I2
sa(dp2046
g7
I114
sg23
VC1384583
p2047
sg10
I26
sg11
VSertoli cell-only syndrome
p2048
sg13
I3
sasa(dp2049
g2
S'However, the expression of HSFY was low or absent in spermatogenic cells of maturation arrest specimens, and the ratio of HSFY expressed in Sertoli cells was different in the specimens with maturation arrest and with Sertoli cell-only syndrome.\n'
p2050
sg4
(lp2051
(dp2052
g7
I27
sg8
g18
sg10
I4
sg11
VHSFY
p2053
sg13
I1
sa(dp2054
g7
I27
sg8
g18
sg10
I4
sg11
VHSFY
p2055
sg13
I1
sasg20
(lp2056
(dp2057
g7
I217
sg23
VC1384583
p2058
sg10
I26
sg11
VSertoli cell-only syndrome
p2059
sg13
I3
sa(dp2060
g7
I76
sg23
VC0333951
p2061
sg10
I17
sg11
Vmaturation arrest
p2062
sg13
I2
sa(dp2063
g7
I76
sg23
VC0333951
p2064
sg10
I17
sg11
Vmaturation arrest
p2065
sg13
I2
sasa(dp2066
g2
S'We propose that deletions of the testis-specific HSFY gene family may be a cause of unexplained cases of idiopathic male infertility.\n'
p2067
sg4
(lp2068
(dp2069
g7
I33
sg8
VP22492
p2070
sg10
I32
sg11
Vtestis-specific HSFY gene family
p2071
sg13
I4
sasg20
(lp2072
(dp2073
g7
I116
sg23
VC0021364
p2074
sg10
I16
sg11
Vmale infertility
p2075
sg13
I2
sasa(dp2076
g2
S'These results may suggest that deletion of HSFY is involved in azoospermia or oligospermia.\n'
p2077
sg4
(lp2078
(dp2079
g7
I43
sg8
g18
sg10
I4
sg11
VHSFY
p2080
sg13
I1
sasg20
(lp2081
(dp2082
g7
I78
sg23
VC0028960
p2083
sg10
I12
sg11
Voligospermia
p2084
sg13
I1
sa(dp2085
g7
I63
sg23
VC1321542
p2086
sg10
I11
sg11
Vazoospermia
p2087
sg13
I1
sasa(dp2088
g2
S'HSFY (heat shock transcription factor, Y chromosome) has been mapped in the AZFb region of the Y chromosome, whose deletion results in severe male infertility.\n'
p2089
sg4
(lp2090
(dp2091
g7
I6
sg8
VP35398
p2092
sg10
I31
sg11
Vheat shock transcription factor
p2093
sg13
I4
sa(dp2094
g7
I0
sg8
g18
sg10
I4
sg11
VHSFY
p2095
sg13
I1
sasg20
(lp2096
(dp2097
g7
I142
sg23
VC0021364
p2098
sg10
I16
sg11
Vmale infertility
p2099
sg13
I2
sasa(dp2100
g2
S'The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in RBV dosing during hepatitis C virus therapy with DAAs.\n'
p2101
sg4
(lp2102
(dp2103
g7
I42
sg8
g18
sg10
I7
sg11
VSLC29A1
p2104
sg13
I1
sasg20
(lp2105
(dp2106
g7
I128
sg23
VC0019196
p2107
sg10
I11
sg11
Vhepatitis C
p2108
sg13
I2
sasa(dp2109
g2
S'Genotypes of IL-28B and ENT1 (rs12980275, rs12979860, rs8099917 and rs760370) were analyzed in 107 HIV/HCV co-infectors in Hunan province and the distributions of gene polymorphisms were compared between chronic hepatitis and spontaneous clearance groups.\n'
p2110
sg4
(lp2111
(dp2112
g7
I13
sg8
g18
sg10
I6
sg11
VIL-28B
p2113
sg13
I1
sa(dp2114
g7
I24
sg8
g18
sg10
I4
sg11
VENT1
p2115
sg13
I1
sasg20
(lp2116
(dp2117
g7
I204
sg23
VC0019189
p2118
sg10
I17
sg11
Vchronic hepatitis
p2119
sg13
I2
sa(dp2120
g7
I99
sg23
VC0019693
p2121
sg10
I3
sg11
VHIV
p2122
sg13
I1
sasa(dp2123
g2
S'Ribavirin (RBV), a guanosine analog for treatment of hepatitis C, is a substrate of a nucleoside transporter, solute carrier family 29 member 1 (SLC29A1).\n'
p2124
sg4
(lp2125
(dp2126
g7
I86
sg8
g18
sg10
I22
sg11
Vnucleoside transporter
p2127
sg13
I2
sa(dp2128
g7
I110
sg8
g18
sg10
I33
sg11
Vsolute carrier family 29 member 1
p2129
sg13
I6
sa(dp2130
g7
I145
sg8
g18
sg10
I7
sg11
VSLC29A1
p2131
sg13
I1
sasg20
(lp2132
(dp2133
g7
I53
sg23
VC0019196
p2134
sg10
I11
sg11
Vhepatitis C
p2135
sg13
I2
sasa(dp2136
g2
S'Patients (n=169) chronically infected with the hepatitis C virus genotype 1, treated with standard doses of pegylated interferon-Alfa and weight-based doses of ribavirin for up to 48 weeks, were genotyped for 21 variants in nucleoside transporter genes SLC28A2, SLC28A3, SLC29A1, and SLC29A2, selected to include reported functional variants and to span the complete gene loci.\n'
p2137
sg4
(lp2138
(dp2139
g7
I224
sg8
g18
sg10
I36
sg11
Vnucleoside transporter genes SLC28A2
p2140
sg13
I4
sa(dp2141
g7
I284
sg8
g18
sg10
I7
sg11
VSLC29A2
p2142
sg13
I1
sa(dp2143
g7
I118
sg8
VP01563
p2144
sg10
I10
sg11
Vinterferon
p2145
sg13
I1
sa(dp2146
g7
I262
sg8
g18
sg10
I7
sg11
VSLC28A3
p2147
sg13
I1
sa(dp2148
g7
I271
sg8
g18
sg10
I7
sg11
VSLC29A1
p2149
sg13
I1
sasg20
(lp2150
(dp2151
g7
I47
sg23
VC0019196
p2152
sg10
I11
sg11
Vhepatitis C
p2153
sg13
I2
sasa(dp2154
g2
S'PPX, cisplatin, and concurrent radiation are well tolerated, easily administered regimen for esophageal cancer with a low incidence of significant esophagitis and a high pathologic CR rate consistent with the preclinical data of PPX and radiation.\n'
p2155
sg4
(lp2156
(dp2157
g7
I0
sg8
VP60510
p2158
sg10
I3
sg11
VPPX
p2159
sg13
I1
sasg20
(lp2160
(dp2161
g7
I147
sg23
VC0014868
p2162
sg10
I11
sg11
Vesophagitis
p2163
sg13
I1
sa(dp2164
g7
I93
sg23
VC0014859
p2165
sg10
I17
sg11
Vesophageal cancer
p2166
sg13
I2
sasa(dp2167
g2
S'Its diagnosis must be confirmed by a CT scan in order to eliminate the other causes that may lead to conductive hearing loss with an absence of stapedial reflex: fixation of the head of the malleus to the lateral wall of the tympanic cavity, absence of the long process of the incus or stapes, gusher syndrome, primary cholesteatoma, or tympanic facial nerve neuroma blocking the stapes.\n'
p2168
sg4
(lp2169
sg20
(lp2170
(dp2171
g7
I190
sg23
VC0017589
p2172
sg10
I7
sg11
Vmalleus
p2173
sg13
I1
sa(dp2174
g7
I367
sg23
VC0233660
p2175
sg10
I8
sg11
Vblocking
p2176
sg13
I1
sa(dp2177
g7
I234
sg23
VC0011334
p2178
sg10
I6
sg11
Vcavity
p2179
sg13
I1
sa(dp2180
g7
I359
sg23
VC0027858
p2181
sg10
I7
sg11
Vneuroma
p2182
sg13
I1
sa(dp2183
g7
I319
sg23
VC0008373
p2184
sg10
I13
sg11
Vcholesteatoma
p2185
sg13
I1
sa(dp2186
g7
I101
sg23
VC0018777
p2187
sg10
I23
sg11
Vconductive hearing loss
p2188
sg13
I3
sa(dp2189
g7
I301
sg23
VC0039082
p2190
sg10
I8
sg11
Vsyndrome
p2191
sg13
I1
sasa(dp2192
g2
S"Protein aggregates are hallmarks of nearly all age-related neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and several polyglutamine diseases such as Huntington's disease and different forms of spinocerebellar ataxias (SCA; SCA1-3, SCA6, and SCA7).\n"
p2193
sg4
(lp2194
(dp2195
g7
I305
sg8
g18
sg10
I4
sg11
VSCA7
p2196
sg13
I1
sa(dp2197
g7
I287
sg8
VP54253
p2198
sg10
I6
sg11
VSCA1-3
p2199
sg13
I1
sasg20
(lp2200
(dp2201
g7
I305
sg23
VC0752125
p2202
sg10
I4
sg11
VSCA7
p2203
sg13
I1
sa(dp2204
g7
I282
sg23
VC0087012
p2205
sg10
I3
sg11
VSCA
p2206
sg13
I1
sa(dp2207
g7
I59
sg23
VC0524851
p2208
sg10
I26
sg11
Vneurodegenerative diseases
p2209
sg13
I2
sa(dp2210
g7
I118
sg23
VC0030567
p2211
sg10
I19
sg11
VParkinson's disease
p2212
sg13
I2
sa(dp2213
g7
I287
sg23
VC0752120
p2214
sg10
I4
sg11
VSCA1
p2215
sg13
I1
sa(dp2216
g7
I139
sg23
VC0002736
p2217
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p2218
sg13
I3
sa(dp2219
g7
I213
sg23
VC0020179
p2220
sg10
I20
sg11
VHuntington's disease
p2221
sg13
I2
sa(dp2222
g7
I257
sg23
VC0087012
p2223
sg10
I23
sg11
Vspinocerebellar ataxias
p2224
sg13
I2
sa(dp2225
g7
I97
sg23
VC1521724
p2226
sg10
I19
sg11
VAlzheimer's disease
p2227
sg13
I2
sa(dp2228
g7
I295
sg23
VC0752124
p2229
sg10
I4
sg11
VSCA6
p2230
sg13
I1
sasa(dp2231
g2
S'Mutation of GRIP1 in mice displays essentially the same phenotype of the mutations of Fras1 or Frem2, which are the animal models of the human genetic disorder Fraser syndrome.\n'
p2232
sg4
(lp2233
(dp2234
g7
I86
sg8
g18
sg10
I5
sg11
VFras1
p2235
sg13
I1
sa(dp2236
g7
I12
sg8
g18
sg10
I5
sg11
VGRIP1
p2237
sg13
I1
sa(dp2238
g7
I95
sg8
g18
sg10
I5
sg11
VFrem2
p2239
sg13
I1
sasg20
(lp2240
(dp2241
g7
I143
sg23
VC0019247
p2242
sg10
I16
sg11
Vgenetic disorder
p2243
sg13
I2
sa(dp2244
g7
I160
sg23
VC0265233
p2245
sg10
I15
sg11
VFraser syndrome
p2246
sg13
I2
sasa(dp2247
g2
S'The GRIP1 PDZ12/Fras1 peptide complex not only provides a mechanistic explanation of the link between GRIP1 and the Fraser syndrome but may also serve as a foundation for searching for potential mutations in GRIP1 that could lead to the Fraser syndrome.\n'
p2248
sg4
(lp2249
(dp2250
g7
I16
sg8
g18
sg10
I5
sg11
VFras1
p2251
sg13
I1
sa(dp2252
g7
I4
sg8
g18
sg10
I5
sg11
VGRIP1
p2253
sg13
I1
sa(dp2254
g7
I4
sg8
g18
sg10
I5
sg11
VGRIP1
p2255
sg13
I1
sa(dp2256
g7
I4
sg8
g18
sg10
I11
sg11
VGRIP1 PDZ12
p2257
sg13
I2
sasg20
(lp2258
(dp2259
g7
I116
sg23
VC0265233
p2260
sg10
I15
sg11
VFraser syndrome
p2261
sg13
I2
sa(dp2262
g7
I116
sg23
VC0265233
p2263
sg10
I15
sg11
VFraser syndrome
p2264
sg13
I2
sasa(dp2265
g2
S'In one animal model of Fraser syndrome, the eye-blebs (eb) mouse, Grip1 is disrupted by a deletion of two coding exons.\n'
p2266
sg4
(lp2267
(dp2268
g7
I66
sg8
g18
sg10
I5
sg11
VGrip1
p2269
sg13
I1
sasg20
(lp2270
(dp2271
g7
I23
sg23
VC0265233
p2272
sg10
I15
sg11
VFraser syndrome
p2273
sg13
I2
sa(dp2274
g7
I48
sg23
VC0005758
p2275
sg10
I5
sg11
Vblebs
p2276
sg13
I1
sasa(dp2277
g2
S'Our data indicate that GRIP1 is required for normal cell-matrix interactions during early embryonic development and that inactivation of Grip1 causes Fraser syndrome-like defects in mice.\n'
p2278
sg4
(lp2279
(dp2280
g7
I23
sg8
g18
sg10
I5
sg11
VGRIP1
p2281
sg13
I1
sa(dp2282
g7
I137
sg8
g18
sg10
I5
sg11
VGrip1
p2283
sg13
I1
sasg20
(lp2284
(dp2285
g7
I150
sg23
VC0265233
p2286
sg10
I15
sg11
VFraser syndrome
p2287
sg13
I2
sa(dp2288
g7
I121
sg23
VC0544461
p2289
sg10
I12
sg11
Vinactivation
p2290
sg13
I1
sasa(dp2291
g2
S'Likelihood ratios (LRs), sensitivity, and specificity were calculated for individual symptoms and physical examination findings for the diagnosis of pneumonia.\n'
p2292
sg4
(lp2293
sg20
(lp2294
(dp2295
g7
I0
sg23
VC1835564
p2296
sg10
I17
sg11
VLikelihood ratios
p2297
sg13
I2
sa(dp2298
g7
I19
sg23
VC1835564
p2299
sg10
I3
sg11
VLRs
p2300
sg13
I1
sa(dp2301
g7
I149
sg23
VC0032285
p2302
sg10
I9
sg11
Vpneumonia
p2303
sg13
I1
sasa(dp2304
g2
S'Pooled sensitivity and specificity for the diagnosis of pneumonia using LUS were 94% (95% CI, 92%-96%) and 96% (94%-97%), respectively; pooled positive and negative LRs were 16.8 (7.7-37.0) and 0.07 (0.05-0.10), respectively; and, the area-under-the-ROC curve was 0.99 (0.98-0.99).\n'
p2305
sg4
(lp2306
sg20
(lp2307
(dp2308
g7
I56
sg23
VC0032285
p2309
sg10
I9
sg11
Vpneumonia
p2310
sg13
I1
sa(dp2311
g7
I165
sg23
VC1835564
p2312
sg10
I3
sg11
VLRs
p2313
sg13
I1
sasa(dp2314
g2
S'Here we report the compound ZCL039, a benzoxaborole-based derivative of AN2690, as a potent anti-pneumococcal agent that inhibits S. pneumoniae LeuRS (SpLeuRS) activity.\n'
p2315
sg4
(lp2316
(dp2317
g7
I130
sg8
g18
sg10
I19
sg11
VS. pneumoniae LeuRS
p2318
sg13
I3
sasg20
(lp2319
sa(dp2320
g2
S'Twelve LRs were revaccinated with the pH1N1 vaccine, and 7 were subsequently vaccinated with the 2010 seasonal trivalent influenza vaccine.\n'
p2321
sg4
(lp2322
sg20
(lp2323
(dp2324
g7
I121
sg23
VC0021400
p2325
sg10
I9
sg11
Vinfluenza
p2326
sg13
I1
sa(dp2327
g7
I7
sg23
VC1835564
p2328
sg10
I3
sg11
VLRs
p2329
sg13
I1
sasa(dp2330
g2
S'Herein we report that loss of Mus81 in Blm hypomorph mutant mice leads to infertility, and growth and developmental defects that are not observed in single mutants.\n'
p2331
sg4
(lp2332
(dp2333
g7
I30
sg8
g18
sg10
I5
sg11
VMus81
p2334
sg13
I1
sa(dp2335
g7
I39
sg8
VP54132
p2336
sg10
I20
sg11
VBlm hypomorph mutant
p2337
sg13
I3
sasg20
(lp2338
(dp2339
g7
I74
sg23
VC0021359
p2340
sg10
I11
sg11
Vinfertility
p2341
sg13
I1
sa(dp2342
g7
I39
sg23
VC0005859
p2343
sg10
I3
sg11
VBlm
p2344
sg13
I1
sa(dp2345
g7
I53
sg23
VC0596988
p2346
sg10
I6
sg11
Vmutant
p2347
sg13
I1
sasa(dp2348
g2
S'Myoferlin, a member of ferlin family of proteins, was first discovered as a candidate gene for muscular dystrophy and cardiomyopathy.\n'
p2349
sg4
(lp2350
sg20
(lp2351
(dp2352
g7
I95
sg23
VC0026850
p2353
sg10
I18
sg11
Vmuscular dystrophy
p2354
sg13
I2
sa(dp2355
g7
I118
sg23
VC0878544
p2356
sg10
I14
sg11
Vcardiomyopathy
p2357
sg13
I1
sasa(dp2358
g2
S'Together, these findings demonstrate the importance of dysferlin and myoferlin for transverse tubule function and in the genesis of muscular dystrophy.\n'
p2359
sg4
(lp2360
sg20
(lp2361
(dp2362
g7
I132
sg23
VC0026850
p2363
sg10
I18
sg11
Vmuscular dystrophy
p2364
sg13
I2
sasa(dp2365
g2
S'Ferlin mutations are associated with muscular dystrophy (dysferlin) and deafness (otoferlin) in humans, and infertility in Caenorhabditis elegans (Fer-1) and Drosophila (misfire), demonstrating their importance for normal cellular functioning.\n'
p2366
sg4
(lp2367
(dp2368
g7
I147
sg8
VP10109
p2369
sg10
I5
sg11
VFer-1
p2370
sg13
I1
sasg20
(lp2371
(dp2372
g7
I37
sg23
VC0026850
p2373
sg10
I18
sg11
Vmuscular dystrophy
p2374
sg13
I2
sa(dp2375
g7
I108
sg23
VC0021359
p2376
sg10
I11
sg11
Vinfertility
p2377
sg13
I1
sa(dp2378
g7
I72
sg23
VC0011053
p2379
sg10
I8
sg11
Vdeafness
p2380
sg13
I1
sasa(dp2381
g2
S'mRNA expression of the AMPs Alfa defensin (HNP-1); cathelicidin (LL-37); and Beta defensins (hBD-1, hBD-2, hBD-3, hBD-4) in human uveal and cutaneous melanoma cell lines, primary human uveal melanocytes, and primary human uveal melanoma cells was determined by reverse transcriptase polymerase chain reaction.\n'
p2382
sg4
(lp2383
(dp2384
g7
I107
sg8
VP81534
p2385
sg10
I5
sg11
VhBD-3
p2386
sg13
I1
sa(dp2387
g7
I93
sg8
VP60022
p2388
sg10
I5
sg11
VhBD-1
p2389
sg13
I1
sa(dp2390
g7
I23
sg8
VP30566
p2391
sg10
I18
sg11
VAMPs Alfa defensin
p2392
sg13
I3
sa(dp2393
g7
I77
sg8
VP59665
p2394
sg10
I14
sg11
VBeta defensins
p2395
sg13
I2
sa(dp2396
g7
I114
sg8
g18
sg10
I5
sg11
VhBD-4
p2397
sg13
I1
sa(dp2398
g7
I43
sg8
VP59665
p2399
sg10
I5
sg11
VHNP-1
p2400
sg13
I1
sa(dp2401
g7
I261
sg8
VP63136
p2402
sg10
I21
sg11
Vreverse transcriptase
p2403
sg13
I2
sa(dp2404
g7
I100
sg8
g18
sg10
I5
sg11
VhBD-2
p2405
sg13
I1
sasg20
(lp2406
(dp2407
g7
I140
sg23
VC0025202
p2408
sg10
I18
sg11
Vcutaneous melanoma
p2409
sg13
I2
sa(dp2410
g7
I93
sg23
VC1840321
p2411
sg10
I3
sg11
VhBD
p2412
sg13
I1
sa(dp2413
g7
I222
sg23
VC0220633
p2414
sg10
I14
sg11
Vuveal melanoma
p2415
sg13
I2
sa(dp2416
g7
I93
sg23
VC1840321
p2417
sg10
I3
sg11
VhBD
p2418
sg13
I1
sa(dp2419
g7
I93
sg23
VC1840321
p2420
sg10
I3
sg11
VhBD
p2421
sg13
I1
sa(dp2422
g7
I93
sg23
VC1840321
p2423
sg10
I3
sg11
VhBD
p2424
sg13
I1
sasa(dp2425
g2
S'Previous studies have reported that LL-37 participates in the development of numerous tumour types, such as ovarian cancer, lung cancer, melanoma and breast cancer.\n'
p2426
sg4
(lp2427
sg20
(lp2428
(dp2429
g7
I108
sg23
VC1140680
p2430
sg10
I14
sg11
Vovarian cancer
p2431
sg13
I2
sa(dp2432
g7
I150
sg23
VC0678222
p2433
sg10
I13
sg11
Vbreast cancer
p2434
sg13
I2
sa(dp2435
g7
I137
sg23
VC0025202
p2436
sg10
I8
sg11
Vmelanoma
p2437
sg13
I1
sa(dp2438
g7
I124
sg23
VC0684249
p2439
sg10
I11
sg11
Vlung cancer
p2440
sg13
I2
sa(dp2441
g7
I86
sg23
VC0027651
p2442
sg10
I6
sg11
Vtumour
p2443
sg13
I1
sasa(dp2444
g2
S'However, the function of LL-37 in the development of skin squamous cell carcinoma (SCC) has not yet been fully elucidated.\n'
p2445
sg4
(lp2446
sg20
(lp2447
(dp2448
g7
I53
sg23
VC0553723
p2449
sg10
I28
sg11
Vskin squamous cell carcinoma
p2450
sg13
I4
sasa(dp2451
g2
S'The roles of LL-37 in oral squamous cell carcinoma (OSCC) are still not clear.\n'
p2452
sg4
(lp2453
sg20
(lp2454
(dp2455
g7
I27
sg23
VC0007137
p2456
sg10
I23
sg11
Vsquamous cell carcinoma
p2457
sg13
I3
sasa(dp2458
g2
S'Here human CAMP/LL-37 expression was assessed by immunohistochemistry in normal and OSCC tissues.\n'
p2459
sg4
(lp2460
sg20
(lp2461
sa(dp2462
g2
S'Taken together, these results suggested that human CAMP/LL-37 might act as a tumor-suppressor in OSCC and DNA methylation might play roles during carcinogenesis via directly downregulating human CAMP promoter activity.\n'
p2463
sg4
(lp2464
(dp2465
g7
I45
sg8
VP49913
p2466
sg10
I16
sg11
Vhuman CAMP/LL-37
p2467
sg13
I2
sa(dp2468
g7
I189
sg8
VP49913
p2469
sg10
I19
sg11
Vhuman CAMP promoter
p2470
sg13
I3
sasg20
(lp2471
(dp2472
g7
I128
sg23
VC0699820
p2473
sg10
I10
sg11
Vplay roles
p2474
sg13
I2
sa(dp2475
g7
I146
sg23
VC0596263
p2476
sg10
I14
sg11
Vcarcinogenesis
p2477
sg13
I1
sa(dp2478
g7
I77
sg23
VC0027651
p2479
sg10
I5
sg11
Vtumor
p2480
sg13
I1
sasa(dp2481
g2
S'miR-663a is upregulated by administration of the human cathelicidin AMP, LL-37, and its analogue peptide, FF/CAP18, in the colon cancer cell line HCT116.\n'
p2482
sg4
(lp2483
(dp2484
g7
I0
sg8
g18
sg10
I8
sg11
VmiR-663a
p2485
sg13
I1
sa(dp2486
g7
I109
sg8
VP49913
p2487
sg10
I5
sg11
VCAP18
p2488
sg13
I1
sasg20
(lp2489
(dp2490
g7
I123
sg23
VC0699790
p2491
sg10
I12
sg11
Vcolon cancer
p2492
sg13
I2
sasa(dp2493
g2
S'Previous studies have demonstrated that it LL-37 serves a functional role in the development of numerous types of cancer including ovarian, breast, prostate and lung cancer.\n'
p2494
sg4
(lp2495
sg20
(lp2496
(dp2497
g7
I114
sg23
VC0006826
p2498
sg10
I6
sg11
Vcancer
p2499
sg13
I1
sa(dp2500
g7
I161
sg23
VC0684249
p2501
sg10
I11
sg11
Vlung cancer
p2502
sg13
I2
sasa(dp2503
g2
S'Studies have shown that LL-37 participates in the development of a variety of tumours, such as lung cancer, ovarian cancer, breast cancer and melanoma.\n'
p2504
sg4
(lp2505
sg20
(lp2506
(dp2507
g7
I100
sg23
VC1140680
p2508
sg10
I15
sg11
Vcancer, ovarian
p2509
sg13
I2
sa(dp2510
g7
I116
sg23
VC0006142
p2511
sg10
I14
sg11
Vcancer, breast
p2512
sg13
I2
sa(dp2513
g7
I142
sg23
VC0025202
p2514
sg10
I8
sg11
Vmelanoma
p2515
sg13
I1
sa(dp2516
g7
I78
sg23
VC0027651
p2517
sg10
I7
sg11
Vtumours
p2518
sg13
I1
sa(dp2519
g7
I100
sg23
VC0006826
p2520
sg10
I6
sg11
Vcancer
p2521
sg13
I1
sasa(dp2522
g2
S'However, the role of LL-37 in the development of skin squamous cell carcinoma (SCC) is not clear.\n'
p2523
sg4
(lp2524
sg20
(lp2525
(dp2526
g7
I49
sg23
VC0553723
p2527
sg10
I28
sg11
Vskin squamous cell carcinoma
p2528
sg13
I4
sasa(dp2529
g2
S'The aim of this study was to evaluate an engineered nanostructure to silence five important oncogenes, including BAG1, MDM2, Bcl-2, BIRC5 (survivin) and XIAP, in acute myeloid leukemia subtype 2 (AML-M2).\n'
p2530
sg4
(lp2531
(dp2532
g7
I125
sg8
VP10415
p2533
sg10
I5
sg11
VBcl-2
p2534
sg13
I1
sa(dp2535
g7
I153
sg8
VP98170
p2536
sg10
I4
sg11
VXIAP
p2537
sg13
I1
sasg20
(lp2538
(dp2539
g7
I196
sg23
VC0023467
p2540
sg10
I3
sg11
VAML
p2541
sg13
I1
sa(dp2542
g7
I69
sg23
VC0858952
p2543
sg10
I7
sg11
Vsilence
p2544
sg13
I1
sa(dp2545
g7
I162
sg23
VC0023467
p2546
sg10
I22
sg11
Vacute myeloid leukemia
p2547
sg13
I3
sasa(dp2548
g2
S'B-cell lymphoma (BCL) 2-associated AthanoGene-1 (BAG-1) is a prosurvival chaperone recently found involved in the maintenance of acute myeloid leukemia (AML) cells survival in vitro.\n'
p2549
sg4
(lp2550
(dp2551
g7
I49
sg8
g18
sg10
I5
sg11
VBAG-1
p2552
sg13
I1
sasg20
(lp2553
(dp2554
g7
I129
sg23
VC0023467
p2555
sg10
I22
sg11
Vacute myeloid leukemia
p2556
sg13
I3
sa(dp2557
g7
I153
sg23
VC0023467
p2558
sg10
I3
sg11
VAML
p2559
sg13
I1
sa(dp2560
g7
I17
sg23
VC0079731
p2561
sg10
I3
sg11
VBCL
p2562
sg13
I1
sa(dp2563
g7
I0
sg23
VC0079731
p2564
sg10
I15
sg11
VB-cell lymphoma
p2565
sg13
I2
sasa(dp2566
g2
S'Silencing of BAG-1 expression confirmed a decreased BCL-2 protein level but, in addition, provoked the increased transcription of GADD34 stress sensor.\n'
p2567
sg4
(lp2568
(dp2569
g7
I52
sg8
VP10415
p2570
sg10
I13
sg11
VBCL-2 protein
p2571
sg13
I2
sa(dp2572
g7
I13
sg8
g18
sg10
I5
sg11
VBAG-1
p2573
sg13
I1
sa(dp2574
g7
I130
sg8
g18
sg10
I6
sg11
VGADD34
p2575
sg13
I1
sasg20
(lp2576
sa(dp2577
g2
S'A similar phenomenon was triggered after addition of Thioflavin S, which was shown to block BAG-1/BCL-2 interaction and to increase cell death, enforcing a prosurvival role of the BAG-1 protein in AML.\n'
p2578
sg4
(lp2579
(dp2580
g7
I98
sg8
VP10415
p2581
sg10
I5
sg11
VBCL-2
p2582
sg13
I1
sa(dp2583
g7
I92
sg8
g18
sg10
I5
sg11
VBAG-1
p2584
sg13
I1
sa(dp2585
g7
I180
sg8
g18
sg10
I13
sg11
VBAG-1 protein
p2586
sg13
I2
sasg20
(lp2587
(dp2588
g7
I197
sg23
VC0023467
p2589
sg10
I3
sg11
VAML
p2590
sg13
I1
sasa(dp2591
g2
S'Neuronal glucocorticoid receptor (GR) overexpressing, B-cell lymphoma 2 (Bcl-2) heterozygous KO, and Bcl-2-associated athanogene (BAG1) heterozygous KO mice show vulnerability to mood swings.\n'
p2592
sg4
(lp2593
(dp2594
g7
I101
sg8
VP10415
p2595
sg10
I27
sg11
VBcl-2-associated athanogene
p2596
sg13
I2
sa(dp2597
g7
I34
sg8
VP00390
p2598
sg10
I2
sg11
VGR
p2599
sg13
I1
sa(dp2600
g7
I54
sg8
VP10415
p2601
sg10
I17
sg11
VB-cell lymphoma 2
p2602
sg13
I3
sa(dp2603
g7
I0
sg8
VP04150
p2604
sg10
I32
sg11
VNeuronal glucocorticoid receptor
p2605
sg13
I3
sa(dp2606
g7
I73
sg8
VP10415
p2607
sg10
I5
sg11
VBcl-2
p2608
sg13
I1
sasg20
(lp2609
(dp2610
g7
I179
sg23
VC0085633
p2611
sg10
I11
sg11
Vmood swings
p2612
sg13
I2
sa(dp2613
g7
I54
sg23
VC0079731
p2614
sg10
I15
sg11
VB-cell lymphoma
p2615
sg13
I2
sasa(dp2616
g2
S'We show that reexpression of miR-28 impairs cell proliferation and clonogenic properties of BL cells by modulating several targets including MAD2 mitotic arrest deficient-like 1, MAD2L1, a component of the spindle checkpoint whose down-regulation is essential in mediating miR-28-induced proliferation arrest, and BCL2-associated athanogene, BAG1, an activator of the ERK pathway.\n'
p2617
sg4
(lp2618
(dp2619
g7
I314
sg8
VP10415
p2620
sg10
I26
sg11
VBCL2-associated athanogene
p2621
sg13
I2
sa(dp2622
g7
I368
sg8
VP29323
p2623
sg10
I3
sg11
VERK
p2624
sg13
I1
sa(dp2625
g7
I141
sg8
g18
sg10
I36
sg11
VMAD2 mitotic arrest deficient-like 1
p2626
sg13
I5
sa(dp2627
g7
I179
sg8
g18
sg10
I6
sg11
VMAD2L1
p2628
sg13
I1
sasg20
(lp2629
(dp2630
g7
I49
sg23
VC0334094
p2631
sg10
I13
sg11
Vproliferation
p2632
sg13
I1
sa(dp2633
g7
I49
sg23
VC0334094
p2634
sg10
I13
sg11
Vproliferation
p2635
sg13
I1
sasa(dp2636
g2
S'The bag-1 and bcl-2 coexpressing cells produced more IgG than the the cells expressing bcl-2 alone.Apoptosis of Friend murine erythroleukemia(F-MEL) cells was suppressed with antisense c-jun expression.\n'
p2637
sg4
(lp2638
(dp2639
g7
I14
sg8
VP10415
p2640
sg10
I5
sg11
Vbcl-2
p2641
sg13
I1
sa(dp2642
g7
I185
sg8
VP05412
p2643
sg10
I5
sg11
Vc-jun
p2644
sg13
I1
sa(dp2645
g7
I14
sg8
VP10415
p2646
sg10
I5
sg11
Vbcl-2
p2647
sg13
I1
sa(dp2648
g7
I4
sg8
g18
sg10
I5
sg11
Vbag-1
p2649
sg13
I1
sasg20
(lp2650
(dp2651
g7
I144
sg23
VC3149631
p2652
sg10
I3
sg11
VMEL
p2653
sg13
I1
sa(dp2654
g7
I126
sg23
VC0023440
p2655
sg10
I15
sg11
Verythroleukemia
p2656
sg13
I1
sasa(dp2657
g2
S'BCL2 associated Athano-Gene 1 (BAG1) is a multifunctional protein that has been described to be involved in different cell processes linked to cell survival.\n'
p2658
sg4
(lp2659
(dp2660
g7
I0
sg8
VP10415
p2661
sg10
I4
sg11
VBCL2
p2662
sg13
I1
sasg20
(lp2663
sa(dp2664
g2
S'Here, BAG1 protein was found highly expressed in children with acute myeloid leukemia at diagnosis, and in a cohort of leukemic cell lines.\n'
p2665
sg4
(lp2666
sg20
(lp2667
(dp2668
g7
I63
sg23
VC0023467
p2669
sg10
I22
sg11
Vacute myeloid leukemia
p2670
sg13
I3
sasa(dp2671
g2
S"A silencing approach was used for determining BAG1's role in AML, finding that its down-regulation decreased expression of BCL2, BCL-XL, MCL1, and phospho-ERK1/2, all proteins able to sustain leukemia, without affecting the pro-apoptotic protein BAX.\n"
p2672
sg4
(lp2673
(dp2674
g7
I123
sg8
VP10415
p2675
sg10
I4
sg11
VBCL2
p2676
sg13
I1
sa(dp2677
g7
I129
sg8
g18
sg10
I6
sg11
VBCL-XL
p2678
sg13
I1
sa(dp2679
g7
I155
sg8
VP27361
p2680
sg10
I6
sg11
VERK1/2
p2681
sg13
I1
sasg20
(lp2682
(dp2683
g7
I61
sg23
VC0023467
p2684
sg10
I3
sg11
VAML
p2685
sg13
I1
sa(dp2686
g7
I192
sg23
VC0023418
p2687
sg10
I8
sg11
Vleukemia
p2688
sg13
I1
sasa(dp2689
g2
S'Cell death was CASPASE-3 dependent, was accompanied by PARP cleavage and documented by an increased release of pro-apoptotic molecules Smac/DIABLO and Cytochrome c. BAG1 was found to directly maintain BCL2 and to protect MCL1 from proteasomal degradation by controlling USP9X expression, which appeared to be its novel target.\n'
p2690
sg4
(lp2691
(dp2692
g7
I270
sg8
g18
sg10
I5
sg11
VUSP9X
p2693
sg13
I1
sa(dp2694
g7
I140
sg8
g18
sg10
I6
sg11
VDIABLO
p2695
sg13
I1
sa(dp2696
g7
I201
sg8
VP10415
p2697
sg10
I4
sg11
VBCL2
p2698
sg13
I1
sa(dp2699
g7
I151
sg8
VP99999
p2700
sg10
I12
sg11
VCytochrome c
p2701
sg13
I2
sa(dp2702
g7
I55
sg8
VP09874
p2703
sg10
I4
sg11
VPARP
p2704
sg13
I1
sa(dp2705
g7
I135
sg8
g18
sg10
I4
sg11
VSmac
p2706
sg13
I1
sasg20
(lp2707
sa(dp2708
g2
S'Finally, BAG1 was found able to affect leukemia cell fate by influencing the expression of anti-apoptotic proteins crucial for AML maintenance.\n'
p2709
sg4
(lp2710
sg20
(lp2711
(dp2712
g7
I127
sg23
VC0023467
p2713
sg10
I3
sg11
VAML
p2714
sg13
I1
sa(dp2715
g7
I39
sg23
VC0023418
p2716
sg10
I8
sg11
Vleukemia
p2717
sg13
I1
sasa(dp2718
g2
S'These agents also upregulate the expression of trophic/protective molecules such as brain-derived neurotrophic factor, nerve growth factor, B-cell lymphoma 2, serine-threonine kinase, and Bcl-2 associated athanogene 1, and inactivate proapoptotic molecules such as GSK-3.\n'
p2719
sg4
(lp2720
(dp2721
g7
I188
sg8
VP10415
p2722
sg10
I29
sg11
VBcl-2 associated athanogene 1
p2723
sg13
I4
sa(dp2724
g7
I119
sg8
VP01138
p2725
sg10
I38
sg11
Vnerve growth factor, B-cell lymphoma 2
p2726
sg13
I6
sa(dp2727
g7
I159
sg8
g18
sg10
I23
sg11
Vserine-threonine kinase
p2728
sg13
I2
sa(dp2729
g7
I265
sg8
VP49841
p2730
sg10
I5
sg11
VGSK-3
p2731
sg13
I1
sasg20
(lp2732
(dp2733
g7
I140
sg23
VC0079731
p2734
sg10
I15
sg11
VB-cell lymphoma
p2735
sg13
I2
sasa(dp2736
g2
S'These studies have produced informative models that have altered the expression of genes/pathways implicated in BD, including the point mutation D181A of mouse mitochondrial DNA polymerase (POLG), glutamate receptor 6 (GluR6), Clock, extracellular regulated kinase 1 (ERK1), glycogen synthase kinase-3beta (GSK-3beta), B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated athanogene (BAG-1).\n'
p2737
sg4
(lp2738
(dp2739
g7
I319
sg8
VP10415
p2740
sg10
I17
sg11
VB-cell lymphoma 2
p2741
sg13
I3
sa(dp2742
g7
I338
sg8
VP10415
p2743
sg10
I5
sg11
VBcl-2
p2744
sg13
I1
sa(dp2745
g7
I234
sg8
VP27361
p2746
sg10
I32
sg11
Vextracellular regulated kinase 1
p2747
sg13
I4
sa(dp2748
g7
I154
sg8
g18
sg10
I34
sg11
Vmouse mitochondrial DNA polymerase
p2749
sg13
I4
sa(dp2750
g7
I190
sg8
VP54098
p2751
sg10
I4
sg11
VPOLG
p2752
sg13
I1
sa(dp2753
g7
I307
sg8
VP49841
p2754
sg10
I9
sg11
VGSK-3beta
p2755
sg13
I1
sa(dp2756
g7
I227
sg8
g18
sg10
I5
sg11
VClock
p2757
sg13
I1
sa(dp2758
g7
I197
sg8
g18
sg10
I20
sg11
Vglutamate receptor 6
p2759
sg13
I3
sa(dp2760
g7
I219
sg8
g18
sg10
I5
sg11
VGluR6
p2761
sg13
I1
sa(dp2762
g7
I268
sg8
VP27361
p2763
sg10
I4
sg11
VERK1
p2764
sg13
I1
sa(dp2765
g7
I275
sg8
VP13807
p2766
sg10
I30
sg11
Vglycogen synthase kinase-3beta
p2767
sg13
I3
sa(dp2768
g7
I378
sg8
g18
sg10
I5
sg11
VBAG-1
p2769
sg13
I1
sa(dp2770
g7
I349
sg8
VP10415
p2771
sg10
I27
sg11
VBcl-2-associated athanogene
p2772
sg13
I2
sasg20
(lp2773
(dp2774
g7
I319
sg23
VC0079731
p2775
sg10
I15
sg11
VB-cell lymphoma
p2776
sg13
I2
sasa(dp2777
g2
S'To evaluate the diagnostic accuracy of the Serum-Ascites Albumin Gradient (GASA), Protein Concentration in the Ascitic Fluid (PTLA), Albumin Concentration in the ascitic fluid (CAA) and the Protein Ascites/Serum Ratio (IPAS) for the diagnosis of ascites due to portal hypertension.\n'
p2778
sg4
(lp2779
(dp2780
g7
I43
sg8
g18
sg10
I21
sg11
VSerum-Ascites Albumin
p2781
sg13
I2
sasg20
(lp2782
(dp2783
g7
I261
sg23
VC0020541
p2784
sg10
I19
sg11
Vportal hypertension
p2785
sg13
I2
sa(dp2786
g7
I177
sg23
VC1842937
p2787
sg10
I3
sg11
VCAA
p2788
sg13
I1
sa(dp2789
g7
I141
sg23
VC1842937
p2790
sg10
I34
sg11
VConcentration in the ascitic fluid
p2791
sg13
I5
sasa(dp2792
g2
S'We obtained the diagnostic accuracy, sensitivity, specificity, PPV and NPV of the Serum-Ascites Albumin Gradient (GASA), Protein Concentration in the Ascitic Fluid (PTLA), Albumin Concentration in the ascitic fluid (CAA) and the Protein Ascites/Serum Ratio (IPAS) for the diagnosis of ascites due to portal hypertension.\n'
p2793
sg4
(lp2794
(dp2795
g7
I82
sg8
g18
sg10
I21
sg11
VSerum-Ascites Albumin
p2796
sg13
I2
sasg20
(lp2797
(dp2798
g7
I300
sg23
VC0020541
p2799
sg10
I19
sg11
Vportal hypertension
p2800
sg13
I2
sa(dp2801
g7
I216
sg23
VC1842937
p2802
sg10
I3
sg11
VCAA
p2803
sg13
I1
sa(dp2804
g7
I180
sg23
VC1842937
p2805
sg10
I34
sg11
VConcentration in the ascitic fluid
p2806
sg13
I5
sasa(dp2807
g2
S'Differences between HIV and AD in the patterns of ABeta and Tau biomarkers suggest that CNS HIV infection and AD may not share some of same mechanisms of neuronal injury.\n'
p2808
sg4
(lp2809
(dp2810
g7
I60
sg8
VP49768
p2811
sg10
I3
sg11
VTau
p2812
sg13
I1
sa(dp2813
g7
I50
sg8
g18
sg10
I5
sg11
VABeta
p2814
sg13
I1
sasg20
(lp2815
(dp2816
g7
I92
sg23
VC0019693
p2817
sg10
I13
sg11
VHIV infection
p2818
sg13
I2
sa(dp2819
g7
I20
sg23
VC0019693
p2820
sg10
I3
sg11
VHIV
p2821
sg13
I1
sasa(dp2822
g2
S'In addition, Ost treatment in APP/PS1 double transgenic (Tg) mice markedly restored cognitive functions, reduced ABeta plague production and rescued functional impairment of hippocampal neurons.\n'
p2823
sg4
(lp2824
(dp2825
g7
I30
sg8
g18
sg10
I3
sg11
VAPP
p2826
sg13
I1
sa(dp2827
g7
I113
sg8
g18
sg10
I5
sg11
VABeta
p2828
sg13
I1
sa(dp2829
g7
I13
sg8
VP02818
p2830
sg10
I3
sg11
VOst
p2831
sg13
I1
sa(dp2832
g7
I34
sg8
VP49768
p2833
sg10
I3
sg11
VPS1
p2834
sg13
I1
sasg20
(lp2835
(dp2836
g7
I160
sg23
VC0684336
p2837
sg10
I10
sg11
Vimpairment
p2838
sg13
I1
sa(dp2839
g7
I119
sg23
VC0032064
p2840
sg10
I6
sg11
Vplague
p2841
sg13
I1
sasa(dp2842
g2
S'We depleted microglia by injecting diphtheria toxin (DT) in CX 3 CR1 CreER/+ :R26 DTR/+ (CX 3 CR1-iDTR) mice crossed with APPswe/PSEN1dE9 (APP/PS1) mice.\n'
p2843
sg4
(lp2844
(dp2845
g7
I35
sg8
g18
sg10
I16
sg11
Vdiphtheria toxin
p2846
sg13
I2
sa(dp2847
g7
I122
sg8
g18
sg10
I3
sg11
VAPP
p2848
sg13
I1
sa(dp2849
g7
I53
sg8
g18
sg10
I2
sg11
VDT
p2850
sg13
I1
sa(dp2851
g7
I60
sg8
VP17927
p2852
sg10
I14
sg11
VCX 3 CR1 CreER
p2853
sg13
I4
sa(dp2854
g7
I143
sg8
VP49768
p2855
sg10
I3
sg11
VPS1
p2856
sg13
I1
sa(dp2857
g7
I89
sg8
VP17927
p2858
sg10
I13
sg11
VCX 3 CR1-iDTR
p2859
sg13
I3
sasg20
(lp2860
(dp2861
g7
I35
sg23
VC0012546
p2862
sg10
I10
sg11
Vdiphtheria
p2863
sg13
I1
sasa(dp2864
g2
S'"Klickbare" 1,2,4-Trioxolan-Proteinprofilingsonden (ABPPs) wurden so entworfen, dass sie ihre Aktivitaet gegen Malaria behalten und die molekularen Targets des Blutstadiums von Plasmodium falciparum in situ alkylieren.\n'
p2865
sg4
(lp2866
sg20
(lp2867
(dp2868
g7
I111
sg23
VC0024530
p2869
sg10
I7
sg11
VMalaria
p2870
sg13
I1
sa(dp2871
g7
I156
sg23
VC0394006
p2872
sg10
I3
sg11
Vdes
p2873
sg13
I1
sasa(dp2874
g2
S'Moreover, four times of infusion of ADSCs resulted in a more significant reduction of blood glucose and insulin resistance, whereas SPX exacerbated hyperglycemia and insulin resistance and attenuated the effects of ADSCs.\n'
p2875
sg4
(lp2876
(dp2877
g7
I104
sg8
VP01308
p2878
sg10
I7
sg11
Vinsulin
p2879
sg13
I1
sa(dp2880
g7
I104
sg8
VP01308
p2881
sg10
I7
sg11
Vinsulin
p2882
sg13
I1
sasg20
(lp2883
(dp2884
g7
I104
sg23
VC0021655
p2885
sg10
I18
sg11
Vinsulin resistance
p2886
sg13
I2
sa(dp2887
g7
I104
sg23
VC0021655
p2888
sg10
I18
sg11
Vinsulin resistance
p2889
sg13
I2
sa(dp2890
g7
I148
sg23
VC0020456
p2891
sg10
I13
sg11
Vhyperglycemia
p2892
sg13
I1
sasa(dp2893
g2
S'The purpose of the current study was to determine the effect of obesity and type 2 diabetes (T2DM), and the effect of glucose ingestion on circulating spexin concentration in adolescents.\n'
p2894
sg4
(lp2895
(dp2896
g7
I151
sg8
g18
sg10
I6
sg11
Vspexin
p2897
sg13
I1
sasg20
(lp2898
(dp2899
g7
I64
sg23
VC0028754
p2900
sg10
I7
sg11
Vobesity
p2901
sg13
I1
sa(dp2902
g7
I76
sg23
VC0011860
p2903
sg10
I15
sg11
Vtype 2 diabetes
p2904
sg13
I3
sasa(dp2905
g2
S'Study 2 examined the effects of spexin, a novel adipokine, on obesity, type 2 diabetes mellitus (T2DM), and HS in these mice.\n'
p2906
sg4
(lp2907
(dp2908
g7
I32
sg8
g18
sg10
I6
sg11
Vspexin
p2909
sg13
I1
sasg20
(lp2910
(dp2911
g7
I62
sg23
VC0028754
p2912
sg10
I7
sg11
Vobesity
p2913
sg13
I1
sa(dp2914
g7
I97
sg23
VC0011860
p2915
sg10
I4
sg11
VT2DM
p2916
sg13
I1
sa(dp2917
g7
I71
sg23
VC0011860
p2918
sg10
I24
sg11
Vtype 2 diabetes mellitus
p2919
sg13
I4
sasa(dp2920
g2
S'Study 2 indicated (1) that obese DIO mice often also have T2DM and/or nonalcoholic fatty liver disease (NAFLD); (2) confirmed that spexin treatment caused weight loss in DIO mice; (3) in DIO mice with T2DM, spexin also improved glucose tolerance, decreasing insulin resistance and HbAlc.\n'
p2921
sg4
(lp2922
(dp2923
g7
I131
sg8
g18
sg10
I6
sg11
Vspexin
p2924
sg13
I1
sa(dp2925
g7
I131
sg8
g18
sg10
I6
sg11
Vspexin
p2926
sg13
I1
sa(dp2927
g7
I258
sg8
VP01308
p2928
sg10
I7
sg11
Vinsulin
p2929
sg13
I1
sasg20
(lp2930
(dp2931
g7
I27
sg23
VC0028754
p2932
sg10
I5
sg11
Vobese
p2933
sg13
I1
sa(dp2934
g7
I70
sg23
VC0400966
p2935
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p2936
sg13
I4
sa(dp2937
g7
I236
sg23
VC0020963
p2938
sg10
I9
sg11
Vtolerance
p2939
sg13
I1
sa(dp2940
g7
I258
sg23
VC0021655
p2941
sg10
I18
sg11
Vinsulin resistance
p2942
sg13
I2
sa(dp2943
g7
I104
sg23
VC0400966
p2944
sg10
I5
sg11
VNAFLD
p2945
sg13
I1
sasa(dp2946
g2
S'Therefore, we aimed to examine its expression in human tissues and test whether spexin could have a role in glucose and lipid metabolism in type 2 diabetes mellitus (T2DM).\n'
p2947
sg4
(lp2948
(dp2949
g7
I80
sg8
g18
sg10
I6
sg11
Vspexin
p2950
sg13
I1
sasg20
(lp2951
(dp2952
g7
I140
sg23
VC0011860
p2953
sg10
I24
sg11
Vtype 2 diabetes mellitus
p2954
sg13
I4
sa(dp2955
g7
I166
sg23
VC0011860
p2956
sg10
I4
sg11
VT2DM
p2957
sg13
I1
sasa(dp2958
g2
S'The prestimulation insulin secretion rate and maximal insulin secretion rate in response to hyperglycemia and arginine were significantly lower in SPx than in WPx, Kx, or Ns (P &lt; 0.05).\n'
p2959
sg4
(lp2960
(dp2961
g7
I19
sg8
VP01308
p2962
sg10
I7
sg11
Vinsulin
p2963
sg13
I1
sa(dp2964
g7
I19
sg8
VP01308
p2965
sg10
I7
sg11
Vinsulin
p2966
sg13
I1
sasg20
(lp2967
(dp2968
g7
I92
sg23
VC0020456
p2969
sg10
I13
sg11
Vhyperglycemia
p2970
sg13
I1
sasa(dp2971
g2
S'Both SPx and WPx demonstrated suppression of glucagon release in response to graded hyperglycemia, but failure to adequately suppress arginine-induced glucagon release.\n'
p2972
sg4
(lp2973
(dp2974
g7
I45
sg8
VP01275
p2975
sg10
I8
sg11
Vglucagon
p2976
sg13
I1
sa(dp2977
g7
I45
sg8
VP01275
p2978
sg10
I8
sg11
Vglucagon
p2979
sg13
I1
sasg20
(lp2980
(dp2981
g7
I30
sg23
VC0221103
p2982
sg10
I11
sg11
Vsuppression
p2983
sg13
I1
sa(dp2984
g7
I84
sg23
VC0020456
p2985
sg10
I13
sg11
Vhyperglycemia
p2986
sg13
I1
sasa(dp2987
g2
S'A population pharmacokinetics (PK) analysis was performed to characterize T-DM1 PK and evaluate the impact of patient characteristics on T-DM1 PK in previously treated patients with HER2-positive advanced gastric cancer (AGC).\n'
p2988
sg4
(lp2989
(dp2990
g7
I182
sg8
VP04626
p2991
sg10
I4
sg11
VHER2
p2992
sg13
I1
sa(dp2993
g7
I74
sg8
g18
sg10
I8
sg11
VT-DM1 PK
p2994
sg13
I2
sa(dp2995
g7
I74
sg8
g18
sg10
I8
sg11
VT-DM1 PK
p2996
sg13
I2
sasg20
(lp2997
(dp2998
g7
I76
sg23
VC2931688
p2999
sg10
I3
sg11
VDM1
p3000
sg13
I1
sa(dp3001
g7
I76
sg23
VC2931688
p3002
sg10
I3
sg11
VDM1
p3003
sg13
I1
sa(dp3004
g7
I205
sg23
VC0024623
p3005
sg10
I14
sg11
Vgastric cancer
p3006
sg13
I2
sasa(dp3007
g2
S'The curcumin analogue DM-1 (sodium 4-[5-(4-hydroxy-3-methoxy-phenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate) has substantial anti-tumor activity in melanoma, but its mechanism of action remains unclear.\n'
p3008
sg4
(lp3009
sg20
(lp3010
(dp3011
g7
I135
sg23
VC0027651
p3012
sg10
I5
sg11
Vtumor
p3013
sg13
I1
sa(dp3014
g7
I153
sg23
VC0025202
p3015
sg10
I8
sg11
Vmelanoma
p3016
sg13
I1
sasa(dp3017
g2
S'Of these TOP1 and ADK were regulated by DM-1 in treatment-naive and vemurafenib-resistant melanoma cells respectively.\n'
p3018
sg4
(lp3019
(dp3020
g7
I9
sg8
VP11387
p3021
sg10
I4
sg11
VTOP1
p3022
sg13
I1
sa(dp3023
g7
I40
sg8
g18
sg10
I4
sg11
VDM-1
p3024
sg13
I1
sa(dp3025
g7
I18
sg8
VP55263
p3026
sg10
I3
sg11
VADK
p3027
sg13
I1
sasg20
(lp3028
(dp3029
g7
I90
sg23
VC0025202
p3030
sg10
I8
sg11
Vmelanoma
p3031
sg13
I1
sasa(dp3032
g2
S'DM-1 is a sodium phenolate and curcumin analog with proven anticancer, anti-proliferative and anti-metastatic properties.\n'
p3033
sg4
(lp3034
sg20
(lp3035
(dp3036
g7
I76
sg23
VC0334094
p3037
sg10
I13
sg11
Vproliferative
p3038
sg13
I1
sasa(dp3039
g2
S'In this paper, the DM-1 compound showed in vivo antitumor activity alone or in combination with chemotherapeutic DTIC in B16F10 melanoma-bearing mice.\n'
p3040
sg4
(lp3041
sg20
(lp3042
(dp3043
g7
I128
sg23
VC0025202
p3044
sg10
I8
sg11
Vmelanoma
p3045
sg13
I1
sasa(dp3046
g2
S'Beneficial effects such as melanoma tumor burden reduction with pyknotic nuclei, decreased nuclei/cytoplasmic ratio and nuclear degradation occurred after DM-1 treatment.\n'
p3047
sg4
(lp3048
sg20
(lp3049
(dp3050
g7
I36
sg23
VC0027651
p3051
sg10
I5
sg11
Vtumor
p3052
sg13
I1
sa(dp3053
g7
I27
sg23
VC0025202
p3054
sg10
I8
sg11
Vmelanoma
p3055
sg13
I1
sasa(dp3056
g2
S'DTIC+DM-1 treatment induced the recovery of anemia arising from melanoma and immunomodulation.\n'
p3057
sg4
(lp3058
sg20
(lp3059
(dp3060
g7
I64
sg23
VC0025202
p3061
sg10
I8
sg11
Vmelanoma
p3062
sg13
I1
sa(dp3063
g7
I44
sg23
VC0002871
p3064
sg10
I6
sg11
Vanemia
p3065
sg13
I1
sasa(dp3066
g2
S'Furthermore, melanoma tumors treated with DM-1 showed a preferential apoptotic intrinsic pathway by decreasing Bcl-2/Bax ratio.\n'
p3067
sg4
(lp3068
(dp3069
g7
I111
sg8
VP10415
p3070
sg10
I5
sg11
VBcl-2
p3071
sg13
I1
sasg20
(lp3072
(dp3073
g7
I13
sg23
VC0025202
p3074
sg10
I8
sg11
Vmelanoma
p3075
sg13
I1
sa(dp3076
g7
I22
sg23
VC0027651
p3077
sg10
I6
sg11
Vtumors
p3078
sg13
I1
sasa(dp3079
g2
S'Considering the chemoresistance exhibited by melanoma towards conventional chemotherapy drugs, DM-1 compound in monotherapy or in combination therapy provides a promising improvement in melanoma treatment with a reduction of side effects.\n'
p3080
sg4
(lp3081
sg20
(lp3082
(dp3083
g7
I45
sg23
VC0025202
p3084
sg10
I8
sg11
Vmelanoma
p3085
sg13
I1
sa(dp3086
g7
I45
sg23
VC0025202
p3087
sg10
I8
sg11
Vmelanoma
p3088
sg13
I1
sasa(dp3089
g2
S'A variant t(1;19)(q23;p13.3) translocation creates reciprocal DAZAP1/MEF2D and MEF2D/DAZAP1 fusion genes that are expressed in acute lymphoblastic leukemia.\n'
p3090
sg4
(lp3091
(dp3092
g7
I69
sg8
g18
sg10
I5
sg11
VMEF2D
p3093
sg13
I1
sa(dp3094
g7
I69
sg8
g18
sg10
I5
sg11
VMEF2D
p3095
sg13
I1
sa(dp3096
g7
I62
sg8
g18
sg10
I6
sg11
VDAZAP1
p3097
sg13
I1
sa(dp3098
g7
I62
sg8
g18
sg10
I6
sg11
VDAZAP1
p3099
sg13
I1
sa(dp3100
g7
I22
sg8
g18
sg10
I5
sg11
Vp13.3
p3101
sg13
I1
sasg20
(lp3102
(dp3103
g7
I127
sg23
VC1961102
p3104
sg10
I28
sg11
Vacute lymphoblastic leukemia
p3105
sg13
I3
sa(dp3106
g7
I29
sg23
VC0040715
p3107
sg10
I13
sg11
Vtranslocation
p3108
sg13
I1
sasa(dp3109
g2
S'In this case, the patient was diagnosed with focal atonic seizures as the cause of the monolimb weakness, which had been initially misdiagnosed aas transient ischemic attacks.\n'
p3110
sg4
(lp3111
sg20
(lp3112
(dp3113
g7
I51
sg23
VC0270846
p3114
sg10
I15
sg11
Vatonic seizures
p3115
sg13
I2
sa(dp3116
g7
I96
sg23
VC1883552
p3117
sg10
I8
sg11
Vweakness
p3118
sg13
I1
sa(dp3119
g7
I148
sg23
VC0007787
p3120
sg10
I26
sg11
Vtransient ischemic attacks
p3121
sg13
I3
sa(dp3122
g7
I144
sg23
VC0175701
p3123
sg10
I3
sg11
Vaas
p3124
sg13
I1
sasa(dp3125
g2
S'Using an in vitro biofilm system, we unexpectedly discovered that several positive regulators of biofilm formation during normoxia, including Tec1, Ace2, Czf1, Och1, and Als3, had little or no influence on biofilm development during hypoxia, irrespective of the carbon dioxide level, indicating that C. albicans biofilm pathways differ depending on the oxygen level.\n'
p3126
sg4
(lp3127
(dp3128
g7
I148
sg8
g18
sg10
I4
sg11
VAce2
p3129
sg13
I1
sa(dp3130
g7
I154
sg8
g18
sg10
I4
sg11
VCzf1
p3131
sg13
I1
sasg20
(lp3132
(dp3133
g7
I170
sg23
VC1847735
p3134
sg10
I4
sg11
VAls3
p3135
sg13
I1
sa(dp3136
g7
I233
sg23
VC0242184
p3137
sg10
I7
sg11
Vhypoxia
p3138
sg13
I1
sasa(dp3139
g2
S'Other cytokine-phenotype associations included increased IL-8 and constitutional symptoms; IL-2R, IL-12, and transfusion need; IL-2R, IL-8, and leukocytosis; IP-10 and thrombocytopenia; HGF, MIG, IL-1RA, and marked splenomegaly; and IL-1RA, IL-2R, IP-10, MIP-1Beta, and JAK2V617F.\n'
p3140
sg4
(lp3141
(dp3142
g7
I196
sg8
VP18510
p3143
sg10
I6
sg11
VIL-1RA
p3144
sg13
I1
sa(dp3145
g7
I91
sg8
VP01589
p3146
sg10
I5
sg11
VIL-2R
p3147
sg13
I1
sa(dp3148
g7
I158
sg8
VP02778
p3149
sg10
I5
sg11
VIP-10
p3150
sg13
I1
sa(dp3151
g7
I91
sg8
VP01589
p3152
sg10
I5
sg11
VIL-2R
p3153
sg13
I1
sa(dp3154
g7
I91
sg8
VP01589
p3155
sg10
I5
sg11
VIL-2R
p3156
sg13
I1
sa(dp3157
g7
I255
sg8
g18
sg10
I9
sg11
VMIP-1Beta
p3158
sg13
I1
sa(dp3159
g7
I196
sg8
VP18510
p3160
sg10
I6
sg11
VIL-1RA
p3161
sg13
I1
sa(dp3162
g7
I191
sg8
g18
sg10
I3
sg11
VMIG
p3163
sg13
I1
sa(dp3164
g7
I186
sg8
VP05231
p3165
sg10
I3
sg11
VHGF
p3166
sg13
I1
sasg20
(lp3167
(dp3168
g7
I255
sg23
VC1851100
p3169
sg10
I3
sg11
VMIP
p3170
sg13
I1
sa(dp3171
g7
I186
sg23
VC0399440
p3172
sg10
I3
sg11
VHGF
p3173
sg13
I1
sa(dp3174
g7
I144
sg23
VC0023518
p3175
sg10
I12
sg11
Vleukocytosis
p3176
sg13
I1
sasa(dp3177
g2
S'Beside this, the procalcitonin levels can be used for monitoring response to antimicrobial therapy, diagnosis of secondary inflammations, diagnosis of renal involvement in paediatric urinary tract infection, etc.\n'
p3178
sg4
(lp3179
(dp3180
g7
I17
sg8
VP06132
p3181
sg10
I13
sg11
Vprocalcitonin
p3182
sg13
I1
sasg20
(lp3183
(dp3184
g7
I183
sg23
VC0042029
p3185
sg10
I23
sg11
Vurinary tract infection
p3186
sg13
I3
sa(dp3187
g7
I123
sg23
VC0021368
p3188
sg10
I13
sg11
Vinflammations
p3189
sg13
I1
sasa(dp3190
g2
S'The changes in DNA methylation associated with chronic cystitis were DNA hypomethylation of the Calca gene in the control tissue and DNA hypermethylation for the Calca, Timp3, Mmp2, and Igf2r genes compared with that in the control tissue.\n'
p3191
sg4
(lp3192
(dp3193
g7
I186
sg8
VP11717
p3194
sg10
I5
sg11
VIgf2r
p3195
sg13
I1
sa(dp3196
g7
I96
sg8
VP06881
p3197
sg10
I10
sg11
VCalca gene
p3198
sg13
I2
sa(dp3199
g7
I96
sg8
VP06881
p3200
sg10
I5
sg11
VCalca
p3201
sg13
I1
sa(dp3202
g7
I176
sg8
VP08253
p3203
sg10
I4
sg11
VMmp2
p3204
sg13
I1
sa(dp3205
g7
I169
sg8
VP35625
p3206
sg10
I5
sg11
VTimp3
p3207
sg13
I1
sasg20
(lp3208
(dp3209
g7
I47
sg23
VC0221763
p3210
sg10
I16
sg11
Vchronic cystitis
p3211
sg13
I2
sasa(dp3212
g2
S'DNA methylation changes were noted in the Calca, Timp3, Mmp2, and Igf2r genes during chronic cystitis in a murine model.\n'
p3213
sg4
(lp3214
(dp3215
g7
I49
sg8
VP35625
p3216
sg10
I5
sg11
VTimp3
p3217
sg13
I1
sa(dp3218
g7
I66
sg8
VP11717
p3219
sg10
I11
sg11
VIgf2r genes
p3220
sg13
I2
sa(dp3221
g7
I56
sg8
VP08253
p3222
sg10
I4
sg11
VMmp2
p3223
sg13
I1
sa(dp3224
g7
I42
sg8
VP06881
p3225
sg10
I5
sg11
VCalca
p3226
sg13
I1
sasg20
(lp3227
(dp3228
g7
I85
sg23
VC0221763
p3229
sg10
I16
sg11
Vchronic cystitis
p3230
sg13
I2
sasa(dp3231
g2
S'Procalcitonin (PCT), a precursor of calcitonin, is a 116 amino acid protein that has been proposed as a marker of disease severity in conditions such as septicaemia, meningitis, pneumonia, urinary tract infection (UTI) and fungal and parasitic infection.\n'
p3232
sg4
(lp3233
(dp3234
g7
I3
sg8
VP06881
p3235
sg10
I10
sg11
Vcalcitonin
p3236
sg13
I1
sa(dp3237
g7
I15
sg8
VP06132
p3238
sg10
I3
sg11
VPCT
p3239
sg13
I1
sa(dp3240
g7
I0
sg8
VP06132
p3241
sg10
I13
sg11
VProcalcitonin
p3242
sg13
I1
sasg20
(lp3243
(dp3244
g7
I0
sg23
VC0162566
p3245
sg10
I13
sg11
VProcalcitonin
p3246
sg13
I1
sa(dp3247
g7
I178
sg23
VC0032285
p3248
sg10
I9
sg11
Vpneumonia
p3249
sg13
I1
sa(dp3250
g7
I166
sg23
VC0025289
p3251
sg10
I10
sg11
Vmeningitis
p3252
sg13
I1
sa(dp3253
g7
I189
sg23
VC0042029
p3254
sg10
I23
sg11
Vurinary tract infection
p3255
sg13
I3
sa(dp3256
g7
I214
sg23
VC0042029
p3257
sg10
I3
sg11
VUTI
p3258
sg13
I1
sa(dp3259
g7
I15
sg23
VC0162566
p3260
sg10
I3
sg11
VPCT
p3261
sg13
I1
sa(dp3262
g7
I153
sg23
VC0036690
p3263
sg10
I11
sg11
Vsepticaemia
p3264
sg13
I1
sa(dp3265
g7
I234
sg23
VC0747256
p3266
sg10
I19
sg11
Vparasitic infection
p3267
sg13
I2
sasa(dp3268
g2
S'LyP-1-SPIONs are promising in treating cancer as they accumulated in the nucleus of MCF-7 cells which expressed p32 and almost stopped tumor growth by combined MIH and targeted therapy.\n'
p3269
sg4
(lp3270
(dp3271
g7
I0
sg8
g18
sg10
I12
sg11
VLyP-1-SPIONs
p3272
sg13
I1
sa(dp3273
g7
I112
sg8
VP01732
p3274
sg10
I3
sg11
Vp32
p3275
sg13
I1
sasg20
(lp3276
(dp3277
g7
I39
sg23
VC0006826
p3278
sg10
I6
sg11
Vcancer
p3279
sg13
I1
sa(dp3280
g7
I0
sg23
VC1868674
p3281
sg10
I3
sg11
VLyP
p3282
sg13
I1
sa(dp3283
g7
I135
sg23
VC0598934
p3284
sg10
I12
sg11
Vtumor growth
p3285
sg13
I2
sasa(dp3286
g2
S'LyP-1 is a cyclic 9 amino acid peptide that can bind to breast cancer cells.\n'
p3287
sg4
(lp3288
(dp3289
g7
I0
sg8
g18
sg10
I5
sg11
VLyP-1
p3290
sg13
I1
sasg20
(lp3291
(dp3292
g7
I56
sg23
VC0678222
p3293
sg10
I13
sg11
Vbreast cancer
p3294
sg13
I2
sa(dp3295
g7
I0
sg23
VC1868674
p3296
sg10
I3
sg11
VLyP
p3297
sg13
I1
sasa(dp3298
g2
S'The results demonstrate that LyP-1-Fe3O4 significantly improves MRI contrast of TNBC, hence has the potential to be exploited for the specific delivery of cancer therapeutics.\n'
p3299
sg4
(lp3300
(dp3301
g7
I29
sg8
g18
sg10
I11
sg11
VLyP-1-Fe3O4
p3302
sg13
I1
sasg20
(lp3303
(dp3304
g7
I155
sg23
VC0006826
p3305
sg10
I6
sg11
Vcancer
p3306
sg13
I1
sa(dp3307
g7
I29
sg23
VC1868674
p3308
sg10
I3
sg11
VLyP
p3309
sg13
I1
sasa(dp3310
g2
S'Statistically significant differences in the allelic and genotypic frequencies of PTPN 22 -1123G&gt;C and CTLA-4 49A&gt;G were observed between the MG(+)-thymoma group and the controls (P = 0.000, 0.003), but not between the MG(-)-thymoma and MG-thymoma(-) groups and the controls (P = 0.192/P = 0.214 and P = 0.067/P = 0.254).\n'
p3311
sg4
(lp3312
(dp3313
g7
I106
sg8
VP16410
p3314
sg10
I10
sg11
VCTLA-4 49A
p3315
sg13
I2
sa(dp3316
g7
I-1
sg8
VP18031
p3317
sg10
I16
sg11
VPTPN 22 -1123G>C
p3318
sg13
I3
sasg20
(lp3319
(dp3320
g7
I154
sg23
VC0040100
p3321
sg10
I7
sg11
Vthymoma
p3322
sg13
I1
sa(dp3323
g7
I154
sg23
VC0040100
p3324
sg10
I7
sg11
Vthymoma
p3325
sg13
I1
sa(dp3326
g7
I154
sg23
VC0040100
p3327
sg10
I7
sg11
Vthymoma
p3328
sg13
I1
sasa(dp3329
g2
S'The results show an association between the PTPN22 1123G&gt;C genotype and thymoma-associated MG, with significant synergy with the CTLA-4 G alleles.\n'
p3330
sg4
(lp3331
(dp3332
g7
I132
sg8
VP16410
p3333
sg10
I16
sg11
VCTLA-4 G alleles
p3334
sg13
I3
sa(dp3335
g7
I44
sg8
g18
sg10
I6
sg11
VPTPN22
p3336
sg13
I1
sasg20
(lp3337
(dp3338
g7
I75
sg23
VC0040100
p3339
sg10
I7
sg11
Vthymoma
p3340
sg13
I1
sasa(dp3341
g2
S'The peptide with the LyP-1 targeting motif was more effective at knockdown in MDA-MB-231 breast cancer cells than the peptide with the iRGD motif.\n'
p3342
sg4
(lp3343
(dp3344
g7
I21
sg8
g18
sg10
I5
sg11
VLyP-1
p3345
sg13
I1
sasg20
(lp3346
(dp3347
g7
I21
sg23
VC1868674
p3348
sg10
I3
sg11
VLyP
p3349
sg13
I1
sa(dp3350
g7
I89
sg23
VC0678222
p3351
sg10
I13
sg11
Vbreast cancer
p3352
sg13
I2
sasa(dp3353
g2
S'Furthermore, the hydrated PEG outer corona is used for prolonging circulation time, while the active targeting ligand, LyP-1, is served to bind to breast cancer cells and lymphatic endothelial cells in tumor for inhibiting metastasis.\n'
p3354
sg4
(lp3355
(dp3356
g7
I119
sg8
g18
sg10
I5
sg11
VLyP-1
p3357
sg13
I1
sasg20
(lp3358
(dp3359
g7
I202
sg23
VC0027651
p3360
sg10
I5
sg11
Vtumor
p3361
sg13
I1
sa(dp3362
g7
I223
sg23
VC0027627
p3363
sg10
I10
sg11
Vmetastasis
p3364
sg13
I1
sa(dp3365
g7
I119
sg23
VC1868674
p3366
sg10
I3
sg11
VLyP
p3367
sg13
I1
sa(dp3368
g7
I147
sg23
VC0678222
p3369
sg10
I13
sg11
Vbreast cancer
p3370
sg13
I2
sasa(dp3371
g2
S'M-DOX NPs with LyP-1 targeting ligand effectively accumulated in MDA-MB-231 breast cancer cells.\n'
p3372
sg4
(lp3373
(dp3374
g7
I0
sg8
VP0C0P6
p3375
sg10
I9
sg11
VM-DOX NPs
p3376
sg13
I2
sa(dp3377
g7
I15
sg8
g18
sg10
I5
sg11
VLyP-1
p3378
sg13
I1
sasg20
(lp3379
(dp3380
g7
I76
sg23
VC0678222
p3381
sg10
I13
sg11
Vbreast cancer
p3382
sg13
I2
sa(dp3383
g7
I6
sg23
VC0027341
p3384
sg10
I3
sg11
VNPs
p3385
sg13
I1
sa(dp3386
g7
I15
sg23
VC1868674
p3387
sg10
I3
sg11
VLyP
p3388
sg13
I1
sasa(dp3389
g2
S'Within the knowledge of the critical role of p32 receptor in cancer cell metabolism, this study can lead to further developments in anticancer therapy by targeting p32 with LyP-1 derivatives as active targeting moiety.\n'
p3390
sg4
(lp3391
(dp3392
g7
I45
sg8
VP01732
p3393
sg10
I12
sg11
Vp32 receptor
p3394
sg13
I2
sa(dp3395
g7
I173
sg8
g18
sg10
I5
sg11
VLyP-1
p3396
sg13
I1
sa(dp3397
g7
I45
sg8
VP01732
p3398
sg10
I3
sg11
Vp32
p3399
sg13
I1
sasg20
(lp3400
(dp3401
g7
I61
sg23
VC0006826
p3402
sg10
I6
sg11
Vcancer
p3403
sg13
I1
sa(dp3404
g7
I173
sg23
VC1868674
p3405
sg10
I3
sg11
VLyP
p3406
sg13
I1
sasa(dp3407
g2
S'This data can also be applied for the development of new drug delivery systems in which LyP-1 can be used for its targeting and anticancer properties.\n'
p3408
sg4
(lp3409
(dp3410
g7
I88
sg8
g18
sg10
I5
sg11
VLyP-1
p3411
sg13
I1
sasg20
(lp3412
(dp3413
g7
I88
sg23
VC1868674
p3414
sg10
I3
sg11
VLyP
p3415
sg13
I1
sasa(dp3416
g2
S'Salivary Alfa-amylase (sAA) activity alternations are observed in major depressive disorder (MDD) being associated with depression severity and its specific psychopathological dimensions with anxiety being attributed to distress.\n'
p3417
sg4
(lp3418
(dp3419
g7
I23
sg8
VP35542
p3420
sg10
I3
sg11
VsAA
p3421
sg13
I1
sa(dp3422
g7
I0
sg8
VP04745
p3423
sg10
I21
sg11
VSalivary Alfa-amylase
p3424
sg13
I2
sasg20
(lp3425
(dp3426
g7
I66
sg23
VC1269683
p3427
sg10
I25
sg11
Vmajor depressive disorder
p3428
sg13
I3
sa(dp3429
g7
I93
sg23
VC1269683
p3430
sg10
I3
sg11
VMDD
p3431
sg13
I1
sa(dp3432
g7
I120
sg23
VC0011581
p3433
sg10
I10
sg11
Vdepression
p3434
sg13
I1
sasa(dp3435
g2
S'Key words:Salivary alpha-amylase, major depressive disorder, Spielberger State-Trait Anxiety Inventory, Hamilton Rating Scale for Depression.\n'
p3436
sg4
(lp3437
(dp3438
g7
I10
sg8
VP04745
p3439
sg10
I22
sg11
VSalivary alpha-amylase
p3440
sg13
I2
sasg20
(lp3441
(dp3442
g7
I34
sg23
VC1269683
p3443
sg10
I25
sg11
Vmajor depressive disorder
p3444
sg13
I3
sa(dp3445
g7
I130
sg23
VC0011581
p3446
sg10
I10
sg11
VDepression
p3447
sg13
I1
sasa(dp3448
g2
S'Differences in evening sAA levels were examined between patient groups (i.e., 752 current major depressive disorder [MDD], 611 remitted MDD, and 329 healthy controls) and between 46 tricyclic antidepressant (TCA) users, 307 selective serotonin reuptake inhibitor (SSRI) users, 97 users of another antidepressant, and 1242 non-users.\n'
p3449
sg4
(lp3450
sg20
(lp3451
(dp3452
g7
I117
sg23
VC1269683
p3453
sg10
I3
sg11
VMDD
p3454
sg13
I1
sa(dp3455
g7
I117
sg23
VC1269683
p3456
sg10
I3
sg11
VMDD
p3457
sg13
I1
sa(dp3458
g7
I90
sg23
VC1269683
p3459
sg10
I25
sg11
Vmajor depressive disorder
p3460
sg13
I3
sasa(dp3461
g2
S'The role of two members of the ETS (E26 avian leukemia oncogene) family of transcription factors, ETS-1 and ETS-2, has been investigated in many cancers but has not yet been studied in ocular tumors.\n'
p3462
sg4
(lp3463
(dp3464
g7
I31
sg8
VP20908
p3465
sg10
I3
sg11
VETS
p3466
sg13
I1
sa(dp3467
g7
I36
sg8
VP05412
p3468
sg10
I27
sg11
VE26 avian leukemia oncogene
p3469
sg13
I4
sa(dp3470
g7
I108
sg8
VP15036
p3471
sg10
I5
sg11
VETS-2
p3472
sg13
I1
sa(dp3473
g7
I98
sg8
VP14921
p3474
sg10
I5
sg11
VETS-1
p3475
sg13
I1
sasg20
(lp3476
(dp3477
g7
I46
sg23
VC0023418
p3478
sg10
I8
sg11
Vleukemia
p3479
sg13
I1
sa(dp3480
g7
I145
sg23
VC0006826
p3481
sg10
I7
sg11
Vcancers
p3482
sg13
I1
sa(dp3483
g7
I192
sg23
VC0027651
p3484
sg10
I6
sg11
Vtumors
p3485
sg13
I1
sasa(dp3486
g2
S'Using semi-quantitative reverse-transcription polymerase chain reaction (RT-PCR) and western blots experiments, we compared changes in ETS-1 and ETS-2 expression, their protein levels, and the regulation of some of their target gene expressions at different stages of the ocular tumoral progression in the transgenic mouse model, Tyrp-1-TAg, with those in normal eyes from control mice of the same age.\n'
p3487
sg4
(lp3488
(dp3489
g7
I135
sg8
VP14921
p3490
sg10
I5
sg11
VETS-1
p3491
sg13
I1
sa(dp3492
g7
I330
sg8
VP17643
p3493
sg10
I10
sg11
VTyrp-1-TAg
p3494
sg13
I1
sa(dp3495
g7
I145
sg8
VP15036
p3496
sg10
I5
sg11
VETS-2
p3497
sg13
I1
sasg20
(lp3498
(dp3499
g7
I337
sg23
VC0037293
p3500
sg10
I3
sg11
VTAg
p3501
sg13
I1
sasa(dp3502
g2
S'Our findings suggest that ETS-1 and ETS-2 are upregulated in ocular tumors derived from the retinal epithelium and may be involved in one or several signaling pathways that activate the expression of a set of genes involved in ocular tumor progression such as those encoding ICAM-1 (intercellular adhesion molecule-1), PAI-1 (Plasminogen activator inhibitor-1), MCP-1 (monocyte chemoattractant protein-1) and p16 (Cyclin dependent kinase inhibitor 2A).\n'
p3503
sg4
(lp3504
(dp3505
g7
I275
sg8
VP05362
p3506
sg10
I6
sg11
VICAM-1
p3507
sg13
I1
sa(dp3508
g7
I36
sg8
VP15036
p3509
sg10
I5
sg11
VETS-2
p3510
sg13
I1
sa(dp3511
g7
I409
sg8
VP42771
p3512
sg10
I3
sg11
Vp16
p3513
sg13
I1
sa(dp3514
g7
I326
sg8
VP00747
p3515
sg10
I33
sg11
VPlasminogen activator inhibitor-1
p3516
sg13
I3
sa(dp3517
g7
I283
sg8
VP05362
p3518
sg10
I33
sg11
Vintercellular adhesion molecule-1
p3519
sg13
I3
sa(dp3520
g7
I319
sg8
VP05121
p3521
sg10
I5
sg11
VPAI-1
p3522
sg13
I1
sa(dp3523
g7
I414
sg8
VP42771
p3524
sg10
I36
sg11
VCyclin dependent kinase inhibitor 2A
p3525
sg13
I5
sa(dp3526
g7
I26
sg8
VP14921
p3527
sg10
I5
sg11
VETS-1
p3528
sg13
I1
sasg20
(lp3529
(dp3530
g7
I234
sg23
VC0178874
p3531
sg10
I17
sg11
Vtumor progression
p3532
sg13
I2
sa(dp3533
g7
I68
sg23
VC0027651
p3534
sg10
I6
sg11
Vtumors
p3535
sg13
I1
sa(dp3536
g7
I297
sg23
VC0001511
p3537
sg10
I8
sg11
Vadhesion
p3538
sg13
I1
sasa(dp3539
g2
S'Epithelial-mesenchymal transition (EMT) marker expression suggested that atypical adenomas maintain their epithelial phenotype to a higher degree than do ATCs.\n'
p3540
sg4
(lp3541
sg20
(lp3542
(dp3543
g7
I154
sg23
VC1866294
p3544
sg10
I4
sg11
VATCs
p3545
sg13
I1
sa(dp3546
g7
I23
sg23
VC0599156
p3547
sg10
I10
sg11
Vtransition
p3548
sg13
I1
sa(dp3549
g7
I82
sg23
VC0001430
p3550
sg10
I8
sg11
Vadenomas
p3551
sg13
I1
sasa(dp3552
g2
S'Significant differences were also found between non-malignant pathological thyroid samples (goiters and adenomas) and malignant tumors (p &lt; 0.001, Wilcoxon test, t approximation), anaplastic carcinomas (ATCs) and all other samples and also between ATCs and all other malignant tumors (p &lt; 0.05, Wilcoxon test, t approximation).\n'
p3553
sg4
(lp3554
sg20
(lp3555
(dp3556
g7
I118
sg23
VC0006826
p3557
sg10
I16
sg11
Vmalignant tumors
p3558
sg13
I2
sa(dp3559
g7
I183
sg23
VC0205696
p3560
sg10
I21
sg11
Vanaplastic carcinomas
p3561
sg13
I2
sa(dp3562
g7
I118
sg23
VC0006826
p3563
sg10
I16
sg11
Vmalignant tumors
p3564
sg13
I2
sa(dp3565
g7
I104
sg23
VC0001430
p3566
sg10
I8
sg11
Vadenomas
p3567
sg13
I1
sa(dp3568
g7
I206
sg23
VC1866294
p3569
sg10
I4
sg11
VATCs
p3570
sg13
I1
sa(dp3571
g7
I92
sg23
VC0018021
p3572
sg10
I7
sg11
Vgoiters
p3573
sg13
I1
sa(dp3574
g7
I206
sg23
VC1866294
p3575
sg10
I4
sg11
VATCs
p3576
sg13
I1
sasa(dp3577
g2
S'Expression levels of MSAC genes (hBUB1, hBUBR1, hBUB3 and hMAD2) were evaluated in 9 follicular thyroid adenomas (FAs), 9 follicular thyroid carcinomas (FTCs), 21 papillary thyroid carcinomas (PTCs), 5 anaplastic (undifferentiated) thyroid carcinomas (ATCs) and 3 adjacent normal thyroid tissues (NTs) by real-time quantitative RT-PCR.\n'
p3578
sg4
(lp3579
(dp3580
g7
I48
sg8
g18
sg10
I5
sg11
VhBUB3
p3581
sg13
I1
sa(dp3582
g7
I33
sg8
g18
sg10
I5
sg11
VhBUB1
p3583
sg13
I1
sasg20
(lp3584
(dp3585
g7
I141
sg23
VC0007097
p3586
sg10
I10
sg11
Vcarcinomas
p3587
sg13
I1
sa(dp3588
g7
I141
sg23
VC0007097
p3589
sg10
I10
sg11
Vcarcinomas
p3590
sg13
I1
sa(dp3591
g7
I114
sg23
VC0015923
p3592
sg10
I3
sg11
VFAs
p3593
sg13
I1
sa(dp3594
g7
I122
sg23
VC0206682
p3595
sg10
I29
sg11
Vfollicular thyroid carcinomas
p3596
sg13
I3
sa(dp3597
g7
I252
sg23
VC1866294
p3598
sg10
I4
sg11
VATCs
p3599
sg13
I1
sa(dp3600
g7
I153
sg23
VC0206682
p3601
sg10
I4
sg11
VFTCs
p3602
sg13
I1
sa(dp3603
g7
I85
sg23
VC0015923
p3604
sg10
I27
sg11
Vfollicular thyroid adenomas
p3605
sg13
I3
sasa(dp3606
g2
S"Archival material from 88 thyroid neoplasms [50 PTCs, eight anaplastic carcinomas (ATCs), 25 follicular thyroid carcinomas (FTCs) and five follicular adenomas (FAs)] were analysed for ret/PTC-1 and H4 expression using 5' nuclease assay (TaqMan RT-PCR).\n"
p3607
sg4
(lp3608
(dp3609
g7
I184
sg8
VP07949
p3610
sg10
I3
sg11
Vret
p3611
sg13
I1
sa(dp3612
g7
I188
sg8
g18
sg10
I5
sg11
VPTC-1
p3613
sg13
I1
sa(dp3614
g7
I218
sg8
g18
sg10
I11
sg11
V5' nuclease
p3615
sg13
I2
sasg20
(lp3616
(dp3617
g7
I60
sg23
VC0205696
p3618
sg10
I21
sg11
Vanaplastic carcinomas
p3619
sg13
I2
sa(dp3620
g7
I26
sg23
VC0040136
p3621
sg10
I17
sg11
Vthyroid neoplasms
p3622
sg13
I2
sa(dp3623
g7
I48
sg23
VC0238463
p3624
sg10
I3
sg11
VPTC
p3625
sg13
I1
sa(dp3626
g7
I124
sg23
VC0206682
p3627
sg10
I4
sg11
VFTCs
p3628
sg13
I1
sa(dp3629
g7
I160
sg23
VC0015923
p3630
sg10
I3
sg11
VFAs
p3631
sg13
I1
sa(dp3632
g7
I93
sg23
VC0206682
p3633
sg10
I29
sg11
Vfollicular thyroid carcinomas
p3634
sg13
I3
sa(dp3635
g7
I83
sg23
VC1866294
p3636
sg10
I4
sg11
VATCs
p3637
sg13
I1
sa(dp3638
g7
I139
sg23
VC0205647
p3639
sg10
I19
sg11
Vfollicular adenomas
p3640
sg13
I2
sasa(dp3641
g2
S'We report the clinical observation of a 2.5-year-old girl, referred for the diagnosis of Morning Glory syndrome in the left eye with severe amblyopia (1/10 Rossano 1/20) and esotropia.\n'
p3642
sg4
(lp3643
sg20
(lp3644
(dp3645
g7
I89
sg23
VC0549307
p3646
sg10
I22
sg11
VMorning Glory syndrome
p3647
sg13
I3
sa(dp3648
g7
I174
sg23
VC0014877
p3649
sg10
I9
sg11
Vesotropia
p3650
sg13
I1
sasa(dp3651
g2
S'The association between the reported mean TTR and major bleeding and stroke/systemic embolism was analyzed by random-effects meta-regression with and without adjustment for relevant clinical cohort characteristics.\n'
p3652
sg4
(lp3653
sg20
(lp3654
(dp3655
g7
I85
sg23
VC0013922
p3656
sg10
I8
sg11
Vembolism
p3657
sg13
I1
sa(dp3658
g7
I69
sg23
VC0038454
p3659
sg10
I6
sg11
Vstroke
p3660
sg13
I1
sa(dp3661
g7
I56
sg23
VC0019080
p3662
sg10
I8
sg11
Vbleeding
p3663
sg13
I1
sasa(dp3664
g2
S'In the adjusted meta-regressions, the impact of mean TTR on the occurrence of hemorrhage was adjusted for the mean age and the proportion of populations with prior stroke or transient ischemic attack.\n'
p3665
sg4
(lp3666
sg20
(lp3667
(dp3668
g7
I164
sg23
VC0038454
p3669
sg10
I6
sg11
Vstroke
p3670
sg13
I1
sa(dp3671
g7
I78
sg23
VC0019080
p3672
sg10
I10
sg11
Vhemorrhage
p3673
sg13
I1
sa(dp3674
g7
I174
sg23
VC0007787
p3675
sg10
I25
sg11
Vtransient ischemic attack
p3676
sg13
I3
sa(dp3677
g7
I21
sg23
VC0684320
p3678
sg10
I11
sg11
Vregressions
p3679
sg13
I1
sasa(dp3680
g2
S'In univariable meta-regression, increasing mean TTR was significantly associated with a decreased rate of both major bleeding and stroke/systemic embolism.\n'
p3681
sg4
(lp3682
sg20
(lp3683
(dp3684
g7
I117
sg23
VC0019080
p3685
sg10
I8
sg11
Vbleeding
p3686
sg13
I1
sa(dp3687
g7
I130
sg23
VC0038454
p3688
sg10
I6
sg11
Vstroke
p3689
sg13
I1
sa(dp3690
g7
I146
sg23
VC0013922
p3691
sg10
I8
sg11
Vembolism
p3692
sg13
I1
sasa(dp3693
g2
S'However, after adjustment mean TTR was no longer significantly associated with stroke/systemic embolism.\n'
p3694
sg4
(lp3695
sg20
(lp3696
(dp3697
g7
I79
sg23
VC0038454
p3698
sg10
I6
sg11
Vstroke
p3699
sg13
I1
sa(dp3700
g7
I95
sg23
VC0013922
p3701
sg10
I8
sg11
Vembolism
p3702
sg13
I1
sasa(dp3703
g2
S'Although higher mean TTR in warfarin therapy was associated with lower complication rates in atrial fibrillation, the strength of the association was decreased when adjusting for differences in relevant clinical characteristics of the patient cohorts.\n'
p3704
sg4
(lp3705
sg20
(lp3706
(dp3707
g7
I93
sg23
VC0004238
p3708
sg10
I19
sg11
Vatrial fibrillation
p3709
sg13
I2
sa(dp3710
g7
I71
sg23
VC0009566
p3711
sg10
I12
sg11
Vcomplication
p3712
sg13
I1
sasa(dp3713
g2
S'Diabetes mellitus [odds ratio (OR) 1.38; P = 0.008], peripheral artery disease (PAD, OR 1.62; P = 0.048), and HAS-BLED (OR 1.13; P = 0.022) were independently associated with TTR &lt; 70%.\n'
p3714
sg4
(lp3715
sg20
(lp3716
(dp3717
g7
I80
sg23
VC1704436
p3718
sg10
I3
sg11
VPAD
p3719
sg13
I1
sa(dp3720
g7
I53
sg23
VC1704436
p3721
sg10
I25
sg11
Vperipheral artery disease
p3722
sg13
I3
sa(dp3723
g7
I0
sg23
VC0011849
p3724
sg10
I17
sg11
VDiabetes mellitus
p3725
sg13
I2
sasa(dp3726
g2
S'Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognized, progressive, and fatal cardiomyopathy, the natural history of which remains unclear.\n'
p3727
sg4
(lp3728
(dp3729
g7
I23
sg8
VP02766
p3730
sg10
I4
sg11
VATTR
p3731
sg13
I1
sa(dp3732
g7
I0
sg8
VP02766
p3733
sg10
I21
sg11
VCardiac transthyretin
p3734
sg13
I2
sasg20
(lp3735
(dp3736
g7
I29
sg23
VC0002726
p3737
sg10
I11
sg11
Vamyloidosis
p3738
sg13
I1
sa(dp3739
g7
I95
sg23
VC0878544
p3740
sg10
I14
sg11
Vcardiomyopathy
p3741
sg13
I1
sasa(dp3742
g2
S'We sought to establish and validate a new prognostic staging system applicable to patients with both wild-type ATTR (ATTRwt) and hereditary variant ATTR (ATTRv) amyloid cardiomyopathy.\n'
p3743
sg4
(lp3744
(dp3745
g7
I129
sg8
VP02766
p3746
sg10
I23
sg11
Vhereditary variant ATTR
p3747
sg13
I3
sa(dp3748
g7
I101
sg8
VP02766
p3749
sg10
I14
sg11
Vwild-type ATTR
p3750
sg13
I2
sasg20
(lp3751
(dp3752
g7
I161
sg23
VC0268407
p3753
sg10
I22
sg11
Vamyloid cardiomyopathy
p3754
sg13
I2
sasa(dp3755
g2
S'This simple, universally applicable staging system stratifies patients with both ATTRwt and ATTRv amyloid cardiomyopathy into prognostic categories.\n'
p3756
sg4
(lp3757
sg20
(lp3758
(dp3759
g7
I98
sg23
VC0268407
p3760
sg10
I22
sg11
Vamyloid cardiomyopathy
p3761
sg13
I2
sasa(dp3762
g2
S'The DENN Domain Containing 1B (DENND1B) gene has an important role on T cell receptor (TCR) down-regulation on Th2 cells and studies have shown that mutations or loss of this factor can be associated with increased Th2 responses and asthma.\n'
p3763
sg4
(lp3764
(dp3765
g7
I87
sg8
g18
sg10
I3
sg11
VTCR
p3766
sg13
I1
sa(dp3767
g7
I70
sg8
g18
sg10
I15
sg11
VT cell receptor
p3768
sg13
I3
sasg20
(lp3769
(dp3770
g7
I233
sg23
VC0004096
p3771
sg10
I6
sg11
Vasthma
p3772
sg13
I1
sasa(dp3773
g2
S'The aim of this work is to evaluate the association of polymorphisms in the DENND1B with asthma and allergy markers phenotypes in Brazilian children.\n'
p3774
sg4
(lp3775
sg20
(lp3776
(dp3777
g7
I89
sg23
VC0004096
p3778
sg10
I6
sg11
Vasthma
p3779
sg13
I1
sa(dp3780
g7
I100
sg23
VC0020517
p3781
sg10
I7
sg11
Vallergy
p3782
sg13
I1
sasa(dp3783
g2
S'The DENND1B gene was associated with different phenotypes such as severe asthma and atopic markers (specific IgE production, skin prick test and IL-13 production).\n'
p3784
sg4
(lp3785
(dp3786
g7
I109
sg8
VP01854
p3787
sg10
I3
sg11
VIgE
p3788
sg13
I1
sa(dp3789
g7
I145
sg8
VP35225
p3790
sg10
I5
sg11
VIL-13
p3791
sg13
I1
sasg20
(lp3792
(dp3793
g7
I73
sg23
VC0004096
p3794
sg10
I6
sg11
Vasthma
p3795
sg13
I1
sa(dp3796
g7
I109
sg23
VC0270850
p3797
sg10
I3
sg11
VIgE
p3798
sg13
I1
sa(dp3799
g7
I125
sg23
VC0476227
p3800
sg10
I10
sg11
Vskin prick
p3801
sg13
I2
sa(dp3802
g7
I84
sg23
VC0392707
p3803
sg10
I6
sg11
Vatopic
p3804
sg13
I1
sasa(dp3805
g2
S'In conclusion, polymorphisms in the DENND1B are significantly associated with development of asthma and atopy and these polymorphisms can influence DENND1B expression and consequently, asthma.\n'
p3806
sg4
(lp3807
sg20
(lp3808
(dp3809
g7
I93
sg23
VC0004096
p3810
sg10
I6
sg11
Vasthma
p3811
sg13
I1
sa(dp3812
g7
I104
sg23
VC0392707
p3813
sg10
I5
sg11
Vatopy
p3814
sg13
I1
sa(dp3815
g7
I93
sg23
VC0004096
p3816
sg10
I6
sg11
Vasthma
p3817
sg13
I1
sasa(dp3818
g2
S'Among those, only the DENND1B risk allele and paternal history of asthma and allergy were associated with increased FeNO values (V) suggesting that raised FeNO in neonatal life is primarily an inherited trait.\n'
p3819
sg4
(lp3820
sg20
(lp3821
(dp3822
g7
I77
sg23
VC0020517
p3823
sg10
I7
sg11
Vallergy
p3824
sg13
I1
sa(dp3825
g7
I66
sg23
VC0004096
p3826
sg10
I6
sg11
Vasthma
p3827
sg13
I1
sasa(dp3828
g2
S'Variants in DENND1B are associated with development of childhood asthma and other immune disorders.\n'
p3829
sg4
(lp3830
sg20
(lp3831
(dp3832
g7
I55
sg23
VC0264408
p3833
sg10
I16
sg11
Vchildhood asthma
p3834
sg13
I2
sa(dp3835
g7
I82
sg23
VC0021053
p3836
sg10
I16
sg11
Vimmune disorders
p3837
sg13
I2
sasa(dp3838
g2
S'Moreover, human TH2 cells carrying asthma-associated DENND1B variants express less DENND1B and phenocopy Dennd1b(-/-) TH2 cells.\n'
p3839
sg4
(lp3840
sg20
(lp3841
(dp3842
g7
I35
sg23
VC0004096
p3843
sg10
I6
sg11
Vasthma
p3844
sg13
I1
sasa(dp3845
g2
S'These results provide a molecular basis for how DENND1B, a previously unrecognized regulator of TCR downmodulation in TH2 cells, contributes to asthma pathogenesis and how DENN-domain-containing proteins may contribute to other human disorders.\n'
p3846
sg4
(lp3847
(dp3848
g7
I172
sg8
g18
sg10
I31
sg11
VDENN-domain-containing proteins
p3849
sg13
I2
sasg20
(lp3850
(dp3851
g7
I151
sg23
VC0699748
p3852
sg10
I12
sg11
Vpathogenesis
p3853
sg13
I1
sa(dp3854
g7
I144
sg23
VC0004096
p3855
sg10
I6
sg11
Vasthma
p3856
sg13
I1
sasa(dp3857
g2
S'show that the asthma susceptibility gene DENND1B controls cytokine production in Th2 lymphocytes by controlling the rate of TCR internalization and routing to endosomes, providing a molecular basis for how DENND1B contributes to asthma pathogenesis.\n'
p3858
sg4
(lp3859
sg20
(lp3860
(dp3861
g7
I14
sg23
VC0004096
p3862
sg10
I6
sg11
Vasthma
p3863
sg13
I1
sa(dp3864
g7
I14
sg23
VC0004096
p3865
sg10
I6
sg11
Vasthma
p3866
sg13
I1
sa(dp3867
g7
I236
sg23
VC0699748
p3868
sg10
I12
sg11
Vpathogenesis
p3869
sg13
I1
sasa(dp3870
g2
S'We report associations between several DENND1B variants (P = 2.2 x 10(-7) for rs4915551) on chromosome 1q31 and BMI from a meta-analysis of GWAS data using 2691 asthmatic children (screening data).\n'
p3871
sg4
(lp3872
sg20
(lp3873
(dp3874
g7
I161
sg23
VC0004096
p3875
sg10
I9
sg11
Vasthmatic
p3876
sg13
I1
sasa(dp3877
g2
S'The top DENND1B single nucleotide polymorphisms(SNPs) were next evaluated in seven independent replication data sets comprising 2014 asthmatics, and rs4915551 was nominally replicated (P &lt; 0.05) in two of the seven studies and of borderline significance in one (P = 0.059).\n'
p3878
sg4
(lp3879
sg20
(lp3880
(dp3881
g7
I133
sg23
VC0004096
p3882
sg10
I10
sg11
Vasthmatics
p3883
sg13
I1
sasa(dp3884
g2
S'DENND1B was recently identified as an asthma susceptibility gene in a GWAS on children, and here, we find evidence that DENND1B variants may also be associated with BMI in asthmatic children.\n'
p3885
sg4
(lp3886
sg20
(lp3887
(dp3888
g7
I172
sg23
VC0004096
p3889
sg10
I9
sg11
Vasthmatic
p3890
sg13
I1
sa(dp3891
g7
I38
sg23
VC0004096
p3892
sg10
I6
sg11
Vasthma
p3893
sg13
I1
sasa(dp3894
g2
S'We sought to search for new variants associated with asthma and attempt to replicate the association with four loci reported previously (ORMDL3, PDE4D, DENND1B and IL1RL1).\n'
p3895
sg4
(lp3896
(dp3897
g7
I164
sg8
g18
sg10
I6
sg11
VIL1RL1
p3898
sg13
I1
sa(dp3899
g7
I137
sg8
g18
sg10
I6
sg11
VORMDL3
p3900
sg13
I1
sasg20
(lp3901
(dp3902
g7
I53
sg23
VC0004096
p3903
sg10
I6
sg11
Vasthma
p3904
sg13
I1
sasa(dp3905
g2
S'We have identified a locus containing DENND1B on chromosome 1q31.3 that is associated with susceptibility to asthma.\n'
p3906
sg4
(lp3907
sg20
(lp3908
(dp3909
g7
I109
sg23
VC0004096
p3910
sg10
I6
sg11
Vasthma
p3911
sg13
I1
sasa(dp3912
g2
S'The recently described Sagliker syndrome (SS) might be an exaggerated version of ROD and is a very striking and prominent feature of secondary hyperparathyroidism in patients with end-stage renal disease (ESRD).\n'
p3913
sg4
(lp3914
(dp3915
g7
I81
sg8
VP50748
p3916
sg10
I3
sg11
VROD
p3917
sg13
I1
sasg20
(lp3918
(dp3919
g7
I180
sg23
VC0022661
p3920
sg10
I23
sg11
Vend-stage renal disease
p3921
sg13
I3
sa(dp3922
g7
I133
sg23
VC0020503
p3923
sg10
I29
sg11
Vsecondary hyperparathyroidism
p3924
sg13
I2
sa(dp3925
g7
I205
sg23
VC0022661
p3926
sg10
I4
sg11
VESRD
p3927
sg13
I1
sa(dp3928
g7
I32
sg23
VC0039082
p3929
sg10
I8
sg11
Vsyndrome
p3930
sg13
I1
sasa(dp3931
g2
S'Growth retardation, decreased final height and renal osteodystrophy (ROD) are common complications of childhood chronic kidney disease (CKD), resulting from a combination of abnormalities in the growth hormone (GH) axis, vitamin D deficiency, hyperparathyroidism, hypogonadism, inadequate nutrition, cachexia and drug toxicity.\n'
p3932
sg4
(lp3933
(dp3934
g7
I195
sg8
VP01242
p3935
sg10
I14
sg11
Vgrowth hormone
p3936
sg13
I2
sa(dp3937
g7
I211
sg8
VP01242
p3938
sg10
I2
sg11
VGH
p3939
sg13
I1
sasg20
(lp3940
(dp3941
g7
I221
sg23
VC0042870
p3942
sg10
I20
sg11
Vvitamin D deficiency
p3943
sg13
I3
sa(dp3944
g7
I47
sg23
VC0035086
p3945
sg10
I20
sg11
Vrenal osteodystrophy
p3946
sg13
I2
sa(dp3947
g7
I112
sg23
VC1561643
p3948
sg10
I22
sg11
Vchronic kidney disease
p3949
sg13
I3
sa(dp3950
g7
I300
sg23
VC0006625
p3951
sg10
I8
sg11
Vcachexia
p3952
sg13
I1
sa(dp3953
g7
I69
sg23
VC0035086
p3954
sg10
I3
sg11
VROD
p3955
sg13
I1
sa(dp3956
g7
I0
sg23
VC0151686
p3957
sg10
I18
sg11
VGrowth retardation
p3958
sg13
I2
sa(dp3959
g7
I264
sg23
VC0020619
p3960
sg10
I12
sg11
Vhypogonadism
p3961
sg13
I1
sa(dp3962
g7
I243
sg23
VC0020502
p3963
sg10
I19
sg11
Vhyperparathyroidism
p3964
sg13
I1
sa(dp3965
g7
I136
sg23
VC1561643
p3966
sg10
I3
sg11
VCKD
p3967
sg13
I1
sasa(dp3968
g2
S'Secondary hyperparathyroidism and 125 dihydroxy vitamin D3 deficiency are the major causative factors in ROD.\n'
p3969
sg4
(lp3970
sg20
(lp3971
(dp3972
g7
I48
sg23
VC1272352
p3973
sg10
I21
sg11
Vvitamin D3 deficiency
p3974
sg13
I3
sa(dp3975
g7
I0
sg23
VC0020503
p3976
sg10
I29
sg11
VSecondary hyperparathyroidism
p3977
sg13
I2
sasa(dp3978
g2
S'Twelve cases of ductal CMBCs (11 not otherwise specified type, and 1 basal phenotype), 11 cases of SGCs (5 eccrine carcinomas, 3 porocarcinomas, and 3 microcystic adnexal carcinomas), 2 benign sweat gland neoplasm cases, and 2 primary breast cancer cases were retrieved and analyzed with the following IHC panel: mammaglobin, gross cystic disease fluid protein (GCDFP) 15, p63, basal cytokeratins (CK5, CK14, and CK17), androgen receptor, and PAX5.\n'
p3979
sg4
(lp3980
(dp3981
g7
I443
sg8
g18
sg10
I4
sg11
VPAX5
p3982
sg13
I1
sa(dp3983
g7
I403
sg8
VP02533
p3984
sg10
I4
sg11
VCK14
p3985
sg13
I1
sa(dp3986
g7
I373
sg8
g18
sg10
I23
sg11
Vp63, basal cytokeratins
p3987
sg13
I3
sa(dp3988
g7
I420
sg8
VP10275
p3989
sg10
I17
sg11
Vandrogen receptor
p3990
sg13
I2
sa(dp3991
g7
I313
sg8
g18
sg10
I58
sg11
Vmammaglobin, gross cystic disease fluid protein (GCDFP) 15
p3992
sg13
I8
sa(dp3993
g7
I398
sg8
VP02533
p3994
sg10
I3
sg11
VCK5
p3995
sg13
I1
sasg20
(lp3996
(dp3997
g7
I186
sg23
VC0684354
p3998
sg10
I27
sg11
Vbenign sweat gland neoplasm
p3999
sg13
I4
sa(dp4000
g7
I115
sg23
VC0007097
p4001
sg10
I10
sg11
Vcarcinomas
p4002
sg13
I1
sa(dp4003
g7
I115
sg23
VC0007097
p4004
sg10
I10
sg11
Vcarcinomas
p4005
sg13
I1
sa(dp4006
g7
I235
sg23
VC0678222
p4007
sg10
I13
sg11
Vbreast cancer
p4008
sg13
I2
sa(dp4009
g7
I332
sg23
VC0334054
p4010
sg10
I14
sg11
Vcystic disease
p4011
sg13
I2
sasa(dp4012
g2
S'The results demonstrated that p-ERK, CGRP and COX-2 mediated neurogenic inflammation and central sensitization in migraine.\n'
p4013
sg4
(lp4014
(dp4015
g7
I46
sg8
VP35354
p4016
sg10
I5
sg11
VCOX-2
p4017
sg13
I1
sa(dp4018
g7
I32
sg8
VP29323
p4019
sg10
I3
sg11
VERK
p4020
sg13
I1
sa(dp4021
g7
I37
sg8
VP80511
p4022
sg10
I4
sg11
VCGRP
p4023
sg13
I1
sasg20
(lp4024
(dp4025
g7
I114
sg23
VC0149931
p4026
sg10
I8
sg11
Vmigraine
p4027
sg13
I1
sa(dp4028
g7
I72
sg23
VC0021368
p4029
sg10
I12
sg11
Vinflammation
p4030
sg13
I1
sa(dp4031
g7
I89
sg23
VC2938905
p4032
sg10
I21
sg11
Vcentral sensitization
p4033
sg13
I2
sasa(dp4034
g2
S'Here, CRFR2 can be recruited by either high (pharmacological) concentrations of CRF or by endogenous CRFR2 ligands, the urocortins, leading to analgesia (pain termination).\n'
p4035
sg4
(lp4036
(dp4037
g7
I101
sg8
g18
sg10
I13
sg11
VCRFR2 ligands
p4038
sg13
I2
sa(dp4039
g7
I6
sg8
g18
sg10
I5
sg11
VCRFR2
p4040
sg13
I1
sa(dp4041
g7
I6
sg8
VP06850
p4042
sg10
I3
sg11
VCRF
p4043
sg13
I1
sasg20
(lp4044
(dp4045
g7
I143
sg23
VC0344307
p4046
sg10
I9
sg11
Vanalgesia
p4047
sg13
I1
sa(dp4048
g7
I6
sg23
VC0022661
p4049
sg10
I3
sg11
VCRF
p4050
sg13
I1
sasa(dp4051
g2
S'The involvement of glucocorticoid and CRF-2 receptors in the development of analgesia evoked by systemic administration of CRF was studied by blockade of these receptors by their specific antagonists RU 38486 and astressin 2-B, respectively, in anesthetized rats.\n'
p4052
sg4
(lp4053
(dp4054
g7
I38
sg8
VP06850
p4055
sg10
I15
sg11
VCRF-2 receptors
p4056
sg13
I2
sasg20
(lp4057
(dp4058
g7
I38
sg23
VC0022661
p4059
sg10
I3
sg11
VCRF
p4060
sg13
I1
sa(dp4061
g7
I76
sg23
VC0344307
p4062
sg10
I9
sg11
Vanalgesia
p4063
sg13
I1
sa(dp4064
g7
I38
sg23
VC0022661
p4065
sg10
I3
sg11
VCRF
p4066
sg13
I1
sasa(dp4067
g2
S'The participation of glucocorticoid receptors and CRF-2 receptors in the CRF-induced analgesia was investigated by the receptors antagonists: RU38486 or astressin 2-B, respectively, in anaesthetized rats.\n'
p4068
sg4
(lp4069
(dp4070
g7
I21
sg8
VP04150
p4071
sg10
I24
sg11
Vglucocorticoid receptors
p4072
sg13
I2
sa(dp4073
g7
I50
sg8
VP06850
p4074
sg10
I15
sg11
VCRF-2 receptors
p4075
sg13
I2
sa(dp4076
g7
I50
sg8
VP06850
p4077
sg10
I3
sg11
VCRF
p4078
sg13
I1
sasg20
(lp4079
(dp4080
g7
I50
sg23
VC0022661
p4081
sg10
I3
sg11
VCRF
p4082
sg13
I1
sa(dp4083
g7
I85
sg23
VC0344307
p4084
sg10
I9
sg11
Vanalgesia
p4085
sg13
I1
sa(dp4086
g7
I50
sg23
VC0022661
p4087
sg10
I3
sg11
VCRF
p4088
sg13
I1
sasa(dp4089
g2
S'In view of the lamina-specific and similar distributions of the two CRF receptor mRNAs with their ligands, we suggest that CRF1 and CRF2 are involved in peripheral stress adaptation processes, such as modulation of stress-induced analgesia and the mediation of visceral nociceptive information by CRF2.\n'
p4090
sg4
(lp4091
(dp4092
g7
I123
sg8
VP34998
p4093
sg10
I4
sg11
VCRF1
p4094
sg13
I1
sa(dp4095
g7
I132
sg8
g18
sg10
I4
sg11
VCRF2
p4096
sg13
I1
sa(dp4097
g7
I68
sg8
VP06850
p4098
sg10
I18
sg11
VCRF receptor mRNAs
p4099
sg13
I3
sa(dp4100
g7
I132
sg8
g18
sg10
I4
sg11
VCRF2
p4101
sg13
I1
sasg20
(lp4102
(dp4103
g7
I68
sg23
VC0022661
p4104
sg10
I3
sg11
VCRF
p4105
sg13
I1
sa(dp4106
g7
I230
sg23
VC0344307
p4107
sg10
I9
sg11
Vanalgesia
p4108
sg13
I1
sasa(dp4109
g2
S'Knockdown of hepatic LIPIN2 in DIO mice reduced fasting hyperglycemia and improved hepatic insulin signaling.\n'
p4110
sg4
(lp4111
(dp4112
g7
I91
sg8
VP01308
p4113
sg10
I7
sg11
Vinsulin
p4114
sg13
I1
sasg20
(lp4115
(dp4116
g7
I56
sg23
VC0020456
p4117
sg10
I13
sg11
Vhyperglycemia
p4118
sg13
I1
sasa(dp4119
g2
S'Growing evidence links the three mammalian lipin proteins, i.e., lipin-1, lipin-2 and lipin-3, to metabolic and cardiovascular diseases such as noninsulin-dependent diabetes mellitus and atherosclerosis.\n'
p4120
sg4
(lp4121
(dp4122
g7
I65
sg8
g18
sg10
I7
sg11
Vlipin-1
p4123
sg13
I1
sa(dp4124
g7
I43
sg8
VP02649
p4125
sg10
I14
sg11
Vlipin proteins
p4126
sg13
I2
sa(dp4127
g7
I86
sg8
g18
sg10
I7
sg11
Vlipin-3
p4128
sg13
I1
sa(dp4129
g7
I74
sg8
g18
sg10
I7
sg11
Vlipin-2
p4130
sg13
I1
sasg20
(lp4131
(dp4132
g7
I144
sg23
VC0011860
p4133
sg10
I38
sg11
Vnoninsulin-dependent diabetes mellitus
p4134
sg13
I3
sa(dp4135
g7
I112
sg23
VC0007222
p4136
sg10
I23
sg11
Vcardiovascular diseases
p4137
sg13
I2
sa(dp4138
g7
I187
sg23
VC0004153
p4139
sg10
I15
sg11
Vatherosclerosis
p4140
sg13
I1
sasa(dp4141
g2
S'Several studies have demonstrated that polymorphisms in the LPIN1 and LPIN2 genes are associated with metabolic disease traits, including insulin sensitivity, diabetes, blood pressure and response to thiazolidinedione drugs.\n'
p4142
sg4
(lp4143
(dp4144
g7
I60
sg8
g18
sg10
I5
sg11
VLPIN1
p4145
sg13
I1
sa(dp4146
g7
I138
sg8
VP01308
p4147
sg10
I7
sg11
Vinsulin
p4148
sg13
I1
sa(dp4149
g7
I70
sg8
g18
sg10
I11
sg11
VLPIN2 genes
p4150
sg13
I2
sasg20
(lp4151
(dp4152
g7
I159
sg23
VC0011849
p4153
sg10
I8
sg11
Vdiabetes
p4154
sg13
I1
sa(dp4155
g7
I102
sg23
VC0025517
p4156
sg10
I17
sg11
Vmetabolic disease
p4157
sg13
I2
sa(dp4158
g7
I138
sg23
VC0920563
p4159
sg10
I19
sg11
Vinsulin sensitivity
p4160
sg13
I2
sasa(dp4161
g2
S"This SNP is located at the 3' untranslated region of the LPIN2 gene, which is a plausible candidate for type 2 diabetes and obesity.\n"
p4162
sg4
(lp4163
(dp4164
g7
I57
sg8
g18
sg10
I10
sg11
VLPIN2 gene
p4165
sg13
I2
sasg20
(lp4166
(dp4167
g7
I124
sg23
VC0028754
p4168
sg10
I7
sg11
Vobesity
p4169
sg13
I1
sa(dp4170
g7
I104
sg23
VC0011860
p4171
sg10
I15
sg11
Vtype 2 diabetes
p4172
sg13
I3
sasa(dp4173
g2
S'rs3745012 SNP of the LPIN2 gene is associated with type 2 diabetes and fat distribution.\n'
p4174
sg4
(lp4175
(dp4176
g7
I21
sg8
g18
sg10
I10
sg11
VLPIN2 gene
p4177
sg13
I2
sasg20
(lp4178
(dp4179
g7
I51
sg23
VC0011860
p4180
sg10
I15
sg11
Vtype 2 diabetes
p4181
sg13
I3
sasa(dp4182
g2
S'Inner-ear hair cell differentiation requires Atoh1 function, while Eya1, Six1, and Sox2 are coexpressed in sensory progenitors and mutations in these genes cause sensorineural hearing loss.\n'
p4183
sg4
(lp4184
(dp4185
g7
I83
sg8
VP48431
p4186
sg10
I4
sg11
VSox2
p4187
sg13
I1
sa(dp4188
g7
I73
sg8
g18
sg10
I4
sg11
VSix1
p4189
sg13
I1
sa(dp4190
g7
I45
sg8
g18
sg10
I5
sg11
VAtoh1
p4191
sg13
I1
sa(dp4192
g7
I67
sg8
g18
sg10
I4
sg11
VEya1
p4193
sg13
I1
sasg20
(lp4194
(dp4195
g7
I162
sg23
VC0018784
p4196
sg10
I26
sg11
Vsensorineural hearing loss
p4197
sg13
I3
sasa(dp4198
g2
S'While mutations in human EYA4 cause late-onset deafness at the DFNA10 locus, mutations in human EYA1 cause branchio-oto-renal (BOR) syndrome.\n'
p4199
sg4
(lp4200
(dp4201
g7
I90
sg8
g18
sg10
I10
sg11
Vhuman EYA1
p4202
sg13
I2
sa(dp4203
g7
I63
sg8
g18
sg10
I12
sg11
VDFNA10 locus
p4204
sg13
I2
sa(dp4205
g7
I19
sg8
g18
sg10
I10
sg11
Vhuman EYA4
p4206
sg13
I2
sasg20
(lp4207
(dp4208
g7
I132
sg23
VC0039082
p4209
sg10
I8
sg11
Vsyndrome
p4210
sg13
I1
sa(dp4211
g7
I63
sg23
VC1832476
p4212
sg10
I6
sg11
VDFNA10
p4213
sg13
I1
sa(dp4214
g7
I47
sg23
VC0011053
p4215
sg10
I8
sg11
Vdeafness
p4216
sg13
I1
sasa(dp4217
g2
S"Pendred's syndrome, distal renal tubular acidosis, waardenburg's syndrome, X-linked congenital mixed deafness, branchio-oto-renal syndrome, and oto-facio-cervical syndrome can express their genotypic alteration as enlarged vestibular aqueduct syndrome.\n"
p4218
sg4
(lp4219
sg20
(lp4220
(dp4221
g7
I20
sg23
VC1704380
p4222
sg10
I29
sg11
Vdistal renal tubular acidosis
p4223
sg13
I4
sa(dp4224
g7
I214
sg23
VC1863752
p4225
sg10
I37
sg11
Venlarged vestibular aqueduct syndrome
p4226
sg13
I4
sa(dp4227
g7
I111
sg23
VC0265234
p4228
sg10
I27
sg11
Vbranchio-oto-renal syndrome
p4229
sg13
I2
sa(dp4230
g7
I51
sg23
VC3266898
p4231
sg10
I22
sg11
Vwaardenburg's syndrome
p4232
sg13
I2
sa(dp4233
g7
I0
sg23
VC0271829
p4234
sg10
I18
sg11
VPendred's syndrome
p4235
sg13
I2
sa(dp4236
g7
I95
sg23
VC0155552
p4237
sg10
I14
sg11
Vmixed deafness
p4238
sg13
I2
sa(dp4239
g7
I154
sg23
VC0543612
p4240
sg10
I17
sg11
Vcervical syndrome
p4241
sg13
I2
sasa(dp4242
g2
S'Allele variants of EYA1 and EYA4, two members of the vertebrate Eya gene family, underlie two types of inherited human deafness, branchio-oto-renal (BOR) syndrome and DFNA10, respectively.\n'
p4243
sg4
(lp4244
(dp4245
g7
I167
sg8
g18
sg10
I6
sg11
VDFNA10
p4246
sg13
I1
sa(dp4247
g7
I19
sg8
g18
sg10
I4
sg11
VEYA1
p4248
sg13
I1
sa(dp4249
g7
I28
sg8
g18
sg10
I4
sg11
VEYA4
p4250
sg13
I1
sasg20
(lp4251
(dp4252
g7
I167
sg23
VC1832476
p4253
sg10
I6
sg11
VDFNA10
p4254
sg13
I1
sa(dp4255
g7
I119
sg23
VC0011053
p4256
sg10
I8
sg11
Vdeafness
p4257
sg13
I1
sa(dp4258
g7
I154
sg23
VC0039082
p4259
sg10
I8
sg11
Vsyndrome
p4260
sg13
I1
sasa(dp4261
g2
S'During early inner ear development, Eya1 is expressed in the ventromedial wall of the otic vesicle (the site of the future sensory epithelia), in the statoacoustic ganglion, and in the periotic mesenchyme, consistent with the cochlear anomalies and sensorineural hearing loss of BOR syndrome.\n'
p4262
sg4
(lp4263
(dp4264
g7
I36
sg8
g18
sg10
I4
sg11
VEya1
p4265
sg13
I1
sasg20
(lp4266
(dp4267
g7
I164
sg23
VC1258666
p4268
sg10
I8
sg11
Vganglion
p4269
sg13
I1
sa(dp4270
g7
I91
sg23
VC0333262
p4271
sg10
I7
sg11
Vvesicle
p4272
sg13
I1
sa(dp4273
g7
I279
sg23
VC0265234
p4274
sg10
I12
sg11
VBOR syndrome
p4275
sg13
I2
sa(dp4276
g7
I249
sg23
VC0018784
p4277
sg10
I26
sg11
Vsensorineural hearing loss
p4278
sg13
I3
sasa(dp4279
g2
S'LIGHT (lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus entry on T cells) is a tumor necrosis factor core family member that regulates T-cell activation and causes experimental inflammatory bowel disease.\n'
p4280
sg4
(lp4281
(dp4282
g7
I7
sg8
VP01374
p4283
sg10
I11
sg11
Vlymphotoxin
p4284
sg13
I1
sa(dp4285
g7
I116
sg8
VP01375
p4286
sg10
I40
sg11
Vtumor necrosis factor core family member
p4287
sg13
I6
sa(dp4288
g7
I0
sg8
g18
sg10
I5
sg11
VLIGHT
p4289
sg13
I1
sasg20
(lp4290
(dp4291
g7
I214
sg23
VC0021390
p4292
sg10
I26
sg11
Vinflammatory bowel disease
p4293
sg13
I3
sa(dp4294
g7
I116
sg23
VC0333516
p4295
sg10
I14
sg11
Vtumor necrosis
p4296
sg13
I2
sa(dp4297
g7
I80
sg23
VC0019340
p4298
sg10
I6
sg11
Vherpes
p4299
sg13
I1
sasa(dp4300
g2
S'To clarify the biological differences between small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC), we investigated the expression of two bHLH type transcription factors, human achaete-scute homolog 1 (hASH1) and hairy/enhancer of split 1 (HES1), which positively and negatively regulate the neuroendocrine differentiation of respiratory epithelial cells, respectively.\n'
p4301
sg4
(lp4302
(dp4303
g7
I199
sg8
VP50553
p4304
sg10
I29
sg11
Vhuman achaete-scute homolog 1
p4305
sg13
I4
sa(dp4306
g7
I230
sg8
VP50553
p4307
sg10
I5
sg11
VhASH1
p4308
sg13
I1
sa(dp4309
g7
I166
sg8
VP19883
p4310
sg10
I31
sg11
VbHLH type transcription factors
p4311
sg13
I4
sa(dp4312
g7
I268
sg8
g18
sg10
I4
sg11
VHES1
p4313
sg13
I1
sa(dp4314
g7
I241
sg8
g18
sg10
I25
sg11
Vhairy/enhancer of split 1
p4315
sg13
I4
sasg20
(lp4316
(dp4317
g7
I46
sg23
VC0149925
p4318
sg10
I25
sg11
Vsmall cell lung carcinoma
p4319
sg13
I4
sa(dp4320
g7
I83
sg23
VC1265996
p4321
sg10
I35
sg11
Vlarge cell neuroendocrine carcinoma
p4322
sg13
I4
sa(dp4323
g7
I120
sg23
VC1265996
p4324
sg10
I5
sg11
VLCNEC
p4325
sg13
I1
sa(dp4326
g7
I73
sg23
VC0149925
p4327
sg10
I4
sg11
VSCLC
p4328
sg13
I1
sasa(dp4329
g2
S'The frequencies of the expressions of CD56, mASH1, TTF-1, and p16 were higher and that of NeuroD was lower in small cell carcinoma than in large cell neuroendocrine carcinoma.\n'
p4330
sg4
(lp4331
(dp4332
g7
I62
sg8
VP42771
p4333
sg10
I3
sg11
Vp16
p4334
sg13
I1
sa(dp4335
g7
I44
sg8
VP50553
p4336
sg10
I5
sg11
VmASH1
p4337
sg13
I1
sa(dp4338
g7
I51
sg8
VP43699
p4339
sg10
I5
sg11
VTTF-1
p4340
sg13
I1
sa(dp4341
g7
I90
sg8
g18
sg10
I6
sg11
VNeuroD
p4342
sg13
I1
sasg20
(lp4343
(dp4344
g7
I139
sg23
VC1265996
p4345
sg10
I35
sg11
Vlarge cell neuroendocrine carcinoma
p4346
sg13
I4
sa(dp4347
g7
I110
sg23
VC0262584
p4348
sg10
I20
sg11
Vsmall cell carcinoma
p4349
sg13
I3
sasa(dp4350
g2
S'Here we show that reduced Daf1 transcription in lupus-prone mice was not associated with a reduction in the Daf1 transcription factor SP1.\n'
p4351
sg4
(lp4352
(dp4353
g7
I108
sg8
VP08047
p4354
sg10
I29
sg11
VDaf1 transcription factor SP1
p4355
sg13
I4
sa(dp4356
g7
I26
sg8
g18
sg10
I4
sg11
VDaf1
p4357
sg13
I1
sasg20
(lp4358
(dp4359
g7
I48
sg23
VC0024131
p4360
sg10
I5
sg11
Vlupus
p4361
sg13
I1
sasa(dp4362
g2
S'Here, we describe a deep sequencing-aided engineering strategy to fine-tune the specificity of an angiopoietin-2 (Ang2)/vascular endothelial growth factor (VEGF) dual action Fab, 5A12.1 for the treatment of age-related macular degeneration.\n'
p4363
sg4
(lp4364
(dp4365
g7
I114
sg8
g18
sg10
I4
sg11
VAng2
p4366
sg13
I1
sa(dp4367
g7
I120
sg8
g18
sg10
I34
sg11
Vvascular endothelial growth factor
p4368
sg13
I4
sa(dp4369
g7
I98
sg8
g18
sg10
I14
sg11
Vangiopoietin-2
p4370
sg13
I1
sasg20
(lp4371
(dp4372
g7
I207
sg23
VC0242383
p4373
sg10
I32
sg11
Vage-related macular degeneration
p4374
sg13
I3
sasa(dp4375
g2
S'Angiopoietin 2 (ANG2) is a proangiogenic cytokine which may have an implication in neovascular age related macular degeneration (nAMD).\n'
p4376
sg4
(lp4377
(dp4378
g7
I0
sg8
g18
sg10
I14
sg11
VAngiopoietin 2
p4379
sg13
I2
sa(dp4380
g7
I16
sg8
g18
sg10
I4
sg11
VANG2
p4381
sg13
I1
sasg20
(lp4382
(dp4383
g7
I95
sg23
VC0242383
p4384
sg10
I32
sg11
Vage related macular degeneration
p4385
sg13
I4
sasa(dp4386
g2
S'Levels of ANG2 in the aqueous were significantly higher in nAMD patients than those of the control group (p &lt; 0.0001), so were hepatocyte growth factor (HGF), interleukin-8 (IL-8) and tissue inhibitor of metalloproteinase 1 (TIMP 1), all with p &lt; 0.001.\n'
p4387
sg4
(lp4388
(dp4389
g7
I130
sg8
VP05231
p4390
sg10
I24
sg11
Vhepatocyte growth factor
p4391
sg13
I3
sa(dp4392
g7
I156
sg8
VP05231
p4393
sg10
I3
sg11
VHGF
p4394
sg13
I1
sa(dp4395
g7
I10
sg8
g18
sg10
I4
sg11
VANG2
p4396
sg13
I1
sa(dp4397
g7
I177
sg8
VP01033
p4398
sg10
I57
sg11
VIL-8) and tissue inhibitor of metalloproteinase 1 (TIMP 1
p4399
sg13
I9
sa(dp4400
g7
I162
sg8
VP60568
p4401
sg10
I13
sg11
Vinterleukin-8
p4402
sg13
I1
sasg20
(lp4403
(dp4404
g7
I130
sg23
VC0399440
p4405
sg10
I24
sg11
Vhepatocyte growth factor
p4406
sg13
I3
sa(dp4407
g7
I156
sg23
VC0399440
p4408
sg10
I3
sg11
VHGF
p4409
sg13
I1
sasa(dp4410
g2
S'ANG2 is upregulated in patients with nAMD and correlates with severity of disease at presentation.\n'
p4411
sg4
(lp4412
(dp4413
g7
I0
sg8
g18
sg10
I4
sg11
VANG2
p4414
sg13
I1
sasg20
(lp4415
sa(dp4416
g2
S'We determine the angiopoietin 2 (ANGPT2) gene as a new susceptibility gene for neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV).\n'
p4417
sg4
(lp4418
(dp4419
g7
I33
sg8
g18
sg10
I6
sg11
VANGPT2
p4420
sg13
I1
sa(dp4421
g7
I17
sg8
g18
sg10
I14
sg11
Vangiopoietin 2
p4422
sg13
I2
sasg20
(lp4423
(dp4424
g7
I125
sg23
VC0271084
p4425
sg10
I4
sg11
VnAMD
p4426
sg13
I1
sa(dp4427
g7
I170
sg23
VC1504336
p4428
sg10
I3
sg11
VPCV
p4429
sg13
I1
sa(dp4430
g7
I135
sg23
VC1504336
p4431
sg10
I33
sg11
Vpolypoidal choroidal vasculopathy
p4432
sg13
I3
sa(dp4433
g7
I79
sg23
VC0271084
p4434
sg10
I44
sg11
Vneovascular age-related macular degeneration
p4435
sg13
I4
sasa(dp4436
g2
S'In the Hong Kong cohort, four SNPs in ANGPT2 (rs13255574, rs4455855, rs13269021, and rs11775442) were nominally associated with nAMD and PCV.\n'
p4437
sg4
(lp4438
(dp4439
g7
I38
sg8
g18
sg10
I6
sg11
VANGPT2
p4440
sg13
I1
sasg20
(lp4441
sa(dp4442
g2
S'Interaction analysis revealed the CFH SNP rs800292 has a highly significant interaction with the ANGPT2 SNP rs13269021 in nAMD and PCV in the combined analysis.\n'
p4443
sg4
(lp4444
(dp4445
g7
I34
sg8
g18
sg10
I16
sg11
VCFH SNP rs800292
p4446
sg13
I3
sa(dp4447
g7
I97
sg8
g18
sg10
I21
sg11
VANGPT2 SNP rs13269021
p4448
sg13
I3
sasg20
(lp4449
sa(dp4450
g2
S'This study reveals ANGPT2 as a new susceptibility gene for nAMD and PCV, and it may affect disease susceptibility in association with CFH.\n'
p4451
sg4
(lp4452
(dp4453
g7
I19
sg8
g18
sg10
I6
sg11
VANGPT2
p4454
sg13
I1
sasg20
(lp4455
sa(dp4456
g2
S'Here, we engineered a Two-in-One VEGF/angiopoietin 2 antibody with dual action Fab (DAF) as a potential therapeutic for neovascular age-related macular degeneration.\n'
p4457
sg4
(lp4458
(dp4459
g7
I84
sg8
VP08174
p4460
sg10
I3
sg11
VDAF
p4461
sg13
I1
sa(dp4462
g7
I67
sg8
VP08174
p4463
sg10
I15
sg11
Vdual action Fab
p4464
sg13
I3
sa(dp4465
g7
I38
sg8
g18
sg10
I23
sg11
Vangiopoietin 2 antibody
p4466
sg13
I3
sasg20
(lp4467
(dp4468
g7
I120
sg23
VC0271084
p4469
sg10
I44
sg11
Vneovascular age-related macular degeneration
p4470
sg13
I4
sasa(dp4471
g2
S'Our study connects the interaction between RhoGDI1 and ephrinB1 to the promotion of cancer cell behavior associated with tumor progression.\n'
p4472
sg4
(lp4473
(dp4474
g7
I55
sg8
VP98172
p4475
sg10
I8
sg11
VephrinB1
p4476
sg13
I1
sasg20
(lp4477
(dp4478
g7
I84
sg23
VC0006826
p4479
sg10
I6
sg11
Vcancer
p4480
sg13
I1
sa(dp4481
g7
I121
sg23
VC0178874
p4482
sg10
I17
sg11
Vtumor progression
p4483
sg13
I2
sasa(dp4484
g2
S'The purpose of the present study was to assess the role of RhoGDIs in the invasiveness and migration of liver cancer, and to determine their clinical prognostic significances in HCC following liver transplantation (LT).\n'
p4485
sg4
(lp4486
sg20
(lp4487
(dp4488
g7
I104
sg23
VC0345904
p4489
sg10
I12
sg11
Vliver cancer
p4490
sg13
I2
sa(dp4491
g7
I178
sg23
VC2239176
p4492
sg10
I3
sg11
VHCC
p4493
sg13
I1
sasa(dp4494
g2
S'In addition, the functions of RhoGDIs in liver cancer cell line were studied in vitro.\n'
p4495
sg4
(lp4496
sg20
(lp4497
(dp4498
g7
I41
sg23
VC0345904
p4499
sg10
I12
sg11
Vliver cancer
p4500
sg13
I2
sasa(dp4501
g2
S'As a result, the downregulation of RhoGDI1 and RhoGDI2 at mRNA and protein levels were detected in HCC when compared with that of adjacent noncancerous tissues (P&lt;0.05).\n'
p4502
sg4
(lp4503
(dp4504
g7
I47
sg8
VP52566
p4505
sg10
I7
sg11
VRhoGDI2
p4506
sg13
I1
sasg20
(lp4507
(dp4508
g7
I99
sg23
VC2239176
p4509
sg10
I3
sg11
VHCC
p4510
sg13
I1
sasa(dp4511
g2
S'However, the level of RhoGDI3 was identified to be similar in tumor and para-carcinoma tissues.\n'
p4512
sg4
(lp4513
(dp4514
g7
I22
sg8
g18
sg10
I7
sg11
VRhoGDI3
p4515
sg13
I1
sasg20
(lp4516
(dp4517
g7
I77
sg23
VC0007097
p4518
sg10
I9
sg11
Vcarcinoma
p4519
sg13
I1
sa(dp4520
g7
I62
sg23
VC0027651
p4521
sg10
I5
sg11
Vtumor
p4522
sg13
I1
sasa(dp4523
g2
S'Results from the present study indicate that RhoGDI dysregulation is a frequent event in human HCC, and that it promotes cancer progression by stimulating cell migration and invasion.\n'
p4524
sg4
(lp4525
(dp4526
g7
I45
sg8
VP31150
p4527
sg10
I6
sg11
VRhoGDI
p4528
sg13
I1
sasg20
(lp4529
(dp4530
g7
I121
sg23
VC0178874
p4531
sg10
I18
sg11
Vcancer progression
p4532
sg13
I2
sa(dp4533
g7
I95
sg23
VC2239176
p4534
sg10
I3
sg11
VHCC
p4535
sg13
I1
sa(dp4536
g7
I174
sg23
VC2699153
p4537
sg10
I8
sg11
Vinvasion
p4538
sg13
I1
sasa(dp4539
g2
S'RhoGDI proteins have been implicated in several human cancers; changes in their expression levels have shown pro- or anti-tumorigenic effects.\n'
p4540
sg4
(lp4541
(dp4542
g7
I0
sg8
VP31150
p4543
sg10
I15
sg11
VRhoGDI proteins
p4544
sg13
I2
sasg20
(lp4545
(dp4546
g7
I54
sg23
VC0006826
p4547
sg10
I7
sg11
Vcancers
p4548
sg13
I1
sasa(dp4549
g2
S'However, the role of RhoGDI3 has not been studied in relation to cancer or to PDAC.\n'
p4550
sg4
(lp4551
(dp4552
g7
I21
sg8
g18
sg10
I7
sg11
VRhoGDI3
p4553
sg13
I1
sasg20
(lp4554
(dp4555
g7
I65
sg23
VC0006826
p4556
sg10
I6
sg11
Vcancer
p4557
sg13
I1
sasa(dp4558
g2
S'Despite the reduction in the expression of RhoGDI3 in PDAC, we found that RhoB was underexpressed while RhoG was overexpressed, suggesting that cancerous cells preserve their capacity to activate this pathway, thus these cells may be more eager to response to the stimuli needed to proliferate and become invasive unlike normal cells.\n'
p4559
sg4
(lp4560
(dp4561
g7
I74
sg8
VP62745
p4562
sg10
I4
sg11
VRhoB
p4563
sg13
I1
sa(dp4564
g7
I43
sg8
g18
sg10
I7
sg11
VRhoGDI3
p4565
sg13
I1
sa(dp4566
g7
I43
sg8
VP84095
p4567
sg10
I4
sg11
VRhoG
p4568
sg13
I1
sasg20
(lp4569
sa(dp4570
g2
S'Surprisingly, we found nuclear localization of RhoGDI3 in non-cancerous pancreatic cell line and normal pancreatic tissue biopsies, which could open the possibility of novel nuclear functions for this protein, impacting gene expression regulation and cellular homeostasis.\n'
p4571
sg4
(lp4572
(dp4573
g7
I47
sg8
g18
sg10
I7
sg11
VRhoGDI3
p4574
sg13
I1
sasg20
(lp4575
sa(dp4576
g2
S'The protein ARHGDIA has been found to play distinct roles in cancer progression for several tumors.\n'
p4577
sg4
(lp4578
sg20
(lp4579
(dp4580
g7
I92
sg23
VC0027651
p4581
sg10
I6
sg11
Vtumors
p4582
sg13
I1
sa(dp4583
g7
I61
sg23
VC0178874
p4584
sg10
I18
sg11
Vcancer progression
p4585
sg13
I2
sasa(dp4586
g2
S'However, it remains elusive whether and how ARHGDIA plays functions in human glioma.\n'
p4587
sg4
(lp4588
(dp4589
g7
I44
sg8
VP52565
p4590
sg10
I7
sg11
VARHGDIA
p4591
sg13
I1
sasg20
(lp4592
(dp4593
g7
I77
sg23
VC0017638
p4594
sg10
I6
sg11
Vglioma
p4595
sg13
I1
sasa(dp4596
g2
S'In this study, we discovered that ARHGDIA is much downregulated in human glioma; meanwhile, its expression negatively correlates with glioma malignancy and positively relates to prognosis of glioma patients.\n'
p4597
sg4
(lp4598
(dp4599
g7
I34
sg8
VP52565
p4600
sg10
I7
sg11
VARHGDIA
p4601
sg13
I1
sasg20
(lp4602
(dp4603
g7
I73
sg23
VC0017638
p4604
sg10
I6
sg11
Vglioma
p4605
sg13
I1
sa(dp4606
g7
I73
sg23
VC0017638
p4607
sg10
I6
sg11
Vglioma
p4608
sg13
I1
sa(dp4609
g7
I73
sg23
VC0017638
p4610
sg10
I6
sg11
Vglioma
p4611
sg13
I1
sa(dp4612
g7
I141
sg23
VC0006826
p4613
sg10
I10
sg11
Vmalignancy
p4614
sg13
I1
sasa(dp4615
g2
S'It has independent predictive value of ARHGDIA expression level for overall survival of human glioma patients.\n'
p4616
sg4
(lp4617
(dp4618
g7
I39
sg8
VP52565
p4619
sg10
I7
sg11
VARHGDIA
p4620
sg13
I1
sasg20
(lp4621
(dp4622
g7
I94
sg23
VC0017638
p4623
sg10
I6
sg11
Vglioma
p4624
sg13
I1
sasa(dp4625
g2
S'Glioma patients with ARHGDIA-positive expression have a longer overall survival time than ARHGDIA-negative patients.\n'
p4626
sg4
(lp4627
sg20
(lp4628
(dp4629
g7
I0
sg23
VC0017638
p4630
sg10
I6
sg11
VGlioma
p4631
sg13
I1
sasa(dp4632
g2
S'ARHGDIA is a potential prognostic marker and therapeutic target for human glioma.\n'
p4633
sg4
(lp4634
(dp4635
g7
I0
sg8
VP52565
p4636
sg10
I7
sg11
VARHGDIA
p4637
sg13
I1
sasg20
(lp4638
(dp4639
g7
I74
sg23
VC0017638
p4640
sg10
I6
sg11
Vglioma
p4641
sg13
I1
sasa(dp4642
g2
S'Furthermore, we demonstrated that ARHGDIA is a potential target of miR-151-5p and miR-16 in gliomas.\n'
p4643
sg4
(lp4644
(dp4645
g7
I82
sg8
g18
sg10
I6
sg11
VmiR-16
p4646
sg13
I1
sa(dp4647
g7
I67
sg8
g18
sg10
I10
sg11
VmiR-151-5p
p4648
sg13
I1
sa(dp4649
g7
I34
sg8
VP52565
p4650
sg10
I7
sg11
VARHGDIA
p4651
sg13
I1
sasg20
(lp4652
(dp4653
g7
I92
sg23
VC0017638
p4654
sg10
I7
sg11
Vgliomas
p4655
sg13
I1
sasa(dp4656
g2
S'PCBP2 may facilitate miR-151-5p and miR-16 promotion of glioma cell migration and invasion through mitigating the function of ARHGDIA.\n'
p4657
sg4
(lp4658
(dp4659
g7
I21
sg8
g18
sg10
I10
sg11
VmiR-151-5p
p4660
sg13
I1
sa(dp4661
g7
I0
sg8
g18
sg10
I5
sg11
VPCBP2
p4662
sg13
I1
sa(dp4663
g7
I126
sg8
VP52565
p4664
sg10
I7
sg11
VARHGDIA
p4665
sg13
I1
sa(dp4666
g7
I36
sg8
g18
sg10
I6
sg11
VmiR-16
p4667
sg13
I1
sasg20
(lp4668
(dp4669
g7
I56
sg23
VC0017638
p4670
sg10
I6
sg11
Vglioma
p4671
sg13
I1
sa(dp4672
g7
I82
sg23
VC2699153
p4673
sg10
I8
sg11
Vinvasion
p4674
sg13
I1
sasa(dp4675
g2
S'We report a case of hypopharyngeal cancer complicated by SIADH following chemotherapy.\n'
p4676
sg4
(lp4677
sg20
(lp4678
(dp4679
g7
I57
sg23
VC0021141
p4680
sg10
I5
sg11
VSIADH
p4681
sg13
I1
sa(dp4682
g7
I20
sg23
VC0153398
p4683
sg10
I21
sg11
Vhypopharyngeal cancer
p4684
sg13
I2
sasa(dp4685
g2
S'Two AldR binding sites (O1 and O2) with the consensus sequence GA-N2-ATC-N2-TC and one putative AldR binding site with the sequence GA-N2-GTT-N2-TC were identified upstream of the ald gene.\n'
p4686
sg4
(lp4687
(dp4688
g7
I180
sg8
VP33897
p4689
sg10
I8
sg11
Vald gene
p4690
sg13
I2
sa(dp4691
g7
I4
sg8
VP15121
p4692
sg10
I4
sg11
VAldR
p4693
sg13
I1
sa(dp4694
g7
I4
sg8
VP15121
p4695
sg10
I4
sg11
VAldR
p4696
sg13
I1
sasg20
(lp4697
(dp4698
g7
I180
sg23
VC0162309
p4699
sg10
I3
sg11
Vald
p4700
sg13
I1
sasa(dp4701
g2
S'When a phenotype of any food allergy was used for meta-analysis, the C11orf30 locus reached genome-wide significance (P = 7.50 x 10-11), whereas SNPs associated with ITGA6, ANGPT4, MMP12/MMP13, and EXOC4 and additional C11orf30 SNPs were suggestive (P &lt;= 1.49 x 10-6).\n'
p4702
sg4
(lp4703
(dp4704
g7
I198
sg8
g18
sg10
I5
sg11
VEXOC4
p4705
sg13
I1
sa(dp4706
g7
I173
sg8
g18
sg10
I6
sg11
VANGPT4
p4707
sg13
I1
sa(dp4708
g7
I69
sg8
g18
sg10
I14
sg11
VC11orf30 locus
p4709
sg13
I2
sa(dp4710
g7
I181
sg8
VP39900
p4711
sg10
I5
sg11
VMMP12
p4712
sg13
I1
sa(dp4713
g7
I187
sg8
VP45452
p4714
sg10
I5
sg11
VMMP13
p4715
sg13
I1
sasg20
(lp4716
(dp4717
g7
I24
sg23
VC0016470
p4718
sg10
I12
sg11
Vfood allergy
p4719
sg13
I2
sasa(dp4720
g2
S'This study identifies multiple novel loci as risk factors for PA and food allergy and establishes C11orf30 as a risk locus for both PA and food allergy.\n'
p4721
sg4
(lp4722
(dp4723
g7
I98
sg8
g18
sg10
I8
sg11
VC11orf30
p4724
sg13
I1
sasg20
(lp4725
(dp4726
g7
I69
sg23
VC0016470
p4727
sg10
I12
sg11
Vfood allergy
p4728
sg13
I2
sa(dp4729
g7
I69
sg23
VC0016470
p4730
sg10
I12
sg11
Vfood allergy
p4731
sg13
I2
sasa(dp4732
g2
S'TAK-448 and TAK-683, investigational agents with potential utility in the treatment of prostate cancer, are potent low molecular weight metastin receptor agonists consisting of nine amino acids.\n'
p4733
sg4
(lp4734
(dp4735
g7
I136
sg8
g18
sg10
I17
sg11
Vmetastin receptor
p4736
sg13
I2
sa(dp4737
g7
I0
sg8
VP50750
p4738
sg10
I7
sg11
VTAK-448
p4739
sg13
I1
sa(dp4740
g7
I0
sg8
VP50750
p4741
sg10
I3
sg11
VTAK
p4742
sg13
I1
sasg20
(lp4743
(dp4744
g7
I87
sg23
VC0600139
p4745
sg10
I15
sg11
Vprostate cancer
p4746
sg13
I2
sasa(dp4747
g2
S'Thus, antagonists of GPR54 are expected to be novel drugs for sex-hormone dependent diseases such as prostate cancer or endometriosis.\n'
p4748
sg4
(lp4749
(dp4750
g7
I21
sg8
g18
sg10
I5
sg11
VGPR54
p4751
sg13
I1
sasg20
(lp4752
(dp4753
g7
I120
sg23
VC0014175
p4754
sg10
I13
sg11
Vendometriosis
p4755
sg13
I1
sa(dp4756
g7
I101
sg23
VC0600139
p4757
sg10
I15
sg11
Vprostate cancer
p4758
sg13
I2
sasa(dp4759
g2
S'Though antagonists of GPR54 are expected to be novel drugs for sex-hormone dependent diseases such as prostate cancer or endometriosis, small molecule GPR54 antagonists have not been reported.\n'
p4760
sg4
(lp4761
(dp4762
g7
I22
sg8
g18
sg10
I5
sg11
VGPR54
p4763
sg13
I1
sa(dp4764
g7
I22
sg8
g18
sg10
I5
sg11
VGPR54
p4765
sg13
I1
sasg20
(lp4766
(dp4767
g7
I102
sg23
VC0600139
p4768
sg10
I15
sg11
Vprostate cancer
p4769
sg13
I2
sa(dp4770
g7
I121
sg23
VC0014175
p4771
sg10
I13
sg11
Vendometriosis
p4772
sg13
I1
sasa(dp4773
g2
S'Methanogenic archaea typically contain 5-hydroxybenzimidazolylcobamide (cba-HBI) as the prosthetic group of a number of methyltransferases involved in their central metabolic pathways.\n'
p4774
sg4
(lp4775
sg20
(lp4776
sa(dp4777
g2
S'In this paper the (acidic) dissociation constants and standard oxidation-reduction potentials of the Co3+/Co2+ and Co2+/Co1+ couples of isolated aquo-cba-HBI were measured.\n'
p4778
sg4
(lp4779
(dp4780
g7
I145
sg8
g18
sg10
I12
sg11
Vaquo-cba-HBI
p4781
sg13
I1
sa(dp4782
g7
I106
sg8
VP06681
p4783
sg10
I4
sg11
VCo2+
p4784
sg13
I1
sa(dp4785
g7
I101
sg8
VP00414
p4786
sg10
I9
sg11
VCo3+/Co2+
p4787
sg13
I1
sa(dp4788
g7
I120
sg8
VP00395
p4789
sg10
I4
sg11
VCo1+
p4790
sg13
I1
sasg20
(lp4791
(dp4792
g7
I27
sg23
VC0086168
p4793
sg10
I12
sg11
Vdissociation
p4794
sg13
I1
sasa(dp4795
g2
S'The implications for the functioning of cba-HBI in biochemical methyl group transfer reactions are discussed.\n'
p4796
sg4
(lp4797
(dp4798
g7
I40
sg8
g18
sg10
I7
sg11
Vcba-HBI
p4799
sg13
I1
sasg20
(lp4800
sa(dp4801
g2
S'Serum samples from patients with systemic lupus erythematosus (SLE) (n = 79), rheumatoid arthritis (RA) (n = 59), ankylosing spondylitis (AS) (n = 25), gout (n = 31), and normal controls (n = 99) were analyzed using ELISA for sCD4 detection.\n'
p4802
sg4
(lp4803
(dp4804
g7
I226
sg8
g18
sg10
I4
sg11
VsCD4
p4805
sg13
I1
sasg20
(lp4806
(dp4807
g7
I78
sg23
VC0003873
p4808
sg10
I20
sg11
Vrheumatoid arthritis
p4809
sg13
I2
sa(dp4810
g7
I100
sg23
VC0003873
p4811
sg10
I2
sg11
VRA
p4812
sg13
I1
sa(dp4813
g7
I114
sg23
VC0038013
p4814
sg10
I22
sg11
Vankylosing spondylitis
p4815
sg13
I2
sa(dp4816
g7
I152
sg23
VC0018099
p4817
sg10
I4
sg11
Vgout
p4818
sg13
I1
sa(dp4819
g7
I63
sg23
VC0024141
p4820
sg10
I3
sg11
VSLE
p4821
sg13
I1
sa(dp4822
g7
I138
sg23
VC0038013
p4823
sg10
I2
sg11
VAS
p4824
sg13
I1
sa(dp4825
g7
I33
sg23
VC0024141
p4826
sg10
I28
sg11
Vsystemic lupus erythematosus
p4827
sg13
I3
sasa(dp4828
g2
S"To investigate the roles of soluble CD4 (sCD4) and CD8 (sCD8) in the severity of autoimmune thyroid diseases, we examined serum concentrations of sCD4 and sCD8 in various degrees of severity of Hashimoto's disease (HD) and Graves' disease (GD) by enzyme immunoassay.\n"
p4829
sg4
(lp4830
(dp4831
g7
I41
sg8
g18
sg10
I4
sg11
VsCD4
p4832
sg13
I1
sa(dp4833
g7
I41
sg8
g18
sg10
I4
sg11
VsCD4
p4834
sg13
I1
sa(dp4835
g7
I51
sg8
VP01732
p4836
sg10
I3
sg11
VCD8
p4837
sg13
I1
sa(dp4838
g7
I28
sg8
g18
sg10
I11
sg11
Vsoluble CD4
p4839
sg13
I2
sasg20
(lp4840
(dp4841
g7
I240
sg23
VC0018213
p4842
sg10
I2
sg11
VGD
p4843
sg13
I1
sa(dp4844
g7
I223
sg23
VC0018213
p4845
sg10
I15
sg11
VGraves' disease
p4846
sg13
I2
sa(dp4847
g7
I81
sg23
VC0443146
p4848
sg10
I10
sg11
Vautoimmune
p4849
sg13
I1
sa(dp4850
g7
I194
sg23
VC0677607
p4851
sg10
I19
sg11
VHashimoto's disease
p4852
sg13
I2
sa(dp4853
g7
I92
sg23
VC0040128
p4854
sg10
I16
sg11
Vthyroid diseases
p4855
sg13
I2
sa(dp4856
g7
I215
sg23
VC0677607
p4857
sg10
I2
sg11
VHD
p4858
sg13
I1
sasa(dp4859
g2
S'The role of CD4 molecules in the autoimmune and lymphoproliferative syndrome caused by murine Fas mutations was studied using the novel systemic lupus erythematosus (SLE) model, MRL-Fas(lpr(cg))/Fas(lprcg) (MRL-lpr(cg)) mice, in combination with the novel mutant CD4 gene producing soluble CD4 (sCD4) instead of membrane-bound CD4 (mCD4).\n'
p4860
sg4
(lp4861
(dp4862
g7
I94
sg8
VP48023
p4863
sg10
I3
sg11
VFas
p4864
sg13
I1
sa(dp4865
g7
I12
sg8
VP01730
p4866
sg10
I13
sg11
VCD4 molecules
p4867
sg13
I2
sa(dp4868
g7
I94
sg8
VP48023
p4869
sg10
I3
sg11
VFas
p4870
sg13
I1
sa(dp4871
g7
I282
sg8
g18
sg10
I11
sg11
Vsoluble CD4
p4872
sg13
I2
sa(dp4873
g7
I295
sg8
g18
sg10
I4
sg11
VsCD4
p4874
sg13
I1
sa(dp4875
g7
I94
sg8
VP48023
p4876
sg10
I3
sg11
VFas
p4877
sg13
I1
sa(dp4878
g7
I186
sg8
g18
sg10
I3
sg11
Vlpr
p4879
sg13
I1
sa(dp4880
g7
I312
sg8
g18
sg10
I18
sg11
Vmembrane-bound CD4
p4881
sg13
I2
sa(dp4882
g7
I256
sg8
VP01730
p4883
sg10
I15
sg11
Vmutant CD4 gene
p4884
sg13
I3
sa(dp4885
g7
I178
sg8
VP09001
p4886
sg10
I3
sg11
VMRL
p4887
sg13
I1
sa(dp4888
g7
I332
sg8
g18
sg10
I4
sg11
VmCD4
p4889
sg13
I1
sasg20
(lp4890
(dp4891
g7
I256
sg23
VC0596988
p4892
sg10
I6
sg11
Vmutant
p4893
sg13
I1
sa(dp4894
g7
I94
sg23
VC0015923
p4895
sg10
I3
sg11
VFas
p4896
sg13
I1
sa(dp4897
g7
I94
sg23
VC0015923
p4898
sg10
I3
sg11
VFas
p4899
sg13
I1
sa(dp4900
g7
I68
sg23
VC0039082
p4901
sg10
I8
sg11
Vsyndrome
p4902
sg13
I1
sa(dp4903
g7
I33
sg23
VC0443146
p4904
sg10
I10
sg11
Vautoimmune
p4905
sg13
I1
sa(dp4906
g7
I94
sg23
VC0015923
p4907
sg10
I3
sg11
VFas
p4908
sg13
I1
sa(dp4909
g7
I166
sg23
VC0024141
p4910
sg10
I3
sg11
VSLE
p4911
sg13
I1
sa(dp4912
g7
I136
sg23
VC0024141
p4913
sg10
I28
sg11
Vsystemic lupus erythematosus
p4914
sg13
I3
sasa(dp4915
g2
S'The results indicate that mCD4 is important and can not be replaced by sCD4 in full development of SLE-like manifestations, and suggest that CD4+ T cells may aggravate the autoimmune disease by stimulating autoreactive B cells to produce autoantibodies through their helper activity in Fas mutant models.\n'
p4916
sg4
(lp4917
(dp4918
g7
I286
sg8
VP48023
p4919
sg10
I10
sg11
VFas mutant
p4920
sg13
I2
sa(dp4921
g7
I141
sg8
VP01730
p4922
sg10
I4
sg11
VCD4+
p4923
sg13
I1
sa(dp4924
g7
I71
sg8
g18
sg10
I4
sg11
VsCD4
p4925
sg13
I1
sa(dp4926
g7
I26
sg8
g18
sg10
I4
sg11
VmCD4
p4927
sg13
I1
sasg20
(lp4928
(dp4929
g7
I290
sg23
VC0596988
p4930
sg10
I6
sg11
Vmutant
p4931
sg13
I1
sa(dp4932
g7
I99
sg23
VC0014060
p4933
sg10
I3
sg11
VSLE
p4934
sg13
I1
sa(dp4935
g7
I172
sg23
VC0004364
p4936
sg10
I18
sg11
Vautoimmune disease
p4937
sg13
I2
sa(dp4938
g7
I286
sg23
VC0015923
p4939
sg10
I3
sg11
VFas
p4940
sg13
I1
sasa(dp4941
g2
S"In a search for serum markers of disease activity in uveitis, we measured the levels of the soluble form of ICAM-1 (sICAM-1), CD4 (sCD4), CD8 (sCD8) and interleukin-2 receptor (sIL-2R) in the serum of patients with Behcet's disease (BD) and Vogt-Koyanagi-Harada's disease (VKH).\n"
p4942
sg4
(lp4943
(dp4944
g7
I126
sg8
VP01730
p4945
sg10
I3
sg11
VCD4
p4946
sg13
I1
sa(dp4947
g7
I153
sg8
VP60568
p4948
sg10
I22
sg11
Vinterleukin-2 receptor
p4949
sg13
I2
sa(dp4950
g7
I138
sg8
VP01732
p4951
sg10
I3
sg11
VCD8
p4952
sg13
I1
sa(dp4953
g7
I108
sg8
VP05362
p4954
sg10
I6
sg11
VICAM-1
p4955
sg13
I1
sa(dp4956
g7
I131
sg8
g18
sg10
I4
sg11
VsCD4
p4957
sg13
I1
sa(dp4958
g7
I177
sg8
VP40967
p4959
sg10
I6
sg11
VsIL-2R
p4960
sg13
I1
sasg20
(lp4961
(dp4962
g7
I233
sg23
VC0004943
p4963
sg10
I2
sg11
VBD
p4964
sg13
I1
sa(dp4965
g7
I53
sg23
VC0042164
p4966
sg10
I7
sg11
Vuveitis
p4967
sg13
I1
sa(dp4968
g7
I215
sg23
VC0004943
p4969
sg10
I16
sg11
VBehcet's disease
p4970
sg13
I2
sa(dp4971
g7
I177
sg23
VC0333873
p4972
sg10
I3
sg11
VsIL
p4973
sg13
I1
sa(dp4974
g7
I255
sg23
VC0042170
p4975
sg10
I16
sg11
VHarada's disease
p4976
sg13
I2
sasa(dp4977
g2
S"To examine 3 soluble circulating T cell antigens: interleukin 2 receptors (sIL-2r), CD4 (sCD4), and CD8 (sCD8) with von Willebrand factor antigen levels (vWF:Ag) and antiendothelial cell antibodies (AECA) as indices of endothelial involvement in patients with Wegener's granulomatosis (WG).\n"
p4978
sg4
(lp4979
(dp4980
g7
I89
sg8
g18
sg10
I4
sg11
VsCD4
p4981
sg13
I1
sa(dp4982
g7
I100
sg8
VP01732
p4983
sg10
I3
sg11
VCD8
p4984
sg13
I1
sa(dp4985
g7
I154
sg8
VP04275
p4986
sg10
I3
sg11
VvWF
p4987
sg13
I1
sa(dp4988
g7
I75
sg8
VP40967
p4989
sg10
I6
sg11
VsIL-2r
p4990
sg13
I1
sa(dp4991
g7
I84
sg8
VP01730
p4992
sg10
I3
sg11
VCD4
p4993
sg13
I1
sa(dp4994
g7
I13
sg8
VP40967
p4995
sg10
I60
sg11
Vsoluble circulating T cell antigens: interleukin 2 receptors
p4996
sg13
I8
sa(dp4997
g7
I116
sg8
VP04275
p4998
sg10
I29
sg11
Vvon Willebrand factor antigen
p4999
sg13
I4
sasg20
(lp5000
(dp5001
g7
I260
sg23
VC0043092
p5002
sg10
I24
sg11
VWegener's granulomatosis
p5003
sg13
I2
sa(dp5004
g7
I286
sg23
VC0043092
p5005
sg10
I2
sg11
VWG
p5006
sg13
I1
sa(dp5007
g7
I75
sg23
VC0333873
p5008
sg10
I3
sg11
VsIL
p5009
sg13
I1
sasa(dp5010
g2
S'In an independent sample set, we identified 5 GIST cases lacking alterations in the KIT/PDGFRA/SDHx/RAS pathways, including two additional cases with FGFR1-TACC1 and ETV6-NTRK3 fusions.\n'
p5011
sg4
(lp5012
(dp5013
g7
I84
sg8
VP10721
p5014
sg10
I3
sg11
VKIT
p5015
sg13
I1
sa(dp5016
g7
I100
sg8
VP01116
p5017
sg10
I3
sg11
VRAS
p5018
sg13
I1
sa(dp5019
g7
I88
sg8
VP16234
p5020
sg10
I6
sg11
VPDGFRA
p5021
sg13
I1
sa(dp5022
g7
I166
sg8
VP41212
p5023
sg10
I4
sg11
VETV6
p5024
sg13
I1
sa(dp5025
g7
I171
sg8
g18
sg10
I5
sg11
VNTRK3
p5026
sg13
I1
sa(dp5027
g7
I150
sg8
VP20930
p5028
sg10
I5
sg11
VFGFR1
p5029
sg13
I1
sasg20
(lp5030
(dp5031
g7
I46
sg23
VC1847319
p5032
sg10
I4
sg11
VGIST
p5033
sg13
I1
sasa(dp5034
g2
S'Long-term silencing of CD133 by a lentiviral-based approach inhibited cancer cell-cycle progression and suppressed in vivo tumorigenicity by down-regulating expression of cytokinesis-related genes, such as TACC1, ACF7, and CKAP5.\n'
p5035
sg4
(lp5036
(dp5037
g7
I223
sg8
g18
sg10
I5
sg11
VCKAP5
p5038
sg13
I1
sa(dp5039
g7
I23
sg8
g18
sg10
I5
sg11
VCD133
p5040
sg13
I1
sa(dp5041
g7
I213
sg8
g18
sg10
I4
sg11
VACF7
p5042
sg13
I1
sasg20
(lp5043
(dp5044
g7
I70
sg23
VC0006826
p5045
sg10
I6
sg11
Vcancer
p5046
sg13
I1
sa(dp5047
g7
I123
sg23
VC1519697
p5048
sg10
I14
sg11
Vtumorigenicity
p5049
sg13
I1
sasa(dp5050
g2
S'No mutations were detected in AKT1 or BRAF, and the fusions FGFR1-TACC1, EML4-ALK, CCDC6-RET and KIF5B-RET were not found in any of the cancers.\n'
p5051
sg4
(lp5052
(dp5053
g7
I97
sg8
VP33176
p5054
sg10
I5
sg11
VKIF5B
p5055
sg13
I1
sa(dp5056
g7
I83
sg8
g18
sg10
I5
sg11
VCCDC6
p5057
sg13
I1
sa(dp5058
g7
I38
sg8
VP15056
p5059
sg10
I4
sg11
VBRAF
p5060
sg13
I1
sa(dp5061
g7
I73
sg8
g18
sg10
I4
sg11
VEML4
p5062
sg13
I1
sa(dp5063
g7
I78
sg8
g18
sg10
I3
sg11
VALK
p5064
sg13
I1
sa(dp5065
g7
I89
sg8
VP07949
p5066
sg10
I3
sg11
VRET
p5067
sg13
I1
sa(dp5068
g7
I60
sg8
VP20930
p5069
sg10
I5
sg11
VFGFR1
p5070
sg13
I1
sa(dp5071
g7
I30
sg8
VP31749
p5072
sg10
I4
sg11
VAKT1
p5073
sg13
I1
sa(dp5074
g7
I89
sg8
VP07949
p5075
sg10
I3
sg11
VRET
p5076
sg13
I1
sasg20
(lp5077
(dp5078
g7
I136
sg23
VC0006826
p5079
sg10
I7
sg11
Vcancers
p5080
sg13
I1
sasa(dp5081
g2
S'We found that rats with diabetes had significantly higher abundance of the Protein disulfide isomerase associated 3, Aspartoacylase-3,3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase, Lactamase beta 2 and Agmat protein.\n'
p5082
sg4
(lp5083
(dp5084
g7
I206
sg8
g18
sg10
I13
sg11
VAgmat protein
p5085
sg13
I2
sa(dp5086
g7
I185
sg8
VP68371
p5087
sg10
I16
sg11
VLactamase beta 2
p5088
sg13
I3
sa(dp5089
g7
I75
sg8
VP07237
p5090
sg10
I40
sg11
VProtein disulfide isomerase associated 3
p5091
sg13
I5
sa(dp5092
g7
I117
sg8
VP45381
p5093
sg10
I66
sg11
VAspartoacylase-3,3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase
p5094
sg13
I3
sasg20
(lp5095
(dp5096
g7
I24
sg23
VC0011849
p5097
sg10
I8
sg11
Vdiabetes
p5098
sg13
I1
sasa(dp5099
g2
S'The transcription factor, Grainyhead-like 2 (GRHL2), is involved in wound healing, epidermal integrity, and epithelial-to-mesenchymal transition (EMT) in various biological processes; however, the biological function of GRHL2 in non-small cell lung cancer (NSCLC) is unknown.\n'
p5100
sg4
(lp5101
(dp5102
g7
I26
sg8
g18
sg10
I17
sg11
VGrainyhead-like 2
p5103
sg13
I2
sa(dp5104
g7
I45
sg8
g18
sg10
I5
sg11
VGRHL2
p5105
sg13
I1
sa(dp5106
g7
I45
sg8
g18
sg10
I5
sg11
VGRHL2
p5107
sg13
I1
sasg20
(lp5108
(dp5109
g7
I229
sg23
VC0007131
p5110
sg10
I26
sg11
Vnon-small cell lung cancer
p5111
sg13
I4
sa(dp5112
g7
I257
sg23
VC0007131
p5113
sg10
I5
sg11
VNSCLC
p5114
sg13
I1
sa(dp5115
g7
I134
sg23
VC0599156
p5116
sg10
I10
sg11
Vtransition
p5117
sg13
I1
sasa(dp5118
g2
S'In the current study, we investigated the effect of GRHL2 on cell growth and migration in NSCLC cell lines and clinical tissues.\n'
p5119
sg4
(lp5120
(dp5121
g7
I52
sg8
g18
sg10
I5
sg11
VGRHL2
p5122
sg13
I1
sasg20
(lp5123
(dp5124
g7
I90
sg23
VC0007131
p5125
sg10
I5
sg11
VNSCLC
p5126
sg13
I1
sasa(dp5127
g2
S'Immunohistochemical analysis of clinical NSCLC specimens revealed that patients with high GRHL2 expression were associated with poor prognosis compared to patients with low GRHL2 expression.\n'
p5128
sg4
(lp5129
(dp5130
g7
I90
sg8
g18
sg10
I5
sg11
VGRHL2
p5131
sg13
I1
sa(dp5132
g7
I90
sg8
g18
sg10
I5
sg11
VGRHL2
p5133
sg13
I1
sasg20
(lp5134
(dp5135
g7
I41
sg23
VC0007131
p5136
sg10
I5
sg11
VNSCLC
p5137
sg13
I1
sasa(dp5138
g2
S'GRHL2 overexpression promoted cell growth and colony formation, and simultaneously suppressed cell migration in NSCLC cells.\n'
p5139
sg4
(lp5140
(dp5141
g7
I0
sg8
g18
sg10
I5
sg11
VGRHL2
p5142
sg13
I1
sasg20
(lp5143
(dp5144
g7
I112
sg23
VC0007131
p5145
sg10
I5
sg11
VNSCLC
p5146
sg13
I1
sasa(dp5147
g2
S'These findings confirm that GRHL2 plays an important role in regulating cell proliferation and migration in NSCLC.\n'
p5148
sg4
(lp5149
(dp5150
g7
I28
sg8
g18
sg10
I5
sg11
VGRHL2
p5151
sg13
I1
sasg20
(lp5152
(dp5153
g7
I77
sg23
VC0334094
p5154
sg10
I13
sg11
Vproliferation
p5155
sg13
I1
sa(dp5156
g7
I108
sg23
VC0007131
p5157
sg10
I5
sg11
VNSCLC
p5158
sg13
I1
sasa(dp5159
g2
S'Bone metastases (BoM) are a significant cause of morbidity in patients with estrogen receptor-positive (ER-positive) breast cancer; yet, characterizations of human specimens are limited.\n'
p5160
sg4
(lp5161
(dp5162
g7
I17
sg8
g18
sg10
I3
sg11
VBoM
p5163
sg13
I1
sa(dp5164
g7
I0
sg8
VP41162
p5165
sg10
I15
sg11
VBone metastases
p5166
sg13
I2
sasg20
(lp5167
(dp5168
g7
I17
sg23
VC0153690
p5169
sg10
I3
sg11
VBoM
p5170
sg13
I1
sa(dp5171
g7
I0
sg23
VC0153690
p5172
sg10
I15
sg11
VBone metastases
p5173
sg13
I2
sa(dp5174
g7
I117
sg23
VC0678222
p5175
sg10
I13
sg11
Vbreast cancer
p5176
sg13
I2
sasa(dp5177
g2
S'ecRNA-seq was then applied on a longitudinal collection of 11 primary breast cancers and patient-matched synchronous or recurrent BoMs.\n'
p5178
sg4
(lp5179
sg20
(lp5180
(dp5181
g7
I70
sg23
VC0006142
p5182
sg10
I14
sg11
Vbreast cancers
p5183
sg13
I2
sasa(dp5184
g2
S'The mammalian homologs of the D. melanogaster Grainyhead gene, Grainyhead-like 1-3 (GRHL1, GRHL2 and GRHL3), are transcription factors implicated in wound healing, tubulogenesis and cancer.\n'
p5185
sg4
(lp5186
(dp5187
g7
I91
sg8
g18
sg10
I5
sg11
VGRHL2
p5188
sg13
I1
sa(dp5189
g7
I101
sg8
g18
sg10
I5
sg11
VGRHL3
p5190
sg13
I1
sasg20
(lp5191
(dp5192
g7
I182
sg23
VC0006826
p5193
sg10
I6
sg11
Vcancer
p5194
sg13
I1
sasa(dp5195
g2
S'GRHL2 colocalized with AR in prostate tumors and was frequently amplified and upregulated in prostate cancer.\n'
p5196
sg4
(lp5197
(dp5198
g7
I0
sg8
g18
sg10
I5
sg11
VGRHL2
p5199
sg13
I1
sasg20
(lp5200
(dp5201
g7
I29
sg23
VC0033578
p5202
sg10
I15
sg11
Vprostate tumors
p5203
sg13
I2
sa(dp5204
g7
I93
sg23
VC0600139
p5205
sg10
I15
sg11
Vprostate cancer
p5206
sg13
I2
sasa(dp5207
g2
S"Importantly, GRHL2 maintained AR expression in multiple prostate cancer model systems, was required for cell proliferation, enhanced AR's transcriptional activity, and colocated with AR at specific sites on chromatin to regulate genes relevant to disease progression.\n"
p5208
sg4
(lp5209
(dp5210
g7
I13
sg8
g18
sg10
I5
sg11
VGRHL2
p5211
sg13
I1
sasg20
(lp5212
(dp5213
g7
I56
sg23
VC0600139
p5214
sg10
I15
sg11
Vprostate cancer
p5215
sg13
I2
sa(dp5216
g7
I109
sg23
VC0334094
p5217
sg10
I13
sg11
Vproliferation
p5218
sg13
I1
sa(dp5219
g7
I247
sg23
VC0242656
p5220
sg10
I19
sg11
Vdisease progression
p5221
sg13
I2
sasa(dp5222
g2
S'However, the reports on grainyhead-like 2 in various cancers are controversial.\n'
p5223
sg4
(lp5224
sg20
(lp5225
(dp5226
g7
I53
sg23
VC0006826
p5227
sg10
I7
sg11
Vcancers
p5228
sg13
I1
sasa(dp5229
g2
S'In this review, we summarized recent progress on grainyhead-like 2 in development and cancer in order to get an insight into the regulation network of grainyhead-like 2 and understand the roles of grainyhead-like 2 in various cancers.\n'
p5230
sg4
(lp5231
(dp5232
g7
I49
sg8
g18
sg10
I17
sg11
Vgrainyhead-like 2
p5233
sg13
I2
sasg20
(lp5234
(dp5235
g7
I226
sg23
VC0006826
p5236
sg10
I7
sg11
Vcancers
p5237
sg13
I1
sa(dp5238
g7
I86
sg23
VC0006826
p5239
sg10
I6
sg11
Vcancer
p5240
sg13
I1
sasa(dp5241
g2
S'Here, we developed a method comprising the miR-200 family and grainyhead-like 2 (GRHL2) to mimic this MET-like phenomenon observed in sarcoma patient samples.We sequentially express GRHL2 and the miR-200 family using cell transduction and transfection, respectively, to better understand the molecular underpinnings of these phenotypic transitions in sarcoma cells.\n'
p5242
sg4
(lp5243
(dp5244
g7
I62
sg8
g18
sg10
I17
sg11
Vgrainyhead-like 2
p5245
sg13
I2
sa(dp5246
g7
I43
sg8
g18
sg10
I14
sg11
VmiR-200 family
p5247
sg13
I2
sa(dp5248
g7
I81
sg8
g18
sg10
I5
sg11
VGRHL2
p5249
sg13
I1
sa(dp5250
g7
I81
sg8
g18
sg10
I5
sg11
VGRHL2
p5251
sg13
I1
sasg20
(lp5252
(dp5253
g7
I134
sg23
VC1261473
p5254
sg10
I7
sg11
Vsarcoma
p5255
sg13
I1
sa(dp5256
g7
I134
sg23
VC1261473
p5257
sg10
I7
sg11
Vsarcoma
p5258
sg13
I1
sasa(dp5259
g2
S'Strong evidence was also found in the literature for the candidate associations detected between Cystic fibrosis disorder and the PPIs between the CFTR_HUMAN, DERL1_HUMAN, RNF5_HUMAN, AHSA1_HUMAN and GOPC_HUMAN proteins, and between the CHIP_HUMAN and HSP7C_HUMAN proteins.\n'
p5260
sg4
(lp5261
(dp5262
g7
I200
sg8
VP02649
p5263
sg10
I19
sg11
VGOPC_HUMAN proteins
p5264
sg13
I2
sa(dp5265
g7
I252
sg8
VP02649
p5266
sg10
I20
sg11
VHSP7C_HUMAN proteins
p5267
sg13
I2
sasg20
(lp5268
(dp5269
g7
I97
sg23
VC0010674
p5270
sg10
I15
sg11
VCystic fibrosis
p5271
sg13
I2
sasa(dp5272
g2
S'This strategy was applied to generate a cell-permeable peptide substrate for real-time detection of intracellular caspase activities during apoptosis and an inhibitor for the CFTR-associated ligand (CAL) PDZ domain as a potential treatment for cystic fibrosis.\n'
p5273
sg4
(lp5274
(dp5275
g7
I199
sg8
g18
sg10
I3
sg11
VCAL
p5276
sg13
I1
sa(dp5277
g7
I114
sg8
VP39880
p5278
sg10
I7
sg11
Vcaspase
p5279
sg13
I1
sa(dp5280
g7
I175
sg8
VP13569
p5281
sg10
I22
sg11
VCFTR-associated ligand
p5282
sg13
I2
sasg20
(lp5283
(dp5284
g7
I244
sg23
VC0010674
p5285
sg10
I15
sg11
Vcystic fibrosis
p5286
sg13
I2
sasa(dp5287
g2
S'GOPC (FIG/PIST/CAL) is a PDZ-domain scaffolding protein that regulates the trafficking of a wide array of proteins, including small GTPases, receptors and cell surface molecules such as cadherin 23 and cystic fibrosis transmembrane regulator.\n'
p5288
sg4
(lp5289
(dp5290
g7
I15
sg8
g18
sg10
I3
sg11
VCAL
p5291
sg13
I1
sa(dp5292
g7
I6
sg8
g18
sg10
I3
sg11
VFIG
p5293
sg13
I1
sa(dp5294
g7
I126
sg8
VP51148
p5295
sg10
I13
sg11
Vsmall GTPases
p5296
sg13
I2
sa(dp5297
g7
I10
sg8
g18
sg10
I4
sg11
VPIST
p5298
sg13
I1
sa(dp5299
g7
I0
sg8
g18
sg10
I4
sg11
VGOPC
p5300
sg13
I1
sa(dp5301
g7
I186
sg8
g18
sg10
I55
sg11
Vcadherin 23 and cystic fibrosis transmembrane regulator
p5302
sg13
I7
sasg20
(lp5303
(dp5304
g7
I202
sg23
VC0010674
p5305
sg10
I15
sg11
Vcystic fibrosis
p5306
sg13
I2
sasa(dp5307
g2
S'In addition, among patients who are not carriers of the CYP2C19 loss-of-function alleles, there is a reduced risk of stroke when clopidogrel is taken with aspirin compared to aspirin alone.\n'
p5308
sg4
(lp5309
(dp5310
g7
I56
sg8
VP33261
p5311
sg10
I32
sg11
VCYP2C19 loss-of-function alleles
p5312
sg13
I3
sasg20
(lp5313
(dp5314
g7
I117
sg23
VC0038454
p5315
sg10
I6
sg11
Vstroke
p5316
sg13
I1
sasa(dp5317
g2
S'To compare the efficacy and safety of antiplatelet agents for the secondary prevention of ischemic stroke based on cytochrome P450 2C19 (CYP2C19) polymorphisms.\n'
p5318
sg4
(lp5319
(dp5320
g7
I115
sg8
VP33261
p5321
sg10
I20
sg11
Vcytochrome P450 2C19
p5322
sg13
I3
sa(dp5323
g7
I137
sg8
VP33261
p5324
sg10
I7
sg11
VCYP2C19
p5325
sg13
I1
sasg20
(lp5326
(dp5327
g7
I90
sg23
VC3272363
p5328
sg10
I15
sg11
Vischemic stroke
p5329
sg13
I2
sasa(dp5330
g2
S'In patients with a poor CYP2C19 genotype for clopidogrel metabolism (n=484), the risk of recurrent stroke among those who received triflusal treatment was 2.9% per year, which was not significantly different from those who received clopidogrel treatment (2.2% per year; hazard ratio [HR], 1.23; 95% confidence interval [CI], 0.60-2.53).\n'
p5331
sg4
(lp5332
(dp5333
g7
I24
sg8
VP33261
p5334
sg10
I16
sg11
VCYP2C19 genotype
p5335
sg13
I2
sasg20
(lp5336
(dp5337
g7
I99
sg23
VC0038454
p5338
sg10
I6
sg11
Vstroke
p5339
sg13
I1
sasa(dp5340
g2
S'The risk of recurrent stroke in patients with a good CYP2C19 genotype was 1.6% per year, which was not significantly different from those with a poor genotype (2.2% per year; HR, 0.69; 95% CI, 0.26-1.79).\n'
p5341
sg4
(lp5342
(dp5343
g7
I53
sg8
VP33261
p5344
sg10
I16
sg11
VCYP2C19 genotype
p5345
sg13
I2
sasg20
(lp5346
(dp5347
g7
I22
sg23
VC0038454
p5348
sg10
I6
sg11
Vstroke
p5349
sg13
I1
sasa(dp5350
g2
S'Whilst there were no significant differences between the treatment groups in the rates of stroke recurrence, major vascular events, or coronary revascularization, the efficacy of antiplatelet agents for the secondary prevention of stroke according to CYP2C19 genotype status remains unclear.\n'
p5351
sg4
(lp5352
(dp5353
g7
I251
sg8
VP33261
p5354
sg10
I16
sg11
VCYP2C19 genotype
p5355
sg13
I2
sasg20
(lp5356
(dp5357
g7
I90
sg23
VC0038454
p5358
sg10
I6
sg11
Vstroke
p5359
sg13
I1
sa(dp5360
g7
I90
sg23
VC0038454
p5361
sg10
I6
sg11
Vstroke
p5362
sg13
I1
sa(dp5363
g7
I97
sg23
VC1458156
p5364
sg10
I10
sg11
Vrecurrence
p5365
sg13
I1
sasa(dp5366
g2
S'PPCD endothelium was completely negative for CK2e, CK9, CK15, and CK20.\n'
p5367
sg4
(lp5368
(dp5369
g7
I56
sg8
VP19012
p5370
sg10
I4
sg11
VCK15
p5371
sg13
I1
sa(dp5372
g7
I66
sg8
VP35900
p5373
sg10
I4
sg11
VCK20
p5374
sg13
I1
sasg20
(lp5375
(dp5376
g7
I0
sg23
VC0339284
p5377
sg10
I4
sg11
VPPCD
p5378
sg13
I1
sasa(dp5379
g2
S'Mutations in CDC14 may have been recovered in the screen because Cdc14p may reduce the cyclin B (Clb)-associated Cdc28 kinase activity in late mitosis, and Cln2p may normally activate Clb-Cdc28 kinase activity by related mechanisms.\n'
p5380
sg4
(lp5381
(dp5382
g7
I13
sg8
g18
sg10
I5
sg11
VCDC14
p5383
sg13
I1
sa(dp5384
g7
I87
sg8
VP14635
p5385
sg10
I8
sg11
Vcyclin B
p5386
sg13
I2
sa(dp5387
g7
I97
sg8
g18
sg10
I3
sg11
VClb
p5388
sg13
I1
sa(dp5389
g7
I97
sg8
g18
sg10
I3
sg11
VClb
p5390
sg13
I1
sasg20
(lp5391
sa(dp5392
g2
S'The clb2 cdc14 strains arrested with replicated but unseparated DNA and unseparated spindle pole bodies; this phenotype is distinct from the late mitotic arrest of the sic1::TRP1 cdc14-1 and the cdc14-1 hct1::LEU2 double mutants and of the cdc14 CLN2 overexpressor.\n'
p5393
sg4
(lp5394
(dp5395
g7
I240
sg8
g18
sg10
I10
sg11
Vcdc14 CLN2
p5396
sg13
I2
sa(dp5397
g7
I174
sg8
VP48995
p5398
sg10
I12
sg11
VTRP1 cdc14-1
p5399
sg13
I2
sa(dp5400
g7
I209
sg8
VP01732
p5401
sg10
I19
sg11
VLEU2 double mutants
p5402
sg13
I3
sa(dp5403
g7
I195
sg8
g18
sg10
I12
sg11
Vcdc14-1 hct1
p5404
sg13
I2
sa(dp5405
g7
I4
sg8
g18
sg10
I10
sg11
Vclb2 cdc14
p5406
sg13
I2
sasg20
(lp5407
(dp5408
g7
I246
sg23
VC1876161
p5409
sg10
I4
sg11
VCLN2
p5410
sg13
I1
sa(dp5411
g7
I23
sg23
VC0018790
p5412
sg10
I8
sg11
Varrested
p5413
sg13
I1
sasa(dp5414
g2
S'In this study, we found that refractoriness to ultraviolet (UVC) light-induced cell death was increased in UVC-radiation-sensitive cells derived from Cockayne syndrome patients when the cells were precultured in medium supplemented with recombinant annexin II (rANX II).\n'
p5415
sg4
(lp5416
(dp5417
g7
I261
sg8
VP07355
p5418
sg10
I7
sg11
VrANX II
p5419
sg13
I2
sa(dp5420
g7
I237
sg8
VP07355
p5421
sg10
I22
sg11
Vrecombinant annexin II
p5422
sg13
I3
sasg20
(lp5423
(dp5424
g7
I150
sg23
VC0009207
p5425
sg10
I17
sg11
VCockayne syndrome
p5426
sg13
I2
sasa(dp5427
g2
S'In CS3BES cells, an immortal cell line derived from Cockayne syndrome patients, the rANX II supplementation-induced UVC-radiation resistance was suppressed by treatment with an anti-annexin II antibody and EGTA.\n'
p5428
sg4
(lp5429
(dp5430
g7
I177
sg8
VP07355
p5431
sg10
I24
sg11
Vanti-annexin II antibody
p5432
sg13
I3
sasg20
(lp5433
(dp5434
g7
I52
sg23
VC0009207
p5435
sg10
I17
sg11
VCockayne syndrome
p5436
sg13
I2
sasa(dp5437
g2
S'Five polymorphisms had significant influence (P &lt; .05): SNPs in the ANXA2, TGFBR3, and TEK genes were associated with increased stroke risk, whereas Alfa-thalassemia and a SNP in the ADCY9 gene were linked with decreased stroke risk.\n'
p5438
sg4
(lp5439
(dp5440
g7
I78
sg8
g18
sg10
I6
sg11
VTGFBR3
p5441
sg13
I1
sa(dp5442
g7
I71
sg8
VP07355
p5443
sg10
I5
sg11
VANXA2
p5444
sg13
I1
sa(dp5445
g7
I90
sg8
g18
sg10
I9
sg11
VTEK genes
p5446
sg13
I2
sa(dp5447
g7
I186
sg8
g18
sg10
I10
sg11
VADCY9 gene
p5448
sg13
I2
sasg20
(lp5449
(dp5450
g7
I131
sg23
VC0038454
p5451
sg10
I6
sg11
Vstroke
p5452
sg13
I1
sa(dp5453
g7
I131
sg23
VC0038454
p5454
sg10
I6
sg11
Vstroke
p5455
sg13
I1
sa(dp5456
g7
I157
sg23
VC0039730
p5457
sg10
I11
sg11
Vthalassemia
p5458
sg13
I1
sasa(dp5459
g2
S'This review focuses on the regulatory mechanism behind annexin A2-S100A10 complex formation, its role in regulating chloride transport in health and cystic fibrosis and the potential of this mechanism to integrate calcium and cAMP signalling in airway epithelia.\n'
p5460
sg4
(lp5461
(dp5462
g7
I55
sg8
VP07355
p5463
sg10
I26
sg11
Vannexin A2-S100A10 complex
p5464
sg13
I3
sasg20
(lp5465
(dp5466
g7
I149
sg23
VC0010674
p5467
sg10
I15
sg11
Vcystic fibrosis
p5468
sg13
I2
sasa(dp5469
g2
S'In contrast, the expression level of the proteins did not show a significant change at 9 weeks, but this increased to 3-fold at 30 weeks for carbonic anhydrase VII, ras related protein Rab 6, Annexin A2, neurofibromatosis type 2 and aldehyde dehydrogenase.\n'
p5470
sg4
(lp5471
(dp5472
g7
I165
sg8
VP11233
p5473
sg10
I25
sg11
Vras related protein Rab 6
p5474
sg13
I5
sa(dp5475
g7
I192
sg8
VP07355
p5476
sg10
I63
sg11
VAnnexin A2, neurofibromatosis type 2 and aldehyde dehydrogenase
p5477
sg13
I8
sa(dp5478
g7
I141
sg8
VP43166
p5479
sg10
I22
sg11
Vcarbonic anhydrase VII
p5480
sg13
I3
sasg20
(lp5481
(dp5482
g7
I204
sg23
VC0027832
p5483
sg10
I24
sg11
Vneurofibromatosis type 2
p5484
sg13
I3
sasa(dp5485
g2
S'The antibody levels of HAV-IgG of Group A and B in 2, 4 and 12 weeks of vaccination and of Group C were higher than that of Group D. After 12 weeks of vaccination, the antibody level of group B became higher than it was Group C. There were no differences on safety among domestic live attenuated hepatitis A vaccine, domestic inactivated hepatitis A vaccine or imported inactivated hepatitis A vaccine under routine or emergency vaccination.\n'
p5486
sg4
(lp5487
sg20
(lp5488
(dp5489
g7
I186
sg23
VC0348801
p5490
sg10
I7
sg11
Vgroup B
p5491
sg13
I2
sa(dp5492
g7
I296
sg23
VC0019159
p5493
sg10
I11
sg11
Vhepatitis A
p5494
sg13
I2
sa(dp5495
g7
I23
sg23
VC0019159
p5496
sg10
I3
sg11
VHAV
p5497
sg13
I1
sa(dp5498
g7
I296
sg23
VC0019159
p5499
sg10
I11
sg11
Vhepatitis A
p5500
sg13
I2
sa(dp5501
g7
I296
sg23
VC0019159
p5502
sg10
I11
sg11
Vhepatitis A
p5503
sg13
I2
sa(dp5504
g7
I419
sg23
VC2745965
p5505
sg10
I9
sg11
Vemergency
p5506
sg13
I1
sasa(dp5507
g2
S'Influenza A(H3N2) predominated in 14 (56%) of the 25 years, seasonal influenza A(H1N1) in 7 (28%), and influenza B in 2 (8%), and in 2 years multiple types cocirculated.\n'
p5508
sg4
(lp5509
sg20
(lp5510
(dp5511
g7
I69
sg23
VC0021400
p5512
sg10
I9
sg11
Vinfluenza
p5513
sg13
I1
sa(dp5514
g7
I0
sg23
VC0021400
p5515
sg10
I9
sg11
VInfluenza
p5516
sg13
I1
sa(dp5517
g7
I69
sg23
VC0021400
p5518
sg10
I9
sg11
Vinfluenza
p5519
sg13
I1
sasa(dp5520
g2
S'Immunofluorescence test confirmed infection with influenza type A in 39 patients, while with type B--in 2 patients.\n'
p5521
sg4
(lp5522
sg20
(lp5523
(dp5524
g7
I34
sg23
VC0009450
p5525
sg10
I9
sg11
Vinfection
p5526
sg13
I1
sa(dp5527
g7
I49
sg23
VC0021400
p5528
sg10
I9
sg11
Vinfluenza
p5529
sg13
I1
sasa(dp5530
g2
S'As a result of virologic studies, adenovirus from the conjunctiva of one patient was obtained; immunofluorescent studies were positive in 11 patients (virus of grip B in 2, of paragrippe in 1, adenovirus in 4, RS virus in 3, mixed virus infection in 1 patient).\n'
p5531
sg4
(lp5532
sg20
(lp5533
(dp5534
g7
I231
sg23
VC0042769
p5535
sg10
I15
sg11
Vvirus infection
p5536
sg13
I2
sa(dp5537
g7
I34
sg23
VC0001486
p5538
sg10
I10
sg11
Vadenovirus
p5539
sg13
I1
sa(dp5540
g7
I34
sg23
VC0001486
p5541
sg10
I10
sg11
Vadenovirus
p5542
sg13
I1
sasa(dp5543
g2
S'Positive serologic reactions were observed in 22 patients (virus of grip A in 7, of grip B in 2, of paragrippe in 1, RS virus in 1, mixed virus infection in 11 persons).\n'
p5544
sg4
(lp5545
sg20
(lp5546
(dp5547
g7
I138
sg23
VC0042769
p5548
sg10
I15
sg11
Vvirus infection
p5549
sg13
I2
sasa(dp5550
g2
S'CKD (estimated glomerular filtration rate [eGFR &lt;60 mls/min) was found in 117 participants (26%).\n'
p5551
sg4
(lp5552
sg20
(lp5553
(dp5554
g7
I55
sg23
VC0796070
p5555
sg10
I3
sg11
Vmls
p5556
sg13
I1
sasa(dp5557
g2
S'Inclusion criteria include being an Aboriginal Australian, having CKD (a. on dialysis; b. eGFR levels of &lt; 60 mls/min/1.73 m(2) (CKD Stages 3 to 5); c. ACR &gt;= 30 mg/mmol irrespective of eGFR (CKD Stages 1 and 2); d. diabetes plus albuminuria (ACR &gt;= 3 mg/mmol) irrespective of eGFR), having moderate or severe periodontal disease, having at least 12 teeth, and living in Central Australia for the 2-year study duration.\n'
p5558
sg4
(lp5559
sg20
(lp5560
(dp5561
g7
I113
sg23
VC0796070
p5562
sg10
I3
sg11
Vmls
p5563
sg13
I1
sa(dp5564
g7
I222
sg23
VC0011849
p5565
sg10
I8
sg11
Vdiabetes
p5566
sg13
I1
sa(dp5567
g7
I319
sg23
VC0031090
p5568
sg10
I19
sg11
Vperiodontal disease
p5569
sg13
I2
sasa(dp5570
g2
S'Progression of CKD will be defined by time to the development of the first of: (1) new development of macroalbuminuria; (2) 30 % loss of baseline eGFR; (3) progression to end stage kidney disease defined by eGFR &lt; 15 mLs/min/1.73 m(2); (4) progression to end stage kidney disease defined by commencement of renal replacement therapy.\n'
p5571
sg4
(lp5572
(dp5573
g7
I137
sg8
VP54132
p5574
sg10
I13
sg11
Vbaseline eGFR
p5575
sg13
I2
sasg20
(lp5576
(dp5577
g7
I171
sg23
VC0022661
p5578
sg10
I24
sg11
Vend stage kidney disease
p5579
sg13
I4
sa(dp5580
g7
I171
sg23
VC0022661
p5581
sg10
I24
sg11
Vend stage kidney disease
p5582
sg13
I4
sa(dp5583
g7
I220
sg23
VC0796070
p5584
sg10
I3
sg11
VmLs
p5585
sg13
I1
sasa(dp5586
g2
S'The authors would also like to highlight recent guidance on atorvastatin as the statin of choice in patients with chronic kidney disease, and of the need for dose adjustment in those with an estimated glomerular filtration rate less than 30 mLs/min/1.73 m^2.\n'
p5587
sg4
(lp5588
sg20
(lp5589
(dp5590
g7
I114
sg23
VC1561643
p5591
sg10
I22
sg11
Vchronic kidney disease
p5592
sg13
I3
sa(dp5593
g7
I241
sg23
VC0796070
p5594
sg10
I3
sg11
VmLs
p5595
sg13
I1
sasa(dp5596
g2
S'We recruit pregnant women into LPG, efficient cookstove, and control arms and track birth weight and physician-assessed severe pneumonia incidence in the first year of life.\n'
p5597
sg4
(lp5598
sg20
(lp5599
(dp5600
g7
I31
sg23
VC2673196
p5601
sg10
I3
sg11
VLPG
p5602
sg13
I1
sa(dp5603
g7
I127
sg23
VC0032285
p5604
sg10
I9
sg11
Vpneumonia
p5605
sg13
I1
sa(dp5606
g7
I69
sg23
VC0206655
p5607
sg10
I4
sg11
Varms
p5608
sg13
I1
sasa(dp5609
g2
S'Serum ApoE was markedly increased in cases with bacterial infections including sepsis, bacterial meningitis, and bacterial pneumonia, compared to healthy controls.\n'
p5610
sg4
(lp5611
(dp5612
g7
I0
sg8
VP02649
p5613
sg10
I10
sg11
VSerum ApoE
p5614
sg13
I2
sasg20
(lp5615
(dp5616
g7
I48
sg23
VC0004623
p5617
sg10
I20
sg11
Vbacterial infections
p5618
sg13
I2
sa(dp5619
g7
I79
sg23
VC0243026
p5620
sg10
I6
sg11
Vsepsis
p5621
sg13
I1
sa(dp5622
g7
I87
sg23
VC0085437
p5623
sg10
I20
sg11
Vbacterial meningitis
p5624
sg13
I2
sa(dp5625
g7
I113
sg23
VC0004626
p5626
sg10
I19
sg11
Vbacterial pneumonia
p5627
sg13
I2
sasa(dp5628
g2
S'No significantly elevated serum ApoE levels were observed in aseptic meningitis patients or mycoplasma pneumonia patients.\n'
p5629
sg4
(lp5630
(dp5631
g7
I32
sg8
VP02649
p5632
sg10
I4
sg11
VApoE
p5633
sg13
I1
sasg20
(lp5634
(dp5635
g7
I92
sg23
VC0032302
p5636
sg10
I20
sg11
Vmycoplasma pneumonia
p5637
sg13
I2
sa(dp5638
g7
I61
sg23
VC0025290
p5639
sg10
I18
sg11
Vaseptic meningitis
p5640
sg13
I2
sasa(dp5641
g2
S'An earlier study from this laboratory suggested that some relationship exists between apolipoprotein E4 (apoE4), the product of the epsilon4 allele, and the pathobiology of C. pneumoniae.\n'
p5642
sg4
(lp5643
(dp5644
g7
I105
sg8
VP02656
p5645
sg10
I5
sg11
VapoE4
p5646
sg13
I1
sa(dp5647
g7
I86
sg8
VP02656
p5648
sg10
I17
sg11
Vapolipoprotein E4
p5649
sg13
I2
sasg20
(lp5650
sa(dp5651
g2
S'These observations indicate that apoE4 enhances attachment of C. pneumoniae EB, but not those of C. trachomatis, to target host cells.\n'
p5652
sg4
(lp5653
sg20
(lp5654
(dp5655
g7
I100
sg23
VC2893398
p5656
sg10
I11
sg11
Vtrachomatis
p5657
sg13
I1
sasa(dp5658
g2
S'APOE4+ patients were younger (53.2 +/- 21.9 vs. 65.4 +/- 13.4, p = .08) and less often admitted for pneumonia (0% vs. 29.3%, p = .05) compared with APOE4- patients, yet they had a duration of delirium that was twice as long: median (interquartile range), 4 (3, 4.5) vs. 2 (1, 4) days (p = .05).\n'
p5659
sg4
(lp5660
sg20
(lp5661
(dp5662
g7
I100
sg23
VC0032285
p5663
sg10
I9
sg11
Vpneumonia
p5664
sg13
I1
sa(dp5665
g7
I192
sg23
VC0011206
p5666
sg10
I8
sg11
Vdelirium
p5667
sg13
I1
sasa(dp5668
g2
S'Using multivariable regression analysis to adjust for age, admission diagnosis of sepsis or acute respiratory distress syndrome or pneumonia, severity of illness, and duration of coma, the presence of APOE4 allele was the strongest predictor of delirium duration (odds ratio, 7.32; 95% confidence interval, 1.82-29.51, p = .005).\n'
p5669
sg4
(lp5670
sg20
(lp5671
(dp5672
g7
I131
sg23
VC0032285
p5673
sg10
I9
sg11
Vpneumonia
p5674
sg13
I1
sa(dp5675
g7
I92
sg23
VC0035222
p5676
sg10
I35
sg11
Vacute respiratory distress syndrome
p5677
sg13
I4
sa(dp5678
g7
I82
sg23
VC0243026
p5679
sg10
I6
sg11
Vsepsis
p5680
sg13
I1
sa(dp5681
g7
I245
sg23
VC0011206
p5682
sg10
I8
sg11
Vdelirium
p5683
sg13
I1
sa(dp5684
g7
I179
sg23
VC0009421
p5685
sg10
I4
sg11
Vcoma
p5686
sg13
I1
sasa(dp5687
g2
S'This study examined the effect of olanzapine on key molecules of the histaminergic system, including histidine decarboxylase (HDC), H1 receptor (H1R) and H3 receptor (H3R), in the brain at different stages of olanzapine-induced obesity.\n'
p5688
sg4
(lp5689
(dp5690
g7
I154
sg8
g18
sg10
I11
sg11
VH3 receptor
p5691
sg13
I2
sa(dp5692
g7
I101
sg8
VP19113
p5693
sg10
I23
sg11
Vhistidine decarboxylase
p5694
sg13
I2
sa(dp5695
g7
I126
sg8
VP19113
p5696
sg10
I3
sg11
VHDC
p5697
sg13
I1
sa(dp5698
g7
I167
sg8
g18
sg10
I3
sg11
VH3R
p5699
sg13
I1
sa(dp5700
g7
I145
sg8
g18
sg10
I3
sg11
VH1R
p5701
sg13
I1
sa(dp5702
g7
I132
sg8
g18
sg10
I11
sg11
VH1 receptor
p5703
sg13
I2
sasg20
(lp5704
(dp5705
g7
I228
sg23
VC0028754
p5706
sg10
I7
sg11
Vobesity
p5707
sg13
I1
sasa(dp5708
g2
S'We found that the lack of endogenous histamine in NOD HDC(-/-) mice decreased the incidence of diabetes in relation to their wild-type counterpart.\n'
p5709
sg4
(lp5710
sg20
(lp5711
(dp5712
g7
I50
sg23
VC0751781
p5713
sg10
I3
sg11
VNOD
p5714
sg13
I1
sa(dp5715
g7
I95
sg23
VC0011849
p5716
sg10
I8
sg11
Vdiabetes
p5717
sg13
I1
sasa(dp5718
g2
S'In this review, we have highlighted the role that histamine, histidine decarboxylase (HDC), histamine receptors and mast cells (the main source of histamine in the body) play during both pancreatitis and pancreatic cancer.\n'
p5719
sg4
(lp5720
(dp5721
g7
I86
sg8
VP19113
p5722
sg10
I3
sg11
VHDC
p5723
sg13
I1
sa(dp5724
g7
I50
sg8
VP19113
p5725
sg10
I34
sg11
Vhistamine, histidine decarboxylase
p5726
sg13
I3
sa(dp5727
g7
I92
sg8
VP08620
p5728
sg10
I19
sg11
Vhistamine receptors
p5729
sg13
I2
sasg20
(lp5730
(dp5731
g7
I187
sg23
VC0030305
p5732
sg10
I12
sg11
Vpancreatitis
p5733
sg13
I1
sa(dp5734
g7
I204
sg23
VC0235974
p5735
sg10
I17
sg11
Vpancreatic cancer
p5736
sg13
I2
sasa(dp5737
g2
S'With aging, blood glucose levels in HDC-KO mice were shifted towards values characteristic of diabetes.\n'
p5738
sg4
(lp5739
sg20
(lp5740
(dp5741
g7
I94
sg23
VC0011849
p5742
sg10
I8
sg11
Vdiabetes
p5743
sg13
I1
sasa(dp5744
g2
S'One of the likely explanations may be that in the chain of events in HDC-KO mice on the one hand and in Streptozotocin-induced diabetes on the other hand, leading to the alterations in the heart electrophysiological parameters, there is a common link.\n'
p5745
sg4
(lp5746
sg20
(lp5747
(dp5748
g7
I127
sg23
VC0011849
p5749
sg10
I8
sg11
Vdiabetes
p5750
sg13
I1
sasa(dp5751
g2
S'Therefore, a study of diabetes-related immune processes was considered of interest in histidine decarboxylase knockout (HDC-KO) mice.\n'
p5752
sg4
(lp5753
(dp5754
g7
I120
sg8
VP19113
p5755
sg10
I6
sg11
VHDC-KO
p5756
sg13
I1
sa(dp5757
g7
I86
sg8
VP19113
p5758
sg10
I32
sg11
Vhistidine decarboxylase knockout
p5759
sg13
I3
sasg20
(lp5760
(dp5761
g7
I22
sg23
VC0011849
p5762
sg10
I8
sg11
Vdiabetes
p5763
sg13
I1
sasa(dp5764
g2
S'The aim of our study was i) to characterize antibody production in response to vaccination with p277 or hsp65 in wild type (WT) BALB/c and HDC-KO mice, and ii) to establish a possible correlation between vaccination and the changes in the pattern of STZ diabetes.\n'
p5765
sg4
(lp5766
(dp5767
g7
I104
sg8
VP10809
p5768
sg10
I5
sg11
Vhsp65
p5769
sg13
I1
sasg20
(lp5770
(dp5771
g7
I254
sg23
VC0011849
p5772
sg10
I8
sg11
Vdiabetes
p5773
sg13
I1
sasa(dp5774
g2
S'Vaccination with p277 and hsp65 altered the pattern of STZ diabetes both in HDC-KO and WT animals, characterized by a transient increase followed by sustained reduction of blood sugar levels as compared to controls.\n'
p5775
sg4
(lp5776
(dp5777
g7
I76
sg8
VP19113
p5778
sg10
I6
sg11
VHDC-KO
p5779
sg13
I1
sa(dp5780
g7
I26
sg8
VP10809
p5781
sg10
I5
sg11
Vhsp65
p5782
sg13
I1
sasg20
(lp5783
(dp5784
g7
I59
sg23
VC0011849
p5785
sg10
I8
sg11
Vdiabetes
p5786
sg13
I1
sasa(dp5787
g2
S'Multiple low-doses of STZ were able to induce diabetes in HDC-KO mice and the development of diabetes was prevented by vaccination with hsps.\n'
p5788
sg4
(lp5789
(dp5790
g7
I136
sg8
VP08107
p5791
sg10
I4
sg11
Vhsps
p5792
sg13
I1
sasg20
(lp5793
(dp5794
g7
I46
sg23
VC0011849
p5795
sg10
I8
sg11
Vdiabetes
p5796
sg13
I1
sa(dp5797
g7
I46
sg23
VC0011849
p5798
sg10
I8
sg11
Vdiabetes
p5799
sg13
I1
sasa(dp5800
g2
S'The purpose of the study was to determine whether there are different patterns of retinal nerve fiber layer (RNFL) thinning as measured by spectral domain optical coherence tomography (SD-OCT) for 4 subtypes of open angle glaucoma (OAG): primary OAG (POAG), normal tension glaucoma (NTG), pseudoexfoliation glaucoma (PXG), and pigmentary glaucoma (PDG) and to compare them with normal controls.\n'
p5801
sg4
(lp5802
sg20
(lp5803
(dp5804
g7
I289
sg23
VC0206368
p5805
sg10
I26
sg11
Vpseudoexfoliation glaucoma
p5806
sg13
I2
sa(dp5807
g7
I238
sg23
VC0339573
p5808
sg10
I11
sg11
Vprimary OAG
p5809
sg13
I2
sa(dp5810
g7
I232
sg23
VC0017612
p5811
sg10
I3
sg11
VOAG
p5812
sg13
I1
sa(dp5813
g7
I211
sg23
VC0017612
p5814
sg10
I19
sg11
Vopen angle glaucoma
p5815
sg13
I3
sa(dp5816
g7
I317
sg23
VC0206368
p5817
sg10
I3
sg11
VPXG
p5818
sg13
I1
sa(dp5819
g7
I283
sg23
VC0152136
p5820
sg10
I3
sg11
VNTG
p5821
sg13
I1
sa(dp5822
g7
I258
sg23
VC0152136
p5823
sg10
I23
sg11
Vnormal tension glaucoma
p5824
sg13
I3
sa(dp5825
g7
I327
sg23
VC0017612
p5826
sg10
I19
sg11
Vpigmentary glaucoma
p5827
sg13
I2
sa(dp5828
g7
I251
sg23
VC0339573
p5829
sg10
I4
sg11
VPOAG
p5830
sg13
I1
sasa(dp5831
g2
S'To assess the use of a computerized program for evaluating the amount of trabecular meshwork (TM) pigmentation in normal (control), primary open-angle glaucoma (POAG), and pseudoexfoliation glaucoma/pigmentary dispersion glaucoma (PXFG/PDG) patients.\n'
p5832
sg4
(lp5833
sg20
(lp5834
(dp5835
g7
I151
sg23
VC0017601
p5836
sg10
I8
sg11
Vglaucoma
p5837
sg13
I1
sa(dp5838
g7
I161
sg23
VC0339573
p5839
sg10
I4
sg11
VPOAG
p5840
sg13
I1
sa(dp5841
g7
I132
sg23
VC0339573
p5842
sg10
I27
sg11
Vprimary open-angle glaucoma
p5843
sg13
I3
sa(dp5844
g7
I172
sg23
VC0206368
p5845
sg10
I26
sg11
Vpseudoexfoliation glaucoma
p5846
sg13
I2
sasa(dp5847
g2
S'We analyzed primary open-angle glaucoma (POAG), pseudoexfoliation glaucoma (PEX), and pigmentary glaucoma (PDG).\n'
p5848
sg4
(lp5849
sg20
(lp5850
(dp5851
g7
I48
sg23
VC0206368
p5852
sg10
I26
sg11
Vpseudoexfoliation glaucoma
p5853
sg13
I2
sa(dp5854
g7
I86
sg23
VC0017612
p5855
sg10
I19
sg11
Vpigmentary glaucoma
p5856
sg13
I2
sa(dp5857
g7
I76
sg23
VC0206368
p5858
sg10
I3
sg11
VPEX
p5859
sg13
I1
sa(dp5860
g7
I12
sg23
VC0339573
p5861
sg10
I27
sg11
Vprimary open-angle glaucoma
p5862
sg13
I3
sa(dp5863
g7
I41
sg23
VC0339573
p5864
sg10
I4
sg11
VPOAG
p5865
sg13
I1
sasa(dp5866
g2
S'In this study, we aimed to evaluate to the utility of aberrant promoter hypermethylation for detection in a panel of 10 genes (KIF1A, EDNRB, CDH4, TERT, CD44, NISCH, PAK3, VGF, MAL and FKBP4) in head and neck squamous cell carcinoma (HNSCC) via a candidate gene approach.\n'
p5867
sg4
(lp5868
(dp5869
g7
I141
sg8
VP55283
p5870
sg10
I4
sg11
VCDH4
p5871
sg13
I1
sa(dp5872
g7
I172
sg8
g18
sg10
I3
sg11
VVGF
p5873
sg13
I1
sa(dp5874
g7
I159
sg8
g18
sg10
I5
sg11
VNISCH
p5875
sg13
I1
sa(dp5876
g7
I177
sg8
VP01732
p5877
sg10
I3
sg11
VMAL
p5878
sg13
I1
sa(dp5879
g7
I185
sg8
g18
sg10
I5
sg11
VFKBP4
p5880
sg13
I1
sa(dp5881
g7
I147
sg8
g18
sg10
I4
sg11
VTERT
p5882
sg13
I1
sasg20
(lp5883
(dp5884
g7
I234
sg23
VC1168401
p5885
sg10
I5
sg11
VHNSCC
p5886
sg13
I1
sa(dp5887
g7
I195
sg23
VC1168401
p5888
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p5889
sg13
I6
sasa(dp5890
g2
S'Consecutive patients with type 1 diabetes were genotyped for single-nucleotide polymorphisms in or near the genes for the Beta1 and Beta2 adrenergic receptor (ADRB1, ADRB2), SORCS1, and BNC2, and for the insertion/deletion polymorphism in the ACE gene.\n'
p5891
sg4
(lp5892
(dp5893
g7
I186
sg8
g18
sg10
I4
sg11
VBNC2
p5894
sg13
I1
sa(dp5895
g7
I132
sg8
g18
sg10
I25
sg11
VBeta2 adrenergic receptor
p5896
sg13
I3
sa(dp5897
g7
I159
sg8
VP08588
p5898
sg10
I5
sg11
VADRB1
p5899
sg13
I1
sa(dp5900
g7
I243
sg8
VP12821
p5901
sg10
I8
sg11
VACE gene
p5902
sg13
I2
sasg20
(lp5903
(dp5904
g7
I26
sg23
VC0011854
p5905
sg10
I15
sg11
Vtype 1 diabetes
p5906
sg13
I3
sasa(dp5907
g2
S'In peripheral blood mononuclear cells isolated from streptozotocin-induced diabetic rats, Beta2AR agonists inhibited diabetes-induced tumor necrosis factor-Alfa production, which was prevented by co-treatment with a selective Beta2AR blocker.\n'
p5908
sg4
(lp5909
(dp5910
g7
I134
sg8
VP01375
p5911
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p5912
sg13
I3
sasg20
(lp5913
(dp5914
g7
I134
sg23
VC0333516
p5915
sg10
I14
sg11
Vtumor necrosis
p5916
sg13
I2
sa(dp5917
g7
I117
sg23
VC0011849
p5918
sg10
I8
sg11
Vdiabetes
p5919
sg13
I1
sasa(dp5920
g2
S'In conclusion, these findings indicated that the ADRB2 SNPs might be a genetic risk factor for dyslipidemia in the Chinese hypertensive patients.\n'
p5921
sg4
(lp5922
(dp5923
g7
I49
sg8
g18
sg10
I10
sg11
VADRB2 SNPs
p5924
sg13
I2
sasg20
(lp5925
(dp5926
g7
I95
sg23
VC0242339
p5927
sg10
I12
sg11
Vdyslipidemia
p5928
sg13
I1
sasa(dp5929
g2
S'These studies elucidate a novel mechanism by which hyperinsulinemia contributes to heart failure by increasing PDE4D expression and identify Beta2AR or GRK2 as plausible therapeutic targets for preventing or treating heart failure in subjects with type 2 DM.\n'
p5930
sg4
(lp5931
(dp5932
g7
I152
sg8
VP25098
p5933
sg10
I4
sg11
VGRK2
p5934
sg13
I1
sasg20
(lp5935
(dp5936
g7
I83
sg23
VC0018802
p5937
sg10
I13
sg11
Vheart failure
p5938
sg13
I2
sa(dp5939
g7
I51
sg23
VC0020459
p5940
sg10
I16
sg11
Vhyperinsulinemia
p5941
sg13
I1
sa(dp5942
g7
I83
sg23
VC0018802
p5943
sg10
I13
sg11
Vheart failure
p5944
sg13
I2
sasa(dp5945
g2
S'Beta-2 Adrenergic receptor (AR) agonists have been reported to diminish nocturnal hypoglycemia; however, whether long-acting inhaled Beta-2 AR agonists could potentially be used to treat or prevent hypoglycemia has not been established.\n'
p5946
sg4
(lp5947
(dp5948
g7
I0
sg8
g18
sg10
I26
sg11
VBeta-2 Adrenergic receptor
p5949
sg13
I3
sasg20
(lp5950
(dp5951
g7
I72
sg23
VC0342315
p5952
sg10
I22
sg11
Vnocturnal hypoglycemia
p5953
sg13
I2
sa(dp5954
g7
I82
sg23
VC0020615
p5955
sg10
I12
sg11
Vhypoglycemia
p5956
sg13
I1
sasa(dp5957
g2
S'Seven patients with type 1 diabetes and seven healthy control subjects received inhaled formoterol (48 myg), a highly specific Beta-2 AR agonist, or a placebo during a hyperinsulinemic-hypoglycemic clamp study to evaluate its capacity to antagonize the effect of insulin.\n'
p5958
sg4
(lp5959
(dp5960
g7
I173
sg8
VP01308
p5961
sg10
I7
sg11
Vinsulin
p5962
sg13
I1
sasg20
(lp5963
(dp5964
g7
I20
sg23
VC0011854
p5965
sg10
I15
sg11
Vtype 1 diabetes
p5966
sg13
I3
sasa(dp5967
g2
S'Inhalation of the Beta-2 AR-specific agonist formoterol may be useful in the prevention or treatment of acute hypoglycemia and thus may help patients with type 1 diabetes achieve optimal glucose control more safely.\n'
p5968
sg4
(lp5969
sg20
(lp5970
(dp5971
g7
I155
sg23
VC0011854
p5972
sg10
I15
sg11
Vtype 1 diabetes
p5973
sg13
I3
sa(dp5974
g7
I104
sg23
VC0745150
p5975
sg10
I18
sg11
Vacute hypoglycemia
p5976
sg13
I2
sasa(dp5977
g2
S'IRF4 distinguished opposing glycemic responses to different types of peptidoglycan and was required for MDP/NOD2-induced insulin sensitization and lower metabolic tissue inflammation during obesity and endotoxemia.\n'
p5978
sg4
(lp5979
(dp5980
g7
I0
sg8
g18
sg10
I4
sg11
VIRF4
p5981
sg13
I1
sa(dp5982
g7
I121
sg8
VP01308
p5983
sg10
I7
sg11
Vinsulin
p5984
sg13
I1
sa(dp5985
g7
I108
sg8
VP22301
p5986
sg10
I4
sg11
VNOD2
p5987
sg13
I1
sa(dp5988
g7
I104
sg8
VP16444
p5989
sg10
I3
sg11
VMDP
p5990
sg13
I1
sasg20
(lp5991
(dp5992
g7
I190
sg23
VC0028754
p5993
sg10
I7
sg11
Vobesity
p5994
sg13
I1
sa(dp5995
g7
I170
sg23
VC0021368
p5996
sg10
I12
sg11
Vinflammation
p5997
sg13
I1
sasa(dp5998
g2
S'IRF4 was dispensable for exacerbated glucose intolerance via NOD1.\n'
p5999
sg4
(lp6000
(dp6001
g7
I61
sg8
g18
sg10
I4
sg11
VNOD1
p6002
sg13
I1
sa(dp6003
g7
I0
sg8
g18
sg10
I4
sg11
VIRF4
p6004
sg13
I1
sasg20
(lp6005
(dp6006
g7
I37
sg23
VC0271650
p6007
sg10
I19
sg11
Vglucose intolerance
p6008
sg13
I2
sasa(dp6009
g2
S'IRF4 is a unique member of the interferon regulatory factor (IRF) family playing critical regulatory roles in immune cell development, regulation of obesity-induced inflammation, and control of thermogenic gene expression.\n'
p6010
sg4
(lp6011
(dp6012
g7
I0
sg8
g18
sg10
I4
sg11
VIRF4
p6013
sg13
I1
sa(dp6014
g7
I0
sg8
g18
sg10
I3
sg11
VIRF
p6015
sg13
I1
sa(dp6016
g7
I31
sg8
VP01563
p6017
sg10
I28
sg11
Vinterferon regulatory factor
p6018
sg13
I3
sasg20
(lp6019
(dp6020
g7
I165
sg23
VC0021368
p6021
sg10
I12
sg11
Vinflammation
p6022
sg13
I1
sa(dp6023
g7
I149
sg23
VC0028754
p6024
sg10
I7
sg11
Vobesity
p6025
sg13
I1
sasa(dp6026
g2
S'Genetic deletion of IRF4 has been shown to suppress autoimmune disease in several mouse models, but its role in autoimmune diabetes in NOD mice remains unknown.\n'
p6027
sg4
(lp6028
(dp6029
g7
I20
sg8
g18
sg10
I4
sg11
VIRF4
p6030
sg13
I1
sasg20
(lp6031
(dp6032
g7
I135
sg23
VC0751781
p6033
sg10
I3
sg11
VNOD
p6034
sg13
I1
sa(dp6035
g7
I112
sg23
VC0205734
p6036
sg10
I19
sg11
Vautoimmune diabetes
p6037
sg13
I2
sa(dp6038
g7
I52
sg23
VC0004364
p6039
sg10
I18
sg11
Vautoimmune disease
p6040
sg13
I2
sasa(dp6041
g2
S'To address the role of IRF4 in the pathogenesis of autoimmune diabetes in NOD mice, we generated IRF4-knockout NOD mice and investigated the impact of the genetic deletion of IRF4 on diabetes, insulitis and insulin autoantibody; the effector function of T cells in vivo and in vitro; and the proportion of dendritic cell subsets.\n'
p6042
sg4
(lp6043
(dp6044
g7
I23
sg8
g18
sg10
I4
sg11
VIRF4
p6045
sg13
I1
sa(dp6046
g7
I23
sg8
g18
sg10
I4
sg11
VIRF4
p6047
sg13
I1
sa(dp6048
g7
I23
sg8
g18
sg10
I4
sg11
VIRF4
p6049
sg13
I1
sa(dp6050
g7
I207
sg8
VP01308
p6051
sg10
I20
sg11
Vinsulin autoantibody
p6052
sg13
I2
sasg20
(lp6053
(dp6054
g7
I74
sg23
VC0751781
p6055
sg10
I3
sg11
VNOD
p6056
sg13
I1
sa(dp6057
g7
I74
sg23
VC0751781
p6058
sg10
I3
sg11
VNOD
p6059
sg13
I1
sa(dp6060
g7
I62
sg23
VC0011849
p6061
sg10
I8
sg11
Vdiabetes
p6062
sg13
I1
sa(dp6063
g7
I35
sg23
VC0699748
p6064
sg10
I12
sg11
Vpathogenesis
p6065
sg13
I1
sa(dp6066
g7
I51
sg23
VC0205734
p6067
sg10
I19
sg11
Vautoimmune diabetes
p6068
sg13
I2
sasa(dp6069
g2
S'However, diabetes and autoantibody production were completely suppressed in both heterozygous and homozygous IRF4-deficient NOD mice.\n'
p6070
sg4
(lp6071
(dp6072
g7
I109
sg8
g18
sg10
I4
sg11
VIRF4
p6073
sg13
I1
sasg20
(lp6074
(dp6075
g7
I9
sg23
VC0011849
p6076
sg10
I8
sg11
Vdiabetes
p6077
sg13
I1
sa(dp6078
g7
I124
sg23
VC0751781
p6079
sg10
I3
sg11
VNOD
p6080
sg13
I1
sasa(dp6081
g2
S'These results suggest that the levels of IRF4 in T cells and dendritic cells are important for the pathogenesis of diabetes in NOD mice.\n'
p6082
sg4
(lp6083
(dp6084
g7
I41
sg8
g18
sg10
I4
sg11
VIRF4
p6085
sg13
I1
sasg20
(lp6086
(dp6087
g7
I127
sg23
VC0751781
p6088
sg10
I3
sg11
VNOD
p6089
sg13
I1
sa(dp6090
g7
I99
sg23
VC0699748
p6091
sg10
I12
sg11
Vpathogenesis
p6092
sg13
I1
sa(dp6093
g7
I115
sg23
VC0011849
p6094
sg10
I8
sg11
Vdiabetes
p6095
sg13
I1
sasa(dp6096
g2
S'Our findings suggest that an IRF4-targeted strategy might be useful for modulating autoimmunity in type 1 diabetes.\n'
p6097
sg4
(lp6098
(dp6099
g7
I29
sg8
g18
sg10
I4
sg11
VIRF4
p6100
sg13
I1
sasg20
(lp6101
(dp6102
g7
I99
sg23
VC0011854
p6103
sg10
I15
sg11
Vtype 1 diabetes
p6104
sg13
I3
sa(dp6105
g7
I83
sg23
VC0004368
p6106
sg10
I12
sg11
Vautoimmunity
p6107
sg13
I1
sasa(dp6108
g2
S'Of these, 1,088 (19.7%) underwent procedures for neurogenic bowel, including 957 (17.3%) ACE/cecostomy tube and 155 (2.8%) ileostomy/colostomy patients.\n'
p6109
sg4
(lp6110
sg20
(lp6111
(dp6112
g7
I49
sg23
VC0695242
p6113
sg10
I16
sg11
Vneurogenic bowel
p6114
sg13
I2
sasa(dp6115
g2
S'We aim to determine the natural history of the ACE in idiopathic constipation and factors predictive of closure.\n'
p6116
sg4
(lp6117
(dp6118
g7
I47
sg8
VP12821
p6119
sg10
I3
sg11
VACE
p6120
sg13
I1
sasg20
(lp6121
(dp6122
g7
I65
sg23
VC0009806
p6123
sg10
I12
sg11
Vconstipation
p6124
sg13
I1
sasa(dp6125
g2
S'A retrospective case-note review of all patients undergo ACE formation for idiopathic constipation Jan 2003-Mar 2016.\n'
p6126
sg4
(lp6127
sg20
(lp6128
(dp6129
g7
I108
sg23
VC0740302
p6130
sg10
I3
sg11
VMar
p6131
sg13
I1
sa(dp6132
g7
I86
sg23
VC0009806
p6133
sg10
I12
sg11
Vconstipation
p6134
sg13
I1
sasa(dp6135
g2
S'The ACE survival curve estimates the proportion of patients with idiopathic constipation who can expect closure (either due to success or failure) at certain timepoints.\n'
p6136
sg4
(lp6137
(dp6138
g7
I4
sg8
VP12821
p6139
sg10
I3
sg11
VACE
p6140
sg13
I1
sasg20
(lp6141
(dp6142
g7
I76
sg23
VC0009806
p6143
sg10
I12
sg11
Vconstipation
p6144
sg13
I1
sasa(dp6145
g2
S'Sacral nerve stimulation (SNS) can be beneficial for children with constipation, but no studies have focused on children with constipation severe enough to require antegrade continence enemas (ACEs).\n'
p6146
sg4
(lp6147
sg20
(lp6148
(dp6149
g7
I67
sg23
VC0009806
p6150
sg10
I12
sg11
Vconstipation
p6151
sg13
I1
sa(dp6152
g7
I67
sg23
VC0009806
p6153
sg10
I12
sg11
Vconstipation
p6154
sg13
I1
sasa(dp6155
g2
S'Our objective was to evaluate the efficacy of SNS in children with constipation treated with ACE.\n'
p6156
sg4
(lp6157
(dp6158
g7
I93
sg8
VP12821
p6159
sg10
I3
sg11
VACE
p6160
sg13
I1
sasg20
(lp6161
(dp6162
g7
I67
sg23
VC0009806
p6163
sg10
I12
sg11
Vconstipation
p6164
sg13
I1
sasa(dp6165
g2
S'In children with severe constipation dependent on ACE, SNS led to a steady decrease in ACE usage with nearly half of patients receiving cecostomy/appendicostomy closure within 2years.\n'
p6166
sg4
(lp6167
(dp6168
g7
I50
sg8
VP12821
p6169
sg10
I3
sg11
VACE
p6170
sg13
I1
sa(dp6171
g7
I50
sg8
VP12821
p6172
sg10
I3
sg11
VACE
p6173
sg13
I1
sa(dp6174
g7
I55
sg8
g18
sg10
I3
sg11
VSNS
p6175
sg13
I1
sasg20
(lp6176
(dp6177
g7
I24
sg23
VC0009806
p6178
sg10
I12
sg11
Vconstipation
p6179
sg13
I1
sasa(dp6180
g2
S'(2) IL10-/-colitis Piroxicam (200 ppm) was administered orally in feed to 5-week-old IL-10-/-mice (C57BL/6J background) for 14 days followed by enalaprilat (ACE-I), CCG-203025 or PBS administered transanally for 14 days.\n'
p6181
sg4
(lp6182
(dp6183
g7
I157
sg8
VP12821
p6184
sg10
I5
sg11
VACE-I
p6185
sg13
I1
sasg20
(lp6186
(dp6187
g7
I179
sg23
VC1720830
p6188
sg10
I3
sg11
VPBS
p6189
sg13
I1
sa(dp6190
g7
I11
sg23
VC0009319
p6191
sg10
I7
sg11
Vcolitis
p6192
sg13
I1
sasa(dp6193
g2
S'This study demonstrated the therapeutic efficacy of both ACE-I and AT1aR-A for preventing the development of both acute and immunologically relevant colitis.\n'
p6194
sg4
(lp6195
(dp6196
g7
I67
sg8
VP30556
p6197
sg10
I7
sg11
VAT1aR-A
p6198
sg13
I1
sa(dp6199
g7
I57
sg8
VP12821
p6200
sg10
I5
sg11
VACE-I
p6201
sg13
I1
sasg20
(lp6202
(dp6203
g7
I149
sg23
VC0009319
p6204
sg10
I7
sg11
Vcolitis
p6205
sg13
I1
sasa(dp6206
g2
S'Gold standard in Hirschsprung disease (HD) diagnosis is rectal suction biopsy (RSB) with hematoxylin and eosin and acetylcholinesterase (ACE) stainings.\n'
p6207
sg4
(lp6208
(dp6209
g7
I115
sg8
VP12821
p6210
sg10
I20
sg11
Vacetylcholinesterase
p6211
sg13
I1
sa(dp6212
g7
I137
sg8
VP12821
p6213
sg10
I3
sg11
VACE
p6214
sg13
I1
sasg20
(lp6215
(dp6216
g7
I17
sg23
VC0019569
p6217
sg10
I20
sg11
VHirschsprung disease
p6218
sg13
I2
sa(dp6219
g7
I39
sg23
VC0019569
p6220
sg10
I2
sg11
VHD
p6221
sg13
I1
sasa(dp6222
g2
S'Most of the data pertaining to antegrade continence enema (the ACE or Malone procedure) comes from the pediatric literature in the management of children with AI, but also with supervening chronic constipation, where the quality of life and compliance with this technique appears superior to retrograde colonic washouts.\n'
p6223
sg4
(lp6224
(dp6225
g7
I63
sg8
VP12821
p6226
sg10
I3
sg11
VACE
p6227
sg13
I1
sasg20
(lp6228
(dp6229
g7
I189
sg23
VC0401149
p6230
sg10
I20
sg11
Vchronic constipation
p6231
sg13
I2
sasa(dp6232
g2
S'For the article titled "Treatment Recommendations Following 3-Day Masked Continuous Glucose Monitoring (CGM) in Youth With Type 1 Diabetes" published in the month of May in the Journal of Diabetes Science and Technology, 2014;8(3):494-497, doi:10.1177/1932296814528135, the authors neglected to include an affiliation for first author Lisa E. Rasbach, MSN.\n'
p6233
sg4
(lp6234
sg20
(lp6235
(dp6236
g7
I123
sg23
VC0011854
p6237
sg10
I15
sg11
VType 1 Diabetes
p6238
sg13
I3
sa(dp6239
g7
I130
sg23
VC0011849
p6240
sg10
I8
sg11
VDiabetes
p6241
sg13
I1
sasa(dp6242
g2
S'We used cell proliferation and apoptosis assays in sarcoma cell lines and benign cells; Gamma-H2AX expression, comet assay, immunoblot analyses and drug combination studies in vitro and in patient derived xenograft (PDX) models.\n'
p6243
sg4
(lp6244
(dp6245
g7
I94
sg8
VP16104
p6246
sg10
I4
sg11
VH2AX
p6247
sg13
I1
sasg20
(lp6248
(dp6249
g7
I13
sg23
VC0334094
p6250
sg10
I13
sg11
Vproliferation
p6251
sg13
I1
sa(dp6252
g7
I51
sg23
VC1261473
p6253
sg10
I7
sg11
Vsarcoma
p6254
sg13
I1
sasa(dp6255
g2
S'Their functional involvement was addressed by HSP90 inhibition, which preferentially sensitized radioresistant sarcoma cells and was accompanied by delayed Gamma-H2AX foci clearance and HSP90 client protein degradation.\n'
p6256
sg4
(lp6257
(dp6258
g7
I46
sg8
VP07900
p6259
sg10
I5
sg11
VHSP90
p6260
sg13
I1
sa(dp6261
g7
I156
sg8
VP16104
p6262
sg10
I10
sg11
VGamma-H2AX
p6263
sg13
I1
sa(dp6264
g7
I46
sg8
VP07900
p6265
sg10
I5
sg11
VHSP90
p6266
sg13
I1
sasg20
(lp6267
(dp6268
g7
I111
sg23
VC1261473
p6269
sg10
I7
sg11
Vsarcoma
p6270
sg13
I1
sasa(dp6271
g2
S'Bladder cancer-associated protein (BLCAP) is a novel candidate tumor suppressor gene identified from human bladder carcinoma and highly associated with the invasion of bladder cancer.\n'
p6272
sg4
(lp6273
(dp6274
g7
I63
sg8
VP25054
p6275
sg10
I21
sg11
Vtumor suppressor gene
p6276
sg13
I3
sa(dp6277
g7
I35
sg8
VP62952
p6278
sg10
I5
sg11
VBLCAP
p6279
sg13
I1
sa(dp6280
g7
I0
sg8
VP62952
p6281
sg10
I33
sg11
VBladder cancer-associated protein
p6282
sg13
I3
sasg20
(lp6283
(dp6284
g7
I156
sg23
VC2699153
p6285
sg10
I8
sg11
Vinvasion
p6286
sg13
I1
sa(dp6287
g7
I0
sg23
VC0699885
p6288
sg10
I14
sg11
VBladder cancer
p6289
sg13
I2
sa(dp6290
g7
I107
sg23
VC0699885
p6291
sg10
I17
sg11
Vbladder carcinoma
p6292
sg13
I2
sa(dp6293
g7
I63
sg23
VC0027651
p6294
sg10
I5
sg11
Vtumor
p6295
sg13
I1
sa(dp6296
g7
I168
sg23
VC0699885
p6297
sg10
I14
sg11
Vbladder cancer
p6298
sg13
I2
sasa(dp6299
g2
S'Bladder cancer-associated protein (BLCAP) is a highly conserved protein among species, and it is considered a novel candidate tumor suppressor gene originally identified from human bladder carcinoma.\n'
p6300
sg4
(lp6301
(dp6302
g7
I35
sg8
VP62952
p6303
sg10
I5
sg11
VBLCAP
p6304
sg13
I1
sa(dp6305
g7
I0
sg8
VP62952
p6306
sg10
I33
sg11
VBladder cancer-associated protein
p6307
sg13
I3
sasg20
(lp6308
(dp6309
g7
I126
sg23
VC0027651
p6310
sg10
I5
sg11
Vtumor
p6311
sg13
I1
sa(dp6312
g7
I0
sg23
VC0699885
p6313
sg10
I14
sg11
VBladder cancer
p6314
sg13
I2
sa(dp6315
g7
I181
sg23
VC0699885
p6316
sg10
I17
sg11
Vbladder carcinoma
p6317
sg13
I2
sasa(dp6318
g2
S'Bladder cancer-associated protein gene (BLCAP) is a novel candidate tumor suppressor gene identified from the human bladder carcinoma.\n'
p6319
sg4
(lp6320
(dp6321
g7
I68
sg8
VP25054
p6322
sg10
I21
sg11
Vtumor suppressor gene
p6323
sg13
I3
sa(dp6324
g7
I40
sg8
VP62952
p6325
sg10
I5
sg11
VBLCAP
p6326
sg13
I1
sa(dp6327
g7
I0
sg8
VP62952
p6328
sg10
I38
sg11
VBladder cancer-associated protein gene
p6329
sg13
I4
sasg20
(lp6330
(dp6331
g7
I116
sg23
VC0699885
p6332
sg10
I17
sg11
Vbladder carcinoma
p6333
sg13
I2
sa(dp6334
g7
I0
sg23
VC0699885
p6335
sg10
I14
sg11
VBladder cancer
p6336
sg13
I2
sa(dp6337
g7
I68
sg23
VC0027651
p6338
sg10
I5
sg11
Vtumor
p6339
sg13
I1
sasa(dp6340
g2
S'The results indicate that ghrelin exerted an antinociceptive effect, which was mediated via TRPV1/opioid systems, in IBS-induced visceral hypersensitivity.\n'
p6341
sg4
(lp6342
(dp6343
g7
I92
sg8
g18
sg10
I5
sg11
VTRPV1
p6344
sg13
I1
sasg20
(lp6345
(dp6346
g7
I117
sg23
VC0022104
p6347
sg10
I3
sg11
VIBS
p6348
sg13
I1
sa(dp6349
g7
I138
sg23
VC0020517
p6350
sg10
I16
sg11
Vhypersensitivity
p6351
sg13
I1
sasa(dp6352
g2
S'Taken together, our results implicate TRPA1 and TRPV1 channels as potential pharmacological targets to address the 7-DHC-induced hypersensitivity to light in patients.\n'
p6353
sg4
(lp6354
(dp6355
g7
I48
sg8
g18
sg10
I14
sg11
VTRPV1 channels
p6356
sg13
I2
sa(dp6357
g7
I38
sg8
g18
sg10
I5
sg11
VTRPA1
p6358
sg13
I1
sasg20
(lp6359
(dp6360
g7
I129
sg23
VC0020517
p6361
sg10
I16
sg11
Vhypersensitivity
p6362
sg13
I1
sasa(dp6363
g2
S'In conclusion, WFM alleviated CCI-induced mechanical allodynia and thermal hypersensitivity via modulating TRPV1.\n'
p6364
sg4
(lp6365
(dp6366
g7
I107
sg8
g18
sg10
I5
sg11
VTRPV1
p6367
sg13
I1
sasg20
(lp6368
(dp6369
g7
I75
sg23
VC0020517
p6370
sg10
I16
sg11
Vhypersensitivity
p6371
sg13
I1
sa(dp6372
g7
I42
sg23
VC2936719
p6373
sg10
I20
sg11
Vmechanical allodynia
p6374
sg13
I2
sasa(dp6375
g2
S'The single nucleotide polymorphism (SNP) rs13438494 in intron 24 of PCLO was significantly associated with bipolar disorder in a meta-analysis of genome-wide association studies.\n'
p6376
sg4
(lp6377
sg20
(lp6378
(dp6379
g7
I107
sg23
VC0005586
p6380
sg10
I16
sg11
Vbipolar disorder
p6381
sg13
I2
sasa(dp6382
g2
S'Of these, one SNP (rs13438494), in an intron of the piccolo (PCLO) gene, was significantly associated with bipolar disorder (FDR adjusted p &lt; .05) in the meta-analysis of GWAS.\n'
p6383
sg4
(lp6384
sg20
(lp6385
(dp6386
g7
I107
sg23
VC0005586
p6387
sg10
I16
sg11
Vbipolar disorder
p6388
sg13
I2
sasa(dp6389
g2
S'These results support the previous findings implicating PCLO in mood disorders and demonstrate the utility of combining gene expression and genetic variation data to improve our understanding of the genetic contribution to bipolar disorder.\n'
p6390
sg4
(lp6391
sg20
(lp6392
(dp6393
g7
I223
sg23
VC0005586
p6394
sg10
I16
sg11
Vbipolar disorder
p6395
sg13
I2
sa(dp6396
g7
I64
sg23
VC0525045
p6397
sg10
I14
sg11
Vmood disorders
p6398
sg13
I2
sasa(dp6399
g2
S'Methylation profiles of AGTR1, GALR1, SLC5A8, ZMYND10 and NTSR1, could be an effective methylation-based assay for NSCLC diagnosis.\n'
p6400
sg4
(lp6401
(dp6402
g7
I31
sg8
VP47211
p6403
sg10
I5
sg11
VGALR1
p6404
sg13
I1
sa(dp6405
g7
I38
sg8
g18
sg10
I6
sg11
VSLC5A8
p6406
sg13
I1
sa(dp6407
g7
I46
sg8
g18
sg10
I7
sg11
VZMYND10
p6408
sg13
I1
sa(dp6409
g7
I58
sg8
VP30989
p6410
sg10
I5
sg11
VNTSR1
p6411
sg13
I1
sa(dp6412
g7
I24
sg8
VP30556
p6413
sg10
I5
sg11
VAGTR1
p6414
sg13
I1
sasg20
(lp6415
(dp6416
g7
I115
sg23
VC0007131
p6417
sg10
I5
sg11
VNSCLC
p6418
sg13
I1
sasa(dp6419
g2
S'Zinc-finger, MYND-type containing 10 (ZMYND10), or more commonly called BLU, expression is frequently downregulated in nasopharyngeal carcinoma (NPC) and many other tumors due to promoter hypermethylation.\n'
p6420
sg4
(lp6421
(dp6422
g7
I72
sg8
VP61088
p6423
sg10
I3
sg11
VBLU
p6424
sg13
I1
sasg20
(lp6425
(dp6426
g7
I165
sg23
VC0027651
p6427
sg10
I6
sg11
Vtumors
p6428
sg13
I1
sa(dp6429
g7
I119
sg23
VC2931822
p6430
sg10
I24
sg11
Vnasopharyngeal carcinoma
p6431
sg13
I2
sa(dp6432
g7
I145
sg23
VC2931822
p6433
sg10
I3
sg11
VNPC
p6434
sg13
I1
sasa(dp6435
g2
S'A possible mechanism of BLU in chemoresistance was investigated in ovarian cancer cell lines by in vitro apoptotic assays.\n'
p6436
sg4
(lp6437
(dp6438
g7
I24
sg8
VP61088
p6439
sg10
I3
sg11
VBLU
p6440
sg13
I1
sasg20
(lp6441
(dp6442
g7
I67
sg23
VC1140680
p6443
sg10
I14
sg11
Vovarian cancer
p6444
sg13
I2
sasa(dp6445
g2
S'In vitro studies have shown that BLU could upregulate the expression of BAX and enhance the effect of paclitaxel-induced apoptosis in ovarian cancer cells.\n'
p6446
sg4
(lp6447
(dp6448
g7
I33
sg8
VP61088
p6449
sg10
I3
sg11
VBLU
p6450
sg13
I1
sasg20
(lp6451
(dp6452
g7
I134
sg23
VC1140680
p6453
sg10
I14
sg11
Vovarian cancer
p6454
sg13
I2
sasa(dp6455
g2
S'Our study suggested that methylation of BLU could be a potential prognostic biomarker for advanced ovarian serous carcinoma.\n'
p6456
sg4
(lp6457
(dp6458
g7
I40
sg8
VP61088
p6459
sg10
I3
sg11
VBLU
p6460
sg13
I1
sasg20
(lp6461
(dp6462
g7
I99
sg23
VC1335177
p6463
sg10
I24
sg11
Vovarian serous carcinoma
p6464
sg13
I3
sasa(dp6465
g2
S'Mutations in connexins expressed in the cochlear epithelium, Cx26 and Cx30, cause sensorineural deafness and in the case of Cx26, is one of the most common causes of non-syndromic, hereditary deafness.\n'
p6466
sg4
(lp6467
(dp6468
g7
I70
sg8
g18
sg10
I4
sg11
VCx30
p6469
sg13
I1
sasg20
(lp6470
(dp6471
g7
I82
sg23
VC0018784
p6472
sg10
I22
sg11
Vsensorineural deafness
p6473
sg13
I2
sa(dp6474
g7
I181
sg23
VC0339789
p6475
sg10
I19
sg11
Vhereditary deafness
p6476
sg13
I2
sasa(dp6477
g2
S'Although hundreds of genes have been reported to be associated with nonsyndromic hearing loss (NSHL), GJB2, GJB6, SLC26A4, and mitochondrial (mt) MT-RNR1 and MTTS are the major contributors.\n'
p6478
sg4
(lp6479
(dp6480
g7
I114
sg8
g18
sg10
I7
sg11
VSLC26A4
p6481
sg13
I1
sa(dp6482
g7
I108
sg8
g18
sg10
I4
sg11
VGJB6
p6483
sg13
I1
sa(dp6484
g7
I149
sg8
VP43354
p6485
sg10
I4
sg11
VRNR1
p6486
sg13
I1
sasg20
(lp6487
(dp6488
g7
I81
sg23
VC0011053
p6489
sg10
I12
sg11
Vhearing loss
p6490
sg13
I2
sasa(dp6491
g2
S'Alterations in genes frequently associated with nonsyndromic hearing loss in the Brazilian population, including connexin 26 (GJB2), connexin 30 (GJB6) and mitochondrial 12 S rRNA (m.A1555 G mutation), were not found.\n'
p6492
sg4
(lp6493
(dp6494
g7
I133
sg8
g18
sg10
I11
sg11
Vconnexin 30
p6495
sg13
I2
sa(dp6496
g7
I146
sg8
g18
sg10
I4
sg11
VGJB6
p6497
sg13
I1
sa(dp6498
g7
I113
sg8
g18
sg10
I11
sg11
Vconnexin 26
p6499
sg13
I2
sasg20
(lp6500
(dp6501
g7
I61
sg23
VC0011053
p6502
sg10
I12
sg11
Vhearing loss
p6503
sg13
I2
sasa(dp6504
g2
S'Canine X-linked progressive retinal atrophy (XLPRA) is a hereditary, progressive retinal degeneration that has been mapped previously to the canine X chromosome in a region flanked by the dystrophin (DMD) and tissue inhibitor of metalloproteinase 1 (TIMP1) genes, and is tightly linked to the gene RPGR.\n'
p6505
sg4
(lp6506
(dp6507
g7
I298
sg8
g18
sg10
I4
sg11
VRPGR
p6508
sg13
I1
sa(dp6509
g7
I188
sg8
VP11532
p6510
sg10
I10
sg11
Vdystrophin
p6511
sg13
I1
sa(dp6512
g7
I209
sg8
VP01033
p6513
sg10
I53
sg11
Vtissue inhibitor of metalloproteinase 1 (TIMP1) genes
p6514
sg13
I7
sasg20
(lp6515
(dp6516
g7
I28
sg23
VC0521694
p6517
sg10
I15
sg11
Vretinal atrophy
p6518
sg13
I2
sa(dp6519
g7
I81
sg23
VC0035304
p6520
sg10
I20
sg11
Vretinal degeneration
p6521
sg13
I2
sa(dp6522
g7
I200
sg23
VC0013264
p6523
sg10
I3
sg11
VDMD
p6524
sg13
I1
sasa(dp6525
g2
S'By typing the XLPRA pedigree with five intragenic markers [dystrophin, retinitis pigmentosa GTPase regulator ( RPGR ), tissue inhibitor of metalloproteinases 1, androgen receptor and factor IX], we established a linkage map of the canine X chromosome, and confirmed that the order of these five genes is identical to that on the human X. XLPRA was tightly linked to an intragenic RPGR polymorphism (LOD 11.7, zero recombination), thus confirming locus homology with RP3.\n'
p6526
sg4
(lp6527
(dp6528
g7
I71
sg8
g18
sg10
I37
sg11
Vretinitis pigmentosa GTPase regulator
p6529
sg13
I4
sa(dp6530
g7
I111
sg8
g18
sg10
I4
sg11
VRPGR
p6531
sg13
I1
sa(dp6532
g7
I119
sg8
VP10275
p6533
sg10
I59
sg11
Vtissue inhibitor of metalloproteinases 1, androgen receptor
p6534
sg13
I7
sa(dp6535
g7
I59
sg8
VP11532
p6536
sg10
I10
sg11
Vdystrophin
p6537
sg13
I1
sa(dp6538
g7
I183
sg8
VP00740
p6539
sg10
I9
sg11
Vfactor IX
p6540
sg13
I2
sa(dp6541
g7
I466
sg8
VP51808
p6542
sg10
I3
sg11
VRP3
p6543
sg13
I1
sasg20
(lp6544
(dp6545
g7
I71
sg23
VC0035334
p6546
sg10
I20
sg11
Vretinitis pigmentosa
p6547
sg13
I2
sa(dp6548
g7
I466
sg23
VC1845667
p6549
sg10
I3
sg11
VRP3
p6550
sg13
I1
sasa(dp6551
g2
S'At this location the dystrophin/dystroglycan complex may play a role in the attachment of the retina to the vitreous, and, under pathological conditions, in traction-induced retinal detachment.\n'
p6552
sg4
(lp6553
(dp6554
g7
I32
sg8
g18
sg10
I12
sg11
Vdystroglycan
p6555
sg13
I1
sa(dp6556
g7
I21
sg8
VP11532
p6557
sg10
I10
sg11
Vdystrophin
p6558
sg13
I1
sasg20
(lp6559
(dp6560
g7
I174
sg23
VC0035305
p6561
sg10
I18
sg11
Vretinal detachment
p6562
sg13
I2
sasa(dp6563
g2
S'The aim of this study was to examine the possible association between advanced fibrosis and IGF-I and IGFBP-1 in NAFLD.\n'
p6564
sg4
(lp6565
(dp6566
g7
I92
sg8
VP01343
p6567
sg10
I5
sg11
VIGF-I
p6568
sg13
I1
sa(dp6569
g7
I102
sg8
VP17936
p6570
sg10
I7
sg11
VIGFBP-1
p6571
sg13
I1
sasg20
(lp6572
(dp6573
g7
I79
sg23
VC0016059
p6574
sg10
I8
sg11
Vfibrosis
p6575
sg13
I1
sa(dp6576
g7
I113
sg23
VC0400966
p6577
sg10
I5
sg11
VNAFLD
p6578
sg13
I1
sasa(dp6579
g2
S'This pilot study suggests an association between serum IGFBP-1 and IGF-I levels with advanced fibrosis in NAFLD patients.\n'
p6580
sg4
(lp6581
(dp6582
g7
I67
sg8
VP01343
p6583
sg10
I5
sg11
VIGF-I
p6584
sg13
I1
sa(dp6585
g7
I49
sg8
g18
sg10
I13
sg11
Vserum IGFBP-1
p6586
sg13
I2
sasg20
(lp6587
(dp6588
g7
I106
sg23
VC0400966
p6589
sg10
I5
sg11
VNAFLD
p6590
sg13
I1
sa(dp6591
g7
I94
sg23
VC0016059
p6592
sg10
I8
sg11
Vfibrosis
p6593
sg13
I1
sasa(dp6594
g2
S'Numerous studies have shown that impairments of the hepatic growth hormone/insulin-like growth factor-1 axis (GH/IGF-1) are common in patients with non-alcoholic fatty liver disease, chronic viral hepatitis, liver cirrhosis, and chronic cholestatic liver disease.\n'
p6595
sg4
(lp6596
(dp6597
g7
I113
sg8
VP01343
p6598
sg10
I5
sg11
VIGF-1
p6599
sg13
I1
sa(dp6600
g7
I52
sg8
g18
sg10
I22
sg11
Vhepatic growth hormone
p6601
sg13
I3
sa(dp6602
g7
I75
sg8
VP01308
p6603
sg10
I33
sg11
Vinsulin-like growth factor-1 axis
p6604
sg13
I4
sasg20
(lp6605
(dp6606
g7
I183
sg23
VC0276623
p6607
sg10
I23
sg11
Vchronic viral hepatitis
p6608
sg13
I3
sa(dp6609
g7
I237
sg23
VC0860204
p6610
sg10
I25
sg11
Vcholestatic liver disease
p6611
sg13
I3
sa(dp6612
g7
I208
sg23
VC0023890
p6613
sg10
I15
sg11
Vliver cirrhosis
p6614
sg13
I2
sa(dp6615
g7
I148
sg23
VC0400966
p6616
sg10
I33
sg11
Vnon-alcoholic fatty liver disease
p6617
sg13
I4
sasa(dp6618
g2
S'It has also been demonstrated that a decrease in the GH insulin-like growth factor-I (IGF-I) axis is closely associated with the progression of general NAFLD, suggesting a physiological role of these hormones for the maintenance of the liver.\n'
p6619
sg4
(lp6620
(dp6621
g7
I53
sg8
VP01308
p6622
sg10
I31
sg11
VGH insulin-like growth factor-I
p6623
sg13
I4
sa(dp6624
g7
I86
sg8
VP01343
p6625
sg10
I5
sg11
VIGF-I
p6626
sg13
I1
sasg20
(lp6627
(dp6628
g7
I152
sg23
VC0400966
p6629
sg10
I5
sg11
VNAFLD
p6630
sg13
I1
sasa(dp6631
g2
S'The aim of the present study was to clarify the relationship between the histological severity of NAFLD and production of the GH/insulin-like growth factor 1 (IGF-1) axis.\n'
p6632
sg4
(lp6633
(dp6634
g7
I159
sg8
VP01343
p6635
sg10
I5
sg11
VIGF-1
p6636
sg13
I1
sa(dp6637
g7
I126
sg8
VP01308
p6638
sg10
I31
sg11
VGH/insulin-like growth factor 1
p6639
sg13
I4
sasg20
(lp6640
(dp6641
g7
I98
sg23
VC0400966
p6642
sg10
I5
sg11
VNAFLD
p6643
sg13
I1
sasa(dp6644
g2
S'Results With respect to the stage of fibrosis in patients with NAFLD, the serum GH levels were higher and the serum IGFBP-3 levels and IGF-1:SDSs were lower in patients with cirrhosis (grade F4 fibrosis) than in patients grade F1-F3 fibrosis; moreover, these differences were statistically significant (all p&lt;0.01).\n'
p6645
sg4
(lp6646
(dp6647
g7
I135
sg8
VP01343
p6648
sg10
I5
sg11
VIGF-1
p6649
sg13
I1
sa(dp6650
g7
I110
sg8
VP17936
p6651
sg10
I13
sg11
Vserum IGFBP-3
p6652
sg13
I2
sa(dp6653
g7
I74
sg8
g18
sg10
I8
sg11
Vserum GH
p6654
sg13
I2
sasg20
(lp6655
(dp6656
g7
I37
sg23
VC0016059
p6657
sg10
I8
sg11
Vfibrosis
p6658
sg13
I1
sa(dp6659
g7
I37
sg23
VC0016059
p6660
sg10
I8
sg11
Vfibrosis
p6661
sg13
I1
sa(dp6662
g7
I174
sg23
VC0023890
p6663
sg10
I9
sg11
Vcirrhosis
p6664
sg13
I1
sa(dp6665
g7
I63
sg23
VC0400966
p6666
sg10
I5
sg11
VNAFLD
p6667
sg13
I1
sa(dp6668
g7
I37
sg23
VC0016059
p6669
sg10
I8
sg11
Vfibrosis
p6670
sg13
I1
sasa(dp6671
g2
S'Conclusion Increased GH levels and decreased IGF-1 and IGFBP-3 levels might contribute to the progression of NAFLD.\n'
p6672
sg4
(lp6673
(dp6674
g7
I55
sg8
VP17936
p6675
sg10
I7
sg11
VIGFBP-3
p6676
sg13
I1
sa(dp6677
g7
I45
sg8
VP01343
p6678
sg10
I5
sg11
VIGF-1
p6679
sg13
I1
sasg20
(lp6680
(dp6681
g7
I109
sg23
VC0400966
p6682
sg10
I5
sg11
VNAFLD
p6683
sg13
I1
sasa(dp6684
g2
S'The GH/IGF-1 axis may be important in the development of NAFLD, but not in patients with HCV-related CLD.\n'
p6685
sg4
(lp6686
(dp6687
g7
I7
sg8
VP01343
p6688
sg10
I5
sg11
VIGF-1
p6689
sg13
I1
sasg20
(lp6690
(dp6691
g7
I101
sg23
VC0746102
p6692
sg10
I3
sg11
VCLD
p6693
sg13
I1
sa(dp6694
g7
I57
sg23
VC0400966
p6695
sg10
I5
sg11
VNAFLD
p6696
sg13
I1
sasa(dp6697
g2
S'Growing evidence suggests that growth hormone (GH) and insulin-like growth factor-1 (IGF-1) may have roles in the development and progression of NAFLD.\n'
p6698
sg4
(lp6699
(dp6700
g7
I85
sg8
VP01343
p6701
sg10
I5
sg11
VIGF-1
p6702
sg13
I1
sa(dp6703
g7
I31
sg8
VP01242
p6704
sg10
I14
sg11
Vgrowth hormone
p6705
sg13
I2
sa(dp6706
g7
I47
sg8
VP01242
p6707
sg10
I2
sg11
VGH
p6708
sg13
I1
sa(dp6709
g7
I55
sg8
VP01308
p6710
sg10
I28
sg11
Vinsulin-like growth factor-1
p6711
sg13
I3
sasg20
(lp6712
(dp6713
g7
I145
sg23
VC0400966
p6714
sg10
I5
sg11
VNAFLD
p6715
sg13
I1
sasa(dp6716
g2
S'Low serum IGF-1 levels are associated with increased histologic severity of NAFLD when rigorously controlled for age, BMI, the presence of diabetes, and after the exclusion of subjects with cirrhosis.\n'
p6717
sg4
(lp6718
(dp6719
g7
I4
sg8
VP01343
p6720
sg10
I11
sg11
Vserum IGF-1
p6721
sg13
I2
sasg20
(lp6722
(dp6723
g7
I76
sg23
VC0400966
p6724
sg10
I5
sg11
VNAFLD
p6725
sg13
I1
sa(dp6726
g7
I139
sg23
VC0011849
p6727
sg10
I8
sg11
Vdiabetes
p6728
sg13
I1
sa(dp6729
g7
I190
sg23
VC0023890
p6730
sg10
I9
sg11
Vcirrhosis
p6731
sg13
I1
sasa(dp6732
g2
S'Further investigation is warranted to determine the differential effects of GH and IGF-1 on the development and progression of NAFLD, which could further elucidate pathophysiology and identify therapeutic targets.\n'
p6733
sg4
(lp6734
(dp6735
g7
I83
sg8
VP01343
p6736
sg10
I5
sg11
VIGF-1
p6737
sg13
I1
sasg20
(lp6738
(dp6739
g7
I127
sg23
VC0400966
p6740
sg10
I5
sg11
VNAFLD
p6741
sg13
I1
sasa(dp6742
g2
S'Idiopathic hypoparathyroidism, inadequate secretion of parathyroid hormone of unknown etiology, may mimic ankylosing spondylitis both clinically and radiologically.\n'
p6743
sg4
(lp6744
(dp6745
g7
I55
sg8
VP01270
p6746
sg10
I19
sg11
Vparathyroid hormone
p6747
sg13
I2
sasg20
(lp6748
(dp6749
g7
I106
sg23
VC0038013
p6750
sg10
I22
sg11
Vankylosing spondylitis
p6751
sg13
I2
sa(dp6752
g7
I0
sg23
VC0342342
p6753
sg10
I29
sg11
VIdiopathic hypoparathyroidism
p6754
sg13
I2
sasa(dp6755
g2
S'121 consecutive pts (85 rheumatoid arthritis (RA), 22 psoriatic arthritis (PSA), 14 ankylosing spondylitis (AS)) underwent clinical and laboratory evaluation which included kidney and liver function tests, serum calcium and phosphor levels, 25(OH)D and parathyroid hormone (PTH).\n'
p6756
sg4
(lp6757
(dp6758
g7
I274
sg8
VP01270
p6759
sg10
I3
sg11
VPTH
p6760
sg13
I1
sa(dp6761
g7
I253
sg8
VP01270
p6762
sg10
I19
sg11
Vparathyroid hormone
p6763
sg13
I2
sasg20
(lp6764
(dp6765
g7
I75
sg23
VC1519176
p6766
sg10
I3
sg11
VPSA
p6767
sg13
I1
sa(dp6768
g7
I24
sg23
VC0003873
p6769
sg10
I20
sg11
Vrheumatoid arthritis
p6770
sg13
I2
sa(dp6771
g7
I84
sg23
VC0038013
p6772
sg10
I22
sg11
Vankylosing spondylitis
p6773
sg13
I2
sa(dp6774
g7
I54
sg23
VC0003872
p6775
sg10
I19
sg11
Vpsoriatic arthritis
p6776
sg13
I2
sasa(dp6777
g2
S'Elevated expression of the activating FcGamma receptor (FcGammaR) I and FcGammaRIIa together with decreased expression of the inhibitory FcGammaRIIb are involved in the pathogenesis of primary immune thrombocytopenia (ITP).\n'
p6778
sg4
(lp6779
(dp6780
g7
I27
sg8
g18
sg10
I40
sg11
Vactivating FcGamma receptor (FcGammaR) I
p6781
sg13
I5
sa(dp6782
g7
I137
sg8
VP31994
p6783
sg10
I11
sg11
VFcGammaRIIb
p6784
sg13
I1
sa(dp6785
g7
I72
sg8
VP31995
p6786
sg10
I11
sg11
VFcGammaRIIa
p6787
sg13
I1
sasg20
(lp6788
(dp6789
g7
I169
sg23
VC0699748
p6790
sg10
I12
sg11
Vpathogenesis
p6791
sg13
I1
sa(dp6792
g7
I193
sg23
VC0272286
p6793
sg10
I23
sg11
Vimmune thrombocytopenia
p6794
sg13
I2
sa(dp6795
g7
I218
sg23
VC0043117
p6796
sg10
I3
sg11
VITP
p6797
sg13
I1
sasa(dp6798
g2
S'Thrombocytopenia was induced in FcGammaRIIb-deficient mice on B6;129S, C57BL/6, and BALB/C backgrounds, as well as splenectomized mice and control mice by platelet (PLT) antibody.\n'
p6799
sg4
(lp6800
(dp6801
g7
I155
sg8
g18
sg10
I23
sg11
Vplatelet (PLT) antibody
p6802
sg13
I3
sasg20
(lp6803
sa(dp6804
g2
S'Anti-CD44 is ineffective at inhibiting thrombocytopenia in B6;129S FcGammaRIIb-deficient mice but, like IVIG, is effective in splenectomized mice and FcGammaRIIb-deficient mice on the BALB/C and C57BL/6 background.\n'
p6805
sg4
(lp6806
sg20
(lp6807
sa(dp6808
g2
S'L-selectin(-/-) mice and L-selectin(-/-) ICAM-1(-/-) mice developed significantly less severe myositis compared to wild-type mice, while ICAM-1 deficiency did not inhibit the development of myositis.\n'
p6809
sg4
(lp6810
(dp6811
g7
I0
sg8
VP14151
p6812
sg10
I10
sg11
VL-selectin
p6813
sg13
I1
sa(dp6814
g7
I0
sg8
VP14151
p6815
sg10
I10
sg11
VL-selectin
p6816
sg13
I1
sa(dp6817
g7
I41
sg8
VP05362
p6818
sg10
I6
sg11
VICAM-1
p6819
sg13
I1
sasg20
(lp6820
(dp6821
g7
I94
sg23
VC0027121
p6822
sg10
I8
sg11
Vmyositis
p6823
sg13
I1
sa(dp6824
g7
I94
sg23
VC0027121
p6825
sg10
I8
sg11
Vmyositis
p6826
sg13
I1
sasa(dp6827
g2
S'L-selectin(-/-) mice that received wild-type T cells developed myositis.\n'
p6828
sg4
(lp6829
(dp6830
g7
I0
sg8
VP14151
p6831
sg10
I10
sg11
VL-selectin
p6832
sg13
I1
sasg20
(lp6833
(dp6834
g7
I63
sg23
VC0027121
p6835
sg10
I8
sg11
Vmyositis
p6836
sg13
I1
sasa(dp6837
g2
S'Aberrant expression of SSTR1 has been implicated in several human diseases, including pseudotumor cerebri, and oncogenic osteomalacia.\n'
p6838
sg4
(lp6839
(dp6840
g7
I23
sg8
VP30872
p6841
sg10
I5
sg11
VSSTR1
p6842
sg13
I1
sasg20
(lp6843
(dp6844
g7
I111
sg23
VC1274103
p6845
sg10
I22
sg11
Voncogenic osteomalacia
p6846
sg13
I2
sa(dp6847
g7
I86
sg23
VC0033845
p6848
sg10
I19
sg11
Vpseudotumor cerebri
p6849
sg13
I2
sasa(dp6850
g2
S'Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME), a rare disorder caused by mutation in the ASAH1 gene, is characterized by progressive muscle weakness and intractable epilepsy.\n'
p6851
sg4
(lp6852
(dp6853
g7
I113
sg8
g18
sg10
I10
sg11
VASAH1 gene
p6854
sg13
I2
sasg20
(lp6855
(dp6856
g7
I157
sg23
VC0030552
p6857
sg10
I15
sg11
Vmuscle weakness
p6858
sg13
I2
sa(dp6859
g7
I29
sg23
VC0751785
p6860
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p6861
sg13
I3
sa(dp6862
g7
I73
sg23
VC0678236
p6863
sg10
I13
sg11
Vrare disorder
p6864
sg13
I2
sa(dp6865
g7
I65
sg23
VC0751785
p6866
sg10
I3
sg11
VPME
p6867
sg13
I1
sa(dp6868
g7
I61
sg23
VC0026847
p6869
sg10
I3
sg11
VSMA
p6870
sg13
I1
sa(dp6871
g7
I0
sg23
VC0026847
p6872
sg10
I23
sg11
VSpinal muscular atrophy
p6873
sg13
I3
sa(dp6874
g7
I177
sg23
VC1096063
p6875
sg10
I20
sg11
Vintractable epilepsy
p6876
sg13
I2
sasa(dp6877
g2
S'Mutations of N-acylsphingosine amidohydrolase 1 are known to separately cause Farber disease (arthritis, subcutaneous nodules, and dysphonia) or SMA with progressive myoclonic epilepsy.\n'
p6878
sg4
(lp6879
(dp6880
g7
I13
sg8
g18
sg10
I34
sg11
VN-acylsphingosine amidohydrolase 1
p6881
sg13
I3
sasg20
(lp6882
(dp6883
g7
I78
sg23
VC0268255
p6884
sg10
I14
sg11
VFarber disease
p6885
sg13
I2
sa(dp6886
g7
I105
sg23
VC0151811
p6887
sg10
I20
sg11
Vsubcutaneous nodules
p6888
sg13
I2
sa(dp6889
g7
I94
sg23
VC0003864
p6890
sg10
I9
sg11
Varthritis
p6891
sg13
I1
sa(dp6892
g7
I145
sg23
VC0026847
p6893
sg10
I3
sg11
VSMA
p6894
sg13
I1
sa(dp6895
g7
I154
sg23
VC0751778
p6896
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p6897
sg13
I3
sasa(dp6898
g2
S'A rare syndrome characterized by lower motor neuron disease associated with progressive myoclonic epilepsy, referred to as "spinal muscular atrophy associated with progressive myoclonic epilepsy" (SMA-PME), has been described in childhood and is inherited as an autosomal recessive trait.\n'
p6899
sg4
(lp6900
sg20
(lp6901
(dp6902
g7
I33
sg23
VC0270764
p6903
sg10
I26
sg11
Vlower motor neuron disease
p6904
sg13
I4
sa(dp6905
g7
I197
sg23
VC0026847
p6906
sg10
I3
sg11
VSMA
p6907
sg13
I1
sa(dp6908
g7
I7
sg23
VC0039082
p6909
sg10
I8
sg11
Vsyndrome
p6910
sg13
I1
sa(dp6911
g7
I76
sg23
VC0751785
p6912
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p6913
sg13
I3
sa(dp6914
g7
I76
sg23
VC0751785
p6915
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p6916
sg13
I3
sa(dp6917
g7
I124
sg23
VC0026847
p6918
sg10
I23
sg11
Vspinal muscular atrophy
p6919
sg13
I3
sa(dp6920
g7
I201
sg23
VC0751785
p6921
sg10
I3
sg11
VPME
p6922
sg13
I1
sasa(dp6923
g2
S'Recent research has revealed that deficiency of the same enzyme is responsible for a rare form of spinal muscular atrophy associated with myoclonic epilepsy (SMA-PME).\n'
p6924
sg4
(lp6925
sg20
(lp6926
(dp6927
g7
I138
sg23
VC0014550
p6928
sg10
I18
sg11
Vmyoclonic epilepsy
p6929
sg13
I2
sa(dp6930
g7
I98
sg23
VC0026847
p6931
sg10
I23
sg11
Vspinal muscular atrophy
p6932
sg13
I3
sa(dp6933
g7
I158
sg23
VC0026847
p6934
sg10
I3
sg11
VSMA
p6935
sg13
I1
sa(dp6936
g7
I162
sg23
VC0751785
p6937
sg10
I3
sg11
VPME
p6938
sg13
I1
sasa(dp6939
g2
S'ASAH1 variants cause both the severe and early-onset Farber disease and rare cases of spinal muscular atrophy (SMA) with progressive myoclonic epilepsy (SMA-PME), phenotypically characterized by childhood onset of proximal muscle weakness and atrophy due to spinal motor neuron degeneration followed by occurrence of severe and intractable myoclonic seizures and death in the teenage years.\n'
p6940
sg4
(lp6941
(dp6942
g7
I0
sg8
g18
sg10
I14
sg11
VASAH1 variants
p6943
sg13
I2
sasg20
(lp6944
(dp6945
g7
I121
sg23
VC0751785
p6946
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p6947
sg13
I3
sa(dp6948
g7
I271
sg23
VC0027746
p6949
sg10
I19
sg11
Vneuron degeneration
p6950
sg13
I2
sa(dp6951
g7
I102
sg23
VC0333641
p6952
sg10
I7
sg11
Vatrophy
p6953
sg13
I1
sa(dp6954
g7
I340
sg23
VC0014550
p6955
sg10
I18
sg11
Vmyoclonic seizures
p6956
sg13
I2
sa(dp6957
g7
I53
sg23
VC0268255
p6958
sg10
I14
sg11
VFarber disease
p6959
sg13
I2
sa(dp6960
g7
I86
sg23
VC0026847
p6961
sg10
I23
sg11
Vspinal muscular atrophy
p6962
sg13
I3
sa(dp6963
g7
I111
sg23
VC0026847
p6964
sg10
I3
sg11
VSMA
p6965
sg13
I1
sa(dp6966
g7
I157
sg23
VC0751785
p6967
sg10
I3
sg11
VPME
p6968
sg13
I1
sa(dp6969
g7
I223
sg23
VC0030552
p6970
sg10
I15
sg11
Vmuscle weakness
p6971
sg13
I2
sa(dp6972
g7
I111
sg23
VC0026847
p6973
sg10
I3
sg11
VSMA
p6974
sg13
I1
sasa(dp6975
g2
S'This study describes for the first time the association between ASAH1 variants and an adult SMA phenotype with no myoclonic epilepsy nor death in early age, thus expanding the phenotypic spectrum of ASAH1-related SMA.\n'
p6976
sg4
(lp6977
(dp6978
g7
I64
sg8
g18
sg10
I5
sg11
VASAH1
p6979
sg13
I1
sa(dp6980
g7
I64
sg8
g18
sg10
I14
sg11
VASAH1 variants
p6981
sg13
I2
sasg20
(lp6982
(dp6983
g7
I92
sg23
VC0026847
p6984
sg10
I3
sg11
VSMA
p6985
sg13
I1
sa(dp6986
g7
I114
sg23
VC0014550
p6987
sg10
I18
sg11
Vmyoclonic epilepsy
p6988
sg13
I2
sa(dp6989
g7
I92
sg23
VC0026847
p6990
sg10
I3
sg11
VSMA
p6991
sg13
I1
sasa(dp6992
g2
S'Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) is an extremely rare disorder related to the lysosomal storage disease, Farber lipogranulomatosis.\n'
p6993
sg4
(lp6994
sg20
(lp6995
(dp6996
g7
I29
sg23
VC0751785
p6997
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p6998
sg13
I3
sa(dp6999
g7
I65
sg23
VC0751785
p7000
sg10
I3
sg11
VPME
p7001
sg13
I1
sa(dp7002
g7
I142
sg23
VC0268255
p7003
sg10
I25
sg11
VFarber lipogranulomatosis
p7004
sg13
I2
sa(dp7005
g7
I86
sg23
VC0678236
p7006
sg10
I13
sg11
Vrare disorder
p7007
sg13
I2
sa(dp7008
g7
I61
sg23
VC0026847
p7009
sg10
I3
sg11
VSMA
p7010
sg13
I1
sa(dp7011
g7
I115
sg23
VC0085078
p7012
sg10
I25
sg11
Vlysosomal storage disease
p7013
sg13
I3
sa(dp7014
g7
I0
sg23
VC0026847
p7015
sg10
I23
sg11
VSpinal muscular atrophy
p7016
sg13
I3
sasa(dp7017
g2
S'Farber disease is associated with joint deformities, lipomatous skin nodules, and often is fatal by 2-3 years of age; while SMA-PME is characterized by childhood-onset motor neuron disease and progressive myoclonic epilepsy.\n'
p7018
sg4
(lp7019
sg20
(lp7020
(dp7021
g7
I40
sg23
VC0000768
p7022
sg10
I11
sg11
Vdeformities
p7023
sg13
I1
sa(dp7024
g7
I128
sg23
VC0751785
p7025
sg10
I3
sg11
VPME
p7026
sg13
I1
sa(dp7027
g7
I0
sg23
VC0268255
p7028
sg10
I14
sg11
VFarber disease
p7029
sg13
I2
sa(dp7030
g7
I69
sg23
VC0028259
p7031
sg10
I7
sg11
Vnodules
p7032
sg13
I1
sa(dp7033
g7
I168
sg23
VC0085084
p7034
sg10
I20
sg11
Vmotor neuron disease
p7035
sg13
I3
sa(dp7036
g7
I124
sg23
VC0026847
p7037
sg10
I3
sg11
VSMA
p7038
sg13
I1
sa(dp7039
g7
I193
sg23
VC0751785
p7040
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p7041
sg13
I3
sasa(dp7042
g2
S'The combination of motor neuron disease and progressive myoclonic epilepsy should prompt genetic evaluation of ASAH1.\n'
p7043
sg4
(lp7044
(dp7045
g7
I111
sg8
g18
sg10
I5
sg11
VASAH1
p7046
sg13
I1
sasg20
(lp7047
(dp7048
g7
I44
sg23
VC0751778
p7049
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p7050
sg13
I3
sa(dp7051
g7
I19
sg23
VC0085084
p7052
sg10
I20
sg11
Vmotor neuron disease
p7053
sg13
I3
sasa(dp7054
g2
S'The enzymatic activity was first identified over four decades ago and is deficient in two rare inherited disorders, Farber lipogranulomatosis (Farber disease) and spinal muscular atrophy with myoclonic epilepsy (SMA-PME).\n'
p7055
sg4
(lp7056
sg20
(lp7057
(dp7058
g7
I143
sg23
VC0268255
p7059
sg10
I14
sg11
VFarber disease
p7060
sg13
I2
sa(dp7061
g7
I116
sg23
VC0268255
p7062
sg10
I25
sg11
VFarber lipogranulomatosis
p7063
sg13
I2
sa(dp7064
g7
I212
sg23
VC0026847
p7065
sg10
I3
sg11
VSMA
p7066
sg13
I1
sa(dp7067
g7
I216
sg23
VC0751785
p7068
sg10
I3
sg11
VPME
p7069
sg13
I1
sa(dp7070
g7
I163
sg23
VC0026847
p7071
sg10
I23
sg11
Vspinal muscular atrophy
p7072
sg13
I3
sa(dp7073
g7
I192
sg23
VC0014550
p7074
sg10
I18
sg11
Vmyoclonic epilepsy
p7075
sg13
I2
sasa(dp7076
g2
S'To present the clinical features and the results of laboratory investigations in three patients with spinal muscular atrophy associated with progressive myoclonic epilepsy (SMA-PME), a rare condition caused by mutations in the N-acylsphingosine amidohydrosilase 1 (ASAH1) gene.\n'
p7077
sg4
(lp7078
(dp7079
g7
I265
sg8
g18
sg10
I5
sg11
VASAH1
p7080
sg13
I1
sa(dp7081
g7
I227
sg8
g18
sg10
I36
sg11
VN-acylsphingosine amidohydrosilase 1
p7082
sg13
I3
sasg20
(lp7083
(dp7084
g7
I190
sg23
VC0012634
p7085
sg10
I9
sg11
Vcondition
p7086
sg13
I1
sa(dp7087
g7
I173
sg23
VC0026847
p7088
sg10
I3
sg11
VSMA
p7089
sg13
I1
sa(dp7090
g7
I101
sg23
VC0026847
p7091
sg10
I23
sg11
Vspinal muscular atrophy
p7092
sg13
I3
sa(dp7093
g7
I177
sg23
VC0751785
p7094
sg10
I3
sg11
VPME
p7095
sg13
I1
sa(dp7096
g7
I141
sg23
VC0751785
p7097
sg10
I30
sg11
Vprogressive myoclonic epilepsy
p7098
sg13
I3
sasa(dp7099
g2
S'These results suggest that the eosinophil number may be regulated by different mechanisms in W/W(v) and +/+ mice, and that the effect of SUN-C8257 on nematode-induced eosinophilia is probably due to chymase inhibition.\n'
p7100
sg4
(lp7101
(dp7102
g7
I199
sg8
VP23946
p7103
sg10
I7
sg11
Vchymase
p7104
sg13
I1
sasg20
(lp7105
(dp7106
g7
I167
sg23
VC0014457
p7107
sg10
I12
sg11
Veosinophilia
p7108
sg13
I1
sasa(dp7109
g2
S'Chymase released by activated mast cells may play a role in helminth-induced eosinophilia.\n'
p7110
sg4
(lp7111
(dp7112
g7
I0
sg8
VP23946
p7113
sg10
I7
sg11
VChymase
p7114
sg13
I1
sasg20
(lp7115
(dp7116
g7
I77
sg23
VC0014457
p7117
sg10
I12
sg11
Veosinophilia
p7118
sg13
I1
sasa(dp7119
g2
S'Injection of chymase provoked marked neutrophilia and eosinophilia in the skin of Dunkin Hartley guinea-pigs.\n'
p7120
sg4
(lp7121
(dp7122
g7
I13
sg8
VP23946
p7123
sg10
I7
sg11
Vchymase
p7124
sg13
I1
sasg20
(lp7125
(dp7126
g7
I54
sg23
VC0014457
p7127
sg10
I12
sg11
Veosinophilia
p7128
sg13
I1
sasa(dp7129
g2
S'The patient presented as a 53yo man with a left upper quadrant mass and synchronous metastases to the spleen and liver (pancreatic neuroendocrine tumor T4N0M1, Stage IV), which were resected (CD56-, synaptophysin+, chromogranin+, Ki-67&lt;1%).\n'
p7130
sg4
(lp7131
(dp7132
g7
I192
sg8
VP08247
p7133
sg10
I21
sg11
VCD56-, synaptophysin+
p7134
sg13
I2
sa(dp7135
g7
I215
sg8
VP08311
p7136
sg10
I13
sg11
Vchromogranin+
p7137
sg13
I1
sasg20
(lp7138
(dp7139
g7
I84
sg23
VC0027627
p7140
sg10
I10
sg11
Vmetastases
p7141
sg13
I1
sa(dp7142
g7
I120
sg23
VC1337011
p7143
sg10
I31
sg11
Vpancreatic neuroendocrine tumor
p7144
sg13
I3
sasa(dp7145
g2
S'Immunohistochemically, the tumor cells were negative for CD117, and CD34, but positive for chromogranin, synaptophysin, and CD56 with a 6% Ki-67 index, consistent with a spindle cell-type well differentiated neuroendocrine tumor, World Health Organization (WHO) Grade 2.\n'
p7146
sg4
(lp7147
(dp7148
g7
I91
sg8
VP08311
p7149
sg10
I12
sg11
Vchromogranin
p7150
sg13
I1
sa(dp7151
g7
I68
sg8
VP28906
p7152
sg10
I4
sg11
VCD34
p7153
sg13
I1
sa(dp7154
g7
I57
sg8
VP10721
p7155
sg10
I5
sg11
VCD117
p7156
sg13
I1
sa(dp7157
g7
I105
sg8
VP08247
p7158
sg10
I13
sg11
Vsynaptophysin
p7159
sg13
I1
sasg20
(lp7160
(dp7161
g7
I208
sg23
VC0206754
p7162
sg10
I20
sg11
Vneuroendocrine tumor
p7163
sg13
I2
sa(dp7164
g7
I27
sg23
VC0027651
p7165
sg10
I5
sg11
Vtumor
p7166
sg13
I1
sasa(dp7167
g2
S'Recent studies have reported low or absent expression of CD56 in papillary thyroid carcinoma (PTC) and its presence in normal thyroid tissue, benign thyroid lesions, and most follicular non-PTC tumors.\n'
p7168
sg4
(lp7169
sg20
(lp7170
(dp7171
g7
I194
sg23
VC0027651
p7172
sg10
I6
sg11
Vtumors
p7173
sg13
I1
sa(dp7174
g7
I94
sg23
VC0238463
p7175
sg10
I3
sg11
VPTC
p7176
sg13
I1
sa(dp7177
g7
I94
sg23
VC0238463
p7178
sg10
I3
sg11
VPTC
p7179
sg13
I1
sa(dp7180
g7
I65
sg23
VC0238463
p7181
sg10
I27
sg11
Vpapillary thyroid carcinoma
p7182
sg13
I3
sasa(dp7183
g2
S'Posterior reversible encephalopathy syndrome (PRES) is a clinic-radiologic entity characterized with temporary vasogenic edema developing typically in posterior circulation of the brain and has been reported as a rare manifestation of IgAV.\n'
p7184
sg4
(lp7185
sg20
(lp7186
(dp7187
g7
I0
sg23
VC3160858
p7188
sg10
I44
sg11
VPosterior reversible encephalopathy syndrome
p7189
sg13
I4
sa(dp7190
g7
I121
sg23
VC0013604
p7191
sg10
I5
sg11
Vedema
p7192
sg13
I1
sa(dp7193
g7
I46
sg23
VC3160858
p7194
sg10
I4
sg11
VPRES
p7195
sg13
I1
sasa(dp7196
g2
S'Serum complement (C3, C4 and CH50), immunoglobulins (IgG, IgM and IgA) and C-reactive protein (CRP) were evaluated in 40 patients with anti-NMDAR encephalitis and 40 controls.\n'
p7197
sg4
(lp7198
(dp7199
g7
I75
sg8
VP02741
p7200
sg10
I18
sg11
VC-reactive protein
p7201
sg13
I2
sa(dp7202
g7
I66
sg8
VP11912
p7203
sg10
I3
sg11
VIgA
p7204
sg13
I1
sa(dp7205
g7
I58
sg8
VP29965
p7206
sg10
I3
sg11
VIgM
p7207
sg13
I1
sa(dp7208
g7
I36
sg8
g18
sg10
I15
sg11
Vimmunoglobulins
p7209
sg13
I1
sa(dp7210
g7
I0
sg8
g18
sg10
I16
sg11
VSerum complement
p7211
sg13
I2
sa(dp7212
g7
I95
sg8
VP02741
p7213
sg10
I3
sg11
VCRP
p7214
sg13
I1
sasg20
(lp7215
(dp7216
g7
I135
sg23
VC2986717
p7217
sg10
I23
sg11
Vanti-NMDAR encephalitis
p7218
sg13
I2
sasa(dp7219
g2
S'ACE-III was administered to 70 patients with Alzheimer disease, 31 patients with behavioural variant frontotemporal dementia, and a control group of 139 healthy volunteers.\n'
p7220
sg4
(lp7221
(dp7222
g7
I0
sg8
VP12821
p7223
sg10
I7
sg11
VACE-III
p7224
sg13
I1
sasg20
(lp7225
(dp7226
g7
I101
sg23
VC0338451
p7227
sg10
I23
sg11
Vfrontotemporal dementia
p7228
sg13
I2
sa(dp7229
g7
I45
sg23
VC0002395
p7230
sg10
I17
sg11
VAlzheimer disease
p7231
sg13
I2
sasa(dp7232
g2
S'While higher out-of-pocket costs were incurred at hospital visits, more people with ACE visited hospitals than clinics for epilepsy care.\n'
p7233
sg4
(lp7234
(dp7235
g7
I84
sg8
VP12821
p7236
sg10
I3
sg11
VACE
p7237
sg13
I1
sasg20
(lp7238
(dp7239
g7
I123
sg23
VC0014544
p7240
sg10
I8
sg11
Vepilepsy
p7241
sg13
I1
sasa(dp7242
g2
S'Additionally, patients with migraine had greater incidence of homozygous mutations for procoagulant genes (MTHFR (C677T), PAI-1 and ACE I/D) than expected.\n'
p7243
sg4
(lp7244
(dp7245
g7
I132
sg8
VP12821
p7246
sg10
I7
sg11
VACE I/D
p7247
sg13
I2
sa(dp7248
g7
I122
sg8
VP05121
p7249
sg10
I5
sg11
VPAI-1
p7250
sg13
I1
sa(dp7251
g7
I107
sg8
VP42898
p7252
sg10
I5
sg11
VMTHFR
p7253
sg13
I1
sasg20
(lp7254
(dp7255
g7
I28
sg23
VC0149931
p7256
sg10
I8
sg11
Vmigraine
p7257
sg13
I1
sasa(dp7258
g2
S'We did this study to see whether an association exists between ACE gene I/D polymorphism and migraine in our region.\n'
p7259
sg4
(lp7260
(dp7261
g7
I63
sg8
VP12821
p7262
sg10
I12
sg11
VACE gene I/D
p7263
sg13
I3
sasg20
(lp7264
(dp7265
g7
I93
sg23
VC0149931
p7266
sg10
I8
sg11
Vmigraine
p7267
sg13
I1
sasa(dp7268
g2
S'We were not able to find a statistically significant association between ACE gene I/D polymorphism with migraine.\n'
p7269
sg4
(lp7270
(dp7271
g7
I73
sg8
VP12821
p7272
sg10
I12
sg11
VACE gene I/D
p7273
sg13
I3
sasg20
(lp7274
(dp7275
g7
I104
sg23
VC0149931
p7276
sg10
I8
sg11
Vmigraine
p7277
sg13
I1
sasa(dp7278
g2
S'The expression of angiopietin-like protein 2 (Angptl2) markedly increased in the neovascularized corneas compared to the normal cornea, and Angtpl2 was(a potent inducer of inflammatory corneal neovascularization.\n'
p7279
sg4
(lp7280
(dp7281
g7
I18
sg8
g18
sg10
I26
sg11
Vangiopietin-like protein 2
p7282
sg13
I3
sa(dp7283
g7
I46
sg8
g18
sg10
I7
sg11
VAngptl2
p7284
sg13
I1
sasg20
(lp7285
(dp7286
g7
I81
sg23
VC0027686
p7287
sg10
I15
sg11
Vneovascularized
p7288
sg13
I1
sa(dp7289
g7
I185
sg23
VC0085109
p7290
sg10
I26
sg11
Vcorneal neovascularization
p7291
sg13
I2
sasa(dp7292
g2
S'Angptl2 mRNA expression and corneal neovascularization were inhibited in a mouse alkari injury model by topical application of this agent.\n'
p7293
sg4
(lp7294
(dp7295
g7
I0
sg8
g18
sg10
I12
sg11
VAngptl2 mRNA
p7296
sg13
I2
sasg20
(lp7297
(dp7298
g7
I28
sg23
VC0085109
p7299
sg10
I26
sg11
Vcorneal neovascularization
p7300
sg13
I2
sasa(dp7301
g2
S'The aim of our study was to investigate the target relationship between miR-143 and mitogen-activated protein kinase 1 (MAPK1) and explore the effect of miR-143 on the endometrial cancers (EC) cells through targeting MAPK1.\n'
p7302
sg4
(lp7303
(dp7304
g7
I120
sg8
VP28482
p7305
sg10
I5
sg11
VMAPK1
p7306
sg13
I1
sa(dp7307
g7
I72
sg8
g18
sg10
I7
sg11
VmiR-143
p7308
sg13
I1
sa(dp7309
g7
I84
sg8
VP28482
p7310
sg10
I34
sg11
Vmitogen-activated protein kinase 1
p7311
sg13
I4
sa(dp7312
g7
I72
sg8
g18
sg10
I7
sg11
VmiR-143
p7313
sg13
I1
sa(dp7314
g7
I120
sg8
VP28482
p7315
sg10
I5
sg11
VMAPK1
p7316
sg13
I1
sasg20
(lp7317
(dp7318
g7
I168
sg23
VC0476089
p7319
sg10
I19
sg11
Vendometrial cancers
p7320
sg13
I2
sa(dp7321
g7
I189
sg23
VC0476089
p7322
sg10
I2
sg11
VEC
p7323
sg13
I1
sasa(dp7324
g2
S'We have identified a subset of miRNAs (miR-142-3p, miR-143-3p, miR-145-5p, miR-150-5p, miR-223-3p, miR-451a, miR-486-5p, miR-605-5p) that are enriched in lung adenocarcinoma extracellular vesicles compared to the donor cells from which they were derived.\n'
p7325
sg4
(lp7326
(dp7327
g7
I63
sg8
g18
sg10
I10
sg11
VmiR-145-5p
p7328
sg13
I1
sa(dp7329
g7
I121
sg8
g18
sg10
I10
sg11
VmiR-605-5p
p7330
sg13
I1
sa(dp7331
g7
I109
sg8
g18
sg10
I10
sg11
VmiR-486-5p
p7332
sg13
I1
sa(dp7333
g7
I75
sg8
g18
sg10
I10
sg11
VmiR-150-5p
p7334
sg13
I1
sa(dp7335
g7
I51
sg8
g18
sg10
I10
sg11
VmiR-143-3p
p7336
sg13
I1
sa(dp7337
g7
I87
sg8
g18
sg10
I10
sg11
VmiR-223-3p
p7338
sg13
I1
sa(dp7339
g7
I99
sg8
g18
sg10
I8
sg11
VmiR-451a
p7340
sg13
I1
sa(dp7341
g7
I39
sg8
g18
sg10
I10
sg11
VmiR-142-3p
p7342
sg13
I1
sasg20
(lp7343
(dp7344
g7
I154
sg23
VC0152013
p7345
sg10
I19
sg11
Vlung adenocarcinoma
p7346
sg13
I2
sa(dp7347
g7
I188
sg23
VC0333262
p7348
sg10
I8
sg11
Vvesicles
p7349
sg13
I1
sasa(dp7350
g2
S'Two well-known tumor suppressors, miR-143-3p and miR-145-5p, were also enriched in serum samples collected during surgery from blood vessels draining directly from lung adenocarcinoma tumor beds.\n'
p7351
sg4
(lp7352
(dp7353
g7
I49
sg8
g18
sg10
I10
sg11
VmiR-145-5p
p7354
sg13
I1
sa(dp7355
g7
I34
sg8
g18
sg10
I10
sg11
VmiR-143-3p
p7356
sg13
I1
sasg20
(lp7357
(dp7358
g7
I164
sg23
VC0152013
p7359
sg10
I19
sg11
Vlung adenocarcinoma
p7360
sg13
I2
sa(dp7361
g7
I15
sg23
VC0027651
p7362
sg10
I5
sg11
Vtumor
p7363
sg13
I1
sa(dp7364
g7
I15
sg23
VC0027651
p7365
sg10
I5
sg11
Vtumor
p7366
sg13
I1
sasa(dp7367
g2
S'We show that the transfer of miR-143-3p and miR-145-5p within extracellular vesicles from lung adenocarcinoma cells to endothelial cells reduces the levels of CAMK1D and increases tube formation by endothelial cells.\n'
p7368
sg4
(lp7369
(dp7370
g7
I29
sg8
g18
sg10
I10
sg11
VmiR-143-3p
p7371
sg13
I1
sa(dp7372
g7
I44
sg8
g18
sg10
I10
sg11
VmiR-145-5p
p7373
sg13
I1
sa(dp7374
g7
I159
sg8
g18
sg10
I6
sg11
VCAMK1D
p7375
sg13
I1
sasg20
(lp7376
(dp7377
g7
I90
sg23
VC0152013
p7378
sg10
I19
sg11
Vlung adenocarcinoma
p7379
sg13
I2
sa(dp7380
g7
I76
sg23
VC0333262
p7381
sg10
I8
sg11
Vvesicles
p7382
sg13
I1
sasa(dp7383
g2
S'UCA1 negatively regulated miR-143 expression in a dose-dependent manner in bladder cancer cells.\n'
p7384
sg4
(lp7385
(dp7386
g7
I26
sg8
g18
sg10
I7
sg11
VmiR-143
p7387
sg13
I1
sasg20
(lp7388
(dp7389
g7
I75
sg23
VC0699885
p7390
sg10
I14
sg11
Vbladder cancer
p7391
sg13
I2
sasa(dp7392
g2
S'In addition, UCA1 and HMGB1 were upregulated and miR-143 was downregulated in bladder cancer specimens.\n'
p7393
sg4
(lp7394
(dp7395
g7
I49
sg8
g18
sg10
I7
sg11
VmiR-143
p7396
sg13
I1
sa(dp7397
g7
I22
sg8
VP09429
p7398
sg10
I5
sg11
VHMGB1
p7399
sg13
I1
sasg20
(lp7400
(dp7401
g7
I78
sg23
VC0699885
p7402
sg10
I14
sg11
Vbladder cancer
p7403
sg13
I2
sasa(dp7404
g2
S'Overall, the data suggested that UCA1 may promote the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway, which exhibits an important regulatory role in the pathology of bladder cancer.\n'
p7405
sg4
(lp7406
(dp7407
g7
I121
sg8
VP09429
p7408
sg10
I5
sg11
VHMGB1
p7409
sg13
I1
sa(dp7410
g7
I113
sg8
g18
sg10
I7
sg11
VmiR-143
p7411
sg13
I1
sasg20
(lp7412
(dp7413
g7
I74
sg23
VC0699885
p7414
sg10
I14
sg11
Vbladder cancer
p7415
sg13
I2
sa(dp7416
g7
I187
sg23
VC0677042
p7417
sg10
I9
sg11
Vpathology
p7418
sg13
I1
sa(dp7419
g7
I74
sg23
VC0699885
p7420
sg10
I14
sg11
Vbladder cancer
p7421
sg13
I2
sa(dp7422
g7
I54
sg23
VC2699153
p7423
sg10
I8
sg11
Vinvasion
p7424
sg13
I1
sasa(dp7425
g2
S'The circulating serum miR-143 level may be a novel, non-invasive predictive marker of a response to nCRT in locally advanced rectal cancer patients.\n'
p7426
sg4
(lp7427
(dp7428
g7
I16
sg8
g18
sg10
I13
sg11
Vserum miR-143
p7429
sg13
I2
sasg20
(lp7430
(dp7431
g7
I125
sg23
VC0007113
p7432
sg10
I13
sg11
Vrectal cancer
p7433
sg13
I2
sasa(dp7434
g2
S'Here, we investigate the functional properties and expression of the miR-143/145 cluster in breast cancer (BC) in vitro and in vivo.\n'
p7435
sg4
(lp7436
(dp7437
g7
I69
sg8
g18
sg10
I19
sg11
VmiR-143/145 cluster
p7438
sg13
I2
sasg20
(lp7439
(dp7440
g7
I107
sg23
VC0678222
p7441
sg10
I2
sg11
VBC
p7442
sg13
I1
sa(dp7443
g7
I92
sg23
VC0678222
p7444
sg10
I13
sg11
Vbreast cancer
p7445
sg13
I2
sasa(dp7446
g2
S'In this randomized controlled trial after 2 weeks of a run-in period on an isocaloric diet, 42 premenopausal women with central obesity were randomly assigned into two groups: (1) Hypocaloric diet enriched in legumes (HDEL) and (2) hypocaloric diet without legumes (HDWL) for 6 weeks.\n'
p7447
sg4
(lp7448
sg20
(lp7449
(dp7450
g7
I120
sg23
VC0311277
p7451
sg10
I15
sg11
Vcentral obesity
p7452
sg13
I2
sasa(dp7453
g2
S'We aimed to discover if L-arginine and selenium alone or together can increase the effect of a hypocaloric diet enriched in legumes (HDEL) on central obesity and cardiovascular risk factors in women with central obesity.\n'
p7454
sg4
(lp7455
sg20
(lp7456
(dp7457
g7
I142
sg23
VC0311277
p7458
sg10
I15
sg11
Vcentral obesity
p7459
sg13
I2
sa(dp7460
g7
I142
sg23
VC0311277
p7461
sg10
I15
sg11
Vcentral obesity
p7462
sg13
I2
sasa(dp7463
g2
S'These data indicate the beneficial effects of L-arginine on central obesity, selenium on insulin resistance and HDEL on serum concentrations of NO(x) and TG.\n'
p7464
sg4
(lp7465
(dp7466
g7
I89
sg8
VP01308
p7467
sg10
I7
sg11
Vinsulin
p7468
sg13
I1
sasg20
(lp7469
(dp7470
g7
I89
sg23
VC0021655
p7471
sg10
I18
sg11
Vinsulin resistance
p7472
sg13
I2
sa(dp7473
g7
I60
sg23
VC0311277
p7474
sg10
I15
sg11
Vcentral obesity
p7475
sg13
I2
sasa(dp7476
g2
S'The study indicates that HDEL + Arg + selenium reduce suprailiac skinfold thicknesses which represents the abdominal obesity reduction.\n'
p7477
sg4
(lp7478
(dp7479
g7
I25
sg8
VP24390
p7480
sg10
I21
sg11
VHDEL + Arg + selenium
p7481
sg13
I5
sasg20
(lp7482
(dp7483
g7
I107
sg23
VC0311277
p7484
sg10
I17
sg11
Vabdominal obesity
p7485
sg13
I2
sasa(dp7486
g2
S'We have previously demonstrated that multiple sclerosis (MS) patients have abnormal cerebrospinal fluid (CSF) levels of the key myelin-related molecules cobalamin (Cbl), epidermal growth factor (EGF), and normal cellular prions (PrP(C)s), thus confirming that some CSF abnormalities may be co-responsible for remyelination failure.\n'
p7487
sg4
(lp7488
(dp7489
g7
I128
sg8
VP22681
p7490
sg10
I34
sg11
Vmyelin-related molecules cobalamin
p7491
sg13
I3
sa(dp7492
g7
I164
sg8
VP22681
p7493
sg10
I3
sg11
VCbl
p7494
sg13
I1
sa(dp7495
g7
I195
sg8
VP01133
p7496
sg10
I3
sg11
VEGF
p7497
sg13
I1
sa(dp7498
g7
I170
sg8
VP01133
p7499
sg10
I23
sg11
Vepidermal growth factor
p7500
sg13
I3
sasg20
(lp7501
(dp7502
g7
I37
sg23
VC0026769
p7503
sg10
I18
sg11
Vmultiple sclerosis
p7504
sg13
I2
sa(dp7505
g7
I57
sg23
VC0026769
p7506
sg10
I2
sg11
VMS
p7507
sg13
I1
sasa(dp7508
g2
S'We also searched for ERBB2 transmembrane mutations in various types of cancers in PubMed, The Cancer Genome Atlas (TCGA), and the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) database.\n'
p7509
sg4
(lp7510
(dp7511
g7
I21
sg8
VP04626
p7512
sg10
I5
sg11
VERBB2
p7513
sg13
I1
sasg20
(lp7514
(dp7515
g7
I94
sg23
VC0006826
p7516
sg10
I6
sg11
VCancer
p7517
sg13
I1
sa(dp7518
g7
I94
sg23
VC0006826
p7519
sg10
I6
sg11
VCancer
p7520
sg13
I1
sa(dp7521
g7
I71
sg23
VC0006826
p7522
sg10
I7
sg11
Vcancers
p7523
sg13
I1
sasa(dp7524
g2
S'In addition, MSK-IMPACT allowed identification of three additional urothelial carcinomas with G660D mutations and two lung adenocarcinomas with V659E mutations.\n'
p7525
sg4
(lp7526
sg20
(lp7527
(dp7528
g7
I78
sg23
VC0007097
p7529
sg10
I10
sg11
Vcarcinomas
p7530
sg13
I1
sa(dp7531
g7
I123
sg23
VC0001418
p7532
sg10
I15
sg11
Vadenocarcinomas
p7533
sg13
I1
sasa(dp7534
g2
S"A greater proportion of MSK radiologists with &gt;5 years' experience provided responses that were discordant with the ISSVA classification compared with less experienced radiologists (0-5 years) in diagnosing hemangiomas in adult patients (P = 0.02), and using the presence of phleboliths to diagnose hemangiomas (P = 0.004).\n"
p7535
sg4
(lp7536
(dp7537
g7
I24
sg8
VP57059
p7538
sg10
I3
sg11
VMSK
p7539
sg13
I1
sasg20
(lp7540
(dp7541
g7
I210
sg23
VC0018916
p7542
sg10
I11
sg11
Vhemangiomas
p7543
sg13
I1
sa(dp7544
g7
I210
sg23
VC0018916
p7545
sg10
I11
sg11
Vhemangiomas
p7546
sg13
I1
sa(dp7547
g7
I278
sg23
VC0031547
p7548
sg10
I11
sg11
Vphleboliths
p7549
sg13
I1
sasa(dp7550
g2
S'Large genomic datasets of NSCLC [MSK-IMPACT(TM) dataset at MSKCC (n=2004), TCGA combined lung cancer dataset (n=1144)] were analyzed to define concurrent mutations and clinical features of RASA1-mutated NSCLCs.\n'
p7551
sg4
(lp7552
(dp7553
g7
I189
sg8
VP20936
p7554
sg10
I5
sg11
VRASA1
p7555
sg13
I1
sasg20
(lp7556
(dp7557
g7
I89
sg23
VC0684249
p7558
sg10
I11
sg11
Vlung cancer
p7559
sg13
I2
sa(dp7560
g7
I26
sg23
VC0007131
p7561
sg10
I5
sg11
VNSCLC
p7562
sg13
I1
sasa(dp7563
g2
S'Here in one rare case of undifferentiated cardiac intimal sarcoma (IS), a next-generation sequencing based assay, MSK-IMPACT (Memorial Sloan Kettering - Integrated Mutation Profiling of Actionable Cancer Targets), identified a somatic, activating mutation in PDGFRB, along with amplification of PDGFRA.\n'
p7564
sg4
(lp7565
(dp7566
g7
I259
sg8
VP09619
p7567
sg10
I6
sg11
VPDGFRB
p7568
sg13
I1
sa(dp7569
g7
I295
sg8
VP16234
p7570
sg10
I6
sg11
VPDGFRA
p7571
sg13
I1
sasg20
(lp7572
(dp7573
g7
I278
sg23
VC1705759
p7574
sg10
I13
sg11
Vamplification
p7575
sg13
I1
sa(dp7576
g7
I67
sg23
VC1708550
p7577
sg10
I2
sg11
VIS
p7578
sg13
I1
sa(dp7579
g7
I50
sg23
VC1708550
p7580
sg10
I15
sg11
Vintimal sarcoma
p7581
sg13
I2
sa(dp7582
g7
I197
sg23
VC0006826
p7583
sg10
I6
sg11
VCancer
p7584
sg13
I1
sasa(dp7585
g2
S'DNA samples extracted from each tumor and matched normal tissue were subjected to targeted massively parallel sequencing using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay.\n'
p7586
sg4
(lp7587
sg20
(lp7588
(dp7589
g7
I200
sg23
VC0006826
p7590
sg10
I6
sg11
VCancer
p7591
sg13
I1
sa(dp7592
g7
I32
sg23
VC0027651
p7593
sg10
I5
sg11
Vtumor
p7594
sg13
I1
sasa(dp7595
g2
S'We analyzed production of ovalbumin (OVA)-specific IgE and nose-scratching symptoms in Lckd-Phf11-Tg mice using an OVA-induced allergic rhinitis model.\n'
p7596
sg4
(lp7597
(dp7598
g7
I92
sg8
g18
sg10
I5
sg11
VPhf11
p7599
sg13
I1
sa(dp7600
g7
I51
sg8
VP01854
p7601
sg10
I3
sg11
VIgE
p7602
sg13
I1
sasg20
(lp7603
(dp7604
g7
I127
sg23
VC2607914
p7605
sg10
I17
sg11
Vallergic rhinitis
p7606
sg13
I2
sa(dp7607
g7
I51
sg23
VC0270850
p7608
sg10
I3
sg11
VIgE
p7609
sg13
I1
sasa(dp7610
g2
S'In an allergic rhinitis model, Lckd-Phf11-Tg mice showed a significant increase in the production of OVA-specific IgE and the frequency of nose scratching.\n'
p7611
sg4
(lp7612
(dp7613
g7
I101
sg8
VP01854
p7614
sg10
I16
sg11
VOVA-specific IgE
p7615
sg13
I2
sa(dp7616
g7
I36
sg8
g18
sg10
I5
sg11
VPhf11
p7617
sg13
I1
sasg20
(lp7618
(dp7619
g7
I114
sg23
VC0270850
p7620
sg10
I3
sg11
VIgE
p7621
sg13
I1
sa(dp7622
g7
I6
sg23
VC2607914
p7623
sg10
I17
sg11
Vallergic rhinitis
p7624
sg13
I2
sasa(dp7625
g2
S'We showed that ANXA10 mRNA was expressed in adult liver and hepatocellular carcinoma (HCC), but not in multiple adult and fetal tissues, cholangiocarcinoma, and several other common carcinomas.\n'
p7626
sg4
(lp7627
(dp7628
g7
I15
sg8
g18
sg10
I11
sg11
VANXA10 mRNA
p7629
sg13
I2
sasg20
(lp7630
(dp7631
g7
I60
sg23
VC2239176
p7632
sg10
I24
sg11
Vhepatocellular carcinoma
p7633
sg13
I2
sa(dp7634
g7
I86
sg23
VC2239176
p7635
sg10
I3
sg11
VHCC
p7636
sg13
I1
sa(dp7637
g7
I137
sg23
VC0206698
p7638
sg10
I18
sg11
Vcholangiocarcinoma
p7639
sg13
I1
sa(dp7640
g7
I182
sg23
VC0007097
p7641
sg10
I10
sg11
Vcarcinomas
p7642
sg13
I1
sasa(dp7643
g2
S"These results suggest that S1P5 agonism is an innovative approach with potential benefit in neurodegenerative disorders involving lipid imbalance and/or compromised blood-brain barrier such as Alzheimer's disease or multiple sclerosis.\n"
p7644
sg4
(lp7645
(dp7646
g7
I27
sg8
g18
sg10
I4
sg11
VS1P5
p7647
sg13
I1
sasg20
(lp7648
(dp7649
g7
I136
sg23
VC1397014
p7650
sg10
I9
sg11
Vimbalance
p7651
sg13
I1
sa(dp7652
g7
I216
sg23
VC0026769
p7653
sg10
I18
sg11
Vmultiple sclerosis
p7654
sg13
I2
sa(dp7655
g7
I92
sg23
VC0524851
p7656
sg10
I27
sg11
Vneurodegenerative disorders
p7657
sg13
I2
sa(dp7658
g7
I193
sg23
VC1521724
p7659
sg10
I19
sg11
VAlzheimer's disease
p7660
sg13
I2
sasa(dp7661
g2
S'Exposure of A549 human lung carcinoma, ZR-75, MDA-MB-231 and MCF-7 human breast cancer and B16-F10 mouse melanoma cells to hypoxia increased Rab5 activation, followed by its re-localization to the leading edge and association with focal adhesions.\n'
p7662
sg4
(lp7663
(dp7664
g7
I141
sg8
VP51148
p7665
sg10
I4
sg11
VRab5
p7666
sg13
I1
sasg20
(lp7667
(dp7668
g7
I237
sg23
VC0001511
p7669
sg10
I9
sg11
Vadhesions
p7670
sg13
I1
sa(dp7671
g7
I99
sg23
VC1522102
p7672
sg10
I14
sg11
Vmouse melanoma
p7673
sg13
I2
sa(dp7674
g7
I23
sg23
VC0684249
p7675
sg10
I14
sg11
Vlung carcinoma
p7676
sg13
I2
sa(dp7677
g7
I123
sg23
VC0242184
p7678
sg10
I7
sg11
Vhypoxia
p7679
sg13
I1
sa(dp7680
g7
I73
sg23
VC0678222
p7681
sg10
I13
sg11
Vbreast cancer
p7682
sg13
I2
sasa(dp7683
g2
S'Immunohistochemistry of Rab5a was performed in human specimens of bone metastasis and pair-matched breast carcinoma; the autophagic-molecular mechanisms affected by Rab5a were evaluated in human 1833 bone metastatic cells, derived from breast-carcinoma MDA-MB231 cells.\n'
p7684
sg4
(lp7685
(dp7686
g7
I24
sg8
VP20339
p7687
sg10
I5
sg11
VRab5a
p7688
sg13
I1
sa(dp7689
g7
I24
sg8
VP20339
p7690
sg10
I5
sg11
VRab5a
p7691
sg13
I1
sasg20
(lp7692
(dp7693
g7
I106
sg23
VC0007097
p7694
sg10
I9
sg11
Vcarcinoma
p7695
sg13
I1
sa(dp7696
g7
I66
sg23
VC0153690
p7697
sg10
I15
sg11
Vbone metastasis
p7698
sg13
I2
sa(dp7699
g7
I99
sg23
VC0678222
p7700
sg10
I16
sg11
Vbreast carcinoma
p7701
sg13
I2
sasa(dp7702
g2
S'Immunohistochemistry verified RAB5A was upregulated in breast cancer tissues.\n'
p7703
sg4
(lp7704
(dp7705
g7
I30
sg8
VP20339
p7706
sg10
I5
sg11
VRAB5A
p7707
sg13
I1
sasg20
(lp7708
(dp7709
g7
I55
sg23
VC0678222
p7710
sg10
I13
sg11
Vbreast cancer
p7711
sg13
I2
sasa(dp7712
g2
S'Therefore, the data reported here demonstrate that miR-130a is an important tumor suppressor in breast cancer, and imply that miR-130a/RAB5A axis have potential as therapeutic targets for breast cancer.\n'
p7713
sg4
(lp7714
(dp7715
g7
I51
sg8
g18
sg10
I8
sg11
VmiR-130a
p7716
sg13
I1
sa(dp7717
g7
I51
sg8
g18
sg10
I8
sg11
VmiR-130a
p7718
sg13
I1
sa(dp7719
g7
I135
sg8
VP20339
p7720
sg10
I5
sg11
VRAB5A
p7721
sg13
I1
sasg20
(lp7722
(dp7723
g7
I96
sg23
VC0678222
p7724
sg10
I13
sg11
Vbreast cancer
p7725
sg13
I2
sa(dp7726
g7
I76
sg23
VC0027651
p7727
sg10
I5
sg11
Vtumor
p7728
sg13
I1
sa(dp7729
g7
I96
sg23
VC0678222
p7730
sg10
I13
sg11
Vbreast cancer
p7731
sg13
I2
sasa(dp7732
g2
S'We report that overexpression of the GTPase RAB5A, a master regulator of endocytosis, is predictive of aggressive behavior and metastatic ability in human breast cancers.\n'
p7733
sg4
(lp7734
(dp7735
g7
I37
sg8
VP84095
p7736
sg10
I12
sg11
VGTPase RAB5A
p7737
sg13
I2
sasg20
(lp7738
(dp7739
g7
I155
sg23
VC0006142
p7740
sg10
I14
sg11
Vbreast cancers
p7741
sg13
I2
sa(dp7742
g7
I103
sg23
VC0001807
p7743
sg10
I19
sg11
Vaggressive behavior
p7744
sg13
I2
sasa(dp7745
g2
S'To investigate the expression of Rab5a and APPL1 in breast cancer and fibroma, and analyze their correlation with HER-2 expression, metastasis and development of breast cancer.\n'
p7746
sg4
(lp7747
(dp7748
g7
I33
sg8
VP20339
p7749
sg10
I5
sg11
VRab5a
p7750
sg13
I1
sa(dp7751
g7
I43
sg8
g18
sg10
I5
sg11
VAPPL1
p7752
sg13
I1
sasg20
(lp7753
(dp7754
g7
I52
sg23
VC0678222
p7755
sg10
I13
sg11
Vbreast cancer
p7756
sg13
I2
sa(dp7757
g7
I52
sg23
VC0678222
p7758
sg10
I13
sg11
Vbreast cancer
p7759
sg13
I2
sa(dp7760
g7
I132
sg23
VC0027627
p7761
sg10
I10
sg11
Vmetastasis
p7762
sg13
I1
sa(dp7763
g7
I70
sg23
VC0016045
p7764
sg10
I7
sg11
Vfibroma
p7765
sg13
I1
sasa(dp7766
g2
S'Rab5a and APPL1 in paraffin embedded tissues of 74 breast carcinomas and 40 breast fibromas were detected by immunohistochemistry.\n'
p7767
sg4
(lp7768
(dp7769
g7
I0
sg8
VP20339
p7770
sg10
I5
sg11
VRab5a
p7771
sg13
I1
sa(dp7772
g7
I10
sg8
g18
sg10
I5
sg11
VAPPL1
p7773
sg13
I1
sasg20
(lp7774
(dp7775
g7
I83
sg23
VC0016045
p7776
sg10
I8
sg11
Vfibromas
p7777
sg13
I1
sa(dp7778
g7
I51
sg23
VC0678222
p7779
sg10
I17
sg11
Vbreast carcinomas
p7780
sg13
I2
sasa(dp7781
g2
S'There was no expression or low expression of Rab5a and APPL1 in the breast fibroma, but the positive expression rate of Rab5a and APPL1 in the breast carcinomas were 91.9% and 83.8%, respectively.\n'
p7782
sg4
(lp7783
(dp7784
g7
I55
sg8
g18
sg10
I5
sg11
VAPPL1
p7785
sg13
I1
sa(dp7786
g7
I55
sg8
g18
sg10
I5
sg11
VAPPL1
p7787
sg13
I1
sa(dp7788
g7
I45
sg8
VP20339
p7789
sg10
I5
sg11
VRab5a
p7790
sg13
I1
sa(dp7791
g7
I45
sg8
VP20339
p7792
sg10
I5
sg11
VRab5a
p7793
sg13
I1
sasg20
(lp7794
(dp7795
g7
I68
sg23
VC1328386
p7796
sg10
I14
sg11
Vbreast fibroma
p7797
sg13
I2
sa(dp7798
g7
I143
sg23
VC0678222
p7799
sg10
I17
sg11
Vbreast carcinomas
p7800
sg13
I2
sasa(dp7801
g2
S'Rab5a and APPL1 are overexpressed in breast cancer, and are positively correlated with the HER-2 expression.\n'
p7802
sg4
(lp7803
(dp7804
g7
I0
sg8
VP20339
p7805
sg10
I5
sg11
VRab5a
p7806
sg13
I1
sa(dp7807
g7
I10
sg8
g18
sg10
I5
sg11
VAPPL1
p7808
sg13
I1
sa(dp7809
g7
I91
sg8
VP04626
p7810
sg10
I5
sg11
VHER-2
p7811
sg13
I1
sasg20
(lp7812
(dp7813
g7
I37
sg23
VC0678222
p7814
sg10
I13
sg11
Vbreast cancer
p7815
sg13
I2
sasa(dp7816
g2
S'A recent study suggested that SLC35F3 which encoded a thiamine transporter was a new candidate gene for hypertension.\n'
p7817
sg4
(lp7818
(dp7819
g7
I30
sg8
g18
sg10
I7
sg11
VSLC35F3
p7820
sg13
I1
sasg20
(lp7821
(dp7822
g7
I104
sg23
VC0020538
p7823
sg10
I12
sg11
Vhypertension
p7824
sg13
I1
sasa(dp7825
g2
S'The goal of this study was to investigate the association between the single-nucleotide polymorphisms (SNPs) in the SLC35F3 gene and hypertension in a Chinese population.\n'
p7826
sg4
(lp7827
(dp7828
g7
I116
sg8
g18
sg10
I12
sg11
VSLC35F3 gene
p7829
sg13
I2
sasg20
(lp7830
(dp7831
g7
I133
sg23
VC0020538
p7832
sg10
I12
sg11
Vhypertension
p7833
sg13
I1
sasa(dp7834
g2
S'We found eight genetic variants in the coding regions of SLC35F3 and subsequently genotyped a non-synonymous variant rs34032258 (C &gt; G) in 1060 hypertension patients and 1467 controls.\n'
p7835
sg4
(lp7836
(dp7837
g7
I57
sg8
g18
sg10
I7
sg11
VSLC35F3
p7838
sg13
I1
sasg20
(lp7839
(dp7840
g7
I147
sg23
VC0020538
p7841
sg10
I12
sg11
Vhypertension
p7842
sg13
I1
sasa(dp7843
g2
S'In conclusion, we found that the rs34032258 in the SLC35F3 gene was associated with high blood pressure and may increase the risk of hypertension.\n'
p7844
sg4
(lp7845
(dp7846
g7
I51
sg8
g18
sg10
I12
sg11
VSLC35F3 gene
p7847
sg13
I2
sasg20
(lp7848
(dp7849
g7
I84
sg23
VC0020538
p7850
sg10
I19
sg11
Vhigh blood pressure
p7851
sg13
I3
sa(dp7852
g7
I133
sg23
VC0020538
p7853
sg10
I12
sg11
Vhypertension
p7854
sg13
I1
sasa(dp7855
g2
S'After chip hybridization and calculation of relative allele scores, the peak associations were typed in individual samples, revealing an association between hypertension, systolic BP, and diastolic BP and the previously uncharacterized solute carrier SLC35F3.\n'
p7856
sg4
(lp7857
(dp7858
g7
I236
sg8
g18
sg10
I22
sg11
Vsolute carrier SLC35F3
p7859
sg13
I3
sasg20
(lp7860
(dp7861
g7
I157
sg23
VC0020538
p7862
sg10
I12
sg11
Vhypertension
p7863
sg13
I1
sasa(dp7864
g2
S'In twin pairs, the SLC35F3 risk allele predicted heritable cardiovascular traits previously associated with thiamine deficiency, including elevated cardiac stroke volume with decreased vascular resistance, and elevated pressor responses to environmental (cold) stress.\n'
p7865
sg4
(lp7866
sg20
(lp7867
(dp7868
g7
I108
sg23
VC0039841
p7869
sg10
I19
sg11
Vthiamine deficiency
p7870
sg13
I2
sa(dp7871
g7
I255
sg23
VC0024117
p7872
sg10
I4
sg11
Vcold
p7873
sg13
I1
sa(dp7874
g7
I156
sg23
VC0038454
p7875
sg10
I6
sg11
Vstroke
p7876
sg13
I1
sasa(dp7877
g2
S'Allelic expression imbalance confirmed that cis variation at the human SLC35F3 locus influenced expression of that gene, and the allelic expression imbalance peak coincided with the hypertension peak.\n'
p7878
sg4
(lp7879
(dp7880
g7
I65
sg8
g18
sg10
I19
sg11
Vhuman SLC35F3 locus
p7881
sg13
I3
sasg20
(lp7882
(dp7883
g7
I19
sg23
VC1397014
p7884
sg10
I9
sg11
Vimbalance
p7885
sg13
I1
sa(dp7886
g7
I44
sg23
VC0007099
p7887
sg10
I3
sg11
Vcis
p7888
sg13
I1
sa(dp7889
g7
I19
sg23
VC1397014
p7890
sg10
I9
sg11
Vimbalance
p7891
sg13
I1
sa(dp7892
g7
I182
sg23
VC0020538
p7893
sg10
I12
sg11
Vhypertension
p7894
sg13
I1
sasa(dp7895
g2
S'LARG (leukemia-associated Rho guanine nucleotide exchange factor (GEF)), PDZ-RhoGEF, and p115RhoGEF augmented interaction between activated GAlfa13 and R7-RGS heterotrimers, indicating that these effector RhoGEFs can engage GAlfa13*R7-RGS complexes.\n'
p7896
sg4
(lp7897
(dp7898
g7
I77
sg8
g18
sg10
I6
sg11
VRhoGEF
p7899
sg13
I1
sa(dp7900
g7
I26
sg8
g18
sg10
I38
sg11
VRho guanine nucleotide exchange factor
p7901
sg13
I5
sa(dp7902
g7
I89
sg8
g18
sg10
I10
sg11
Vp115RhoGEF
p7903
sg13
I1
sa(dp7904
g7
I130
sg8
g18
sg10
I42
sg11
Vactivated GAlfa13 and R7-RGS heterotrimers
p7905
sg13
I5
sa(dp7906
g7
I66
sg8
VP10911
p7907
sg10
I3
sg11
VGEF
p7908
sg13
I1
sa(dp7909
g7
I224
sg8
g18
sg10
I24
sg11
VGAlfa13*R7-RGS complexes
p7910
sg13
I2
sasg20
(lp7911
(dp7912
g7
I155
sg23
VC0265341
p7913
sg10
I3
sg11
VRGS
p7914
sg13
I1
sa(dp7915
g7
I155
sg23
VC0265341
p7916
sg10
I3
sg11
VRGS
p7917
sg13
I1
sa(dp7918
g7
I6
sg23
VC0023418
p7919
sg10
I8
sg11
Vleukemia
p7920
sg13
I1
sasa(dp7921
g2
S'ARHGEF11 variants are reported to be associated with a higher risk for the onset of schizophrenia in a Japanese population; however, how ARHGEF11 contributes to the pathogenesis of schizophrenia in dendritic spines is unknown.\n'
p7922
sg4
(lp7923
(dp7924
g7
I0
sg8
g18
sg10
I8
sg11
VARHGEF11
p7925
sg13
I1
sa(dp7926
g7
I0
sg8
g18
sg10
I8
sg11
VARHGEF11
p7927
sg13
I1
sasg20
(lp7928
(dp7929
g7
I84
sg23
VC0036341
p7930
sg10
I13
sg11
Vschizophrenia
p7931
sg13
I1
sa(dp7932
g7
I165
sg23
VC0699748
p7933
sg10
I12
sg11
Vpathogenesis
p7934
sg13
I1
sa(dp7935
g7
I84
sg23
VC0036341
p7936
sg10
I13
sg11
Vschizophrenia
p7937
sg13
I1
sasa(dp7938
g2
S'The metastatic behavior exhibited by ovarian cancer cells overe-xpressing ETAR is now explained by the interplay with Beta-arrestin1 (Beta-arr1), a scaffold protein acting as signal-integrating module of RhoC and cofilin signaling for specific invadopodia formation, accomplished by its interaction with a Rho guanine nucleotide exchange factor (GEF), PDZ-RhoGEF, in a G-protein independent manner.\n'
p7939
sg4
(lp7940
(dp7941
g7
I356
sg8
g18
sg10
I6
sg11
VRhoGEF
p7942
sg13
I1
sa(dp7943
g7
I213
sg8
VP23528
p7944
sg10
I7
sg11
Vcofilin
p7945
sg13
I1
sa(dp7946
g7
I306
sg8
g18
sg10
I38
sg11
VRho guanine nucleotide exchange factor
p7947
sg13
I5
sa(dp7948
g7
I139
sg8
VP49407
p7949
sg10
I4
sg11
Varr1
p7950
sg13
I1
sa(dp7951
g7
I175
sg8
VP35555
p7952
sg10
I25
sg11
Vsignal-integrating module
p7953
sg13
I2
sa(dp7954
g7
I204
sg8
VP08134
p7955
sg10
I4
sg11
VRhoC
p7956
sg13
I1
sa(dp7957
g7
I74
sg8
VP25101
p7958
sg10
I4
sg11
VETAR
p7959
sg13
I1
sa(dp7960
g7
I346
sg8
VP10911
p7961
sg10
I3
sg11
VGEF
p7962
sg13
I1
sasg20
(lp7963
(dp7964
g7
I37
sg23
VC1140680
p7965
sg10
I14
sg11
Vovarian cancer
p7966
sg13
I2
sasa(dp7967
g2
S'PDZ-RhoGEF-deficient mice were protected from diet-induced obesity and T2D.\n'
p7968
sg4
(lp7969
(dp7970
g7
I4
sg8
g18
sg10
I6
sg11
VRhoGEF
p7971
sg13
I1
sasg20
(lp7972
(dp7973
g7
I71
sg23
VC0011860
p7974
sg10
I3
sg11
VT2D
p7975
sg13
I1
sa(dp7976
g7
I59
sg23
VC0028754
p7977
sg10
I7
sg11
Vobesity
p7978
sg13
I1
sasa(dp7979
g2
S'Our results demonstrate that PDZ-RhoGEF acts as a key determinant of mammalian metabolism and obesity-associated pathologies.\n'
p7980
sg4
(lp7981
(dp7982
g7
I33
sg8
g18
sg10
I6
sg11
VRhoGEF
p7983
sg13
I1
sasg20
(lp7984
(dp7985
g7
I94
sg23
VC0028754
p7986
sg10
I7
sg11
Vobesity
p7987
sg13
I1
sasa(dp7988
g2
S'Previously, genetic analyses identified that variants in Arhgef11 may influence kidney injury in the Dahl salt-sensitive (S) rat, a model of hypertensive chronic kidney disease.\n'
p7989
sg4
(lp7990
sg20
(lp7991
(dp7992
g7
I141
sg23
VC1719463
p7993
sg10
I35
sg11
Vhypertensive chronic kidney disease
p7994
sg13
I4
sasa(dp7995
g2
S'The aim of this study was to investigate the effect of the modified Nissen fundoplication after resection of adenocarcinoma from the esophagogastric junction (AEG) on controlling the reflux and the role of duodenogastroesophageal reflux (DGER) and cyclooxygenase-2 (COX-2) expression level in the remnant esophagus.\n'
p7996
sg4
(lp7997
(dp7998
g7
I248
sg8
VP35354
p7999
sg10
I16
sg11
Vcyclooxygenase-2
p8000
sg13
I1
sa(dp8001
g7
I266
sg8
VP35354
p8002
sg10
I5
sg11
VCOX-2
p8003
sg13
I1
sasg20
(lp8004
(dp8005
g7
I109
sg23
VC0001418
p8006
sg10
I14
sg11
Vadenocarcinoma
p8007
sg13
I1
sa(dp8008
g7
I183
sg23
VC0017168
p8009
sg10
I6
sg11
Vreflux
p8010
sg13
I1
sa(dp8011
g7
I183
sg23
VC0017168
p8012
sg10
I6
sg11
Vreflux
p8013
sg13
I1
sasa(dp8014
g2
S'COX-2 up-regulation as well as high prevalence of esophagitis were observed in simultaneous acid reflux and DGER (p &lt; 0.05).\n'
p8015
sg4
(lp8016
(dp8017
g7
I0
sg8
VP35354
p8018
sg10
I5
sg11
VCOX-2
p8019
sg13
I1
sasg20
(lp8020
(dp8021
g7
I50
sg23
VC0014868
p8022
sg10
I11
sg11
Vesophagitis
p8023
sg13
I1
sa(dp8024
g7
I92
sg23
VC0017168
p8025
sg10
I11
sg11
Vacid reflux
p8026
sg13
I2
sasa(dp8027
g2
S'These results stand for a close relationship between progression of initial steps of gastroesophageal reflux disease (GERD) and COX-2, proliferative activity and EGF/VEGF expression and could have implications in GERD treatment in order to prevent its neoplastic evolution.\n'
p8028
sg4
(lp8029
(dp8030
g7
I162
sg8
VP01133
p8031
sg10
I3
sg11
VEGF
p8032
sg13
I1
sa(dp8033
g7
I128
sg8
VP35354
p8034
sg10
I5
sg11
VCOX-2
p8035
sg13
I1
sasg20
(lp8036
(dp8037
g7
I85
sg23
VC0017168
p8038
sg10
I31
sg11
Vgastroesophageal reflux disease
p8039
sg13
I3
sa(dp8040
g7
I118
sg23
VC0017168
p8041
sg10
I4
sg11
VGERD
p8042
sg13
I1
sa(dp8043
g7
I135
sg23
VC0334094
p8044
sg10
I13
sg11
Vproliferative
p8045
sg13
I1
sa(dp8046
g7
I118
sg23
VC0017168
p8047
sg10
I4
sg11
VGERD
p8048
sg13
I1
sasa(dp8049
g2
S'We therefore evaluated whether EGFR, ASAP1, ERBB2 and ERBB4, which signal downstream after ligation of EGF, and which show aberrant expression in several other invasive cancers, would also predict HBL tumor invasiveness.\n'
p8050
sg4
(lp8051
(dp8052
g7
I37
sg8
g18
sg10
I5
sg11
VASAP1
p8053
sg13
I1
sa(dp8054
g7
I44
sg8
VP04626
p8055
sg10
I5
sg11
VERBB2
p8056
sg13
I1
sa(dp8057
g7
I197
sg8
VP09382
p8058
sg10
I3
sg11
VHBL
p8059
sg13
I1
sa(dp8060
g7
I54
sg8
g18
sg10
I5
sg11
VERBB4
p8061
sg13
I1
sa(dp8062
g7
I31
sg8
VP01133
p8063
sg10
I3
sg11
VEGF
p8064
sg13
I1
sasg20
(lp8065
(dp8066
g7
I201
sg23
VC0027651
p8067
sg10
I5
sg11
Vtumor
p8068
sg13
I1
sa(dp8069
g7
I169
sg23
VC0006826
p8070
sg10
I7
sg11
Vcancers
p8071
sg13
I1
sasa(dp8072
g2
S'Immunohistochemistry of HBL tumors (n = 60), which are histologically heterogeneous, shows that compared with well-differentiated fetal cells, less differentiated embryonal and undifferentiated small cells (SCU) progressively lose EGFR and ASAP1 expression.\n'
p8073
sg4
(lp8074
(dp8075
g7
I240
sg8
g18
sg10
I5
sg11
VASAP1
p8076
sg13
I1
sasg20
(lp8077
(dp8078
g7
I28
sg23
VC0027651
p8079
sg10
I6
sg11
Vtumors
p8080
sg13
I1
sasa(dp8081
g2
S'Loss of EGFR-ASAP1 signaling characterizes undifferentiated and invasive HBL.\n'
p8082
sg4
(lp8083
(dp8084
g7
I13
sg8
g18
sg10
I5
sg11
VASAP1
p8085
sg13
I1
sasg20
(lp8086
sa(dp8087
g2
S'In colorectal cancers, a splicing variant of FIR that lacks exon2 (FIRDeltaexon2) is overexpressed as a dominant negative form of FIR.\n'
p8088
sg4
(lp8089
sg20
(lp8090
(dp8091
g7
I3
sg23
VC1527249
p8092
sg10
I18
sg11
Vcolorectal cancers
p8093
sg13
I2
sa(dp8094
g7
I104
sg23
VC1512032
p8095
sg10
I17
sg11
Vdominant negative
p8096
sg13
I2
sasa(dp8097
g2
S'In this study, to reveal the presence and the significance of anti-FIRs (FIR/FIRDeltaexon2) antibodies in cancers were explored in the sera of colorectal and other cancer patients.\n'
p8098
sg4
(lp8099
(dp8100
g7
I62
sg8
g18
sg10
I9
sg11
Vanti-FIRs
p8101
sg13
I1
sasg20
(lp8102
(dp8103
g7
I106
sg23
VC0006826
p8104
sg10
I7
sg11
Vcancers
p8105
sg13
I1
sa(dp8106
g7
I106
sg23
VC0006826
p8107
sg10
I6
sg11
Vcancer
p8108
sg13
I1
sasa(dp8109
g2
S'Anti-FIRs antibodies were surely detected in the preoperative sera of 28 colorectal cancer patients (32.2% of positive rates), and the detection rate was significantly higher than that in healthy control sera (Mann-Whitney U test, p &lt; 0.01).\n'
p8110
sg4
(lp8111
(dp8112
g7
I0
sg8
g18
sg10
I20
sg11
VAnti-FIRs antibodies
p8113
sg13
I2
sasg20
(lp8114
(dp8115
g7
I73
sg23
VC1527249
p8116
sg10
I17
sg11
Vcolorectal cancer
p8117
sg13
I2
sasa(dp8118
g2
S'Anti-FIRs antibodies were detected in the sera of early-stage and/or recurrent colon cancer patients in which anti-p53 antibodies, CEA, and CA19-9 were not detected as well as in the sera of other cancer patients.\n'
p8119
sg4
(lp8120
(dp8121
g7
I0
sg8
g18
sg10
I20
sg11
VAnti-FIRs antibodies
p8122
sg13
I2
sa(dp8123
g7
I110
sg8
VP42771
p8124
sg10
I19
sg11
Vanti-p53 antibodies
p8125
sg13
I2
sasg20
(lp8126
(dp8127
g7
I69
sg23
VC0278553
p8128
sg10
I22
sg11
Vrecurrent colon cancer
p8129
sg13
I3
sa(dp8130
g7
I85
sg23
VC0006826
p8131
sg10
I6
sg11
Vcancer
p8132
sg13
I1
sasa(dp8133
g2
S'In conclusions, the combination of anti-FIRs antibodies with other clinically available tumor markers further improved the specificity and accuracy of cancer diagnosis.\n'
p8134
sg4
(lp8135
(dp8136
g7
I35
sg8
g18
sg10
I20
sg11
Vanti-FIRs antibodies
p8137
sg13
I2
sasg20
(lp8138
(dp8139
g7
I88
sg23
VC0027651
p8140
sg10
I5
sg11
Vtumor
p8141
sg13
I1
sa(dp8142
g7
I151
sg23
VC0006826
p8143
sg10
I6
sg11
Vcancer
p8144
sg13
I1
sasa(dp8145
g2
S'Because over-expression of DNA-interacting far upstream element binding protein (FBP) supports non-small cell lung cancer (NSCLC) migration, we asked whether its repressor, FBP-interacting repressor (FIR) is functionally inactivated and how FIR might affect NSCLC cell biology.\n'
p8146
sg4
(lp8147
(dp8148
g7
I43
sg8
g18
sg10
I36
sg11
Vfar upstream element binding protein
p8149
sg13
I5
sa(dp8150
g7
I200
sg8
g18
sg10
I3
sg11
VFIR
p8151
sg13
I1
sa(dp8152
g7
I81
sg8
g18
sg10
I3
sg11
VFBP
p8153
sg13
I1
sa(dp8154
g7
I173
sg8
g18
sg10
I25
sg11
VFBP-interacting repressor
p8155
sg13
I2
sa(dp8156
g7
I200
sg8
g18
sg10
I3
sg11
VFIR
p8157
sg13
I1
sasg20
(lp8158
(dp8159
g7
I123
sg23
VC0007131
p8160
sg10
I5
sg11
VNSCLC
p8161
sg13
I1
sa(dp8162
g7
I95
sg23
VC0007131
p8163
sg10
I26
sg11
Vnon-small cell lung cancer
p8164
sg13
I4
sa(dp8165
g7
I123
sg23
VC0007131
p8166
sg10
I5
sg11
VNSCLC
p8167
sg13
I1
sasa(dp8168
g2
S'Different FIR splice variants were highly expressed in the majority of NSCLCs, with the highest levels in tumours carrying genomic gains of chromosome 8q24.3, which contained the FIR gene locus.\n'
p8169
sg4
(lp8170
(dp8171
g7
I179
sg8
g18
sg10
I14
sg11
VFIR gene locus
p8172
sg13
I3
sasg20
(lp8173
(dp8174
g7
I106
sg23
VC0027651
p8175
sg10
I7
sg11
Vtumours
p8176
sg13
I1
sasa(dp8177
g2
S'Nuclear FIR expression was significantly enriched at the invasion front of primary NSCLCs, but this did not correlate with tumour cell proliferation.\n'
p8178
sg4
(lp8179
sg20
(lp8180
(dp8181
g7
I123
sg23
VC0027651
p8182
sg10
I6
sg11
Vtumour
p8183
sg13
I1
sa(dp8184
g7
I57
sg23
VC2699153
p8185
sg10
I8
sg11
Vinvasion
p8186
sg13
I1
sa(dp8187
g7
I135
sg23
VC0334094
p8188
sg10
I13
sg11
Vproliferation
p8189
sg13
I1
sasa(dp8190
g2
S'In summary, by using scale-spanning data derived from primary human tissues, quantitative cellular analyses and mathematical modelling, we have demonstrated that concomitant over-expression of FIR and its splice variants drives NSCLC migration and dissemination.\n'
p8191
sg4
(lp8192
(dp8193
g7
I193
sg8
g18
sg10
I3
sg11
VFIR
p8194
sg13
I1
sasg20
(lp8195
(dp8196
g7
I228
sg23
VC0007131
p8197
sg10
I5
sg11
VNSCLC
p8198
sg13
I1
sasa(dp8199
g2
S'FIR is alternatively spliced to lack the transcriptional repression domain within exon 2 (FIRDeltaexon2) in colorectal cancers.\n'
p8200
sg4
(lp8201
(dp8202
g7
I0
sg8
g18
sg10
I3
sg11
VFIR
p8203
sg13
I1
sasg20
(lp8204
(dp8205
g7
I108
sg23
VC1527249
p8206
sg10
I18
sg11
Vcolorectal cancers
p8207
sg13
I2
sasa(dp8208
g2
S'This novel function of FIR splicing will contribute to clinical studies of cancer management through elucidating the mechanical interaction of FIR/FIRDeltaexon2/SAP155 as a potential target for cancer treatment.\n'
p8209
sg4
(lp8210
(dp8211
g7
I23
sg8
g18
sg10
I3
sg11
VFIR
p8212
sg13
I1
sa(dp8213
g7
I161
sg8
g18
sg10
I6
sg11
VSAP155
p8214
sg13
I1
sa(dp8215
g7
I23
sg8
g18
sg10
I3
sg11
VFIR
p8216
sg13
I1
sasg20
(lp8217
(dp8218
g7
I75
sg23
VC0006826
p8219
sg10
I6
sg11
Vcancer
p8220
sg13
I1
sa(dp8221
g7
I75
sg23
VC0006826
p8222
sg10
I6
sg11
Vcancer
p8223
sg13
I1
sasa(dp8224
g2
S'To investigate a novel therapeutic strategy to target and suppress c-myc in human cancers using far up stream element (FUSE)-binding protein-interacting repressor (FIR).\n'
p8225
sg4
(lp8226
(dp8227
g7
I67
sg8
VP12524
p8228
sg10
I5
sg11
Vc-myc
p8229
sg13
I1
sa(dp8230
g7
I164
sg8
g18
sg10
I3
sg11
VFIR
p8231
sg13
I1
sasg20
(lp8232
(dp8233
g7
I82
sg23
VC0006826
p8234
sg10
I7
sg11
Vcancers
p8235
sg13
I1
sasa(dp8236
g2
S'SeV/dF/FIR was examined for its gene transduction efficiency, viral dose dependency of antitumor effect and apoptosis induction in HeLa (cervical squamous cell carcinoma) cells and SW480 (colon adenocarcinoma) cells.\n'
p8237
sg4
(lp8238
sg20
(lp8239
(dp8240
g7
I188
sg23
VC0338106
p8241
sg10
I20
sg11
Vcolon adenocarcinoma
p8242
sg13
I2
sa(dp8243
g7
I137
sg23
VC0279671
p8244
sg10
I32
sg11
Vcervical squamous cell carcinoma
p8245
sg13
I4
sasa(dp8246
g2
S'Thus, FIR expressing vectors are potentially applicable for cancer therapy.\n'
p8247
sg4
(lp8248
sg20
(lp8249
(dp8250
g7
I60
sg23
VC0006826
p8251
sg10
I6
sg11
Vcancer
p8252
sg13
I1
sasa(dp8253
g2
S'FIR is alternatively spliced by SAP155 in cancer cells lacking the transcriptional repression domain within exon 2 (FIRDeltaexon2), counteracting FIR for c-Myc protein expression.\n'
p8254
sg4
(lp8255
(dp8256
g7
I0
sg8
g18
sg10
I3
sg11
VFIR
p8257
sg13
I1
sa(dp8258
g7
I0
sg8
g18
sg10
I3
sg11
VFIR
p8259
sg13
I1
sa(dp8260
g7
I32
sg8
g18
sg10
I6
sg11
VSAP155
p8261
sg13
I1
sa(dp8262
g7
I154
sg8
VP01106
p8263
sg10
I13
sg11
Vc-Myc protein
p8264
sg13
I2
sasg20
(lp8265
(dp8266
g7
I42
sg23
VC0006826
p8267
sg10
I6
sg11
Vcancer
p8268
sg13
I1
sasa(dp8269
g2
S'Furthermore, in nude mouse tumor xenograft models, SeV/dF/FIR displayed high antitumor efficiency against human cancer cells.\n'
p8270
sg4
(lp8271
(dp8272
g7
I58
sg8
g18
sg10
I3
sg11
VFIR
p8273
sg13
I1
sasg20
(lp8274
(dp8275
g7
I112
sg23
VC0006826
p8276
sg10
I6
sg11
Vcancer
p8277
sg13
I1
sa(dp8278
g7
I27
sg23
VC0027651
p8279
sg10
I5
sg11
Vtumor
p8280
sg13
I1
sasa(dp8281
g2
S'SeV/dF/FIR showed strong tumor growth suppression with no significant side effects in an animal xenograft model, thus SeV/dF/FIR is potentially applicable for future clinical cancer treatment.\n'
p8282
sg4
(lp8283
(dp8284
g7
I7
sg8
g18
sg10
I3
sg11
VFIR
p8285
sg13
I1
sasg20
(lp8286
(dp8287
g7
I31
sg23
VC0151686
p8288
sg10
I18
sg11
Vgrowth suppression
p8289
sg13
I2
sa(dp8290
g7
I25
sg23
VC0598934
p8291
sg10
I12
sg11
Vtumor growth
p8292
sg13
I2
sa(dp8293
g7
I175
sg23
VC0006826
p8294
sg10
I6
sg11
Vcancer
p8295
sg13
I1
sasa(dp8296
g2
S'In this regard, the aim of this study was to evaluate and correlate both relative quantification of microRNA-7 using quantitative real time polymerase chain reaction and quantitative analysis of selenoprotein P using enzyme-linked immunosorbent assay in sera of hepatocellular carcinoma patients, chronic liver disease patients, as well as normal healthy subjects in order to establish a new diagnostic biomarker with a valid non-invasive technique.\n'
p8297
sg4
(lp8298
(dp8299
g7
I195
sg8
VP49908
p8300
sg10
I15
sg11
Vselenoprotein P
p8301
sg13
I2
sasg20
(lp8302
(dp8303
g7
I262
sg23
VC1512411
p8304
sg10
I24
sg11
Vhepatocellular carcinoma
p8305
sg13
I2
sa(dp8306
g7
I297
sg23
VC0341439
p8307
sg10
I21
sg11
Vchronic liver disease
p8308
sg13
I3
sasa(dp8309
g2
S'In addition, this study aimed to investigate whether changes in selenium supply affect microRNA-7 expression and selenoprotein P levels in human hepatocarcinoma cell line (HepG2).\n'
p8310
sg4
(lp8311
(dp8312
g7
I113
sg8
VP49908
p8313
sg10
I15
sg11
Vselenoprotein P
p8314
sg13
I2
sasg20
(lp8315
(dp8316
g7
I145
sg23
VC2239176
p8317
sg10
I15
sg11
Vhepatocarcinoma
p8318
sg13
I1
sasa(dp8319
g2
S'The best cutoff for serum microRNA-7 and selenoprotein P to discriminate hepatocellular carcinoma group from benign and control groups was 0.06 and 4.30 mg/L, respectively.\n'
p8320
sg4
(lp8321
(dp8322
g7
I20
sg8
VP49908
p8323
sg10
I36
sg11
Vserum microRNA-7 and selenoprotein P
p8324
sg13
I5
sasg20
(lp8325
(dp8326
g7
I73
sg23
VC1512411
p8327
sg10
I24
sg11
Vhepatocellular carcinoma
p8328
sg13
I2
sasa(dp8329
g2
S'Hence, serum microRNA-7 and selenoprotein P appear to be potential non-invasive diagnostic markers for hepatocellular carcinoma.\n'
p8330
sg4
(lp8331
(dp8332
g7
I7
sg8
VP49908
p8333
sg10
I36
sg11
Vserum microRNA-7 and selenoprotein P
p8334
sg13
I5
sasg20
(lp8335
(dp8336
g7
I103
sg23
VC1512411
p8337
sg10
I24
sg11
Vhepatocellular carcinoma
p8338
sg13
I2
sasa(dp8339
g2
S'Moreover, the results suggest that selenium could be used as an anticancer therapy for hepatocellular carcinoma by affecting both microRNA-7 and selenoprotein P.\n'
p8340
sg4
(lp8341
(dp8342
g7
I130
sg8
VP49908
p8343
sg10
I30
sg11
VmicroRNA-7 and selenoprotein P
p8344
sg13
I4
sasg20
(lp8345
(dp8346
g7
I87
sg23
VC1512411
p8347
sg10
I24
sg11
Vhepatocellular carcinoma
p8348
sg13
I2
sasa(dp8349
g2
S'These experiments determined SEPP1 loss altered immune and epithelial cellular function in a murine model of colitis-associated carcinoma.\n'
p8350
sg4
(lp8351
(dp8352
g7
I29
sg8
VP49908
p8353
sg10
I5
sg11
VSEPP1
p8354
sg13
I1
sasg20
(lp8355
(dp8356
g7
I128
sg23
VC0007097
p8357
sg10
I9
sg11
Vcarcinoma
p8358
sg13
I1
sa(dp8359
g7
I109
sg23
VC0009319
p8360
sg10
I7
sg11
Vcolitis
p8361
sg13
I1
sasa(dp8362
g2
S'Through our genome-wide gene expression profile analyses of pancreatic ductal adenocarcinoma (PDAC) cells, we identified the overexpression of tubulin tyrosine ligase-like family member 4 (TTLL4) in PDAC cells.\n'
p8363
sg4
(lp8364
(dp8365
g7
I189
sg8
g18
sg10
I5
sg11
VTTLL4
p8366
sg13
I1
sa(dp8367
g7
I143
sg8
g18
sg10
I44
sg11
Vtubulin tyrosine ligase-like family member 4
p8368
sg13
I6
sasg20
(lp8369
(dp8370
g7
I94
sg23
VC1335302
p8371
sg10
I4
sg11
VPDAC
p8372
sg13
I1
sa(dp8373
g7
I60
sg23
VC1335302
p8374
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p8375
sg13
I3
sa(dp8376
g7
I94
sg23
VC1335302
p8377
sg10
I4
sg11
VPDAC
p8378
sg13
I1
sasa(dp8379
g2
S'To understand the molecular and genetic bases of neuroblastoma, we have generated its cDNA libraries and identified a human ortholog of tubulin tyrosine ligase gene (hTTL/Nbla0660) as a differentially expressed gene at high levels in a favorable subset of the tumor.\n'
p8380
sg4
(lp8381
(dp8382
g7
I136
sg8
g18
sg10
I23
sg11
Vtubulin tyrosine ligase
p8383
sg13
I3
sasg20
(lp8384
(dp8385
g7
I260
sg23
VC0027651
p8386
sg10
I5
sg11
Vtumor
p8387
sg13
I1
sa(dp8388
g7
I49
sg23
VC0027819
p8389
sg10
I13
sg11
Vneuroblastoma
p8390
sg13
I1
sasa(dp8391
g2
S"Serum antibodies to four common food antigens, three cows' milk proteins (casein, alpha-lactalbumin and beta-lactoglobulin) and ovalbumin, were investigated in 21 children with atopic dermatitis (aged 3 months to 3 years) and in 15 age-matched healthy controls.\n"
p8392
sg4
(lp8393
(dp8394
g7
I82
sg8
VP00709
p8395
sg10
I17
sg11
Valpha-lactalbumin
p8396
sg13
I1
sasg20
(lp8397
(dp8398
g7
I177
sg23
VC0011615
p8399
sg10
I17
sg11
Vatopic dermatitis
p8400
sg13
I2
sasa(dp8401
g2
S'Specific IgE was found in 76% of patients, while antigen-directed IgG and IgA were present both in patients and healthy controls; IgG to ovalbumin and IgA to alpha-lactalbumin were significantly higher in children with atopic dermatitis.\n'
p8402
sg4
(lp8403
(dp8404
g7
I74
sg8
VP11912
p8405
sg10
I3
sg11
VIgA
p8406
sg13
I1
sa(dp8407
g7
I9
sg8
VP01854
p8408
sg10
I3
sg11
VIgE
p8409
sg13
I1
sa(dp8410
g7
I158
sg8
VP00709
p8411
sg10
I17
sg11
Valpha-lactalbumin
p8412
sg13
I1
sa(dp8413
g7
I74
sg8
VP11912
p8414
sg10
I3
sg11
VIgA
p8415
sg13
I1
sasg20
(lp8416
(dp8417
g7
I9
sg23
VC0270850
p8418
sg10
I3
sg11
VIgE
p8419
sg13
I1
sa(dp8420
g7
I219
sg23
VC0011615
p8421
sg10
I17
sg11
Vatopic dermatitis
p8422
sg13
I2
sasa(dp8423
g2
S"An ELISA was applied to measure IgG sub-class antibodies to cow's milk beta-lactoglobulin (BLG), alpha-lactalbumin (ALA) and alpha-casein (AC) and to hen's egg ovalbumin (OA) in the sera of nineteen adult patients with milk intolerance causing either asthma, eczema or both.\n"
p8424
sg4
(lp8425
(dp8426
g7
I97
sg8
VP00709
p8427
sg10
I23
sg11
Valpha-lactalbumin (ALA)
p8428
sg13
I2
sa(dp8429
g7
I139
sg8
g18
sg10
I2
sg11
VAC
p8430
sg13
I1
sa(dp8431
g7
I125
sg8
g18
sg10
I12
sg11
Valpha-casein
p8432
sg13
I1
sasg20
(lp8433
(dp8434
g7
I251
sg23
VC0004096
p8435
sg10
I6
sg11
Vasthma
p8436
sg13
I1
sa(dp8437
g7
I219
sg23
VC0022951
p8438
sg10
I16
sg11
Vmilk intolerance
p8439
sg13
I2
sa(dp8440
g7
I259
sg23
VC0013595
p8441
sg10
I6
sg11
Veczema
p8442
sg13
I1
sasa(dp8443
g2
S'Occurrence and subclass distribution of IgG to alpha-lactalbumin (ALA), beta-lactoglobulin (BLG), and ovalbumin (OA) have been determined in 30 children with atopic dermatitis (AD) and in their mothers.\n'
p8444
sg4
(lp8445
(dp8446
g7
I47
sg8
VP00709
p8447
sg10
I43
sg11
Valpha-lactalbumin (ALA), beta-lactoglobulin
p8448
sg13
I3
sasg20
(lp8449
(dp8450
g7
I177
sg23
VC0011615
p8451
sg10
I2
sg11
VAD
p8452
sg13
I1
sa(dp8453
g7
I158
sg23
VC0011615
p8454
sg10
I17
sg11
Vatopic dermatitis
p8455
sg13
I2
sasa(dp8456
g2
S'With high connectivity degrees in the pink module, TPX2, microtubule-associated (TPX2; degree, 25), minichromosome maintenance complex component 2 (MCM2; degree, 25), ubiquitin-like with PHD and ring finger domains 1 (UHRF1; degree, 22), cyclin-dependent kinase 2 (CDK2; degree, 20) and protein regulator of cytokinesis 1 (PRC1; degree, 20) may be involved in LSCC.\n'
p8457
sg4
(lp8458
(dp8459
g7
I51
sg8
g18
sg10
I4
sg11
VTPX2
p8460
sg13
I1
sa(dp8461
g7
I218
sg8
g18
sg10
I5
sg11
VUHRF1
p8462
sg13
I1
sa(dp8463
g7
I323
sg8
g18
sg10
I4
sg11
VPRC1
p8464
sg13
I1
sa(dp8465
g7
I51
sg8
g18
sg10
I4
sg11
VTPX2
p8466
sg13
I1
sa(dp8467
g7
I167
sg8
g18
sg10
I49
sg11
Vubiquitin-like with PHD and ring finger domains 1
p8468
sg13
I8
sa(dp8469
g7
I148
sg8
VP33993
p8470
sg10
I4
sg11
VMCM2
p8471
sg13
I1
sa(dp8472
g7
I287
sg8
g18
sg10
I34
sg11
Vprotein regulator of cytokinesis 1
p8473
sg13
I5
sa(dp8474
g7
I265
sg8
VP24941
p8475
sg10
I4
sg11
VCDK2
p8476
sg13
I1
sa(dp8477
g7
I238
sg8
VP24941
p8478
sg10
I25
sg11
Vcyclin-dependent kinase 2
p8479
sg13
I3
sa(dp8480
g7
I100
sg8
VP49736
p8481
sg10
I46
sg11
Vminichromosome maintenance complex component 2
p8482
sg13
I5
sasg20
(lp8483
sa(dp8484
g2
S'To report a case of bilateral papilloma virus-positive conjunctival intraepithelial neoplasm and the treatment results of using adjunctive interferon alpha-2b.\n'
p8485
sg4
(lp8486
(dp8487
g7
I139
sg8
VP01570
p8488
sg10
I19
sg11
Vinterferon alpha-2b
p8489
sg13
I2
sasg20
(lp8490
(dp8491
g7
I68
sg23
VC0878500
p8492
sg10
I24
sg11
Vintraepithelial neoplasm
p8493
sg13
I2
sa(dp8494
g7
I30
sg23
VC0030354
p8495
sg10
I9
sg11
Vpapilloma
p8496
sg13
I1
sasa(dp8497
g2
S'We reported that p62 (sequestosome 1) serves as a signaling hub in bone marrow stromal cells (BMSCs) for the formation of signaling complexes, including NFKB, p38MAPK and JNK, that are involved in the increased osteoclastogenesis and multiple myeloma (MM) cell growth induced by BMSCs that are key contributors to multiple myeloma bone disease (MMBD), and demonstrated that the ZZ domain of p62 (p62-ZZ) is required for BMSC enhancement of MMBD.\n'
p8498
sg4
(lp8499
(dp8500
g7
I171
sg8
VP53779
p8501
sg10
I3
sg11
VJNK
p8502
sg13
I1
sa(dp8503
g7
I153
sg8
g18
sg10
I4
sg11
VNFKB
p8504
sg13
I1
sa(dp8505
g7
I159
sg8
g18
sg10
I7
sg11
Vp38MAPK
p8506
sg13
I1
sa(dp8507
g7
I17
sg8
VP37198
p8508
sg10
I3
sg11
Vp62
p8509
sg13
I1
sa(dp8510
g7
I396
sg8
VP37198
p8511
sg10
I6
sg11
Vp62-ZZ
p8512
sg13
I1
sasg20
(lp8513
(dp8514
g7
I323
sg23
VC0005940
p8515
sg10
I20
sg11
Vmyeloma bone disease
p8516
sg13
I3
sa(dp8517
g7
I234
sg23
VC0026764
p8518
sg10
I16
sg11
Vmultiple myeloma
p8519
sg13
I2
sa(dp8520
g7
I345
sg23
VC0005940
p8521
sg10
I4
sg11
VMMBD
p8522
sg13
I1
sa(dp8523
g7
I345
sg23
VC0005940
p8524
sg10
I4
sg11
VMMBD
p8525
sg13
I1
sa(dp8526
g7
I234
sg23
VC0026764
p8527
sg10
I16
sg11
Vmultiple myeloma
p8528
sg13
I2
sasa(dp8529
g2
S'In this study, we constructed a recombinant adenovirus 5-EVA1A vector (Ad5-EVA1A) to overexpress EVA1A in glioblastoma (GBM) cell lines and evaluated its anti-tumor activities in vitro and in vivo.\n'
p8530
sg4
(lp8531
(dp8532
g7
I71
sg8
VP49810
p8533
sg10
I9
sg11
VAd5-EVA1A
p8534
sg13
I1
sa(dp8535
g7
I32
sg8
VP55042
p8536
sg10
I37
sg11
Vrecombinant adenovirus 5-EVA1A vector
p8537
sg13
I4
sasg20
(lp8538
(dp8539
g7
I120
sg23
VC0017636
p8540
sg10
I3
sg11
VGBM
p8541
sg13
I1
sa(dp8542
g7
I44
sg23
VC0001486
p8543
sg10
I10
sg11
Vadenovirus
p8544
sg13
I1
sa(dp8545
g7
I159
sg23
VC0027651
p8546
sg10
I5
sg11
Vtumor
p8547
sg13
I1
sa(dp8548
g7
I71
sg23
VC1865868
p8549
sg10
I3
sg11
VAd5
p8550
sg13
I1
sa(dp8551
g7
I106
sg23
VC0017636
p8552
sg10
I12
sg11
Vglioblastoma
p8553
sg13
I1
sasa(dp8554
g2
S'We found that overexpression of EVA1A in three GBM cell lines (U251, U87 and SHG44) resulted in a suppression of tumor cell growth via activation of autophagy and induction of cell apoptosis in a dose- and time-dependent manner.\n'
p8555
sg4
(lp8556
sg20
(lp8557
(dp8558
g7
I47
sg23
VC0017636
p8559
sg10
I3
sg11
VGBM
p8560
sg13
I1
sa(dp8561
g7
I98
sg23
VC0221103
p8562
sg10
I11
sg11
Vsuppression
p8563
sg13
I1
sa(dp8564
g7
I113
sg23
VC0027651
p8565
sg10
I5
sg11
Vtumor
p8566
sg13
I1
sasa(dp8567
g2
S'Our data suggest that EVA1A-induced autophagy and apoptosis play a role in suppressing the development of GBM and their up-regulation may be an effective method for treating this form of cancer.\n'
p8568
sg4
(lp8569
sg20
(lp8570
(dp8571
g7
I187
sg23
VC0006826
p8572
sg10
I6
sg11
Vcancer
p8573
sg13
I1
sa(dp8574
g7
I106
sg23
VC0017636
p8575
sg10
I3
sg11
VGBM
p8576
sg13
I1
sasa(dp8577
g2
S'Although the tissue architecture was deformed, EVA1A was absent in the alpha cells of pancreatic ductal adenocarcinomas, intraductal papillary mucinous neoplasms, mucinous cystadenomas, solid papillary tumors and pancreatic neuroendocrine tumors.\n'
p8578
sg4
(lp8579
sg20
(lp8580
(dp8581
g7
I163
sg23
VC0010635
p8582
sg10
I21
sg11
Vmucinous cystadenomas
p8583
sg13
I2
sa(dp8584
g7
I202
sg23
VC0027651
p8585
sg10
I6
sg11
Vtumors
p8586
sg13
I1
sa(dp8587
g7
I152
sg23
VC0027651
p8588
sg10
I9
sg11
Vneoplasms
p8589
sg13
I1
sa(dp8590
g7
I224
sg23
VC0206754
p8591
sg10
I21
sg11
Vneuroendocrine tumors
p8592
sg13
I2
sa(dp8593
g7
I104
sg23
VC0001418
p8594
sg10
I15
sg11
Vadenocarcinomas
p8595
sg13
I1
sasa(dp8596
g2
S'A decreased expression of FAM176A has been found in several types of human tumors in including lung cancers.\n'
p8597
sg4
(lp8598
(dp8599
g7
I26
sg8
g18
sg10
I7
sg11
VFAM176A
p8600
sg13
I1
sasg20
(lp8601
(dp8602
g7
I95
sg23
VC0242379
p8603
sg10
I12
sg11
Vlung cancers
p8604
sg13
I2
sa(dp8605
g7
I75
sg23
VC0027651
p8606
sg10
I6
sg11
Vtumors
p8607
sg13
I1
sasa(dp8608
g2
S'In the present study, we investigated the biological activities of FAM176A on the human non-small cell lung cancer cell line H1299 cells.\n'
p8609
sg4
(lp8610
(dp8611
g7
I67
sg8
g18
sg10
I7
sg11
VFAM176A
p8612
sg13
I1
sasg20
(lp8613
(dp8614
g7
I88
sg23
VC0007131
p8615
sg10
I26
sg11
Vnon-small cell lung cancer
p8616
sg13
I4
sasa(dp8617
g2
S'In addition, cell cycle analysis suggested that Ad5-FAM176A could induce cell cycle arrest at the G2/M phase, all of which suggested that adenovirus-mediated FAM176A gene transfer might present a new therapeutic approach for lung cancer treatment.\n'
p8618
sg4
(lp8619
(dp8620
g7
I52
sg8
g18
sg10
I7
sg11
VFAM176A
p8621
sg13
I1
sa(dp8622
g7
I48
sg8
VP49810
p8623
sg10
I11
sg11
VAd5-FAM176A
p8624
sg13
I1
sasg20
(lp8625
(dp8626
g7
I138
sg23
VC0001486
p8627
sg10
I10
sg11
Vadenovirus
p8628
sg13
I1
sa(dp8629
g7
I225
sg23
VC0684249
p8630
sg10
I11
sg11
Vlung cancer
p8631
sg13
I2
sa(dp8632
g7
I48
sg23
VC1865868
p8633
sg10
I3
sg11
VAd5
p8634
sg13
I1
sasa(dp8635
g2
S'Our data indicated that Ad5-TMEM166 may be a novel gene therapy candidate for cancer.\n'
p8636
sg4
(lp8637
(dp8638
g7
I24
sg8
VP49810
p8639
sg10
I3
sg11
VAd5
p8640
sg13
I1
sa(dp8641
g7
I28
sg8
g18
sg10
I7
sg11
VTMEM166
p8642
sg13
I1
sasg20
(lp8643
(dp8644
g7
I24
sg23
VC1865868
p8645
sg10
I3
sg11
VAd5
p8646
sg13
I1
sa(dp8647
g7
I78
sg23
VC0006826
p8648
sg10
I6
sg11
Vcancer
p8649
sg13
I1
sasa(dp8650
g2
S'In comparing human normal and tumor tissues, TMEM166 expression was widely downregulated in the cancer tissues.\n'
p8651
sg4
(lp8652
sg20
(lp8653
(dp8654
g7
I96
sg23
VC0006826
p8655
sg10
I6
sg11
Vcancer
p8656
sg13
I1
sa(dp8657
g7
I30
sg23
VC0027651
p8658
sg10
I5
sg11
Vtumor
p8659
sg13
I1
sasa(dp8660
g2
S'The putative sarcoma, Sp24, showed clear evidence of epithelial differentiation but no evidence of vimentin expression.\n'
p8661
sg4
(lp8662
(dp8663
g7
I22
sg8
g18
sg10
I4
sg11
VSp24
p8664
sg13
I1
sasg20
(lp8665
(dp8666
g7
I13
sg23
VC1261473
p8667
sg10
I7
sg11
Vsarcoma
p8668
sg13
I1
sasa(dp8669
g2
S'However, the conjugate was not cytotoxic to p102 antigen negative rat fibrosarcoma SP-24 cells.\n'
p8670
sg4
(lp8671
(dp8672
g7
I44
sg8
VP25205
p8673
sg10
I4
sg11
Vp102
p8674
sg13
I1
sasg20
(lp8675
(dp8676
g7
I66
sg23
VC1882672
p8677
sg10
I16
sg11
Vrat fibrosarcoma
p8678
sg13
I2
sasa(dp8679
g2
S'IM-ADRs mediated by T cells are associated with phenotypically distinct clinical diagnoses and can vary from a mild delayed rash to a life threatening cutaneous, systemic or organ disease, such as Stephen Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and drug-induced liver disease (DILI).\n'
p8680
sg4
(lp8681
(dp8682
g7
I0
sg8
VP10275
p8683
sg10
I7
sg11
VIM-ADRs
p8684
sg13
I1
sa(dp8685
g7
I250
sg8
VP98160
p8686
sg10
I3
sg11
VSJS
p8687
sg13
I1
sa(dp8688
g7
I254
sg8
VP24821
p8689
sg10
I3
sg11
VTEN
p8690
sg13
I1
sasg20
(lp8691
(dp8692
g7
I326
sg23
VC0860207
p8693
sg10
I26
sg11
Vdrug-induced liver disease
p8694
sg13
I3
sa(dp8695
g7
I250
sg23
VC0036391
p8696
sg10
I3
sg11
VSJS
p8697
sg13
I1
sa(dp8698
g7
I222
sg23
VC0014518
p8699
sg10
I26
sg11
Vtoxic epidermal necrolysis
p8700
sg13
I3
sa(dp8701
g7
I213
sg23
VC0039082
p8702
sg10
I8
sg11
Vsyndrome
p8703
sg13
I1
sa(dp8704
g7
I124
sg23
VC0015230
p8705
sg10
I4
sg11
Vrash
p8706
sg13
I1
sa(dp8707
g7
I354
sg23
VC0860207
p8708
sg10
I4
sg11
VDILI
p8709
sg13
I1
sa(dp8710
g7
I279
sg23
VC0014457
p8711
sg10
I12
sg11
Veosinophilia
p8712
sg13
I1
sasa(dp8713
g2
S"The three distinct entities of importance are the former Lyell's syndrome, now identified as SJS-TEN syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis), the DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), and the AGEP syndrome (acute generalized exanthematous pustulosis).\n"
p8714
sg4
(lp8715
sg20
(lp8716
(dp8717
g7
I249
sg23
VC0863129
p8718
sg10
I4
sg11
VAGEP
p8719
sg13
I1
sa(dp8720
g7
I136
sg23
VC0014518
p8721
sg10
I26
sg11
Vtoxic epidermal necrolysis
p8722
sg13
I3
sa(dp8723
g7
I264
sg23
VC0877055
p8724
sg10
I42
sg11
Vacute generalized exanthematous pustulosis
p8725
sg13
I4
sa(dp8726
g7
I93
sg23
VC0036391
p8727
sg10
I3
sg11
VSJS
p8728
sg13
I1
sa(dp8729
g7
I204
sg23
VC0014457
p8730
sg10
I12
sg11
Veosinophilia
p8731
sg13
I1
sa(dp8732
g7
I65
sg23
VC0039082
p8733
sg10
I8
sg11
Vsyndrome
p8734
sg13
I1
sa(dp8735
g7
I65
sg23
VC0039082
p8736
sg10
I8
sg11
Vsyndrome
p8737
sg13
I1
sa(dp8738
g7
I57
sg23
VC0014518
p8739
sg10
I16
sg11
VLyell's syndrome
p8740
sg13
I2
sa(dp8741
g7
I169
sg23
VC1142139
p8742
sg10
I14
sg11
VDRESS syndrome
p8743
sg13
I2
sa(dp8744
g7
I111
sg23
VC0038325
p8745
sg10
I24
sg11
VStevens-Johnson syndrome
p8746
sg13
I2
sasa(dp8747
g2
S"Ils concernent trois entites distinctes qui sont l'ancien syndrome de Lyell, actuellement identifie comme SJS-NET (syndrome de Stevens-Johnson/necrolyse epidermique toxique), le syndrome DRESS (drug reaction with eosinophilia and systemic symptoms) et le syndrome AGEP (acute generalized exanthematous pustulosis).\n"
p8748
sg4
(lp8749
(dp8750
g7
I0
sg8
VP05231
p8751
sg10
I3
sg11
VIls
p8752
sg13
I1
sasg20
(lp8753
(dp8754
g7
I270
sg23
VC0877055
p8755
sg10
I42
sg11
Vacute generalized exanthematous pustulosis
p8756
sg13
I4
sa(dp8757
g7
I175
sg23
VC0024141
p8758
sg10
I11
sg11
Vle syndrome
p8759
sg13
I2
sa(dp8760
g7
I58
sg23
VC0853695
p8761
sg10
I11
sg11
Vsyndrome de
p8762
sg13
I2
sa(dp8763
g7
I175
sg23
VC0024141
p8764
sg10
I11
sg11
Vle syndrome
p8765
sg13
I2
sa(dp8766
g7
I106
sg23
VC0036391
p8767
sg10
I3
sg11
VSJS
p8768
sg13
I1
sa(dp8769
g7
I0
sg23
VC1843916
p8770
sg10
I3
sg11
VIls
p8771
sg13
I1
sa(dp8772
g7
I213
sg23
VC0014457
p8773
sg10
I12
sg11
Veosinophilia
p8774
sg13
I1
sa(dp8775
g7
I70
sg23
VC0014518
p8776
sg10
I5
sg11
VLyell
p8777
sg13
I1
sa(dp8778
g7
I264
sg23
VC0863129
p8779
sg10
I4
sg11
VAGEP
p8780
sg13
I1
sa(dp8781
g7
I58
sg23
VC0853695
p8782
sg10
I11
sg11
Vsyndrome de
p8783
sg13
I2
sasa(dp8784
g2
S'Potentially lifethreatening severe cutaneous adverse reactions (SCAR), namely drug reaction with eosinophilia and systemic symptoms (DRESS: 14 cases) and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN: 6 cases) comprise almost 50% of cADRs.\n'
p8785
sg4
(lp8786
(dp8787
g7
I64
sg8
VP62701
p8788
sg10
I4
sg11
VSCAR
p8789
sg13
I1
sa(dp8790
g7
I28
sg8
VP62701
p8791
sg10
I34
sg11
Vsevere cutaneous adverse reactions
p8792
sg13
I4
sasg20
(lp8793
(dp8794
g7
I28
sg23
VC2004491
p8795
sg10
I34
sg11
Vsevere cutaneous adverse reactions
p8796
sg13
I4
sa(dp8797
g7
I64
sg23
VC2004491
p8798
sg10
I4
sg11
VSCAR
p8799
sg13
I1
sa(dp8800
g7
I179
sg23
VC0014518
p8801
sg10
I26
sg11
VToxic Epidermal Necrolysis
p8802
sg13
I3
sa(dp8803
g7
I207
sg23
VC0036391
p8804
sg10
I3
sg11
VSJS
p8805
sg13
I1
sa(dp8806
g7
I154
sg23
VC0038325
p8807
sg10
I24
sg11
VStevens-Johnson Syndrome
p8808
sg13
I2
sa(dp8809
g7
I97
sg23
VC0014457
p8810
sg10
I12
sg11
Veosinophilia
p8811
sg13
I1
sasa(dp8812
g2
S'Drug-induced severe cutaneous adverse reactions (SCARs) include acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms (DRESS), and epidermal necrolysis (Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis).\n'
p8813
sg4
(lp8814
(dp8815
g7
I13
sg8
VP62701
p8816
sg10
I34
sg11
Vsevere cutaneous adverse reactions
p8817
sg13
I4
sa(dp8818
g7
I49
sg8
VP62701
p8819
sg10
I5
sg11
VSCARs
p8820
sg13
I1
sasg20
(lp8821
(dp8822
g7
I229
sg23
VC0014518
p8823
sg10
I26
sg11
Vtoxic epidermal necrolysis
p8824
sg13
I3
sa(dp8825
g7
I13
sg23
VC2004491
p8826
sg10
I34
sg11
Vsevere cutaneous adverse reactions
p8827
sg13
I4
sa(dp8828
g7
I64
sg23
VC0877055
p8829
sg10
I42
sg11
Vacute generalized exanthematous pustulosis
p8830
sg13
I4
sa(dp8831
g7
I175
sg23
VC0151626
p8832
sg10
I20
sg11
Vepidermal necrolysis
p8833
sg13
I2
sa(dp8834
g7
I197
sg23
VC0038325
p8835
sg10
I24
sg11
VStevens-Johnson syndrome
p8836
sg13
I2
sa(dp8837
g7
I49
sg23
VC2004491
p8838
sg10
I5
sg11
VSCARs
p8839
sg13
I1
sa(dp8840
g7
I127
sg23
VC0014457
p8841
sg10
I12
sg11
Veosinophilia
p8842
sg13
I1
sa(dp8843
g7
I223
sg23
VC0036391
p8844
sg10
I3
sg11
VSJS
p8845
sg13
I1
sasa(dp8846
g2
S'In opposite to the main cutaneous allergic drug reactions such as urticaria or maculopapular skin rash, in which antibiotics are the main culprits, in severe drug allergic reactions such as SJS (Stevens-Johnson Syndrome), TEN (Toxic Epidermal Necrolysis), or DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) Syndrome, compounds like allopurinol and anticonvulsants are the main causes.\n'
p8847
sg4
(lp8848
sg20
(lp8849
(dp8850
g7
I93
sg23
VC0015230
p8851
sg10
I9
sg11
Vskin rash
p8852
sg13
I2
sa(dp8853
g7
I34
sg23
VC0013182
p8854
sg10
I23
sg11
Vallergic drug reactions
p8855
sg13
I3
sa(dp8856
g7
I190
sg23
VC0036391
p8857
sg10
I3
sg11
VSJS
p8858
sg13
I1
sa(dp8859
g7
I211
sg23
VC0039082
p8860
sg10
I8
sg11
VSyndrome
p8861
sg13
I1
sa(dp8862
g7
I227
sg23
VC0014518
p8863
sg10
I26
sg11
VToxic Epidermal Necrolysis
p8864
sg13
I3
sa(dp8865
g7
I222
sg23
VC0014518
p8866
sg10
I3
sg11
VTEN
p8867
sg13
I1
sa(dp8868
g7
I195
sg23
VC0038325
p8869
sg10
I24
sg11
VStevens-Johnson Syndrome
p8870
sg13
I2
sa(dp8871
g7
I285
sg23
VC0014457
p8872
sg10
I12
sg11
VEosinophilia
p8873
sg13
I1
sa(dp8874
g7
I163
sg23
VC1527304
p8875
sg10
I18
sg11
Vallergic reactions
p8876
sg13
I2
sa(dp8877
g7
I66
sg23
VC0042109
p8878
sg10
I9
sg11
Vurticaria
p8879
sg13
I1
sasa(dp8880
g2
S'The second DHR includes exanthema, erythroderma, DRESS, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), hepatitis, and agranulocytosis.\n'
p8881
sg4
(lp8882
(dp8883
g7
I109
sg8
VP98160
p8884
sg10
I3
sg11
VSJS
p8885
sg13
I1
sa(dp8886
g7
I113
sg8
VP24821
p8887
sg10
I3
sg11
VTEN
p8888
sg13
I1
sasg20
(lp8889
(dp8890
g7
I134
sg23
VC0001824
p8891
sg10
I15
sg11
Vagranulocytosis
p8892
sg13
I1
sa(dp8893
g7
I109
sg23
VC0036391
p8894
sg10
I3
sg11
VSJS
p8895
sg13
I1
sa(dp8896
g7
I24
sg23
VC0015230
p8897
sg10
I9
sg11
Vexanthema
p8898
sg13
I1
sa(dp8899
g7
I81
sg23
VC0014518
p8900
sg10
I26
sg11
Vtoxic epidermal necrolysis
p8901
sg13
I3
sa(dp8902
g7
I56
sg23
VC0038325
p8903
sg10
I24
sg11
VStevens-Johnson syndrome
p8904
sg13
I2
sa(dp8905
g7
I119
sg23
VC0019159
p8906
sg10
I9
sg11
Vhepatitis
p8907
sg13
I1
sa(dp8908
g7
I35
sg23
VC0011606
p8909
sg10
I12
sg11
Verythroderma
p8910
sg13
I1
sasa(dp8911
g2
S'We enrolled 50 patients with OXC-cADRs, including 20 OXC-SJS/TEN and 6  drug reaction with eosinophilia and systemic symptoms, of Chinese patients from Taiwan and Thai patients from Thailand.\n'
p8912
sg4
(lp8913
sg20
(lp8914
(dp8915
g7
I57
sg23
VC0036391
p8916
sg10
I3
sg11
VSJS
p8917
sg13
I1
sa(dp8918
g7
I91
sg23
VC0014457
p8919
sg10
I12
sg11
Veosinophilia
p8920
sg13
I1
sasa(dp8921
g2
S'Nonimmediate HSRs included linear IgA bullous dermatosis (LABD, n = 34), drug rash eosinophilia and systemic symptoms (DRESS) syndrome (n = 16), acute interstitial nephritis (AIN, n = 8), and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN, n = 6).\n'
p8922
sg4
(lp8923
(dp8924
g7
I34
sg8
VP11912
p8925
sg10
I3
sg11
VIgA
p8926
sg13
I1
sasg20
(lp8927
(dp8928
g7
I58
sg23
VC0396059
p8929
sg10
I4
sg11
VLABD
p8930
sg13
I1
sa(dp8931
g7
I126
sg23
VC0039082
p8932
sg10
I8
sg11
Vsyndrome
p8933
sg13
I1
sa(dp8934
g7
I175
sg23
VC0149937
p8935
sg10
I3
sg11
VAIN
p8936
sg13
I1
sa(dp8937
g7
I27
sg23
VC0406650
p8938
sg10
I29
sg11
Vlinear IgA bullous dermatosis
p8939
sg13
I4
sa(dp8940
g7
I83
sg23
VC0014457
p8941
sg10
I12
sg11
Veosinophilia
p8942
sg13
I1
sa(dp8943
g7
I217
sg23
VC0014518
p8944
sg10
I26
sg11
Vtoxic epidermal necrolysis
p8945
sg13
I3
sa(dp8946
g7
I73
sg23
VC0011609
p8947
sg10
I9
sg11
Vdrug rash
p8948
sg13
I2
sa(dp8949
g7
I192
sg23
VC0038325
p8950
sg10
I24
sg11
VStevens-Johnson syndrome
p8951
sg13
I2
sa(dp8952
g7
I245
sg23
VC0036391
p8953
sg10
I3
sg11
VSJS
p8954
sg13
I1
sa(dp8955
g7
I145
sg23
VC0149937
p8956
sg10
I28
sg11
Vacute interstitial nephritis
p8957
sg13
I3
sasa(dp8958
g2
S'Severe cutaneous adverse reactions to drugs (SCARs) such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DIHS) serve as one of the main reasons for inpatient ophthalmic consultation.\n'
p8959
sg4
(lp8960
(dp8961
g7
I113
sg8
VP98160
p8962
sg10
I3
sg11
VSJS
p8963
sg13
I1
sa(dp8964
g7
I117
sg8
VP24821
p8965
sg10
I3
sg11
VTEN
p8966
sg13
I1
sasg20
(lp8967
(dp8968
g7
I85
sg23
VC0014518
p8969
sg10
I26
sg11
Vtoxic epidermal necrolysis
p8970
sg13
I3
sa(dp8971
g7
I113
sg23
VC0036391
p8972
sg10
I3
sg11
VSJS
p8973
sg13
I1
sa(dp8974
g7
I180
sg23
VC1168290
p8975
sg10
I38
sg11
Vdrug-induced hypersensitivity syndrome
p8976
sg13
I3
sa(dp8977
g7
I60
sg23
VC0038325
p8978
sg10
I24
sg11
VStevens-Johnson syndrome
p8979
sg13
I2
sa(dp8980
g7
I145
sg23
VC0014457
p8981
sg10
I12
sg11
Veosinophilia
p8982
sg13
I1
sa(dp8983
g7
I0
sg23
VC2004491
p8984
sg10
I43
sg11
VSevere cutaneous adverse reactions to drugs
p8985
sg13
I6
sa(dp8986
g7
I45
sg23
VC2004491
p8987
sg10
I5
sg11
VSCARs
p8988
sg13
I1
sasa(dp8989
g2
S"Research over the last decade has established a central role for SPAK in the regulation of ion and water transport in the distal nephron, colonic crypts, and pancreatic ducts, and has implicated deregulated SPAK signaling in NaCl-sensitive hypertension, ulcerative colitis and Crohn's disease, and cystic fibrosis.\n"
p8990
sg4
(lp8991
(dp8992
g7
I65
sg8
g18
sg10
I4
sg11
VSPAK
p8993
sg13
I1
sasg20
(lp8994
(dp8995
g7
I298
sg23
VC0010674
p8996
sg10
I15
sg11
Vcystic fibrosis
p8997
sg13
I2
sa(dp8998
g7
I240
sg23
VC0020538
p8999
sg10
I12
sg11
Vhypertension
p9000
sg13
I1
sa(dp9001
g7
I277
sg23
VC0010346
p9002
sg10
I15
sg11
VCrohn's disease
p9003
sg13
I2
sa(dp9004
g7
I254
sg23
VC0009324
p9005
sg10
I18
sg11
Vulcerative colitis
p9006
sg13
I2
sasa(dp9007
g2
S'Expert opinion: The development of novel drugs that antagonize the SPAK-WNK interaction, inhibit SPAK kinase activity, or disrupt SPAK kinase activation by interfering with its binding to MO25Alfa/Beta could be useful adjuncts in essential hypertension, inflammatory colitis, and cystic fibrosis.\n'
p9008
sg4
(lp9009
(dp9010
g7
I67
sg8
g18
sg10
I4
sg11
VSPAK
p9011
sg13
I1
sa(dp9012
g7
I67
sg8
g18
sg10
I4
sg11
VSPAK
p9013
sg13
I1
sa(dp9014
g7
I97
sg8
g18
sg10
I11
sg11
VSPAK kinase
p9015
sg13
I2
sa(dp9016
g7
I72
sg8
g18
sg10
I3
sg11
VWNK
p9017
sg13
I1
sasg20
(lp9018
(dp9019
g7
I280
sg23
VC0010674
p9020
sg10
I15
sg11
Vcystic fibrosis
p9021
sg13
I2
sa(dp9022
g7
I230
sg23
VC0085580
p9023
sg10
I22
sg11
Vessential hypertension
p9024
sg13
I2
sa(dp9025
g7
I267
sg23
VC0009319
p9026
sg10
I7
sg11
Vcolitis
p9027
sg13
I1
sasa(dp9028
g2
S'In conclusion, SPAK deficiency increases intestinal innate immune homeostasis, which is important for control or attenuation of pathological responses in inflammatory bowel diseases.\n'
p9029
sg4
(lp9030
(dp9031
g7
I15
sg8
g18
sg10
I4
sg11
VSPAK
p9032
sg13
I1
sasg20
(lp9033
(dp9034
g7
I154
sg23
VC0021390
p9035
sg10
I27
sg11
Vinflammatory bowel diseases
p9036
sg13
I3
sasa(dp9037
g2
S'In conclusion, overexpression of SPAK inhibits maintenance of intestinal mucosal innate immune homeostasis, which makes regulation of SPAK important to attenuate pathological responses in inflammatory bowel disease.\n'
p9038
sg4
(lp9039
(dp9040
g7
I33
sg8
g18
sg10
I4
sg11
VSPAK
p9041
sg13
I1
sa(dp9042
g7
I33
sg8
g18
sg10
I4
sg11
VSPAK
p9043
sg13
I1
sasg20
(lp9044
(dp9045
g7
I188
sg23
VC0021390
p9046
sg10
I26
sg11
Vinflammatory bowel disease
p9047
sg13
I3
sasa(dp9048
g2
S"Here we report significantly increased SPAK expression levels in hyperosmotic environments, such as mucosal biopsy samples from patients with Crohn's disease, as well as colon tissues of C57BL/6 mice and Caco2-BBE cells treated with hyperosmotic medium.\n"
p9049
sg4
(lp9050
(dp9051
g7
I39
sg8
g18
sg10
I4
sg11
VSPAK
p9052
sg13
I1
sasg20
(lp9053
(dp9054
g7
I142
sg23
VC0010346
p9055
sg10
I15
sg11
VCrohn's disease
p9056
sg13
I2
sasa(dp9057
g2
S'We tested if changes on plasma levels of Brain Derived Neurotrophic Factor (BDNF), S100 calcium binding protein B (S100-B), Stem Cell Factor (SCF), Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2), Epidermal Growth Factor (EGF), Platelet-Derived Growth Factor-BB (PDGF-BB), and Vascular Endothelial Growth Factor (VEGF) are associated with response to TSD + LT in 26 inpatients affected by a major depressive episode in the course of bipolar disorder.\n'
p9058
sg4
(lp9059
(dp9060
g7
I194
sg8
VP01308
p9061
sg10
I7
sg11
VIGFBP-2
p9062
sg13
I1
sa(dp9063
g7
I284
sg8
g18
sg10
I34
sg11
VVascular Endothelial Growth Factor
p9064
sg13
I4
sa(dp9065
g7
I83
sg8
VP04271
p9066
sg10
I30
sg11
VS100 calcium binding protein B
p9067
sg13
I5
sa(dp9068
g7
I229
sg8
VP01133
p9069
sg10
I3
sg11
VEGF
p9070
sg13
I1
sa(dp9071
g7
I142
sg8
VP21583
p9072
sg10
I3
sg11
VSCF
p9073
sg13
I1
sa(dp9074
g7
I358
sg8
VP06865
p9075
sg10
I8
sg11
VTSD + LT
p9076
sg13
I3
sa(dp9077
g7
I320
sg8
g18
sg10
I4
sg11
VVEGF
p9078
sg13
I1
sa(dp9079
g7
I270
sg8
VP04085
p9080
sg10
I7
sg11
VPDGF-BB
p9081
sg13
I1
sa(dp9082
g7
I204
sg8
VP01133
p9083
sg10
I23
sg11
VEpidermal Growth Factor
p9084
sg13
I3
sa(dp9085
g7
I124
sg8
VP21583
p9086
sg10
I16
sg11
VStem Cell Factor
p9087
sg13
I3
sa(dp9088
g7
I148
sg8
VP01308
p9089
sg10
I44
sg11
VInsulin-like Growth Factor-Binding Protein 2
p9090
sg13
I5
sa(dp9091
g7
I41
sg8
VP20783
p9092
sg10
I33
sg11
VBrain Derived Neurotrophic Factor
p9093
sg13
I4
sa(dp9094
g7
I115
sg8
VP04271
p9095
sg10
I6
sg11
VS100-B
p9096
sg13
I1
sa(dp9097
g7
I235
sg8
VP01127
p9098
sg10
I33
sg11
VPlatelet-Derived Growth Factor-BB
p9099
sg13
I3
sa(dp9100
g7
I76
sg8
VP20783
p9101
sg10
I4
sg11
VBDNF
p9102
sg13
I1
sasg20
(lp9103
(dp9104
g7
I358
sg23
VC0039373
p9105
sg10
I3
sg11
VTSD
p9106
sg13
I1
sa(dp9107
g7
I440
sg23
VC0005586
p9108
sg10
I16
sg11
Vbipolar disorder
p9109
sg13
I2
sa(dp9110
g7
I398
sg23
VC0024517
p9111
sg10
I24
sg11
Vmajor depressive episode
p9112
sg13
I3
sasa(dp9113
g2
S"A possible role of the factors 'physical activity' and 'posture' in the antidepressant effect of a total night's sleep deprivation (TSD) was investigated in 30 patients with major depressive disorder.\n"
p9114
sg4
(lp9115
sg20
(lp9116
(dp9117
g7
I132
sg23
VC0039373
p9118
sg10
I3
sg11
VTSD
p9119
sg13
I1
sa(dp9120
g7
I99
sg23
VC0039373
p9121
sg10
I31
sg11
Vtotal night's sleep deprivation
p9122
sg13
I4
sa(dp9123
g7
I174
sg23
VC1269683
p9124
sg10
I25
sg11
Vmajor depressive disorder
p9125
sg13
I3
sasa(dp9126
g2
S'Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA).\n'
p9127
sg4
(lp9128
sg20
(lp9129
(dp9130
g7
I211
sg23
VC1865926
p9131
sg10
I4
sg11
ViCCA
p9132
sg13
I1
sa(dp9133
g7
I0
sg23
VC0206698
p9134
sg10
I18
sg11
VCholangiocarcinoma
p9135
sg13
I1
sa(dp9136
g7
I229
sg23
VC3151140
p9137
sg10
I4
sg11
VpCCA
p9138
sg13
I1
sa(dp9139
g7
I69
sg23
VC0027651
p9140
sg10
I7
sg11
Vtumours
p9141
sg13
I1
sa(dp9142
g7
I125
sg23
VC0206698
p9143
sg10
I19
sg11
Vcholangiocarcinomas
p9144
sg13
I1
sasa(dp9145
g2
S'Cholangiocarcinoma (CCA) represents a diverse group of epithelial cancers associated with the biliary tract, and can best be stratified anatomically into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) subsets.\n'
p9146
sg4
(lp9147
sg20
(lp9148
(dp9149
g7
I0
sg23
VC0206698
p9150
sg10
I18
sg11
VCholangiocarcinoma
p9151
sg13
I1
sa(dp9152
g7
I168
sg23
VC1865926
p9153
sg10
I4
sg11
ViCCA
p9154
sg13
I1
sa(dp9155
g7
I186
sg23
VC3151140
p9156
sg10
I4
sg11
VpCCA
p9157
sg13
I1
sa(dp9158
g7
I20
sg23
VC0220668
p9159
sg10
I3
sg11
VCCA
p9160
sg13
I1
sa(dp9161
g7
I66
sg23
VC0006826
p9162
sg10
I7
sg11
Vcancers
p9163
sg13
I1
sasa(dp9164
g2
S'Preoperative evaluation of vasculobiliary anatomy in the umbilical fissure (U-point) is pivotal for perihilar cholangiocarcinoma (PCCA) applied to right-sided hepatectomy.\n'
p9165
sg4
(lp9166
sg20
(lp9167
(dp9168
g7
I100
sg23
VC3151140
p9169
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p9170
sg13
I2
sa(dp9171
g7
I130
sg23
VC3151140
p9172
sg10
I4
sg11
VPCCA
p9173
sg13
I1
sasa(dp9174
g2
S'This study sought to define the role of adjuvant radiation therapy (RT) for patients with curative intent resection of perihilar cholangiocarcinoma (pCCA).\n'
p9175
sg4
(lp9176
sg20
(lp9177
(dp9178
g7
I119
sg23
VC3151140
p9179
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p9180
sg13
I2
sa(dp9181
g7
I149
sg23
VC3151140
p9182
sg10
I4
sg11
VpCCA
p9183
sg13
I1
sasa(dp9184
g2
S'Our goal was to characterize PD-L1 expression in intra-hepatic (iCCA) and perihilar (pCCA) cholangiocarcinomas, and to correlate our results with clinicopathological features, density of tumor-infiltrating lymphocytes (TILs) and PD-1 expression.A series of 58 iCCAs and 41 pCCAs was included in the study.\n'
p9185
sg4
(lp9186
(dp9187
g7
I229
sg8
VP18621
p9188
sg10
I4
sg11
VPD-1
p9189
sg13
I1
sasg20
(lp9190
(dp9191
g7
I91
sg23
VC0206698
p9192
sg10
I19
sg11
Vcholangiocarcinomas
p9193
sg13
I1
sa(dp9194
g7
I193
sg23
VC0332448
p9195
sg10
I12
sg11
Vinfiltrating
p9196
sg13
I1
sa(dp9197
g7
I85
sg23
VC3151140
p9198
sg10
I4
sg11
VpCCA
p9199
sg13
I1
sa(dp9200
g7
I64
sg23
VC1865926
p9201
sg10
I4
sg11
ViCCA
p9202
sg13
I1
sa(dp9203
g7
I187
sg23
VC0027651
p9204
sg10
I5
sg11
Vtumor
p9205
sg13
I1
sasa(dp9206
g2
S'Promising candidates for targeted, personalized therapy have emerged, including potential driver fibroblast growth factor receptor (FGFR) gene fusions and somatic mutations in isocitrate dehydrogenase (IDH)1/2 in iCCA, protein kinase cAMP-activated catalytic subunit alpha (PRKACA) or beta (PRKACB) gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma.\n'
p9207
sg4
(lp9208
(dp9209
g7
I176
sg8
VP48735
p9210
sg10
I113
sg11
Visocitrate dehydrogenase (IDH)1/2 in iCCA, protein kinase cAMP-activated catalytic subunit alpha (PRKACA) or beta
p9211
sg13
I14
sa(dp9212
g7
I315
sg8
VP05165
p9213
sg10
I4
sg11
VpCCA
p9214
sg13
I1
sa(dp9215
g7
I138
sg8
VP35637
p9216
sg10
I12
sg11
Vgene fusions
p9217
sg13
I2
sa(dp9218
g7
I325
sg8
VP78545
p9219
sg10
I4
sg11
VELF3
p9220
sg13
I1
sa(dp9221
g7
I132
sg8
g18
sg10
I4
sg11
VFGFR
p9222
sg13
I1
sa(dp9223
g7
I138
sg8
VP35637
p9224
sg10
I12
sg11
Vgene fusions
p9225
sg13
I2
sa(dp9226
g7
I97
sg8
g18
sg10
I33
sg11
Vfibroblast growth factor receptor
p9227
sg13
I4
sasg20
(lp9228
(dp9229
g7
I348
sg23
VC0262401
p9230
sg10
I19
sg11
Vampullary carcinoma
p9231
sg13
I2
sa(dp9232
g7
I155
sg23
VC0544886
p9233
sg10
I17
sg11
Vsomatic mutations
p9234
sg13
I2
sa(dp9235
g7
I213
sg23
VC1865926
p9236
sg10
I4
sg11
ViCCA
p9237
sg13
I1
sa(dp9238
g7
I315
sg23
VC3151140
p9239
sg10
I4
sg11
VpCCA
p9240
sg13
I1
sasa(dp9241
g2
S'Liver transplantation (LT) provides a good chance of cure for selected patients with hepatocellular carcinoma (HCC) and perihilar cholangiocarcinoma (pCCA).\n'
p9242
sg4
(lp9243
sg20
(lp9244
(dp9245
g7
I150
sg23
VC3151140
p9246
sg10
I4
sg11
VpCCA
p9247
sg13
I1
sa(dp9248
g7
I111
sg23
VC2239176
p9249
sg10
I3
sg11
VHCC
p9250
sg13
I1
sa(dp9251
g7
I120
sg23
VC3151140
p9252
sg10
I28
sg11
Vperihilar cholangiocarcinoma
p9253
sg13
I2
sa(dp9254
g7
I85
sg23
VC2239176
p9255
sg10
I24
sg11
Vhepatocellular carcinoma
p9256
sg13
I2
sasa(dp9257
g2
S"Here, we investigated BANCR's role in papillary thyroid carcinoma (PTC) by assessing BANCR levels in PTC and matched normal thyroid epithelial tissues from 92 patients using qRT-PCR.\n"
p9258
sg4
(lp9259
sg20
(lp9260
(dp9261
g7
I38
sg23
VC0238463
p9262
sg10
I27
sg11
Vpapillary thyroid carcinoma
p9263
sg13
I3
sa(dp9264
g7
I67
sg23
VC0238463
p9265
sg10
I3
sg11
VPTC
p9266
sg13
I1
sa(dp9267
g7
I67
sg23
VC0238463
p9268
sg10
I3
sg11
VPTC
p9269
sg13
I1
sasa(dp9270
g2
S'Of the three lncRNAs (BANCR, PTCSC3, and NAMA), expression of BANCR was significantly up-regulated while PTCSC3 and NAMA were significantly down-regulated in papillary thyroid carcinoma (PTC) compared to that in normal tissue.\n'
p9271
sg4
(lp9272
sg20
(lp9273
(dp9274
g7
I158
sg23
VC0238463
p9275
sg10
I27
sg11
Vpapillary thyroid carcinoma
p9276
sg13
I3
sa(dp9277
g7
I29
sg23
VC0238463
p9278
sg10
I3
sg11
VPTC
p9279
sg13
I1
sasa(dp9280
g2
S'However, little is known about the role of BANCR in the development of papillary thyroid carcinoma (PTC).\n'
p9281
sg4
(lp9282
sg20
(lp9283
(dp9284
g7
I100
sg23
VC0238463
p9285
sg10
I3
sg11
VPTC
p9286
sg13
I1
sa(dp9287
g7
I71
sg23
VC0238463
p9288
sg10
I27
sg11
Vpapillary thyroid carcinoma
p9289
sg13
I3
sasa(dp9290
g2
S'A Japanese randomized controlled study showed that Interferon a (IFN-a1b) therapy is clinically effective in decreasing the frequency of attacks in multiple sclerosis (MS), even in optico-spinal MS (OSMS).\n'
p9291
sg4
(lp9292
(dp9293
g7
I51
sg8
VP01571
p9294
sg10
I12
sg11
VInterferon a
p9295
sg13
I2
sa(dp9296
g7
I65
sg8
VP01562
p9297
sg10
I7
sg11
VIFN-a1b
p9298
sg13
I1
sasg20
(lp9299
(dp9300
g7
I168
sg23
VC0036429
p9301
sg10
I2
sg11
VMS
p9302
sg13
I1
sa(dp9303
g7
I168
sg23
VC0036429
p9304
sg10
I2
sg11
VMS
p9305
sg13
I1
sa(dp9306
g7
I148
sg23
VC0026769
p9307
sg10
I18
sg11
Vmultiple sclerosis
p9308
sg13
I2
sasa(dp9309
g2
S'Cytokines have a central role in multiple sclerosis (MS) pathogenesis and may contribute to the aetiology of MS. A polymorphism in the IFNA17 gene with an allele carrying a pre-mature stop codon has been suggested to convey a 26-fold increased risk for MS. We investigated the possible association between this polymorphism and MS using population-based samples from a genetically well-characterized population.\n'
p9310
sg4
(lp9311
(dp9312
g7
I135
sg8
VP01571
p9313
sg10
I11
sg11
VIFNA17 gene
p9314
sg13
I2
sasg20
(lp9315
(dp9316
g7
I53
sg23
VC0036429
p9317
sg10
I2
sg11
VMS
p9318
sg13
I1
sa(dp9319
g7
I33
sg23
VC0026769
p9320
sg10
I18
sg11
Vmultiple sclerosis
p9321
sg13
I2
sa(dp9322
g7
I53
sg23
VC0036429
p9323
sg10
I2
sg11
VMS
p9324
sg13
I1
sa(dp9325
g7
I57
sg23
VC0699748
p9326
sg10
I12
sg11
Vpathogenesis
p9327
sg13
I1
sasa(dp9328
g2
S'Interferon beta-1a (IFNa-1a) has demonstrated efficacy in multiple sclerosis (MS), although its mechanism of action remains only partly understood.\n'
p9329
sg4
(lp9330
(dp9331
g7
I0
sg8
VP01574
p9332
sg10
I18
sg11
VInterferon beta-1a
p9333
sg13
I2
sa(dp9334
g7
I20
sg8
VP05000
p9335
sg10
I7
sg11
VIFNa-1a
p9336
sg13
I1
sasg20
(lp9337
(dp9338
g7
I78
sg23
VC0026769
p9339
sg10
I2
sg11
VMS
p9340
sg13
I1
sa(dp9341
g7
I58
sg23
VC0026769
p9342
sg10
I18
sg11
Vmultiple sclerosis
p9343
sg13
I2
sasa(dp9344
g2
S'We evaluated the ex vivo and in vitro effects of IFNa-1a (Rebif) on regulatory T-cell (T(Reg)) function in 22 relapsing-remitting MS patients and 16 healthy controls.\n'
p9345
sg4
(lp9346
(dp9347
g7
I49
sg8
VP05000
p9348
sg10
I7
sg11
VIFNa-1a
p9349
sg13
I1
sasg20
(lp9350
sa(dp9351
g2
S'These patients were 40.6% of 14,553 enrolled in the parent study who had either chest radiography or chest CT. Occult injuries were pneumothorax, hemothorax, sternal or greater than 2 rib fractures, pulmonary contusion, thoracic spine or scapula fracture, and diaphragm or great vessel injury found on chest CT but not on preceding chest radiography.\n'
p9352
sg4
(lp9353
sg20
(lp9354
(dp9355
g7
I220
sg23
VC0729233
p9356
sg10
I8
sg11
Vthoracic
p9357
sg13
I1
sa(dp9358
g7
I146
sg23
VC0019123
p9359
sg10
I10
sg11
Vhemothorax
p9360
sg13
I1
sa(dp9361
g7
I132
sg23
VC0032326
p9362
sg10
I12
sg11
Vpneumothorax
p9363
sg13
I1
sasa(dp9364
g2
S'Patients with occult injury included 514 with pulmonary contusions (of 682 total, 75.4% occult), 405 with pneumothorax (of 597 total, 67.8% occult), 184 with hemothorax (of 230 total, 80.0% occult), those with greater than 2 rib fractures (n=672/1,120, 60.0% occult) or sternal fracture (n=269/281, 95.7% occult), 12 with great vessel injury (of 18 total, 66.7% occult), 5 with diaphragm injury (of 6, 83.3% occult), and 537 with multiple occult injuries.\n'
p9365
sg4
(lp9366
sg20
(lp9367
(dp9368
g7
I158
sg23
VC0019123
p9369
sg10
I10
sg11
Vhemothorax
p9370
sg13
I1
sa(dp9371
g7
I106
sg23
VC0032326
p9372
sg10
I12
sg11
Vpneumothorax
p9373
sg13
I1
sasa(dp9374
g2
S'Paraffin-embedded lung tissues obtained from 20 autopsied cadavers with complicated pneumonia and 10 control cadavers without pneumonia were used for immunohistochemical analyses using primary antibodies against podoplanin, vascular endothelial growth factor receptor-3 (VEGFR-3), CD34, vascular endothelial growth factor (VEGF)-C, VEGF-D, CD73, and CD163.\n'
p9375
sg4
(lp9376
(dp9377
g7
I212
sg8
g18
sg10
I10
sg11
Vpodoplanin
p9378
sg13
I1
sa(dp9379
g7
I271
sg8
VP35916
p9380
sg10
I7
sg11
VVEGFR-3
p9381
sg13
I1
sa(dp9382
g7
I350
sg8
g18
sg10
I5
sg11
VCD163
p9383
sg13
I1
sa(dp9384
g7
I340
sg8
VP21589
p9385
sg10
I4
sg11
VCD73
p9386
sg13
I1
sa(dp9387
g7
I332
sg8
g18
sg10
I6
sg11
VVEGF-D
p9388
sg13
I1
sa(dp9389
g7
I287
sg8
g18
sg10
I43
sg11
Vvascular endothelial growth factor (VEGF)-C
p9390
sg13
I5
sa(dp9391
g7
I224
sg8
VP35916
p9392
sg10
I45
sg11
Vvascular endothelial growth factor receptor-3
p9393
sg13
I5
sa(dp9394
g7
I281
sg8
VP28906
p9395
sg10
I4
sg11
VCD34
p9396
sg13
I1
sasg20
(lp9397
(dp9398
g7
I84
sg23
VC0032285
p9399
sg10
I9
sg11
Vpneumonia
p9400
sg13
I1
sa(dp9401
g7
I84
sg23
VC0032285
p9402
sg10
I9
sg11
Vpneumonia
p9403
sg13
I1
sasa(dp9404
g2
S'No significant difference was noticed in the sCD163 in patients with chronic hepatitis B, community acquired pneumonia, chronic glomerulonephritis, and acute pancreatitis (P &gt; 0.05).\n'
p9405
sg4
(lp9406
sg20
(lp9407
(dp9408
g7
I152
sg23
VC0001339
p9409
sg10
I18
sg11
Vacute pancreatitis
p9410
sg13
I2
sa(dp9411
g7
I90
sg23
VC0694549
p9412
sg10
I28
sg11
Vcommunity acquired pneumonia
p9413
sg13
I3
sa(dp9414
g7
I69
sg23
VC0524909
p9415
sg10
I19
sg11
Vchronic hepatitis B
p9416
sg13
I3
sa(dp9417
g7
I120
sg23
VC0152451
p9418
sg10
I26
sg11
Vchronic glomerulonephritis
p9419
sg13
I2
sasa(dp9420
g2
S'The follow-up after treatment for three HLH patients showed that serum levels of soluble CD163 were significantly reduced, but the soluble CD163 levels rebounded in one patient who was complicated by fungal pneumonia infection.\n'
p9421
sg4
(lp9422
(dp9423
g7
I89
sg8
g18
sg10
I5
sg11
VCD163
p9424
sg13
I1
sa(dp9425
g7
I89
sg8
g18
sg10
I5
sg11
VCD163
p9426
sg13
I1
sasg20
(lp9427
(dp9428
g7
I40
sg23
VC0024291
p9429
sg10
I3
sg11
VHLH
p9430
sg13
I1
sa(dp9431
g7
I200
sg23
VC0339961
p9432
sg10
I16
sg11
Vfungal pneumonia
p9433
sg13
I2
sa(dp9434
g7
I217
sg23
VC0009450
p9435
sg10
I9
sg11
Vinfection
p9436
sg13
I1
sasa(dp9437
g2
S'### #################(obstructive sleep apnea hypopnea syndrome, OSAHS)########(resistant hypertension, RH)###, OSAHS############ ### 80#OSAHS##RH##[##3######(#####)##, ##################(140/90 mmHg, 1 mmHg=0.133 kPa)]############, ######6#################, ###########(apnea hypopnea index, AHI)########(SaO(2))###########, ################ ### ###, AHI#(32.9+/-10.8)#/h(x+/-s, ##)##(9.4+/-6.5)#/h, ##SaO(2)#(0.682+/-0.062)##(0.884+/-0.056), #########(t####18.863#26.614, P##&lt;0.001)#######(150.5+/-9.8) mmHg##(140.7+/-6.8) mmHg, ####(97.8+/-7.3) mmHg##(88.6+/-6.3) mmHg#######(154.3+/-8.9) mmHg##(144.8+/-5.8) mmHg, ####(100.6+/-7.4) mmHg##(91.3+/-5.5) mmHg#######(145.5+/-8.8) mmHg##(135.8+/-5.7) mmHg, ####(93.8+/-6.4) mmHg##(84.6+/-5.9) mmHg, #########(t####7.832#6.903#7.005#6.848#8.025#7.554, P##&lt;0.001)##########(11.5+/-2.2)mmHg########(10.2+/-3.1)mmHg, #########(9.0+/-2.8)mmHg########(7.9+/-3.5)mmHg, #################, #########(t####9.732#6.936, P##&lt;0.001)########&lt;10%##########75.0%######37.5%, ########(X(2)=22.857, P&lt;0.01), ###############45##############, #####(3.2+/-0.4)#######(2.6+/-0.5)#, ########(t=9.276, P&lt;0.01)# ### OSAHS##RH###, ##OSAHS###########, ########, ##########.\n'
p9438
sg4
(lp9439
sg20
(lp9440
(dp9441
g7
I22
sg23
VC0520679
p9442
sg10
I23
sg11
Vobstructive sleep apnea
p9443
sg13
I3
sa(dp9444
g7
I65
sg23
VC0520679
p9445
sg10
I5
sg11
VOSAHS
p9446
sg13
I1
sa(dp9447
g7
I65
sg23
VC0520679
p9448
sg10
I5
sg11
VOSAHS
p9449
sg13
I1
sa(dp9450
g7
I90
sg23
VC0020538
p9451
sg10
I12
sg11
Vhypertension
p9452
sg13
I1
sa(dp9453
g7
I40
sg23
VC0003578
p9454
sg10
I5
sg11
Vapnea
p9455
sg13
I1
sa(dp9456
g7
I65
sg23
VC0520679
p9457
sg10
I5
sg11
VOSAHS
p9458
sg13
I1
sa(dp9459
g7
I65
sg23
VC0520679
p9460
sg10
I5
sg11
VOSAHS
p9461
sg13
I1
sa(dp9462
g7
I65
sg23
VC0520679
p9463
sg10
I5
sg11
VOSAHS
p9464
sg13
I1
sa(dp9465
g7
I46
sg23
VC2748060
p9466
sg10
I17
sg11
Vhypopnea syndrome
p9467
sg13
I2
sasa(dp9468
g2
S'This study intended to investigate the role of microRNA-27b (miR-27b) in proliferation of oral squamous cell carcinoma (OSCC) cells and to explore the potential molecular mechanism.\n'
p9469
sg4
(lp9470
(dp9471
g7
I47
sg8
g18
sg10
I12
sg11
VmicroRNA-27b
p9472
sg13
I1
sa(dp9473
g7
I61
sg8
g18
sg10
I7
sg11
VmiR-27b
p9474
sg13
I1
sasg20
(lp9475
(dp9476
g7
I95
sg23
VC0007137
p9477
sg10
I23
sg11
Vsquamous cell carcinoma
p9478
sg13
I3
sa(dp9479
g7
I73
sg23
VC0334094
p9480
sg10
I13
sg11
Vproliferation
p9481
sg13
I1
sasa(dp9482
g2
S'The miR-27b expression in OSCC cell lines was significantly decreased compared with control.\n'
p9483
sg4
(lp9484
(dp9485
g7
I4
sg8
g18
sg10
I7
sg11
VmiR-27b
p9486
sg13
I1
sasg20
(lp9487
sa(dp9488
g2
S'Overexpression of miR-27b remarkably inhibited OSCC cell proliferation.\n'
p9489
sg4
(lp9490
(dp9491
g7
I18
sg8
g18
sg10
I7
sg11
VmiR-27b
p9492
sg13
I1
sasg20
(lp9493
(dp9494
g7
I57
sg23
VC0334094
p9495
sg10
I13
sg11
Vproliferation
p9496
sg13
I1
sasa(dp9497
g2
S'Additionally, miR-27b could target and inhibit FZD7 expression and decrease the activity of Wnt signaling pathway.miR-27b could inhibit OSCC cell proliferation through inhibiting FZD7 and FZD7-mediated Wnt signaling pathway.\n'
p9498
sg4
(lp9499
(dp9500
g7
I47
sg8
g18
sg10
I4
sg11
VFZD7
p9501
sg13
I1
sa(dp9502
g7
I14
sg8
g18
sg10
I7
sg11
VmiR-27b
p9503
sg13
I1
sa(dp9504
g7
I47
sg8
g18
sg10
I4
sg11
VFZD7
p9505
sg13
I1
sa(dp9506
g7
I47
sg8
g18
sg10
I4
sg11
VFZD7
p9507
sg13
I1
sasg20
(lp9508
(dp9509
g7
I146
sg23
VC0334094
p9510
sg10
I13
sg11
Vproliferation
p9511
sg13
I1
sasa(dp9512
g2
S'The aim of this study was to investigate the functional significance of miR-23b and miR-27b in OSCC and to identify novel miR-23b/27b-mediated cancer pathways and target genes involved in OSCC oncogenesis and metastasis.\n'
p9513
sg4
(lp9514
(dp9515
g7
I84
sg8
g18
sg10
I7
sg11
VmiR-27b
p9516
sg13
I1
sa(dp9517
g7
I72
sg8
g18
sg10
I7
sg11
VmiR-23b
p9518
sg13
I1
sasg20
(lp9519
(dp9520
g7
I143
sg23
VC0006826
p9521
sg10
I6
sg11
Vcancer
p9522
sg13
I1
sa(dp9523
g7
I193
sg23
VC0007621
p9524
sg10
I11
sg11
Voncogenesis
p9525
sg13
I1
sa(dp9526
g7
I209
sg23
VC0027627
p9527
sg10
I10
sg11
Vmetastasis
p9528
sg13
I1
sasa(dp9529
g2
S'Expression levels of miR-23b and miR-27b were significantly reduced in OSCC specimens.\n'
p9530
sg4
(lp9531
(dp9532
g7
I21
sg8
g18
sg10
I7
sg11
VmiR-23b
p9533
sg13
I1
sa(dp9534
g7
I33
sg8
g18
sg10
I7
sg11
VmiR-27b
p9535
sg13
I1
sasg20
(lp9536
sa(dp9537
g2
S'Dysregulation of miR-27b has been detected in numerous types of human cancer, including hepatocellular carcinoma (HCC); however, the detailed role of miR-27b in HCC has yet to be elucidated.\n'
p9538
sg4
(lp9539
(dp9540
g7
I17
sg8
g18
sg10
I7
sg11
VmiR-27b
p9541
sg13
I1
sa(dp9542
g7
I17
sg8
g18
sg10
I7
sg11
VmiR-27b
p9543
sg13
I1
sasg20
(lp9544
(dp9545
g7
I70
sg23
VC0006826
p9546
sg10
I6
sg11
Vcancer
p9547
sg13
I1
sa(dp9548
g7
I88
sg23
VC2239176
p9549
sg10
I24
sg11
Vhepatocellular carcinoma
p9550
sg13
I2
sa(dp9551
g7
I114
sg23
VC2239176
p9552
sg10
I3
sg11
VHCC
p9553
sg13
I1
sa(dp9554
g7
I114
sg23
VC2239176
p9555
sg10
I3
sg11
VHCC
p9556
sg13
I1
sasa(dp9557
g2
S'Re-expression of miR-27b in human colon cancer HCT116 cells caused morphological changes and suppressed tumor growth, cell adhesion, and invasion.\n'
p9558
sg4
(lp9559
(dp9560
g7
I17
sg8
g18
sg10
I7
sg11
VmiR-27b
p9561
sg13
I1
sasg20
(lp9562
(dp9563
g7
I104
sg23
VC0598934
p9564
sg10
I12
sg11
Vtumor growth
p9565
sg13
I2
sa(dp9566
g7
I123
sg23
VC0001511
p9567
sg10
I8
sg11
Vadhesion
p9568
sg13
I1
sa(dp9569
g7
I137
sg23
VC2699153
p9570
sg10
I8
sg11
Vinvasion
p9571
sg13
I1
sa(dp9572
g7
I34
sg23
VC0699790
p9573
sg10
I12
sg11
Vcolon cancer
p9574
sg13
I2
sasa(dp9575
g2
S'The purposes of the current study were to investigate the effects of a monoclonal antibody (mAb) on cytosolic phospholipase A2 alpha (cPLA2Alfa) in mice with cerebral ischemia-reperfusion (IR) injury and to ascertain the potential mechanisms of those effects.\n'
p9576
sg4
(lp9577
(dp9578
g7
I100
sg8
VP47712
p9579
sg10
I32
sg11
Vcytosolic phospholipase A2 alpha
p9580
sg13
I4
sasg20
(lp9581
(dp9582
g7
I158
sg23
VC0917798
p9583
sg10
I17
sg11
Vcerebral ischemia
p9584
sg13
I2
sasa(dp9585
g2
S'This study evaluated whether the use of anti-cPLA2Alfa mAb could reduce stroke injury in a mouse model of cerebral IR injury.\n'
p9586
sg4
(lp9587
sg20
(lp9588
(dp9589
g7
I72
sg23
VC0038454
p9590
sg10
I6
sg11
Vstroke
p9591
sg13
I1
sasa(dp9592
g2
S'At the end of treatment, the levels of serum inflammatory factors of leukotriene B4 (LTB4), prostaglandin E2 (PGE2), tumor necrosis factor-Alfa (TNF-Alfa), and interleukin-6 (IL-6) were measured by enzyme linked immunosorbent assay (ELISA); the changes of the indexes of hemodynamic [left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), the maximal rate of increase/decrease in left ventricular pressure (+/-dp/dt max)], the ratio of the heart weight/body weight, and the ratio of the left ventricular weight/heart weight (LVW/HW), the myocardial infarction area, myocardial histopathological changes were observed in the three groups; myocardial tissues inflammatory related factors [the mRNA and protein expressions of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX)], and the expression levels of transforming growth factor-Beta (TGF-Beta)/Smads signal transduction pathway related protein (TGF-Beta1, Smad2/3, Collagen I, Collagen III) and cell apoptosis related factors (Bcl-2, Bax) protein were measured.\n'
p9593
sg4
(lp9594
(dp9595
g7
I1020
sg8
VP19883
p9596
sg10
I30
sg11
Vcell apoptosis related factors
p9597
sg13
I4
sa(dp9598
g7
I788
sg8
VP47712
p9599
sg10
I5
sg11
VcPLA2
p9600
sg13
I1
sa(dp9601
g7
I919
sg8
VP35555
p9602
sg10
I49
sg11
VSmads signal transduction pathway related protein
p9603
sg13
I6
sa(dp9604
g7
I909
sg8
VP18075
p9605
sg10
I8
sg11
VTGF-Beta
p9606
sg13
I1
sa(dp9607
g7
I814
sg8
VP35354
p9608
sg10
I5
sg11
VCOX-2
p9609
sg13
I1
sa(dp9610
g7
I970
sg8
VP01137
p9611
sg10
I9
sg11
VTGF-Beta1
p9612
sg13
I1
sa(dp9613
g7
I1052
sg8
VP10415
p9614
sg10
I5
sg11
VBcl-2
p9615
sg13
I1
sa(dp9616
g7
I160
sg8
VP05231
p9617
sg10
I13
sg11
Vinterleukin-6
p9618
sg13
I1
sa(dp9619
g7
I876
sg8
VP18075
p9620
sg10
I31
sg11
Vtransforming growth factor-Beta
p9621
sg13
I3
sa(dp9622
g7
I796
sg8
VP35354
p9623
sg10
I16
sg11
Vcyclooxygenase-2
p9624
sg13
I1
sa(dp9625
g7
I175
sg8
VP05231
p9626
sg10
I4
sg11
VIL-6
p9627
sg13
I1
sa(dp9628
g7
I117
sg8
VP01375
p9629
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p9630
sg13
I3
sa(dp9631
g7
I760
sg8
VP47712
p9632
sg10
I26
sg11
Vcytosolic phospholipase A2
p9633
sg13
I3
sa(dp9634
g7
I145
sg8
VP01375
p9635
sg10
I8
sg11
VTNF-Alfa
p9636
sg13
I1
sa(dp9637
g7
I981
sg8
g18
sg10
I7
sg11
VSmad2/3
p9638
sg13
I1
sasg20
(lp9639
(dp9640
g7
I117
sg23
VC0333516
p9641
sg10
I14
sg11
Vtumor necrosis
p9642
sg13
I2
sa(dp9643
g7
I575
sg23
VC0027051
p9644
sg10
I21
sg11
Vmyocardial infarction
p9645
sg13
I2
sasa(dp9646
g2
S'SNHG14 increased the expression of PLA2G4A by inhibition of miR-145-5p, which resulted in the activation of MCs in cerebral infarction.\n'
p9647
sg4
(lp9648
(dp9649
g7
I35
sg8
VP47712
p9650
sg10
I7
sg11
VPLA2G4A
p9651
sg13
I1
sa(dp9652
g7
I60
sg8
g18
sg10
I10
sg11
VmiR-145-5p
p9653
sg13
I1
sasg20
(lp9654
(dp9655
g7
I115
sg23
VC0038454
p9656
sg10
I19
sg11
Vcerebral infarction
p9657
sg13
I2
sa(dp9658
g7
I108
sg23
VC0036221
p9659
sg10
I3
sg11
VMCs
p9660
sg13
I1
sasa(dp9661
g2
S"We covered an introduction to sphingomyelinases and its enzymatic product ceramide, in membrane domains or lipid rafts and the nucleus; followed by crosstalk between sphingomyelinase and cytosolic phospholipase A2 (cPLA2) catalysed products including arachidonic acid, functions of acid sphingomyelinase (aSMase) and neutral sphingomyelinase (N-SMase) in neurons, neuronal progenitor cells, glial cells, and brain endothelial cells; alterations in acid and N-SMases in Niemann Pick Disease Type A, major depression, Alzheimer's disease, cerebral ischemia, and pain; and recent developments in identification of inhibitors to sphingomyelinases.\n"
p9662
sg4
(lp9663
(dp9664
g7
I469
sg8
g18
sg10
I27
sg11
VNiemann Pick Disease Type A
p9665
sg13
I5
sa(dp9666
g7
I317
sg8
g18
sg10
I24
sg11
Vneutral sphingomyelinase
p9667
sg13
I2
sa(dp9668
g7
I457
sg8
g18
sg10
I8
sg11
VN-SMases
p9669
sg13
I1
sa(dp9670
g7
I282
sg8
VP17405
p9671
sg10
I21
sg11
Vacid sphingomyelinase
p9672
sg13
I2
sa(dp9673
g7
I343
sg8
g18
sg10
I7
sg11
VN-SMase
p9674
sg13
I1
sa(dp9675
g7
I187
sg8
VP47712
p9676
sg10
I26
sg11
Vcytosolic phospholipase A2
p9677
sg13
I3
sa(dp9678
g7
I305
sg8
VP17405
p9679
sg10
I6
sg11
VaSMase
p9680
sg13
I1
sa(dp9681
g7
I215
sg8
VP47712
p9682
sg10
I5
sg11
VcPLA2
p9683
sg13
I1
sasg20
(lp9684
(dp9685
g7
I469
sg23
VC0028064
p9686
sg10
I20
sg11
VNiemann Pick Disease
p9687
sg13
I3
sa(dp9688
g7
I516
sg23
VC1521724
p9689
sg10
I19
sg11
VAlzheimer's disease
p9690
sg13
I2
sa(dp9691
g7
I498
sg23
VC1269683
p9692
sg10
I16
sg11
Vmajor depression
p9693
sg13
I2
sa(dp9694
g7
I537
sg23
VC0917798
p9695
sg10
I17
sg11
Vcerebral ischemia
p9696
sg13
I2
sasa(dp9697
g2
S'To compare the expression of c-myc and c-fms proto-oncogenes in the placenta and hydatidiform mole.\n'
p9698
sg4
(lp9699
(dp9700
g7
I29
sg8
VP12524
p9701
sg10
I5
sg11
Vc-myc
p9702
sg13
I1
sa(dp9703
g7
I39
sg8
VP09619
p9704
sg10
I5
sg11
Vc-fms
p9705
sg13
I1
sasg20
(lp9706
(dp9707
g7
I81
sg23
VC0020217
p9708
sg10
I17
sg11
Vhydatidiform mole
p9709
sg13
I2
sa(dp9710
g7
I41
sg23
VC0016053
p9711
sg10
I3
sg11
Vfms
p9712
sg13
I1
sasa(dp9713
g2
S'The results of northern blot hybridisation analysis showed that c-fms was expressed more strongly in hydatidiform moles compared with normal placenta of similar gestational age.\n'
p9714
sg4
(lp9715
(dp9716
g7
I64
sg8
VP09619
p9717
sg10
I5
sg11
Vc-fms
p9718
sg13
I1
sasg20
(lp9719
(dp9720
g7
I101
sg23
VC0020217
p9721
sg10
I18
sg11
Vhydatidiform moles
p9722
sg13
I2
sa(dp9723
g7
I66
sg23
VC0016053
p9724
sg10
I3
sg11
Vfms
p9725
sg13
I1
sasa(dp9726
g2
S'The difference in c-fms expression between hydatidiform moles and normal placentas suggests that c-fms may have a role in the development of molar pregnancies.\n'
p9727
sg4
(lp9728
(dp9729
g7
I18
sg8
VP09619
p9730
sg10
I5
sg11
Vc-fms
p9731
sg13
I1
sa(dp9732
g7
I18
sg8
VP09619
p9733
sg10
I5
sg11
Vc-fms
p9734
sg13
I1
sasg20
(lp9735
(dp9736
g7
I43
sg23
VC0020217
p9737
sg10
I18
sg11
Vhydatidiform moles
p9738
sg13
I2
sa(dp9739
g7
I20
sg23
VC0016053
p9740
sg10
I3
sg11
Vfms
p9741
sg13
I1
sa(dp9742
g7
I20
sg23
VC0016053
p9743
sg10
I3
sg11
Vfms
p9744
sg13
I1
sa(dp9745
g7
I141
sg23
VC0020217
p9746
sg10
I17
sg11
Vmolar pregnancies
p9747
sg13
I2
sasa(dp9748
g2
S'Here, employing multiple experimental models of CKD, we studied the effects of inhibition of the EP4 receptor, one of four receptor subtypes for the prostanoid prostaglandin E2.\n'
p9749
sg4
(lp9750
(dp9751
g7
I97
sg8
VP35408
p9752
sg10
I12
sg11
VEP4 receptor
p9753
sg13
I2
sasg20
(lp9754
sa(dp9755
g2
S'Indicating a glucose-independent mechanism of action, EP4 inhibition also attenuated proteinuria development and glomerular scarring in non-diabetic rats subjected to surgical renal mass ablation.\n'
p9756
sg4
(lp9757
(dp9758
g7
I54
sg8
VP35408
p9759
sg10
I3
sg11
VEP4
p9760
sg13
I1
sasg20
(lp9761
(dp9762
g7
I124
sg23
VC0008767
p9763
sg10
I8
sg11
Vscarring
p9764
sg13
I1
sasa(dp9765
g2
S'In rodent models of diabetic and non-diabetic CKD, EP4 inhibition attenuated renal injury through mechanisms that were distinct from either broadspectrum COX inhibition or "standard of care" renin angiotensin system blockade.\n'
p9766
sg4
(lp9767
(dp9768
g7
I191
sg8
VP00797
p9769
sg10
I17
sg11
Vrenin angiotensin
p9770
sg13
I2
sa(dp9771
g7
I51
sg8
VP35408
p9772
sg10
I3
sg11
VEP4
p9773
sg13
I1
sasg20
(lp9774
sa(dp9775
g2
S'EP4 inhibition may represent a viable repurposing opportunity for the treatment of CKD.\n'
p9776
sg4
(lp9777
(dp9778
g7
I0
sg8
VP35408
p9779
sg10
I3
sg11
VEP4
p9780
sg13
I1
sasg20
(lp9781
sa(dp9782
g2
S'In the endometriotic lesions, prostaglandin E2 (PGE2) produced by cyclooxygenase-2 (COX-2), binds to its EP4 receptor (EP4), and via c-Src kinase induces MMPs activation, promoting endometriosis.\n'
p9783
sg4
(lp9784
(dp9785
g7
I105
sg8
VP35408
p9786
sg10
I12
sg11
VEP4 receptor
p9787
sg13
I2
sa(dp9788
g7
I154
sg8
g18
sg10
I4
sg11
VMMPs
p9789
sg13
I1
sa(dp9790
g7
I105
sg8
VP35408
p9791
sg10
I3
sg11
VEP4
p9792
sg13
I1
sa(dp9793
g7
I66
sg8
VP35354
p9794
sg10
I16
sg11
Vcyclooxygenase-2
p9795
sg13
I1
sa(dp9796
g7
I84
sg8
VP35354
p9797
sg10
I5
sg11
VCOX-2
p9798
sg13
I1
sa(dp9799
g7
I133
sg8
VP41240
p9800
sg10
I12
sg11
Vc-Src kinase
p9801
sg13
I2
sasg20
(lp9802
(dp9803
g7
I181
sg23
VC0014175
p9804
sg10
I13
sg11
Vendometriosis
p9805
sg13
I1
sasa(dp9806
g2
S'The objective of the present study was to determine the effects of pharmacological inhibition of PGE2 receptors, EP2 and EP4, on molecular and cellular aspects of the pathogenesis of endometriosis and associated clinical symptoms.\n'
p9807
sg4
(lp9808
(dp9809
g7
I113
sg8
VP35408
p9810
sg10
I3
sg11
VEP2
p9811
sg13
I1
sa(dp9812
g7
I121
sg8
VP35408
p9813
sg10
I3
sg11
VEP4
p9814
sg13
I1
sa(dp9815
g7
I97
sg8
g18
sg10
I14
sg11
VPGE2 receptors
p9816
sg13
I2
sasg20
(lp9817
(dp9818
g7
I183
sg23
VC0014175
p9819
sg10
I13
sg11
Vendometriosis
p9820
sg13
I1
sa(dp9821
g7
I167
sg23
VC0699748
p9822
sg10
I12
sg11
Vpathogenesis
p9823
sg13
I1
sasa(dp9824
g2
S'Using human fluorescent endometriotic cell lines and chimeric mouse model as preclinical testing platform, our results, to our knowledge for the first time, indicate that selective inhibition of EP2/EP4: (i) decreases growth and survival of endometriosis lesions; (ii) decreases angiogenesis and innervation of endometriosis lesions; (iii) suppresses proinflammatory state of dorsal root ganglia neurons to decrease pelvic pain; (iv) decreases proinflammatory, estrogen-dominant, and progesterone-resistant molecular environment of the endometrium and endometriosis lesions; and (v) restores endometrial functional receptivity through multiple mechanisms.\n'
p9825
sg4
(lp9826
(dp9827
g7
I199
sg8
VP35408
p9828
sg10
I3
sg11
VEP4
p9829
sg13
I1
sa(dp9830
g7
I195
sg8
VP35408
p9831
sg10
I3
sg11
VEP2
p9832
sg13
I1
sasg20
(lp9833
(dp9834
g7
I241
sg23
VC0014175
p9835
sg10
I13
sg11
Vendometriosis
p9836
sg13
I1
sa(dp9837
g7
I241
sg23
VC0014175
p9838
sg10
I13
sg11
Vendometriosis
p9839
sg13
I1
sa(dp9840
g7
I241
sg23
VC0014175
p9841
sg10
I13
sg11
Vendometriosis
p9842
sg13
I1
sa(dp9843
g7
I416
sg23
VC0030794
p9844
sg10
I11
sg11
Vpelvic pain
p9845
sg13
I2
sasa(dp9846
g2
S'However, the effects of the secreted growth factors CCN2, TGF-Beta, and BMP4 on stromal tissues in ameloblastoma remain unclear.\n'
p9847
sg4
(lp9848
(dp9849
g7
I72
sg8
VP12644
p9850
sg10
I4
sg11
VBMP4
p9851
sg13
I1
sa(dp9852
g7
I28
sg8
VP19883
p9853
sg10
I28
sg11
Vsecreted growth factors CCN2
p9854
sg13
I4
sa(dp9855
g7
I58
sg8
VP18075
p9856
sg10
I8
sg11
VTGF-Beta
p9857
sg13
I1
sasg20
(lp9858
(dp9859
g7
I99
sg23
VC0002448
p9860
sg10
I13
sg11
Vameloblastoma
p9861
sg13
I1
sasa(dp9862
g2
S'Expression analysis revealed several genes that were differentially expressed between benign and malignant nodules (transforming growth factor, cadherin 1, collagen Alfa1, catenin Alfa1, integrin Alfa3, and fibronectin 1 [FN1]), between follicular adenomas and follicular variant of papillary thyroid carcinoma (FN1, laminin Gamma1, integrin Beta2, connective tissue growth factor, catenin Delta1, and integrin AlfaV), and between BRAF-wild-type and BRAF-mutated papillary thyroid carcinomas (TIMP metallopeptidase inhibitor 1; catenin Alfa1; secreted phosphoprotein 1; FN1; ADAM metallopeptidase with thrombospondin type 1 motif, 1; and selectin L).\n'
p9863
sg4
(lp9864
(dp9865
g7
I552
sg8
g18
sg10
I16
sg11
Vphosphoprotein 1
p9866
sg13
I2
sa(dp9867
g7
I382
sg8
g18
sg10
I14
sg11
Vcatenin Delta1
p9868
sg13
I2
sa(dp9869
g7
I575
sg8
g18
sg10
I21
sg11
VADAM metallopeptidase
p9870
sg13
I2
sa(dp9871
g7
I144
sg8
VP12830
p9872
sg10
I10
sg11
Vcadherin 1
p9873
sg13
I2
sa(dp9874
g7
I317
sg8
g18
sg10
I14
sg11
Vlaminin Gamma1
p9875
sg13
I2
sa(dp9876
g7
I493
sg8
VP01033
p9877
sg10
I33
sg11
VTIMP metallopeptidase inhibitor 1
p9878
sg13
I4
sa(dp9879
g7
I431
sg8
VP15056
p9880
sg10
I4
sg11
VBRAF
p9881
sg13
I1
sa(dp9882
g7
I349
sg8
VP29279
p9883
sg10
I31
sg11
Vconnective tissue growth factor
p9884
sg13
I4
sa(dp9885
g7
I602
sg8
VP07996
p9886
sg10
I46
sg11
Vthrombospondin type 1 motif, 1; and selectin L
p9887
sg13
I8
sasg20
(lp9888
(dp9889
g7
I283
sg23
VC0238463
p9890
sg10
I27
sg11
Vpapillary thyroid carcinoma
p9891
sg13
I3
sa(dp9892
g7
I481
sg23
VC0007097
p9893
sg10
I10
sg11
Vcarcinomas
p9894
sg13
I1
sa(dp9895
g7
I237
sg23
VC0205647
p9896
sg10
I19
sg11
Vfollicular adenomas
p9897
sg13
I2
sa(dp9898
g7
I107
sg23
VC0028259
p9899
sg10
I7
sg11
Vnodules
p9900
sg13
I1
sasa(dp9901
g2
S"The gain of function of miR-93/106b in leiomyoma smooth muscle cells, myometrial smooth muscle cells, and the leiomyosarcoma cell line dose dependently repressed F3 and IL8 through direct interactions with their respective 3'-untranslated region and indirectly through F3 repression inhibited IL8, CTGF, and PAI-1 expression, confirmed by using small interfering RNA silencing or factor Vlla (FVIIa) activation of F3, as well as reducing the rate of proliferation, while increasing caspase-3/7 activity.\n"
p9902
sg4
(lp9903
(dp9904
g7
I482
sg8
VP42574
p9905
sg10
I11
sg11
Vcaspase-3/7
p9906
sg13
I1
sa(dp9907
g7
I298
sg8
VP29279
p9908
sg10
I4
sg11
VCTGF
p9909
sg13
I1
sa(dp9910
g7
I380
sg8
g18
sg10
I11
sg11
Vfactor Vlla
p9911
sg13
I2
sa(dp9912
g7
I24
sg8
g18
sg10
I11
sg11
VmiR-93/106b
p9913
sg13
I1
sa(dp9914
g7
I308
sg8
VP05121
p9915
sg10
I5
sg11
VPAI-1
p9916
sg13
I1
sasg20
(lp9917
(dp9918
g7
I110
sg23
VC0023269
p9919
sg10
I14
sg11
Vleiomyosarcoma
p9920
sg13
I1
sa(dp9921
g7
I450
sg23
VC0334094
p9922
sg10
I13
sg11
Vproliferation
p9923
sg13
I1
sa(dp9924
g7
I39
sg23
VC0023267
p9925
sg10
I9
sg11
Vleiomyoma
p9926
sg13
I1
sasa(dp9927
g2
S'We concluded that differential expression of miR-93/106b and their direct and/or indirect regulatory functions on F3, IL8, CTGF, and PAI-1 expression, with key roles in inflammation and tissue turnover may be of significance in the outcome of leiomyoma growth and associated symptoms.\n'
p9928
sg4
(lp9929
(dp9930
g7
I45
sg8
g18
sg10
I11
sg11
VmiR-93/106b
p9931
sg13
I1
sa(dp9932
g7
I123
sg8
VP29279
p9933
sg10
I4
sg11
VCTGF
p9934
sg13
I1
sa(dp9935
g7
I133
sg8
VP05121
p9936
sg10
I5
sg11
VPAI-1
p9937
sg13
I1
sasg20
(lp9938
(dp9939
g7
I243
sg23
VC0023267
p9940
sg10
I9
sg11
Vleiomyoma
p9941
sg13
I1
sa(dp9942
g7
I264
sg23
VC0521989
p9943
sg10
I19
sg11
Vassociated symptoms
p9944
sg13
I2
sa(dp9945
g7
I169
sg23
VC0021368
p9946
sg10
I12
sg11
Vinflammation
p9947
sg13
I1
sasa(dp9948
g2
S'Immortalized leiomyoma and myometrial cells demonstrate increased mRNA and protein production of the ECM proteins, collagen 1A1 (15.0-fold), fibronectin 1 (2.93 fold), and connective tissue growth factor (9.40-fold) with exogenous TGF-beta3 stimulation.\n'
p9949
sg4
(lp9950
(dp9951
g7
I101
sg8
g18
sg10
I12
sg11
VECM proteins
p9952
sg13
I2
sa(dp9953
g7
I231
sg8
VP10600
p9954
sg10
I9
sg11
VTGF-beta3
p9955
sg13
I1
sa(dp9956
g7
I115
sg8
g18
sg10
I12
sg11
Vcollagen 1A1
p9957
sg13
I2
sasg20
(lp9958
(dp9959
g7
I13
sg23
VC0023267
p9960
sg10
I9
sg11
Vleiomyoma
p9961
sg13
I1
sasa(dp9962
g2
S'Notably, the expression of collagen 1A1, fibronectin 1, and connective tissue growth factor in myometrial cells increase to similar expression levels as those found in leiomyoma cells.\n'
p9963
sg4
(lp9964
(dp9965
g7
I71
sg8
g18
sg10
I20
sg11
Vtissue growth factor
p9966
sg13
I3
sa(dp9967
g7
I27
sg8
g18
sg10
I12
sg11
Vcollagen 1A1
p9968
sg13
I2
sasg20
(lp9969
(dp9970
g7
I168
sg23
VC0023267
p9971
sg10
I9
sg11
Vleiomyoma
p9972
sg13
I1
sasa(dp9973
g2
S'Gene-based association analyses using SKAT-O shows nominal significant association with multifocal FMD (N = 164) for myosin light chain kinase (MYLK, P = 0.01) previously involved in thoracic aortic aneurysm, obscurin (OBSCN), a sarcomeric protein (P = 0.003), dynein cytoplasmic heavy chain 1 (DYNC2H1, P = 0.02) and RNF213 previously associated with Moyamoya disease (P = 0.01).\n'
p9974
sg4
(lp9975
(dp9976
g7
I261
sg8
g18
sg10
I32
sg11
Vdynein cytoplasmic heavy chain 1
p9977
sg13
I5
sa(dp9978
g7
I144
sg8
g18
sg10
I4
sg11
VMYLK
p9979
sg13
I1
sa(dp9980
g7
I117
sg8
g18
sg10
I25
sg11
Vmyosin light chain kinase
p9981
sg13
I4
sa(dp9982
g7
I318
sg8
g18
sg10
I6
sg11
VRNF213
p9983
sg13
I1
sasg20
(lp9984
(dp9985
g7
I352
sg23
VC0026654
p9986
sg10
I16
sg11
VMoyamoya disease
p9987
sg13
I2
sa(dp9988
g7
I99
sg23
VC0265293
p9989
sg10
I3
sg11
VFMD
p9990
sg13
I1
sa(dp9991
g7
I183
sg23
VC0162872
p9992
sg10
I24
sg11
Vthoracic aortic aneurysm
p9993
sg13
I3
sasa(dp9994
g2
S'SKH-1 hairless mice immunosuppressed with cyclophosphamide and hairless SCID mice (SHO strain) were infected cutaneously with vaccinia virus.\n'
p9995
sg4
(lp9996
sg20
(lp9997
(dp9998
g7
I126
sg23
VC0042214
p9999
sg10
I8
sg11
Vvaccinia
p10000
sg13
I1
sa(dp10001
g7
I72
sg23
VC0085110
p10002
sg10
I4
sg11
VSCID
p10003
sg13
I1
sasa(dp10004
g2
S'To explore the risk factors associated with acute/subacute cerebral infarction (ASCI) in HIV-negative patients with cryptococcal meningitis (CM).\n'
p10005
sg4
(lp10006
sg20
(lp10007
(dp10008
g7
I116
sg23
VC0085436
p10009
sg10
I23
sg11
Vcryptococcal meningitis
p10010
sg13
I2
sa(dp10011
g7
I141
sg23
VC0085436
p10012
sg10
I2
sg11
VCM
p10013
sg13
I1
sa(dp10014
g7
I59
sg23
VC0038454
p10015
sg10
I19
sg11
Vcerebral infarction
p10016
sg13
I2
sa(dp10017
g7
I89
sg23
VC0019693
p10018
sg10
I3
sg11
VHIV
p10019
sg13
I1
sasa(dp10020
g2
S'Acute/subacute cerebral infarction (ASCI) in HIV-negative cryptococcal meningoencephalitis (CM) adults has rarely been examined by a series of MRI-based follow-up study.\n'
p10021
sg4
(lp10022
sg20
(lp10023
(dp10024
g7
I71
sg23
VC0025309
p10025
sg10
I19
sg11
Vmeningoencephalitis
p10026
sg13
I1
sa(dp10027
g7
I15
sg23
VC0038454
p10028
sg10
I19
sg11
Vcerebral infarction
p10029
sg13
I2
sa(dp10030
g7
I45
sg23
VC0019693
p10031
sg10
I3
sg11
VHIV
p10032
sg13
I1
sasa(dp10033
g2
S'In polycythemia vera (PV), leukocytosis, abnormal karyotype, phlebotomy requirement on hydroxyurea, increased bone marrow fibrosis, and mutations in ASXL1, SRSF2, and IDH2 were identified as additional adverse prognostic factors.\n'
p10034
sg4
(lp10035
(dp10036
g7
I167
sg8
VP48735
p10037
sg10
I4
sg11
VIDH2
p10038
sg13
I1
sasg20
(lp10039
(dp10040
g7
I110
sg23
VC0001815
p10041
sg10
I20
sg11
Vbone marrow fibrosis
p10042
sg13
I3
sa(dp10043
g7
I3
sg23
VC0032463
p10044
sg10
I17
sg11
Vpolycythemia vera
p10045
sg13
I2
sa(dp10046
g7
I27
sg23
VC0023518
p10047
sg10
I12
sg11
Vleukocytosis
p10048
sg13
I1
sa(dp10049
g7
I22
sg23
VC0032463
p10050
sg10
I2
sg11
VPV
p10051
sg13
I1
sasa(dp10052
g2
S'For essential thrombocythemia, reported risk factors for leukemic transformation include advanced age, extreme thrombocytosis, anemia, leukocytosis, and sequence variants/mutations involving TP53 and EZH2 (for expansion of gene symbols, see www.genenames.org); for polycythemia vera, advanced age, leukocytosis, abnormal karyotype, mutations involving SRSF2 and IDH2, and treatment with pipobroman, chlorambucil, or P32; and for PMF, increased blast percentage, thrombocytopenia, abnormal karyotype, triple-negative driver mutational status, and sequence variants/mutations involving SRSF2, RUNX1, CEBPA, and SH2B3.\n'
p10053
sg4
(lp10054
(dp10055
g7
I598
sg8
VP49715
p10056
sg10
I5
sg11
VCEBPA
p10057
sg13
I1
sa(dp10058
g7
I200
sg8
g18
sg10
I4
sg11
VEZH2
p10059
sg13
I1
sa(dp10060
g7
I362
sg8
VP48735
p10061
sg10
I4
sg11
VIDH2
p10062
sg13
I1
sa(dp10063
g7
I609
sg8
g18
sg10
I5
sg11
VSH2B3
p10064
sg13
I1
sasg20
(lp10065
(dp10066
g7
I265
sg23
VC0032463
p10067
sg10
I17
sg11
Vpolycythemia vera
p10068
sg13
I2
sa(dp10069
g7
I4
sg23
VC0040028
p10070
sg10
I25
sg11
Vessential thrombocythemia
p10071
sg13
I2
sa(dp10072
g7
I66
sg23
VC1510411
p10073
sg10
I14
sg11
Vtransformation
p10074
sg13
I1
sa(dp10075
g7
I135
sg23
VC0023518
p10076
sg10
I12
sg11
Vleukocytosis
p10077
sg13
I1
sa(dp10078
g7
I127
sg23
VC0002871
p10079
sg10
I6
sg11
Vanemia
p10080
sg13
I1
sa(dp10081
g7
I135
sg23
VC0023518
p10082
sg10
I12
sg11
Vleukocytosis
p10083
sg13
I1
sa(dp10084
g7
I111
sg23
VC0836924
p10085
sg10
I14
sg11
Vthrombocytosis
p10086
sg13
I1
sasa(dp10087
g2
S'It is caused by steroid sulfatase deficiency and is often associated with further clinical problems, such as cryptorchidism (~20%) or social communication deficits, such as attention deficit hyperactivity syndrome (40%) or autism (25%).\n'
p10088
sg4
(lp10089
(dp10090
g7
I16
sg8
VP08842
p10091
sg10
I17
sg11
Vsteroid sulfatase
p10092
sg13
I2
sasg20
(lp10093
(dp10094
g7
I109
sg23
VC0010417
p10095
sg10
I14
sg11
Vcryptorchidism
p10096
sg13
I1
sa(dp10097
g7
I173
sg23
VC0041671
p10098
sg10
I17
sg11
Vattention deficit
p10099
sg13
I2
sa(dp10100
g7
I205
sg23
VC0039082
p10101
sg10
I8
sg11
Vsyndrome
p10102
sg13
I1
sa(dp10103
g7
I16
sg23
VC2720163
p10104
sg10
I28
sg11
Vsteroid sulfatase deficiency
p10105
sg13
I3
sa(dp10106
g7
I223
sg23
VC0004352
p10107
sg10
I6
sg11
Vautism
p10108
sg13
I1
sasa(dp10109
g2
S'In fact, abnormal activation of GFI1B and GFI1 has been related to human medulloblastoma and is also likely to be relevant in blood malignancies.\n'
p10110
sg4
(lp10111
(dp10112
g7
I32
sg8
g18
sg10
I5
sg11
VGFI1B
p10113
sg13
I1
sa(dp10114
g7
I32
sg8
g18
sg10
I4
sg11
VGFI1
p10115
sg13
I1
sasg20
(lp10116
(dp10117
g7
I132
sg23
VC0006826
p10118
sg10
I12
sg11
Vmalignancies
p10119
sg13
I1
sa(dp10120
g7
I73
sg23
VC0025149
p10121
sg10
I15
sg11
Vmedulloblastoma
p10122
sg13
I1
sasa(dp10123
g2
S'In addition to the BRCA2 6174delT, the medulloblastoma cells had amplification of MYC, deletion at Xp11.2, and isochromosome 17, but no structural variations or overexpression of GFI1 or GFI1B.\n'
p10124
sg4
(lp10125
(dp10126
g7
I179
sg8
g18
sg10
I4
sg11
VGFI1
p10127
sg13
I1
sa(dp10128
g7
I187
sg8
g18
sg10
I5
sg11
VGFI1B
p10129
sg13
I1
sa(dp10130
g7
I82
sg8
VP12524
p10131
sg10
I3
sg11
VMYC
p10132
sg13
I1
sa(dp10133
g7
I19
sg8
VP51587
p10134
sg10
I14
sg11
VBRCA2 6174delT
p10135
sg13
I2
sasg20
(lp10136
(dp10137
g7
I39
sg23
VC0025149
p10138
sg10
I15
sg11
Vmedulloblastoma
p10139
sg13
I1
sa(dp10140
g7
I111
sg23
VC0242621
p10141
sg10
I13
sg11
Visochromosome
p10142
sg13
I1
sa(dp10143
g7
I65
sg23
VC1705759
p10144
sg10
I13
sg11
Vamplification
p10145
sg13
I1
sasa(dp10146
g2
S'In a recent publication in Nature, Northcott and colleagues identify a novel region of structural variation in medulloblastoma that leads to oncogenic activation of GFI1B and GFI1 by repositioning these genes next to super-enhancers.\n'
p10147
sg4
(lp10148
(dp10149
g7
I165
sg8
g18
sg10
I5
sg11
VGFI1B
p10150
sg13
I1
sa(dp10151
g7
I165
sg8
g18
sg10
I4
sg11
VGFI1
p10152
sg13
I1
sasg20
(lp10153
(dp10154
g7
I111
sg23
VC0025149
p10155
sg10
I15
sg11
Vmedulloblastoma
p10156
sg13
I1
sasa(dp10157
g2
S"Our results, supported by evidence from mouse models, identify GFI1 and GFI1B as prominent medulloblastoma oncogenes and implicate 'enhancer hijacking' as an efficient mechanism driving oncogene activation in a childhood cancer.\n"
p10158
sg4
(lp10159
(dp10160
g7
I72
sg8
g18
sg10
I5
sg11
VGFI1B
p10161
sg13
I1
sa(dp10162
g7
I63
sg8
g18
sg10
I4
sg11
VGFI1
p10163
sg13
I1
sasg20
(lp10164
(dp10165
g7
I211
sg23
VC0278704
p10166
sg10
I16
sg11
Vchildhood cancer
p10167
sg13
I2
sa(dp10168
g7
I186
sg23
VC1518575
p10169
sg10
I19
sg11
Voncogene activation
p10170
sg13
I2
sa(dp10171
g7
I91
sg23
VC0025149
p10172
sg10
I15
sg11
Vmedulloblastoma
p10173
sg13
I1
sasa(dp10174
g2
S'The fact that this woman could respond consistently to hMG 20 years after the diagnosis of premature menopause, it is clear that initially the etiology of the extremely high LH and FSH levels in an estrogen-deficient 18-year-old was the presence of gonadotropinoma secreting inert LH and FSH.\n'
p10175
sg4
(lp10176
(dp10177
g7
I181
sg8
VP01225
p10178
sg10
I3
sg11
VFSH
p10179
sg13
I1
sa(dp10180
g7
I55
sg8
VP52926
p10181
sg10
I6
sg11
VhMG 20
p10182
sg13
I2
sa(dp10183
g7
I181
sg8
VP01225
p10184
sg10
I3
sg11
VFSH
p10185
sg13
I1
sasg20
(lp10186
(dp10187
g7
I91
sg23
VC0025322
p10188
sg10
I19
sg11
Vpremature menopause
p10189
sg13
I2
sasa(dp10190
g2
S'Immunoglobulin (CD79a) binding protein 1 (IGBP1) is universally overexpressed in lung adenocarcinoma and exerts an anti-apoptotic effect by binding to PP2Ac.\n'
p10191
sg4
(lp10192
(dp10193
g7
I0
sg8
VP14222
p10194
sg10
I40
sg11
VImmunoglobulin (CD79a) binding protein 1
p10195
sg13
I5
sa(dp10196
g7
I151
sg8
VP67775
p10197
sg10
I5
sg11
VPP2Ac
p10198
sg13
I1
sa(dp10199
g7
I42
sg8
VP78318
p10200
sg10
I5
sg11
VIGBP1
p10201
sg13
I1
sasg20
(lp10202
(dp10203
g7
I81
sg23
VC0152013
p10204
sg10
I19
sg11
Vlung adenocarcinoma
p10205
sg13
I2
sasa(dp10206
g2
S'The Tfh cells from NSCLC patients were also less effective at downregulating IgD and upregulating CD27 expression in naive B cells, and induced less IgM, IgG and IgA secretion, than those from healthy controls.\n'
p10207
sg4
(lp10208
(dp10209
g7
I98
sg8
VP26842
p10210
sg10
I4
sg11
VCD27
p10211
sg13
I1
sa(dp10212
g7
I149
sg8
VP29965
p10213
sg10
I3
sg11
VIgM
p10214
sg13
I1
sa(dp10215
g7
I162
sg8
VP11912
p10216
sg10
I3
sg11
VIgA
p10217
sg13
I1
sasg20
(lp10218
(dp10219
g7
I19
sg23
VC0007131
p10220
sg10
I5
sg11
VNSCLC
p10221
sg13
I1
sasa(dp10222
g2
S'There were no findings in the bronchoscopy, but the lung biopsy showed a B-cell pulmonary lymphoma (positive to CD20 and CD79a in immunostaining).\n'
p10223
sg4
(lp10224
(dp10225
g7
I121
sg8
VP11912
p10226
sg10
I5
sg11
VCD79a
p10227
sg13
I1
sa(dp10228
g7
I112
sg8
VP35900
p10229
sg10
I4
sg11
VCD20
p10230
sg13
I1
sasg20
(lp10231
(dp10232
g7
I80
sg23
VC0519063
p10233
sg10
I18
sg11
Vpulmonary lymphoma
p10234
sg13
I2
sasa(dp10235
g2
S'To evaluate the possible synergistic effect of at risk genotypes of ARMS2/LOC387715 (A69S), DNA repair SMUG1 rs3087404, CCL2-2518, C3 (R102G), CFH Y402H, complement factor B (L9H), and complement factor I (CFI) (G119R) in advanced age-related macular degeneration compared to those of healthy controls.\n'
p10236
sg4
(lp10237
(dp10238
g7
I154
sg8
g18
sg10
I19
sg11
Vcomplement factor B
p10239
sg13
I3
sa(dp10240
g7
I120
sg8
VP13500
p10241
sg10
I9
sg11
VCCL2-2518
p10242
sg13
I1
sa(dp10243
g7
I74
sg8
VP0C7Q2
p10244
sg10
I9
sg11
VLOC387715
p10245
sg13
I1
sa(dp10246
g7
I206
sg8
VP05156
p10247
sg10
I3
sg11
VCFI
p10248
sg13
I1
sa(dp10249
g7
I92
sg8
g18
sg10
I26
sg11
VDNA repair SMUG1 rs3087404
p10250
sg13
I4
sa(dp10251
g7
I185
sg8
VP05156
p10252
sg10
I19
sg11
Vcomplement factor I
p10253
sg13
I3
sa(dp10254
g7
I68
sg8
VP0C7Q2
p10255
sg10
I5
sg11
VARMS2
p10256
sg13
I1
sasg20
(lp10257
(dp10258
g7
I231
sg23
VC0242383
p10259
sg10
I32
sg11
Vage-related macular degeneration
p10260
sg13
I3
sasa(dp10261
g2
S'The aim of this study was to determine the potential association between 10 single nucleotide polymorphisms (SNPs) located in 4 different genetic regions (CFI, COL8A1, LIPC, and APOE), and choroidal neovascularization in age-related macular degeneration and the development of choroidal neovascularization in highly myopic eyes of a Caucasian population.\n'
p10262
sg4
(lp10263
(dp10264
g7
I155
sg8
VP05156
p10265
sg10
I3
sg11
VCFI
p10266
sg13
I1
sa(dp10267
g7
I178
sg8
VP02649
p10268
sg10
I4
sg11
VAPOE
p10269
sg13
I1
sa(dp10270
g7
I160
sg8
VP27658
p10271
sg10
I6
sg11
VCOL8A1
p10272
sg13
I1
sa(dp10273
g7
I168
sg8
VP11150
p10274
sg10
I4
sg11
VLIPC
p10275
sg13
I1
sasg20
(lp10276
(dp10277
g7
I189
sg23
VC0600518
p10278
sg10
I28
sg11
Vchoroidal neovascularization
p10279
sg13
I2
sa(dp10280
g7
I189
sg23
VC0600518
p10281
sg10
I28
sg11
Vchoroidal neovascularization
p10282
sg13
I2
sa(dp10283
g7
I221
sg23
VC0242383
p10284
sg10
I32
sg11
Vage-related macular degeneration
p10285
sg13
I3
sasa(dp10286
g2
S'Furthermore we conducted a meta-analysis of COL8A1, CFI and LIPC genes SNPs (rs669676, rs10033900 and rs10468017) and found that only rs669676 of these SNPs were associated with high myopia neovascularization.\n'
p10287
sg4
(lp10288
(dp10289
g7
I60
sg8
VP11150
p10290
sg10
I15
sg11
VLIPC genes SNPs
p10291
sg13
I3
sa(dp10292
g7
I44
sg8
VP27658
p10293
sg10
I6
sg11
VCOL8A1
p10294
sg13
I1
sa(dp10295
g7
I52
sg8
VP05156
p10296
sg10
I3
sg11
VCFI
p10297
sg13
I1
sasg20
(lp10298
(dp10299
g7
I178
sg23
VC0271183
p10300
sg10
I11
sg11
Vhigh myopia
p10301
sg13
I2
sa(dp10302
g7
I190
sg23
VC0027686
p10303
sg10
I18
sg11
Vneovascularization
p10304
sg13
I1
sasa(dp10305
g2
S'To systematically review the association between complement factors I (CFI) polymorphisms and age-related macular degeneration (AMD) and to explore whether CFI polymorphisms are associated with AMD.\n'
p10306
sg4
(lp10307
(dp10308
g7
I71
sg8
VP05156
p10309
sg10
I3
sg11
VCFI
p10310
sg13
I1
sa(dp10311
g7
I71
sg8
g18
sg10
I3
sg11
VCFI
p10312
sg13
I1
sa(dp10313
g7
I49
sg8
g18
sg10
I20
sg11
Vcomplement factors I
p10314
sg13
I3
sasg20
(lp10315
(dp10316
g7
I94
sg23
VC0242383
p10317
sg10
I32
sg11
Vage-related macular degeneration
p10318
sg13
I3
sa(dp10319
g7
I128
sg23
VC0242383
p10320
sg10
I3
sg11
VAMD
p10321
sg13
I1
sa(dp10322
g7
I128
sg23
VC0242383
p10323
sg10
I3
sg11
VAMD
p10324
sg13
I1
sasa(dp10325
g2
S'Cytogenetic anomalies involving the 3q26 chromosomal region are rare in acute myeloid leukemia (AML).\n'
p10326
sg4
(lp10327
sg20
(lp10328
(dp10329
g7
I96
sg23
VC0023467
p10330
sg10
I3
sg11
VAML
p10331
sg13
I1
sa(dp10332
g7
I72
sg23
VC0023467
p10333
sg10
I22
sg11
Vacute myeloid leukemia
p10334
sg13
I3
sasa(dp10335
g2
S'The t(3;21)(q26.2;q22) translocation is a rare chromosomal abnormality exhibited almost exclusively in therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) or in the blastic crisis phase of chronic myelogenous leukemia, which results in the fusion of the runt related transcription factor 1 (RUNX1, also called AML1) gene at 21q22 to the myelodysplasia syndrome 1 (MDS1)-ecotropic virus integration site 1 (EVI1) complex locus (MECOM) at 3q26.2, generating various fusion transcripts, including AML1/MDS1/EVI1 (AME).\n'
p10336
sg4
(lp10337
(dp10338
g7
I278
sg8
VP20823
p10339
sg10
I35
sg11
Vrunt related transcription factor 1
p10340
sg13
I5
sa(dp10341
g7
I388
sg8
g18
sg10
I4
sg11
VMDS1
p10342
sg13
I1
sa(dp10343
g7
I430
sg8
VP32248
p10344
sg10
I4
sg11
VEVI1
p10345
sg13
I1
sa(dp10346
g7
I361
sg8
g18
sg10
I67
sg11
Vmyelodysplasia syndrome 1 (MDS1)-ecotropic virus integration site 1
p10347
sg13
I8
sa(dp10348
g7
I430
sg8
VP32248
p10349
sg10
I4
sg11
VEVI1
p10350
sg13
I1
sasg20
(lp10351
(dp10352
g7
I174
sg23
VC0023467
p10353
sg10
I3
sg11
VAML
p10354
sg13
I1
sa(dp10355
g7
I144
sg23
VC0023467
p10356
sg10
I22
sg11
Vacute myeloid leukemia
p10357
sg13
I3
sa(dp10358
g7
I47
sg23
VC0008625
p10359
sg10
I23
sg11
Vchromosomal abnormality
p10360
sg13
I2
sa(dp10361
g7
I213
sg23
VC0023473
p10362
sg10
I28
sg11
Vchronic myelogenous leukemia
p10363
sg13
I3
sa(dp10364
g7
I361
sg23
VC0026985
p10365
sg10
I14
sg11
Vmyelodysplasia
p10366
sg13
I1
sa(dp10367
g7
I170
sg23
VC0265219
p10368
sg10
I3
sg11
VMDS
p10369
sg13
I1
sa(dp10370
g7
I23
sg23
VC0040715
p10371
sg10
I13
sg11
Vtranslocation
p10372
sg13
I1
sa(dp10373
g7
I135
sg23
VC0039082
p10374
sg10
I8
sg11
Vsyndrome
p10375
sg13
I1
sa(dp10376
g7
I103
sg23
VC1292780
p10377
sg10
I40
sg11
Vtherapy-related myelodysplastic syndrome
p10378
sg13
I3
sa(dp10379
g7
I278
sg23
VC0013336
p10380
sg10
I4
sg11
Vrunt
p10381
sg13
I1
sasa(dp10382
g2
S'Chromosomal rearrangements between 3q21 and 3q26 induce inappropriate EVI1 expression by recruiting a GATA2-distal hematopoietic enhancer (G2DHE) to the proximity of the EVI1 gene, leading to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).\n'
p10383
sg4
(lp10384
(dp10385
g7
I139
sg8
VP23769
p10386
sg10
I5
sg11
VG2DHE
p10387
sg13
I1
sa(dp10388
g7
I70
sg8
VP32248
p10389
sg10
I4
sg11
VEVI1
p10390
sg13
I1
sa(dp10391
g7
I102
sg8
VP23769
p10392
sg10
I35
sg11
VGATA2-distal hematopoietic enhancer
p10393
sg13
I3
sa(dp10394
g7
I170
sg8
VP32248
p10395
sg10
I9
sg11
VEVI1 gene
p10396
sg13
I2
sasg20
(lp10397
(dp10398
g7
I218
sg23
VC0265219
p10399
sg10
I3
sg11
VMDS
p10400
sg13
I1
sa(dp10401
g7
I227
sg23
VC0023467
p10402
sg10
I22
sg11
Vacute myeloid leukemia
p10403
sg13
I3
sa(dp10404
g7
I192
sg23
VC3463824
p10405
sg10
I24
sg11
Vmyelodysplastic syndrome
p10406
sg13
I2
sa(dp10407
g7
I251
sg23
VC0023467
p10408
sg10
I3
sg11
VAML
p10409
sg13
I1
sasa(dp10410
g2
S'Transcriptional activation of the EVI1 oncogene (3q26) leads to aggressive forms of human acute myeloid leukemia (AML).\n'
p10411
sg4
(lp10412
(dp10413
g7
I34
sg8
VP32248
p10414
sg10
I13
sg11
VEVI1 oncogene
p10415
sg13
I2
sasg20
(lp10416
(dp10417
g7
I90
sg23
VC0023467
p10418
sg10
I22
sg11
Vacute myeloid leukemia
p10419
sg13
I3
sa(dp10420
g7
I114
sg23
VC0023467
p10421
sg10
I3
sg11
VAML
p10422
sg13
I1
sa(dp10423
g7
I64
sg23
VC0001807
p10424
sg10
I10
sg11
Vaggressive
p10425
sg13
I1
sasa(dp10426
g2
S'The significance of 3q26.2/EVI1 rearrangement has been well recognized in acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia.\n'
p10427
sg4
(lp10428
(dp10429
g7
I27
sg8
VP32248
p10430
sg10
I4
sg11
VEVI1
p10431
sg13
I1
sasg20
(lp10432
(dp10433
g7
I74
sg23
VC0023467
p10434
sg10
I22
sg11
Vacute myeloid leukemia
p10435
sg13
I3
sa(dp10436
g7
I128
sg23
VC0023473
p10437
sg10
I24
sg11
Vchronic myeloid leukemia
p10438
sg13
I3
sa(dp10439
g7
I98
sg23
VC0033027
p10440
sg10
I24
sg11
Vmyelodysplastic syndrome
p10441
sg13
I2
sasa(dp10442
g2
S'The transcription factor, zinc-finger protein 545 (ZNF545), that belongs to the Kruppel-associated box zinc-finger protein (KRAB-ZFP) family, acts as a tumor suppressor and is inactivated by promoter methylation in cancers such as nasopharyngeal carcinoma, breast cancer, and gastric cancer, but its role in colorectal cancer (CRC) is unknown.\n'
p10443
sg4
(lp10444
(dp10445
g7
I26
sg8
VP51504
p10446
sg10
I23
sg11
Vzinc-finger protein 545
p10447
sg13
I3
sa(dp10448
g7
I51
sg8
g18
sg10
I6
sg11
VZNF545
p10449
sg13
I1
sa(dp10450
g7
I124
sg8
g18
sg10
I8
sg11
VKRAB-ZFP
p10451
sg13
I1
sa(dp10452
g7
I80
sg8
g18
sg10
I42
sg11
VKruppel-associated box zinc-finger protein
p10453
sg13
I4
sasg20
(lp10454
(dp10455
g7
I276
sg23
VC0024623
p10456
sg10
I14
sg11
Vgastric cancer
p10457
sg13
I2
sa(dp10458
g7
I152
sg23
VC0027651
p10459
sg10
I5
sg11
Vtumor
p10460
sg13
I1
sa(dp10461
g7
I215
sg23
VC0006826
p10462
sg10
I7
sg11
Vcancers
p10463
sg13
I1
sa(dp10464
g7
I327
sg23
VC1527249
p10465
sg10
I3
sg11
VCRC
p10466
sg13
I1
sa(dp10467
g7
I308
sg23
VC1527249
p10468
sg10
I17
sg11
Vcolorectal cancer
p10469
sg13
I2
sa(dp10470
g7
I231
sg23
VC2931822
p10471
sg10
I24
sg11
Vnasopharyngeal carcinoma
p10472
sg13
I2
sa(dp10473
g7
I257
sg23
VC0678222
p10474
sg10
I13
sg11
Vbreast cancer
p10475
sg13
I2
sasa(dp10476
g2
S'ZBRK1, a zinc finger protein that interacts with breast cancer 1 (BRCA1) and KRAB-ZFP-associated protein 1 (KAP1), has been suggested to serve as a tumor suppressor via repression of tumor metastasis/invasion.\n'
p10477
sg4
(lp10478
(dp10479
g7
I49
sg8
VP38398
p10480
sg10
I15
sg11
Vbreast cancer 1
p10481
sg13
I3
sa(dp10482
g7
I108
sg8
VP31321
p10483
sg10
I4
sg11
VKAP1
p10484
sg13
I1
sa(dp10485
g7
I0
sg8
g18
sg10
I5
sg11
VZBRK1
p10486
sg13
I1
sa(dp10487
g7
I77
sg8
VP14222
p10488
sg10
I29
sg11
VKRAB-ZFP-associated protein 1
p10489
sg13
I3
sa(dp10490
g7
I66
sg8
VP38398
p10491
sg10
I5
sg11
VBRCA1
p10492
sg13
I1
sa(dp10493
g7
I9
sg8
VP13682
p10494
sg10
I19
sg11
Vzinc finger protein
p10495
sg13
I3
sasg20
(lp10496
(dp10497
g7
I49
sg23
VC0678222
p10498
sg10
I13
sg11
Vbreast cancer
p10499
sg13
I2
sa(dp10500
g7
I200
sg23
VC2699153
p10501
sg10
I8
sg11
Vinvasion
p10502
sg13
I1
sa(dp10503
g7
I148
sg23
VC0027651
p10504
sg10
I5
sg11
Vtumor
p10505
sg13
I1
sa(dp10506
g7
I183
sg23
VC0027627
p10507
sg10
I16
sg11
Vtumor metastasis
p10508
sg13
I2
sasa(dp10509
g2
S'Paroxysmal nocturnal hemoglobinuria (PNH) clones deficient in glycosylphosphatidylinositol-anchored molecules, including CD55 and CD59, have been previously described in patients with multiple myeloma (MM).\n'
p10510
sg4
(lp10511
(dp10512
g7
I121
sg8
VP08174
p10513
sg10
I4
sg11
VCD55
p10514
sg13
I1
sa(dp10515
g7
I130
sg8
VP13987
p10516
sg10
I4
sg11
VCD59
p10517
sg13
I1
sasg20
(lp10518
(dp10519
g7
I0
sg23
VC0024790
p10520
sg10
I35
sg11
VParoxysmal nocturnal hemoglobinuria
p10521
sg13
I3
sa(dp10522
g7
I184
sg23
VC0026764
p10523
sg10
I16
sg11
Vmultiple myeloma
p10524
sg13
I2
sa(dp10525
g7
I37
sg23
VC0024790
p10526
sg10
I3
sg11
VPNH
p10527
sg13
I1
sasa(dp10528
g2
S"We demonstrate that expression of the complement regulator CD59 is associated with resistance to rituximab-mediated complement lysis of multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) cell lines.\n"
p10529
sg4
(lp10530
(dp10531
g7
I59
sg8
VP13987
p10532
sg10
I4
sg11
VCD59
p10533
sg13
I1
sasg20
(lp10534
(dp10535
g7
I162
sg23
VC0024305
p10536
sg10
I22
sg11
Vnon-Hodgkin's lymphoma
p10537
sg13
I2
sa(dp10538
g7
I136
sg23
VC0026764
p10539
sg10
I16
sg11
Vmultiple myeloma
p10540
sg13
I2
sa(dp10541
g7
I127
sg23
VC0024348
p10542
sg10
I5
sg11
Vlysis
p10543
sg13
I1
sa(dp10544
g7
I186
sg23
VC0024305
p10545
sg10
I3
sg11
VNHL
p10546
sg13
I1
sasa(dp10547
g2
S"We demonstrate that expression of the complement regulator CD59 is associated with resistance to rituximab-mediated complement lysis of multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) cell lines.\n"
p10548
sg4
(lp10549
(dp10550
g7
I59
sg8
VP13987
p10551
sg10
I4
sg11
VCD59
p10552
sg13
I1
sasg20
(lp10553
(dp10554
g7
I162
sg23
VC0024305
p10555
sg10
I22
sg11
Vnon-Hodgkin's lymphoma
p10556
sg13
I2
sa(dp10557
g7
I136
sg23
VC0026764
p10558
sg10
I16
sg11
Vmultiple myeloma
p10559
sg13
I2
sa(dp10560
g7
I127
sg23
VC0024348
p10561
sg10
I5
sg11
Vlysis
p10562
sg13
I1
sa(dp10563
g7
I186
sg23
VC0024305
p10564
sg10
I3
sg11
VNHL
p10565
sg13
I1
sasa(dp10566
g2
S'Thirty-nine retinoblastoma cases were histopathologically diagnosed and analyzed by immunohistochemistry using monoclonal antibodies against the immature neural cell marker SRY-box containing gene 2 (SOX-2), the mature neuronal cell marker microtubule-associated protein 2 (MAP2), and the mature glial cell marker glial fibrillary acidic protein (GFAP).\n'
p10567
sg4
(lp10568
(dp10569
g7
I173
sg8
VP48431
p10570
sg10
I25
sg11
VSRY-box containing gene 2
p10571
sg13
I4
sa(dp10572
g7
I200
sg8
VP48431
p10573
sg10
I5
sg11
VSOX-2
p10574
sg13
I1
sa(dp10575
g7
I274
sg8
VP11137
p10576
sg10
I4
sg11
VMAP2
p10577
sg13
I1
sa(dp10578
g7
I240
sg8
VP11137
p10579
sg10
I32
sg11
Vmicrotubule-associated protein 2
p10580
sg13
I3
sasg20
(lp10581
(dp10582
g7
I12
sg23
VC0035335
p10583
sg10
I14
sg11
Vretinoblastoma
p10584
sg13
I1
sasa(dp10585
g2
S'Expression of SOX-2 was strong in 97.4% of retinoblastoma cases, while MAP-2 was expressed in 59% of cases.\n'
p10586
sg4
(lp10587
(dp10588
g7
I71
sg8
VP11137
p10589
sg10
I5
sg11
VMAP-2
p10590
sg13
I1
sa(dp10591
g7
I14
sg8
VP48431
p10592
sg10
I5
sg11
VSOX-2
p10593
sg13
I1
sasg20
(lp10594
(dp10595
g7
I43
sg23
VC0035335
p10596
sg10
I14
sg11
Vretinoblastoma
p10597
sg13
I1
sasa(dp10598
g2
S'Retinoblastoma cell lines showed strong positivity for SOX2 (90% of WERI-1 cells and 70% of Y79 cells) and MAP2 (90% of cells in both lines).\n'
p10599
sg4
(lp10600
(dp10601
g7
I55
sg8
VP48431
p10602
sg10
I4
sg11
VSOX2
p10603
sg13
I1
sa(dp10604
g7
I107
sg8
VP11137
p10605
sg10
I4
sg11
VMAP2
p10606
sg13
I1
sasg20
(lp10607
(dp10608
g7
I0
sg23
VC0035335
p10609
sg10
I14
sg11
VRetinoblastoma
p10610
sg13
I1
sasa(dp10611
g2
S'In the present study, the 4 Yamanaka transcription factors, Oct4, Sox2, Klf4 and c-myc, were transduced into retinoblastoma cells (Rbc51).\n'
p10612
sg4
(lp10613
(dp10614
g7
I72
sg8
g18
sg10
I4
sg11
VKlf4
p10615
sg13
I1
sa(dp10616
g7
I81
sg8
VP12524
p10617
sg10
I5
sg11
Vc-myc
p10618
sg13
I1
sa(dp10619
g7
I66
sg8
VP48431
p10620
sg10
I4
sg11
VSox2
p10621
sg13
I1
sasg20
(lp10622
(dp10623
g7
I109
sg23
VC0035335
p10624
sg10
I14
sg11
Vretinoblastoma
p10625
sg13
I1
sasa(dp10626
g2
S'Furthermore, we showed that CA promoted proteasomal degradation of several substrate proteins, including Cyclin B1, retinoblastoma (RB), SOX2, and glial fibrillary acid protein (GFAP), whereas MYC levels were not modified.\n'
p10627
sg4
(lp10628
(dp10629
g7
I116
sg8
g18
sg10
I19
sg11
Vretinoblastoma (RB)
p10630
sg13
I2
sa(dp10631
g7
I193
sg8
VP12524
p10632
sg10
I3
sg11
VMYC
p10633
sg13
I1
sa(dp10634
g7
I105
sg8
VP14635
p10635
sg10
I9
sg11
VCyclin B1
p10636
sg13
I2
sa(dp10637
g7
I137
sg8
VP48431
p10638
sg10
I4
sg11
VSOX2
p10639
sg13
I1
sasg20
(lp10640
(dp10641
g7
I132
sg23
VC0035335
p10642
sg10
I2
sg11
VRB
p10643
sg13
I1
sa(dp10644
g7
I116
sg23
VC0035335
p10645
sg10
I14
sg11
Vretinoblastoma
p10646
sg13
I1
sasa(dp10647
g2
S'Then, the expression of some cell-cycle-regulating genes including cyclin A2 (cyclin A2), Cyclin-dependent kinases 2 (CDK2), cyclin-dependent kinase inhibitors (P16, P18 and P27), Retinoblastoma (RB) and transcription factors (SMAD 4, SOX2 and SOX17) was investigated using quantitative RT-PCR.\n'
p10648
sg4
(lp10649
(dp10650
g7
I90
sg8
VP12004
p10651
sg10
I26
sg11
VCyclin-dependent kinases 2
p10652
sg13
I3
sa(dp10653
g7
I118
sg8
VP24941
p10654
sg10
I4
sg11
VCDK2
p10655
sg13
I1
sa(dp10656
g7
I125
sg8
VP49336
p10657
sg10
I34
sg11
Vcyclin-dependent kinase inhibitors
p10658
sg13
I3
sa(dp10659
g7
I244
sg8
g18
sg10
I5
sg11
VSOX17
p10660
sg13
I1
sa(dp10661
g7
I67
sg8
VP20248
p10662
sg10
I9
sg11
Vcyclin A2
p10663
sg13
I2
sa(dp10664
g7
I161
sg8
VP42771
p10665
sg10
I3
sg11
VP16
p10666
sg13
I1
sa(dp10667
g7
I166
sg8
VP42773
p10668
sg10
I3
sg11
VP18
p10669
sg13
I1
sa(dp10670
g7
I67
sg8
VP20248
p10671
sg10
I9
sg11
Vcyclin A2
p10672
sg13
I2
sa(dp10673
g7
I180
sg8
VP19883
p10674
sg10
I45
sg11
VRetinoblastoma (RB) and transcription factors
p10675
sg13
I5
sa(dp10676
g7
I174
sg8
VP40305
p10677
sg10
I3
sg11
VP27
p10678
sg13
I1
sa(dp10679
g7
I235
sg8
VP48431
p10680
sg10
I4
sg11
VSOX2
p10681
sg13
I1
sa(dp10682
g7
I227
sg8
g18
sg10
I6
sg11
VSMAD 4
p10683
sg13
I2
sasg20
(lp10684
(dp10685
g7
I196
sg23
VC0035335
p10686
sg10
I2
sg11
VRB
p10687
sg13
I1
sa(dp10688
g7
I180
sg23
VC0035335
p10689
sg10
I14
sg11
VRetinoblastoma
p10690
sg13
I1
sasa(dp10691
g2
S'This study investigates the association between angiogenic factors in retinoblastomas with choroidal and/or optic nerve invasion (high-risk/invasive retinoblastoma) and expression of Sox2, a stem cell marker.\n'
p10692
sg4
(lp10693
(dp10694
g7
I183
sg8
VP48431
p10695
sg10
I4
sg11
VSox2
p10696
sg13
I1
sa(dp10697
g7
I48
sg8
VP19883
p10698
sg10
I18
sg11
Vangiogenic factors
p10699
sg13
I2
sasg20
(lp10700
(dp10701
g7
I70
sg23
VC0035335
p10702
sg10
I15
sg11
Vretinoblastomas
p10703
sg13
I1
sa(dp10704
g7
I70
sg23
VC0035335
p10705
sg10
I14
sg11
Vretinoblastoma
p10706
sg13
I1
sa(dp10707
g7
I120
sg23
VC2699153
p10708
sg10
I8
sg11
Vinvasion
p10709
sg13
I1
sasa(dp10710
g2
S'To investigate the association between the expression of angiogenic factors and markers of tumor invasiveness, such as the stem cell marker Sox2, in retinoblastoma tissues.\n'
p10711
sg4
(lp10712
(dp10713
g7
I140
sg8
VP48431
p10714
sg10
I4
sg11
VSox2
p10715
sg13
I1
sasg20
(lp10716
(dp10717
g7
I91
sg23
VC0027651
p10718
sg10
I5
sg11
Vtumor
p10719
sg13
I1
sa(dp10720
g7
I149
sg23
VC0035335
p10721
sg10
I14
sg11
Vretinoblastoma
p10722
sg13
I1
sasa(dp10723
g2
S'Increased expression of angiogenic factors, with a concomitant increase in expression of the stem cell marker Sox2 observed in retinoblastoma tissues, may partially explain the aggressiveness of these tumors.\n'
p10724
sg4
(lp10725
(dp10726
g7
I24
sg8
VP19883
p10727
sg10
I18
sg11
Vangiogenic factors
p10728
sg13
I2
sa(dp10729
g7
I110
sg8
VP48431
p10730
sg10
I4
sg11
VSox2
p10731
sg13
I1
sasg20
(lp10732
(dp10733
g7
I201
sg23
VC0027651
p10734
sg10
I6
sg11
Vtumors
p10735
sg13
I1
sa(dp10736
g7
I127
sg23
VC0035335
p10737
sg10
I14
sg11
Vretinoblastoma
p10738
sg13
I1
sa(dp10739
g7
I177
sg23
VC0001807
p10740
sg10
I14
sg11
Vaggressiveness
p10741
sg13
I1
sasa(dp10742
g2
S'The present study aimed to investigate the association between the expression of sex-determining region Y box 2 (SOX2) in retinoblastoma (Rb) tissues and peripheral blood, and the clinicopathological characteristics of Rb.\n'
p10743
sg4
(lp10744
(dp10745
g7
I81
sg8
g18
sg10
I30
sg11
Vsex-determining region Y box 2
p10746
sg13
I5
sa(dp10747
g7
I122
sg8
g18
sg10
I19
sg11
Vretinoblastoma (Rb)
p10748
sg13
I2
sa(dp10749
g7
I113
sg8
VP48431
p10750
sg10
I4
sg11
VSOX2
p10751
sg13
I1
sasg20
(lp10752
(dp10753
g7
I138
sg23
VC0035335
p10754
sg10
I2
sg11
VRb
p10755
sg13
I1
sa(dp10756
g7
I138
sg23
VC0035335
p10757
sg10
I2
sg11
VRb
p10758
sg13
I1
sa(dp10759
g7
I122
sg23
VC0035335
p10760
sg10
I14
sg11
Vretinoblastoma
p10761
sg13
I1
sasa(dp10762
g2
S"We identified BACH2 (rs62408233-A, OR = 2.01 (1.71-2.37), P = 1.66 x 10-15 , MAF 0.46/0.29 in cases/controls) as a novel gene associated with Addison's disease development.\n"
p10763
sg4
(lp10764
(dp10765
g7
I14
sg8
g18
sg10
I5
sg11
VBACH2
p10766
sg13
I1
sasg20
(lp10767
(dp10768
g7
I142
sg23
VC0001403
p10769
sg10
I17
sg11
VAddison's disease
p10770
sg13
I2
sasa(dp10771
g2
S"Whilst BACH2 has been previously reported to associate with organ-specific autoimmune diseases co-inherited with Addison's disease, we have identified BACH2 as a major risk locus in Addison's disease, independent of concomitant autoimmune diseases.\n"
p10772
sg4
(lp10773
sg20
(lp10774
(dp10775
g7
I75
sg23
VC0004364
p10776
sg10
I19
sg11
Vautoimmune diseases
p10777
sg13
I2
sa(dp10778
g7
I75
sg23
VC0004364
p10779
sg10
I19
sg11
Vautoimmune diseases
p10780
sg13
I2
sa(dp10781
g7
I113
sg23
VC0001403
p10782
sg10
I17
sg11
VAddison's disease
p10783
sg13
I2
sa(dp10784
g7
I113
sg23
VC0001403
p10785
sg10
I17
sg11
VAddison's disease
p10786
sg13
I2
sasa(dp10787
g2
S"We aimed to evaluate the accuracy of fecal matrix metalloprotease-9 (MMP-9) and fecal lipocalin-2 (LCN-2) compared with calprotectin in detecting endoscopic activity in IBD STUDY:: Overall, 86 IBD adults underwent colonoscopy consecutively and prospectively, with Crohn's disease Endoscopic Index of Severity (CDEIS) in Crohn's disease (CD) patients or Mayo endoscopic subscore calculation for ulcerative colitis (UC) patients, and stool collection.\n"
p10788
sg4
(lp10789
(dp10790
g7
I99
sg8
VP80188
p10791
sg10
I5
sg11
VLCN-2
p10792
sg13
I1
sa(dp10793
g7
I43
sg8
g18
sg10
I24
sg11
Vmatrix metalloprotease-9
p10794
sg13
I2
sa(dp10795
g7
I69
sg8
VP14780
p10796
sg10
I5
sg11
VMMP-9
p10797
sg13
I1
sa(dp10798
g7
I86
sg8
VP80188
p10799
sg10
I11
sg11
Vlipocalin-2
p10800
sg13
I1
sasg20
(lp10801
(dp10802
g7
I264
sg23
VC0010346
p10803
sg10
I15
sg11
VCrohn's disease
p10804
sg13
I2
sa(dp10805
g7
I394
sg23
VC0009324
p10806
sg10
I18
sg11
Vulcerative colitis
p10807
sg13
I2
sa(dp10808
g7
I169
sg23
VC0021390
p10809
sg10
I3
sg11
VIBD
p10810
sg13
I1
sa(dp10811
g7
I169
sg23
VC0021390
p10812
sg10
I3
sg11
VIBD
p10813
sg13
I1
sa(dp10814
g7
I310
sg23
VC0010346
p10815
sg10
I2
sg11
VCD
p10816
sg13
I1
sa(dp10817
g7
I414
sg23
VC0009324
p10818
sg10
I2
sg11
VUC
p10819
sg13
I1
sa(dp10820
g7
I264
sg23
VC0010346
p10821
sg10
I15
sg11
VCrohn's disease
p10822
sg13
I2
sasa(dp10823
g2
S'Studies in the murine model of colitis have demonstrated that Lcn2 deficiency exacerbates colitogenesis; however, the therapeutic potential of Lcn2 supplementation has yet to be elucidated.\n'
p10824
sg4
(lp10825
(dp10826
g7
I62
sg8
VP80188
p10827
sg10
I4
sg11
VLcn2
p10828
sg13
I1
sa(dp10829
g7
I62
sg8
VP80188
p10830
sg10
I4
sg11
VLcn2
p10831
sg13
I1
sasg20
(lp10832
(dp10833
g7
I31
sg23
VC0009319
p10834
sg10
I7
sg11
Vcolitis
p10835
sg13
I1
sasa(dp10836
g2
S'In light of its potential mucoprotective functions, we, herein, investigated whether expression of Lcn2 in the probiotic bacterium can be exploited to alleviate experimental colitis.\n'
p10837
sg4
(lp10838
(dp10839
g7
I99
sg8
VP80188
p10840
sg10
I4
sg11
VLcn2
p10841
sg13
I1
sasg20
(lp10842
(dp10843
g7
I174
sg23
VC0009319
p10844
sg10
I7
sg11
Vcolitis
p10845
sg13
I1
sasa(dp10846
g2
S'Dextran sodium sulfate colitis model was used to investigate the colonization ability and therapeutic potential of Lactis-Lcn2 and Lactis-Con.\n'
p10847
sg4
(lp10848
(dp10849
g7
I122
sg8
VP80188
p10850
sg10
I4
sg11
VLcn2
p10851
sg13
I1
sasg20
(lp10852
(dp10853
g7
I23
sg23
VC0009319
p10854
sg10
I7
sg11
Vcolitis
p10855
sg13
I1
sasa(dp10856
g2
S'Consistent with these features, Lactis-Lcn2 displayed better mucoprotection against intestinal inflammation than Lactis-Con when administered into mice with dextran sulfate sodium-induced acute colitis.\n'
p10857
sg4
(lp10858
(dp10859
g7
I39
sg8
VP80188
p10860
sg10
I4
sg11
VLcn2
p10861
sg13
I1
sasg20
(lp10862
(dp10863
g7
I194
sg23
VC0009319
p10864
sg10
I7
sg11
Vcolitis
p10865
sg13
I1
sa(dp10866
g7
I95
sg23
VC0021368
p10867
sg10
I12
sg11
Vinflammation
p10868
sg13
I1
sasa(dp10869
g2
S'Our findings suggest that Lcn2 expression can be exploited to enhance the survivability of probiotic bacteria during inflammation, which could further improve its efficacy to treat experimental colitis.\n'
p10870
sg4
(lp10871
(dp10872
g7
I26
sg8
VP80188
p10873
sg10
I4
sg11
VLcn2
p10874
sg13
I1
sasg20
(lp10875
(dp10876
g7
I117
sg23
VC0021368
p10877
sg10
I12
sg11
Vinflammation
p10878
sg13
I1
sa(dp10879
g7
I194
sg23
VC0009319
p10880
sg10
I7
sg11
Vcolitis
p10881
sg13
I1
sasa(dp10882
g2
S'The data herein is related to the research article entitled "Microbiota-inducible Innate Immune, Siderophore Binding Protein Lipocalin 2 is Critical for Intestinal Homeostasis" (Singh et al., 2016) [1] where we have demonstrated that C57BL/6 Lipocalin 2 deficient mice (Lcn2KO) developed chronic colitis upon anti-interleukin-10 receptor (AlfaIL-10R) monoclonal antibody administration.\n'
p10883
sg4
(lp10884
(dp10885
g7
I309
sg8
VP22301
p10886
sg10
I28
sg11
Vanti-interleukin-10 receptor
p10887
sg13
I2
sa(dp10888
g7
I125
sg8
VP80188
p10889
sg10
I11
sg11
VLipocalin 2
p10890
sg13
I2
sa(dp10891
g7
I125
sg8
VP80188
p10892
sg10
I11
sg11
VLipocalin 2
p10893
sg13
I2
sasg20
(lp10894
(dp10895
g7
I288
sg23
VC0267375
p10896
sg10
I15
sg11
Vchronic colitis
p10897
sg13
I2
sasa(dp10898
g2
S'In the present article, we evaluated the susceptibility of BALB/c Lcn2KO mice and their WT littermates to the AlfaIL-10R neutralization-induced chronic colitis.\n'
p10899
sg4
(lp10900
sg20
(lp10901
(dp10902
g7
I144
sg23
VC0267375
p10903
sg10
I15
sg11
Vchronic colitis
p10904
sg13
I2
sasa(dp10905
g2
S'Our data showed that AlfaIL-10R mAb-treated BALB/c Lcn2KO mice exhibited severe chronic colitis (i.e., splenomegaly, colomegaly, colonic pathology, and incidence of rectal prolapse) when compared to WT mice.\n'
p10906
sg4
(lp10907
sg20
(lp10908
(dp10909
g7
I137
sg23
VC0677042
p10910
sg10
I9
sg11
Vpathology
p10911
sg13
I1
sa(dp10912
g7
I165
sg23
VC0034888
p10913
sg10
I15
sg11
Vrectal prolapse
p10914
sg13
I2
sa(dp10915
g7
I80
sg23
VC0267375
p10916
sg10
I15
sg11
Vchronic colitis
p10917
sg13
I2
sasa(dp10918
g2
S'Although Lcn2/NGAL expression is increased in the inflamed intestinal tissues of patients with inflammatory bowel disease, the role of Lcn2/NGAL in the development of intestinal inflammation remains unclear.\n'
p10919
sg4
(lp10920
(dp10921
g7
I9
sg8
VP80188
p10922
sg10
I4
sg11
VLcn2
p10923
sg13
I1
sa(dp10924
g7
I14
sg8
VP80188
p10925
sg10
I4
sg11
VNGAL
p10926
sg13
I1
sa(dp10927
g7
I9
sg8
VP80188
p10928
sg10
I4
sg11
VLcn2
p10929
sg13
I1
sa(dp10930
g7
I14
sg8
VP80188
p10931
sg10
I4
sg11
VNGAL
p10932
sg13
I1
sasg20
(lp10933
(dp10934
g7
I95
sg23
VC0021390
p10935
sg10
I26
sg11
Vinflammatory bowel disease
p10936
sg13
I3
sa(dp10937
g7
I178
sg23
VC0021368
p10938
sg10
I12
sg11
Vinflammation
p10939
sg13
I1
sasa(dp10940
g2
S'Here we investigated the role of Lcn2/NGAL in intestinal inflammation using a spontaneous mouse colitis model, interleukin-10 knock out (IL-10 KO) mice.\n'
p10941
sg4
(lp10942
(dp10943
g7
I33
sg8
VP80188
p10944
sg10
I4
sg11
VLcn2
p10945
sg13
I1
sa(dp10946
g7
I38
sg8
VP80188
p10947
sg10
I4
sg11
VNGAL
p10948
sg13
I1
sa(dp10949
g7
I111
sg8
VP22301
p10950
sg10
I14
sg11
Vinterleukin-10
p10951
sg13
I1
sasg20
(lp10952
(dp10953
g7
I57
sg23
VC0021368
p10954
sg10
I12
sg11
Vinflammation
p10955
sg13
I1
sa(dp10956
g7
I96
sg23
VC0009319
p10957
sg10
I7
sg11
Vcolitis
p10958
sg13
I1
sasa(dp10959
g2
S'Lcn2 expression in the colonic tissues of IL-10 KO mice increased with the development of colitis.\n'
p10960
sg4
(lp10961
(dp10962
g7
I0
sg8
VP80188
p10963
sg10
I4
sg11
VLcn2
p10964
sg13
I1
sasg20
(lp10965
(dp10966
g7
I90
sg23
VC0009319
p10967
sg10
I7
sg11
Vcolitis
p10968
sg13
I1
sasa(dp10969
g2
S'Lcn2/IL-10 double-KO mice showed a more rapid onset and development of colitis compared to IL-10 KO mice.\n'
p10970
sg4
(lp10971
(dp10972
g7
I0
sg8
VP80188
p10973
sg10
I4
sg11
VLcn2
p10974
sg13
I1
sasg20
(lp10975
(dp10976
g7
I71
sg23
VC0009319
p10977
sg10
I7
sg11
Vcolitis
p10978
sg13
I1
sasa(dp10979
g2
S'Transfer of Lcn2-repleted macrophages prevented the development of colitis in Lcn2/IL-10 double-KO mice in vivo.\n'
p10980
sg4
(lp10981
(dp10982
g7
I12
sg8
VP80188
p10983
sg10
I4
sg11
VLcn2
p10984
sg13
I1
sa(dp10985
g7
I12
sg8
VP80188
p10986
sg10
I4
sg11
VLcn2
p10987
sg13
I1
sasg20
(lp10988
(dp10989
g7
I67
sg23
VC0009319
p10990
sg10
I7
sg11
Vcolitis
p10991
sg13
I1
sasa(dp10992
g2
S'Mutations in NR5A1 have been reported as a frequent cause of 46,XY disorders of sex development (DSD) associated to a broad phenotypic spectrum ranging from infertility, ambiguous genitalia, anorchia to gonadal dygenesis and female genitalia.\n'
p10993
sg4
(lp10994
(dp10995
g7
I13
sg8
g18
sg10
I5
sg11
VNR5A1
p10996
sg13
I1
sasg20
(lp10997
(dp10998
g7
I61
sg23
VC2751824
p10999
sg10
I34
sg11
V46,XY disorders of sex development
p11000
sg13
I5
sa(dp11001
g7
I170
sg23
VC0266362
p11002
sg10
I19
sg11
Vambiguous genitalia
p11003
sg13
I2
sa(dp11004
g7
I97
sg23
VC0036875
p11005
sg10
I3
sg11
VDSD
p11006
sg13
I1
sa(dp11007
g7
I191
sg23
VC1261504
p11008
sg10
I8
sg11
Vanorchia
p11009
sg13
I1
sa(dp11010
g7
I157
sg23
VC0021359
p11011
sg10
I11
sg11
Vinfertility
p11012
sg13
I1
sasa(dp11013
g2
S'In 46,XX individuals, NR5A1 mutations are a rare genetic cause of POI, manifesting as primary or secondary amenorrhea, infertility, hypoestrogenism, and elevated gonadotropin levels.\n'
p11014
sg4
(lp11015
(dp11016
g7
I22
sg8
g18
sg10
I5
sg11
VNR5A1
p11017
sg13
I1
sasg20
(lp11018
(dp11019
g7
I97
sg23
VC0232940
p11020
sg10
I20
sg11
Vsecondary amenorrhea
p11021
sg13
I2
sa(dp11022
g7
I119
sg23
VC0021359
p11023
sg10
I11
sg11
Vinfertility
p11024
sg13
I1
sasa(dp11025
g2
S'In 46, XY individuals with mutation of SF-1 gene, adrenal failure, testis dysgenesis, androgen synthesis defects, hypospadias and anorchia with microphallus, infertility can occur from severe to mild.\n'
p11026
sg4
(lp11027
(dp11028
g7
I39
sg8
g18
sg10
I9
sg11
VSF-1 gene
p11029
sg13
I2
sasg20
(lp11030
(dp11031
g7
I158
sg23
VC0021359
p11032
sg10
I11
sg11
Vinfertility
p11033
sg13
I1
sa(dp11034
g7
I114
sg23
VC1691215
p11035
sg10
I11
sg11
Vhypospadias
p11036
sg13
I1
sa(dp11037
g7
I50
sg23
VC0001623
p11038
sg10
I15
sg11
Vadrenal failure
p11039
sg13
I2
sa(dp11040
g7
I130
sg23
VC1261504
p11041
sg10
I8
sg11
Vanorchia
p11042
sg13
I1
sa(dp11043
g7
I74
sg23
VC0000768
p11044
sg10
I10
sg11
Vdysgenesis
p11045
sg13
I1
sasa(dp11046
g2
S'Variants in SF-1/NR5A1 more commonly cause a spectrum of reproductive phenotypes ranging from 46,XY DSD (partial testicular dysgenesis or reduced androgen production) and hypospadias to male factor infertility or primary ovarian insufficiency.\n'
p11047
sg4
(lp11048
(dp11049
g7
I12
sg8
g18
sg10
I4
sg11
VSF-1
p11050
sg13
I1
sa(dp11051
g7
I17
sg8
g18
sg10
I5
sg11
VNR5A1
p11052
sg13
I1
sasg20
(lp11053
(dp11054
g7
I213
sg23
VC0041408
p11055
sg10
I29
sg11
Vprimary ovarian insufficiency
p11056
sg13
I3
sa(dp11057
g7
I94
sg23
VC2751824
p11058
sg10
I9
sg11
V46,XY DSD
p11059
sg13
I2
sa(dp11060
g7
I198
sg23
VC0021359
p11061
sg10
I11
sg11
Vinfertility
p11062
sg13
I1
sa(dp11063
g7
I113
sg23
VC0302885
p11064
sg10
I21
sg11
Vtesticular dysgenesis
p11065
sg13
I2
sa(dp11066
g7
I171
sg23
VC1691215
p11067
sg10
I11
sg11
Vhypospadias
p11068
sg13
I1
sasa(dp11069
g2
S'To study the role of NR5A1 in cryptorchidism and male factor infertility.\n'
p11070
sg4
(lp11071
(dp11072
g7
I21
sg8
g18
sg10
I5
sg11
VNR5A1
p11073
sg13
I1
sasg20
(lp11074
(dp11075
g7
I30
sg23
VC0010417
p11076
sg10
I14
sg11
Vcryptorchidism
p11077
sg13
I1
sa(dp11078
g7
I61
sg23
VC0021359
p11079
sg10
I11
sg11
Vinfertility
p11080
sg13
I1
sasa(dp11081
g2
S'Mutations in NR5A1 have been initially associated with primary adrenal insufficiency and 46,XY gonadal dysgenesis and more recently with less severe phenotypes, including preliminary descriptions in severe forms of male factor infertility.\n'
p11082
sg4
(lp11083
(dp11084
g7
I13
sg8
g18
sg10
I5
sg11
VNR5A1
p11085
sg13
I1
sasg20
(lp11086
(dp11087
g7
I95
sg23
VC0041408
p11088
sg10
I18
sg11
Vgonadal dysgenesis
p11089
sg13
I2
sa(dp11090
g7
I55
sg23
VC0001403
p11091
sg10
I29
sg11
Vprimary adrenal insufficiency
p11092
sg13
I3
sa(dp11093
g7
I227
sg23
VC0021359
p11094
sg10
I11
sg11
Vinfertility
p11095
sg13
I1
sasa(dp11096
g2
S'Newborns with cryptorchidism carry NR5A1 mutations at low frequency (0.7%), whereas no mutations were found in milder forms of infertility and normozoospermia, irrespective of the presence of cryptorchidism.\n'
p11097
sg4
(lp11098
(dp11099
g7
I14
sg8
VP51460
p11100
sg10
I36
sg11
Vcryptorchidism carry NR5A1 mutations
p11101
sg13
I4
sasg20
(lp11102
(dp11103
g7
I14
sg23
VC0010417
p11104
sg10
I14
sg11
Vcryptorchidism
p11105
sg13
I1
sa(dp11106
g7
I14
sg23
VC0010417
p11107
sg10
I14
sg11
Vcryptorchidism
p11108
sg13
I1
sa(dp11109
g7
I127
sg23
VC0021359
p11110
sg10
I11
sg11
Vinfertility
p11111
sg13
I1
sasa(dp11112
g2
S'This study, combined with what is already known about NR5A1-associated phenotypes, suggests considering mutations in this gene as a novel genetic cause of more severe forms of male factor infertility, especially when associated with a history of cryptorchidism.\n'
p11113
sg4
(lp11114
(dp11115
g7
I54
sg8
g18
sg10
I27
sg11
VNR5A1-associated phenotypes
p11116
sg13
I2
sasg20
(lp11117
(dp11118
g7
I246
sg23
VC0010417
p11119
sg10
I14
sg11
Vcryptorchidism
p11120
sg13
I1
sa(dp11121
g7
I188
sg23
VC0021359
p11122
sg10
I11
sg11
Vinfertility
p11123
sg13
I1
sasa(dp11124
g2
S'In the present study, we observed that the high expression of TXNDC17 (thioredoxin domain containing 17) was associated with Taxol resistance in colorectal cancer cells.\n'
p11125
sg4
(lp11126
(dp11127
g7
I62
sg8
g18
sg10
I7
sg11
VTXNDC17
p11128
sg13
I1
sa(dp11129
g7
I71
sg8
VP10599
p11130
sg10
I32
sg11
Vthioredoxin domain containing 17
p11131
sg13
I4
sasg20
(lp11132
(dp11133
g7
I145
sg23
VC1527249
p11134
sg10
I17
sg11
Vcolorectal cancer
p11135
sg13
I2
sasa(dp11136
g2
S'Taxol exposure induced high levels of phospho-STAT3 (Tyr 705) and TXNDC17; and increase of basal autophagy in colorectal cancer cells.\n'
p11137
sg4
(lp11138
(dp11139
g7
I66
sg8
g18
sg10
I7
sg11
VTXNDC17
p11140
sg13
I1
sa(dp11141
g7
I46
sg8
VP40763
p11142
sg10
I5
sg11
VSTAT3
p11143
sg13
I1
sasg20
(lp11144
(dp11145
g7
I110
sg23
VC1527249
p11146
sg10
I17
sg11
Vcolorectal cancer
p11147
sg13
I2
sasa(dp11148
g2
S'These results suggest the possibility that TXNDC17 could play an important role in Taxol resistance via enhancing autophagy in human colorectal cancer cells.\n'
p11149
sg4
(lp11150
(dp11151
g7
I43
sg8
g18
sg10
I7
sg11
VTXNDC17
p11152
sg13
I1
sasg20
(lp11153
(dp11154
g7
I133
sg23
VC1527249
p11155
sg10
I17
sg11
Vcolorectal cancer
p11156
sg13
I2
sasa(dp11157
g2
S'TXNDC17 may become a potential target of colorectal cancer therapeutics.\n'
p11158
sg4
(lp11159
(dp11160
g7
I0
sg8
g18
sg10
I7
sg11
VTXNDC17
p11161
sg13
I1
sasg20
(lp11162
(dp11163
g7
I41
sg23
VC1527249
p11164
sg10
I17
sg11
Vcolorectal cancer
p11165
sg13
I2
sasa(dp11166
g2
S'Sickle-(DeltaBeta)0-thalassemia is a rare variant of sickle cell disease (delta-beta thalassemia occurring in association with sickle hemoglobin, HbS), sparsely reported in literature, and has been associated with symptomatology necessitating careful monitoring and follow-up.\n'
p11167
sg4
(lp11168
(dp11169
g7
I127
sg8
g18
sg10
I17
sg11
Vsickle hemoglobin
p11170
sg13
I2
sasg20
(lp11171
(dp11172
g7
I74
sg23
VC0271985
p11173
sg10
I22
sg11
Vdelta-beta thalassemia
p11174
sg13
I2
sa(dp11175
g7
I20
sg23
VC0039730
p11176
sg10
I11
sg11
Vthalassemia
p11177
sg13
I1
sa(dp11178
g7
I53
sg23
VC0002895
p11179
sg10
I19
sg11
Vsickle cell disease
p11180
sg13
I3
sasa(dp11181
g2
S'Although much progress has been made in our understanding of the natural history, pathogenesis and clinical manifestations of Beta- and DeltaBeta-thalassemia, bone manifestations remain a puzzle for the clinician.\n'
p11182
sg4
(lp11183
sg20
(lp11184
(dp11185
g7
I146
sg23
VC0039730
p11186
sg10
I11
sg11
Vthalassemia
p11187
sg13
I1
sa(dp11188
g7
I82
sg23
VC0699748
p11189
sg10
I12
sg11
Vpathogenesis
p11190
sg13
I1
sasa(dp11191
g2
S'Background: Xmn-1 polymorphism of #Gglobin gene (HBG2) is a prominent quantitative trait loci (QTL) in Beta-thalassemia intermediate (Beta-TI).\n'
p11192
sg4
(lp11193
(dp11194
g7
I49
sg8
VP69892
p11195
sg10
I4
sg11
VHBG2
p11196
sg13
I1
sasg20
(lp11197
(dp11198
g7
I103
sg23
VC0005283
p11199
sg10
I16
sg11
VBeta-thalassemia
p11200
sg13
I1
sasa(dp11201
g2
S'A Ly1 antibody reactive (LYAR)-binding motif disruptive rSNP rs368698783 (G/A) from LD block 5 in the proximal promoter of hemoglobin subunit gamma 1 (HBG1) was found to be a significant predictor for Beta-thalassemia clinical severity by epigenetic-mediated variant-dependent HbF elevation.\n'
p11202
sg4
(lp11203
(dp11204
g7
I25
sg8
g18
sg10
I4
sg11
VLYAR
p11205
sg13
I1
sa(dp11206
g7
I151
sg8
VP69892
p11207
sg10
I4
sg11
VHBG1
p11208
sg13
I1
sa(dp11209
g7
I2
sg8
g18
sg10
I21
sg11
VLy1 antibody reactive
p11210
sg13
I3
sa(dp11211
g7
I123
sg8
VP69891
p11212
sg10
I26
sg11
Vhemoglobin subunit gamma 1
p11213
sg13
I4
sasg20
(lp11214
(dp11215
g7
I201
sg23
VC0005283
p11216
sg10
I16
sg11
VBeta-thalassemia
p11217
sg13
I1
sasa(dp11218
g2
S'Hereditary persistence of fetal hemoglobin deletion type-2 (HPFH-2) and Sicilian-DeltaBeta-thalassemia are conditions described as large deletions of the human Beta-like globin cluster, with absent Beta-globin chains and a compensatory variable increase in Gamma-globin.\n'
p11219
sg4
(lp11220
(dp11221
g7
I26
sg8
VP14207
p11222
sg10
I16
sg11
Vfetal hemoglobin
p11223
sg13
I2
sasg20
(lp11224
(dp11225
g7
I0
sg23
VC0271995
p11226
sg10
I56
sg11
VHereditary persistence of fetal hemoglobin deletion type
p11227
sg13
I7
sa(dp11228
g7
I91
sg23
VC0039730
p11229
sg10
I11
sg11
Vthalassemia
p11230
sg13
I1
sa(dp11231
g7
I60
sg23
VC1841621
p11232
sg10
I4
sg11
VHPFH
p11233
sg13
I1
sasa(dp11234
g2
S'Forty-nine differentially expressed miRNAs were identified by microarrays in CD34+-derived erythroid cells of two subjects heterozygous for Sicilian-DeltaBeta-thalassemia, 2 for HPFH-2 and 3 for controls after 13 days of culture.\n'
p11235
sg4
(lp11236
(dp11237
g7
I77
sg8
VP28906
p11238
sg10
I5
sg11
VCD34+
p11239
sg13
I1
sasg20
(lp11240
(dp11241
g7
I159
sg23
VC0039730
p11242
sg10
I11
sg11
Vthalassemia
p11243
sg13
I1
sa(dp11244
g7
I178
sg23
VC1841621
p11245
sg10
I4
sg11
VHPFH
p11246
sg13
I1
sasa(dp11247
g2
S'These data suggest an important action for miRNA that may partially explain the phenotypic differences between HPFH-2 and Sicilian DeltaBeta-thalassemia and the increased expression of Gamma-globin in these conditions.\n'
p11248
sg4
(lp11249
sg20
(lp11250
(dp11251
g7
I141
sg23
VC0039730
p11252
sg10
I11
sg11
Vthalassemia
p11253
sg13
I1
sa(dp11254
g7
I111
sg23
VC1841621
p11255
sg10
I4
sg11
VHPFH
p11256
sg13
I1
sasa(dp11257
g2
S'We assessed the effectiveness of this method for detecting Beta-thalassemia (Beta-thal), DeltaBeta-thalassemia (DeltaBeta-thal) and most common Hb variants.\n'
p11258
sg4
(lp11259
(dp11260
g7
I144
sg8
VP26640
p11261
sg10
I11
sg11
VHb variants
p11262
sg13
I2
sasg20
(lp11263
(dp11264
g7
I59
sg23
VC0005283
p11265
sg10
I16
sg11
VBeta-thalassemia
p11266
sg13
I1
sa(dp11267
g7
I64
sg23
VC0039730
p11268
sg10
I11
sg11
Vthalassemia
p11269
sg13
I1
sa(dp11270
g7
I59
sg23
VC0005283
p11271
sg10
I9
sg11
VBeta-thal
p11272
sg13
I1
sasa(dp11273
g2
S'Disorders resulting from mutations in the hemoglobin subunit beta gene (HBB; which encodes Beta-globin), mainly sickle cell disease (SCD) and Beta-thalassemia, become symptomatic postnatally as fetal Gamma-globin expression from two paralogous genes, hemoglobin subunit gamma 1 (HBG1) and HBG2, decreases and adult Beta-globin expression increases, thereby shifting red blood cell (RBC) hemoglobin from the fetal (referred to as HbF or Alfa2Gamma2) to adult (referred to as HbA or Alfa2Beta2) form.\n'
p11274
sg4
(lp11275
(dp11276
g7
I42
sg8
g18
sg10
I28
sg11
Vhemoglobin subunit beta gene
p11277
sg13
I4
sa(dp11278
g7
I251
sg8
VP69891
p11279
sg10
I26
sg11
Vhemoglobin subunit gamma 1
p11280
sg13
I4
sa(dp11281
g7
I72
sg8
VP02042
p11282
sg10
I3
sg11
VHBB
p11283
sg13
I1
sa(dp11284
g7
I279
sg8
VP69892
p11285
sg10
I4
sg11
VHBG1
p11286
sg13
I1
sa(dp11287
g7
I42
sg8
g18
sg10
I10
sg11
Vhemoglobin
p11288
sg13
I1
sa(dp11289
g7
I474
sg8
g18
sg10
I3
sg11
VHbA
p11290
sg13
I1
sa(dp11291
g7
I289
sg8
VP69892
p11292
sg10
I4
sg11
VHBG2
p11293
sg13
I1
sa(dp11294
g7
I194
sg8
VP14207
p11295
sg10
I18
sg11
Vfetal Gamma-globin
p11296
sg13
I2
sasg20
(lp11297
(dp11298
g7
I112
sg23
VC0002895
p11299
sg10
I19
sg11
Vsickle cell disease
p11300
sg13
I3
sa(dp11301
g7
I142
sg23
VC0005283
p11302
sg10
I16
sg11
VBeta-thalassemia
p11303
sg13
I1
sa(dp11304
g7
I133
sg23
VC0002895
p11305
sg10
I3
sg11
VSCD
p11306
sg13
I1
sasa(dp11307
g2
S'Hepatocellular carcinoma development is complex because of the metabolism disequilibrium involving SULT1A3/4, a predominant sulfotransferase that metabolizes sulfonic xenobiotics and endogenous catecholamines.\n'
p11308
sg4
(lp11309
(dp11310
g7
I99
sg8
VP50224
p11311
sg10
I9
sg11
VSULT1A3/4
p11312
sg13
I1
sa(dp11313
g7
I124
sg8
g18
sg10
I16
sg11
Vsulfotransferase
p11314
sg13
I1
sasg20
(lp11315
(dp11316
g7
I0
sg23
VC1512411
p11317
sg10
I24
sg11
VHepatocellular carcinoma
p11318
sg13
I2
sa(dp11319
g7
I74
sg23
VC0394006
p11320
sg10
I14
sg11
Vdisequilibrium
p11321
sg13
I1
sasa(dp11322
g2
S'However, the correlation between SULT1A3/4 and hepatocellular carcinoma progression is unclear.\n'
p11323
sg4
(lp11324
(dp11325
g7
I33
sg8
VP50224
p11326
sg10
I9
sg11
VSULT1A3/4
p11327
sg13
I1
sasg20
(lp11328
(dp11329
g7
I47
sg23
VC1512411
p11330
sg10
I24
sg11
Vhepatocellular carcinoma
p11331
sg13
I2
sasa(dp11332
g2
S'By utilizing immunofluorescence and immunohistochemical analysis, we found that in nine hepatocellular carcinoma clinical specimens, SULT1A3/4 was abundantly expressed in tumor tissues compared to that in the adjacent tissues.\n'
p11333
sg4
(lp11334
(dp11335
g7
I133
sg8
VP50224
p11336
sg10
I9
sg11
VSULT1A3/4
p11337
sg13
I1
sasg20
(lp11338
(dp11339
g7
I88
sg23
VC1512411
p11340
sg10
I24
sg11
Vhepatocellular carcinoma
p11341
sg13
I2
sa(dp11342
g7
I171
sg23
VC0027651
p11343
sg10
I5
sg11
Vtumor
p11344
sg13
I1
sasa(dp11345
g2
S'Moreover, liver cancer cells (HepG2, MHCC97-L, and MHCC97-H) had higher basal expression of SULT1A3/4 than immortalized liver cells (L02 and Chang liver).\n'
p11346
sg4
(lp11347
(dp11348
g7
I92
sg8
VP50224
p11349
sg10
I9
sg11
VSULT1A3/4
p11350
sg13
I1
sasg20
(lp11351
(dp11352
g7
I10
sg23
VC0345904
p11353
sg10
I12
sg11
Vliver cancer
p11354
sg13
I2
sasa(dp11355
g2
S'Interestingly, dopamine significantly induced SULT1A3/4 expression in liver cancer HepG2 cells, while decreased that in L02 cells.\n'
p11356
sg4
(lp11357
(dp11358
g7
I46
sg8
VP50224
p11359
sg10
I9
sg11
VSULT1A3/4
p11360
sg13
I1
sasg20
(lp11361
(dp11362
g7
I70
sg23
VC0345904
p11363
sg10
I12
sg11
Vliver cancer
p11364
sg13
I2
sasa(dp11365
g2
S'Our results implied that SULT1A3/4 exhibited bidirectional effect on tumor and normal hepatocytes and may thus provide a novel strategy for hepatocellular carcinoma clinical targeting.\n'
p11366
sg4
(lp11367
(dp11368
g7
I25
sg8
VP50224
p11369
sg10
I9
sg11
VSULT1A3/4
p11370
sg13
I1
sasg20
(lp11371
(dp11372
g7
I140
sg23
VC1512411
p11373
sg10
I24
sg11
Vhepatocellular carcinoma
p11374
sg13
I2
sa(dp11375
g7
I69
sg23
VC0027651
p11376
sg10
I5
sg11
Vtumor
p11377
sg13
I1
sasa(dp11378
g2
S'In addition, SULT1A3/4 re-expression could serve as a biomarker for hepatocellular carcinoma prognosis.\n'
p11379
sg4
(lp11380
(dp11381
g7
I13
sg8
VP50224
p11382
sg10
I9
sg11
VSULT1A3/4
p11383
sg13
I1
sasg20
(lp11384
(dp11385
g7
I68
sg23
VC1512411
p11386
sg10
I24
sg11
Vhepatocellular carcinoma
p11387
sg13
I2
sasa(dp11388
g2
S'The aim of our study was to compare microvascular changes examined by nailfold videocapillaroscopy (NVC) examination with serum concentrations of vascular endothelial growth factor (VEGF), soluble thrombomodulin (sTM) and endothelin-1 (ET-1) in people with Type 1 diabetes with and without microangiopathy.\n'
p11389
sg4
(lp11390
(dp11391
g7
I189
sg8
g18
sg10
I22
sg11
Vsoluble thrombomodulin
p11392
sg13
I2
sa(dp11393
g7
I236
sg8
VP05305
p11394
sg10
I4
sg11
VET-1
p11395
sg13
I1
sa(dp11396
g7
I182
sg8
g18
sg10
I4
sg11
VVEGF
p11397
sg13
I1
sa(dp11398
g7
I146
sg8
g18
sg10
I34
sg11
Vvascular endothelial growth factor
p11399
sg13
I4
sa(dp11400
g7
I213
sg8
g18
sg10
I3
sg11
VsTM
p11401
sg13
I1
sa(dp11402
g7
I222
sg8
VP20800
p11403
sg10
I12
sg11
Vendothelin-1
p11404
sg13
I1
sasg20
(lp11405
(dp11406
g7
I290
sg23
VC0155765
p11407
sg10
I15
sg11
Vmicroangiopathy
p11408
sg13
I1
sa(dp11409
g7
I257
sg23
VC0011854
p11410
sg10
I15
sg11
VType 1 diabetes
p11411
sg13
I3
sasa(dp11412
g2
S'Higher serum concentration of VEGF (p&lt;0.001), ET-1 (p&lt;0.001) and sTM (p&lt;0.05) were demonstrated in people with diabetes complicated with microangiopathy compared to healthy controls.\n'
p11413
sg4
(lp11414
(dp11415
g7
I71
sg8
g18
sg10
I3
sg11
VsTM
p11416
sg13
I1
sa(dp11417
g7
I49
sg8
VP05305
p11418
sg10
I4
sg11
VET-1
p11419
sg13
I1
sasg20
(lp11420
(dp11421
g7
I120
sg23
VC0011849
p11422
sg10
I8
sg11
Vdiabetes
p11423
sg13
I1
sa(dp11424
g7
I146
sg23
VC0155765
p11425
sg10
I15
sg11
Vmicroangiopathy
p11426
sg13
I1
sasa(dp11427
g2
S'Moreover, comparison between people with and without microangiopathic complications showed a significantly higher capillaroscopic score and sTM serum concentration in the group with retinopathy (p&lt;0.001) nephropathy (p&lt;0.001) and neuropathy (p&lt;0.01).\n'
p11428
sg4
(lp11429
sg20
(lp11430
(dp11431
g7
I236
sg23
VC0442874
p11432
sg10
I10
sg11
Vneuropathy
p11433
sg13
I1
sa(dp11434
g7
I207
sg23
VC0022658
p11435
sg10
I11
sg11
Vnephropathy
p11436
sg13
I1
sa(dp11437
g7
I182
sg23
VC0035309
p11438
sg10
I11
sg11
Vretinopathy
p11439
sg13
I1
sasa(dp11440
g2
S"In the present study, copy number variation of the SULT1A3/4 genes in healthy individuals, as well as a cohort of Parkinson's disease and Alzheimer's disease patients was examined.\n"
p11441
sg4
(lp11442
(dp11443
g7
I51
sg8
VP50224
p11444
sg10
I15
sg11
VSULT1A3/4 genes
p11445
sg13
I2
sasg20
(lp11446
(dp11447
g7
I138
sg23
VC1521724
p11448
sg10
I19
sg11
VAlzheimer's disease
p11449
sg13
I2
sa(dp11450
g7
I114
sg23
VC0030567
p11451
sg10
I19
sg11
VParkinson's disease
p11452
sg13
I2
sasa(dp11453
g2
S'This study reports the involvement of stathmin in the mTOR/HIF-1 Alfa /VEGF pathway in ovarian clear cell adenocarcinoma (CCA) during hypoxia.\n'
p11454
sg4
(lp11455
(dp11456
g7
I38
sg8
VP16949
p11457
sg10
I8
sg11
Vstathmin
p11458
sg13
I1
sa(dp11459
g7
I54
sg8
VP42345
p11460
sg10
I4
sg11
VmTOR
p11461
sg13
I1
sa(dp11462
g7
I59
sg8
g18
sg10
I10
sg11
VHIF-1 Alfa
p11463
sg13
I2
sasg20
(lp11464
(dp11465
g7
I122
sg23
VC0220668
p11466
sg10
I3
sg11
VCCA
p11467
sg13
I1
sa(dp11468
g7
I87
sg23
VC1518693
p11469
sg10
I33
sg11
Vovarian clear cell adenocarcinoma
p11470
sg13
I4
sa(dp11471
g7
I134
sg23
VC0242184
p11472
sg10
I7
sg11
Vhypoxia
p11473
sg13
I1
sasa(dp11474
g2
S'We examined 94 surgically resected ovarian clear cell adenocarcinoma specimens from patients treated with taxane-containing regimens (n=44) and with taxane-free regimens (n=50), using immunohistochemistry to detect expression of beta-tubulin III, stathmin, and MAP4.\n'
p11475
sg4
(lp11476
(dp11477
g7
I261
sg8
VP27816
p11478
sg10
I4
sg11
VMAP4
p11479
sg13
I1
sa(dp11480
g7
I229
sg8
VP68371
p11481
sg10
I16
sg11
Vbeta-tubulin III
p11482
sg13
I2
sa(dp11483
g7
I247
sg8
VP16949
p11484
sg10
I8
sg11
Vstathmin
p11485
sg13
I1
sasg20
(lp11486
(dp11487
g7
I35
sg23
VC1518693
p11488
sg10
I33
sg11
Vovarian clear cell adenocarcinoma
p11489
sg13
I4
sasa(dp11490
g2
S'MIMA-8 is the first example of a Mab anti-Jsb and was used in the clinical laboratory for screening donor RBCs for Js(b-) blood and for typing RBCs from patients even when the RBCs were coated with anti-IgG as is the case in autoimmune haemolytic anaemia.\n'
p11491
sg4
(lp11492
(dp11493
g7
I0
sg8
g18
sg10
I6
sg11
VMIMA-8
p11494
sg13
I1
sasg20
(lp11495
(dp11496
g7
I225
sg23
VC0002880
p11497
sg10
I29
sg11
Vautoimmune haemolytic anaemia
p11498
sg13
I3
sasa(dp11499
g2
S'We localized this gene (C2orf8 encoding 288L6 SAM-methyltransferase) to chromosome 2p22--&gt;p21 by FISH, and sublocalized it to BAC RP11 288L6 flanked by D2S2238 and D2S2331.\n'
p11500
sg4
(lp11501
(dp11502
g7
I93
sg8
VP42857
p11503
sg10
I3
sg11
Vp21
p11504
sg13
I1
sa(dp11505
g7
I24
sg8
g18
sg10
I6
sg11
VC2orf8
p11506
sg13
I1
sa(dp11507
g7
I40
sg8
g18
sg10
I27
sg11
V288L6 SAM-methyltransferase
p11508
sg13
I2
sa(dp11509
g7
I100
sg8
g18
sg10
I4
sg11
VFISH
p11510
sg13
I1
sasg20
(lp11511
(dp11512
g7
I133
sg23
VC1838601
p11513
sg10
I4
sg11
VRP11
p11514
sg13
I1
sa(dp11515
g7
I46
sg23
VC1563296
p11516
sg10
I3
sg11
VSAM
p11517
sg13
I1
sasa(dp11518
g2
S'Regulatory factor X4 variant transcript 3 (Rfx4_v3) gene disruption in mice demonstrated that interruption of a single allele (heterozygous, +/-) prevented formation of the subcommissural organ, resulting in congenital hydrocephalus, while interruption of two alleles (homozygous, -/-) caused fatal failure of dorsal midline brain structure formation.\n'
p11519
sg4
(lp11520
(dp11521
g7
I0
sg8
g18
sg10
I41
sg11
VRegulatory factor X4 variant transcript 3
p11522
sg13
I6
sa(dp11523
g7
I43
sg8
g18
sg10
I7
sg11
VRfx4_v3
p11524
sg13
I1
sasg20
(lp11525
(dp11526
g7
I208
sg23
VC0020256
p11527
sg10
I24
sg11
Vcongenital hydrocephalus
p11528
sg13
I2
sasa(dp11529
g2
S'Immunization of rabbits with GM1-containing ganglioside mixtures, purified GM1, or Campylobacter jejuni lipo-oligosaccharide exhibiting a GM1-like structure elicits GM1-specific antibodies, but axonal polyneuropathy only occurs in a subset of animals.\n'
p11530
sg4
(lp11531
sg20
(lp11532
(dp11533
g7
I104
sg23
VC3489413
p11534
sg10
I4
sg11
Vlipo
p11535
sg13
I1
sa(dp11536
g7
I201
sg23
VC0152025
p11537
sg10
I14
sg11
Vpolyneuropathy
p11538
sg13
I1
sasa(dp11539
g2
S'Molecular mimicry of Campylobacter jejuni lipo-oligosaccharides (LOS) with gangliosides in nervous tissue is considered to induce cross-reactive antibodies that lead to Guillain-Barre syndrome (GBS), an acute polyneuropathy.\n'
p11540
sg4
(lp11541
(dp11542
g7
I130
sg8
g18
sg10
I25
sg11
Vcross-reactive antibodies
p11543
sg13
I2
sasg20
(lp11544
(dp11545
g7
I10
sg23
VC0233577
p11546
sg10
I7
sg11
Vmimicry
p11547
sg13
I1
sa(dp11548
g7
I42
sg23
VC3489413
p11549
sg10
I4
sg11
Vlipo
p11550
sg13
I1
sa(dp11551
g7
I91
sg23
VC0027769
p11552
sg10
I7
sg11
Vnervous
p11553
sg13
I1
sa(dp11554
g7
I194
sg23
VC1841700
p11555
sg10
I3
sg11
VGBS
p11556
sg13
I1
sa(dp11557
g7
I169
sg23
VC0018378
p11558
sg10
I23
sg11
VGuillain-Barre syndrome
p11559
sg13
I2
sa(dp11560
g7
I203
sg23
VC0852421
p11561
sg10
I20
sg11
Vacute polyneuropathy
p11562
sg13
I2
sasa(dp11563
g2
S'The objective of this study is to investigate the levels of interleukin (IL)-21 and autoantibodies (AAbs) against IL-21 and their association with clinical characteristics and laboratory parameters in patients with rheumatoid arthritis (RA).\n'
p11564
sg4
(lp11565
(dp11566
g7
I114
sg8
g18
sg10
I5
sg11
VIL-21
p11567
sg13
I1
sa(dp11568
g7
I60
sg8
VP60568
p11569
sg10
I16
sg11
Vinterleukin (IL)
p11570
sg13
I2
sasg20
(lp11571
(dp11572
g7
I215
sg23
VC0003873
p11573
sg10
I20
sg11
Vrheumatoid arthritis
p11574
sg13
I2
sa(dp11575
g7
I237
sg23
VC0003873
p11576
sg10
I2
sg11
VRA
p11577
sg13
I1
sasa(dp11578
g2
S'Interleukin-21 (IL-21) is a cytokine which plays a significant role in the pathogenesis and disease activity of rheumatoid arthritis (RA).\n'
p11579
sg4
(lp11580
(dp11581
g7
I0
sg8
g18
sg10
I14
sg11
VInterleukin-21
p11582
sg13
I1
sa(dp11583
g7
I16
sg8
g18
sg10
I5
sg11
VIL-21
p11584
sg13
I1
sasg20
(lp11585
(dp11586
g7
I75
sg23
VC0699748
p11587
sg10
I12
sg11
Vpathogenesis
p11588
sg13
I1
sa(dp11589
g7
I112
sg23
VC0003873
p11590
sg10
I20
sg11
Vrheumatoid arthritis
p11591
sg13
I2
sa(dp11592
g7
I134
sg23
VC0003873
p11593
sg10
I2
sg11
VRA
p11594
sg13
I1
sasa(dp11595
g2
S'Interleukin-21 (IL-21) is a T-cell-derived cytokine whose receptor is expressed on a variety of cells and therefore might have pleiotropic roles in the pathogenesis of rheumatoid arthritis (RA).\n'
p11596
sg4
(lp11597
(dp11598
g7
I0
sg8
g18
sg10
I14
sg11
VInterleukin-21
p11599
sg13
I1
sa(dp11600
g7
I16
sg8
g18
sg10
I5
sg11
VIL-21
p11601
sg13
I1
sasg20
(lp11602
(dp11603
g7
I152
sg23
VC0699748
p11604
sg10
I12
sg11
Vpathogenesis
p11605
sg13
I1
sa(dp11606
g7
I190
sg23
VC0003873
p11607
sg10
I2
sg11
VRA
p11608
sg13
I1
sa(dp11609
g7
I168
sg23
VC0003873
p11610
sg10
I20
sg11
Vrheumatoid arthritis
p11611
sg13
I2
sasa(dp11612
g2
S'In this study, we investigated the involvement of IL-21 signaling in the development of collagen-induced arthritis (CIA), an animal model of RA, using IL-21 receptor knockout (Il21r KO) mice.\n'
p11613
sg4
(lp11614
(dp11615
g7
I50
sg8
g18
sg10
I5
sg11
VIL-21
p11616
sg13
I1
sa(dp11617
g7
I176
sg8
g18
sg10
I8
sg11
VIl21r KO
p11618
sg13
I2
sa(dp11619
g7
I151
sg8
g18
sg10
I23
sg11
VIL-21 receptor knockout
p11620
sg13
I3
sasg20
(lp11621
(dp11622
g7
I105
sg23
VC0003864
p11623
sg10
I9
sg11
Varthritis
p11624
sg13
I1
sasa(dp11625
g2
S'We explored the differential reactions of melanocortin 1-5 receptors (MC1-5R) gene expressions in pathogenetic leucocyte subsets in rheumatoid arthritis (RA) to treatment with TNF-Alfa inhibitor adalimumab.\n'
p11626
sg4
(lp11627
(dp11628
g7
I70
sg8
g18
sg10
I6
sg11
VMC1-5R
p11629
sg13
I1
sa(dp11630
g7
I42
sg8
g18
sg10
I26
sg11
Vmelanocortin 1-5 receptors
p11631
sg13
I3
sa(dp11632
g7
I176
sg8
VP01375
p11633
sg10
I8
sg11
VTNF-Alfa
p11634
sg13
I1
sasg20
(lp11635
(dp11636
g7
I132
sg23
VC0003873
p11637
sg10
I20
sg11
Vrheumatoid arthritis
p11638
sg13
I2
sa(dp11639
g7
I154
sg23
VC0003873
p11640
sg10
I2
sg11
VRA
p11641
sg13
I1
sasa(dp11642
g2
S'Metabolic cutis laxa results from Menkes syndrome, caused by a defect in the ATPase copper transporting alpha (ATP7A) gene; congenital disorders of glycosylation due to mutations in subunit 7 of the component of oligomeric Golgi (COG7)-congenital disorders of glycosylation (CDG) complex; combined disorder of N- and O-linked glycosylation, due to mutations in ATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene; pyrroline-5-carboxylate reductase 1 deficiency; pyrroline-5-carboxylate synthase deficiency; macrocephaly, alopecia, cutis laxa, and scoliosis (MACS) syndrome, due to Ras and Rab interactor 2 (RIN2) mutations; transaldolase deficiency caused by mutations in the transaldolase 1 (TALDO1) gene; Gerodermia osteodysplastica due to mutations in the golgin, RAB6-interacting (GORAB or SCYL1BP1) gene; and mitogen-activated pathway (MAP) kinase defects, caused by mutations in several genes [protein tyrosine phosphatase, non-receptor-type 11 (PTPN11), RAF, NF, HRas proto-oncogene, GTPase (HRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF), MEK1/2, KRAS proto-oncogene, GTPase (KRAS), SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein (SHOC2), NRAS proto-oncogene, GTPase (NRAS), and Raf-1 proto-oncogene, serine/threonine kinase (RAF1)], which regulate the Ras-MAPK cascade.\n'
p11643
sg4
(lp11644
(dp11645
g7
I582
sg8
VP01116
p11646
sg10
I3
sg11
VRas
p11647
sg13
I1
sa(dp11648
g7
I1200
sg8
g18
sg10
I5
sg11
VSHOC2
p11649
sg13
I1
sa(dp11650
g7
I795
sg8
g18
sg10
I8
sg11
VSCYL1BP1
p11651
sg13
I1
sa(dp11652
g7
I1208
sg8
VP01111
p11653
sg10
I4
sg11
VNRAS
p11654
sg13
I1
sa(dp11655
g7
I625
sg8
VP37837
p11656
sg10
I13
sg11
Vtransaldolase
p11657
sg13
I1
sa(dp11658
g7
I590
sg8
VP52594
p11659
sg10
I16
sg11
VRab interactor 2
p11660
sg13
I3
sa(dp11661
g7
I1000
sg8
VP01112
p11662
sg10
I4
sg11
VHRAS
p11663
sg13
I1
sa(dp11664
g7
I931
sg8
g18
sg10
I20
sg11
Vnon-receptor-type 11
p11665
sg13
I2
sa(dp11666
g7
I1007
sg8
VP62304
p11667
sg10
I20
sg11
VB-Raf proto-oncogene
p11668
sg13
I2
sa(dp11669
g7
I1069
sg8
VP01116
p11670
sg10
I4
sg11
VKRAS
p11671
sg13
I1
sa(dp11672
g7
I463
sg8
VP52209
p11673
sg10
I32
sg11
Vpyrroline-5-carboxylate synthase
p11674
sg13
I2
sa(dp11675
g7
I677
sg8
VP37837
p11676
sg10
I15
sg11
Vtransaldolase 1
p11677
sg13
I2
sa(dp11678
g7
I608
sg8
g18
sg10
I4
sg11
VRIN2
p11679
sg13
I1
sa(dp11680
g7
I901
sg8
VP60484
p11681
sg10
I28
sg11
Vprotein tyrosine phosphatase
p11682
sg13
I3
sa(dp11683
g7
I768
sg8
VP20340
p11684
sg10
I16
sg11
VRAB6-interacting
p11685
sg13
I1
sa(dp11686
g7
I361
sg8
VP38606
p11687
sg10
I52
sg11
VATPase H+ transporting V0 subunit a2 (ATP6VOA2) gene
p11688
sg13
I8
sa(dp11689
g7
I1326
sg8
VP53779
p11690
sg10
I4
sg11
VMAPK
p11691
sg13
I1
sa(dp11692
g7
I1061
sg8
g18
sg10
I6
sg11
VMEK1/2
p11693
sg13
I1
sa(dp11694
g7
I967
sg8
VP01112
p11695
sg10
I31
sg11
VNF, HRas proto-oncogene, GTPase
p11696
sg13
I4
sa(dp11697
g7
I1208
sg8
VP01111
p11698
sg10
I27
sg11
VNRAS proto-oncogene, GTPase
p11699
sg13
I3
sa(dp11700
g7
I1295
sg8
VP04049
p11701
sg10
I4
sg11
VRAF1
p11702
sg13
I1
sa(dp11703
g7
I786
sg8
g18
sg10
I5
sg11
VGORAB
p11704
sg13
I1
sa(dp11705
g7
I1054
sg8
VP15056
p11706
sg10
I4
sg11
VBRAF
p11707
sg13
I1
sa(dp11708
g7
I1113
sg8
g18
sg10
I85
sg11
VRho guanine nucleotide exchange factor 2 (SOS2), leucine rich repeat scaffold protein
p11709
sg13
I12
sa(dp11710
g7
I962
sg8
VP04049
p11711
sg10
I3
sg11
VRAF
p11712
sg13
I1
sa(dp11713
g7
I77
sg8
VP38606
p11714
sg10
I32
sg11
VATPase copper transporting alpha
p11715
sg13
I4
sa(dp11716
g7
I111
sg8
g18
sg10
I5
sg11
VATP7A
p11717
sg13
I1
sa(dp11718
g7
I415
sg8
VP32322
p11719
sg10
I35
sg11
Vpyrroline-5-carboxylate reductase 1
p11720
sg13
I3
sa(dp11721
g7
I582
sg8
VP01116
p11722
sg10
I3
sg11
VRas
p11723
sg13
I1
sa(dp11724
g7
I582
sg8
VP01116
p11725
sg10
I3
sg11
VRas
p11726
sg13
I1
sa(dp11727
g7
I953
sg8
g18
sg10
I6
sg11
VPTPN11
p11728
sg13
I1
sa(dp11729
g7
I1029
sg8
VP42345
p11730
sg10
I23
sg11
Vserine/threonine kinase
p11731
sg13
I2
sa(dp11732
g7
I1069
sg8
VP01116
p11733
sg10
I27
sg11
VKRAS proto-oncogene, GTPase
p11734
sg13
I3
sa(dp11735
g7
I1029
sg8
VP42345
p11736
sg10
I23
sg11
Vserine/threonine kinase
p11737
sg13
I2
sa(dp11738
g7
I694
sg8
VP37837
p11739
sg10
I6
sg11
VTALDO1
p11740
sg13
I1
sa(dp11741
g7
I1248
sg8
VP04049
p11742
sg10
I20
sg11
VRaf-1 proto-oncogene
p11743
sg13
I2
sasg20
(lp11744
(dp11745
g7
I10
sg23
VC0010495
p11746
sg10
I10
sg11
Vcutis laxa
p11747
sg13
I2
sa(dp11748
g7
I625
sg23
VC1291329
p11749
sg10
I24
sg11
Vtransaldolase deficiency
p11750
sg13
I2
sa(dp11751
g7
I508
sg23
VC2751321
p11752
sg10
I49
sg11
Vmacrocephaly, alopecia, cutis laxa, and scoliosis
p11753
sg13
I6
sa(dp11754
g7
I124
sg23
VC0282577
p11755
sg10
I37
sg11
Vcongenital disorders of glycosylation
p11756
sg13
I4
sa(dp11757
g7
I41
sg23
VC0039082
p11758
sg10
I8
sg11
Vsyndrome
p11759
sg13
I1
sa(dp11760
g7
I124
sg23
VC0282577
p11761
sg10
I37
sg11
Vcongenital disorders of glycosylation
p11762
sg13
I4
sa(dp11763
g7
I708
sg23
VC0432255
p11764
sg10
I27
sg11
VGerodermia osteodysplastica
p11765
sg13
I2
sa(dp11766
g7
I34
sg23
VC0022716
p11767
sg10
I15
sg11
VMenkes syndrome
p11768
sg13
I2
sasa(dp11769
g2
S'This study aimed to assess the tolerability of the extended use (&lt;=35 days) of MNK-155, a biphasic (immediate-release/extended-release) hydrocodone bitartrate/N-acetyl-p-aminophenol (acetaminophen) (IR/ER HB/APAP) 7.5/325-mg fixed-dose combination analgesic agent, in patients with chronic noncancer pain (CNCP) caused by osteoarthritis or chronic low back pain.\n'
p11770
sg4
(lp11771
(dp11772
g7
I202
sg8
VP06213
p11773
sg10
I2
sg11
VIR
p11774
sg13
I1
sa(dp11775
g7
I82
sg8
g18
sg10
I7
sg11
VMNK-155
p11776
sg13
I1
sasg20
(lp11777
(dp11778
g7
I325
sg23
VC0029408
p11779
sg10
I14
sg11
Vosteoarthritis
p11780
sg13
I1
sa(dp11781
g7
I343
sg23
VC0457949
p11782
sg10
I21
sg11
Vchronic low back pain
p11783
sg13
I4
sa(dp11784
g7
I82
sg23
VC0022716
p11785
sg10
I3
sg11
VMNK
p11786
sg13
I1
sasa(dp11787
g2
S'We found that CHD7 expression was positively correlated with a small subset of classical oncogenes, notably NRAS, in breast cancer.\n'
p11788
sg4
(lp11789
(dp11790
g7
I108
sg8
VP01111
p11791
sg10
I4
sg11
VNRAS
p11792
sg13
I1
sa(dp11793
g7
I14
sg8
g18
sg10
I4
sg11
VCHD7
p11794
sg13
I1
sasg20
(lp11795
(dp11796
g7
I117
sg23
VC0678222
p11797
sg10
I13
sg11
Vbreast cancer
p11798
sg13
I2
sasa(dp11799
g2
S'Knockdown of CHD7 inhibits cell proliferation and decreases gene expression of several CHD7 targets, including NRAS, in breast cancer cell lines.\n'
p11800
sg4
(lp11801
(dp11802
g7
I13
sg8
g18
sg10
I4
sg11
VCHD7
p11803
sg13
I1
sa(dp11804
g7
I111
sg8
VP01111
p11805
sg10
I4
sg11
VNRAS
p11806
sg13
I1
sa(dp11807
g7
I87
sg8
g18
sg10
I12
sg11
VCHD7 targets
p11808
sg13
I2
sasg20
(lp11809
(dp11810
g7
I32
sg23
VC0334094
p11811
sg10
I13
sg11
Vproliferation
p11812
sg13
I1
sa(dp11813
g7
I120
sg23
VC0678222
p11814
sg10
I13
sg11
Vbreast cancer
p11815
sg13
I2
sasa(dp11816
g2
S'Overexpression of CSTF3 was common in triple-negative breast cancer cell lines, and elevated CSTF3 levels were sufficient to induce APA of NRAS and c-JUN.\n'
p11817
sg4
(lp11818
(dp11819
g7
I18
sg8
g18
sg10
I5
sg11
VCSTF3
p11820
sg13
I1
sa(dp11821
g7
I18
sg8
g18
sg10
I5
sg11
VCSTF3
p11822
sg13
I1
sa(dp11823
g7
I148
sg8
VP05412
p11824
sg10
I5
sg11
Vc-JUN
p11825
sg13
I1
sa(dp11826
g7
I139
sg8
VP01111
p11827
sg10
I4
sg11
VNRAS
p11828
sg13
I1
sa(dp11829
g7
I132
sg8
g18
sg10
I3
sg11
VAPA
p11830
sg13
I1
sasg20
(lp11831
(dp11832
g7
I54
sg23
VC0678222
p11833
sg10
I13
sg11
Vbreast cancer
p11834
sg13
I2
sasa(dp11835
g2
S'The definite function of PEBP4 in regulating the EMT of prostate cancer, however, is still unclear.\n'
p11836
sg4
(lp11837
(dp11838
g7
I25
sg8
g18
sg10
I5
sg11
VPEBP4
p11839
sg13
I1
sasg20
(lp11840
(dp11841
g7
I56
sg23
VC0600139
p11842
sg10
I15
sg11
Vprostate cancer
p11843
sg13
I2
sasa(dp11844
g2
S'Here, we examined the functional role of PEBP4 and the underlying molecular mechanisms in hypoxia-induced EMT in prostate cancer cells.\n'
p11845
sg4
(lp11846
(dp11847
g7
I41
sg8
g18
sg10
I5
sg11
VPEBP4
p11848
sg13
I1
sa(dp11849
g7
I106
sg8
g18
sg10
I3
sg11
VEMT
p11850
sg13
I1
sasg20
(lp11851
(dp11852
g7
I90
sg23
VC0242184
p11853
sg10
I7
sg11
Vhypoxia
p11854
sg13
I1
sa(dp11855
g7
I113
sg23
VC0600139
p11856
sg10
I15
sg11
Vprostate cancer
p11857
sg13
I2
sasa(dp11858
g2
S'Our results showed that PEBP4 mRNA and protein expression was markedly increased in the human prostate cancer tissues and cell lines.\n'
p11859
sg4
(lp11860
(dp11861
g7
I24
sg8
g18
sg10
I10
sg11
VPEBP4 mRNA
p11862
sg13
I2
sasg20
(lp11863
(dp11864
g7
I94
sg23
VC0600139
p11865
sg10
I15
sg11
Vprostate cancer
p11866
sg13
I2
sasa(dp11867
g2
S'Furthermore, knockdown of PEBP4 prevented hypoxia-induced the expression of p-Akt and p-mTOR in prostate cancer cells.\n'
p11868
sg4
(lp11869
(dp11870
g7
I86
sg8
VP42345
p11871
sg10
I6
sg11
Vp-mTOR
p11872
sg13
I1
sa(dp11873
g7
I76
sg8
g18
sg10
I5
sg11
Vp-Akt
p11874
sg13
I1
sa(dp11875
g7
I26
sg8
g18
sg10
I5
sg11
VPEBP4
p11876
sg13
I1
sasg20
(lp11877
(dp11878
g7
I42
sg23
VC0242184
p11879
sg10
I7
sg11
Vhypoxia
p11880
sg13
I1
sa(dp11881
g7
I96
sg23
VC0600139
p11882
sg10
I15
sg11
Vprostate cancer
p11883
sg13
I2
sasa(dp11884
g2
S'Taken together, this study reported here provided evidence that knockdown of PEBP4 inhibited hypoxia-induced EMT in prostate cancer cells.\n'
p11885
sg4
(lp11886
(dp11887
g7
I77
sg8
g18
sg10
I5
sg11
VPEBP4
p11888
sg13
I1
sa(dp11889
g7
I109
sg8
g18
sg10
I3
sg11
VEMT
p11890
sg13
I1
sasg20
(lp11891
(dp11892
g7
I93
sg23
VC0242184
p11893
sg10
I7
sg11
Vhypoxia
p11894
sg13
I1
sa(dp11895
g7
I116
sg23
VC0600139
p11896
sg10
I15
sg11
Vprostate cancer
p11897
sg13
I2
sasa(dp11898
g2
S'Our study uncovered a novel role for PEBP4 in prostate cancer progression, which might support the potential for PEBP4 targeting in prostate cancer therapy.\n'
p11899
sg4
(lp11900
(dp11901
g7
I37
sg8
g18
sg10
I5
sg11
VPEBP4
p11902
sg13
I1
sa(dp11903
g7
I37
sg8
g18
sg10
I5
sg11
VPEBP4
p11904
sg13
I1
sasg20
(lp11905
(dp11906
g7
I46
sg23
VC0600139
p11907
sg10
I15
sg11
Vprostate cancer
p11908
sg13
I2
sa(dp11909
g7
I55
sg23
VC0178874
p11910
sg10
I18
sg11
Vcancer progression
p11911
sg13
I2
sasa(dp11912
g2
S'Here we found the expression levels of hPEBP4 were positively correlated with the severity of clinical prostate cancer.\n'
p11913
sg4
(lp11914
sg20
(lp11915
(dp11916
g7
I103
sg23
VC0600139
p11917
sg10
I15
sg11
Vprostate cancer
p11918
sg13
I2
sasa(dp11919
g2
S'Furthermore, hPEBP4 was not expressed in TRAIL-sensitive DU145 prostate cancer cells, but was highly expressed in TRAIL-resistant LNCaP cells, which show highly activated Akt.\n'
p11920
sg4
(lp11921
(dp11922
g7
I171
sg8
g18
sg10
I3
sg11
VAkt
p11923
sg13
I1
sa(dp11924
g7
I41
sg8
VP50591
p11925
sg10
I5
sg11
VTRAIL
p11926
sg13
I1
sasg20
(lp11927
(dp11928
g7
I63
sg23
VC0600139
p11929
sg10
I15
sg11
Vprostate cancer
p11930
sg13
I2
sasa(dp11931
g2
S'Therefore, hPEBP4 expression in prostate cancer can activate Akt and deactivate ERK1/2 signaling, leading to TRAIL resistance.\n'
p11932
sg4
(lp11933
(dp11934
g7
I109
sg8
VP50591
p11935
sg10
I5
sg11
VTRAIL
p11936
sg13
I1
sa(dp11937
g7
I80
sg8
VP27361
p11938
sg10
I6
sg11
VERK1/2
p11939
sg13
I1
sa(dp11940
g7
I61
sg8
g18
sg10
I3
sg11
VAkt
p11941
sg13
I1
sasg20
(lp11942
(dp11943
g7
I32
sg23
VC0600139
p11944
sg10
I15
sg11
Vprostate cancer
p11945
sg13
I2
sasa(dp11946
g2
S'We also demonstrated that hPEBP4-mediated resistance to TRAIL-induced apoptosis occurred downstream of caspase-8 and at the level of BID cleavage via the regulation of Akt and ERK pathways, and that hPEBP4-regulated ERK deactivation was upstream of Akt activation in prostate cancer cells.\n'
p11947
sg4
(lp11948
(dp11949
g7
I56
sg8
VP50591
p11950
sg10
I5
sg11
VTRAIL
p11951
sg13
I1
sa(dp11952
g7
I103
sg8
VP39880
p11953
sg10
I9
sg11
Vcaspase-8
p11954
sg13
I1
sa(dp11955
g7
I168
sg8
g18
sg10
I3
sg11
VAkt
p11956
sg13
I1
sa(dp11957
g7
I168
sg8
g18
sg10
I3
sg11
VAkt
p11958
sg13
I1
sa(dp11959
g7
I176
sg8
VP29323
p11960
sg10
I3
sg11
VERK
p11961
sg13
I1
sa(dp11962
g7
I176
sg8
VP29323
p11963
sg10
I3
sg11
VERK
p11964
sg13
I1
sasg20
(lp11965
(dp11966
g7
I267
sg23
VC0600139
p11967
sg10
I15
sg11
Vprostate cancer
p11968
sg13
I2
sasa(dp11969
g2
S'Considering that hPEBP4 confers cellular resistance to TRAIL-induced apoptosis and is abundantly expressed in poorly differentiated prostate cancer, silencing of hPEBP4 suggests a promising approach for prostate cancer treatment.\n'
p11970
sg4
(lp11971
(dp11972
g7
I55
sg8
VP50591
p11973
sg10
I5
sg11
VTRAIL
p11974
sg13
I1
sasg20
(lp11975
(dp11976
g7
I132
sg23
VC0600139
p11977
sg10
I15
sg11
Vprostate cancer
p11978
sg13
I2
sa(dp11979
g7
I132
sg23
VC0600139
p11980
sg10
I15
sg11
Vprostate cancer
p11981
sg13
I2
sasa(dp11982
g2
S'Six of these mAbs, including anti-cluster of differentiation (CD)61, anti-CD18, anti-CD14, anti-CD235a, anti-CD41 and anti-CD29, cross-reacted with normal feline bone marrow cells, whereas anti-CD33 and anti-CD117 cross-reacted with the blast cells in the bone marrow of two cats with myelodysplastic syndrome, and anti-CD71, anti-235a, anti-41 and anti-42 cross-reacted with immature erythroid cells in a cat with erythroleukaemia.\n'
p11983
sg4
(lp11984
(dp11985
g7
I104
sg8
VP08514
p11986
sg10
I9
sg11
Vanti-CD41
p11987
sg13
I1
sa(dp11988
g7
I203
sg8
VP10721
p11989
sg10
I10
sg11
Vanti-CD117
p11990
sg13
I1
sa(dp11991
g7
I80
sg8
VP08571
p11992
sg10
I9
sg11
Vanti-CD14
p11993
sg13
I1
sa(dp11994
g7
I315
sg8
VP02786
p11995
sg10
I9
sg11
Vanti-CD71
p11996
sg13
I1
sa(dp11997
g7
I91
sg8
VP02724
p11998
sg10
I11
sg11
Vanti-CD235a
p11999
sg13
I1
sa(dp12000
g7
I189
sg8
VP20138
p12001
sg10
I9
sg11
Vanti-CD33
p12002
sg13
I1
sa(dp12003
g7
I69
sg8
VP05107
p12004
sg10
I9
sg11
Vanti-CD18
p12005
sg13
I1
sasg20
(lp12006
(dp12007
g7
I415
sg23
VC0023440
p12008
sg10
I16
sg11
Verythroleukaemia
p12009
sg13
I1
sa(dp12010
g7
I285
sg23
VC0033027
p12011
sg10
I24
sg11
Vmyelodysplastic syndrome
p12012
sg13
I2
sasa(dp12013
g2
S'Incubation of B16F10 melanoma cells with Asm activates p38 MAP kinase (p38K), phospholipase Cx03B3; (PLCx03B3;), ezrin, and extracellular signal-regulated kinases.\n'
p12014
sg4
(lp12015
(dp12016
g7
I41
sg8
VP17405
p12017
sg10
I3
sg11
VAsm
p12018
sg13
I1
sa(dp12019
g7
I124
sg8
g18
sg10
I38
sg11
Vextracellular signal-regulated kinases
p12020
sg13
I3
sa(dp12021
g7
I113
sg8
VP15311
p12022
sg10
I5
sg11
Vezrin
p12023
sg13
I1
sa(dp12024
g7
I78
sg8
VP04054
p12025
sg10
I20
sg11
Vphospholipase Cx03B3
p12026
sg13
I2
sa(dp12027
g7
I71
sg8
g18
sg10
I4
sg11
Vp38K
p12028
sg13
I1
sa(dp12029
g7
I55
sg8
g18
sg10
I14
sg11
Vp38 MAP kinase
p12030
sg13
I3
sasg20
(lp12031
(dp12032
g7
I21
sg23
VC0025202
p12033
sg10
I8
sg11
Vmelanoma
p12034
sg13
I1
sasa(dp12035
g2
S'Co-incubation of B16F10 melanoma cells with wild-type or Asm-deficient platelets showed that the phosphorylation/activation of p38K is dependent on Asm.\n'
p12036
sg4
(lp12037
sg20
(lp12038
(dp12039
g7
I24
sg23
VC0025202
p12040
sg10
I8
sg11
Vmelanoma
p12041
sg13
I1
sasa(dp12042
g2
S'Asm, secreted from activated platelets after tumor cell-platelet contact, induces p38K phosphorylation in tumor cells.\n'
p12043
sg4
(lp12044
sg20
(lp12045
(dp12046
g7
I45
sg23
VC0027651
p12047
sg10
I5
sg11
Vtumor
p12048
sg13
I1
sa(dp12049
g7
I45
sg23
VC0027651
p12050
sg10
I5
sg11
Vtumor
p12051
sg13
I1
sasa(dp12052
g2
S'In 1 patient with progressive, idiopathic visual loss, this last-line analysis implicated retinal autoimmunity, a diagnosis that was validated when her serum sample was found to contain antibodies to S-arrestin, a retinal protein and potent cause of autoimmune retinal degeneration.\n'
p12053
sg4
(lp12054
(dp12055
g7
I200
sg8
VP10523
p12056
sg10
I10
sg11
VS-arrestin
p12057
sg13
I1
sasg20
(lp12058
(dp12059
g7
I250
sg23
VC0443146
p12060
sg10
I10
sg11
Vautoimmune
p12061
sg13
I1
sa(dp12062
g7
I98
sg23
VC0004368
p12063
sg10
I12
sg11
Vautoimmunity
p12064
sg13
I1
sa(dp12065
g7
I261
sg23
VC0035304
p12066
sg10
I20
sg11
Vretinal degeneration
p12067
sg13
I2
sa(dp12068
g7
I42
sg23
VC0042798
p12069
sg10
I11
sg11
Vvisual loss
p12070
sg13
I2
sasa(dp12071
g2
S'From 235 Caucasian patients, the homozygous IGHG *bf-n/*bf-n diplotype (B*(bf-n)/B*(bf-n) cells) dominated significantly in 43 IgG2 deficiency (OR 6.0), 32 common variable immunodeficiency (OR 4.6) and 22 Ataxia telangiectasia (OR 3.0) and the IGHG*ga-n/*ga-n diplotype (B*(ga-n)/B*(ga-n) cells) dominated in 53 IgG3 deficiency (OR 10.6) and 21 Wiscott-Aldrich syndrome (OR 4.1).\n'
p12072
sg4
(lp12073
(dp12074
g7
I312
sg8
VP01860
p12075
sg10
I4
sg11
VIgG3
p12076
sg13
I1
sa(dp12077
g7
I127
sg8
VP01859
p12078
sg10
I4
sg11
VIgG2
p12079
sg13
I1
sasg20
(lp12080
(dp12081
g7
I205
sg23
VC0004135
p12082
sg10
I21
sg11
VAtaxia telangiectasia
p12083
sg13
I2
sa(dp12084
g7
I127
sg23
VC0398701
p12085
sg10
I15
sg11
VIgG2 deficiency
p12086
sg13
I2
sa(dp12087
g7
I353
sg23
VC0043194
p12088
sg10
I16
sg11
VAldrich syndrome
p12089
sg13
I2
sa(dp12090
g7
I312
sg23
VC0398703
p12091
sg10
I15
sg11
VIgG3 deficiency
p12092
sg13
I2
sa(dp12093
g7
I156
sg23
VC0009447
p12094
sg10
I32
sg11
Vcommon variable immunodeficiency
p12095
sg13
I3
sasa(dp12096
g2
S'Additionally, Inos and Slpi expression were unchanged following anti-IFN-Gamma treatment, suggesting that Inos and Slpi regulation is independent of IFN-Gamma during C. difficile colitis.\n'
p12097
sg4
(lp12098
(dp12099
g7
I64
sg8
VP01579
p12100
sg10
I14
sg11
Vanti-IFN-Gamma
p12101
sg13
I1
sa(dp12102
g7
I23
sg8
VP03973
p12103
sg10
I4
sg11
VSlpi
p12104
sg13
I1
sa(dp12105
g7
I69
sg8
VP01579
p12106
sg10
I9
sg11
VIFN-Gamma
p12107
sg13
I1
sa(dp12108
g7
I14
sg8
g18
sg10
I4
sg11
VInos
p12109
sg13
I1
sa(dp12110
g7
I23
sg8
VP03973
p12111
sg10
I4
sg11
VSlpi
p12112
sg13
I1
sa(dp12113
g7
I14
sg8
g18
sg10
I4
sg11
VInos
p12114
sg13
I1
sasg20
(lp12115
(dp12116
g7
I179
sg23
VC0009319
p12117
sg10
I7
sg11
Vcolitis
p12118
sg13
I1
sasa(dp12119
g2
S'We have collated and selectively reviewed data on the most prominent well-established and emerging neutrophil-related biomarkers and potential therapeutic targets (calprotectin, lactoferrin, CXCR1, CXCR2, MMP-9, NGAL, elafin, HNE, pANCAs, MPO, CD16, CD177, CD64, HNPs, SLPI and PTX3) in ulcerative colitis.\n'
p12120
sg4
(lp12121
(dp12122
g7
I269
sg8
VP03973
p12123
sg10
I4
sg11
VSLPI
p12124
sg13
I1
sa(dp12125
g7
I205
sg8
VP14780
p12126
sg10
I5
sg11
VMMP-9
p12127
sg13
I1
sa(dp12128
g7
I212
sg8
VP80188
p12129
sg10
I4
sg11
VNGAL
p12130
sg13
I1
sa(dp12131
g7
I226
sg8
VP08246
p12132
sg10
I3
sg11
VHNE
p12133
sg13
I1
sa(dp12134
g7
I278
sg8
VP26022
p12135
sg10
I4
sg11
VPTX3
p12136
sg13
I1
sa(dp12137
g7
I198
sg8
VP25025
p12138
sg10
I5
sg11
VCXCR2
p12139
sg13
I1
sa(dp12140
g7
I239
sg8
VP05164
p12141
sg10
I3
sg11
VMPO
p12142
sg13
I1
sa(dp12143
g7
I250
sg8
g18
sg10
I5
sg11
VCD177
p12144
sg13
I1
sa(dp12145
g7
I257
sg8
VP12314
p12146
sg10
I4
sg11
VCD64
p12147
sg13
I1
sa(dp12148
g7
I244
sg8
VP08637
p12149
sg10
I4
sg11
VCD16
p12150
sg13
I1
sa(dp12151
g7
I218
sg8
VP19957
p12152
sg10
I6
sg11
Velafin
p12153
sg13
I1
sa(dp12154
g7
I263
sg8
VP59665
p12155
sg10
I4
sg11
VHNPs
p12156
sg13
I1
sasg20
(lp12157
(dp12158
g7
I287
sg23
VC0009324
p12159
sg10
I18
sg11
Vulcerative colitis
p12160
sg13
I2
sasa(dp12161
g2
S'In order to identify the best strategy to treat IBD using recLAB, we compared the efficacy of different recombinant strains of Lactococcus lactis (the model LAB) secreting two types of anti-inflammatory molecules: cytokines (IL-10 and TGF-Beta1) and serine protease inhibitors (Elafin and Secretory Leukocyte Protease Inhibitor: SLPI), using a dextran sulfate sodium (DSS)-induced mouse model of colitis.\n'
p12162
sg4
(lp12163
(dp12164
g7
I235
sg8
VP01137
p12165
sg10
I9
sg11
VTGF-Beta1
p12166
sg13
I1
sa(dp12167
g7
I250
sg8
VP57727
p12168
sg10
I26
sg11
Vserine protease inhibitors
p12169
sg13
I3
sa(dp12170
g7
I278
sg8
VP19957
p12171
sg10
I6
sg11
VElafin
p12172
sg13
I1
sasg20
(lp12173
(dp12174
g7
I368
sg23
VC0011195
p12175
sg10
I3
sg11
VDSS
p12176
sg13
I1
sa(dp12177
g7
I48
sg23
VC0021390
p12178
sg10
I3
sg11
VIBD
p12179
sg13
I1
sa(dp12180
g7
I396
sg23
VC0009319
p12181
sg10
I7
sg11
Vcolitis
p12182
sg13
I1
sa(dp12183
g7
I344
sg23
VC0011195
p12184
sg10
I22
sg11
Vdextran sulfate sodium
p12185
sg13
I3
sasa(dp12186
g2
S'A few natural AMPs were shown to be able to modulate colitis when delivered intravenously or intracolonically (cathelicidin, elafin and SLPI) in mouse colitis models.\n'
p12187
sg4
(lp12188
sg20
(lp12189
(dp12190
g7
I53
sg23
VC0009319
p12191
sg10
I7
sg11
Vcolitis
p12192
sg13
I1
sa(dp12193
g7
I53
sg23
VC0009319
p12194
sg10
I7
sg11
Vcolitis
p12195
sg13
I1
sasa(dp12196
g2
S"As compared with ulcerative colitis, Crohn's disease of the colon is characterized by an impaired induction of beta defensins, and antimicrobial antiproteases elafin and SLPI, as well as the cathelicidin LL37.\n"
p12197
sg4
(lp12198
(dp12199
g7
I111
sg8
VP59665
p12200
sg10
I14
sg11
Vbeta defensins
p12201
sg13
I2
sa(dp12202
g7
I191
sg8
VP49913
p12203
sg10
I17
sg11
Vcathelicidin LL37
p12204
sg13
I2
sasg20
(lp12205
(dp12206
g7
I17
sg23
VC0009324
p12207
sg10
I18
sg11
Vulcerative colitis
p12208
sg13
I2
sa(dp12209
g7
I37
sg23
VC0010346
p12210
sg10
I15
sg11
VCrohn's disease
p12211
sg13
I2
sa(dp12212
g7
I89
sg23
VC0684336
p12213
sg10
I8
sg11
Vimpaired
p12214
sg13
I1
sasa(dp12215
g2
S'The neuronal PAS domain proteins NPAS1 and NPAS3 are members of the basic helix-loop-helix-PER-ARNT-SIM (bHLH-PAS) family, and their genetic deficiencies are linked to a variety of human psychiatric disorders including schizophrenia, autism spectrum disorders and bipolar disease.\n'
p12216
sg4
(lp12217
(dp12218
g7
I95
sg8
VP27540
p12219
sg10
I4
sg11
VARNT
p12220
sg13
I1
sa(dp12221
g7
I33
sg8
g18
sg10
I5
sg11
VNPAS1
p12222
sg13
I1
sa(dp12223
g7
I13
sg8
VP05165
p12224
sg10
I3
sg11
VPAS
p12225
sg13
I1
sa(dp12226
g7
I105
sg8
g18
sg10
I4
sg11
VbHLH
p12227
sg13
I1
sa(dp12228
g7
I100
sg8
g18
sg10
I3
sg11
VSIM
p12229
sg13
I1
sa(dp12230
g7
I43
sg8
g18
sg10
I5
sg11
VNPAS3
p12231
sg13
I1
sa(dp12232
g7
I13
sg8
VP05165
p12233
sg10
I3
sg11
VPAS
p12234
sg13
I1
sasg20
(lp12235
(dp12236
g7
I187
sg23
VC0004936
p12237
sg10
I21
sg11
Vpsychiatric disorders
p12238
sg13
I2
sa(dp12239
g7
I234
sg23
VC1510586
p12240
sg10
I25
sg11
Vautism spectrum disorders
p12241
sg13
I3
sa(dp12242
g7
I219
sg23
VC0036341
p12243
sg10
I13
sg11
Vschizophrenia
p12244
sg13
I1
sasa(dp12245
g2
S"Median C(A)NO was significantly higher in SSc patients with alveolitis as compared with SSc patients without alveolitis (8.4ppb; 1st and 3rd interquartile range: 6.0-10.5 vs 3.3ppb; 2.2-3.5; p=0.004 for 2CM and 5.4ppb; 3.2-9.2 vs 3.2ppb; 1.4-3.3, p=0.02 for TMAD), while bronchial airway output of NO (J'awNO, p=0.19), and fractional exhaled NO (F(E)NO, p=0.12) were comparable.\n"
p12246
sg4
(lp12247
sg20
(lp12248
(dp12249
g7
I60
sg23
VC0549493
p12250
sg10
I10
sg11
Valveolitis
p12251
sg13
I1
sa(dp12252
g7
I60
sg23
VC0549493
p12253
sg10
I10
sg11
Valveolitis
p12254
sg13
I1
sasa(dp12255
g2
S'In this present study, one-step quantitative reverse transcription-polymerase chain reaction (qPCR) and western blotting tests with 10 fresh-frozen laryngeal squamous cell carcinoma (LSCC) samples and immunohistochemistry (IHC) analysis in 109 LSCC cases were performed to investigate the relationship between NDRG3 expression and the clinicopathological characteristics of LSCC.\n'
p12256
sg4
(lp12257
sg20
(lp12258
(dp12259
g7
I183
sg23
VC0280324
p12260
sg10
I4
sg11
VLSCC
p12261
sg13
I1
sa(dp12262
g7
I183
sg23
VC0280324
p12263
sg10
I4
sg11
VLSCC
p12264
sg13
I1
sa(dp12265
g7
I148
sg23
VC0280324
p12266
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p12267
sg13
I4
sa(dp12268
g7
I183
sg23
VC0280324
p12269
sg10
I4
sg11
VLSCC
p12270
sg13
I1
sasa(dp12271
g2
S'Results demonstrated that NDRG3 mRNA and protein expression levels were statistically higher in LSCC tissues than that in non-cancerous tissues (all p&lt;0.05).\n'
p12272
sg4
(lp12273
sg20
(lp12274
sa(dp12275
g2
S'Univariate and multivariate survival analysis implied that high NDRG3 expression (p=0.004), lymph node metastasis (p=0.044) and TNM stage (p=0.020) were independently associated with the unfavourable overall survival of patients with LSCC.\n'
p12276
sg4
(lp12277
sg20
(lp12278
(dp12279
g7
I92
sg23
VC0686619
p12280
sg10
I21
sg11
Vlymph node metastasis
p12281
sg13
I3
sasa(dp12282
g2
S'The above findings suggested that NDRG3 may be identified as a novel biomarker predicting the prognosis of LSCC.\n'
p12283
sg4
(lp12284
sg20
(lp12285
sa(dp12286
g2
S'GM1 gangliosidosis and Morquio syndrome type B (MPS IVB) are inherited lyosomal storage disorders associated with deficiency of beta-galactosidase-A (beta GALA) activity.\n'
p12287
sg4
(lp12288
sg20
(lp12289
(dp12290
g7
I114
sg23
VC2718068
p12291
sg10
I32
sg11
Vdeficiency of beta-galactosidase
p12292
sg13
I3
sa(dp12293
g7
I48
sg23
VC0086652
p12294
sg10
I7
sg11
VMPS IVB
p12295
sg13
I2
sa(dp12296
g7
I0
sg23
VC0085131
p12297
sg10
I18
sg11
VGM1 gangliosidosis
p12298
sg13
I2
sa(dp12299
g7
I23
sg23
VC0026707
p12300
sg10
I16
sg11
VMorquio syndrome
p12301
sg13
I2
sasa(dp12302
g2
S'The results of experiments with the enzyme samples from skin fibroblasts of healthy individuals and of patients with GM1-gangliosidosis (GM1-beta-D-galactosidase deficiency) suggest that Gal-A-sphingenin is a specific substrate for GC.\n'
p12303
sg4
(lp12304
(dp12305
g7
I141
sg8
g18
sg10
I20
sg11
Vbeta-D-galactosidase
p12306
sg13
I1
sa(dp12307
g7
I187
sg8
VP16278
p12308
sg10
I16
sg11
VGal-A-sphingenin
p12309
sg13
I1
sasg20
(lp12310
(dp12311
g7
I121
sg23
VC0017083
p12312
sg10
I14
sg11
Vgangliosidosis
p12313
sg13
I1
sasa(dp12314
g2
S'The evidence suggests that GM1 gangliosidosis is a consequence of mutation at this beta GALA locus on chromosome 3.\n'
p12315
sg4
(lp12316
(dp12317
g7
I83
sg8
VP06280
p12318
sg10
I9
sg11
Vbeta GALA
p12319
sg13
I2
sasg20
(lp12320
(dp12321
g7
I27
sg23
VC0085131
p12322
sg10
I18
sg11
VGM1 gangliosidosis
p12323
sg13
I2
sasa(dp12324
g2
S'A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.\n'
p12325
sg4
(lp12326
sg20
(lp12327
(dp12328
g7
I185
sg23
VC0149871
p12329
sg10
I22
sg11
Vdeep venous thrombosis
p12330
sg13
I3
sa(dp12331
g7
I218
sg23
VC0034065
p12332
sg10
I18
sg11
Vpulmonary embolism
p12333
sg13
I2
sa(dp12334
g7
I209
sg23
VC0149871
p12335
sg10
I3
sg11
VDVT
p12336
sg13
I1
sa(dp12337
g7
I33
sg23
VC0268382
p12338
sg10
I17
sg11
Vrenal amyloidosis
p12339
sg13
I2
sa(dp12340
g7
I250
sg23
VC0272285
p12341
sg10
I32
sg11
Vheparin-induced thrombocytopenia
p12342
sg13
I2
sasa(dp12343
g2
S'Anemia occurred in 61%, thrombocytosis in 16%, pulmonary involvement in 10%, and renal amyloidosis, vasculitis and Felty syndrome were present in 6%, 2% and 1%, respectively.\n'
p12344
sg4
(lp12345
sg20
(lp12346
(dp12347
g7
I47
sg23
VC0748159
p12348
sg10
I21
sg11
Vpulmonary involvement
p12349
sg13
I2
sa(dp12350
g7
I115
sg23
VC0015773
p12351
sg10
I14
sg11
VFelty syndrome
p12352
sg13
I2
sa(dp12353
g7
I100
sg23
VC0042384
p12354
sg10
I10
sg11
Vvasculitis
p12355
sg13
I1
sa(dp12356
g7
I24
sg23
VC0836924
p12357
sg10
I14
sg11
Vthrombocytosis
p12358
sg13
I1
sa(dp12359
g7
I81
sg23
VC0268382
p12360
sg10
I17
sg11
Vrenal amyloidosis
p12361
sg13
I2
sa(dp12362
g7
I0
sg23
VC0002871
p12363
sg10
I6
sg11
VAnemia
p12364
sg13
I1
sasa(dp12365
g2
S'The CTA, Sperm Protein 17 (SP17), has been found to be aberrantly expressed in different neoplasms, including ovarian and esophageal cancers, nervous system tumors and multiple myeloma, and has been suggested as a candidate target for immunotherapy.\n'
p12366
sg4
(lp12367
(dp12368
g7
I4
sg8
VP49585
p12369
sg10
I21
sg11
VCTA, Sperm Protein 17
p12370
sg13
I4
sa(dp12371
g7
I27
sg8
g18
sg10
I4
sg11
VSP17
p12372
sg13
I1
sasg20
(lp12373
(dp12374
g7
I168
sg23
VC0026764
p12375
sg10
I16
sg11
Vmultiple myeloma
p12376
sg13
I2
sa(dp12377
g7
I122
sg23
VC0546837
p12378
sg10
I18
sg11
Vesophageal cancers
p12379
sg13
I2
sa(dp12380
g7
I142
sg23
VC0027766
p12381
sg10
I21
sg11
Vnervous system tumors
p12382
sg13
I3
sa(dp12383
g7
I89
sg23
VC0027651
p12384
sg10
I9
sg11
Vneoplasms
p12385
sg13
I1
sasa(dp12386
g2
S'Sperm protein 17 (Sp17) was originally identified by our group as a novel cancer-testis antigen in various malignancies, including multiple myeloma.\n'
p12387
sg4
(lp12388
(dp12389
g7
I0
sg8
g18
sg10
I16
sg11
VSperm protein 17
p12390
sg13
I3
sa(dp12391
g7
I18
sg8
g18
sg10
I4
sg11
VSp17
p12392
sg13
I1
sasg20
(lp12393
(dp12394
g7
I131
sg23
VC0026764
p12395
sg10
I16
sg11
Vmultiple myeloma
p12396
sg13
I2
sa(dp12397
g7
I107
sg23
VC0006826
p12398
sg10
I12
sg11
Vmalignancies
p12399
sg13
I1
sa(dp12400
g7
I74
sg23
VC0006826
p12401
sg10
I6
sg11
Vcancer
p12402
sg13
I1
sasa(dp12403
g2
S'We previously identified sperm protein 17 (Sp17) as a normal testicular protein aberrantly expressed in a proportion of multiple myeloma (MM).\n'
p12404
sg4
(lp12405
(dp12406
g7
I25
sg8
g18
sg10
I16
sg11
Vsperm protein 17
p12407
sg13
I3
sa(dp12408
g7
I43
sg8
g18
sg10
I4
sg11
VSp17
p12409
sg13
I1
sasg20
(lp12410
(dp12411
g7
I120
sg23
VC0026764
p12412
sg10
I16
sg11
Vmultiple myeloma
p12413
sg13
I2
sasa(dp12414
g2
S'Sp17 expression was demonstrated recently in multiple myeloma, suggesting that it may be a novel cancer-testis antigen.\n'
p12415
sg4
(lp12416
(dp12417
g7
I0
sg8
g18
sg10
I4
sg11
VSp17
p12418
sg13
I1
sasg20
(lp12419
(dp12420
g7
I97
sg23
VC0006826
p12421
sg10
I6
sg11
Vcancer
p12422
sg13
I1
sa(dp12423
g7
I45
sg23
VC0026764
p12424
sg10
I16
sg11
Vmultiple myeloma
p12425
sg13
I2
sasa(dp12426
g2
S'Sperm protein 17 (Sp17) is a highly immunogenic cancer-testis antigen expressed by tumour cells from up to 30% of patients with multiple myeloma (MM).\n'
p12427
sg4
(lp12428
(dp12429
g7
I0
sg8
g18
sg10
I16
sg11
VSperm protein 17
p12430
sg13
I3
sa(dp12431
g7
I18
sg8
g18
sg10
I4
sg11
VSp17
p12432
sg13
I1
sa(dp12433
g7
I36
sg8
VP15735
p12434
sg10
I33
sg11
Vimmunogenic cancer-testis antigen
p12435
sg13
I3
sasg20
(lp12436
(dp12437
g7
I48
sg23
VC0006826
p12438
sg10
I6
sg11
Vcancer
p12439
sg13
I1
sa(dp12440
g7
I83
sg23
VC0027651
p12441
sg10
I6
sg11
Vtumour
p12442
sg13
I1
sa(dp12443
g7
I128
sg23
VC0026764
p12444
sg10
I16
sg11
Vmultiple myeloma
p12445
sg13
I2
sasa(dp12446
g2
S'Sperm protein 17 (Sp17) is a protein recently identified as a novel cancer-testis (CT) antigen in multiple myeloma (MM).\n'
p12447
sg4
(lp12448
(dp12449
g7
I0
sg8
g18
sg10
I16
sg11
VSperm protein 17
p12450
sg13
I3
sa(dp12451
g7
I18
sg8
g18
sg10
I4
sg11
VSp17
p12452
sg13
I1
sa(dp12453
g7
I68
sg8
VP15735
p12454
sg10
I26
sg11
Vcancer-testis (CT) antigen
p12455
sg13
I3
sasg20
(lp12456
(dp12457
g7
I98
sg23
VC0026764
p12458
sg10
I16
sg11
Vmultiple myeloma
p12459
sg13
I2
sa(dp12460
g7
I68
sg23
VC0006826
p12461
sg10
I6
sg11
Vcancer
p12462
sg13
I1
sasa(dp12463
g2
S'The c.3634+1G&gt;T DIAPH1 mutation causes autosomal dominant nonsyndromic sensorineural hearing loss, DFNA1, characterized by progressive deafness starting in childhood.\n'
p12464
sg4
(lp12465
(dp12466
g7
I102
sg8
g18
sg10
I5
sg11
VDFNA1
p12467
sg13
I1
sa(dp12468
g7
I-1
sg8
g18
sg10
I27
sg11
Vc.3634+1G>T DIAPH1 mutation
p12469
sg13
I3
sasg20
(lp12470
(dp12471
g7
I102
sg23
VC1852282
p12472
sg10
I5
sg11
VDFNA1
p12473
sg13
I1
sa(dp12474
g7
I74
sg23
VC0018784
p12475
sg10
I26
sg11
Vsensorineural hearing loss
p12476
sg13
I3
sa(dp12477
g7
I138
sg23
VC0011053
p12478
sg10
I8
sg11
Vdeafness
p12479
sg13
I1
sasa(dp12480
g2
S'We describe 2 unrelated pedigrees with MTP and sensorineural hearing loss that segregate with a DIAPH1 R1213* variant predicting partial truncation of the DIAPH1 diaphanous autoregulatory domain.\n'
p12481
sg4
(lp12482
(dp12483
g7
I96
sg8
g18
sg10
I6
sg11
VDIAPH1
p12484
sg13
I1
sa(dp12485
g7
I96
sg8
g18
sg10
I21
sg11
VDIAPH1 R1213* variant
p12486
sg13
I3
sasg20
(lp12487
(dp12488
g7
I137
sg23
VC1706395
p12489
sg10
I10
sg11
Vtruncation
p12490
sg13
I1
sa(dp12491
g7
I47
sg23
VC0018784
p12492
sg10
I26
sg11
Vsensorineural hearing loss
p12493
sg13
I3
sasa(dp12494
g2
S'BCAS2 cKO mice showed a microcephaly-like phenotype with a reduced volume in the dentate gyrus (DG) and low levels of learning and memory, as evaluated using Morris water maze analysis and passive avoidance, respectively.\n'
p12495
sg4
(lp12496
(dp12497
g7
I0
sg8
g18
sg10
I9
sg11
VBCAS2 cKO
p12498
sg13
I2
sasg20
(lp12499
(dp12500
g7
I24
sg23
VC0025958
p12501
sg10
I12
sg11
Vmicrocephaly
p12502
sg13
I1
sasa(dp12503
g2
S'The purpose of this study is to determine whether the first trimester maternal serum levels of follistatin like 3 (FSTL3) are altered in patients who develop gestational diabetes mellitus (GDM).\n'
p12504
sg4
(lp12505
(dp12506
g7
I95
sg8
VP19883
p12507
sg10
I18
sg11
Vfollistatin like 3
p12508
sg13
I3
sa(dp12509
g7
I115
sg8
g18
sg10
I5
sg11
VFSTL3
p12510
sg13
I1
sasg20
(lp12511
(dp12512
g7
I158
sg23
VC0085207
p12513
sg10
I29
sg11
Vgestational diabetes mellitus
p12514
sg13
I3
sa(dp12515
g7
I189
sg23
VC0085207
p12516
sg10
I3
sg11
VGDM
p12517
sg13
I1
sasa(dp12518
g2
S'Rodent models suggest that follistatin-like 3 (fstl3) is associated with diabetes and obesity.\n'
p12519
sg4
(lp12520
(dp12521
g7
I27
sg8
g18
sg10
I18
sg11
Vfollistatin-like 3
p12522
sg13
I2
sa(dp12523
g7
I47
sg8
g18
sg10
I5
sg11
Vfstl3
p12524
sg13
I1
sasg20
(lp12525
(dp12526
g7
I73
sg23
VC0011849
p12527
sg10
I8
sg11
Vdiabetes
p12528
sg13
I1
sa(dp12529
g7
I86
sg23
VC0028754
p12530
sg10
I7
sg11
Vobesity
p12531
sg13
I1
sasa(dp12532
g2
S'In humans, plasma fstl3 is reduced with gestational diabetes.\n'
p12533
sg4
(lp12534
(dp12535
g7
I18
sg8
g18
sg10
I5
sg11
Vfstl3
p12536
sg13
I1
sasg20
(lp12537
(dp12538
g7
I40
sg23
VC0085207
p12539
sg10
I20
sg11
Vgestational diabetes
p12540
sg13
I2
sasa(dp12541
g2
S'Plasma fstl3 levels were determined in a cross-sectional study including three groups: patients with type 2 diabetes, impaired glucose tolerance, and healthy controls.\n'
p12542
sg4
(lp12543
(dp12544
g7
I0
sg8
g18
sg10
I12
sg11
VPlasma fstl3
p12545
sg13
I2
sasg20
(lp12546
(dp12547
g7
I118
sg23
VC0271650
p12548
sg10
I26
sg11
Vimpaired glucose tolerance
p12549
sg13
I3
sa(dp12550
g7
I101
sg23
VC0011860
p12551
sg10
I15
sg11
Vtype 2 diabetes
p12552
sg13
I3
sasa(dp12553
g2
S'The objective of this study was to determine maternal and placental concentrations of follistatin-like 3 (FSTL3), and, maternal concentrations of myostatin in gestational diabetes mellitus (GDM).\n'
p12554
sg4
(lp12555
(dp12556
g7
I146
sg8
g18
sg10
I9
sg11
Vmyostatin
p12557
sg13
I1
sa(dp12558
g7
I106
sg8
g18
sg10
I5
sg11
VFSTL3
p12559
sg13
I1
sa(dp12560
g7
I86
sg8
g18
sg10
I18
sg11
Vfollistatin-like 3
p12561
sg13
I2
sasg20
(lp12562
(dp12563
g7
I159
sg23
VC0085207
p12564
sg10
I29
sg11
Vgestational diabetes mellitus
p12565
sg13
I3
sa(dp12566
g7
I190
sg23
VC0085207
p12567
sg10
I3
sg11
VGDM
p12568
sg13
I1
sasa(dp12569
g2
S'Maternal and placental FSTL3 concentrations were reduced in GDM women compared with normally pregnant women, suggesting FSTL3 may play an important role in the pathogenesis of gestational diabetes.\n'
p12570
sg4
(lp12571
(dp12572
g7
I23
sg8
g18
sg10
I5
sg11
VFSTL3
p12573
sg13
I1
sa(dp12574
g7
I23
sg8
g18
sg10
I5
sg11
VFSTL3
p12575
sg13
I1
sasg20
(lp12576
(dp12577
g7
I176
sg23
VC0085207
p12578
sg10
I20
sg11
Vgestational diabetes
p12579
sg13
I2
sa(dp12580
g7
I160
sg23
VC0699748
p12581
sg10
I12
sg11
Vpathogenesis
p12582
sg13
I1
sa(dp12583
g7
I60
sg23
VC0085207
p12584
sg10
I3
sg11
VGDM
p12585
sg13
I1
sasa(dp12586
g2
S'OBJECTIVE To determine whether maternal levels of follistatin-like-3 (FSTL3), an inhibitor of activin and myostatin involved in glucose homeostasis, are altered in the first trimester of pregnancies complicated by subsequent gestational diabetes mellitus (GDM).\n'
p12587
sg4
(lp12588
(dp12589
g7
I70
sg8
g18
sg10
I5
sg11
VFSTL3
p12590
sg13
I1
sa(dp12591
g7
I50
sg8
VP19883
p12592
sg10
I18
sg11
Vfollistatin-like-3
p12593
sg13
I1
sa(dp12594
g7
I106
sg8
g18
sg10
I9
sg11
Vmyostatin
p12595
sg13
I1
sa(dp12596
g7
I94
sg8
VP58166
p12597
sg10
I7
sg11
Vactivin
p12598
sg13
I1
sasg20
(lp12599
(dp12600
g7
I225
sg23
VC0085207
p12601
sg10
I29
sg11
Vgestational diabetes mellitus
p12602
sg13
I3
sa(dp12603
g7
I256
sg23
VC0085207
p12604
sg10
I3
sg11
VGDM
p12605
sg13
I1
sasa(dp12606
g2
S'CONCLUSIONS First-trimester FSTL3 levels are associated with glucose intolerance and GDM later in pregnancy.\n'
p12607
sg4
(lp12608
(dp12609
g7
I28
sg8
g18
sg10
I5
sg11
VFSTL3
p12610
sg13
I1
sasg20
(lp12611
(dp12612
g7
I85
sg23
VC0085207
p12613
sg10
I3
sg11
VGDM
p12614
sg13
I1
sa(dp12615
g7
I61
sg23
VC0271650
p12616
sg10
I19
sg11
Vglucose intolerance
p12617
sg13
I2
sasa(dp12618
g2
S'In contrast, only 2 cases of endocervical adenocarcinoma were positive for PAX2 [invasive adenocarcinoma of the minimal deviation type (0 of 5), usual type (1 of 22), and endometrioid type (1 of 1)].\n'
p12619
sg4
(lp12620
(dp12621
g7
I75
sg8
g18
sg10
I4
sg11
VPAX2
p12622
sg13
I1
sasg20
(lp12623
(dp12624
g7
I29
sg23
VC1263762
p12625
sg10
I27
sg11
Vendocervical adenocarcinoma
p12626
sg13
I2
sa(dp12627
g7
I42
sg23
VC0001418
p12628
sg10
I14
sg11
Vadenocarcinoma
p12629
sg13
I1
sasa(dp12630
g2
S'PAX2 expression in the 2 positive endocervical adenocarcinomas was patchy and weak.\n'
p12631
sg4
(lp12632
(dp12633
g7
I0
sg8
g18
sg10
I4
sg11
VPAX2
p12634
sg13
I1
sasg20
(lp12635
(dp12636
g7
I47
sg23
VC0001418
p12637
sg10
I15
sg11
Vadenocarcinomas
p12638
sg13
I1
sasa(dp12639
g2
S'These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.\n'
p12640
sg4
(lp12641
(dp12642
g7
I27
sg8
g18
sg10
I4
sg11
VPAX2
p12643
sg13
I1
sasg20
(lp12644
(dp12645
g7
I330
sg23
VC3163987
p12646
sg10
I35
sg11
Vendocervical adenocarcinoma in situ
p12647
sg13
I4
sa(dp12648
g7
I185
sg23
VC0334000
p12649
sg10
I21
sg11
Vglandular hyperplasia
p12650
sg13
I2
sa(dp12651
g7
I282
sg23
VC1265962
p12652
sg10
I16
sg11
Vtubal metaplasia
p12653
sg13
I2
sa(dp12654
g7
I82
sg23
VC1334702
p12655
sg10
I23
sg11
Vmesonephric hyperplasia
p12656
sg13
I2
sa(dp12657
g7
I302
sg23
VC0269107
p12658
sg10
I22
sg11
Vcervical endometriosis
p12659
sg13
I2
sa(dp12660
g7
I129
sg23
VC0001418
p12661
sg10
I14
sg11
Vadenocarcinoma
p12662
sg13
I1
sa(dp12663
g7
I129
sg23
VC0001418
p12664
sg10
I14
sg11
Vadenocarcinoma
p12665
sg13
I1
sasa(dp12666
g2
S'To this end, translocator protein, a biomarker of inflammation, was imaged by means of positron emission tomography (PET) 2 and 4weeks post-status epilepticus using [18F]-PBR111.\n'
p12667
sg4
(lp12668
sg20
(lp12669
(dp12670
g7
I140
sg23
VC0038220
p12671
sg10
I18
sg11
Vstatus epilepticus
p12672
sg13
I2
sa(dp12673
g7
I50
sg23
VC0021368
p12674
sg10
I12
sg11
Vinflammation
p12675
sg13
I1
sasa(dp12676
g2
S'Translocator protein was highly upregulated 2weeks post-status epilepticus in limbic structures (up to 2.1-fold increase compared to controls in temporal lobe, P&lt;0.001), whereas 4weeks post-status epilepticus, upregulation decreased (up to 1.6-fold increase compared to controls in temporal lobe, P&lt;0.01) and was only apparent in a subset of these regions.\n'
p12677
sg4
(lp12678
sg20
(lp12679
(dp12680
g7
I56
sg23
VC0038220
p12681
sg10
I18
sg11
Vstatus epilepticus
p12682
sg13
I2
sa(dp12683
g7
I56
sg23
VC0038220
p12684
sg10
I18
sg11
Vstatus epilepticus
p12685
sg13
I2
sasa(dp12686
g2
S'Regional PET imaging did not correlate with SRS frequency, however, by applying a multivariate data-driven modeling approach based on translocator protein PET imaging at 2weeks post-status epilepticus, we accurately predicted the frequency of SRS (R=0.92; R2=0.86; P&lt;0.0001) at the onset of epilepsy.\n'
p12687
sg4
(lp12688
sg20
(lp12689
(dp12690
g7
I44
sg23
VC0175693
p12691
sg10
I3
sg11
VSRS
p12692
sg13
I1
sa(dp12693
g7
I182
sg23
VC0038220
p12694
sg10
I18
sg11
Vstatus epilepticus
p12695
sg13
I2
sa(dp12696
g7
I44
sg23
VC0175693
p12697
sg10
I3
sg11
VSRS
p12698
sg13
I1
sa(dp12699
g7
I294
sg23
VC0014544
p12700
sg10
I8
sg11
Vepilepsy
p12701
sg13
I1
sasa(dp12702
g2
S'TSPO expression, microglial activation, astrocyte reactivity and cell loss in several brain regions were evaluated at five time points during epileptogenesis, including the chronic epilepsy phase in the kainic acid-induced status epilepticus (KASE) model (n = 52) and control Wistar Han rats (n = 33).\n'
p12703
sg4
(lp12704
(dp12705
g7
I0
sg8
VP30536
p12706
sg10
I4
sg11
VTSPO
p12707
sg13
I1
sasg20
(lp12708
(dp12709
g7
I223
sg23
VC0038220
p12710
sg10
I18
sg11
Vstatus epilepticus
p12711
sg13
I2
sa(dp12712
g7
I181
sg23
VC0014544
p12713
sg10
I8
sg11
Vepilepsy
p12714
sg13
I1
sasa(dp12715
g2
S'In 2 patients with severe exocrine pancreatic insufficiency, cerulein had no effect on the concentration of plasma amino acids, whereas the addition of glucagon caused a marked decrease.\n'
p12716
sg4
(lp12717
(dp12718
g7
I152
sg8
VP01275
p12719
sg10
I8
sg11
Vglucagon
p12720
sg13
I1
sasg20
(lp12721
(dp12722
g7
I26
sg23
VC0267963
p12723
sg10
I33
sg11
Vexocrine pancreatic insufficiency
p12724
sg13
I3
sasa(dp12725
g2
S'For example, there was an increase in the expression of ERG, K(v)LQT1, K(ir)2.4, TASK1, TWIK1, TWIK2, calsequestrin 2, and the A1 adenosine receptor in the SAN that could explain the slowing of the intrinsic heart rate.\n'
p12726
sg4
(lp12727
(dp12728
g7
I81
sg8
g18
sg10
I5
sg11
VTASK1
p12729
sg13
I1
sa(dp12730
g7
I56
sg8
VP11308
p12731
sg10
I3
sg11
VERG
p12732
sg13
I1
sa(dp12733
g7
I71
sg8
VP06213
p12734
sg10
I8
sg11
VK(ir)2.4
p12735
sg13
I1
sa(dp12736
g7
I102
sg8
g18
sg10
I15
sg11
Vcalsequestrin 2
p12737
sg13
I2
sa(dp12738
g7
I88
sg8
g18
sg10
I5
sg11
VTWIK1
p12739
sg13
I1
sa(dp12740
g7
I61
sg8
VP51787
p12741
sg10
I8
sg11
VK(v)LQT1
p12742
sg13
I1
sa(dp12743
g7
I95
sg8
g18
sg10
I5
sg11
VTWIK2
p12744
sg13
I1
sa(dp12745
g7
I127
sg8
VP30542
p12746
sg10
I21
sg11
VA1 adenosine receptor
p12747
sg13
I3
sasg20
(lp12748
(dp12749
g7
I65
sg23
VC0035828
p12750
sg10
I4
sg11
VLQT1
p12751
sg13
I1
sasa(dp12752
g2
S'Our results show a significant over-expression of SphK1 mRNA and protein expression in the carcinomas compared with adenomas (P &lt; 0.01 for all comparisons).\n'
p12753
sg4
(lp12754
(dp12755
g7
I50
sg8
g18
sg10
I10
sg11
VSphK1 mRNA
p12756
sg13
I2
sasg20
(lp12757
(dp12758
g7
I116
sg23
VC0001430
p12759
sg10
I8
sg11
Vadenomas
p12760
sg13
I1
sa(dp12761
g7
I91
sg23
VC0007097
p12762
sg10
I10
sg11
Vcarcinomas
p12763
sg13
I1
sasa(dp12764
g2
S'To evaluate the role of sphingosine kinase 1 (SphK1) in insulin secretion, we used stable transfection to knock down the expression of the Sphk1 gene in the rat insulinoma INS-1 832/13 cell line.\n'
p12765
sg4
(lp12766
(dp12767
g7
I139
sg8
g18
sg10
I10
sg11
VSphk1 gene
p12768
sg13
I2
sa(dp12769
g7
I46
sg8
g18
sg10
I5
sg11
VSphK1
p12770
sg13
I1
sa(dp12771
g7
I24
sg8
g18
sg10
I20
sg11
Vsphingosine kinase 1
p12772
sg13
I3
sa(dp12773
g7
I56
sg8
VP01308
p12774
sg10
I7
sg11
Vinsulin
p12775
sg13
I1
sa(dp12776
g7
I157
sg8
VP01308
p12777
sg10
I20
sg11
Vrat insulinoma INS-1
p12778
sg13
I3
sasg20
(lp12779
(dp12780
g7
I172
sg23
VC1533172
p12781
sg10
I3
sg11
VINS
p12782
sg13
I1
sa(dp12783
g7
I161
sg23
VC0021670
p12784
sg10
I10
sg11
Vinsulinoma
p12785
sg13
I1
sasa(dp12786
g2
S'In rat uterine leiomyoma cells (ELT3), SphK1/S1P axis controls survival and proliferation.\n'
p12787
sg4
(lp12788
(dp12789
g7
I39
sg8
g18
sg10
I5
sg11
VSphK1
p12790
sg13
I1
sa(dp12791
g7
I45
sg8
g18
sg10
I3
sg11
VS1P
p12792
sg13
I1
sasg20
(lp12793
(dp12794
g7
I76
sg23
VC0334094
p12795
sg10
I13
sg11
Vproliferation
p12796
sg13
I1
sa(dp12797
g7
I7
sg23
VC0042133
p12798
sg10
I17
sg11
Vuterine leiomyoma
p12799
sg13
I2
sasa(dp12800
g2
S'A role for SPHK activity in beta-cell growth was confirmed when small interfering (si)SPHK2 RNA transfection reduced rat insulinoma INS-1e cell SPHK levels and activity and cell growth.\n'
p12801
sg4
(lp12802
(dp12803
g7
I86
sg8
g18
sg10
I9
sg11
VSPHK2 RNA
p12804
sg13
I2
sa(dp12805
g7
I11
sg8
g18
sg10
I4
sg11
VSPHK
p12806
sg13
I1
sa(dp12807
g7
I117
sg8
VP01308
p12808
sg10
I31
sg11
Vrat insulinoma INS-1e cell SPHK
p12809
sg13
I5
sasg20
(lp12810
(dp12811
g7
I132
sg23
VC1533172
p12812
sg10
I3
sg11
VINS
p12813
sg13
I1
sa(dp12814
g7
I121
sg23
VC0021670
p12815
sg10
I10
sg11
Vinsulinoma
p12816
sg13
I1
sasa(dp12817
g2
S'Adenomas had higher expression of SphK1 vs. normal mucosa, and colon cancers with metastasis had higher expression of SphK1 than those without metastasis.\n'
p12818
sg4
(lp12819
(dp12820
g7
I34
sg8
g18
sg10
I5
sg11
VSphK1
p12821
sg13
I1
sa(dp12822
g7
I34
sg8
g18
sg10
I5
sg11
VSphK1
p12823
sg13
I1
sasg20
(lp12824
(dp12825
g7
I0
sg23
VC0001430
p12826
sg10
I8
sg11
VAdenomas
p12827
sg13
I1
sa(dp12828
g7
I82
sg23
VC0027627
p12829
sg10
I10
sg11
Vmetastasis
p12830
sg13
I1
sa(dp12831
g7
I82
sg23
VC0027627
p12832
sg10
I10
sg11
Vmetastasis
p12833
sg13
I1
sa(dp12834
g7
I63
sg23
VC0007102
p12835
sg10
I13
sg11
Vcolon cancers
p12836
sg13
I2
sasa(dp12837
g2
S'Adenoma size but not incidence was dramatically reduced in Apc Min/+ Sphk(-/-) mice.\n'
p12838
sg4
(lp12839
(dp12840
g7
I59
sg8
VP25054
p12841
sg10
I7
sg11
VApc Min
p12842
sg13
I2
sasg20
(lp12843
(dp12844
g7
I0
sg23
VC0001430
p12845
sg10
I7
sg11
VAdenoma
p12846
sg13
I1
sa(dp12847
g7
I59
sg23
VC0033036
p12848
sg10
I3
sg11
VApc
p12849
sg13
I1
sasa(dp12850
g2
S'Concomitantly, epithelial cell proliferation in the polyps was significantly attenuated, suggesting that Sphk1 regulates adenoma progression.\n'
p12851
sg4
(lp12852
(dp12853
g7
I105
sg8
g18
sg10
I5
sg11
VSphk1
p12854
sg13
I1
sasg20
(lp12855
(dp12856
g7
I31
sg23
VC0334094
p12857
sg10
I13
sg11
Vproliferation
p12858
sg13
I1
sa(dp12859
g7
I52
sg23
VC0032584
p12860
sg10
I6
sg11
Vpolyps
p12861
sg13
I1
sa(dp12862
g7
I121
sg23
VC0001430
p12863
sg10
I7
sg11
Vadenoma
p12864
sg13
I1
sasa(dp12865
g2
S'Interestingly, tissue sphingosine content was elevated in the adenomas of Apc Min/+ Sphk1(-/-) mice, whereas S1P levels were not significantly altered.\n'
p12866
sg4
(lp12867
(dp12868
g7
I74
sg8
VP25054
p12869
sg10
I15
sg11
VApc Min/+ Sphk1
p12870
sg13
I3
sa(dp12871
g7
I109
sg8
g18
sg10
I3
sg11
VS1P
p12872
sg13
I1
sasg20
(lp12873
(dp12874
g7
I74
sg23
VC0033036
p12875
sg10
I3
sg11
VApc
p12876
sg13
I1
sa(dp12877
g7
I62
sg23
VC0001430
p12878
sg10
I8
sg11
Vadenomas
p12879
sg13
I1
sasa(dp12880
g2
S'These findings highlight the critical role of miR-137-c-Met nexus in CRC development and reveal Mecp2-regulated epigenetic silence causes the downregulation of miR-137 in colorectal adenoma and carcinoma.\n'
p12881
sg4
(lp12882
(dp12883
g7
I46
sg8
g18
sg10
I19
sg11
VmiR-137-c-Met nexus
p12884
sg13
I2
sa(dp12885
g7
I96
sg8
VP51608
p12886
sg10
I5
sg11
VMecp2
p12887
sg13
I1
sa(dp12888
g7
I46
sg8
g18
sg10
I7
sg11
VmiR-137
p12889
sg13
I1
sa(dp12890
g7
I69
sg8
VP31749
p12891
sg10
I3
sg11
VCRC
p12892
sg13
I1
sasg20
(lp12893
(dp12894
g7
I171
sg23
VC1302401
p12895
sg10
I18
sg11
Vcolorectal adenoma
p12896
sg13
I2
sa(dp12897
g7
I123
sg23
VC0858952
p12898
sg10
I7
sg11
Vsilence
p12899
sg13
I1
sa(dp12900
g7
I194
sg23
VC0007097
p12901
sg10
I9
sg11
Vcarcinoma
p12902
sg13
I1
sa(dp12903
g7
I69
sg23
VC1527249
p12904
sg10
I3
sg11
VCRC
p12905
sg13
I1
sasa(dp12906
g2
S'In this study we examined the expression of c-MET in colorectal adenomas, primary adenocarcinomas and their corresponding lymph node, peritoneal and liver metastases.\n'
p12907
sg4
(lp12908
(dp12909
g7
I44
sg8
VP08581
p12910
sg10
I5
sg11
Vc-MET
p12911
sg13
I1
sasg20
(lp12912
(dp12913
g7
I82
sg23
VC0001418
p12914
sg10
I15
sg11
Vadenocarcinomas
p12915
sg13
I1
sa(dp12916
g7
I53
sg23
VC1302401
p12917
sg10
I19
sg11
Vcolorectal adenomas
p12918
sg13
I2
sa(dp12919
g7
I149
sg23
VC0494165
p12920
sg10
I16
sg11
Vliver metastases
p12921
sg13
I2
sasa(dp12922
g2
S'Twenty three cases of colorectal adenoma and 102 cases of primary colorectal carcinoma and their corresponding metastases (44 lymph nodes, 21 peritoneal deposits and 16 liver metastases) were studied to evaluate c-MET expression by immunohistochemistry.\n'
p12923
sg4
(lp12924
sg20
(lp12925
(dp12926
g7
I22
sg23
VC1302401
p12927
sg10
I18
sg11
Vcolorectal adenoma
p12928
sg13
I2
sa(dp12929
g7
I66
sg23
VC0009402
p12930
sg10
I20
sg11
Vcolorectal carcinoma
p12931
sg13
I2
sa(dp12932
g7
I111
sg23
VC0027627
p12933
sg10
I10
sg11
Vmetastases
p12934
sg13
I1
sa(dp12935
g7
I169
sg23
VC0494165
p12936
sg10
I16
sg11
Vliver metastases
p12937
sg13
I2
sasa(dp12938
g2
S'Expression of c-MET was positive in 47.8% of adenomas.\n'
p12939
sg4
(lp12940
(dp12941
g7
I14
sg8
VP08581
p12942
sg10
I5
sg11
Vc-MET
p12943
sg13
I1
sasg20
(lp12944
(dp12945
g7
I45
sg23
VC0001430
p12946
sg10
I8
sg11
Vadenomas
p12947
sg13
I1
sasa(dp12948
g2
S'c-MET expression is gradually up-regulated in the development and progression of colorectal cancer (CRC) from normal epithelium to adenoma to colorectal carcinoma to metastases.\n'
p12949
sg4
(lp12950
(dp12951
g7
I0
sg8
VP08581
p12952
sg10
I5
sg11
Vc-MET
p12953
sg13
I1
sasg20
(lp12954
(dp12955
g7
I100
sg23
VC1527249
p12956
sg10
I3
sg11
VCRC
p12957
sg13
I1
sa(dp12958
g7
I166
sg23
VC0027627
p12959
sg10
I10
sg11
Vmetastases
p12960
sg13
I1
sa(dp12961
g7
I142
sg23
VC0009402
p12962
sg10
I20
sg11
Vcolorectal carcinoma
p12963
sg13
I2
sa(dp12964
g7
I81
sg23
VC1527249
p12965
sg10
I17
sg11
Vcolorectal cancer
p12966
sg13
I2
sa(dp12967
g7
I131
sg23
VC0001430
p12968
sg10
I7
sg11
Vadenoma
p12969
sg13
I1
sasa(dp12970
g2
S'The positive rate of F-FDG PET/CT in patients with somatostatin analog treatment, radiosurgery, transsphenoidal surgery, and microadenoma was 63% (5/8), 50% (1/2), 33% (4/12), and 48%(10/21), respectively, while that of C-MET PET/CT was 86% (6/7), 50% (1/2), 100% (12/12), and 100% (21/21), respectively.\n'
p12971
sg4
(lp12972
(dp12973
g7
I51
sg8
VP61278
p12974
sg10
I12
sg11
Vsomatostatin
p12975
sg13
I1
sasg20
(lp12976
sa(dp12977
g2
S'In the 9 patients with a recurrent microadenoma, the positive rate of F-FDG PET/CT was as low as 22% while that of C-MET PET/CT was 100%.\n'
p12978
sg4
(lp12979
sg20
(lp12980
sa(dp12981
g2
S'C-MET PET/CT can provide valuable diagnostic information when F-FDG PET/CT yields negative results, especially in patients with recurrent microadenomas.\n'
p12982
sg4
(lp12983
sg20
(lp12984
sa(dp12985
g2
S'Also, increased phospho-HLXB9 coincided with reduced Cblb and increased c-Met in insulinomas of two mouse models of menin loss.\n'
p12986
sg4
(lp12987
(dp12988
g7
I53
sg8
g18
sg10
I4
sg11
VCblb
p12989
sg13
I1
sa(dp12990
g7
I24
sg8
VP50219
p12991
sg10
I5
sg11
VHLXB9
p12992
sg13
I1
sa(dp12993
g7
I72
sg8
VP08581
p12994
sg10
I5
sg11
Vc-Met
p12995
sg13
I1
sasg20
(lp12996
(dp12997
g7
I81
sg23
VC0021670
p12998
sg10
I11
sg11
Vinsulinomas
p12999
sg13
I1
sasa(dp13000
g2
S'These mechanisms have therapeutic implications for reducing Beta-cell proliferation in insulinomas by inhibiting phospho-HLXB9 or its interaction with Nono and modulating the expression of its direct (Cblb) or indirect (c-Met) targets.\n'
p13001
sg4
(lp13002
(dp13003
g7
I121
sg8
VP50219
p13004
sg10
I5
sg11
VHLXB9
p13005
sg13
I1
sasg20
(lp13006
(dp13007
g7
I87
sg23
VC0021670
p13008
sg10
I11
sg11
Vinsulinomas
p13009
sg13
I1
sa(dp13010
g7
I70
sg23
VC0334094
p13011
sg10
I13
sg11
Vproliferation
p13012
sg13
I1
sasa(dp13013
g2
S'The common SNPs tested in DDOST, PRKCSH and LGALS3 do not seem to be associated with diabetic micro- or macrovascular complications or with type 1 diabetes in Finnish patients.\n'
p13014
sg4
(lp13015
(dp13016
g7
I33
sg8
VP14314
p13017
sg10
I6
sg11
VPRKCSH
p13018
sg13
I1
sa(dp13019
g7
I26
sg8
VP39656
p13020
sg10
I5
sg11
VDDOST
p13021
sg13
I1
sa(dp13022
g7
I44
sg8
VP17931
p13023
sg10
I6
sg11
VLGALS3
p13024
sg13
I1
sasg20
(lp13025
(dp13026
g7
I140
sg23
VC0011854
p13027
sg10
I15
sg11
Vtype 1 diabetes
p13028
sg13
I3
sasa(dp13029
g2
S'Loss of CD26 (&gt;=80% CD4(+) T cells) and/or CD7 (&gt;=40% CD4(+) T cells) and combination of altered expression of STAT4, TWIST1, and DNM3 or PLS3 could distinguish, respectively, 83% and 98% of patients with Sezary syndrome from patients with erythrodermic inflammatory dermatoses with 100% specificity.\n'
p13030
sg4
(lp13031
(dp13032
g7
I23
sg8
VP01730
p13033
sg10
I3
sg11
VCD4
p13034
sg13
I1
sa(dp13035
g7
I46
sg8
VP09564
p13036
sg10
I3
sg11
VCD7
p13037
sg13
I1
sa(dp13038
g7
I124
sg8
g18
sg10
I6
sg11
VTWIST1
p13039
sg13
I1
sa(dp13040
g7
I8
sg8
VP27487
p13041
sg10
I4
sg11
VCD26
p13042
sg13
I1
sa(dp13043
g7
I144
sg8
VP13797
p13044
sg10
I4
sg11
VPLS3
p13045
sg13
I1
sa(dp13046
g7
I117
sg8
g18
sg10
I5
sg11
VSTAT4
p13047
sg13
I1
sa(dp13048
g7
I23
sg8
VP01730
p13049
sg10
I3
sg11
VCD4
p13050
sg13
I1
sasg20
(lp13051
(dp13052
g7
I211
sg23
VC0036920
p13053
sg10
I15
sg11
VSezary syndrome
p13054
sg13
I2
sa(dp13055
g7
I273
sg23
VC0037274
p13056
sg10
I10
sg11
Vdermatoses
p13057
sg13
I1
sasa(dp13058
g2
S'Sezary Syndrome (SS/L-CTCL) is a rare but aggressive variant of cutaneous T cell lymphoma (CTCL), characterized by erythroderma, lymphadenopathy, and the presence of a circulating memory CD4(+) T cell malignant clone with a skin homing behavior, lacking CD26 and CD49d and over-expressing CD60.\n'
p13059
sg4
(lp13060
(dp13061
g7
I263
sg8
VP13612
p13062
sg10
I5
sg11
VCD49d
p13063
sg13
I1
sa(dp13064
g7
I254
sg8
VP27487
p13065
sg10
I4
sg11
VCD26
p13066
sg13
I1
sa(dp13067
g7
I187
sg8
VP01730
p13068
sg10
I3
sg11
VCD4
p13069
sg13
I1
sasg20
(lp13070
(dp13071
g7
I22
sg23
VC0079773
p13072
sg10
I4
sg11
VCTCL
p13073
sg13
I1
sa(dp13074
g7
I42
sg23
VC0001807
p13075
sg10
I10
sg11
Vaggressive
p13076
sg13
I1
sa(dp13077
g7
I0
sg23
VC0036920
p13078
sg10
I15
sg11
VSezary Syndrome
p13079
sg13
I2
sa(dp13080
g7
I115
sg23
VC0011606
p13081
sg10
I12
sg11
Verythroderma
p13082
sg13
I1
sa(dp13083
g7
I22
sg23
VC0079773
p13084
sg10
I4
sg11
VCTCL
p13085
sg13
I1
sa(dp13086
g7
I64
sg23
VC0079773
p13087
sg10
I25
sg11
Vcutaneous T cell lymphoma
p13088
sg13
I4
sasa(dp13089
g2
S'By using flow cytometry with markers for CD3, CD4, CD26, and CD7, we examined the blood samples of 109 patients for abnormal T cells: 69 patients with mycosis fungoides (MF)/Sezary syndrome (SS), 31 hospitalized control subjects, and 9 patients with inflammatory skin disease.\n'
p13090
sg4
(lp13091
(dp13092
g7
I46
sg8
VP01730
p13093
sg10
I3
sg11
VCD4
p13094
sg13
I1
sa(dp13095
g7
I51
sg8
VP27487
p13096
sg10
I4
sg11
VCD26
p13097
sg13
I1
sa(dp13098
g7
I61
sg8
VP09564
p13099
sg10
I3
sg11
VCD7
p13100
sg13
I1
sasg20
(lp13101
(dp13102
g7
I174
sg23
VC0036920
p13103
sg10
I15
sg11
VSezary syndrome
p13104
sg13
I2
sa(dp13105
g7
I151
sg23
VC0026948
p13106
sg10
I17
sg11
Vmycosis fungoides
p13107
sg13
I2
sa(dp13108
g7
I263
sg23
VC0037274
p13109
sg10
I12
sg11
Vskin disease
p13110
sg13
I2
sa(dp13111
g7
I170
sg23
VC0026948
p13112
sg10
I2
sg11
VMF
p13113
sg13
I1
sasa(dp13114
g2
S"Individuals with Down syndrome (DS) have an increased risk of early-onset Alzheimer's Disease (AD), largely owing to a triplication of the APP gene, located on chromosome 21.\n"
p13115
sg4
(lp13116
(dp13117
g7
I139
sg8
g18
sg10
I8
sg11
VAPP gene
p13118
sg13
I2
sasg20
(lp13119
(dp13120
g7
I74
sg23
VC1521724
p13121
sg10
I19
sg11
VAlzheimer's Disease
p13122
sg13
I2
sa(dp13123
g7
I17
sg23
VC0013080
p13124
sg10
I13
sg11
VDown syndrome
p13125
sg13
I2
sa(dp13126
g7
I95
sg23
VC1521724
p13127
sg10
I2
sg11
VAD
p13128
sg13
I1
sa(dp13129
g7
I32
sg23
VC0013080
p13130
sg10
I2
sg11
VDS
p13131
sg13
I1
sasa(dp13132
g2
S'The ABeta4-x staining pattern was restricted mainly to amyloid plaque cores and cerebral amyloid angiopathy in AD and Down syndrome cases and in both AD mouse models.\n'
p13133
sg4
(lp13134
sg20
(lp13135
(dp13136
g7
I55
sg23
VC2936349
p13137
sg10
I14
sg11
Vamyloid plaque
p13138
sg13
I2
sa(dp13139
g7
I118
sg23
VC0013080
p13140
sg10
I13
sg11
VDown syndrome
p13141
sg13
I2
sa(dp13142
g7
I80
sg23
VC0085220
p13143
sg10
I27
sg11
Vcerebral amyloid angiopathy
p13144
sg13
I3
sasa(dp13145
g2
S'This review focuses on the role of ABeta in AD pathogenesis in Down syndrome and current approaches for imaging ABeta in vivo.\n'
p13146
sg4
(lp13147
(dp13148
g7
I35
sg8
g18
sg10
I5
sg11
VABeta
p13149
sg13
I1
sasg20
(lp13150
(dp13151
g7
I63
sg23
VC0013080
p13152
sg10
I13
sg11
VDown syndrome
p13153
sg13
I2
sa(dp13154
g7
I47
sg23
VC0699748
p13155
sg10
I12
sg11
Vpathogenesis
p13156
sg13
I1
sasa(dp13157
g2
S"Alzheimer's disease (AD) may affect in excess of 90% of individuals with Down syndrome (DS) after age 60, due to duplication of the APP gene in trisomy of chromosome 21, with neuropathology that is comparable to Sporadic AD and Familial AD (FAD).\n"
p13158
sg4
(lp13159
(dp13160
g7
I132
sg8
g18
sg10
I8
sg11
VAPP gene
p13161
sg13
I2
sasg20
(lp13162
(dp13163
g7
I21
sg23
VC1521724
p13164
sg10
I2
sg11
VAD
p13165
sg13
I1
sa(dp13166
g7
I175
sg23
VC1540677
p13167
sg10
I14
sg11
Vneuropathology
p13168
sg13
I1
sa(dp13169
g7
I88
sg23
VC0013080
p13170
sg10
I2
sg11
VDS
p13171
sg13
I1
sa(dp13172
g7
I73
sg23
VC0013080
p13173
sg10
I13
sg11
VDown syndrome
p13174
sg13
I2
sa(dp13175
g7
I21
sg23
VC1521724
p13176
sg10
I2
sg11
VAD
p13177
sg13
I1
sa(dp13178
g7
I0
sg23
VC1521724
p13179
sg10
I19
sg11
VAlzheimer's disease
p13180
sg13
I2
sa(dp13181
g7
I144
sg23
VC0041107
p13182
sg10
I7
sg11
Vtrisomy
p13183
sg13
I1
sa(dp13184
g7
I113
sg23
VC1705960
p13185
sg10
I11
sg11
Vduplication
p13186
sg13
I1
sa(dp13187
g7
I21
sg23
VC1521724
p13188
sg10
I2
sg11
VAD
p13189
sg13
I1
sasa(dp13190
g2
S'In addition, adhesion of lymphoma cells to fibronectin or stroma cells (HS-5 cells) decreased CKIP-1 expression, which led to the upregulation of Akt phosphorylation.\n'
p13191
sg4
(lp13192
(dp13193
g7
I94
sg8
g18
sg10
I6
sg11
VCKIP-1
p13194
sg13
I1
sa(dp13195
g7
I146
sg8
g18
sg10
I3
sg11
VAkt
p13196
sg13
I1
sasg20
(lp13197
(dp13198
g7
I25
sg23
VC0024299
p13199
sg10
I8
sg11
Vlymphoma
p13200
sg13
I1
sa(dp13201
g7
I13
sg23
VC0001511
p13202
sg10
I8
sg11
Vadhesion
p13203
sg13
I1
sasa(dp13204
g2
S"This study was performed to evaluate the potential association of the tumor necrosis factor alpha inducible protein 3gene (TNFAIP3) polymorphisms with Fuchs' heterochromic iridocyclitis (Fuchs' Syndrome) in a Chinese Han population.\n"
p13205
sg4
(lp13206
(dp13207
g7
I123
sg8
VP21580
p13208
sg10
I7
sg11
VTNFAIP3
p13209
sg13
I1
sa(dp13210
g7
I70
sg8
VP01375
p13211
sg10
I51
sg11
Vtumor necrosis factor alpha inducible protein 3gene
p13212
sg13
I7
sasg20
(lp13213
(dp13214
g7
I151
sg23
VC0016782
p13215
sg10
I34
sg11
VFuchs' heterochromic iridocyclitis
p13216
sg13
I3
sa(dp13217
g7
I187
sg23
VC0544015
p13218
sg10
I15
sg11
VFuchs' Syndrome
p13219
sg13
I2
sa(dp13220
g7
I70
sg23
VC0333516
p13221
sg10
I14
sg11
Vtumor necrosis
p13222
sg13
I2
sasa(dp13223
g2
S'Structural studies of collagen IV have been utilized to differentiate between subepidermal blistering diseases, including bullous pemphigoid, acquired epidermolysis bullosa, anti-epiligrin cicatricial pemphigoid, and bullous lupus erythematosus.\n'
p13224
sg4
(lp13225
(dp13226
g7
I174
sg8
g18
sg10
I14
sg11
Vanti-epiligrin
p13227
sg13
I1
sasg20
(lp13228
(dp13229
g7
I91
sg23
VC0005758
p13230
sg10
I10
sg11
Vblistering
p13231
sg13
I1
sa(dp13232
g7
I142
sg23
VC0079293
p13233
sg10
I30
sg11
Vacquired epidermolysis bullosa
p13234
sg13
I3
sa(dp13235
g7
I189
sg23
VC0030804
p13236
sg10
I22
sg11
Vcicatricial pemphigoid
p13237
sg13
I2
sa(dp13238
g7
I225
sg23
VC0409974
p13239
sg10
I19
sg11
Vlupus erythematosus
p13240
sg13
I2
sa(dp13241
g7
I122
sg23
VC0030805
p13242
sg10
I18
sg11
Vbullous pemphigoid
p13243
sg13
I2
sasa(dp13244
g2
S'Anti-epiligrin cicatricial pemphigoid is an autoimmune blistering disorder that has recently been associated with the development of solid organ malignancy.\n'
p13245
sg4
(lp13246
(dp13247
g7
I0
sg8
g18
sg10
I14
sg11
VAnti-epiligrin
p13248
sg13
I1
sasg20
(lp13249
(dp13250
g7
I55
sg23
VC0005758
p13251
sg10
I10
sg11
Vblistering
p13252
sg13
I1
sa(dp13253
g7
I15
sg23
VC0030804
p13254
sg10
I22
sg11
Vcicatricial pemphigoid
p13255
sg13
I2
sa(dp13256
g7
I145
sg23
VC0006826
p13257
sg10
I10
sg11
Vmalignancy
p13258
sg13
I1
sa(dp13259
g7
I44
sg23
VC0443146
p13260
sg10
I10
sg11
Vautoimmune
p13261
sg13
I1
sasa(dp13262
g2
S'Anti-epiligrin cicatricial pemphigoid (AECP) is a chronic, mucous membrane-dominated, subepithelial blistering disease characterized by circulating anti-basement membrane zone auto-antibodies to laminin 5.\n'
p13263
sg4
(lp13264
(dp13265
g7
I0
sg8
g18
sg10
I14
sg11
VAnti-epiligrin
p13266
sg13
I1
sa(dp13267
g7
I195
sg8
g18
sg10
I9
sg11
Vlaminin 5
p13268
sg13
I2
sasg20
(lp13269
(dp13270
g7
I15
sg23
VC0030804
p13271
sg10
I22
sg11
Vcicatricial pemphigoid
p13272
sg13
I2
sa(dp13273
g7
I100
sg23
VC0005758
p13274
sg10
I10
sg11
Vblistering
p13275
sg13
I1
sasa(dp13276
g2
S'Recently, it has been reported that patients with MMP who have autoantibodies to laminin 5, known as anti-epiligrin cicatricial pemphigoid (AECP) have a high incidence of malignancy.\n'
p13277
sg4
(lp13278
(dp13279
g7
I81
sg8
g18
sg10
I9
sg11
Vlaminin 5
p13280
sg13
I2
sa(dp13281
g7
I101
sg8
g18
sg10
I14
sg11
Vanti-epiligrin
p13282
sg13
I1
sasg20
(lp13283
(dp13284
g7
I116
sg23
VC0030804
p13285
sg10
I22
sg11
Vcicatricial pemphigoid
p13286
sg13
I2
sa(dp13287
g7
I171
sg23
VC0006826
p13288
sg10
I10
sg11
Vmalignancy
p13289
sg13
I1
sasa(dp13290
g2
S'Anti-epiligrin cicatricial pemphigoid (AECP) is a chronic, autoimmune, subepidermal blistering disease characterized by circulating anti-basement membrane autoantibodies to laminin 5.\n'
p13291
sg4
(lp13292
(dp13293
g7
I0
sg8
g18
sg10
I14
sg11
VAnti-epiligrin
p13294
sg13
I1
sa(dp13295
g7
I173
sg8
g18
sg10
I9
sg11
Vlaminin 5
p13296
sg13
I2
sasg20
(lp13297
(dp13298
g7
I15
sg23
VC0030804
p13299
sg10
I22
sg11
Vcicatricial pemphigoid
p13300
sg13
I2
sa(dp13301
g7
I84
sg23
VC0005758
p13302
sg10
I10
sg11
Vblistering
p13303
sg13
I1
sa(dp13304
g7
I59
sg23
VC0443146
p13305
sg10
I10
sg11
Vautoimmune
p13306
sg13
I1
sasa(dp13307
g2
S'To report an anti-epiligrin cicatricial pemphigoid (AECP) patient with severe ocular involvement and to provide a practical approach to distinguishing AECP patients from those with other subepidermal blistering diseases.\n'
p13308
sg4
(lp13309
(dp13310
g7
I13
sg8
g18
sg10
I14
sg11
Vanti-epiligrin
p13311
sg13
I1
sasg20
(lp13312
(dp13313
g7
I200
sg23
VC0005758
p13314
sg10
I10
sg11
Vblistering
p13315
sg13
I1
sa(dp13316
g7
I13
sg23
VC0030804
p13317
sg10
I37
sg11
Vanti-epiligrin cicatricial pemphigoid
p13318
sg13
I3
sa(dp13319
g7
I52
sg23
VC0030804
p13320
sg10
I4
sg11
VAECP
p13321
sg13
I1
sa(dp13322
g7
I52
sg23
VC0030804
p13323
sg10
I4
sg11
VAECP
p13324
sg13
I1
sasa(dp13325
g2
S'A subset, known as anti-epiligrin cicatricial pemphigoid is associated with a high risk for malignancy.\n'
p13326
sg4
(lp13327
(dp13328
g7
I19
sg8
g18
sg10
I14
sg11
Vanti-epiligrin
p13329
sg13
I1
sasg20
(lp13330
(dp13331
g7
I34
sg23
VC0030804
p13332
sg10
I22
sg11
Vcicatricial pemphigoid
p13333
sg13
I2
sa(dp13334
g7
I92
sg23
VC0006826
p13335
sg10
I10
sg11
Vmalignancy
p13336
sg13
I1
sasa(dp13337
g2
S'In 14 cases of hidradenitis suppurativa, cytokeratin (CK) expression was studied immunohistochemically, using six antikeratin antibodies against CK1, CK10, CK14, CK16, CK17 and CK19, respectively.\n'
p13338
sg4
(lp13339
(dp13340
g7
I54
sg8
g18
sg10
I2
sg11
VCK
p13341
sg13
I1
sa(dp13342
g7
I41
sg8
g18
sg10
I11
sg11
Vcytokeratin
p13343
sg13
I1
sa(dp13344
g7
I150
sg8
VP13645
p13345
sg10
I4
sg11
VCK10
p13346
sg13
I1
sa(dp13347
g7
I145
sg8
VP48729
p13348
sg10
I3
sg11
VCK1
p13349
sg13
I1
sa(dp13350
g7
I156
sg8
VP02533
p13351
sg10
I4
sg11
VCK14
p13352
sg13
I1
sa(dp13353
g7
I162
sg8
VP04264
p13354
sg10
I4
sg11
VCK16
p13355
sg13
I1
sasg20
(lp13356
(dp13357
g7
I15
sg23
VC0162836
p13358
sg10
I24
sg11
Vhidradenitis suppurativa
p13359
sg13
I2
sasa(dp13360
g2
S'Recessive mutations in CLN7/MFSD8 usually cause variant late-infantile onset neuronal ceroid lipofuscinosis (vLINCL), a poorly understood neurodegenerative condition, though mutations may also cause nonsyndromic maculopathy.\n'
p13361
sg4
(lp13362
(dp13363
g7
I109
sg8
g18
sg10
I6
sg11
VvLINCL
p13364
sg13
I1
sa(dp13365
g7
I48
sg8
g18
sg10
I59
sg11
Vvariant late-infantile onset neuronal ceroid lipofuscinosis
p13366
sg13
I6
sa(dp13367
g7
I23
sg8
g18
sg10
I4
sg11
VCLN7
p13368
sg13
I1
sa(dp13369
g7
I28
sg8
g18
sg10
I5
sg11
VMFSD8
p13370
sg13
I1
sasg20
(lp13371
(dp13372
g7
I109
sg23
VC1850442
p13373
sg10
I6
sg11
VvLINCL
p13374
sg13
I1
sa(dp13375
g7
I48
sg23
VC1850442
p13376
sg10
I59
sg11
Vvariant late-infantile onset neuronal ceroid lipofuscinosis
p13377
sg13
I6
sa(dp13378
g7
I23
sg23
VC1838571
p13379
sg10
I4
sg11
VCLN7
p13380
sg13
I1
sa(dp13381
g7
I156
sg23
VC0012634
p13382
sg10
I9
sg11
Vcondition
p13383
sg13
I1
sa(dp13384
g7
I212
sg23
VC0730362
p13385
sg10
I11
sg11
Vmaculopathy
p13386
sg13
I1
sasa(dp13387
g2
S'A series of 12 patients with nonsyndromic retinopathy due to novel CLN7/MFSD8 mutation combinations were investigated in this study.\n'
p13388
sg4
(lp13389
(dp13390
g7
I67
sg8
g18
sg10
I4
sg11
VCLN7
p13391
sg13
I1
sa(dp13392
g7
I72
sg8
g18
sg10
I5
sg11
VMFSD8
p13393
sg13
I1
sasg20
(lp13394
(dp13395
g7
I67
sg23
VC1838571
p13396
sg10
I4
sg11
VCLN7
p13397
sg13
I1
sa(dp13398
g7
I42
sg23
VC0035309
p13399
sg10
I11
sg11
Vretinopathy
p13400
sg13
I1
sasa(dp13401
g2
S'The NCL family of proteins is comprised of lysosomal enzymes (PPT1/CLN1, TPP1/CLN2, CTSD/CLN10, CTSF/CLN13), proteins that peripherally associate with membranes (DNAJC5/CLN4, KCTD7/CLN14), a soluble lysosomal protein (CLN5), a protein present in the secretory pathway (PGRN/CLN11), and several proteins that display different subcellular localizations (CLN3, CLN6, MFSD8/CLN7, CLN8, ATP13A2/CLN12).\n'
p13402
sg4
(lp13403
(dp13404
g7
I62
sg8
VP50897
p13405
sg10
I4
sg11
VPPT1
p13406
sg13
I1
sa(dp13407
g7
I359
sg8
g18
sg10
I4
sg11
VCLN6
p13408
sg13
I1
sa(dp13409
g7
I353
sg8
g18
sg10
I4
sg11
VCLN3
p13410
sg13
I1
sa(dp13411
g7
I175
sg8
g18
sg10
I5
sg11
VKCTD7
p13412
sg13
I1
sa(dp13413
g7
I73
sg8
VP49638
p13414
sg10
I4
sg11
VTPP1
p13415
sg13
I1
sa(dp13416
g7
I89
sg8
VP07339
p13417
sg10
I5
sg11
VCLN10
p13418
sg13
I1
sa(dp13419
g7
I67
sg8
VP50897
p13420
sg10
I4
sg11
VCLN1
p13421
sg13
I1
sa(dp13422
g7
I218
sg8
g18
sg10
I4
sg11
VCLN5
p13423
sg13
I1
sa(dp13424
g7
I96
sg8
g18
sg10
I4
sg11
VCTSF
p13425
sg13
I1
sa(dp13426
g7
I199
sg8
g18
sg10
I17
sg11
Vlysosomal protein
p13427
sg13
I2
sa(dp13428
g7
I84
sg8
VP07339
p13429
sg10
I4
sg11
VCTSD
p13430
sg13
I1
sa(dp13431
g7
I162
sg8
g18
sg10
I6
sg11
VDNAJC5
p13432
sg13
I1
sa(dp13433
g7
I78
sg8
g18
sg10
I4
sg11
VCLN2
p13434
sg13
I1
sa(dp13435
g7
I371
sg8
g18
sg10
I4
sg11
VCLN7
p13436
sg13
I1
sa(dp13437
g7
I365
sg8
g18
sg10
I5
sg11
VMFSD8
p13438
sg13
I1
sa(dp13439
g7
I383
sg8
g18
sg10
I7
sg11
VATP13A2
p13440
sg13
I1
sa(dp13441
g7
I4
sg8
VP19338
p13442
sg10
I10
sg11
VNCL family
p13443
sg13
I2
sa(dp13444
g7
I377
sg8
g18
sg10
I4
sg11
VCLN8
p13445
sg13
I1
sasg20
(lp13446
(dp13447
g7
I359
sg23
VC1866282
p13448
sg10
I4
sg11
VCLN6
p13449
sg13
I1
sa(dp13450
g7
I353
sg23
VC2931674
p13451
sg10
I4
sg11
VCLN3
p13452
sg13
I1
sa(dp13453
g7
I89
sg23
VC1864669
p13454
sg10
I5
sg11
VCLN10
p13455
sg13
I1
sa(dp13456
g7
I67
sg23
VC1850451
p13457
sg10
I4
sg11
VCLN1
p13458
sg13
I1
sa(dp13459
g7
I218
sg23
VC1850442
p13460
sg10
I4
sg11
VCLN5
p13461
sg13
I1
sa(dp13462
g7
I78
sg23
VC1876161
p13463
sg10
I4
sg11
VCLN2
p13464
sg13
I1
sa(dp13465
g7
I371
sg23
VC1838571
p13466
sg10
I4
sg11
VCLN7
p13467
sg13
I1
sa(dp13468
g7
I377
sg23
VC1838570
p13469
sg10
I4
sg11
VCLN8
p13470
sg13
I1
sasa(dp13471
g2
S'Here, we performed a detailed analysis of retinal degeneration in mice deficient in the lysosomal membrane protein CLN7, a novel animal model of CLN7 disease.\n'
p13472
sg4
(lp13473
(dp13474
g7
I115
sg8
g18
sg10
I4
sg11
VCLN7
p13475
sg13
I1
sa(dp13476
g7
I88
sg8
VP35968
p13477
sg10
I31
sg11
Vlysosomal membrane protein CLN7
p13478
sg13
I4
sasg20
(lp13479
(dp13480
g7
I115
sg23
VC1838571
p13481
sg10
I4
sg11
VCLN7
p13482
sg13
I1
sa(dp13483
g7
I42
sg23
VC0035304
p13484
sg10
I20
sg11
Vretinal degeneration
p13485
sg13
I2
sa(dp13486
g7
I115
sg23
VC1838571
p13487
sg10
I4
sg11
VCLN7
p13488
sg13
I1
sasa(dp13489
g2
S'We conclude that the retina of CLN7-deficient mice represents a useful model to elucidate the pathomechanisms ultimately leading to neurodegeneration in CLN7 disease, and to evaluate the efficacy of strategies aimed at developing treatments for this fatal neurodegenerative lysosomal storage disorder.\n'
p13490
sg4
(lp13491
(dp13492
g7
I31
sg8
g18
sg10
I4
sg11
VCLN7
p13493
sg13
I1
sa(dp13494
g7
I31
sg8
g18
sg10
I4
sg11
VCLN7
p13495
sg13
I1
sasg20
(lp13496
(dp13497
g7
I31
sg23
VC1838571
p13498
sg10
I4
sg11
VCLN7
p13499
sg13
I1
sa(dp13500
g7
I274
sg23
VC0085078
p13501
sg10
I26
sg11
Vlysosomal storage disorder
p13502
sg13
I3
sa(dp13503
g7
I132
sg23
VC0027746
p13504
sg10
I17
sg11
Vneurodegeneration
p13505
sg13
I1
sa(dp13506
g7
I31
sg23
VC1838571
p13507
sg10
I4
sg11
VCLN7
p13508
sg13
I1
sasa(dp13509
g2
S'After sequence alignment and variant calling against the canine reference genome, variants were identified in the coding region or splicing regions of four previously known NCL genes (CLN6, ARSG, CLN2 [=TPP1], and CLN7 [=MFSD8]).\n'
p13510
sg4
(lp13511
(dp13512
g7
I214
sg8
g18
sg10
I4
sg11
VCLN7
p13513
sg13
I1
sa(dp13514
g7
I196
sg8
g18
sg10
I12
sg11
VCLN2 [=TPP1]
p13515
sg13
I2
sa(dp13516
g7
I184
sg8
g18
sg10
I4
sg11
VCLN6
p13517
sg13
I1
sa(dp13518
g7
I190
sg8
g18
sg10
I4
sg11
VARSG
p13519
sg13
I1
sa(dp13520
g7
I173
sg8
VP19338
p13521
sg10
I9
sg11
VNCL genes
p13522
sg13
I2
sasg20
(lp13523
(dp13524
g7
I196
sg23
VC1876161
p13525
sg10
I4
sg11
VCLN2
p13526
sg13
I1
sa(dp13527
g7
I184
sg23
VC1866282
p13528
sg10
I4
sg11
VCLN6
p13529
sg13
I1
sa(dp13530
g7
I214
sg23
VC1838571
p13531
sg10
I4
sg11
VCLN7
p13532
sg13
I1
sasa(dp13533
g2
S'Because of the similarities of the clinical signs and histopathological changes with the human form of the disease, we propose that the Chihuahua dog could be a good animal model of CLN7 disease.\n'
p13534
sg4
(lp13535
(dp13536
g7
I182
sg8
g18
sg10
I4
sg11
VCLN7
p13537
sg13
I1
sasg20
(lp13538
(dp13539
g7
I182
sg23
VC1838571
p13540
sg10
I4
sg11
VCLN7
p13541
sg13
I1
sasa(dp13542
g2
S'CLN7 disease is an autosomal recessive, childhood-onset neurodegenerative lysosomal storage disorder caused by the defective lysosomal membrane protein CLN7.\n'
p13543
sg4
(lp13544
(dp13545
g7
I125
sg8
VP35968
p13546
sg10
I31
sg11
Vlysosomal membrane protein CLN7
p13547
sg13
I4
sa(dp13548
g7
I0
sg8
g18
sg10
I4
sg11
VCLN7
p13549
sg13
I1
sasg20
(lp13550
(dp13551
g7
I0
sg23
VC1838571
p13552
sg10
I4
sg11
VCLN7
p13553
sg13
I1
sa(dp13554
g7
I74
sg23
VC0085078
p13555
sg10
I26
sg11
Vlysosomal storage disorder
p13556
sg13
I3
sa(dp13557
g7
I0
sg23
VC1838571
p13558
sg10
I4
sg11
VCLN7
p13559
sg13
I1
sasa(dp13560
g2
S'We have disrupted the Cln7/Mfsd8 gene in mice by targeted deletion of exon 2 generating a novel knockout (KO) mouse model for CLN7 disease, which recapitulates key features of human CLN7 disease pathology.\n'
p13561
sg4
(lp13562
(dp13563
g7
I22
sg8
g18
sg10
I4
sg11
VCln7
p13564
sg13
I1
sa(dp13565
g7
I27
sg8
g18
sg10
I10
sg11
VMfsd8 gene
p13566
sg13
I2
sa(dp13567
g7
I126
sg8
g18
sg10
I4
sg11
VCLN7
p13568
sg13
I1
sasg20
(lp13569
(dp13570
g7
I126
sg23
VC1838571
p13571
sg10
I4
sg11
VCLN7
p13572
sg13
I1
sa(dp13573
g7
I195
sg23
VC0677042
p13574
sg10
I9
sg11
Vpathology
p13575
sg13
I1
sa(dp13576
g7
I22
sg23
VC1838571
p13577
sg10
I4
sg11
VCln7
p13578
sg13
I1
sa(dp13579
g7
I126
sg23
VC1838571
p13580
sg10
I4
sg11
VCLN7
p13581
sg13
I1
sasa(dp13582
g2
S'Phenotypic studies comprised epileptic seizures and movement disorders, ophthalmology, neurophysiology, image analysis, rating scales, enzyme testing, and electron microscopy, carried out under a consensus algorithm; 2) DNA screening and validation of mutations in genes PPT1 (CLN1), TPP1 (CLN2), CLN3, CLN5, CLN6, MFSD8 (CLN7), and CLN8: characterization of variant types, novel/known mutations and polymorphisms; 3) Progress of the epidemiological picture in Latin America; and 4) NCL-like pathology studies in progress.\n'
p13583
sg4
(lp13584
(dp13585
g7
I271
sg8
VP50897
p13586
sg10
I4
sg11
VPPT1
p13587
sg13
I1
sa(dp13588
g7
I277
sg8
VP50897
p13589
sg10
I4
sg11
VCLN1
p13590
sg13
I1
sa(dp13591
g7
I309
sg8
g18
sg10
I4
sg11
VCLN6
p13592
sg13
I1
sa(dp13593
g7
I297
sg8
g18
sg10
I4
sg11
VCLN3
p13594
sg13
I1
sa(dp13595
g7
I284
sg8
VP49638
p13596
sg10
I4
sg11
VTPP1
p13597
sg13
I1
sa(dp13598
g7
I290
sg8
g18
sg10
I4
sg11
VCLN2
p13599
sg13
I1
sa(dp13600
g7
I333
sg8
g18
sg10
I4
sg11
VCLN8
p13601
sg13
I1
sa(dp13602
g7
I315
sg8
g18
sg10
I5
sg11
VMFSD8
p13603
sg13
I1
sa(dp13604
g7
I303
sg8
g18
sg10
I4
sg11
VCLN5
p13605
sg13
I1
sa(dp13606
g7
I322
sg8
g18
sg10
I4
sg11
VCLN7
p13607
sg13
I1
sasg20
(lp13608
(dp13609
g7
I309
sg23
VC1866282
p13610
sg10
I4
sg11
VCLN6
p13611
sg13
I1
sa(dp13612
g7
I52
sg23
VC0026650
p13613
sg10
I18
sg11
Vmovement disorders
p13614
sg13
I2
sa(dp13615
g7
I277
sg23
VC1850451
p13616
sg10
I4
sg11
VCLN1
p13617
sg13
I1
sa(dp13618
g7
I492
sg23
VC0677042
p13619
sg10
I9
sg11
Vpathology
p13620
sg13
I1
sa(dp13621
g7
I29
sg23
VC0014544
p13622
sg10
I18
sg11
Vepileptic seizures
p13623
sg13
I2
sa(dp13624
g7
I297
sg23
VC2931674
p13625
sg10
I4
sg11
VCLN3
p13626
sg13
I1
sa(dp13627
g7
I290
sg23
VC1876161
p13628
sg10
I4
sg11
VCLN2
p13629
sg13
I1
sa(dp13630
g7
I333
sg23
VC1838570
p13631
sg10
I4
sg11
VCLN8
p13632
sg13
I1
sa(dp13633
g7
I303
sg23
VC1850442
p13634
sg10
I4
sg11
VCLN5
p13635
sg13
I1
sa(dp13636
g7
I322
sg23
VC1838571
p13637
sg10
I4
sg11
VCLN7
p13638
sg13
I1
sasa(dp13639
g2
S'In several genome-wide association studies, nonalcoholic fatty liver disease and alanine aminotransferase susceptibility variants have been identified in several genes, including LYPLAL1, ZP4, GCKR, HSD17B13, PALLD, PPP1R3B, FDFT1, TRIB1, COL13A1, CPN1, ERLIN1, CWF19L1, EFCAB4B, PZP, and NCAN.\n'
p13640
sg4
(lp13641
(dp13642
g7
I262
sg8
g18
sg10
I7
sg11
VCWF19L1
p13643
sg13
I1
sa(dp13644
g7
I81
sg8
VP24298
p13645
sg10
I48
sg11
Valanine aminotransferase susceptibility variants
p13646
sg13
I4
sa(dp13647
g7
I193
sg8
g18
sg10
I4
sg11
VGCKR
p13648
sg13
I1
sa(dp13649
g7
I232
sg8
g18
sg10
I5
sg11
VTRIB1
p13650
sg13
I1
sa(dp13651
g7
I179
sg8
g18
sg10
I7
sg11
VLYPLAL1
p13652
sg13
I1
sa(dp13653
g7
I199
sg8
g18
sg10
I8
sg11
VHSD17B13
p13654
sg13
I1
sa(dp13655
g7
I248
sg8
VP15538
p13656
sg10
I4
sg11
VCPN1
p13657
sg13
I1
sa(dp13658
g7
I280
sg8
VP20742
p13659
sg10
I3
sg11
VPZP
p13660
sg13
I1
sa(dp13661
g7
I254
sg8
g18
sg10
I6
sg11
VERLIN1
p13662
sg13
I1
sa(dp13663
g7
I216
sg8
g18
sg10
I7
sg11
VPPP1R3B
p13664
sg13
I1
sa(dp13665
g7
I271
sg8
g18
sg10
I7
sg11
VEFCAB4B
p13666
sg13
I1
sa(dp13667
g7
I225
sg8
VP37268
p13668
sg10
I5
sg11
VFDFT1
p13669
sg13
I1
sa(dp13670
g7
I289
sg8
g18
sg10
I4
sg11
VNCAN
p13671
sg13
I1
sa(dp13672
g7
I188
sg8
g18
sg10
I3
sg11
VZP4
p13673
sg13
I1
sasg20
(lp13674
(dp13675
g7
I44
sg23
VC0400966
p13676
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p13677
sg13
I4
sasa(dp13678
g2
S'Recent efforts to develop cure for chronic diabetic complications have led to the discovery of potent inhibitors against aldose reductase (AKR1B1, EC 1.1.1.21) whose role in diabetes is well-evident.\n'
p13679
sg4
(lp13680
(dp13681
g7
I139
sg8
VP15121
p13682
sg10
I6
sg11
VAKR1B1
p13683
sg13
I1
sa(dp13684
g7
I121
sg8
VP15121
p13685
sg10
I16
sg11
Valdose reductase
p13686
sg13
I2
sasg20
(lp13687
(dp13688
g7
I174
sg23
VC0011849
p13689
sg10
I8
sg11
Vdiabetes
p13690
sg13
I1
sa(dp13691
g7
I43
sg23
VC0342257
p13692
sg10
I22
sg11
Vdiabetic complications
p13693
sg13
I2
sasa(dp13694
g2
S'Beta catenin, phosducin and aldehyde reductase were increased in expression in diabetes whilst succinyl coA ligase and dihydropyrimidase-related protein were decreased.\n'
p13695
sg4
(lp13696
(dp13697
g7
I0
sg8
VP35222
p13698
sg10
I12
sg11
VBeta catenin
p13699
sg13
I2
sa(dp13700
g7
I14
sg8
VP20941
p13701
sg10
I32
sg11
Vphosducin and aldehyde reductase
p13702
sg13
I4
sasg20
(lp13703
(dp13704
g7
I104
sg23
VC2678439
p13705
sg10
I3
sg11
VcoA
p13706
sg13
I1
sa(dp13707
g7
I79
sg23
VC0011849
p13708
sg10
I8
sg11
Vdiabetes
p13709
sg13
I1
sasa(dp13710
g2
S'The crystal structures of porcine and human aldehyde reductase, an enzyme implicated in complications of diabetes, have been determined by X-ray diffraction methods.\n'
p13711
sg4
(lp13712
(dp13713
g7
I26
sg8
VP28332
p13714
sg10
I36
sg11
Vporcine and human aldehyde reductase
p13715
sg13
I5
sasg20
(lp13716
(dp13717
g7
I105
sg23
VC0011849
p13718
sg10
I8
sg11
Vdiabetes
p13719
sg13
I1
sasa(dp13720
g2
S'Data from a validation cohort of&gt;10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic "androgen-type" pathomechanism in EO-PCA.\n'
p13721
sg4
(lp13722
(dp13723
g7
I73
sg8
VP10275
p13724
sg10
I17
sg11
Vandrogen receptor
p13725
sg13
I2
sasg20
(lp13726
(dp13727
g7
I251
sg23
VC0268398
p13728
sg10
I3
sg11
VPCA
p13729
sg13
I1
sa(dp13730
g7
I118
sg23
VC0175693
p13731
sg10
I3
sg11
VSRs
p13732
sg13
I1
sasa(dp13733
g2
S'These induced Tfm (iTfm) animals also displayed more anxiety-like behaviors than WTs.\n'
p13734
sg4
(lp13735
(dp13736
g7
I14
sg8
VP10275
p13737
sg10
I3
sg11
VTfm
p13738
sg13
I1
sasg20
(lp13739
(dp13740
g7
I14
sg23
VC0039585
p13741
sg10
I3
sg11
VTfm
p13742
sg13
I1
sa(dp13743
g7
I81
sg23
VC1839736
p13744
sg10
I3
sg11
VWTs
p13745
sg13
I1
sasa(dp13746
g2
S'When tested in the resting phase, iTfms appeared more anxious than WTs in the open field, novel object and elevated plus maze tests, but not the light/dark box.\n'
p13747
sg4
(lp13748
sg20
(lp13749
(dp13750
g7
I67
sg23
VC1839736
p13751
sg10
I3
sg11
VWTs
p13752
sg13
I1
sasa(dp13753
g2
S'However, when tested during the active phase (lights off), iTfms showed more anxiety-related behavior than WTs in all four tests.\n'
p13754
sg4
(lp13755
sg20
(lp13756
(dp13757
g7
I107
sg23
VC1839736
p13758
sg10
I3
sg11
VWTs
p13759
sg13
I1
sasa(dp13760
g2
S'Data from a validation cohort of &gt; 10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic "androgen-type" pathomechanism in EO-PCA.\n'
p13761
sg4
(lp13762
(dp13763
g7
I75
sg8
VP10275
p13764
sg10
I17
sg11
Vandrogen receptor
p13765
sg13
I2
sasg20
(lp13766
(dp13767
g7
I253
sg23
VC0268398
p13768
sg10
I3
sg11
VPCA
p13769
sg13
I1
sa(dp13770
g7
I120
sg23
VC0175693
p13771
sg10
I3
sg11
VSRs
p13772
sg13
I1
sasa(dp13773
g2
S'Second, the structural similarity between the ligand-binding sites of AR and its mutated forms and closely related steroid receptors (SRs) such as progesterone receptors presents challenges for the development of drugs with receptor-selective function.\n'
p13774
sg4
(lp13775
(dp13776
g7
I115
sg8
VP52788
p13777
sg10
I17
sg11
Vsteroid receptors
p13778
sg13
I2
sa(dp13779
g7
I147
sg8
VP06401
p13780
sg10
I22
sg11
Vprogesterone receptors
p13781
sg13
I2
sa(dp13782
g7
I134
sg8
VP35270
p13783
sg10
I3
sg11
VSRs
p13784
sg13
I1
sasg20
(lp13785
(dp13786
g7
I115
sg23
VC0175693
p13787
sg10
I17
sg11
Vsteroid receptors
p13788
sg13
I2
sa(dp13789
g7
I134
sg23
VC0175693
p13790
sg10
I3
sg11
VSRs
p13791
sg13
I1
sasa(dp13792
g2
S'This conference report highlights selected presentations on the development of the third-generation camptothecin analog TH-1320 (Threshold Pharmaceuticals Inc), the silencing of the androgen receptor in prostate cancer by the novel locked nucleic acid-based antisense oligonucleotide EZN-4176 (Enzon Pharmaceuticals Inc/Santaris Pharma A/S), the inhibition of PC-3 cell invasiveness and metastasis by the CXCR4 antagonist CTCE-9908 (British Canadian BioSciences Corp), the antitumor efficacy of the CDH3 mAb PPMX-2017 (Perseus Proteomics Inc), and an anti-IL-6 mAb (MedImmune LLC) that suppresses tumor growth in vivo.\n'
p13793
sg4
(lp13794
(dp13795
g7
I499
sg8
VP22223
p13796
sg10
I8
sg11
VCDH3 mAb
p13797
sg13
I2
sa(dp13798
g7
I551
sg8
VP05231
p13799
sg10
I13
sg11
Vanti-IL-6 mAb
p13800
sg13
I2
sa(dp13801
g7
I405
sg8
VP61073
p13802
sg10
I5
sg11
VCXCR4
p13803
sg13
I1
sa(dp13804
g7
I182
sg8
VP10275
p13805
sg10
I17
sg11
Vandrogen receptor
p13806
sg13
I2
sa(dp13807
g7
I508
sg8
VP51608
p13808
sg10
I4
sg11
VPPMX
p13809
sg13
I1
sasg20
(lp13810
(dp13811
g7
I387
sg23
VC0027627
p13812
sg10
I10
sg11
Vmetastasis
p13813
sg13
I1
sa(dp13814
g7
I203
sg23
VC0600139
p13815
sg10
I15
sg11
Vprostate cancer
p13816
sg13
I2
sa(dp13817
g7
I508
sg23
VC1848211
p13818
sg10
I4
sg11
VPPMX
p13819
sg13
I1
sa(dp13820
g7
I597
sg23
VC0598934
p13821
sg10
I12
sg11
Vtumor growth
p13822
sg13
I2
sasa(dp13823
g2
S'Furthermore, NDCBE has an important role in the prevention of hypokalemia.\n'
p13824
sg4
(lp13825
sg20
(lp13826
sa(dp13827
g2
S'Because NCC and NDCBE are both thiazide targets, the combined inhibition of NCC and the NDCBE/pendrin system may explain thiazide-induced hypokalemia in some patients.\n'
p13828
sg4
(lp13829
(dp13830
g7
I94
sg8
g18
sg10
I7
sg11
Vpendrin
p13831
sg13
I1
sa(dp13832
g7
I16
sg8
g18
sg10
I5
sg11
VNDCBE
p13833
sg13
I1
sasg20
(lp13834
sa(dp13835
g2
S'We recently developed a systems biological approach to vaccine safety evaluation where identification of specific biomarkers in a rat pre-clinical study evaluated the safety of vaccines for pandemic H5N1 influenza including Irf7, Lgals9, Lgalsbp3, Cxcl11, Timp1, Tap2, Psmb9, Psme1, Tapbp, C2, Csf1, Mx2, Zbp1, Ifrd1, Trafd1, Cxcl9, Beta2m, Npc1, Ngfr and Ifi47.\n'
p13836
sg4
(lp13837
(dp13838
g7
I318
sg8
g18
sg10
I6
sg11
VTrafd1
p13839
sg13
I1
sa(dp13840
g7
I326
sg8
g18
sg10
I5
sg11
VCxcl9
p13841
sg13
I1
sa(dp13842
g7
I311
sg8
g18
sg10
I5
sg11
VIfrd1
p13843
sg13
I1
sa(dp13844
g7
I300
sg8
VP20592
p13845
sg10
I3
sg11
VMx2
p13846
sg13
I1
sa(dp13847
g7
I256
sg8
VP01033
p13848
sg10
I5
sg11
VTimp1
p13849
sg13
I1
sa(dp13850
g7
I248
sg8
g18
sg10
I6
sg11
VCxcl11
p13851
sg13
I1
sa(dp13852
g7
I347
sg8
VP08138
p13853
sg10
I4
sg11
VNgfr
p13854
sg13
I1
sa(dp13855
g7
I224
sg8
g18
sg10
I4
sg11
VIrf7
p13856
sg13
I1
sa(dp13857
g7
I341
sg8
g18
sg10
I4
sg11
VNpc1
p13858
sg13
I1
sa(dp13859
g7
I230
sg8
g18
sg10
I6
sg11
VLgals9
p13860
sg13
I1
sa(dp13861
g7
I333
sg8
VP61769
p13862
sg10
I6
sg11
VBeta2m
p13863
sg13
I1
sa(dp13864
g7
I269
sg8
VP28065
p13865
sg10
I5
sg11
VPsmb9
p13866
sg13
I1
sa(dp13867
g7
I294
sg8
VP09919
p13868
sg10
I4
sg11
VCsf1
p13869
sg13
I1
sa(dp13870
g7
I263
sg8
g18
sg10
I4
sg11
VTap2
p13871
sg13
I1
sa(dp13872
g7
I276
sg8
g18
sg10
I5
sg11
VPsme1
p13873
sg13
I1
sa(dp13874
g7
I305
sg8
g18
sg10
I4
sg11
VZbp1
p13875
sg13
I1
sasg20
(lp13876
(dp13877
g7
I341
sg23
VC3179455
p13878
sg10
I4
sg11
VNpc1
p13879
sg13
I1
sa(dp13880
g7
I199
sg23
VC2748361
p13881
sg10
I14
sg11
VH5N1 influenza
p13882
sg13
I2
sasa(dp13883
g2
S'Here we report that enhanced expression of PA28alpha at a level similar to that obtained after IFN-gamma induction resulted in a marked enhancement of recognition by pp89-specific cytotoxic T cells; the presentation of influenza nucleoprotein was also significantly improved.\n'
p13884
sg4
(lp13885
(dp13886
g7
I43
sg8
g18
sg10
I9
sg11
VPA28alpha
p13887
sg13
I1
sa(dp13888
g7
I95
sg8
VP01579
p13889
sg10
I9
sg11
VIFN-gamma
p13890
sg13
I1
sasg20
(lp13891
(dp13892
g7
I219
sg23
VC0021400
p13893
sg10
I9
sg11
Vinfluenza
p13894
sg13
I1
sasa(dp13895
g2
S'Two different cardiologists measured corrected QT (QTc), QT dispersion (QTd), QT peak (QTp), T wave peak to T wave end (TpTe), TpTe/QT ratio, and TpTe/QTc ratio in 12-lead ECG.Results: When compared with the control group, QTp (P: 0.021), QT (P: 0.003), TpTe (P &lt; 0.001), TpTe/QTc ratio (P &lt; 0.001), and TpTe/QT ratio (P: 0.005) were significantly higher in patients with myocarditis.\n'
p13896
sg4
(lp13897
sg20
(lp13898
(dp13899
g7
I378
sg23
VC0027059
p13900
sg10
I11
sg11
Vmyocarditis
p13901
sg13
I1
sasa(dp13902
g2
S'The area under the curve (AUC) of the electrocardiographic characteristics QT (AUC: 0.736; 95% CI [0.600-0.846]), QTP (AUC: 0.680; 95% CI [0.540-0.799]), and TpTe (AUC: 0.771; 95% CI [0.638-873]) and TpTe/QTc (AUC: 0.774; 95% CI [0.641-0.876]) and TpTe/QT (AUC: 0.726; 95% CI [0.589-0.838]) in myocarditis were not significantly different from each other but all of them were different from 0.5.Conclusion: Baseline ECGs of patients with myocarditis were associated with repolarization abnormalities.\n'
p13903
sg4
(lp13904
(dp13905
g7
I158
sg8
VP56180
p13906
sg10
I4
sg11
VTpTe
p13907
sg13
I1
sasg20
(lp13908
(dp13909
g7
I294
sg23
VC0027059
p13910
sg10
I11
sg11
Vmyocarditis
p13911
sg13
I1
sa(dp13912
g7
I294
sg23
VC0027059
p13913
sg10
I11
sg11
Vmyocarditis
p13914
sg13
I1
sasa(dp13915
g2
S'Some previous studies have proposed the electrocardiographic Tpeak-Tend (TpTe) as a possible predictor of ventricular arrhythmic events in patients with Brugada syndrome (BrS).\n'
p13916
sg4
(lp13917
sg20
(lp13918
(dp13919
g7
I153
sg23
VC1142166
p13920
sg10
I16
sg11
VBrugada syndrome
p13921
sg13
I2
sa(dp13922
g7
I171
sg23
VC1142166
p13923
sg10
I3
sg11
VBrS
p13924
sg13
I1
sasa(dp13925
g2
S'The binding of methotrexate (MTX) to IgG in conjugates was examined by studies on a direct MTX conjugate with a monoclonal antibody (aMM46) to mouse mammary tumor MM46 cells and corresponding irrelevant antibody and normal gamma-globulin conjugates, all prepared by the active ester method with MTX N-succinimidyl ester (MTX-OSu).\n'
p13926
sg4
(lp13927
(dp13928
g7
I223
sg8
g18
sg10
I14
sg11
Vgamma-globulin
p13929
sg13
I1
sasg20
(lp13930
(dp13931
g7
I149
sg23
VC1458155
p13932
sg10
I13
sg11
Vmammary tumor
p13933
sg13
I2
sasa(dp13934
g2
S'The majority of the loci can be linked to genes related to immune cell function and to myelin and neural growth; some (SYK, MYT1L, TRAPPC9, SLITKR6 and RIC3) have been previously associated with the distribution of white matter lesions in multiple sclerosis.\n'
p13935
sg4
(lp13936
(dp13937
g7
I152
sg8
g18
sg10
I4
sg11
VRIC3
p13938
sg13
I1
sa(dp13939
g7
I124
sg8
g18
sg10
I5
sg11
VMYT1L
p13940
sg13
I1
sa(dp13941
g7
I119
sg8
VP43405
p13942
sg10
I3
sg11
VSYK
p13943
sg13
I1
sasg20
(lp13944
(dp13945
g7
I239
sg23
VC0026769
p13946
sg10
I18
sg11
Vmultiple sclerosis
p13947
sg13
I2
sasa(dp13948
g2
S'To gain insight into the function of the native CCDC28A gene, we collected information on any differential expression of CCDC28A among normal hematologic cell types and within subgroups of acute leukemia.\n'
p13949
sg4
(lp13950
(dp13951
g7
I41
sg8
g18
sg10
I19
sg11
Vnative CCDC28A gene
p13952
sg13
I3
sasg20
(lp13953
(dp13954
g7
I189
sg23
VC0085669
p13955
sg10
I14
sg11
Vacute leukemia
p13956
sg13
I2
sasa(dp13957
g2
S'They also suggested selective enrichment of CCDC28A in the French-American-British M6 class of human acute leukemia.\n'
p13958
sg4
(lp13959
(dp13960
g7
I44
sg8
g18
sg10
I7
sg11
VCCDC28A
p13961
sg13
I1
sasg20
(lp13962
(dp13963
g7
I101
sg23
VC0085669
p13964
sg10
I14
sg11
Vacute leukemia
p13965
sg13
I2
sasa(dp13966
g2
S'APOA1, SFRP4, and PAPPA, which are normally down-regulated by hCG were up-regulated by hCG in animals with endometriosis.\n'
p13967
sg4
(lp13968
(dp13969
g7
I62
sg8
VP01215
p13970
sg10
I3
sg11
VhCG
p13971
sg13
I1
sa(dp13972
g7
I0
sg8
VP02647
p13973
sg10
I5
sg11
VAPOA1
p13974
sg13
I1
sa(dp13975
g7
I62
sg8
VP01215
p13976
sg10
I3
sg11
VhCG
p13977
sg13
I1
sa(dp13978
g7
I18
sg8
g18
sg10
I5
sg11
VPAPPA
p13979
sg13
I1
sa(dp13980
g7
I7
sg8
g18
sg10
I5
sg11
VSFRP4
p13981
sg13
I1
sasg20
(lp13982
(dp13983
g7
I62
sg23
VC1855900
p13984
sg10
I3
sg11
VhCG
p13985
sg13
I1
sa(dp13986
g7
I107
sg23
VC0014175
p13987
sg10
I13
sg11
Vendometriosis
p13988
sg13
I1
sa(dp13989
g7
I62
sg23
VC1855900
p13990
sg10
I3
sg11
VhCG
p13991
sg13
I1
sasa(dp13992
g2
S"Here, we review the biological relevance of Sox2 and Sox9 genes in osteosarcoma, chondrosarcoma and chordoma; Sox2, Sox6, and Sox17 genes in Ewing's sarcoma; Sox2, Sox9, and Sox10 genes in synovial sarcoma; Sox2 gene in fibrosarcoma; and Sox21 gene in liposarcoma.\n"
p13993
sg4
(lp13994
(dp13995
g7
I44
sg8
VP48431
p13996
sg10
I4
sg11
VSox2
p13997
sg13
I1
sa(dp13998
g7
I174
sg8
VP56693
p13999
sg10
I11
sg11
VSox10 genes
p14000
sg13
I2
sa(dp14001
g7
I238
sg8
g18
sg10
I10
sg11
VSox21 gene
p14002
sg13
I2
sa(dp14003
g7
I53
sg8
VP48436
p14004
sg10
I10
sg11
VSox9 genes
p14005
sg13
I2
sa(dp14006
g7
I207
sg8
VP48431
p14007
sg10
I9
sg11
VSox2 gene
p14008
sg13
I2
sa(dp14009
g7
I53
sg8
VP48436
p14010
sg10
I4
sg11
VSox9
p14011
sg13
I1
sa(dp14012
g7
I44
sg8
VP48431
p14013
sg10
I4
sg11
VSox2
p14014
sg13
I1
sa(dp14015
g7
I44
sg8
VP48431
p14016
sg10
I4
sg11
VSox2
p14017
sg13
I1
sa(dp14018
g7
I116
sg8
VP35712
p14019
sg10
I4
sg11
VSox6
p14020
sg13
I1
sa(dp14021
g7
I126
sg8
g18
sg10
I11
sg11
VSox17 genes
p14022
sg13
I2
sasg20
(lp14023
(dp14024
g7
I67
sg23
VC0029463
p14025
sg10
I12
sg11
Vosteosarcoma
p14026
sg13
I1
sa(dp14027
g7
I141
sg23
VC0553580
p14028
sg10
I15
sg11
VEwing's sarcoma
p14029
sg13
I2
sa(dp14030
g7
I81
sg23
VC0008479
p14031
sg10
I14
sg11
Vchondrosarcoma
p14032
sg13
I1
sa(dp14033
g7
I189
sg23
VC0039101
p14034
sg10
I16
sg11
Vsynovial sarcoma
p14035
sg13
I2
sa(dp14036
g7
I220
sg23
VC0016057
p14037
sg10
I12
sg11
Vfibrosarcoma
p14038
sg13
I1
sa(dp14039
g7
I252
sg23
VC0023827
p14040
sg10
I11
sg11
Vliposarcoma
p14041
sg13
I1
sa(dp14042
g7
I100
sg23
VC0008487
p14043
sg10
I8
sg11
Vchordoma
p14044
sg13
I1
sasa(dp14045
g2
S'The objective of this study was to analyze circadian patterns of urinary 6-sulphatoxymelatonin (aMT6s) excretion in children with primary sleep disorders in comparison with healthy controls.\n'
p14046
sg4
(lp14047
sg20
(lp14048
(dp14049
g7
I130
sg23
VC0236991
p14050
sg10
I23
sg11
Vprimary sleep disorders
p14051
sg13
I3
sasa(dp14052
g2
S'Four different melatonin (aMT) production and excretion patterns were distinguished in the group with sleep disorders: (1) standard aMT production pattern, (2) low aMT production pattern, (3) aMT production pattern with absence of circadian variation, and (4) aMT hyperproduction pattern.\n'
p14053
sg4
(lp14054
(dp14055
g7
I26
sg8
VP48728
p14056
sg10
I3
sg11
VaMT
p14057
sg13
I1
sa(dp14058
g7
I26
sg8
VP48728
p14059
sg10
I3
sg11
VaMT
p14060
sg13
I1
sa(dp14061
g7
I26
sg8
VP48728
p14062
sg10
I3
sg11
VaMT
p14063
sg13
I1
sa(dp14064
g7
I26
sg8
VP48728
p14065
sg10
I3
sg11
VaMT
p14066
sg13
I1
sa(dp14067
g7
I26
sg8
VP48728
p14068
sg10
I3
sg11
VaMT
p14069
sg13
I1
sasg20
(lp14070
(dp14071
g7
I102
sg23
VC0851578
p14072
sg10
I15
sg11
Vsleep disorders
p14073
sg13
I2
sasa(dp14074
g2
S'This study highlights the importance of analyzing specific alterations of aMT secretion in each sleep disorder and provides evidences to explain why not all children with sleep disturbances do respond to aMT treatment.\n'
p14075
sg4
(lp14076
(dp14077
g7
I74
sg8
VP48728
p14078
sg10
I3
sg11
VaMT
p14079
sg13
I1
sa(dp14080
g7
I74
sg8
VP48728
p14081
sg10
I3
sg11
VaMT
p14082
sg13
I1
sasg20
(lp14083
(dp14084
g7
I96
sg23
VC0851578
p14085
sg10
I14
sg11
Vsleep disorder
p14086
sg13
I2
sa(dp14087
g7
I171
sg23
VC0037317
p14088
sg10
I18
sg11
Vsleep disturbances
p14089
sg13
I2
sasa(dp14090
g2
S'Here we describe a case of EME caused by NKH in which a new mutation in aminomethyltransferase (AMT) gene has been detected.\n'
p14091
sg4
(lp14092
(dp14093
g7
I60
sg8
VP48728
p14094
sg10
I34
sg11
Vmutation in aminomethyltransferase
p14095
sg13
I3
sa(dp14096
g7
I96
sg8
VP48728
p14097
sg10
I3
sg11
VAMT
p14098
sg13
I1
sasg20
(lp14099
(dp14100
g7
I41
sg23
VC0751748
p14101
sg10
I3
sg11
VNKH
p14102
sg13
I1
sa(dp14103
g7
I56
sg23
VC2985439
p14104
sg10
I12
sg11
Vnew mutation
p14105
sg13
I2
sasa(dp14106
g2
S'Alipogene tiparvovec (Glybera(R); AMT-011, AAV1-LPL(S447X)) is an adeno-associated virus serotype 1-based gene therapy for adult patients with familial lipoprotein lipase (LPL) deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions.\n'
p14107
sg4
(lp14108
(dp14109
g7
I152
sg8
VP06858
p14110
sg10
I18
sg11
Vlipoprotein lipase
p14111
sg13
I2
sa(dp14112
g7
I48
sg8
VP06858
p14113
sg10
I3
sg11
VLPL
p14114
sg13
I1
sa(dp14115
g7
I43
sg8
VP06858
p14116
sg10
I8
sg11
VAAV1-LPL
p14117
sg13
I1
sasg20
(lp14118
(dp14119
g7
I233
sg23
VC0030305
p14120
sg10
I12
sg11
Vpancreatitis
p14121
sg13
I1
sa(dp14122
g7
I199
sg23
VC0683278
p14123
sg10
I9
sg11
Vsuffering
p14124
sg13
I1
sasa(dp14125
g2
S'Glycine encephalopathy (GCE) or nonketotic hyperglycinemia is an inborn error of glycine metabolism, inherited in an autosomal recessive manner due to a defect in any one of the four enzymes aminomethyltransferase (AMT), glycine decarboxylase (GLDC), glycine cleavage system protein-H (GCSH) and dehydrolipoamide dehydrogenase in the glycine cleavage system.\n'
p14126
sg4
(lp14127
(dp14128
g7
I244
sg8
VP23378
p14129
sg10
I4
sg11
VGLDC
p14130
sg13
I1
sa(dp14131
g7
I296
sg8
VP49366
p14132
sg10
I30
sg11
Vdehydrolipoamide dehydrogenase
p14133
sg13
I2
sa(dp14134
g7
I286
sg8
VP48506
p14135
sg10
I4
sg11
VGCSH
p14136
sg13
I1
sa(dp14137
g7
I221
sg8
VP23378
p14138
sg10
I21
sg11
Vglycine decarboxylase
p14139
sg13
I2
sa(dp14140
g7
I251
sg8
VP04921
p14141
sg10
I33
sg11
Vglycine cleavage system protein-H
p14142
sg13
I4
sasg20
(lp14143
(dp14144
g7
I24
sg23
VC0751748
p14145
sg10
I3
sg11
VGCE
p14146
sg13
I1
sa(dp14147
g7
I32
sg23
VC0751748
p14148
sg10
I26
sg11
Vnonketotic hyperglycinemia
p14149
sg13
I2
sa(dp14150
g7
I0
sg23
VC0751748
p14151
sg10
I22
sg11
VGlycine encephalopathy
p14152
sg13
I2
sasa(dp14153
g2
S'Leucine-rich alpha-2-glycoprotein-1 (encoded by LRG1) has been shown to be involved in multiple cancer progression and angiogenesis.\n'
p14154
sg4
(lp14155
(dp14156
g7
I0
sg8
VP02750
p14157
sg10
I35
sg11
VLeucine-rich alpha-2-glycoprotein-1
p14158
sg13
I2
sa(dp14159
g7
I48
sg8
VP02750
p14160
sg10
I4
sg11
VLRG1
p14161
sg13
I1
sasg20
(lp14162
(dp14163
g7
I96
sg23
VC0178874
p14164
sg10
I18
sg11
Vcancer progression
p14165
sg13
I2
sasa(dp14166
g2
S'LRG1 has been shown to be one of the five plasma proteins that can be used for colorectal cancer (CRC) diagnosis.\n'
p14167
sg4
(lp14168
(dp14169
g7
I0
sg8
VP02750
p14170
sg10
I4
sg11
VLRG1
p14171
sg13
I1
sasg20
(lp14172
(dp14173
g7
I79
sg23
VC1527249
p14174
sg10
I17
sg11
Vcolorectal cancer
p14175
sg13
I2
sa(dp14176
g7
I98
sg23
VC1527249
p14177
sg10
I3
sg11
VCRC
p14178
sg13
I1
sasa(dp14179
g2
S'To investigate the relationship between tumor regression grade (TRG) and lymph node regression grade (LRG) after neoadjuvant chemoradiotherapy (CRT) for rectal cancer and its clinical implication.\n'
p14180
sg4
(lp14181
sg20
(lp14182
(dp14183
g7
I153
sg23
VC0007113
p14184
sg10
I13
sg11
Vrectal cancer
p14185
sg13
I2
sa(dp14186
g7
I40
sg23
VC0027651
p14187
sg10
I5
sg11
Vtumor
p14188
sg13
I1
sasa(dp14189
g2
S'TRG and LRG of postoperative specimens (including tumor and lymph nodes) were carried out based on the percentage of the fibrosis and the cancer residue.\n'
p14190
sg4
(lp14191
sg20
(lp14192
(dp14193
g7
I121
sg23
VC0016059
p14194
sg10
I8
sg11
Vfibrosis
p14195
sg13
I1
sa(dp14196
g7
I50
sg23
VC0027651
p14197
sg10
I5
sg11
Vtumor
p14198
sg13
I1
sa(dp14199
g7
I138
sg23
VC0006826
p14200
sg10
I6
sg11
Vcancer
p14201
sg13
I1
sasa(dp14202
g2
S'No cancer residue was defined as TRG1 and LRG1; rare cancer cell residue as TRG2 and LRG2; fibrosis growth over residual cancer as TRG3 and LRG3; residual cancer growth over fibrosis as TRG4 and LRG4; absence of regressive changes as TRG5 and LRG5; and normal lymph nodes as LRG0.\n'
p14203
sg4
(lp14204
(dp14205
g7
I131
sg8
g18
sg10
I4
sg11
VTRG3
p14206
sg13
I1
sa(dp14207
g7
I42
sg8
VP02750
p14208
sg10
I4
sg11
VLRG1
p14209
sg13
I1
sasg20
(lp14210
(dp14211
g7
I112
sg23
VC0242594
p14212
sg10
I15
sg11
Vresidual cancer
p14213
sg13
I2
sa(dp14214
g7
I91
sg23
VC0016059
p14215
sg10
I8
sg11
Vfibrosis
p14216
sg13
I1
sa(dp14217
g7
I91
sg23
VC0016059
p14218
sg10
I8
sg11
Vfibrosis
p14219
sg13
I1
sa(dp14220
g7
I3
sg23
VC0006826
p14221
sg10
I6
sg11
Vcancer
p14222
sg13
I1
sa(dp14223
g7
I112
sg23
VC0242594
p14224
sg10
I15
sg11
Vresidual cancer
p14225
sg13
I2
sa(dp14226
g7
I3
sg23
VC0006826
p14227
sg10
I6
sg11
Vcancer
p14228
sg13
I1
sasa(dp14229
g2
S'Therefore, both TRG and LRG should be assessed when evaluating the response of rectal cancer to neoadjuvant CRT.\n'
p14230
sg4
(lp14231
(dp14232
g7
I16
sg8
VP03986
p14233
sg10
I3
sg11
VTRG
p14234
sg13
I1
sa(dp14235
g7
I24
sg8
VP02750
p14236
sg10
I3
sg11
VLRG
p14237
sg13
I1
sasg20
(lp14238
(dp14239
g7
I79
sg23
VC0007113
p14240
sg10
I13
sg11
Vrectal cancer
p14241
sg13
I2
sasa(dp14242
g2
S'The plasma level of LRG1 was significantly increased in CRC patients, but it was remarkably decreased in patients with resected colorectal cancers.\n'
p14243
sg4
(lp14244
(dp14245
g7
I20
sg8
VP02750
p14246
sg10
I4
sg11
VLRG1
p14247
sg13
I1
sasg20
(lp14248
(dp14249
g7
I56
sg23
VC1527249
p14250
sg10
I3
sg11
VCRC
p14251
sg13
I1
sa(dp14252
g7
I128
sg23
VC1527249
p14253
sg10
I18
sg11
Vcolorectal cancers
p14254
sg13
I2
sasa(dp14255
g2
S'In addition, LRG1 silencing led to the downregulation of the levels of key cell cycle factors, such as cyclin D1, B, and E and anti-apoptotic B-cell lymphoma-2(Bcl-2).\n'
p14256
sg4
(lp14257
(dp14258
g7
I103
sg8
VP24385
p14259
sg10
I9
sg11
Vcyclin D1
p14260
sg13
I2
sa(dp14261
g7
I160
sg8
VP10415
p14262
sg10
I5
sg11
VBcl-2
p14263
sg13
I1
sa(dp14264
g7
I13
sg8
VP02750
p14265
sg10
I4
sg11
VLRG1
p14266
sg13
I1
sa(dp14267
g7
I127
sg8
VP10415
p14268
sg10
I32
sg11
Vanti-apoptotic B-cell lymphoma-2
p14269
sg13
I3
sasg20
(lp14270
(dp14271
g7
I142
sg23
VC0079731
p14272
sg10
I15
sg11
VB-cell lymphoma
p14273
sg13
I2
sasa(dp14274
g2
S'We conclude that the LRG system may be an independent predictive factor of long-term oncologic outcomes of rectal cancer patients after NT and radical surgery.\n'
p14275
sg4
(lp14276
(dp14277
g7
I21
sg8
VP02750
p14278
sg10
I3
sg11
VLRG
p14279
sg13
I1
sasg20
(lp14280
(dp14281
g7
I107
sg23
VC0007113
p14282
sg10
I13
sg11
Vrectal cancer
p14283
sg13
I2
sasa(dp14284
g2
S'Leucine-rich-alpha-2-glycoprotein 1 (LRG1) has been reported to be involved in several tumors, whether it participates in colorectal cancer (CRC) progression remains unclear.\n'
p14285
sg4
(lp14286
(dp14287
g7
I0
sg8
VP30740
p14288
sg10
I35
sg11
VLeucine-rich-alpha-2-glycoprotein 1
p14289
sg13
I2
sa(dp14290
g7
I37
sg8
VP02750
p14291
sg10
I4
sg11
VLRG1
p14292
sg13
I1
sasg20
(lp14293
(dp14294
g7
I122
sg23
VC1527249
p14295
sg10
I17
sg11
Vcolorectal cancer
p14296
sg13
I2
sa(dp14297
g7
I141
sg23
VC1527249
p14298
sg10
I3
sg11
VCRC
p14299
sg13
I1
sa(dp14300
g7
I87
sg23
VC0027651
p14301
sg10
I6
sg11
Vtumors
p14302
sg13
I1
sasa(dp14303
g2
S'LRG1 was overexpressed in CRC tissues and associated with cancer aggressiveness.\n'
p14304
sg4
(lp14305
(dp14306
g7
I0
sg8
VP02750
p14307
sg10
I4
sg11
VLRG1
p14308
sg13
I1
sasg20
(lp14309
(dp14310
g7
I58
sg23
VC0006826
p14311
sg10
I6
sg11
Vcancer
p14312
sg13
I1
sa(dp14313
g7
I26
sg23
VC1527249
p14314
sg10
I3
sg11
VCRC
p14315
sg13
I1
sa(dp14316
g7
I65
sg23
VC0001807
p14317
sg10
I14
sg11
Vaggressiveness
p14318
sg13
I1
sasa(dp14319
g2
S'Leucine-rich-alpha-2-glycoprotein1 (LRG1) is a novel oncogene-associated protein which has been clarified vital to the progression of human cancers, but its role in hepatocellular carcinoma (HCC) remains unclear.\n'
p14320
sg4
(lp14321
(dp14322
g7
I36
sg8
VP02750
p14323
sg10
I4
sg11
VLRG1
p14324
sg13
I1
sa(dp14325
g7
I0
sg8
VP30740
p14326
sg10
I34
sg11
VLeucine-rich-alpha-2-glycoprotein1
p14327
sg13
I1
sasg20
(lp14328
(dp14329
g7
I140
sg23
VC0006826
p14330
sg10
I7
sg11
Vcancers
p14331
sg13
I1
sa(dp14332
g7
I191
sg23
VC2239176
p14333
sg10
I3
sg11
VHCC
p14334
sg13
I1
sa(dp14335
g7
I165
sg23
VC2239176
p14336
sg10
I24
sg11
Vhepatocellular carcinoma
p14337
sg13
I2
sasa(dp14338
g2
S'those of glucose-6-phosphate dehydrogenase (G6PDH; EC 1.1.1.49), lactic dehydrogenase (LDH; EC 1.1.1.27), pyruvate dehydrogenase complex (PDC) and citrate synthase (CS; EC 4.1.3.7) were estimated in posterior root ganglion cells (PRGCs) of the spinal cord in patients suffering from olivopontocerebellar atrophy (OPCA), amyotrophic lateral sclerosis (ALS), and Duchenne muscular dystrophy (DMD) by means of the NAD, NADP and CoA cycling methods.\n'
p14339
sg4
(lp14340
(dp14341
g7
I9
sg8
VP49366
p14342
sg10
I33
sg11
Vglucose-6-phosphate dehydrogenase
p14343
sg13
I2
sa(dp14344
g7
I138
sg8
VP20941
p14345
sg10
I3
sg11
VPDC
p14346
sg13
I1
sa(dp14347
g7
I44
sg8
VP11413
p14348
sg10
I5
sg11
VG6PDH
p14349
sg13
I1
sa(dp14350
g7
I147
sg8
g18
sg10
I16
sg11
Vcitrate synthase
p14351
sg13
I2
sa(dp14352
g7
I87
sg8
g18
sg10
I3
sg11
VLDH
p14353
sg13
I1
sasg20
(lp14354
(dp14355
g7
I251
sg23
VC0035334
p14356
sg10
I4
sg11
Vcord
p14357
sg13
I1
sa(dp14358
g7
I361
sg23
VC0013264
p14359
sg10
I27
sg11
VDuchenne muscular dystrophy
p14360
sg13
I3
sa(dp14361
g7
I411
sg23
VC1850380
p14362
sg10
I3
sg11
VNAD
p14363
sg13
I1
sa(dp14364
g7
I268
sg23
VC0683278
p14365
sg10
I9
sg11
Vsuffering
p14366
sg13
I1
sa(dp14367
g7
I138
sg23
VC1869117
p14368
sg10
I3
sg11
VPDC
p14369
sg13
I1
sa(dp14370
g7
I351
sg23
VC0002736
p14371
sg10
I3
sg11
VALS
p14372
sg13
I1
sa(dp14373
g7
I214
sg23
VC1258666
p14374
sg10
I8
sg11
Vganglion
p14375
sg13
I1
sa(dp14376
g7
I390
sg23
VC0013264
p14377
sg10
I3
sg11
VDMD
p14378
sg13
I1
sa(dp14379
g7
I283
sg23
VC0028968
p14380
sg10
I28
sg11
Volivopontocerebellar atrophy
p14381
sg13
I2
sa(dp14382
g7
I425
sg23
VC2678439
p14383
sg10
I3
sg11
VCoA
p14384
sg13
I1
sa(dp14385
g7
I320
sg23
VC0002736
p14386
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p14387
sg13
I3
sasa(dp14388
g2
S'Three cell lines were examined in detail: two human glioblastoma cell lines, GB-1 and GB-2, and one gliosarcoma cell line, GS-1.\n'
p14389
sg4
(lp14390
sg20
(lp14391
(dp14392
g7
I100
sg23
VC0206726
p14393
sg10
I11
sg11
Vgliosarcoma
p14394
sg13
I1
sa(dp14395
g7
I52
sg23
VC0017636
p14396
sg10
I12
sg11
Vglioblastoma
p14397
sg13
I1
sasa(dp14398
g2
S'We first created a paclitaxel-resistant, triple-negative breast cancer cell line [paclitaxel-resistant MDA-MB-231 breast cancer cells (231-TXL)] from drug-sensitive control MDA-MB-231 cells (231-CON).\n'
p14399
sg4
(lp14400
sg20
(lp14401
(dp14402
g7
I57
sg23
VC0678222
p14403
sg10
I13
sg11
Vbreast cancer
p14404
sg13
I2
sa(dp14405
g7
I57
sg23
VC0678222
p14406
sg10
I13
sg11
Vbreast cancer
p14407
sg13
I2
sasa(dp14408
g2
S'To investigate therapeutic potential of such nanoparticle mediated delivery system, we examined the efficacy of dual drug-loaded, pH and thermo liable lipid coated mesoporous iron oxide-based magnetic nanoassemblies (DOX:TXL-LMMNA) in mice bearing both drug sensitive (A2780(S)) and drug resistant (A2780-CisR) ovarian cancer tumor xenografts.\n'
p14409
sg4
(lp14410
(dp14411
g7
I221
sg8
g18
sg10
I9
sg11
VTXL-LMMNA
p14412
sg13
I1
sasg20
(lp14413
(dp14414
g7
I326
sg23
VC0027651
p14415
sg10
I5
sg11
Vtumor
p14416
sg13
I1
sa(dp14417
g7
I311
sg23
VC1140680
p14418
sg10
I14
sg11
Vovarian cancer
p14419
sg13
I2
sasa(dp14420
g2
S'Here we report the histone deacetylase inhibitor apicidin (APC) or ER stressor thapsigargin (TG) potentiate paclitaxel (TXL)-induced apoptosis in PCa cells and limit accumulation of cancer stem cells.\n'
p14421
sg4
(lp14422
(dp14423
g7
I19
sg8
VP56524
p14424
sg10
I19
sg11
Vhistone deacetylase
p14425
sg13
I2
sa(dp14426
g7
I49
sg8
VP25054
p14427
sg10
I14
sg11
Vapicidin (APC)
p14428
sg13
I2
sa(dp14429
g7
I67
sg8
g18
sg10
I24
sg11
VER stressor thapsigargin
p14430
sg13
I3
sasg20
(lp14431
(dp14432
g7
I146
sg23
VC0268398
p14433
sg10
I3
sg11
VPCa
p14434
sg13
I1
sa(dp14435
g7
I49
sg23
VC0033036
p14436
sg10
I8
sg11
Vapicidin
p14437
sg13
I1
sa(dp14438
g7
I182
sg23
VC0006826
p14439
sg10
I6
sg11
Vcancer
p14440
sg13
I1
sa(dp14441
g7
I59
sg23
VC0033036
p14442
sg10
I3
sg11
VAPC
p14443
sg13
I1
sasa(dp14444
g2
S'Taken together, combination treatment with TXL and either APC or TG induces efficient apoptosis in both proliferating and cancer stem cells, suggesting this therapeutic combination may overcome drug resistance and recurrence in PCa.\n'
p14445
sg4
(lp14446
(dp14447
g7
I58
sg8
VP25054
p14448
sg10
I3
sg11
VAPC
p14449
sg13
I1
sasg20
(lp14450
(dp14451
g7
I122
sg23
VC0006826
p14452
sg10
I6
sg11
Vcancer
p14453
sg13
I1
sa(dp14454
g7
I228
sg23
VC0268398
p14455
sg10
I3
sg11
VPCa
p14456
sg13
I1
sa(dp14457
g7
I214
sg23
VC1458156
p14458
sg10
I10
sg11
Vrecurrence
p14459
sg13
I1
sa(dp14460
g7
I58
sg23
VC0033036
p14461
sg10
I3
sg11
VAPC
p14462
sg13
I1
sasa(dp14463
g2
S'Analysis of the DHS sequences uncovers one mutation (chr18: 52417839G&gt;C) in the tumour cells of a patient with follicular thyroid carcinoma, which affects the binding of the tumour suppressor protein p53 and correlates with decreased expression of its target gene TXNL1.\n'
p14464
sg4
(lp14465
(dp14466
g7
I267
sg8
g18
sg10
I5
sg11
VTXNL1
p14467
sg13
I1
sa(dp14468
g7
I177
sg8
VP43146
p14469
sg10
I29
sg11
Vtumour suppressor protein p53
p14470
sg13
I4
sa(dp14471
g7
I16
sg8
VP49366
p14472
sg10
I13
sg11
VDHS sequences
p14473
sg13
I2
sasg20
(lp14474
(dp14475
g7
I83
sg23
VC0027651
p14476
sg10
I6
sg11
Vtumour
p14477
sg13
I1
sa(dp14478
g7
I114
sg23
VC0206682
p14479
sg10
I28
sg11
Vfollicular thyroid carcinoma
p14480
sg13
I3
sa(dp14481
g7
I83
sg23
VC0027651
p14482
sg10
I6
sg11
Vtumour
p14483
sg13
I1
sa(dp14484
g7
I16
sg23
VC0272051
p14485
sg10
I3
sg11
VDHS
p14486
sg13
I1
sasa(dp14487
g2
S'The in vitro cytotoxic effect, the ROS generation level and cell cycle distribution analysis of DOX:TXL-MMNPs and DOX:Cis-Pt-MMNPs treated MDA-MB231, MCF-7 and PC3 cancer cells are demonstrated.\n'
p14488
sg4
(lp14489
sg20
(lp14490
(dp14491
g7
I164
sg23
VC0006826
p14492
sg10
I6
sg11
Vcancer
p14493
sg13
I1
sa(dp14494
g7
I118
sg23
VC0007099
p14495
sg10
I3
sg11
VCis
p14496
sg13
I1
sasa(dp14497
g2
S'The objective of this study was to determine if and how ROS contribute to jadomycin cytotoxicity in drug-sensitive MCF7 (MCF7-CON) and taxol-resistant MCF7 (MCF7-TXL) breast cancer cells.\n'
p14498
sg4
(lp14499
sg20
(lp14500
(dp14501
g7
I167
sg23
VC0678222
p14502
sg10
I13
sg11
Vbreast cancer
p14503
sg13
I2
sa(dp14504
g7
I84
sg23
VC0596402
p14505
sg10
I12
sg11
Vcytotoxicity
p14506
sg13
I1
sasa(dp14507
g2
S'Our previous work identified thioredoxin-like protein 2 (Txl-2), a novel thioredoxin family member, as the target of the monoclonal antibody MC3 which can detect colon cancer with high sensitivity and specificity.\n'
p14508
sg4
(lp14509
(dp14510
g7
I29
sg8
VP10599
p14511
sg10
I26
sg11
Vthioredoxin-like protein 2
p14512
sg13
I3
sa(dp14513
g7
I57
sg8
g18
sg10
I5
sg11
VTxl-2
p14514
sg13
I1
sa(dp14515
g7
I121
sg8
VP41968
p14516
sg10
I23
sg11
Vmonoclonal antibody MC3
p14517
sg13
I3
sa(dp14518
g7
I29
sg8
VP10599
p14519
sg10
I11
sg11
Vthioredoxin
p14520
sg13
I1
sasg20
(lp14521
(dp14522
g7
I162
sg23
VC0699790
p14523
sg10
I12
sg11
Vcolon cancer
p14524
sg13
I2
sasa(dp14525
g2
S'In vivo studies validated that Txl-2b expression promoted colon cancer tumorigenesis in nude mice.\n'
p14526
sg4
(lp14527
(dp14528
g7
I31
sg8
g18
sg10
I6
sg11
VTxl-2b
p14529
sg13
I1
sasg20
(lp14530
(dp14531
g7
I58
sg23
VC0699790
p14532
sg10
I12
sg11
Vcolon cancer
p14533
sg13
I2
sa(dp14534
g7
I71
sg23
VC0007621
p14535
sg10
I13
sg11
Vtumorigenesis
p14536
sg13
I1
sasa(dp14537
g2
S'Overall, our results indicate that Txl-2b expression stimulates cancer cell proliferation, accelerates the cell cycle and contributes to apoptosis resistance in colon cancer and provides a potential therapeutic target for colon cancer treatment.\n'
p14538
sg4
(lp14539
(dp14540
g7
I35
sg8
g18
sg10
I6
sg11
VTxl-2b
p14541
sg13
I1
sasg20
(lp14542
(dp14543
g7
I76
sg23
VC0334094
p14544
sg10
I13
sg11
Vproliferation
p14545
sg13
I1
sa(dp14546
g7
I64
sg23
VC0006826
p14547
sg10
I6
sg11
Vcancer
p14548
sg13
I1
sa(dp14549
g7
I161
sg23
VC0699790
p14550
sg10
I12
sg11
Vcolon cancer
p14551
sg13
I2
sa(dp14552
g7
I161
sg23
VC0699790
p14553
sg10
I12
sg11
Vcolon cancer
p14554
sg13
I2
sasa(dp14555
g2
S'Our data showed that the expression of TXNL1 in the cisplatin resistant gastric cancer cell lines BGC823/DDP and SGC7901/DDP cells was significantly lower compared with the cisplatin sensitive cell lines BGC823 and SGC7901.\n'
p14556
sg4
(lp14557
(dp14558
g7
I39
sg8
g18
sg10
I5
sg11
VTXNL1
p14559
sg13
I1
sasg20
(lp14560
(dp14561
g7
I105
sg23
VC0796074
p14562
sg10
I3
sg11
VDDP
p14563
sg13
I1
sa(dp14564
g7
I105
sg23
VC0796074
p14565
sg10
I3
sg11
VDDP
p14566
sg13
I1
sa(dp14567
g7
I72
sg23
VC0024623
p14568
sg10
I14
sg11
Vgastric cancer
p14569
sg13
I2
sasa(dp14570
g2
S'In conclusion, these findings suggest that TXNL1 was a feasible modulator and potential chemotherapeutic target for the cisplatin resistant phenotype of human gastric cancer cells.\n'
p14571
sg4
(lp14572
(dp14573
g7
I43
sg8
g18
sg10
I5
sg11
VTXNL1
p14574
sg13
I1
sasg20
(lp14575
(dp14576
g7
I159
sg23
VC0024623
p14577
sg10
I14
sg11
Vgastric cancer
p14578
sg13
I2
sasa(dp14579
g2
S'In addition, nongenomic estrogen signaling pathways mediated by orphan receptors (eg, GPR30 and ERRAlfa) has also been implicated in prostate cancer progression.\n'
p14580
sg4
(lp14581
sg20
(lp14582
(dp14583
g7
I142
sg23
VC0178874
p14584
sg10
I18
sg11
Vcancer progression
p14585
sg13
I2
sasa(dp14586
g2
S'Previously, we reported that GPR30 activation by the receptor-specific, non-estrogenic ligand G-1 inhibited in vitro and in vivo growth of prostate cancer (PCa) cells via sustained Erk1/2 activation.\n'
p14587
sg4
(lp14588
(dp14589
g7
I181
sg8
VP27361
p14590
sg10
I6
sg11
VErk1/2
p14591
sg13
I1
sasg20
(lp14592
(dp14593
g7
I139
sg23
VC0600139
p14594
sg10
I15
sg11
Vprostate cancer
p14595
sg13
I2
sa(dp14596
g7
I156
sg23
VC0268398
p14597
sg10
I3
sg11
VPCa
p14598
sg13
I1
sasa(dp14599
g2
S'The aim of this study was to identify the expression, cellular localization and regulation of classic estrogen receptors ERAlfa and ERBeta, ER-Alfa36 isoform and GPER in the androgen-independent prostate cancer cell line PC-3.\n'
p14600
sg4
(lp14601
(dp14602
g7
I140
sg8
VP38606
p14603
sg10
I17
sg11
VER-Alfa36 isoform
p14604
sg13
I2
sasg20
(lp14605
(dp14606
g7
I195
sg23
VC0600139
p14607
sg10
I15
sg11
Vprostate cancer
p14608
sg13
I2
sasa(dp14609
g2
S'In contrast, these cells express classical (Alfa and/or Beta) and novel (GPR30) estrogen receptors, which may represent new putative targets in prostate cancer treatment.In the present review, we discuss the still-debated mechanisms, both genomic and non-genomic, by which androgen and estradiol receptors (classical and novel) mediate the hormonal control of prostate cell stemness, transformation, and the continued growth of prostate cancer.\n'
p14610
sg4
(lp14611
(dp14612
g7
I80
sg8
VP03372
p14613
sg10
I18
sg11
Vestrogen receptors
p14614
sg13
I2
sasg20
(lp14615
(dp14616
g7
I144
sg23
VC0600139
p14617
sg10
I15
sg11
Vprostate cancer
p14618
sg13
I2
sa(dp14619
g7
I144
sg23
VC0600139
p14620
sg10
I15
sg11
Vprostate cancer
p14621
sg13
I2
sa(dp14622
g7
I384
sg23
VC1510411
p14623
sg10
I14
sg11
Vtransformation
p14624
sg13
I1
sasa(dp14625
g2
S'Extracellular fibrinolysis, controlled by the cell-associated fibrinolytic system (urokinase plasminogen activator, uPA; uPA receptor, uPAR; plasminogen activator inhibitor type-1, PAI-1), is involved in cartilage damage generation and in rheumatoid arthritis (RA) synovitis.\n'
p14626
sg4
(lp14627
(dp14628
g7
I83
sg8
VP00747
p14629
sg10
I31
sg11
Vurokinase plasminogen activator
p14630
sg13
I3
sa(dp14631
g7
I141
sg8
VP00747
p14632
sg10
I38
sg11
Vplasminogen activator inhibitor type-1
p14633
sg13
I4
sa(dp14634
g7
I181
sg8
VP05121
p14635
sg10
I5
sg11
VPAI-1
p14636
sg13
I1
sa(dp14637
g7
I121
sg8
VP00749
p14638
sg10
I12
sg11
VuPA receptor
p14639
sg13
I2
sa(dp14640
g7
I116
sg8
VP00749
p14641
sg10
I3
sg11
VuPA
p14642
sg13
I1
sasg20
(lp14643
(dp14644
g7
I261
sg23
VC0003873
p14645
sg10
I2
sg11
VRA
p14646
sg13
I1
sa(dp14647
g7
I265
sg23
VC0039103
p14648
sg10
I9
sg11
Vsynovitis
p14649
sg13
I1
sa(dp14650
g7
I239
sg23
VC0003873
p14651
sg10
I20
sg11
Vrheumatoid arthritis
p14652
sg13
I2
sasa(dp14653
g2
S'We report the arthroscopic treatment of pigmented villonodular synovitis (PVNS) in a 13-year-old Japanese boy with congenital partial deficiency of plasminogen activator inhibitor-1 (PAI-1).\n'
p14654
sg4
(lp14655
(dp14656
g7
I148
sg8
VP00747
p14657
sg10
I33
sg11
Vplasminogen activator inhibitor-1
p14658
sg13
I3
sa(dp14659
g7
I183
sg8
VP05121
p14660
sg10
I5
sg11
VPAI-1
p14661
sg13
I1
sasg20
(lp14662
(dp14663
g7
I74
sg23
VC0039106
p14664
sg10
I4
sg11
VPVNS
p14665
sg13
I1
sa(dp14666
g7
I40
sg23
VC0039106
p14667
sg10
I32
sg11
Vpigmented villonodular synovitis
p14668
sg13
I3
sasa(dp14669
g2
S'Sinoatrial nodes (SANs) and pulmonary veins (PVs) play a critical role in the pathophysiology of atrial fibrillation.\n'
p14670
sg4
(lp14671
sg20
(lp14672
(dp14673
g7
I97
sg23
VC0004238
p14674
sg10
I19
sg11
Vatrial fibrillation
p14675
sg13
I2
sasa(dp14676
g2
S'Since it was previously proposed that increased SOXB2 proteins level interfere with the activity of SOXB1 counteracting partners, we compared expression patterns of SOXB members during retinoic acid induction of embryonal carcinoma cells.\n'
p14677
sg4
(lp14678
(dp14679
g7
I48
sg8
VP02649
p14680
sg10
I14
sg11
VSOXB2 proteins
p14681
sg13
I2
sa(dp14682
g7
I165
sg8
VP41225
p14683
sg10
I12
sg11
VSOXB members
p14684
sg13
I2
sasg20
(lp14685
(dp14686
g7
I212
sg23
VC0206659
p14687
sg10
I19
sg11
Vembryonal carcinoma
p14688
sg13
I2
sasa(dp14689
g2
S'Data presented here provide an insight into SOX14 expression during in vitro neural differentiation of embryonal carcinoma cells and demonstrate the effect of its ectopic expression on protein levels of SOXB members in HeLa cells.\n'
p14690
sg4
(lp14691
(dp14692
g7
I203
sg8
VP41225
p14693
sg10
I12
sg11
VSOXB members
p14694
sg13
I2
sa(dp14695
g7
I44
sg8
g18
sg10
I5
sg11
VSOX14
p14696
sg13
I1
sasg20
(lp14697
(dp14698
g7
I103
sg23
VC0206659
p14699
sg10
I19
sg11
Vembryonal carcinoma
p14700
sg13
I2
sasa(dp14701
g2
S'Experiments with human embryonal carcinoma cells identified two response elements involved in retinoic acid/retinoid X receptor-dependent activation of the SOX3 gene expression: distal atypical retinoic acid-response element, consisting of two unique G-rich boxes separated by 49 bp, and proximal element comprising DR-3-like motif, composed of two imperfect hexameric half-sites.\n'
p14702
sg4
(lp14703
(dp14704
g7
I108
sg8
g18
sg10
I19
sg11
Vretinoid X receptor
p14705
sg13
I3
sa(dp14706
g7
I156
sg8
VP41225
p14707
sg10
I9
sg11
VSOX3 gene
p14708
sg13
I2
sasg20
(lp14709
(dp14710
g7
I23
sg23
VC0206659
p14711
sg10
I19
sg11
Vembryonal carcinoma
p14712
sg13
I2
sasa(dp14713
g2
S'We have previously shown that early phases of differentiation and neural induction of NT2/D1 embryonal carcinoma cells by retinoic acid (RA) involve up-regulation of the SOX3 gene expression.\n'
p14714
sg4
(lp14715
(dp14716
g7
I170
sg8
VP41225
p14717
sg10
I9
sg11
VSOX3 gene
p14718
sg13
I2
sasg20
(lp14719
(dp14720
g7
I93
sg23
VC0206659
p14721
sg10
I19
sg11
Vembryonal carcinoma
p14722
sg13
I2
sasa(dp14723
g2
S'Analysis of brain tissues from HIV-1-infected patients validated these findings, and showed transcriptional upregulation of Rac1 and cortactin, as well as increased activation of Rac1 in brain tissues of HIV-1-infected humans, compared to seronegative individuals and subjects with HIV-1-encephalitis.\n'
p14724
sg4
(lp14725
(dp14726
g7
I124
sg8
VP63000
p14727
sg10
I4
sg11
VRac1
p14728
sg13
I1
sa(dp14729
g7
I124
sg8
VP63000
p14730
sg10
I4
sg11
VRac1
p14731
sg13
I1
sa(dp14732
g7
I133
sg8
g18
sg10
I9
sg11
Vcortactin
p14733
sg13
I1
sasg20
(lp14734
(dp14735
g7
I31
sg23
VC0019693
p14736
sg10
I3
sg11
VHIV
p14737
sg13
I1
sa(dp14738
g7
I31
sg23
VC0019693
p14739
sg10
I3
sg11
VHIV
p14740
sg13
I1
sa(dp14741
g7
I31
sg23
VC0019693
p14742
sg10
I3
sg11
VHIV
p14743
sg13
I1
sa(dp14744
g7
I288
sg23
VC0014038
p14745
sg10
I12
sg11
Vencephalitis
p14746
sg13
I1
sasa(dp14747
g2
S'Rho-GDI2, Rab2 and Cofilin1 were found to be associated with down-regulated and naive group phenotypes; Cortactin and Fibrinogen beta-Chain Precursor were found to be associated with down-regulated and group-related IFN-treated RR-MS phenotypes.\n'
p14748
sg4
(lp14749
(dp14750
g7
I0
sg8
VP08100
p14751
sg10
I3
sg11
VRho
p14752
sg13
I1
sa(dp14753
g7
I10
sg8
VP61019
p14754
sg10
I4
sg11
VRab2
p14755
sg13
I1
sa(dp14756
g7
I4
sg8
VP50395
p14757
sg10
I4
sg11
VGDI2
p14758
sg13
I1
sa(dp14759
g7
I216
sg8
VP01562
p14760
sg10
I3
sg11
VIFN
p14761
sg13
I1
sa(dp14762
g7
I104
sg8
g18
sg10
I9
sg11
VCortactin
p14763
sg13
I1
sa(dp14764
g7
I118
sg8
VP22087
p14765
sg10
I15
sg11
VFibrinogen beta
p14766
sg13
I2
sasg20
(lp14767
sa(dp14768
g2
S'The objective of this study was to investigate the effect of genes previously identified as risk alleles, including microtubule-associated protein tau, myelin-associated oligodendrocyte basic protein, eukaryotic translation initiation factor 2-alpha kinase 3, and syntaxin 6, as well as apolipoprotein E, on cognitive function in progressive supranuclear palsy.\n'
p14769
sg4
(lp14770
(dp14771
g7
I264
sg8
g18
sg10
I10
sg11
Vsyntaxin 6
p14772
sg13
I2
sa(dp14773
g7
I287
sg8
VP02649
p14774
sg10
I16
sg11
Vapolipoprotein E
p14775
sg13
I2
sa(dp14776
g7
I201
sg8
g18
sg10
I57
sg11
Veukaryotic translation initiation factor 2-alpha kinase 3
p14777
sg13
I7
sa(dp14778
g7
I152
sg8
g18
sg10
I47
sg11
Vmyelin-associated oligodendrocyte basic protein
p14779
sg13
I4
sa(dp14780
g7
I116
sg8
g18
sg10
I34
sg11
Vmicrotubule-associated protein tau
p14781
sg13
I3
sasg20
(lp14782
(dp14783
g7
I330
sg23
VC0038868
p14784
sg10
I30
sg11
Vprogressive supranuclear palsy
p14785
sg13
I3
sasa(dp14786
g2
S'Atlastin 1 (ATL1, also known as SPG3A) encodes an ER membrane fusion GTPase and reticulon 2 (RTN2, also known as SPG12) helps shape ER tube formation.\n'
p14787
sg4
(lp14788
(dp14789
g7
I32
sg8
g18
sg10
I5
sg11
VSPG3A
p14790
sg13
I1
sa(dp14791
g7
I50
sg8
VP35637
p14792
sg10
I25
sg11
VER membrane fusion GTPase
p14793
sg13
I4
sa(dp14794
g7
I93
sg8
g18
sg10
I4
sg11
VRTN2
p14795
sg13
I1
sa(dp14796
g7
I0
sg8
g18
sg10
I10
sg11
VAtlastin 1
p14797
sg13
I2
sa(dp14798
g7
I12
sg8
g18
sg10
I4
sg11
VATL1
p14799
sg13
I1
sa(dp14800
g7
I80
sg8
g18
sg10
I11
sg11
Vreticulon 2
p14801
sg13
I2
sasg20
(lp14802
(dp14803
g7
I113
sg23
VC1858106
p14804
sg10
I5
sg11
VSPG12
p14805
sg13
I1
sa(dp14806
g7
I32
sg23
VC2931355
p14807
sg10
I5
sg11
VSPG3A
p14808
sg13
I1
sasa(dp14809
g2
S'Protrudin was found to interact with other HSP-related proteins including myelin proteolipid protein 1 (SPG2), atlastin-1 (SPG3A), REEP1 (SPG31), REEP5 (similar to REEP1), Kif5A (SPG10), Kif5B, Kif5C, and reticulon 1, 3, and 4 (similar to reticulon 2, SPG12).\n'
p14810
sg4
(lp14811
(dp14812
g7
I138
sg8
g18
sg10
I5
sg11
VSPG31
p14813
sg13
I1
sa(dp14814
g7
I187
sg8
VP33176
p14815
sg10
I5
sg11
VKif5B
p14816
sg13
I1
sa(dp14817
g7
I146
sg8
g18
sg10
I5
sg11
VREEP5
p14818
sg13
I1
sa(dp14819
g7
I111
sg8
g18
sg10
I10
sg11
Vatlastin-1
p14820
sg13
I1
sa(dp14821
g7
I74
sg8
VP60201
p14822
sg10
I28
sg11
Vmyelin proteolipid protein 1
p14823
sg13
I4
sa(dp14824
g7
I43
sg8
g18
sg10
I20
sg11
VHSP-related proteins
p14825
sg13
I2
sa(dp14826
g7
I131
sg8
g18
sg10
I5
sg11
VREEP1
p14827
sg13
I1
sa(dp14828
g7
I179
sg8
g18
sg10
I5
sg11
VSPG10
p14829
sg13
I1
sa(dp14830
g7
I172
sg8
g18
sg10
I5
sg11
VKif5A
p14831
sg13
I1
sa(dp14832
g7
I123
sg8
g18
sg10
I5
sg11
VSPG3A
p14833
sg13
I1
sa(dp14834
g7
I131
sg8
g18
sg10
I5
sg11
VREEP1
p14835
sg13
I1
sa(dp14836
g7
I194
sg8
g18
sg10
I5
sg11
VKif5C
p14837
sg13
I1
sa(dp14838
g7
I104
sg8
VP60201
p14839
sg10
I4
sg11
VSPG2
p14840
sg13
I1
sasg20
(lp14841
(dp14842
g7
I138
sg23
VC1853247
p14843
sg10
I5
sg11
VSPG31
p14844
sg13
I1
sa(dp14845
g7
I179
sg23
VC1858712
p14846
sg10
I5
sg11
VSPG10
p14847
sg13
I1
sa(dp14848
g7
I123
sg23
VC2931355
p14849
sg10
I5
sg11
VSPG3A
p14850
sg13
I1
sa(dp14851
g7
I104
sg23
VC1839264
p14852
sg10
I4
sg11
VSPG2
p14853
sg13
I1
sa(dp14854
g7
I43
sg23
VC0034152
p14855
sg10
I3
sg11
VHSP
p14856
sg13
I1
sa(dp14857
g7
I252
sg23
VC1858106
p14858
sg10
I5
sg11
VSPG12
p14859
sg13
I1
sasa(dp14860
g2
S'Although more than 50 genetic loci are known [spastic gait (SPG)1 to -57], over half of hereditary spastic paraplegia cases are caused by pathogenic mutations in four genes encoding proteins that function in tubular endoplasmic reticulum (ER) network formation: atlastin-1 (SPG3A), spastin (SPG4), reticulon 2 (SPG12), and receptor expression-enhancing protein 1 (SPG31).\n'
p14861
sg4
(lp14862
(dp14863
g7
I364
sg8
g18
sg10
I5
sg11
VSPG31
p14864
sg13
I1
sa(dp14865
g7
I282
sg8
g18
sg10
I7
sg11
Vspastin
p14866
sg13
I1
sa(dp14867
g7
I262
sg8
g18
sg10
I10
sg11
Vatlastin-1
p14868
sg13
I1
sa(dp14869
g7
I291
sg8
g18
sg10
I4
sg11
VSPG4
p14870
sg13
I1
sa(dp14871
g7
I353
sg8
VP14222
p14872
sg10
I9
sg11
Vprotein 1
p14873
sg13
I2
sa(dp14874
g7
I298
sg8
g18
sg10
I11
sg11
Vreticulon 2
p14875
sg13
I2
sa(dp14876
g7
I274
sg8
g18
sg10
I5
sg11
VSPG3A
p14877
sg13
I1
sasg20
(lp14878
(dp14879
g7
I364
sg23
VC1853247
p14880
sg10
I5
sg11
VSPG31
p14881
sg13
I1
sa(dp14882
g7
I88
sg23
VC0037773
p14883
sg10
I29
sg11
Vhereditary spastic paraplegia
p14884
sg13
I3
sa(dp14885
g7
I311
sg23
VC1858106
p14886
sg10
I5
sg11
VSPG12
p14887
sg13
I1
sa(dp14888
g7
I291
sg23
VC1866855
p14889
sg10
I4
sg11
VSPG4
p14890
sg13
I1
sa(dp14891
g7
I46
sg23
VC0443306
p14892
sg10
I7
sg11
Vspastic
p14893
sg13
I1
sa(dp14894
g7
I274
sg23
VC2931355
p14895
sg10
I5
sg11
VSPG3A
p14896
sg13
I1
sasa(dp14897
g2
S'SPG3A/Atlastin, SPG4/Spastin, SPG12/reticulon 2, and SPG31/REEP1, all of which interact); (3) mitochondrial function (e.g.\n'
p14898
sg4
(lp14899
(dp14900
g7
I21
sg8
g18
sg10
I7
sg11
VSpastin
p14901
sg13
I1
sa(dp14902
g7
I59
sg8
g18
sg10
I5
sg11
VREEP1
p14903
sg13
I1
sa(dp14904
g7
I53
sg8
g18
sg10
I5
sg11
VSPG31
p14905
sg13
I1
sa(dp14906
g7
I6
sg8
g18
sg10
I8
sg11
VAtlastin
p14907
sg13
I1
sa(dp14908
g7
I0
sg8
g18
sg10
I5
sg11
VSPG3A
p14909
sg13
I1
sa(dp14910
g7
I30
sg8
g18
sg10
I17
sg11
VSPG12/reticulon 2
p14911
sg13
I2
sa(dp14912
g7
I16
sg8
g18
sg10
I4
sg11
VSPG4
p14913
sg13
I1
sasg20
(lp14914
(dp14915
g7
I53
sg23
VC1853247
p14916
sg10
I5
sg11
VSPG31
p14917
sg13
I1
sa(dp14918
g7
I30
sg23
VC1858106
p14919
sg10
I5
sg11
VSPG12
p14920
sg13
I1
sa(dp14921
g7
I16
sg23
VC1866855
p14922
sg10
I4
sg11
VSPG4
p14923
sg13
I1
sa(dp14924
g7
I0
sg23
VC2931355
p14925
sg10
I5
sg11
VSPG3A
p14926
sg13
I1
sasa(dp14927
g2
S'RNase 1 and 3 were higher in respiratory failure than without respiratory failure (p &lt; 0.0001 and p = 0.02, respectively).\n'
p14928
sg4
(lp14929
(dp14930
g7
I0
sg8
VP07998
p14931
sg10
I7
sg11
VRNase 1
p14932
sg13
I2
sasg20
(lp14933
(dp14934
g7
I29
sg23
VC1145670
p14935
sg10
I19
sg11
Vrespiratory failure
p14936
sg13
I2
sa(dp14937
g7
I29
sg23
VC1145670
p14938
sg10
I19
sg11
Vrespiratory failure
p14939
sg13
I2
sasa(dp14940
g2
S'At least 30% of purified product RNA shows resistance to degradation by ribonuclease A and T1 before and after annealing with exogenous RNA from influenza virions.\n'
p14941
sg4
(lp14942
(dp14943
g7
I72
sg8
VP07998
p14944
sg10
I14
sg11
Vribonuclease A
p14945
sg13
I2
sasg20
(lp14946
(dp14947
g7
I145
sg23
VC0021400
p14948
sg10
I9
sg11
Vinfluenza
p14949
sg13
I1
sasa(dp14950
g2
S'Circulating miR-122 was associated with prevalent insulin resistance, obesity, metabolic syndrome, type 2 diabetes, and an adverse lipid profile.\n'
p14951
sg4
(lp14952
(dp14953
g7
I50
sg8
VP01308
p14954
sg10
I7
sg11
Vinsulin
p14955
sg13
I1
sa(dp14956
g7
I12
sg8
g18
sg10
I7
sg11
VmiR-122
p14957
sg13
I1
sasg20
(lp14958
(dp14959
g7
I70
sg23
VC0028754
p14960
sg10
I7
sg11
Vobesity
p14961
sg13
I1
sa(dp14962
g7
I79
sg23
VC0524620
p14963
sg10
I18
sg11
Vmetabolic syndrome
p14964
sg13
I2
sa(dp14965
g7
I99
sg23
VC0011860
p14966
sg10
I15
sg11
Vtype 2 diabetes
p14967
sg13
I3
sa(dp14968
g7
I50
sg23
VC0021655
p14969
sg10
I18
sg11
Vinsulin resistance
p14970
sg13
I2
sasa(dp14971
g2
S'Over up to 15 years of follow-up in the Bruneck Study, multivariable adjusted risk ratios per one-SD higher log miR-122 were 1.60 (95% CI 1.30-1.96; P &lt; 0.001) for metabolic syndrome and 1.37 (1.03-1.82; P = 0.021) for type 2 diabetes.\n'
p14972
sg4
(lp14973
sg20
(lp14974
(dp14975
g7
I167
sg23
VC0524620
p14976
sg10
I18
sg11
Vmetabolic syndrome
p14977
sg13
I2
sa(dp14978
g7
I222
sg23
VC0011860
p14979
sg10
I15
sg11
Vtype 2 diabetes
p14980
sg13
I3
sasa(dp14981
g2
S'In conclusion, circulating miR-122 is strongly associated with the risk of developing metabolic syndrome and type 2 diabetes in the general population.\n'
p14982
sg4
(lp14983
(dp14984
g7
I27
sg8
g18
sg10
I7
sg11
VmiR-122
p14985
sg13
I1
sasg20
(lp14986
(dp14987
g7
I86
sg23
VC0524620
p14988
sg10
I18
sg11
Vmetabolic syndrome
p14989
sg13
I2
sa(dp14990
g7
I109
sg23
VC0011860
p14991
sg10
I15
sg11
Vtype 2 diabetes
p14992
sg13
I3
sasa(dp14993
g2
S'Tricho-hepato-enteric syndrome (THES) is a rare disorder caused by mutations in the TTC37 or SKIV2L genes and characterized by chronic diarrhea, liver disease, hair abnormalities, and high mortality in early childhood due to severe infection or liver cirrhosis.\n'
p14994
sg4
(lp14995
(dp14996
g7
I84
sg8
g18
sg10
I5
sg11
VTTC37
p14997
sg13
I1
sa(dp14998
g7
I93
sg8
g18
sg10
I12
sg11
VSKIV2L genes
p14999
sg13
I2
sasg20
(lp15000
(dp15001
g7
I245
sg23
VC0023890
p15002
sg10
I15
sg11
Vliver cirrhosis
p15003
sg13
I2
sa(dp15004
g7
I145
sg23
VC0023895
p15005
sg10
I13
sg11
Vliver disease
p15006
sg13
I2
sa(dp15007
g7
I127
sg23
VC0401151
p15008
sg10
I16
sg11
Vchronic diarrhea
p15009
sg13
I2
sa(dp15010
g7
I232
sg23
VC0009450
p15011
sg10
I9
sg11
Vinfection
p15012
sg13
I1
sa(dp15013
g7
I22
sg23
VC0039082
p15014
sg10
I8
sg11
Vsyndrome
p15015
sg13
I1
sa(dp15016
g7
I43
sg23
VC0678236
p15017
sg10
I13
sg11
Vrare disorder
p15018
sg13
I2
sasa(dp15019
g2
S'Physicians must be aware of THES when they encounter a patient with infantile diarrhea, hair abnormalities, immune deficiency, mental retardation, and liver disease.\n'
p15020
sg4
(lp15021
sg20
(lp15022
(dp15023
g7
I151
sg23
VC0023895
p15024
sg10
I13
sg11
Vliver disease
p15025
sg13
I2
sa(dp15026
g7
I127
sg23
VC0025362
p15027
sg10
I18
sg11
Vmental retardation
p15028
sg13
I2
sa(dp15029
g7
I68
sg23
VC0011992
p15030
sg10
I18
sg11
Vinfantile diarrhea
p15031
sg13
I2
sa(dp15032
g7
I108
sg23
VC0850497
p15033
sg10
I17
sg11
Vimmune deficiency
p15034
sg13
I2
sasa(dp15035
g2
S'Two neonates, born to nonconsanguineous parents, suffered from intractable diarrhea, recurrent infections, and massive hematemesis from esopharyngeal varices due to liver cirrhosis or accompanying Trichorrhexis nodosa that developed with age and thus guided the diagnosis of SD/THE compatible to TTC37 mutations (homozygous DelK1155H, Fs*2; heterozygous Y1169Ter and InsA1143, Fs*3).\n'
p15036
sg4
(lp15037
(dp15038
g7
I296
sg8
g18
sg10
I5
sg11
VTTC37
p15039
sg13
I1
sa(dp15040
g7
I335
sg8
VP19883
p15041
sg10
I4
sg11
VFs*2
p15042
sg13
I1
sasg20
(lp15043
(dp15044
g7
I95
sg23
VC0021311
p15045
sg10
I10
sg11
Vinfections
p15046
sg13
I1
sa(dp15047
g7
I165
sg23
VC0023890
p15048
sg10
I15
sg11
Vliver cirrhosis
p15049
sg13
I2
sa(dp15050
g7
I49
sg23
VC0683278
p15051
sg10
I8
sg11
Vsuffered
p15052
sg13
I1
sa(dp15053
g7
I63
sg23
VC0743178
p15054
sg10
I20
sg11
Vintractable diarrhea
p15055
sg13
I2
sa(dp15056
g7
I150
sg23
VC0042345
p15057
sg10
I7
sg11
Vvarices
p15058
sg13
I1
sa(dp15059
g7
I197
sg23
VC0263485
p15060
sg10
I20
sg11
VTrichorrhexis nodosa
p15061
sg13
I2
sa(dp15062
g7
I111
sg23
VC0858247
p15063
sg10
I19
sg11
Vmassive hematemesis
p15064
sg13
I2
sasa(dp15065
g2
S'Trichohepatoenteric syndrome (THES) is an autosomal-recessive disorder characterized by life-threatening diarrhea in infancy, immunodeficiency, liver disease, trichorrhexis nodosa, facial dysmorphism, hypopigmentation, and cardiac defects.\n'
p15066
sg4
(lp15067
sg20
(lp15068
(dp15069
g7
I105
sg23
VC0011991
p15070
sg10
I8
sg11
Vdiarrhea
p15071
sg13
I1
sa(dp15072
g7
I223
sg23
VC0741916
p15073
sg10
I15
sg11
Vcardiac defects
p15074
sg13
I2
sa(dp15075
g7
I144
sg23
VC0023895
p15076
sg10
I13
sg11
Vliver disease
p15077
sg13
I2
sa(dp15078
g7
I159
sg23
VC0263485
p15079
sg10
I20
sg11
Vtrichorrhexis nodosa
p15080
sg13
I2
sa(dp15081
g7
I126
sg23
VC0021051
p15082
sg10
I16
sg11
Vimmunodeficiency
p15083
sg13
I1
sa(dp15084
g7
I201
sg23
VC1876214
p15085
sg10
I16
sg11
Vhypopigmentation
p15086
sg13
I1
sa(dp15087
g7
I0
sg23
VC1857276
p15088
sg10
I28
sg11
VTrichohepatoenteric syndrome
p15089
sg13
I2
sa(dp15090
g7
I30
sg23
VC1857276
p15091
sg10
I4
sg11
VTHES
p15092
sg13
I1
sa(dp15093
g7
I181
sg23
VC0266617
p15094
sg10
I18
sg11
Vfacial dysmorphism
p15095
sg13
I2
sasa(dp15096
g2
S'In this report, transfection of tau plasmids into human neuroblastoma SK-N-SH cells caused a significant reduction in the messenger RNA (mRNA) levels of several Kv channels, including Kv2.1, Kv3.1, Kv5.1, Kv9.2, and KCNH4.\n'
p15097
sg4
(lp15098
(dp15099
g7
I184
sg8
g18
sg10
I5
sg11
VKv2.1
p15100
sg13
I1
sa(dp15101
g7
I198
sg8
g18
sg10
I5
sg11
VKv5.1
p15102
sg13
I1
sa(dp15103
g7
I216
sg8
g18
sg10
I5
sg11
VKCNH4
p15104
sg13
I1
sa(dp15105
g7
I191
sg8
VP48547
p15106
sg10
I5
sg11
VKv3.1
p15107
sg13
I1
sa(dp15108
g7
I205
sg8
g18
sg10
I5
sg11
VKv9.2
p15109
sg13
I1
sasg20
(lp15110
(dp15111
g7
I56
sg23
VC0027819
p15112
sg10
I13
sg11
Vneuroblastoma
p15113
sg13
I1
sasa(dp15114
g2
S'Three staff physicians and 22 gastroenterology fellows classified eight randomly assigned unknown still ECS pictures (two images per each classification) into one of four histopathologic categories as follows: (1) BEC1-squamous epithelium; (2) BEC2-BE without dysplasia; (3) BEC3-BE with dysplasia; and (4) BEC4-esophageal adenocarcinoma (EAC) in BE.\n'
p15115
sg4
(lp15116
sg20
(lp15117
(dp15118
g7
I260
sg23
VC0334044
p15119
sg10
I9
sg11
Vdysplasia
p15120
sg13
I1
sa(dp15121
g7
I260
sg23
VC0334044
p15122
sg10
I9
sg11
Vdysplasia
p15123
sg13
I1
sa(dp15124
g7
I307
sg23
VC1275122
p15125
sg10
I30
sg11
VBEC4-esophageal adenocarcinoma
p15126
sg13
I2
sa(dp15127
g7
I339
sg23
VC1275122
p15128
sg10
I3
sg11
VEAC
p15129
sg13
I1
sasa(dp15130
g2
S'Five hundred and fifteen LD SCLC patients were randomised to receive five vaccinations of Bec2 (2.5mg)/BCG vaccine arm (VA) or an observational arm (OA) administered over a 10-week period.\n'
p15131
sg4
(lp15132
sg20
(lp15133
(dp15134
g7
I28
sg23
VC0149925
p15135
sg10
I4
sg11
VSCLC
p15136
sg13
I1
sasa(dp15137
g2
S'We found no benefits to patient HRQOL by additional vaccination with Bec2/BCG to LD SCLC for patients who have been undergoing standard therapy.\n'
p15138
sg4
(lp15139
(dp15140
g7
I69
sg8
g18
sg10
I4
sg11
VBec2
p15141
sg13
I1
sasg20
(lp15142
(dp15143
g7
I84
sg23
VC0149925
p15144
sg10
I4
sg11
VSCLC
p15145
sg13
I1
sasa(dp15146
g2
S'This article reviews the following seven vaccines, which have entered randomized trials: L-BLP25 (Stimuvax), BEC-2, 1E10, PF-3512676 (Promune), melanoma-associated antigen A3 immunotherapeutic, granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy, and belagenpumatucel-L (Lucanix).\n'
p15147
sg4
(lp15148
(dp15149
g7
I194
sg8
VP04141
p15150
sg10
I48
sg11
Vgranulocyte-macrophage colony-stimulating factor
p15151
sg13
I3
sa(dp15152
g7
I144
sg8
VP08962
p15153
sg10
I30
sg11
Vmelanoma-associated antigen A3
p15154
sg13
I3
sasg20
(lp15155
(dp15156
g7
I265
sg23
VC0006826
p15157
sg10
I6
sg11
Vcancer
p15158
sg13
I1
sa(dp15159
g7
I144
sg23
VC0025202
p15160
sg10
I8
sg11
Vmelanoma
p15161
sg13
I1
sasa(dp15162
g2
S'We assessed whether Bec2/bacille Calmette-Guerin (BCG) vaccination prolongs survival in patients with limited-disease small-cell lung cancer (SCLC) after a major response to chemotherapy and chest radiation.\n'
p15163
sg4
(lp15164
(dp15165
g7
I20
sg8
g18
sg10
I4
sg11
VBec2
p15166
sg13
I1
sasg20
(lp15167
(dp15168
g7
I142
sg23
VC0149925
p15169
sg10
I4
sg11
VSCLC
p15170
sg13
I1
sa(dp15171
g7
I118
sg23
VC0149925
p15172
sg10
I22
sg11
Vsmall-cell lung cancer
p15173
sg13
I3
sasa(dp15174
g2
S'Vaccination with Bec2/BCG has no impact on outcome of patients with limited-disease SCLC responding to combined-modality treatment.\n'
p15175
sg4
(lp15176
(dp15177
g7
I17
sg8
g18
sg10
I4
sg11
VBec2
p15178
sg13
I1
sasg20
(lp15179
(dp15180
g7
I84
sg23
VC0149925
p15181
sg10
I4
sg11
VSCLC
p15182
sg13
I1
sasa(dp15183
g2
S'Twenty-four melanoma patients were randomized to be immunized with either BEC2 followed by GD3-L-KLH or in the opposite order.\n'
p15184
sg4
(lp15185
(dp15186
g7
I74
sg8
g18
sg10
I4
sg11
VBEC2
p15187
sg13
I1
sa(dp15188
g7
I91
sg8
g18
sg10
I9
sg11
VGD3-L-KLH
p15189
sg13
I1
sasg20
(lp15190
(dp15191
g7
I12
sg23
VC0025202
p15192
sg10
I8
sg11
Vmelanoma
p15193
sg13
I1
sasa(dp15194
g2
S'Therefore, this investigation was designed to examine the excitatory effect of PGE1 on signal transmission in neuroblastoma x glioma hybrid cells (NG 108-15) overexpressing Phd.\n'
p15195
sg4
(lp15196
(dp15197
g7
I173
sg8
VP20941
p15198
sg10
I3
sg11
VPhd
p15199
sg13
I1
sasg20
(lp15200
(dp15201
g7
I126
sg23
VC0017638
p15202
sg10
I6
sg11
Vglioma
p15203
sg13
I1
sa(dp15204
g7
I110
sg23
VC0027819
p15205
sg10
I13
sg11
Vneuroblastoma
p15206
sg13
I1
sasa(dp15207
g2
S'Mothers and fathers of twins are personally interviewed about their lifetime history of DSM-III-R alcoholism, antisocial personality disorder, generalized anxiety disorder, major depression, panic disorder/agoraphobia, social phobia, and simple phobia using a modified version of the SCID and the DIS.\n'
p15208
sg4
(lp15209
sg20
(lp15210
(dp15211
g7
I110
sg23
VC0003431
p15212
sg10
I31
sg11
Vantisocial personality disorder
p15213
sg13
I3
sa(dp15214
g7
I98
sg23
VC0001973
p15215
sg10
I10
sg11
Valcoholism
p15216
sg13
I1
sa(dp15217
g7
I191
sg23
VC1868649
p15218
sg10
I14
sg11
Vpanic disorder
p15219
sg13
I2
sa(dp15220
g7
I238
sg23
VC0236801
p15221
sg10
I13
sg11
Vsimple phobia
p15222
sg13
I2
sa(dp15223
g7
I173
sg23
VC1269683
p15224
sg10
I16
sg11
Vmajor depression
p15225
sg13
I2
sa(dp15226
g7
I284
sg23
VC0085110
p15227
sg10
I4
sg11
VSCID
p15228
sg13
I1
sa(dp15229
g7
I206
sg23
VC0001818
p15230
sg10
I11
sg11
Vagoraphobia
p15231
sg13
I1
sa(dp15232
g7
I143
sg23
VC0270549
p15233
sg10
I28
sg11
Vgeneralized anxiety disorder
p15234
sg13
I3
sa(dp15235
g7
I219
sg23
VC0031572
p15236
sg10
I13
sg11
Vsocial phobia
p15237
sg13
I2
sasa(dp15238
g2
S'Patients with untreated disorders were identified using the Q-DIS-III-R to diagnose six DIS-anxiety disorders (generalized anxiety disorder, post-traumatic stress disorder (PTSD), simple phobia, social phobia, panic/agoraphobia, obsessive/compulsive disorder) and major depression.\n'
p15239
sg4
(lp15240
sg20
(lp15241
(dp15242
g7
I92
sg23
VC0003469
p15243
sg10
I17
sg11
Vanxiety disorders
p15244
sg13
I2
sa(dp15245
g7
I131
sg23
VC0038436
p15246
sg10
I31
sg11
Vdisorder, post-traumatic stress
p15247
sg13
I3
sa(dp15248
g7
I187
sg23
VC0349231
p15249
sg10
I6
sg11
Vphobia
p15250
sg13
I1
sa(dp15251
g7
I187
sg23
VC0031572
p15252
sg10
I14
sg11
Vphobia, social
p15253
sg13
I2
sa(dp15254
g7
I264
sg23
VC1269683
p15255
sg10
I16
sg11
Vmajor depression
p15256
sg13
I2
sa(dp15257
g7
I216
sg23
VC0001818
p15258
sg10
I11
sg11
Vagoraphobia
p15259
sg13
I1
sa(dp15260
g7
I173
sg23
VC0038436
p15261
sg10
I4
sg11
VPTSD
p15262
sg13
I1
sasa(dp15263
g2
S'C-DIS kappas ranged from -.05 for generalized anxiety to .70 for simple phobia.\n'
p15264
sg4
(lp15265
(dp15266
g7
I0
sg8
VP21145
p15267
sg10
I12
sg11
VC-DIS kappas
p15268
sg13
I2
sasg20
(lp15269
(dp15270
g7
I34
sg23
VC0262376
p15271
sg10
I19
sg11
Vgeneralized anxiety
p15272
sg13
I2
sa(dp15273
g7
I65
sg23
VC0236801
p15274
sg10
I13
sg11
Vsimple phobia
p15275
sg13
I2
sasa(dp15276
g2
S'Duke Epidemiologic Catchment Area (ECA) data were used to examine the relationships between: (a) early childhood maternal death, paternal death, and parental separation/divorce, and (b) six-month DIS/DSM-III diagnoses of agoraphobia with and without panic attacks, simple phobia, social phobia, panic disorder, generalised anxiety disorder, and obsessive-compulsive disorder.\n'
p15277
sg4
(lp15278
sg20
(lp15279
(dp15280
g7
I311
sg23
VC0270549
p15281
sg10
I28
sg11
Vgeneralised anxiety disorder
p15282
sg13
I3
sa(dp15283
g7
I345
sg23
VC0028768
p15284
sg10
I29
sg11
Vobsessive-compulsive disorder
p15285
sg13
I2
sa(dp15286
g7
I295
sg23
VC1868649
p15287
sg10
I14
sg11
Vpanic disorder
p15288
sg13
I2
sa(dp15289
g7
I226
sg23
VC0349231
p15290
sg10
I6
sg11
Vphobia
p15291
sg13
I1
sa(dp15292
g7
I221
sg23
VC0001818
p15293
sg10
I11
sg11
Vagoraphobia
p15294
sg13
I1
sa(dp15295
g7
I250
sg23
VC0086769
p15296
sg10
I13
sg11
Vpanic attacks
p15297
sg13
I2
sa(dp15298
g7
I272
sg23
VC0031572
p15299
sg10
I14
sg11
Vphobia, social
p15300
sg13
I2
sa(dp15301
g7
I158
sg23
VC0036679
p15302
sg10
I10
sg11
Vseparation
p15303
sg13
I1
sasa(dp15304
g2
S'Since SNP rs12587742 is located within the promoter region and one CpG island of DCAF4, we further performed in silico functional analyses and found that the rs12587742 variant A allele was associated with an increased mRNA expression (P = 2.20 x 10-16, 1.79 x 10-13 and 0.001 in blood cells, normal lung tissues and tumor tissues of lung squamous carcinoma, respectively) and a decreased methylation status (P = 2.48 x 10-9 and 0.032 in adipose and lung tumor tissues, respectively).\n'
p15305
sg4
(lp15306
(dp15307
g7
I6
sg8
g18
sg10
I14
sg11
VSNP rs12587742
p15308
sg13
I2
sa(dp15309
g7
I81
sg8
g18
sg10
I5
sg11
VDCAF4
p15310
sg13
I1
sa(dp15311
g7
I158
sg8
VP26640
p15312
sg10
I27
sg11
Vrs12587742 variant A allele
p15313
sg13
I4
sasg20
(lp15314
(dp15315
g7
I450
sg23
VC0024121
p15316
sg10
I10
sg11
Vlung tumor
p15317
sg13
I2
sa(dp15318
g7
I339
sg23
VC0007137
p15319
sg10
I18
sg11
Vsquamous carcinoma
p15320
sg13
I2
sa(dp15321
g7
I317
sg23
VC0027651
p15322
sg10
I5
sg11
Vtumor
p15323
sg13
I1
sasa(dp15324
g2
S'Moreover, evidence from differential expression analyses further supported an oncogenic effect of DCAF4 on lung cancer, with higher mRNA levels in both lung squamous carcinoma and adenocarcinoma (P = 4.48 x 10-11 and 1.22 x 10-9, respectively) than in adjacent normal tissues.\n'
p15325
sg4
(lp15326
(dp15327
g7
I98
sg8
g18
sg10
I5
sg11
VDCAF4
p15328
sg13
I1
sasg20
(lp15329
(dp15330
g7
I157
sg23
VC0007137
p15331
sg10
I18
sg11
Vsquamous carcinoma
p15332
sg13
I2
sa(dp15333
g7
I107
sg23
VC0684249
p15334
sg10
I11
sg11
Vlung cancer
p15335
sg13
I2
sa(dp15336
g7
I180
sg23
VC0001418
p15337
sg10
I14
sg11
Vadenocarcinoma
p15338
sg13
I1
sasa(dp15339
g2
S'Here we infer the potential impact of 19 well-defined DCAFs in human lung adenocarcinomas (LuADCs) using integrative omics analyses, and discover that mRNA levels of DTL, DCAF4, 12 and 13 are consistently elevated whereas VBRBP is reduced in LuADCs compared to normal lung tissues.\n'
p15340
sg4
(lp15341
sg20
(lp15342
(dp15343
g7
I74
sg23
VC0001418
p15344
sg10
I15
sg11
Vadenocarcinomas
p15345
sg13
I1
sasa(dp15346
g2
S'In addition, six of eight patients with both lymphopenia and malar rash had anti-Gal-8 in their sera.\n'
p15347
sg4
(lp15348
(dp15349
g7
I76
sg8
VP16278
p15350
sg10
I10
sg11
Vanti-Gal-8
p15351
sg13
I1
sasg20
(lp15352
(dp15353
g7
I67
sg23
VC0015230
p15354
sg10
I4
sg11
Vrash
p15355
sg13
I1
sa(dp15356
g7
I45
sg23
VC0024312
p15357
sg10
I11
sg11
Vlymphopenia
p15358
sg13
I1
sasa(dp15359
g2
S'To explore the expression and correlation of RAR-beta receptor and galectin-8 in acquired middle ear cholesteatoma, and to evaluate their roles in the formation of middle ear cholesteatoma.\n'
p15360
sg4
(lp15361
(dp15362
g7
I45
sg8
VP10826
p15363
sg10
I17
sg11
VRAR-beta receptor
p15364
sg13
I2
sa(dp15365
g7
I67
sg8
VP09382
p15366
sg10
I10
sg11
Vgalectin-8
p15367
sg13
I1
sa(dp15368
g7
I90
sg8
VP31947
p15369
sg10
I24
sg11
Vmiddle ear cholesteatoma
p15370
sg13
I3
sasg20
(lp15371
(dp15372
g7
I90
sg23
VC0155490
p15373
sg10
I24
sg11
Vmiddle ear cholesteatoma
p15374
sg13
I3
sa(dp15375
g7
I90
sg23
VC0155490
p15376
sg10
I24
sg11
Vmiddle ear cholesteatoma
p15377
sg13
I3
sasa(dp15378
g2
S'Tissue specimens from 42 cases of acquired middle ear cholesteatoma and 18 cases of external ear skin were examined by immunohistochemical SABC method for RAR-beta receptors and galectin-8, also by Western Blot for these two factors.\n'
p15379
sg4
(lp15380
(dp15381
g7
I155
sg8
VP10826
p15382
sg10
I18
sg11
VRAR-beta receptors
p15383
sg13
I2
sa(dp15384
g7
I178
sg8
VP09382
p15385
sg10
I10
sg11
Vgalectin-8
p15386
sg13
I1
sasg20
(lp15387
(dp15388
g7
I43
sg23
VC0155490
p15389
sg10
I24
sg11
Vmiddle ear cholesteatoma
p15390
sg13
I3
sasa(dp15391
g2
S'These clinicopathological features were significantly different from 154 randomly chosen CD200-negative mantle cell lymphoma patients, in SOX11 positivity (24% versus 74%, P&lt;0.0001), CD23 expression (76% versus 8%, P&lt;0.0001), a non-nodal leukemic presentation (44% versus 2%, P&lt;0.001), and therapy requirement (50% versus 92%, P&lt;0.0001).\n'
p15392
sg4
(lp15393
(dp15394
g7
I138
sg8
VP35716
p15395
sg10
I5
sg11
VSOX11
p15396
sg13
I1
sa(dp15397
g7
I186
sg8
VP06734
p15398
sg10
I4
sg11
VCD23
p15399
sg13
I1
sasg20
(lp15400
(dp15401
g7
I104
sg23
VC0334634
p15402
sg10
I20
sg11
Vmantle cell lymphoma
p15403
sg13
I3
sasa(dp15404
g2
S'Deregulated expression of SOX11 has been shown to be involved in the progression of various types of cancer.\n'
p15405
sg4
(lp15406
(dp15407
g7
I26
sg8
VP35716
p15408
sg10
I5
sg11
VSOX11
p15409
sg13
I1
sasg20
(lp15410
(dp15411
g7
I101
sg23
VC0006826
p15412
sg10
I6
sg11
Vcancer
p15413
sg13
I1
sasa(dp15414
g2
S'However, the role of SOX11 in head and neck cancer remains largely unknown.\n'
p15415
sg4
(lp15416
(dp15417
g7
I21
sg8
VP35716
p15418
sg10
I5
sg11
VSOX11
p15419
sg13
I1
sasg20
(lp15420
(dp15421
g7
I30
sg23
VC0278996
p15422
sg10
I20
sg11
Vhead and neck cancer
p15423
sg13
I4
sasa(dp15424
g2
S'In this study, coimmunoprecipitation (Co-IP) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) were performed to identify the proteins that bind to SOX11 at significantly higher levels in head and neck cancer cells than in normal human oral keratinocytes.\n'
p15425
sg4
(lp15426
(dp15427
g7
I160
sg8
VP35716
p15428
sg10
I5
sg11
VSOX11
p15429
sg13
I1
sasg20
(lp15430
(dp15431
g7
I200
sg23
VC0278996
p15432
sg10
I20
sg11
Vhead and neck cancer
p15433
sg13
I4
sasa(dp15434
g2
S'The binding of HSP90Alfa with SOX11 in head and neck cancer cells was validated by Co-IP with western blotting.\n'
p15435
sg4
(lp15436
(dp15437
g7
I30
sg8
VP35716
p15438
sg10
I5
sg11
VSOX11
p15439
sg13
I1
sasg20
(lp15440
(dp15441
g7
I39
sg23
VC0278996
p15442
sg10
I20
sg11
Vhead and neck cancer
p15443
sg13
I4
sasa(dp15444
g2
S'Collectively, our studies indicate that SOX11 binds to HSP90Alfa, a highly overexpressed protein that may promote invasion and progression of head and neck cancer cells.\n'
p15445
sg4
(lp15446
(dp15447
g7
I40
sg8
VP35716
p15448
sg10
I5
sg11
VSOX11
p15449
sg13
I1
sasg20
(lp15450
(dp15451
g7
I142
sg23
VC0278996
p15452
sg10
I20
sg11
Vhead and neck cancer
p15453
sg13
I4
sa(dp15454
g7
I114
sg23
VC2699153
p15455
sg10
I8
sg11
Vinvasion
p15456
sg13
I1
sasa(dp15457
g2
S'Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions.\n'
p15458
sg4
(lp15459
(dp15460
g7
I126
sg8
VP03372
p15461
sg10
I18
sg11
Voestrogen receptor
p15462
sg13
I2
sa(dp15463
g7
I19
sg8
VP35716
p15464
sg10
I5
sg11
VSOX11
p15465
sg13
I1
sasg20
(lp15466
(dp15467
g7
I166
sg23
VC0007124
p15468
sg10
I24
sg11
Vductal carcinoma in situ
p15469
sg13
I4
sa(dp15470
g7
I192
sg23
VC0007124
p15471
sg10
I4
sg11
VDCIS
p15472
sg13
I1
sasa(dp15473
g2
S'DCIS.com cells engineered to express SOX11 showed increased ALDH activity, which is a feature of cancer stem cells.\n'
p15474
sg4
(lp15475
(dp15476
g7
I60
sg8
VP00352
p15477
sg10
I4
sg11
VALDH
p15478
sg13
I1
sa(dp15479
g7
I37
sg8
VP35716
p15480
sg10
I5
sg11
VSOX11
p15481
sg13
I1
sasg20
(lp15482
(dp15483
g7
I97
sg23
VC0006826
p15484
sg10
I6
sg11
Vcancer
p15485
sg13
I1
sa(dp15486
g7
I0
sg23
VC0007124
p15487
sg10
I4
sg11
VDCIS
p15488
sg13
I1
sasa(dp15489
g2
S'Invasive lesions formed sooner and tumour growth was augmented in vivo, suggesting that SOX11 contributes to the progression of DCIS to invasive breast cancer.\n'
p15490
sg4
(lp15491
(dp15492
g7
I88
sg8
VP35716
p15493
sg10
I5
sg11
VSOX11
p15494
sg13
I1
sasg20
(lp15495
(dp15496
g7
I136
sg23
VC0853879
p15497
sg10
I22
sg11
Vinvasive breast cancer
p15498
sg13
I3
sa(dp15499
g7
I128
sg23
VC0007124
p15500
sg10
I4
sg11
VDCIS
p15501
sg13
I1
sa(dp15502
g7
I35
sg23
VC0027651
p15503
sg10
I6
sg11
Vtumour
p15504
sg13
I1
sasa(dp15505
g2
S'Our findings suggest that SOX11 is a potential biomarker for DCIS lesions containing cells harbouring distinct biological features that are likely to progress to invasive breast cancer.\n'
p15506
sg4
(lp15507
(dp15508
g7
I26
sg8
VP35716
p15509
sg10
I5
sg11
VSOX11
p15510
sg13
I1
sasg20
(lp15511
(dp15512
g7
I61
sg23
VC0007124
p15513
sg10
I4
sg11
VDCIS
p15514
sg13
I1
sa(dp15515
g7
I162
sg23
VC0853879
p15516
sg10
I22
sg11
Vinvasive breast cancer
p15517
sg13
I3
sasa(dp15518
g2
S'The expression levels of P-gp and its encoded gene mdr1a/b were significantly up-regulated on the brain of KA-induced chronic epilepsy rats or the epilepsy rats treated with CBZ for 1 week, meanwhile with a high expression of PXR.\n'
p15519
sg4
(lp15520
(dp15521
g7
I25
sg8
g18
sg10
I4
sg11
VP-gp
p15522
sg13
I1
sasg20
(lp15523
(dp15524
g7
I126
sg23
VC0014544
p15525
sg10
I8
sg11
Vepilepsy
p15526
sg13
I1
sa(dp15527
g7
I126
sg23
VC0014544
p15528
sg10
I8
sg11
Vepilepsy
p15529
sg13
I1
sasa(dp15530
g2
S'The treatment of PMA dramatically reduced both PXR and P-gp expressions at the protein and mRNA levels in the chronic epilepsy brain.\n'
p15531
sg4
(lp15532
(dp15533
g7
I55
sg8
g18
sg10
I4
sg11
VP-gp
p15534
sg13
I1
sasg20
(lp15535
(dp15536
g7
I118
sg23
VC0014544
p15537
sg10
I8
sg11
Vepilepsy
p15538
sg13
I1
sasa(dp15539
g2
S'This study demonstrates for the first time that P-gp up-regulation is due to increase PXR expression in the chronic phase of epilepsy, differently from that NF-KB signaling may induce the P-gp expression in the acute seizure phase.\n'
p15540
sg4
(lp15541
sg20
(lp15542
(dp15543
g7
I217
sg23
VC0036572
p15544
sg10
I7
sg11
Vseizure
p15545
sg13
I1
sa(dp15546
g7
I125
sg23
VC0014544
p15547
sg10
I8
sg11
Vepilepsy
p15548
sg13
I1
sasa(dp15549
g2
S'We therefore investigated the expression and function of pregnane xenobiotic (PXR) and glucocorticoid (GR) nuclear receptors in endothelial cells established from post-epilepsy surgery brain samples.\n'
p15550
sg4
(lp15551
(dp15552
g7
I87
sg8
VP48506
p15553
sg10
I14
sg11
Vglucocorticoid
p15554
sg13
I1
sa(dp15555
g7
I103
sg8
VP00390
p15556
sg10
I2
sg11
VGR
p15557
sg13
I1
sasg20
(lp15558
(dp15559
g7
I168
sg23
VC0014544
p15560
sg10
I8
sg11
Vepilepsy
p15561
sg13
I1
sasa(dp15562
g2
S'The objective was to examine the link between selected single nucleotide polymorphisms (SNPs) 69789A/G rs 7643645 and 66034T/C rs 13059232 hPXR and the lack of response to epilepsy treatment.\n'
p15563
sg4
(lp15564
sg20
(lp15565
(dp15566
g7
I172
sg23
VC0014544
p15567
sg10
I8
sg11
Vepilepsy
p15568
sg13
I1
sasa(dp15569
g2
S'The distribution of genotypes of the 66034T/C rs 13059232 hPXR polymorphism was significantly different in the group with drug-resistant epilepsy and the control group.\n'
p15570
sg4
(lp15571
sg20
(lp15572
(dp15573
g7
I137
sg23
VC0014544
p15574
sg10
I8
sg11
Vepilepsy
p15575
sg13
I1
sasa(dp15576
g2
S'Twelve single nucleotide polymorphisms (SNPs) involved in LTG metabolism and transport pathways, including UGT2B7, ABCB1, ABCG2, NR1I2 and HNF4Alfa were genotyped in 140 Chinese epilepsy patients.\n'
p15577
sg4
(lp15578
(dp15579
g7
I115
sg8
VP08183
p15580
sg10
I5
sg11
VABCB1
p15581
sg13
I1
sa(dp15582
g7
I107
sg8
VP16662
p15583
sg10
I6
sg11
VUGT2B7
p15584
sg13
I1
sasg20
(lp15585
(dp15586
g7
I178
sg23
VC0014544
p15587
sg10
I8
sg11
Vepilepsy
p15588
sg13
I1
sasa(dp15589
g2
S'To observe the expression of trophinin in the cycling endometrium and investigate its relationship with infertility.\n'
p15590
sg4
(lp15591
(dp15592
g7
I29
sg8
g18
sg10
I9
sg11
Vtrophinin
p15593
sg13
I1
sasg20
(lp15594
(dp15595
g7
I104
sg23
VC0021359
p15596
sg10
I11
sg11
Vinfertility
p15597
sg13
I1
sasa(dp15598
g2
S'Trophinin expression in the endometrium was observed in 39 normal cycling women during different menstrual phases and 24 women with infertility during mid-luteal phase by immunohistochemical technique.\n'
p15599
sg4
(lp15600
(dp15601
g7
I0
sg8
g18
sg10
I9
sg11
VTrophinin
p15602
sg13
I1
sasg20
(lp15603
(dp15604
g7
I132
sg23
VC0021359
p15605
sg10
I11
sg11
Vinfertility
p15606
sg13
I1
sasa(dp15607
g2
S'In comparison with normal women, infertile women with endometriosis or unexplained infertility had significantly weakened trophinin expression in the endometrium in the mid-luteal (P&lt;0.001).\n'
p15608
sg4
(lp15609
(dp15610
g7
I122
sg8
g18
sg10
I9
sg11
Vtrophinin
p15611
sg13
I1
sasg20
(lp15612
(dp15613
g7
I54
sg23
VC0014175
p15614
sg10
I13
sg11
Vendometriosis
p15615
sg13
I1
sa(dp15616
g7
I71
sg23
VC0404585
p15617
sg10
I23
sg11
Vunexplained infertility
p15618
sg13
I2
sa(dp15619
g7
I33
sg23
VC0021359
p15620
sg10
I9
sg11
Vinfertile
p15621
sg13
I1
sasa(dp15622
g2
S'Trophinin may play an important role in the process of implantation, and abnormal endometrial trophinin expression might be one of the major causes of infertility.\n'
p15623
sg4
(lp15624
(dp15625
g7
I94
sg8
g18
sg10
I9
sg11
Vtrophinin
p15626
sg13
I1
sa(dp15627
g7
I0
sg8
g18
sg10
I9
sg11
VTrophinin
p15628
sg13
I1
sasg20
(lp15629
(dp15630
g7
I151
sg23
VC0021359
p15631
sg10
I11
sg11
Vinfertility
p15632
sg13
I1
sasa(dp15633
g2
S'Griscelli syndrome (GS) is a rare autosomal recessive disorder caused by mutation in the MYO5A (GS1), RAB27A (GS2), and MLPH (GS3) genes, characterized by a common feature, partial albinism.\n'
p15634
sg4
(lp15635
(dp15636
g7
I89
sg8
g18
sg10
I5
sg11
VMYO5A
p15637
sg13
I1
sa(dp15638
g7
I96
sg8
g18
sg10
I3
sg11
VGS1
p15639
sg13
I1
sa(dp15640
g7
I120
sg8
g18
sg10
I4
sg11
VMLPH
p15641
sg13
I1
sa(dp15642
g7
I110
sg8
VP41247
p15643
sg10
I3
sg11
VGS2
p15644
sg13
I1
sa(dp15645
g7
I102
sg8
VP51159
p15646
sg10
I6
sg11
VRAB27A
p15647
sg13
I1
sa(dp15648
g7
I126
sg8
g18
sg10
I3
sg11
VGS3
p15649
sg13
I1
sasg20
(lp15650
(dp15651
g7
I173
sg23
VC0080024
p15652
sg10
I16
sg11
Vpartial albinism
p15653
sg13
I2
sa(dp15654
g7
I96
sg23
VC1859194
p15655
sg10
I3
sg11
VGS1
p15656
sg13
I1
sa(dp15657
g7
I10
sg23
VC0039082
p15658
sg10
I8
sg11
Vsyndrome
p15659
sg13
I1
sa(dp15660
g7
I126
sg23
VC1836573
p15661
sg10
I3
sg11
VGS3
p15662
sg13
I1
sa(dp15663
g7
I110
sg23
VC1868679
p15664
sg10
I3
sg11
VGS2
p15665
sg13
I1
sasa(dp15666
g2
S'Many of these were not previously associated with skin disease in the organ (Mysm1, Vangl1, Trpc4ap, Nom1, Sparc, Farp2, and Prkab1), while others were ascribed new cutaneous functions on the basis of the screening approach (Krt76, Lrig1, Myo5a, Nsun2, and Nf1).\n'
p15667
sg4
(lp15668
(dp15669
g7
I114
sg8
g18
sg10
I5
sg11
VFarp2
p15670
sg13
I1
sa(dp15671
g7
I101
sg8
g18
sg10
I4
sg11
VNom1
p15672
sg13
I1
sa(dp15673
g7
I107
sg8
VP09486
p15674
sg10
I5
sg11
VSparc
p15675
sg13
I1
sa(dp15676
g7
I232
sg8
g18
sg10
I5
sg11
VLrig1
p15677
sg13
I1
sa(dp15678
g7
I77
sg8
g18
sg10
I5
sg11
VMysm1
p15679
sg13
I1
sa(dp15680
g7
I84
sg8
g18
sg10
I6
sg11
VVangl1
p15681
sg13
I1
sa(dp15682
g7
I239
sg8
g18
sg10
I5
sg11
VMyo5a
p15683
sg13
I1
sa(dp15684
g7
I225
sg8
g18
sg10
I5
sg11
VKrt76
p15685
sg13
I1
sa(dp15686
g7
I246
sg8
g18
sg10
I5
sg11
VNsun2
p15687
sg13
I1
sa(dp15688
g7
I92
sg8
g18
sg10
I7
sg11
VTrpc4ap
p15689
sg13
I1
sa(dp15690
g7
I257
sg8
VP21359
p15691
sg10
I3
sg11
VNf1
p15692
sg13
I1
sa(dp15693
g7
I125
sg8
g18
sg10
I6
sg11
VPrkab1
p15694
sg13
I1
sasg20
(lp15695
(dp15696
g7
I50
sg23
VC0037274
p15697
sg10
I12
sg11
Vskin disease
p15698
sg13
I2
sa(dp15699
g7
I257
sg23
VC0027831
p15700
sg10
I3
sg11
VNf1
p15701
sg13
I1
sasa(dp15702
g2
S'Extensive tumoral calcinosis affecting a large joint is uncommon in patients with systemic sclerosis.\n'
p15703
sg4
(lp15704
sg20
(lp15705
(dp15706
g7
I10
sg23
VC0263628
p15707
sg10
I18
sg11
Vtumoral calcinosis
p15708
sg13
I2
sa(dp15709
g7
I82
sg23
VC0036421
p15710
sg10
I18
sg11
Vsystemic sclerosis
p15711
sg13
I2
sasa(dp15712
g2
S"We review 8 of the following diseases linked to defects in the synthesis of O-xylosylglycans, O-N acetylgalactosaminylglycans, O-xylosyl/N-acetylglycans, O-mannosylglycans, and O-fucosylglycans: multiple exostoses, progeroid variant of Ehlers-Danlos syndrome, progeria, familial tumoral calcinosis, Schneckenbecken dysplasia, Walker-Warburg syndrome, spondylocostal dysostosis type 3, and Peter's plus syndrome.\n"
p15713
sg4
(lp15714
sg20
(lp15715
(dp15716
g7
I351
sg23
VC0265343
p15717
sg10
I25
sg11
Vspondylocostal dysostosis
p15718
sg13
I2
sa(dp15719
g7
I215
sg23
VC1869122
p15720
sg10
I43
sg11
Vprogeroid variant of Ehlers-Danlos syndrome
p15721
sg13
I5
sa(dp15722
g7
I250
sg23
VC0039082
p15723
sg10
I8
sg11
Vsyndrome
p15724
sg13
I1
sa(dp15725
g7
I279
sg23
VC0263628
p15726
sg10
I18
sg11
Vtumoral calcinosis
p15727
sg13
I2
sa(dp15728
g7
I195
sg23
VC0015306
p15729
sg10
I18
sg11
Vmultiple exostoses
p15730
sg13
I2
sa(dp15731
g7
I260
sg23
VC0033300
p15732
sg10
I8
sg11
Vprogeria
p15733
sg13
I1
sa(dp15734
g7
I299
sg23
VC0432194
p15735
sg10
I25
sg11
VSchneckenbecken dysplasia
p15736
sg13
I2
sa(dp15737
g7
I326
sg23
VC0265221
p15738
sg10
I23
sg11
VWalker-Warburg syndrome
p15739
sg13
I2
sasa(dp15740
g2
S'Here we describe a case of EME caused by NKH in which a new mutation in aminomethyltransferase (AMT) gene has been detected.\n'
p15741
sg4
(lp15742
(dp15743
g7
I60
sg8
VP48728
p15744
sg10
I34
sg11
Vmutation in aminomethyltransferase
p15745
sg13
I3
sa(dp15746
g7
I96
sg8
VP48728
p15747
sg10
I3
sg11
VAMT
p15748
sg13
I1
sasg20
(lp15749
(dp15750
g7
I41
sg23
VC0751748
p15751
sg10
I3
sg11
VNKH
p15752
sg13
I1
sa(dp15753
g7
I56
sg23
VC2985439
p15754
sg10
I12
sg11
Vnew mutation
p15755
sg13
I2
sasa(dp15756
g2
S'Glycine encephalopathy (GCE) or nonketotic hyperglycinemia is an inborn error of glycine metabolism, inherited in an autosomal recessive manner due to a defect in any one of the four enzymes aminomethyltransferase (AMT), glycine decarboxylase (GLDC), glycine cleavage system protein-H (GCSH) and dehydrolipoamide dehydrogenase in the glycine cleavage system.\n'
p15757
sg4
(lp15758
(dp15759
g7
I244
sg8
VP23378
p15760
sg10
I4
sg11
VGLDC
p15761
sg13
I1
sa(dp15762
g7
I296
sg8
VP49366
p15763
sg10
I30
sg11
Vdehydrolipoamide dehydrogenase
p15764
sg13
I2
sa(dp15765
g7
I286
sg8
VP48506
p15766
sg10
I4
sg11
VGCSH
p15767
sg13
I1
sa(dp15768
g7
I221
sg8
VP23378
p15769
sg10
I21
sg11
Vglycine decarboxylase
p15770
sg13
I2
sa(dp15771
g7
I251
sg8
VP04921
p15772
sg10
I33
sg11
Vglycine cleavage system protein-H
p15773
sg13
I4
sasg20
(lp15774
(dp15775
g7
I24
sg23
VC0751748
p15776
sg10
I3
sg11
VGCE
p15777
sg13
I1
sa(dp15778
g7
I32
sg23
VC0751748
p15779
sg10
I26
sg11
Vnonketotic hyperglycinemia
p15780
sg13
I2
sa(dp15781
g7
I0
sg23
VC0751748
p15782
sg10
I22
sg11
VGlycine encephalopathy
p15783
sg13
I2
sasa(dp15784
g2
S'We recently identified that the KITENIN/ErbB4-Dvl2-c-Jun axis works as a novel unconventional downstream signal of epidermal growth factor (EGF) in colorectal cancer (CRC) tissues.\n'
p15785
sg4
(lp15786
(dp15787
g7
I32
sg8
g18
sg10
I7
sg11
VKITENIN
p15788
sg13
I1
sa(dp15789
g7
I115
sg8
VP01133
p15790
sg10
I56
sg11
Vepidermal growth factor (EGF) in colorectal cancer (CRC)
p15791
sg13
I8
sa(dp15792
g7
I51
sg8
VP05412
p15793
sg10
I5
sg11
Vc-Jun
p15794
sg13
I1
sa(dp15795
g7
I46
sg8
g18
sg10
I4
sg11
VDvl2
p15796
sg13
I1
sa(dp15797
g7
I40
sg8
g18
sg10
I5
sg11
VErbB4
p15798
sg13
I1
sasg20
(lp15799
(dp15800
g7
I148
sg23
VC1527249
p15801
sg10
I17
sg11
Vcolorectal cancer
p15802
sg13
I2
sa(dp15803
g7
I167
sg23
VC1527249
p15804
sg10
I3
sg11
VCRC
p15805
sg13
I1
sasa(dp15806
g2
S'Hypermethylation of AXIN2, DKK1, VANGL1, and WNT5A gene promoters was higher, while those of SOX17, PRICKLE1, DAAM2, and MYC was lower in colon carcinoma compared to adenoma.\n'
p15807
sg4
(lp15808
(dp15809
g7
I93
sg8
g18
sg10
I5
sg11
VSOX17
p15810
sg13
I1
sa(dp15811
g7
I100
sg8
g18
sg10
I8
sg11
VPRICKLE1
p15812
sg13
I1
sa(dp15813
g7
I121
sg8
VP12524
p15814
sg10
I3
sg11
VMYC
p15815
sg13
I1
sa(dp15816
g7
I20
sg8
g18
sg10
I5
sg11
VAXIN2
p15817
sg13
I1
sa(dp15818
g7
I45
sg8
VP41221
p15819
sg10
I10
sg11
VWNT5A gene
p15820
sg13
I2
sa(dp15821
g7
I110
sg8
g18
sg10
I5
sg11
VDAAM2
p15822
sg13
I1
sa(dp15823
g7
I33
sg8
g18
sg10
I6
sg11
VVANGL1
p15824
sg13
I1
sa(dp15825
g7
I27
sg8
g18
sg10
I4
sg11
VDKK1
p15826
sg13
I1
sasg20
(lp15827
(dp15828
g7
I166
sg23
VC0001430
p15829
sg10
I7
sg11
Vadenoma
p15830
sg13
I1
sa(dp15831
g7
I138
sg23
VC0699790
p15832
sg10
I15
sg11
Vcolon carcinoma
p15833
sg13
I2
sasa(dp15834
g2
S'KITENIN (KAI1 C-terminal interacting tetraspanin) increases the invasiveness of colorectal cancer cells, and we identified a novel EGFR-independent oncogenic signal of EGF that works under coexpressed KITENIN and ErbB4.\n'
p15835
sg4
(lp15836
(dp15837
g7
I0
sg8
g18
sg10
I7
sg11
VKITENIN
p15838
sg13
I1
sa(dp15839
g7
I0
sg8
g18
sg10
I7
sg11
VKITENIN
p15840
sg13
I1
sa(dp15841
g7
I131
sg8
VP01133
p15842
sg10
I3
sg11
VEGF
p15843
sg13
I1
sa(dp15844
g7
I9
sg8
g18
sg10
I39
sg11
VKAI1 C-terminal interacting tetraspanin
p15845
sg13
I4
sa(dp15846
g7
I213
sg8
g18
sg10
I5
sg11
VErbB4
p15847
sg13
I1
sasg20
(lp15848
(dp15849
g7
I80
sg23
VC1527249
p15850
sg10
I17
sg11
Vcolorectal cancer
p15851
sg13
I2
sasa(dp15852
g2
S'Furthermore, the mRNA expression of KITENIN and that of ErbB4-CYT-2 were positively correlated in human colorectal cancer tissue.\n'
p15853
sg4
(lp15854
(dp15855
g7
I56
sg8
g18
sg10
I11
sg11
VErbB4-CYT-2
p15856
sg13
I1
sa(dp15857
g7
I36
sg8
g18
sg10
I7
sg11
VKITENIN
p15858
sg13
I1
sasg20
(lp15859
(dp15860
g7
I104
sg23
VC1527249
p15861
sg10
I17
sg11
Vcolorectal cancer
p15862
sg13
I2
sasa(dp15863
g2
S'Elevated coexpression of KITENIN and ErbB4-CYT-2 promotes the transition of colon adenoma to adenocarcinoma within an APC loss-associated tumor microenvironment.\n'
p15864
sg4
(lp15865
(dp15866
g7
I25
sg8
g18
sg10
I7
sg11
VKITENIN
p15867
sg13
I1
sa(dp15868
g7
I37
sg8
g18
sg10
I11
sg11
VErbB4-CYT-2
p15869
sg13
I1
sasg20
(lp15870
(dp15871
g7
I138
sg23
VC0027651
p15872
sg10
I5
sg11
Vtumor
p15873
sg13
I1
sa(dp15874
g7
I76
sg23
VC0850572
p15875
sg10
I13
sg11
Vcolon adenoma
p15876
sg13
I2
sa(dp15877
g7
I118
sg23
VC0033036
p15878
sg10
I3
sg11
VAPC
p15879
sg13
I1
sa(dp15880
g7
I62
sg23
VC0599156
p15881
sg10
I10
sg11
Vtransition
p15882
sg13
I1
sa(dp15883
g7
I93
sg23
VC0001418
p15884
sg10
I14
sg11
Vadenocarcinoma
p15885
sg13
I1
sasa(dp15886
g2
S'KAI1 COOH-terminal interacting tetraspanin (KITENIN) contributes to tumor progression and poor clinical outcomes in various cancers including colorectal cancer.\n'
p15887
sg4
(lp15888
(dp15889
g7
I0
sg8
VP27701
p15890
sg10
I42
sg11
VKAI1 COOH-terminal interacting tetraspanin
p15891
sg13
I4
sa(dp15892
g7
I44
sg8
g18
sg10
I7
sg11
VKITENIN
p15893
sg13
I1
sasg20
(lp15894
(dp15895
g7
I68
sg23
VC0178874
p15896
sg10
I17
sg11
Vtumor progression
p15897
sg13
I2
sa(dp15898
g7
I142
sg23
VC1527249
p15899
sg10
I17
sg11
Vcolorectal cancer
p15900
sg13
I2
sa(dp15901
g7
I124
sg23
VC0006826
p15902
sg10
I7
sg11
Vcancers
p15903
sg13
I1
sasa(dp15904
g2
S'The aim of the present study was to evaluate whether KITENIN affects tumor angiogenesis and lymphangiogenesis in colorectal cancer.\n'
p15905
sg4
(lp15906
sg20
(lp15907
(dp15908
g7
I113
sg23
VC1527249
p15909
sg10
I17
sg11
Vcolorectal cancer
p15910
sg13
I2
sa(dp15911
g7
I69
sg23
VC1519670
p15912
sg10
I18
sg11
Vtumor angiogenesis
p15913
sg13
I2
sasa(dp15914
g2
S'A KITENIN small interfering RNA vector was used to silence KITENIN expression in colorectal cancer cell lines including DLD1 and SW480 cells.\n'
p15915
sg4
(lp15916
(dp15917
g7
I2
sg8
g18
sg10
I7
sg11
VKITENIN
p15918
sg13
I1
sasg20
(lp15919
(dp15920
g7
I51
sg23
VC0858952
p15921
sg10
I7
sg11
Vsilence
p15922
sg13
I1
sa(dp15923
g7
I81
sg23
VC1527249
p15924
sg10
I17
sg11
Vcolorectal cancer
p15925
sg13
I2
sasa(dp15926
g2
S'Immunohistochemistry was used to determine the expression of KITENIN in colorectal cancer tissues.\n'
p15927
sg4
(lp15928
(dp15929
g7
I61
sg8
g18
sg10
I7
sg11
VKITENIN
p15930
sg13
I1
sasg20
(lp15931
(dp15932
g7
I72
sg23
VC1527249
p15933
sg10
I17
sg11
Vcolorectal cancer
p15934
sg13
I2
sasa(dp15935
g2
S'These results suggest that KITENIN promotes tumor progression by enhancing angiogenesis in colorectal cancer.\n'
p15936
sg4
(lp15937
(dp15938
g7
I27
sg8
g18
sg10
I7
sg11
VKITENIN
p15939
sg13
I1
sasg20
(lp15940
(dp15941
g7
I44
sg23
VC0178874
p15942
sg10
I17
sg11
Vtumor progression
p15943
sg13
I2
sa(dp15944
g7
I91
sg23
VC1527249
p15945
sg10
I17
sg11
Vcolorectal cancer
p15946
sg13
I2
sasa(dp15947
g2
S'We previously observed that KAI1 C-terminal interacting tetraspanin (KITENIN) is highly expressed in sporadic human colorectal cancer (CRC) tissues and hence the functional KITENIN complex acts to promote progression of CRC.\n'
p15948
sg4
(lp15949
(dp15950
g7
I173
sg8
g18
sg10
I15
sg11
VKITENIN complex
p15951
sg13
I2
sa(dp15952
g7
I69
sg8
g18
sg10
I7
sg11
VKITENIN
p15953
sg13
I1
sa(dp15954
g7
I135
sg8
VP31749
p15955
sg10
I3
sg11
VCRC
p15956
sg13
I1
sa(dp15957
g7
I116
sg8
VP31749
p15958
sg10
I17
sg11
Vcolorectal cancer
p15959
sg13
I2
sa(dp15960
g7
I28
sg8
g18
sg10
I39
sg11
VKAI1 C-terminal interacting tetraspanin
p15961
sg13
I4
sasg20
(lp15962
(dp15963
g7
I135
sg23
VC1527249
p15964
sg10
I3
sg11
VCRC
p15965
sg13
I1
sa(dp15966
g7
I116
sg23
VC1527249
p15967
sg10
I17
sg11
Vcolorectal cancer
p15968
sg13
I2
sa(dp15969
g7
I135
sg23
VC1527249
p15970
sg10
I3
sg11
VCRC
p15971
sg13
I1
sasa(dp15972
g2
S'Previously, we identified KAI1 C-terminal interacting tetraspanin (KITENIN) as a metastasis-enhancing gene and found it to be highly expressed in sporadic colorectal cancer tissues.\n'
p15973
sg4
(lp15974
(dp15975
g7
I26
sg8
g18
sg10
I39
sg11
VKAI1 C-terminal interacting tetraspanin
p15976
sg13
I4
sa(dp15977
g7
I67
sg8
g18
sg10
I7
sg11
VKITENIN
p15978
sg13
I1
sasg20
(lp15979
(dp15980
g7
I81
sg23
VC0027627
p15981
sg10
I10
sg11
Vmetastasis
p15982
sg13
I1
sa(dp15983
g7
I155
sg23
VC1527249
p15984
sg10
I17
sg11
Vcolorectal cancer
p15985
sg13
I2
sasa(dp15986
g2
S'We analyzed how EGF modulates the downstream signaling pathway of oncogenic KITENIN in colorectal cancer cells.\n'
p15987
sg4
(lp15988
(dp15989
g7
I16
sg8
VP01133
p15990
sg10
I3
sg11
VEGF
p15991
sg13
I1
sa(dp15992
g7
I66
sg8
g18
sg10
I17
sg11
Voncogenic KITENIN
p15993
sg13
I2
sasg20
(lp15994
(dp15995
g7
I87
sg23
VC1527249
p15996
sg10
I17
sg11
Vcolorectal cancer
p15997
sg13
I2
sasa(dp15998
g2
S'Biological alterations following EGF treatment were identified in KITENIN-overexpressed colorectal cancer cells with or without alteration of EGFR activity.\n'
p15999
sg4
(lp16000
(dp16001
g7
I33
sg8
VP01133
p16002
sg10
I3
sg11
VEGF
p16003
sg13
I1
sasg20
(lp16004
(dp16005
g7
I88
sg23
VC1527249
p16006
sg10
I17
sg11
Vcolorectal cancer
p16007
sg13
I2
sasa(dp16008
g2
S'In addition, tumor tissues from metastatic patients with colorectal cancer who showed initial poor responses to cetuximab/chemotherapy expressed higher levels of KITENIN than did responders to therapy.\n'
p16009
sg4
(lp16010
sg20
(lp16011
(dp16012
g7
I13
sg23
VC0027651
p16013
sg10
I5
sg11
Vtumor
p16014
sg13
I1
sa(dp16015
g7
I57
sg23
VC1527249
p16016
sg10
I17
sg11
Vcolorectal cancer
p16017
sg13
I2
sasa(dp16018
g2
S'KITENIN (KAI1 C-terminal interacting tetraspanin) promotes invasion and metastasis in mouse colon cancer models.\n'
p16019
sg4
(lp16020
(dp16021
g7
I0
sg8
g18
sg10
I7
sg11
VKITENIN
p16022
sg13
I1
sa(dp16023
g7
I9
sg8
g18
sg10
I39
sg11
VKAI1 C-terminal interacting tetraspanin
p16024
sg13
I4
sasg20
(lp16025
(dp16026
g7
I72
sg23
VC0027627
p16027
sg10
I10
sg11
Vmetastasis
p16028
sg13
I1
sa(dp16029
g7
I59
sg23
VC2699153
p16030
sg10
I8
sg11
Vinvasion
p16031
sg13
I1
sa(dp16032
g7
I92
sg23
VC0699790
p16033
sg10
I12
sg11
Vcolon cancer
p16034
sg13
I2
sasa(dp16035
g2
S'In the present study, we evaluated the effects of KITENIN knockdown by intravenous administration of short hairpin RNAs (shRNAs) in an orthotopic mouse colon cancer model, simulating a primary or adjuvant treatment setting.\n'
p16036
sg4
(lp16037
sg20
(lp16038
(dp16039
g7
I152
sg23
VC0699790
p16040
sg10
I12
sg11
Vcolon cancer
p16041
sg13
I2
sasa(dp16042
g2
S'Our results suggest that shRNA targeting KITENIN has the potential to be an effective tool for the treatment of colon cancer in both adjuvant and metastatic setting.\n'
p16043
sg4
(lp16044
sg20
(lp16045
(dp16046
g7
I112
sg23
VC0699790
p16047
sg10
I12
sg11
Vcolon cancer
p16048
sg13
I2
sasa(dp16049
g2
S'KAI1 COOH-terminal interacting tetraspanin (KITENIN) has been found to act as a promoter of metastasis in murine models of colon cancer and squamous cell carcinoma (SCC).\n'
p16050
sg4
(lp16051
(dp16052
g7
I0
sg8
VP27701
p16053
sg10
I42
sg11
VKAI1 COOH-terminal interacting tetraspanin
p16054
sg13
I4
sa(dp16055
g7
I44
sg8
g18
sg10
I7
sg11
VKITENIN
p16056
sg13
I1
sasg20
(lp16057
(dp16058
g7
I165
sg23
VC0007137
p16059
sg10
I3
sg11
VSCC
p16060
sg13
I1
sa(dp16061
g7
I123
sg23
VC0699790
p16062
sg10
I12
sg11
Vcolon cancer
p16063
sg13
I2
sa(dp16064
g7
I140
sg23
VC0007137
p16065
sg10
I23
sg11
Vsquamous cell carcinoma
p16066
sg13
I3
sa(dp16067
g7
I92
sg23
VC0027627
p16068
sg10
I10
sg11
Vmetastasis
p16069
sg13
I1
sasa(dp16070
g2
S'The suppression of tumor progression and metastasis of established colon cancer in mice was observed after intravenous delivery of small interfering RNA (siRNA) targeting KITENIN.\n'
p16071
sg4
(lp16072
sg20
(lp16073
(dp16074
g7
I4
sg23
VC0221103
p16075
sg10
I11
sg11
Vsuppression
p16076
sg13
I1
sa(dp16077
g7
I19
sg23
VC0178874
p16078
sg10
I17
sg11
Vtumor progression
p16079
sg13
I2
sa(dp16080
g7
I67
sg23
VC0699790
p16081
sg10
I12
sg11
Vcolon cancer
p16082
sg13
I2
sa(dp16083
g7
I41
sg23
VC0027627
p16084
sg10
I10
sg11
Vmetastasis
p16085
sg13
I1
sasa(dp16086
g2
S'The purposes of this study were to observe the effect of KITENIN on tumor cell behaviors of human hepatocellular carcinoma (HCC) cells and to evaluate its expression in human HCC tissues.\n'
p16087
sg4
(lp16088
sg20
(lp16089
(dp16090
g7
I98
sg23
VC2239176
p16091
sg10
I24
sg11
Vhepatocellular carcinoma
p16092
sg13
I2
sa(dp16093
g7
I124
sg23
VC2239176
p16094
sg10
I3
sg11
VHCC
p16095
sg13
I1
sa(dp16096
g7
I68
sg23
VC0027651
p16097
sg10
I5
sg11
Vtumor
p16098
sg13
I1
sa(dp16099
g7
I124
sg23
VC2239176
p16100
sg10
I3
sg11
VHCC
p16101
sg13
I1
sasa(dp16102
g2
S'We found that two classes of ciliary disease genes were highly represented among the basal body proteome: cystic kidney disease (especially nephronophthisis) syndromes, including Meckel/Joubert-like and oral-facial-digital syndrome, caused by mutations in CEP290, MKS1, OFD1, and AHI1/Jouberin proteins and cone-rod dystrophy syndrome genes, including UNC-119/HRG4, NPHP4, and RPGR1.\n'
p16103
sg4
(lp16104
(dp16105
g7
I285
sg8
g18
sg10
I8
sg11
VJouberin
p16106
sg13
I1
sa(dp16107
g7
I352
sg8
g18
sg10
I7
sg11
VUNC-119
p16108
sg13
I1
sa(dp16109
g7
I360
sg8
g18
sg10
I4
sg11
VHRG4
p16110
sg13
I1
sa(dp16111
g7
I366
sg8
g18
sg10
I5
sg11
VNPHP4
p16112
sg13
I1
sa(dp16113
g7
I256
sg8
g18
sg10
I6
sg11
VCEP290
p16114
sg13
I1
sa(dp16115
g7
I264
sg8
g18
sg10
I4
sg11
VMKS1
p16116
sg13
I1
sa(dp16117
g7
I270
sg8
g18
sg10
I4
sg11
VOFD1
p16118
sg13
I1
sa(dp16119
g7
I280
sg8
g18
sg10
I4
sg11
VAHI1
p16120
sg13
I1
sasg20
(lp16121
(dp16122
g7
I106
sg23
VC1691228
p16123
sg10
I21
sg11
Vcystic kidney disease
p16124
sg13
I3
sa(dp16125
g7
I140
sg23
VC0687120
p16126
sg10
I16
sg11
Vnephronophthisis
p16127
sg13
I1
sa(dp16128
g7
I203
sg23
VC1510460
p16129
sg10
I28
sg11
Voral-facial-digital syndrome
p16130
sg13
I2
sa(dp16131
g7
I158
sg23
VC0039082
p16132
sg10
I9
sg11
Vsyndromes
p16133
sg13
I1
sa(dp16134
g7
I307
sg23
VC0035334
p16135
sg10
I18
sg11
Vcone-rod dystrophy
p16136
sg13
I2
sa(dp16137
g7
I366
sg23
VC1847013
p16138
sg10
I5
sg11
VNPHP4
p16139
sg13
I1
sa(dp16140
g7
I158
sg23
VC0039082
p16141
sg10
I8
sg11
Vsyndrome
p16142
sg13
I1
sa(dp16143
g7
I264
sg23
VC0265215
p16144
sg10
I4
sg11
VMKS1
p16145
sg13
I1
sa(dp16146
g7
I270
sg23
VC1510460
p16147
sg10
I4
sg11
VOFD1
p16148
sg13
I1
sasa(dp16149
g2
S'Deregulated expression of AP-1 transcription factors is implicated in the pathogenesis of various lymphomas such as classical Hodgkin lymphomas, anaplastic large cell lymphomas, diffuse large B cell lymphomas and adult T cell leukemia/lymphoma.\n'
p16150
sg4
(lp16151
(dp16152
g7
I26
sg8
VP19883
p16153
sg10
I26
sg11
VAP-1 transcription factors
p16154
sg13
I3
sasg20
(lp16155
(dp16156
g7
I126
sg23
VC0019829
p16157
sg10
I17
sg11
VHodgkin lymphomas
p16158
sg13
I2
sa(dp16159
g7
I213
sg23
VC0023492
p16160
sg10
I21
sg11
Vadult T cell leukemia
p16161
sg13
I4
sa(dp16162
g7
I192
sg23
VC0079731
p16163
sg10
I16
sg11
VB cell lymphomas
p16164
sg13
I3
sa(dp16165
g7
I98
sg23
VC0024299
p16166
sg10
I9
sg11
Vlymphomas
p16167
sg13
I1
sa(dp16168
g7
I74
sg23
VC0699748
p16169
sg10
I12
sg11
Vpathogenesis
p16170
sg13
I1
sa(dp16171
g7
I98
sg23
VC0024299
p16172
sg10
I8
sg11
Vlymphoma
p16173
sg13
I1
sa(dp16174
g7
I167
sg23
VC0079734
p16175
sg10
I18
sg11
Vlymphomas, diffuse
p16176
sg13
I2
sasa.